<SEC-DOCUMENT>0001520138-20-000106.txt : 20200311
<SEC-HEADER>0001520138-20-000106.hdr.sgml : 20200311
<ACCEPTANCE-DATETIME>20200311171327
ACCESSION NUMBER:		0001520138-20-000106
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		62
FILED AS OF DATE:		20200311
DATE AS OF CHANGE:		20200311

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOVIE INC.
		CENTRAL INDEX KEY:			0001580149
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				462510769
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-231136
		FILM NUMBER:		20706158

	BUSINESS ADDRESS:	
		STREET 1:		2120 COLORADO AVE.
		STREET 2:		SUITE 230
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90404
		BUSINESS PHONE:		310-444-4300

	MAIL ADDRESS:	
		STREET 1:		2120 COLORADO AVE.
		STREET 2:		SUITE 230
		CITY:			LOS ANGELES
		STATE:			CA
		ZIP:			90404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOANTIBIOTICS, INC.
		DATE OF NAME CHANGE:	20130625
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>bivi-20200311_s1a9.htm
<DESCRIPTION>FORM S-1 AMENDMENT NO. 9
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"> <B>As filed with the U.S. Securities
and Exchange Commission on  March 11, 2020</B> </P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: right"><B>Registration No. 333-231136</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 3pt solid; font: 3pt/107% Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font: 3pt/107% Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 3pt; text-align: center"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>FORM S-1/A</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Amendment No. 9 </B></P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>REGISTRATION STATEMENT&nbsp;UNDER&nbsp;THE
SECURITIES ACT OF&nbsp;1933</B></P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>BioVie
Inc.</B></FONT><BR>
<FONT STYLE="font-size: 9pt">(Exact Name of Registrant as Specified in its Charter)</FONT></P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>46-2510769</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">(State
    or other jurisdiction of</FONT><FONT STYLE="font-size: 9pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">incorporation or organization)</FONT></FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">(Primary
    Standard Industrial</FONT><FONT STYLE="font-size: 9pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">Classification Code Number)</FONT></FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">(I.R.S.
    Employer</FONT><FONT STYLE="font-size: 9pt"><BR>
    <FONT STYLE="font-family: Times New Roman, Times, Serif">Identification No.)</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>2120 Colorado Avenue, #230, </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Santa Monica, California 90404</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>(310) 444-4300</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&rsquo;s Principal Executive Offices)</P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Terren S. Peizer</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Chief Executive Officer</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>c/o BioVie Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>2120 Colorado Avenue, #230</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Santa Monica, California 90404</B></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: center"><B>(310) 444-4300</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)</P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Copies to:</B></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B><BR>
        Mitchell Nussbaum, Esq.</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Norwood P. Beveridge, Jr., Esq.</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Lili Taheri, Esq.</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Loeb &amp; Loeb LLP</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>345 Park Avenue</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>New York, NY 10154</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Phone: (212) 407-4000</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Fax: (212) 407-4990</B></P></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: center; vertical-align: bottom">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><BR>
        Alan Annex, Esq.</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Jason Simon, Esq.</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Greenberg Traurig, LLP</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>1750 Tysons Blvd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Suite 1000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>McLean, VA 22102</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Phone: (703) 749-1300</B></P>

<P STYLE="margin: 0"><B>Fax: (703) 749-1301</B></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B></B></P></TD></TR>
</TABLE>
<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Approximate date of commencement of
proposed sale to public:<BR>
As soon as practicable after the effective date hereof.</B></P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415
under the Securities Act of 1933, check the following box. </FONT> <FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9746;</FONT> </P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check
the following box and list the Securities Act registration statement number of the earlier effective registration statement for
the same offering.&nbsp;</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth
company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 9pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; line-height: 107%; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Large&nbsp;accelerated&nbsp;filer&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 9pt">&#9744;</FONT></TD>
    <TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%; width: 164px"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; line-height: 107%; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Accelerated&nbsp;filer&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; line-height: 107%; vertical-align: middle"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 9pt">&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; line-height: 107%; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Non-accelerated&nbsp;filer&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 9pt">&#9746;</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; line-height: 107%; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Smaller&nbsp;reporting&nbsp;company
    </FONT></TD>
    <TD STYLE="text-align: left; line-height: 107%; vertical-align: middle"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 9pt">&#9746;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; line-height: 107%; vertical-align: middle"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; line-height: 107%; vertical-align: middle"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Emerging
    growth company </FONT></TD>
    <TD STYLE="text-align: left; line-height: 107%; vertical-align: middle"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 9pt">&#9744;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
</FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 9pt">&#9744;</FONT></P>

<DIV STYLE="page-break-before: always; margin-top: 0pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"> <B>CALCULATION OF REGISTRATION FEE</B> </P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"> <B>Title of each class of</B> </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"> <B>securities to be registered</B> </P></TD>
    <TD STYLE="line-height: 105%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 105%"> <FONT STYLE="line-height: 105%"><B>Proposed
    maximum aggregate offering&nbsp;</B><BR>
    <B>price(1)</B></FONT> </TD>
    <TD STYLE="line-height: 105%"> &nbsp; </TD>
    <TD STYLE="line-height: 105%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 105%"> <FONT STYLE="line-height: 105%"><B>Amount
    of registration fee(2)</B></FONT> </TD>
    <TD STYLE="line-height: 105%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 78%; line-height: 105%"> <FONT STYLE="line-height: 105%">Units, each unit consisting of one share of Class
    A common stock, par value $0.0001 per share (&ldquo;common stock&rdquo;) and one-half warrant to purchase one share of common stock</FONT> </TD>
    <TD STYLE="width: 1%; line-height: 105%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: center; line-height: 105%"> <FONT STYLE="line-height: 105%">$</FONT> </TD>
    <TD STYLE="width: 8%; text-align: right; line-height: 105%"> <FONT STYLE="line-height: 105%">5,000,000</FONT> </TD>
    <TD STYLE="width: 1%; line-height: 105%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 105%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: center; line-height: 105%"> <FONT STYLE="line-height: 105%">$</FONT> </TD>
    <TD STYLE="width: 8%; text-align: right; line-height: 105%"> <FONT STYLE="line-height: 105%">469.00</FONT> </TD>
    <TD STYLE="width: 1%; line-height: 105%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 105%"> <FONT STYLE="line-height: 105%">Shares of common stock included in the units</FONT> </TD>
    <TD STYLE="line-height: 105%"> &nbsp; </TD>
    <TD STYLE="line-height: 105%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 105%"> <FONT STYLE="line-height: 105%">(3)</FONT> </TD>
    <TD STYLE="line-height: 105%"> &nbsp; </TD>
    <TD STYLE="line-height: 105%"> &nbsp; </TD>
    <TD STYLE="line-height: 105%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 105%"> &nbsp; </TD>
    <TD STYLE="line-height: 105%"> &nbsp; </TD></TR>
<TR>
    <TD> Warrants included in the units&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: center"> (3) </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR>
    <TD> Shares of common stock underlying the warrants included in the units (at an exercise price of 125% of the price of
    the units) </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> $ </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> 3,125,000 </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> $ </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> 405.63 </TD>
    <TD> &nbsp; </TD></TR>
<TR>
    <TD> Total </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> $ </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> 8,125,000 </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; text-align: center"> $ </TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> 1,054.63 </TD>
    <TD> &nbsp; </TD></TR>
</TABLE>
<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; line-height: 105%"> <FONT STYLE="line-height: 105%">(1)</FONT> </TD>
    <TD STYLE="width: 99%; text-align: justify; line-height: 105%"> <FONT STYLE="line-height: 105%">Pursuant to Rule 416 under
    the Securities Act of 1933, as amended (or the Securities Act), the securities being registered hereunder include such indeterminate
    number of additional shares of common stock as may be issued after the date hereof as a result of stock splits, stock dividends
    or similar transactions.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; line-height: 105%"> <FONT STYLE="line-height: 105%">(2)</FONT> </TD>
    <TD STYLE="width: 99%; text-align: justify; line-height: 105%"> <FONT STYLE="line-height: 105%">Calculated pursuant to Rule&nbsp;457(o)
    based on an estimate of the proposed maximum aggregate offering price. The Registrant previously paid such filing fee.</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%; line-height: 105%"> <FONT STYLE="line-height: 105%">(3)</FONT> </TD>
    <TD STYLE="width: 99%; text-align: justify; line-height: 105%"> <FONT STYLE="line-height: 105%">No fee required pursuant
    to Rule 457(g).</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>The registrant hereby amends this
registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file&nbsp;a
further amendment which specifically states that this registration statement shall thereafter become effective in accordance with
Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such
date as the Commission, acting pursuant to Section&nbsp;8(a), may determine.</B></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1pt solid; font: 10pt/107% Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 3pt solid; font: 3pt/107% Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
</TABLE>

<DIV STYLE="page-break-before: always; margin-top: 0pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; color: red"><B>The information contained
in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement
filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; color: #B10021"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt/95% Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 34%; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>PRELIMINARY PROSPECTUS</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 32%; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>SUBJECT TO COMPLETION</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 32%; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>DATED
     MARCH 11, 2020 </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 14pt/90% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B> 1,538,462 Units</B></P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center; color: red">&nbsp;<IMG SRC="image_001.jpg" ALT="CzAwX4YXEAAAOf2 (1)" STYLE="height: 50px; width: 145px"></P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 18pt"><B>BioVie
Inc.</B></FONT></P>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0; text-align: justify"> We are offering 1,538,462 units of BioVie Inc., at a price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per unit, each unit consisting
of one share of Class A common stock ("common stock") and one-half warrant. Each whole warrant will entitle the holder
to purchase one share of common stock at an exercise price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. The
warrants will expire on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2025. The units will not be issued or certificated.
Instead, the shares of common stock and the warrants underlying the units will be issued separately and may be resold separately,
although they will have been purchased together in this offering. </P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0; text-align: justify"> Prior to this offering, there has been
a limited public market for our common stock on the OTCQB Marketplace under the ticker BIVI. On March 2, 2020, the last reported
sale price for our common stock as reported on the OTCQB Marketplace was $[3.25] per share. The final public offering price will
be determined through negotiation between us and the potential investors in the offering and the recent market price used throughout
this prospectus may not be indicative of the final offering price. </P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0; text-align: justify"> We may complete the offering even if we
do not raise the entire maximum offering amount. The amount raised may be substantially less than the total maximum offering amount
and any investor funds received may be used by the Company prior to the maximum offering being sold. </P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Investing in our securities is highly speculative and involves
a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page&nbsp;5.</B></P>


<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt/95% Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
    Unit</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 78%; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    </FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">offering price</FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement agent
    fees</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (1)</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds to us, before expenses</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt/95% Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 97%; text-align: justify; line-height: 107%; padding-left: -20pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
    not include a non-accountable expense allowance equal to 1.0% of the gross proceeds of this offering payable to ThinkEquity,
    a division of Fordham Financial Management, Inc. We refer you to &ldquo;Plan of Distribution&rdquo; beginning on page [__]
    for additional information regarding compensation payable to the placement agent.</FONT> </TD></TR>
    <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> (2) </FONT></TD>
    <TD STYLE="width: 97%; text-align: justify; line-height: 107%; padding-left: -20pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents a fee of 7% of the purchase price for the units sold by the placement agent in the
offering and warrants to purchase up to [_____] shares of common stock (7% of the units sold by the placement agent in the offering)
at an exercise price of $[___].</FONT> </TD></TR>
</TABLE>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> We have retained ThinkEquity, a division
of Fordham Financial Management, Inc. as our exclusive placement agent
to use its reasonable efforts to solicit offers to purchase the securities in this offering. In addition, members of our management
and/or controlling stockholder will also attempt to assist us in the sales of the securities pursuant to this prospectus, with
no commission or other remuneration payable to them or to ThinkEquity, a division of Fordham Financial Management, Inc. for any
units they may sell. Management and our controlling stockholder will rely on the safe harbor from broker-dealer registration set
forth in Rule 3a4-1 under the Securities Exchange Act of 1934, as amended. Neither the placement agent nor our management or controlling
stockholder has any obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number
or dollar amount of the securities. Because there is no minimum offering amount required as a condition to closing in this offering,
and such is being conducted on an &ldquo;any or all&rdquo; basis, the actual public offering amount, placement agent fees, and
proceeds to us, if any, are not presently determinable and may be substantially less than the total offering amount set forth above. </P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> Delivery of the common stock and warrants
to purchasers is expected to take place&nbsp;on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2020.</P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>ThinkEquity</B></P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>a division of Fordham Financial Management,
Inc.</B></P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">The date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2020 </P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>


<DIV STYLE="page-break-before: always; border-top: black 1.5pt solid; margin-top: 0pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><IMG SRC="image_019.jpg" ALT=""></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>&nbsp;<IMG SRC="image_025.jpg" ALT=""></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>BIV201 (continuous infusion terlipressin)
is an investigational therapy</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>&nbsp;</I></P>

<DIV STYLE="page-break-before: always; border-top: black 1.5pt solid; margin-top: 0pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I><IMG SRC="image_013.jpg" ALT=""></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>&nbsp;<IMG SRC="image_014.jpg" ALT=""></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>&nbsp;</I></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"></P>


<DIV STYLE="page-break-before: always; border-top: black 1.5pt solid; margin-top: 0pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="toc"></A>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 90%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page </B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001">Prospectus Summary</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right; line-height: 107%">1</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">Risk Factors</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">5</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">Cautionary Note Regarding Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">19</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">Use of Proceeds</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">20</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">Dividend Policy</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right; line-height: 107%">20</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">Capitalization</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">21</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">Dilution</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">22</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_008">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">23</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">Business</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">27</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">Management</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">35</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">Executive Compensation</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">42</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">Principal Stockholders</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">44</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">Certain Relationships and Related Party Transactions</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">46</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_014">Description of Capital Stock</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">48</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_015"> Plan
    of Distribution </A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top">52</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_016">Experts</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top"> 56 </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_017">Legal Matters</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top"> 56 </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_018">Where You Can Find More Information</A></FONT></TD>
    <TD STYLE="text-align: right; vertical-align: top"> 56 </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_019">Index to Financial Statements</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: right; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">You should rely only on the information
contained in this prospectus. We have not authorized any other person to provide you with information different from or in addition
to that contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on
it. We are not making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. You should
assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus.
Our business, financial condition, results of operations and prospects may have changed since that date.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">In this prospectus, we rely on and refer
to information and statistics regarding our industry. We obtained this statistical, market and other industry data and forecasts
from publicly available information. While we believe that the statistical data, market data and other industry data and forecasts
are reliable, we have not independently verified the data.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">As used in this prospectus, unless the
context indicates or otherwise requires, &ldquo;the Company,&rdquo; &ldquo;our Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo;
and &ldquo;our&rdquo; refer to BioVie Inc., a Nevada corporation, and its consolidated subsidiaries.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">i</P>
<DIV STYLE="page-break-before: always; border-top: black 1.5pt solid; margin-top: 6pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_001"></A>Prospectus
Summary</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><I>This summary highlights certain
information appearing elsewhere in this prospectus. Because it is only a summary, it does not contain all of the information that
you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction
with, the more detailed information appearing elsewhere in this prospectus. Before you decide to invest in our securities, you
should read the entire prospectus carefully, including &ldquo;Risk Factors&rdquo; beginning on page 5 and the financial statements
and related notes included in this prospectus.</I></P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><I>A 1:125 reverse stock split of
our common stock was effected in November 2019. All share amounts in this prospectus have been retroactively adjusted
to give effect to this reverse stock split (subject to rounding up fractional shares).</I></P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><I>This prospectus includes trademarks,
service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this prospectus
are the property of their respective owners.</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Our Company</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">We are a clinical-stage company
pursuing the discovery, development, and commercialization of innovative drug therapies. We are currently focused on developing
and commercializing BIV201 (continuous infusion terlipressin), a novel approach to the treatment of ascites due to chronic liver
cirrhosis. Our therapy BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver
cirrhosis (part of the same disease pathway as ascites), but not yet available in the United States. BIV201&rsquo;s active agent
is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension in studies around the world. The goal is for
BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.</P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In April 2017, we entered into
a Cooperative Research and Development Agreement (&ldquo;CRADA&rdquo;) with the McGuire Research Institute Inc. in Richmond, VA,
and began administering BIV201 to patients in September 2017. In April 2019, we announced top-line results for our Phase 2a clinical
trial of BIV201 (continuous infusion terlipressin) in six patients with refractory ascites due to advanced liver cirrhosis. The
following results were observed:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuous
                                         infusion of terlipressin via portable infusion pump was maintained for 28 days in three
                                         patients with refractory ascites, and all patients remained hemodynamically stable during
                                         treatment.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                         steady state plasma concentration data characterized terlipressin pharmacokinetics (PK)
                                         within the predicted PK model concentrations.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin-top: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Four
                                         of the six patients treated with BIV201 experienced an increase in the number of days
                                         between paracenteses ranging from 71% to 414% compared to prior to initiating therapy.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On June 18, 2019, we met
with representatives of the U.S. Food &amp; Drug Administration ("FDA") for a Type C Guidance Meeting to plan our next clinical
study following the recently completed Phase 2a clinical trial. We discussed our clinical development efforts with the FDA and
proposed safety and efficacy endpoints for our next clinical trial. In July 2019, the FDA provided its meeting minutes for this
meeting that documented general agreement with the Company's proposed randomized clinical study design. The FDA also provided
its suggestions and guidance regarding primary and secondary endpoints and other key aspects of our clinical trial design including
appropriate quality of life measures. On October 1, 2019, the Company submitted a Phase 2b/3 randomized, controlled clinical trial
protocol to the FDA incorporating these suggestions. If this trial demonstrates significant improvement on various measures of
patient health status, we believe it could potentially form the basis to submit a new drug application (NDA) for the eventual
marketing of BIV201 in the US. While the FDA has not provided final guidance nor do we have certainty as to what that guidance
would entail, our goal remains to commence the planned Phase 2b/3 trial in the next several months in a manner consistent with
what was reviewed with the FDA. We may still need to address certain risks associated with yet to be validated quality of life
measures.</P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">In September 2019, the Company manufactured the first batch of prefilled syringes containing a novel patent-pending liquid formulation
of terlipressin. This new product format is intended to improve convenience for outpatient administration and avoid potential formulation
errors when pharmacists reconstitute the powder version. In November 2019, the Company completed quality control testing and released
the batch for use in the planned Phase 2b/3 trial subject to FDA clearance.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/95% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">BIV201 (continuous infusion
terlipressin) has the potential to improve the health of thousands of patients suffering from life-threatening complications of
liver cirrhosis due to hepatitis, NASH, and alcoholism. We have a pending patent application for a method of treating a
patient diagnosed with ascites due to liver cirrhosis by administering BIV201 (terlipressin) as a continuous infusion within specified
doses over a specified duration. The FDA has granted Fast-Track status and Orphan Drug designation for the most common of these
complications, ascites, which represents a significant unmet medical need. Patients with cirrhosis and ascites account for an
estimated 116,000 U.S. hospital discharges annually, with frequent early readmissions. Those requiring paracentesis (removal of
ascites fluid) experience an average hospital stay lasting 8 days incurring over $86,000 in medical costs (HCUP Nationwide Readmissions
Database 2016). This translates into a total addressable ascites market size for BIV201 therapy exceeding $500 million based on
Company estimates. The FDA has never approved any drug specifically for treating ascites. BIV201 received Orphan Drug designation
for hepatorenal syndrome ("HRS") in November 2018.</P>

</div>
<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The BIV201 development program
began at LAT Pharma LLC. On April 11, 2016, we acquired LAT Pharma LLC and the rights to its BIV201 development program and currently
own all development and marketing rights to BIV201. We and PharmaIN, Corp. (&ldquo;PharmaIN&rdquo;), LAT Pharma&rsquo;s former
partner focused on the development of new modified product candidates in the same therapeutic field but not including BIV201,
had agreed to pay royalties equal to less than 1% of future net sales of each company&rsquo;s ascites drug development programs,
or if such program is licensed to a third party, less than 5% of each company&rsquo;s net license revenues. On December 24, 2018,
we returned our partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the
remaining balance due on a related debt. PharmaIN&rsquo;s rights to our program remain unchanged. We have a pending patent
application for the use of BIV201 for the treatment of patients diagnosed with ascites due to liver cirrhosis in the outpatient
setting using ambulatory pump infusion, and have corresponding patent applications pending in Japan, Europe, China and Hong Kong.</P>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Risks Associated with our Business</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Our business and ability to execute
our business strategy are subject to a number of risks of which you should be aware before you decide to buy our common stock.
In particular, you should consider the following risks, which are discussed more fully in the section entitled &ldquo;Risk Factors&rdquo;
in this prospectus:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are a development stage company with a limited operating history, making it difficult for you to evaluate our business and your investment;&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%; width: 24px">&nbsp;</TD>
    <TD STYLE="line-height: 107%; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we have no products approved for commercial sale, have never generated any revenues and may never achieve revenues or profitability, which could cause us to cease operations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we will need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we have limited experience in drug development and may not be able to successfully develop any drugs, which would cause us to cease operations;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we have no manufacturing experience, and the failure to comply with all applicable manufacturing regulations and requirements could have a materially adverse effect on our business; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if we fail to maintain an effective system of internal controls, we may not be able to accurately report financial results or detect fraud;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 107%; width: 24px">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may be unable to obtain or protect intellectual property rights relating to our products, and we may be liable for infringing upon the intellectual property rights of others, which could have a materially adverse effect on our business;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the biotechnology and biopharmaceutical industries are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with enterprises equipped with more substantial resources than us, which could cause us to curtail or cease operations;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    can be no assurance that there will be liquidity in the trading market for our securities;&nbsp;</FONT> </TD></TR>
</TABLE>
<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain stockholders who are also officers and directors may have significant control over our management;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    are subject to risks associated with the recent outbreak of the novel coronavirus (also known as COVID-19), which may negatively
    affect our ability to recruit candidates for our clinical trials and financing to support the development of our product candidates.
    and</FONT> </TD></TR>
</TABLE>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are subject to the periodic reporting requirements of the Exchange Act, which require us to incur audit fees and legal fees in connection with the preparation of such reports. These additional costs will negatively affect our ability to earn a profit<B>.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Our principal executive office is
located at 2120 Colorado Avenue, #230, Santa Monica, California 90404, and our phone number (310) 444-4300.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

</div>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>The
Offering&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; text-align: justify; line-height: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%">Units
    offered by us</FONT></TD>
    <TD STYLE="width: 2%; text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="width: 69%; text-align: justify; line-height: 100%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%">Up
    to 1,538,462 units, each consisting of one share of common stock and
one-half warrant, each whole warrant exercisable for one share of common stock.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%">Separability
    of shares of common stock and warrants:</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%">The
    units will not be issued or certificated. Instead, the shares of common stock and the warrants underlying the units will be
    issued separately and may be resold separately, although they will have been purchased together in this offering.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%">Shares
    Offered:</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%"> 1,538,462
    </FONT><FONT STYLE="font: 10pt/100% Times New Roman, Times, Serif">shares of common stock are included in the units.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%">Warrants
    Offered:</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%">769,231
    </FONT> <FONT STYLE="font: 10pt/100% Times New Roman, Times, Serif">warrants are included in the units. Each whole
    warrant     will entitle the holder to purchase one share of common stock at an exercise price of
    $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per     share. The warrants shall be exercisable from the date of
    issuance, which is the closing date of this offering, and expire     on
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025. Upon exercise of the warrants, a
    holder would be entitled to receive a fractional interest in a share, we will, at our election, upon exercise, either pay
    a cash adjustment in respect of such fraction (in an amount equal to such fraction multiplied by the exercise price) or
    round     the number of shares to be received by the holder up to the next whole number.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%">Common
    stock to be outstanding after this offering</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%">[13,347,640]
    shares, assuming that the maximum offering amount is sold.</FONT> </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%">Use
    of proceeds</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%">We
    intend to use the net proceeds of this offering primarily to fund the Lead-in stage of our planned Phase 2b/3 clinical
    trial of our lead product candidate BIV201, repay bridge financing extended by our controlling stockholder and for
    working capital and other general corporate purposes.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%">Concentration
    of ownership</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%">Upon
    completion of this offering, our executive officers and directors will beneficially own, in the aggregate, approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%
    of the outstanding shares of our common stock.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 100%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%">OTCQB
    trading</FONT> <FONT STYLE="font: 10pt/100% Times New Roman, Times, Serif"> symbols</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD><P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&ldquo;BIVI&rdquo;</P>
        <P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&ldquo;BIVIW&rdquo;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%">Risk
    Factors</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%">Investing
    in our securities involves a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 5 and the other information
    in this prospectus for a discussion of the factors you should consider carefully before you decide to invest in our securities.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%">Lock-Up</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 100%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 100%">We,
    each of our officers, directors, and all of our 5% or greater stockholders have agreed, subject to certain exceptions, not
    to sell, offer, agree to sell, contract to sell, hypothecate, pledge, grant any option to purchase, make any short sale of,
    or otherwise dispose of or hedge, directly or indirectly, any shares of our capital stock or any securities convertible into
    or exercisable or exchangeable for shares of capital stock, for a period of (i) six (6) months after the date of this prospectus
    in the case of our directors and officers and (ii) three (3) months after the date of this prospectus in the case of the Company
    and any other 5% or greater holder of our outstanding securities, without the prior written consent of the placement agent.
    See &ldquo;Plan of Distribution&rdquo; for additional information. </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> All information in this prospectus assumes no exercise of the warrants included in the units,
that our controlling stockholder, Acuitas Group Holdings, LLC (&ldquo;Acuitas&rdquo;), receives an aggregate of 6,609,832 shares
of common stock upon the closing of this offering pursuant to the automatic exercise of warrants issued in connection with a bridge
financing (the "Bridge Financing") and the committed exercise of its existing purchase option, in each case as described
elsewhere herein. The total number of shares of our common stock outstanding as of March 2, 2020 was 5,199,346 and excludes 1,442,266
shares of common stock reserved for issuance pursuant to currently outstanding options and warrants. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>
</div>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Summary
Financial Information</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The following tables present
our summary consolidated financial and other data as of and for the periods indicated. The summary consolidated statements
of operations data for the fiscal years ended June 30, 2019 and June 30, 2018 are derived from our audited financial statements
included elsewhere in this prospectus. The consolidated statement of operations data for the three months ended September
30, 2019 and 2018 and the summary consolidated balance sheet data as of September 30, 2019, are derived from our unaudited consolidated
financial statements included elsewhere in this prospectus and have been prepared on the same basis as the audited consolidated
financial statements.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"></P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The summarized financial information
presented below is derived from and should be read in conjunction with our audited consolidated financial statements including
the notes to those financial statements, which are included elsewhere in this prospectus along with the section entitled &ldquo;Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations.&rdquo; Our historical results are not necessarily indicative of
our future results.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the fiscal year ended <BR> June 30:</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> For the six months ended
    <BR> December 31: </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">CONSOLIDATED STATEMENTS OF OPERATIONS DATA:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left; text-indent: -10pt; padding-left: 10pt">Operating expenses</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,496,573</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">2,372,166</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,416,665</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">992,298</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 10pt">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,496,573</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,372,166</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,416,665</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(992,298</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Total other expense (income), net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(52,286</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">40,956</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,260,476</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(51,917</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net (loss) income</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(2,444,287</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(2,413,122</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,843,811</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(940,381</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Deemed dividend</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(48,659</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(20,995</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(17,099,058</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(48,659</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net loss attributable to Company stockholders</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(2,492,946</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(2,434,117</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(14,255,247</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(989,040</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Net loss per common share, basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.98</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3.18</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3.06</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.40</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Weighted average shares outstanding, basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,539,611</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">766,065</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4,661,183</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,497,457</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>As of December 31, 2019</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><B>CONSOLIDATED BALANCE SHEET DATA:</B></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>Actual</B></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>Pro Forma</B></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>Pro Forma As Adjusted</B></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; width: 55%">Cash</TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">$</TD>
    <TD STYLE="width: 11%; text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3,108 </TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 11%; text-align: right"> 3,108 </TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">$</TD>
    <TD STYLE="vertical-align: bottom; width: 11%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom">Total current assets</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;553,918 </TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> 553,918 </TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom">Total assets</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,339,544 </TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> 2,339,544 </TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom">Total current liabilities</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;4,383,972 </TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> 1,085,177 </TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom">Total liabilities</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;4,383,972 </TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> 1,085,177 </TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom">Total stockholders&rsquo; (deficit) equity</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"> &nbsp;&nbsp;&nbsp;(2,044,428) </TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"> 1,203,433 </TD>
    <TD STYLE="vertical-align: bottom"></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The preceding table presents
a summary of our unaudited balance sheet data as of December 31, 2019: </P>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 5%; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 86%; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    an actual basis;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 5%; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 86%; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    pro-forma basis to give effect to the following transactions with our controlling stockholder Acuitas (i) the issuance
    of 4,422 shares of common stock as interest on the 10% OID Convertible Delayed Draw Debenture issued in the Bridge Financing
    (the &ldquo;Debenture&rdquo;) in January 2020, (ii) the issuance of an aggregate of 1,250,000 shares of common stock upon
    the automatic exercise of warrants issued in the Bridge Financing (the &ldquo;Bridge Financing Warrants&rdquo;), (iii)
    the issuance of an aggregate of 5,359,832 shares of common stock pursuant to a committed exercise by Acuitas of its purchase
    option granted in connection with its initial investment in the Company, and (iv) the related derivative liabilities of approximately
    $2,674,000 related to the warrants will be relieved to additional capital and approximately $573,000 related to the conversion
    option of the convertible debenture will be relieved through the statement of operations; in each case upon the closing of
    this offering; and </FONT></TD></TR>
</TABLE>

<P STYLE="font: 5pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 5%; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 86%; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    pro-forma as adjusted basis to give effect to the pro-forma adjustment above, as well as the receipt of the estimated net
    proceeds from the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; units
    in this offering at the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per unit, after deducting the placement
    agent fees and estimated expenses payable by us, and the application of a portion of such net proceeds to satisfy all amounts
    due with respect to the Debenture as of the closing date of this offering. </FONT></TD></TR>
</TABLE>
</div>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_002"></A>Risk
Factors</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><I>Any investment in our securities
involves a high degree of risk. You should carefully consider the risks described below, which we believe represent certain of
the material risks to our business, together with the information contained elsewhere in this prospectus, before you make a decision
to invest in our securities. Please note that the risks highlighted here are not the only ones that we may face. For
example, additional risks presently unknown to us or that we currently consider immaterial or unlikely to occur could also impair
our operations. If any of the following events occur or any additional risks presently unknown to us actually occur, our business,
financial condition and operating results may be materially adversely affected. In that event, the trading price of our securities
could decline and you could lose all or part of your investment.</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Risks Relating to Our Business and Industry</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>We have no products approved for commercial sale, have
never generated any revenues and may never achieve revenues or profitability, which could cause us to cease operations.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We have no products approved for commercial sale and, to
date, we have not generated any revenues. Our ability to generate revenue depends heavily on (a) successful development program
and thereafter demonstration in human clinical trials that BIV201, our product candidate, is safe and effective; (b) our ability
to seek and obtain regulatory approvals, including, without limitation, with respect to the indications we are seeking; (c) successful
commercialization of our product candidates; and (d) market acceptance of our products. There are no assurances that we will achieve
any of the forgoing objectives. Furthermore, our product candidate is in the development stage, and we have not evaluated it in
full human clinical trials. If we do not successfully develop and commercialize our product candidate we will not achieve revenues
or profitability in the foreseeable future, if at all. If we are unable to generate revenues or achieve profitability, we may be
unable to continue our operations.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>We are a development stage company with a limited operating
history, making it difficult for you to evaluate our business and your investment.&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">BioVie Inc. was incorporated on April 10, 2013. We are a
development stage biopharmaceutical company with a potential therapy that has not been fully evaluated in clinical trials, and
our operations are subject to all of the risks inherent in the establishment of a new business enterprise, including but not limited
to the absence of an operating history, the lack of commercialized products, insufficient capital, expected substantial and continual
losses for the foreseeable future, limited experience in dealing with regulatory issues, the lack of manufacturing experience and
limited marketing experience, possible reliance on third parties for the development and commercialization of our proposed products,
a competitive environment characterized by numerous, well-established and well capitalized competitors and reliance on key personnel.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Since inception, we have not established any revenues or
operations that shall provide financial stability in the long term, and there can be no assurance that we will realize our plans
on our projected timetable in order to reach sustainable or profitable operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Investors are subject to all the risks incident to the creation
and development of a new business and each Investor should be prepared to withstand a complete loss of his, her or its investment.
Furthermore, the accompanying financial statements have been prepared assuming that we will continue as a going concern. We have
not emerged from the development stage, and may be unable to raise further equity. These factors raise substantial doubt about
its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the
outcome of this uncertainty.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Because we are subject to these risks, you may have a difficult
time evaluating our business and your investment in our Company. Our ability to become profitable depends primarily on our ability
to develop drugs, to obtain approval for such drugs, and if approved, to successfully commercialize our drugs, our research and
development (&ldquo;R&amp;D&rdquo;) efforts, including the timing and cost of clinical trials; and our ability to enter into favorable
alliances with third-parties who can provide substantial capabilities in clinical development, regulatory affairs, sales, marketing
and distribution.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Even if we successfully develop and market BIV201, we may
not generate sufficient or sustainable revenue to achieve or sustain profitability, which could cause us to cease operations and
cause you to lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>
<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>If the FDA or comparable foreign regulatory authorities
approve generic versions of any of our products that receive marketing approval, or such authorities do not grant our products
appropriate periods of exclusivity before approving generic versions of our products, the sales of our products could be adversely
affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Once a new drug application (&ldquo;NDA&rdquo;) is approved,
the product covered thereby becomes a &ldquo;reference listed drug&rdquo; in the FDA&rsquo;s publication, &ldquo;Approved Drug
Products with Therapeutic Equivalence Evaluations,&rdquo; commonly known as the Orange Book. Manufacturers may seek approval of
generic versions of reference listed drugs through submission of abbreviated new drug applications (&ldquo;ANDAs&rdquo;) in the
United States. In support of an ANDA, a generic manufacturer need not conduct clinical trials. Rather, the applicant generally
must show that its product has the same active ingredient(s), dosage form, strength, route of administration and conditions of
use or labeling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug, meaning
it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring
to market than the reference listed drug and companies that produce generic products are generally able to offer them at lower
prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference
listed drug is typically lost to the generic product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The FDA may not approve an ANDA for a generic product until any
applicable period of non-patent exclusivity for the reference listed drug has expired. The United States Federal Food, Drug, and
Cosmetic Act (&ldquo;FDCA&rdquo;) provides a period of five years of non-patent exclusivity for a new drug containing a new chemical
entity (&ldquo;NCE&rdquo;). Specifically, in cases where such exclusivity has been granted, an ANDA may not be submitted to the
FDA until the expiration of five years unless the submission is accompanied by a Paragraph&nbsp;IV certification that a patent
covering the reference listed drug is either invalid or will not be infringed by the generic product, in which case the applicant
may submit its application four years following approval of the reference listed drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">While we believe that BIV201 contains active
ingredients that would be treated as NCEs by the FDA and, therefore, if approved, should be afforded five years of data exclusivity,
the FDA may disagree with that conclusion and may approve generic products after a period that is less than five years. If the
FDA were to award NCE exclusivity to someone other than us, we believe that we would still be awarded three year &ldquo;Other&rdquo;
exclusivity protection from generic competition, which is awarded when an application or supplement contains reports of new clinical
investigations (not bioavailability studies) conducted or sponsored by an applicant and essential for approval. Manufacturers
may seek to launch these generic products following the expiration of the applicable marketing exclusivity period, even if we
still have patent protection for our product. If we do not maintain patent protection and data exclusivity for our product candidates,
our business may be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Competition that our products may face
from generic versions of our products could materially and adversely impact our future revenue, profitability and cash flows and
substantially limit our ability to obtain a return on the investments we have made in those product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; background-color: white; text-align: justify"><B><I>If we fail to obtain or maintain
Orphan Drug exclusivity for BIV201, we will have to rely on our data and marketing exclusivity, if any, and on our intellectual
property rights, which may reduce the length of time that we can prevent competitors from selling generic versions of BIV201.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify">We have obtained
Orphan Drug designation for BIV201 in the U.S. for the treatment of hepatorenal syndrome (received November 21, 2018) and treatment
of ascites due to all etiologies except cancer (received September 8, 2016). Under the Orphan Drug Act, the FDA may designate a
product as an Orphan Drug if it is a drug intended to treat a rare disease or condition, defined, in part, as a patient population
of fewer than 200,000 in the U.S. In the EU, Orphan Drug designation may be granted to drugs intended to treat, diagnose or prevent
a life-threatening or chronically debilitating disease having a prevalence of no more than five in 10,000 people in the EU. The
company that first obtains FDA approval for a designated Orphan Drug for the associated rare disease receives marketing exclusivity
for use of that drug for the stated condition for a period of seven years. Orphan Drug exclusive marketing rights may be lost under
several circumstances, including a later determination by the FDA that the request for designation was materially defective or
if the manufacturer is unable to assure sufficient quantity of the drug. Similar regulations are available in the EU with a ten-year
period of market exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify">Even though
BioVie has obtained Orphan Drug designation for its lead product candidate, and intends to seek other Orphan Drug designations
for BIV201, and Orphan Drug designation for other product candidates, there is no assurance that BioVie will be the first to obtain
marketing approval for any particular rare indication. Further, even though BioVie has obtained Orphan Drug designation for its
lead product candidate, or even if BioVie obtains Orphan Drug designation for other potential product candidates, such designation
may not effectively protect BioVie from competition because different drugs can be approved for the same condition and the same
drug can be approved for different conditions and potentially used off-label in the Orphan indication. Even after an Orphan Drug
is approved, the FDA can subsequently approve the same drug for the same condition for several reasons, including, if the FDA concludes
that the later drug is safer or more effective or makes a major contribution to patient care. Orphan Drug designation neither shortens
the development time or regulatory review time of a drug, nor gives the drug any advantage in the regulatory review or approval
process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-indent: 0.25in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">In addition,
other companies have received Orphan Drug designations for terlipressin. Mallinckrodt Hospital Products IP Limited received Orphan
Drug designation in 2004 for terlipressin for the treatment of Hepatorenal Syndrome and Ferring Pharmaceuticals Inc. received Orphan
Drug designation in 1986 for terlipressin for the treatment of bleeding esophageal varices. If Mallinckrodt Hospital Products IP
Limited receives FDA approval for terlipressin for the treatment of Hepatorenal Syndrome before we do, they may obtain a competitive
advantage associated with being the first to market. Further, in connection with obtaining marketing approval for terlipressin
for the treatment of Hepatorenal Syndrome, Mallinckrodt Hospital Products IP Limited would also obtain Orphan Drug exclusivity
for terlipressin, that could prevent our approval for the same indication for seven years, although we could continue to pursue
other indications for the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: justify">If Ferring Pharmaceuticals
Inc. receives FDA approval for terlipressin for the treatment of bleeding esophageal varices, they would also obtain a competitive
advantage associated with being the first to market. In connection with obtaining marketing approval for terlipressin for the treatment
of bleeding esophageal varices, Ferring Pharmaceuticals Inc. would also obtain Orphan Drug exclusivity for terlipressin, but we
do not believe that Orphan Drug exclusivity for Ferring Pharmaceuticals Inc.&rsquo;s terlipressin product would have an adverse
effect on our ability to market BIV201, as the same drug would be approved for different indications under FDA rules, and we can
maintain Orphan Drug exclusivity for BIV201 for the different indication.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>We will need to raise substantial additional capital
in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could
have a materially adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Developing biopharmaceutical
products, including conducting pre-clinical studies and clinical trials and establishing manufacturing capabilities, requires
substantial funding. As of December 31, 2019, we had cash and cash equivalents of approximately $3,000. Although
we entered into a Securities Purchase Agreement on September 24, 2019 with our controlling stockholder regarding a bridge financing
in the form of up to $2.0 million in convertible debt and warrants, of which $886,000 has been drawn to date, additional
financing will be required to fund the research and development of our product candidates. We have not generated any product revenues,
and do not expect to generate any revenues until, and only if, we develop, and receive approval to sell our product candidates
from the FDA and other regulatory authorities for our product candidates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We do not have the resources
to complete the development and commercialization of any of our proposed product candidates. We will require additional financing
to further the clinical development of our product candidates. In the event that we cannot obtain the required financing, we will
be unable to complete the development necessary to file an NDA with the FDA for BIV201. This will delay research and development
programs, preclinical studies and clinical trials, material characterization studies, regulatory processes, the establishment
of our own laboratory or a search for third party marketing partners to market our products for us, which could have a materially
adverse effect on our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The amount of capital we may need will depend on many factors,
including the progress, timing and scope of our research and development programs, the progress, timing and scope of our preclinical
studies and clinical trials, the time and cost necessary to obtain regulatory approvals, the time and cost necessary to establish
our own marketing capabilities or to seek marketing partners, the time and cost necessary to respond to technological and market
developments, changes made or new developments in our existing collaborative, licensing and other commercial relationships, and
new collaborative, licensing and other commercial relationships that we may establish.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Until we can generate a sufficient amount of product revenue,
if ever, we expect to finance future cash needs, through public or private equity offerings, debt financings, or corporate collaboration
and licensing arrangements. Additional funds may not be available when we need them on terms that are acceptable to us, or at all.
If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research
or development programs or our commercialization efforts. In addition, we could be forced to discontinue product development and
reduce or forego attractive business opportunities. To the extent that we raise additional funds by issuing equity securities,
our stockholders may experience additional significant dilution, and debt financing, if available, may involve restrictive covenants.
To the extent that we raise additional funds through collaboration and licensing arrangements, it may be necessary to relinquish
some rights to our technologies or our product candidates, or grant licenses on terms that may not be favorable to us. We may seek
to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for
additional capital at that time.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Our fixed expenses, such as rent and other contractual commitments,
will likely increase in the future, as we may enter into leases for new facilities and capital equipment and/or enter into additional
licenses and collaborative agreements. Therefore, if we fail to raise substantial additional capital to fund these expenses, we
could be forced to cease operations, which could cause you to lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>We have limited experience in drug development and
may not be able to successfully develop any drugs, which would cause us to cease operations.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We have never successfully developed a new drug and brought
it to market. Our management and clinical teams have experience in drug development but they may not be able to successfully develop
any drugs. Our ability to achieve revenues and profitability in our business will depend on, among other things, our ability to
develop products internally or to obtain rights to them from others on favorable terms; complete laboratory testing and human studies;
obtain and maintain necessary intellectual property rights to our products;&nbsp;successfully complete regulatory review to obtain
requisite governmental agency approvals;&nbsp;enter into arrangements with third parties to manufacture our products on our behalf;
and&nbsp;enter into arrangements with third parties to provide sales and marketing functions. If we are unable to achieve these
objectives we will be forced to cease operations and you will lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>Development of pharmaceutical products is a time-consuming
process, subject to a number of factors, many of which are outside of our control. Consequently, if we are unsuccessful or fail
to timely develop new drugs, we could be forced to discontinue our operations.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Our lead product candidate, BIV201,
has been cleared by the FDA to undergo testing in a mid-stage (Phase 2a) clinical trial. On June 18, 2019, we met with representatives
of the FDA for Type C Guidance Meeting to plan our next clinical study following the recently completed Phase 2a clinical trial.
We discussed our clinical development efforts with the FDA and proposed trial endpoints. While the FDA has not provided final
guidance nor do we have certainty as to what that guidance would entail, our goal remains to proceed into a Phase 2b/3 or Phase
3 clinical trial in a manner consistent with what was reviewed with the FDA. We may still need to address certain risks associated
with yet to be validated quality of life measures and the FDA expressed concern about the inadequacy of the topline results
of our Phase 2a clinical trial and their views that an additional Phase 2 clinical trial would be advisable. In July 2019, the
FDA provided meeting minutes for the June 18, 2019 meeting that documented general agreement with the Company proposed randomized
study design. The FDA also provided its suggestions and guidance regarding primary and secondary endpoints and other key aspects
of our clinical trial design and the Company is incorporating those suggestions as it moves forward.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Further development and extensive
testing will be required to determine its technical feasibility and commercial viability. Our success will depend on our ability
to achieve scientific and technological advances and to translate such advances into reliable, commercially competitive drugs
on a timely basis. Drugs that we may develop are not likely to be commercially available, at a minimum, for a few years, if ever.
The proposed development schedules for our product candidates may be affected by a variety of factors, including technological
difficulties, proprietary technology of others, and changes in government regulation, many of which will not be within our control.
Any delay in the development, introduction or marketing of our product candidates could result either in such drugs being marketed
at a time when their cost and performance characteristics would not be competitive in the marketplace or in the shortening of
their commercial lives. In light of the long-term nature of our projects and other risk factors described elsewhere in this document,
we may not be able to successfully complete the development or marketing of any drugs which could cause us to cease operations.&nbsp;</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We may fail to successfully develop and commercialize our
product candidate(s) if it is found to be unsafe or ineffective in clinical trials; does not receive necessary approval from the
FDA or foreign regulatory agencies; fails to conform to a changing standard of care for the disease it seeks to treat; or is less
effective or more expensive than current or alternative treatment methods.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Drug development failure can occur at any stage of clinical
trials and as a result of many factors, there can be no assurance that we or our collaborators will reach our anticipated clinical
targets. Even if we or our collaborators complete our clinical trials, we do not know what the long-term effects of exposure to
our product candidates will be. Furthermore, our product candidates may be used in combination with other treatments and there
can be no assurance that such use will not lead to unique safety issues. Failure to complete clinical trials or to prove that our
product candidates are safe and effective would have a material adverse effect on our ability to generate revenue and could require
us to reduce the scope of or discontinue our operations, which could cause you to lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: justify; font: 10pt/95% Times New Roman, Times, Serif; margin: 0"> <B><I>We face business disruption and
related risks resulting from the recent outbreak of the novel coronavirus 2019 (COVID-19), which could have a material adverse
effect on our business plan.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"> The development of
our product candidates could be disrupted and materially adversely affected by the recent outbreak of COVID-19. As a result of
measures imposed by the governments in affected regions, businesses and schools have been suspended due to quarantines intended
to contain this outbreak. The spread of COVID-19 from China to other countries has resulted in the Director General of the World
Health Organization declaring the outbreak of COVID-19 as a Public Health Emergency of International Concern (PHEIC), based on
the advice of the Emergency Committee under the International Health Regulations (2005), and the Centers for Disease Control and
Prevention in the U.S. issued a warning on February 25, 2020 regarding the likely spread of COVID-19 to the U.S. While the COVID-19
outbreak is still in very early stages, international stock markets have begun to reflect the uncertainty associated with the
slow-down in the Chinese economy and the reduced levels of international travel experienced since the beginning of January and
the significant declines in the Dow Industrial Average at the end of February and beginning of March 2020 were largely attributed
to the effects of COVID-19. We are still assessing our business plans and the impact COVID-19 may have on our ability to recruit
candidates for clinical trials or to raise financing to support the development of our product candidates, but there can be no
assurance that this analysis will enable us to avoid part or all of any impact from the spread of COVID-019 or its consequences,
including downturns in business sentiment generally or in our sector in particular. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>We have no manufacturing experience, and the failure
to comply with all applicable manufacturing regulations and requirements could have a materially adverse effect on our business.&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We have never manufactured FDA
approved products in the highly regulated environment of pharmaceutical manufacturing, and our team has limited experience
in the manufacture of drug therapies. There are numerous regulations and requirements that must be maintained to obtain licensure
and permitting required prior to the commencement of manufacturing, as well as additional requirements to continue manufacturing
pharmaceutical products. We currently do not own or lease facilities that could be used to manufacture any products that might
be developed by us, and have contracted with an experienced Contract Manufacturing Organization (&ldquo;CMO&rdquo;) to perform
the manufacturing of our new product candidate BIV201. In addition, we do not have the resources at this time to acquire or lease
suitable facilities. If we or our CMO fail to comply with regulations, to obtain the necessary licenses and knowhow or to obtain
the requisite financing in order to comply with all applicable regulations and to own or lease the required facilities in order
to manufacture our products, we could be forced to cease operations, which would cause you to lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">In addition, the FDA and other regulatory authorities require
that product candidates and drug products be manufactured according to current good manufacturing practices (&ldquo;cGMP&rdquo;).
Any failure by our third-party manufacturers to comply with cGMP could lead to a shortage of BIV201. In addition, such failure
could be the basis for action by the FDA to withdraw approval, if granted to us, and for other regulatory action, including seizure,
injunction or other civil or criminal penalties.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">BIV201 and any other product candidate that we develop may
compete with other products and product candidates for access to manufacturing facilities. There are a limited number of manufacturers
that operate under cGMP regulations and that are both capable of manufacturing for us and willing to do so. If we need to find
another source of drug substance or drug product for BIV201, we may not be able to identify, or reach agreement with, commercial-scale
manufacturers on commercially reasonably terms, or at all. If we are unable to do so, we will need to develop our own commercial-scale
manufacturing capabilities, which would: impact commercialization of BIV201 in the U.S. and other countries where it may be approved;
require a capital investment by us that could be quite costly; and increase our operating expenses.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">If our existing third-party manufacturers, or the third parties
that we engage in the future to manufacture a product for commercial sale or for our clinical trials, should cease to continue
to do so for any reason, we likely would experience significant delays in obtaining sufficient quantities of product for us to
meet commercial demand or to advance our clinical trials while we identify and qualify replacement suppliers. If for any reason
we are unable to obtain adequate supplies of BIV201 or any other product candidate that we develop, or the drug substances used
to manufacture it, it will be more difficult for us to compete effectively, generate revenue, and further develop our products.
In addition, if we are unable to assure a sufficient quantity of the drug for patients with rare diseases or conditions, we may
lose any Orphan Drug exclusivity to which the product otherwise would be entitled.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>We do not currently have the sales and marketing personnel
necessary to sell products, and the failure to hire and retain such staff could have a materially adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We are an early stage development company with limited resources.
Even if we had products available for sale, which we currently do not, we have not secured sales and marketing staff at this early
stage of operations to sell products. We cannot generate sales without sales or marketing staff and must rely on officers to provide
any sales or marketing services until such personnel are secured, if ever. If we fail to hire and retain the requisite expertise
in order to market and sell our products or fail to raise sufficient capital in order to afford to pay such sales or marketing
staff, then we could be forced to cease operations and you could lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>Even if we were to successfully develop approvable
drugs, we will not be able to sell these drugs if we or our third-party manufacturers fail to comply with manufacturing regulations,
which could have a materially adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">If we were to successfully develop approvable drugs, before
we can begin selling these drugs, we must obtain regulatory approval of our manufacturing facility and process or the manufacturing
facility and process of the third party or parties with whom we may outsource our manufacturing activities. In addition, the manufacture
of our products must comply with the FDA&rsquo;s current Good Manufacturing Practices regulations, commonly known as GMP regulations.
The GMP regulations govern quality control and documentation policies and procedures. Our manufacturing facilities, if any in the
future, and the manufacturing facilities of our third-party manufacturers will be continually subject to inspection by the FDA
and other state, local and foreign regulatory authorities, before and after product approval. We cannot guarantee that we, or any
potential third-party manufacturer of our products, will be able to comply with the GMP regulations or other applicable manufacturing
regulations. The failure to comply with all necessary regulations would have a materially adverse effect on our business and could
force us to cease operations and you could lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>We must comply with significant and complex government
regulations, compliance with which may delay or prevent the commercialization of our product candidates, which could have a materially
adverse effect on our business.&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The R&amp;D, manufacture and marketing of product candidates
are subject to regulation, primarily by the FDA in the United States and by comparable authorities in other countries. These national
agencies and other federal, state, local and foreign entities regulate, among other things, R&amp;D activities (including testing
in animals and in humans) and the testing, manufacturing, handling, labeling, storage, record keeping, approval, advertising and
promotion of the product that we are developing. Noncompliance with applicable requirements can result in various adverse consequences,
including approval delays or refusals to approve drug licenses or other applications, suspension or termination of clinical investigations,
revocation of approvals previously granted, fines, criminal prosecution, recalls or seizures of products, injunctions against shipping
drugs and total or partial suspension of production and/or refusal to allow a company to enter into governmental supply contracts.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The process of obtaining FDA approval has historically been
costly and time consuming. Current FDA requirements for a new human drug or biological product to be marketed in the United States
include: (a) the successful conclusion of pre-clinical laboratory and animal tests, if appropriate, to gain preliminary information
on the product&rsquo;s safety; (b) filing with the FDA of an IND application to conduct human clinical trials for drugs or biologics;
(c) the successful completion of adequate and well-controlled human clinical investigations to establish the safety and efficacy
of the product for its recommended use; and (d) filing by a company and acceptance and approval by the FDA of a NDA for a drug
product or a biological license application (BLA) for a biological product to allow commercial distribution of the drug or biologic.
A delay in one or more of the procedural steps outlined above could be harmful to us in terms of getting our product candidates
through clinical testing and to market, which could have a materially adverse effect on our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The FDA reviews the results of the clinical trials and may
order the temporary or permanent discontinuation of clinical trials at any time if it believes the product candidate exposes clinical
subjects to an unacceptable health risk. Investigational drugs used in clinical studies must be produced in compliance with cGMP
rules pursuant to FDA regulations.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Sales outside the United States of products that we develop
will also be subject to regulatory requirements governing human clinical trials and marketing for drugs and biological products
and devices. The requirements vary widely from country to country, but typically the registration and approval process takes several
years and requires significant resources.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">If we experience delays or discontinuations of our clinical
trials by the FDA or comparable authorities in other countries, or if we fail to obtain registration or other approvals of our
products or devices then we could be forced to cease our operations and you will lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B>&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Even if we are successful in developing BIV201, our product
candidate, we have limited experience in conducting or supervising clinical trials that must be performed to obtain data to submit
in concert with applications for approval by the FDA. The regulatory process to obtain approval for drugs for commercial sale involves
numerous steps. Drugs are subjected to clinical trials that allow development of case studies to examine safety, efficacy, and
other issues to ensure that sale of drugs meets the requirements set forth by various governmental agencies, including the FDA.
In the event that our protocols do not meet standards set forth by the FDA, or that our data is not sufficient to allow such trials
to validate our drugs in the face of such examination, we might not be able to meet the requirements that allow our drugs to be
approved for sale which could have a materially adverse effect on our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>We can provide no assurance that our product candidate
will obtain regulatory approval or that the results of clinical studies will be favorable.&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The business plan we have developed
for the next twenty-four months is to complete the Phase 2 clinical development program for our lead new product candidate BIV201,
commence a pivotal Phase 3 trial required for new drug approval, and to pursue other key milestones such as additional patent
issuances and U.S. Orphan Drug designations. Due to our financial constraints, we may not have the resources necessary to complete
our application. In light of the FDA meeting minutes, we plan to proceed to larger Phase 2b/3 or Phase 3 clinical trials upon
receipt of the net proceeds of this offering. There is no guarantee the FDA will approve a Phase 2b/3 or Phase 3 trial, and
even if they do our financial constraints may prevent us from undertaking clinical trials.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>Confidentiality agreements with employees and others
may not adequately prevent disclosure of trade secrets and other proprietary information and disclosure of our trade secrets or
proprietary information could compromise any competitive advantage that we have, which could have a materially adverse effect on
our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Our success depends, in part, on our ability to protect our
proprietary rights to the technologies used in our products. We depend heavily upon confidentiality agreements with our officers,
employees, consultants and subcontractors to maintain the proprietary nature of our technology. These measures may not afford us
complete or even sufficient protection, and may not afford an adequate remedy in the event of an unauthorized disclosure of confidential
information. If we fail to protect and/or maintain our intellectual property, third parties may be able to compete more effectively
against us, we may lose our technological or competitive advantage, and/or we may incur substantial litigation costs in our attempts
to recover or restrict use of our intellectual property. In addition, others may independently develop technology similar to ours,
otherwise avoiding the confidentiality agreements, or produce patents that would materially and adversely affect our business,
prospects, financial condition and results of operations, in which event you could lose all of your investment.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>We may be unable to obtain or protect intellectual
property rights relating to our products, and we may be liable for infringing upon the intellectual property rights of others,
which could have a materially adverse effect on our business.&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Our ability to compete effectively
will depend on our ability to maintain the proprietary nature of our technologies. We cannot assure investors that we will continue
to innovate and file new patent applications, or that if filed any future patent applications will result in granted patents with
respect to the technology owned by us or licensed to us. Further, we cannot predict how long it will take for such patents to
issue, if at all. The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and
involves complex legal and factual considerations and, therefore, validity and enforceability cannot be predicted with certainty.
Patents may be challenged, deemed unenforceable, invalidated or circumvented. For example, on November 13, 2019, the Patent Trial
and Appeal Board of the United States Patent and Trademark Office (the &ldquo;PTAB&rdquo;) issued a written decision in the <I>inter
partes</I> review action that was brought by Mallinckrodt Pharmaceuticals Ireland Limited (&ldquo;Mallinckrodt&rdquo;) against
us. In that action, Mallinckrodt sought to invalidate our previously-issued patent (U.S. Pat. No. 9,655,945, &ldquo;Treatment
of Ascites&rdquo;) (the &ldquo;&rsquo;945 Patent&rdquo;). In its decision, the PTAB determined that all claims of the &lsquo;945
Patent were not patentable because they were either anticipated or obvious in light of prior art. The PTAB also denied our Motion
to Amend the claims on similar grounds. The result of the PTAB&rsquo;s decision is that the &lsquo;945 patent is no longer valid
or enforceable. When the original &lsquo;945 Patent application was filed, we simultaneously filed a continuation patent application
16/379,446 Angeli et al., and we intend to re-submit this more narrowly defined application for patent covering for the treatment
of ascites. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that
our proprietary technologies, product candidates and any future products are covered by valid and enforceable patents or are effectively
maintained as trade secrets.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Any patents we do obtain may be
challenged by re-examination or otherwise invalidated or eventually found unenforceable. Both the patent application process
and the process of managing patent disputes can be time consuming and expensive. If we were to initiate legal proceedings
against a third party to enforce a patent related to one of our products or services, the defendant in such litigation could
counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims
alleging invalidity and/or unenforceability are commonplace, as are validity challenges by the defendant against the subject
patent or other patents before the USPTO. Grounds for a validity challenge could be an alleged failure to meet any of several
statutory requirements, including lack of novelty, obviousness or non-enablement, failure to meet the written description
requirement, indefiniteness, and/or failure to claim patent eligible subject matter. Grounds for an unenforceability
assertion could be an allegation that someone connected with prosecution of the patent intentionally withheld material
information from the USPTO, or made a misleading statement, during prosecution. Additional grounds for an unenforceability
assertion include an allegation of misuse or anticompetitive use of patent rights, and an allegation of incorrect
inventorship with deceptive intent. Third parties may also raise similar claims before the USPTO even outside the context of
litigation. The outcome is unpredictable following legal assertions of invalidity and unenforceability. With respect to the
validity question, for example, we cannot be certain that no invalidating prior art existed of which we and the patent
examiner were unaware during prosecution. These assertions may also be based on information known to us or the Patent Office.
If a defendant or third party were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at
least part, and perhaps all, of the claims of the challenged patent. Such a loss of patent protection would or could have a
material adverse impact on our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The standards that the United States Patent and Trademark
Office (and foreign countries) use to grant patents are not always applied predictably or uniformly and can change. There is also
no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology
patents. Accordingly, we do not know the degree of future protection for our proprietary rights or the breadth of claims that will
be allowed in any patents issued to us or to others.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Further, we rely on a combination of trade secrets, know-how,
technology and nondisclosure, and other contractual agreements and technical measures to protect our rights in the technology.
If any trade secret, know-how or other technology not protected by a patent were to be disclosed to or independently developed
by a competitor, our business and financial condition could be materially adversely affected. The laws of some foreign countries
do not protect our proprietary rights to the same extent as the laws of the U.S., and we may encounter significant problems in
protecting our proprietary rights in these countries.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We do not believe that BIV201, the product candidate we are
currently developing, infringes upon the rights of any third parties nor are they infringed upon by third parties. However, there
can be no assurance that our technology will not be found in the future to infringe upon the rights of others or be infringed upon
by others. Moreover, patent applications are in some cases maintained in secrecy until patents are issued. The publication of discoveries
in the scientific or patent literature frequently occurs substantially later than the date on which the underlying discoveries
were made and patent applications were filed. Because patents can take many years to issue, there may be currently pending applications
of which we are unaware that may later result in issued patents that our products or product candidates infringe. For example,
pending applications may exist that provide support or can be amended to provide support for a claim that results in an issued
patent that our product infringes. In such a case, others may assert infringement claims against us, and should we be found to
infringe upon their patents, or otherwise impermissibly utilize their intellectual property, we might be forced to pay damages,
potentially including treble damages, if we are found to have willfully infringed on such parties&rsquo; patent rights. In addition to
any damages we might have to pay, we may be required to obtain licenses from the holders of this intellectual property. We may
fail to obtain any of these licenses or intellectual property rights on commercially reasonable terms. Even if we are able to obtain
a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event,
we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do
so, we may be unable to develop or commercialize the affected products, which could materially harm our business and the third
parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our
sales, an obligation on our part to pay royalties and/or other forms of compensation. Conversely, we may not always be able to
successfully pursue our claims against others that infringe upon our technology. Thus, the proprietary nature of our technology
or technology licensed by us may not provide adequate protection against competitors.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The pharmaceutical industry is characterized by extensive
litigation regarding patents and other intellectual property rights. Moreover, the cost to us of any litigation or other proceeding
relating to our patents and other intellectual property rights, even if resolved in our favor, could be substantial, and the litigation
would divert our management&rsquo;s efforts. We may not have sufficient resources to bring any such action to a successful conclusion.
Uncertainties resulting from the initiation and continuation of any litigation could limit our ability to continue our operations
and you could lose all of your investment.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>We depend upon our management and their loss or unavailability
could put us at a competitive disadvantage which could have a material adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We currently depend upon the efforts and abilities of our
executive management team of Terren Peizer, our Chief Executive Officer, Jonathan Adams, our President and Chief Operating Officer,
and Wendy Kim, our Chief Financial Officer and Corporate Secretary. Mr. Adams serves the Company full-time and Ms. Kim serves the
Company part-time. The loss or unavailability of the services of either of these individuals for any significant period of time
could have a material adverse effect on our business, prospects, financial condition and results of operations which may cause
you to lose all of your investment. We have not obtained, do not own, nor are we the beneficiary of key-person life insurance.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>We may not be able to attract and retain highly skilled
personnel, which could have a materially adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Our ability to attract and retain highly skilled personnel
is critical to our operations and expansion. We face competition for these types of personnel from other pharmaceutical companies
and more established organizations, many of which have significantly larger operations and greater financial, technical, human
and other resources than us. We may not be successful in attracting and retaining qualified personnel on a timely basis, on competitive
terms, or at all. If we are not successful in attracting and retaining these personnel, our business, prospects, financial condition
and results of operations will be materially and adversely affected.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>The biotechnology and biopharmaceutical industries
are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with enterprises
equipped with more substantial resources than us, which could cause us to curtail or cease operations.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The biotechnology and biopharmaceutical industries are characterized
by rapid technological developments and a high degree of competition based primarily on scientific and technological factors. These
factors include the availability of patent and other protection for technology and products, the ability to commercialize technological
developments and the ability to obtain government approval for testing, manufacturing and marketing.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We compete with biopharmaceutical firms in the United States,
Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to their operations.
Many biopharmaceutical companies have focused their development efforts in the human therapeutics area. Many major pharmaceutical
companies have developed or acquired internal biotechnology capabilities or made commercial arrangements with other biopharmaceutical
companies. These companies, as well as academic institutions, government agencies and private research organizations, also compete
with us in recruiting and retaining highly qualified scientific personnel and consultants. Our ability to compete successfully
with other companies in the pharmaceutical field will also depend to a considerable degree on the continuing availability of capital
to us.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Although there are not currently any therapies approved by
the FDA specifically for the treatment of ascites due to liver cirrhosis, we still face significant competitive and market risk.
Other companies, such as Mallinckrodt Inc., are developing therapies for severe complications of advanced liver cirrhosis, which
may in the future be developed for the treatment of ascites, and these therapies could compete indirectly or directly with our
product candidate. There may be other competitive development programs of which we are unaware. Even if our product candidate is
ultimately approved by the FDA, there is no guarantee that once it is on the market doctors will adopt it in favor of current ascites
treatment procedures such as diuretics and paracentesis. These competitive and market risks could have a material adverse effect
on our business, prospects, financial condition and results of operations which may cause you to lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Our competition will be determined in part by the potential
indications for which drugs are developed and ultimately approved by regulatory authorities. Additionally, the timing of the market
introduction of some of our potential product candidate or of competitors&rsquo; products may be an important competitive factor. Accordingly,
the relative speed with which we can develop drugs, complete pre-clinical testing, clinical trials, approval processes and supply
commercial quantities to market are important competitive factors. We expect that competition among drugs approved for sale will
be based on various factors, including product efficacy, safety, reliability, availability, price and patent protection.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The successful development of biopharmaceuticals is highly
uncertain. A variety of factors including, pre-clinical study results or regulatory approvals, could cause us to abandon the development
of our product candidates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>Successful development of biopharmaceuticals is highly
uncertain and is dependent on numerous factors, many of which are beyond our control. </I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Products that appear promising in the early phases of development
may fail to reach the market for several reasons. Pre-clinical study results may show the product to be less effective than desired
(e.g., the study failed to meet its primary objectives) or to have harmful or problematic side effects. Products may fail to receive
the necessary regulatory approvals or may be delayed in receiving such approvals. Among other things, such delays may be caused
by slow enrollment in clinical studies, length of time to achieve study endpoints, additional time requirements for data analysis
or a IND and later NDA, preparation, discussions with the FDA, an FDA request for additional pre-clinical or clinical data or unexpected
safety or manufacturing issues;&nbsp;manufacturing costs, pricing or reimbursement issues, or other factors that make the product
not economical. Proprietary rights of others and their competing products and technologies may also prevent the product from being
commercialized.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Success in pre-clinical and early clinical studies does not
ensure that large-scale clinical studies will be successful. Clinical results are frequently susceptible to varying interpretations
that may delay, limit or prevent regulatory approvals. The length of time necessary to complete clinical studies and to submit
an application for marketing approval for a final decision by a regulatory authority varies significantly from one product to the
next, and may be difficult to predict. There can be no assurance that any of our products will develop successfully, and the failure
to develop our products will have a materially adverse effect on our business and will cause you to lose all of your investment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>There may be conflicts of interest among our officers,
directors and stockholders. </I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Certain of our executive officers and directors and their
affiliates are engaged in other activities and have interests in other entities on their own behalf or on behalf of other persons.
Neither we nor any of our shareholders will have any rights in these ventures or their income or profits. In particular, our executive
officers or directors or their affiliates may have an economic interest in or other business relationship with partner companies
that invest in us or are engaged in competing drug development. Our executive officers or directors may have conflicting fiduciary
duties to us and third parties. The terms of transactions with third parties may not be subject to arm&rsquo;s length negotiations and
therefore may be on terms less favorable to us than those that could be procured through arm&rsquo;s length negotiations. Although we
have established an audit committee comprised solely of independent directors to oversee transactions between us and our insiders,
we do not have any formal policies in place to deal with such conflicting fiduciary duties should such a conflict arise.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;<B><I>If we fail to maintain an effective system of
internal controls, we may not be able to accurately report our financial results or detect fraud. Consequently, investors could
lose confidence in our financial reporting and this may decrease the trading price of our common stock.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We must maintain effective internal controls to provide reliable
financial reports and detect fraud. We have concluded that our disclosure controls and procedures internal controls, as well as
internal controls over financial reporting, are effective. Failure to implement changes to our internal controls or any others
that we identify as necessary to establish an effective system of internal controls could harm our operating results and cause
investors to lose confidence in our reported financial information. Any such loss of confidence would have a negative effect on
the trading price of our common stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>We may enter into employment agreements with our executive
officers and compensation payable thereunder may not be based on arms-length negotiations. </I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Certain of our current executive officers
also serve as directors of our Board of Directors, and we have not yet formed an independent compensation committee to determine
compensation and to approve employment agreements. Therefore, compensation which may be paid by us to our management under current
arrangements may not have been determined based on arms-length negotiations. We may grant stock options and other equity incentives
to our executive officers and directors that are consistent with the nature of the pharmaceutical industry. Although we have
established a compensation committee in connection with this offering comprised of only independent directors, there can be
no assurance made that the consideration which may be payable to management will reflect the true market value of services provided
to us.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>RISKS RELATING TO OUR COMMON STOCK</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> <B><I>This is a best efforts offering,
no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for
our business plans.</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> <B><I>&nbsp;</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> The placement agent has agreed to use its
reasonable best efforts to solicit offers to purchase the securities in this offering. The placement agent has no obligation to
buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities.
There is no required minimum number of securities that must be sold as a condition to completion of this offering. Because there
is no minimum offering amount required as a condition to the closing of this offering, the actual offering amount, placement agent
fees and proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth above.
We may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by
us, and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient
to pursue the business plans outlined in this prospectus. Thus, we may not raise the amount of capital we believe is required
for our business and may need to raise additional funds, which may not be available or available on terms acceptable to us. </P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>There is a risk of dilution of your percentage ownership
of common stock in the Company. </I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We have the right to raise additional
capital or incur borrowings from third parties to finance its business. We may also implement public or private mergers, business
combinations, business acquisitions and similar transactions pursuant to which it would issue substantial additional capital stock
to outside parties, causing substantial dilution in the ownership of the Company by our existing stockholders. Our Board of Directors
has the authority, without the consent of any of the stockholders, to cause us to issue more shares of common stock and/or preferred
stock at such price and on such terms and conditions as are determined by the Board of Directors in its sole discretion. As of
March 2, 2020, there were warrants outstanding to purchase an aggregate of 1,374,667 shares of common stock at exercise
prices ranging from $1.875 to $75.00 per share, excluding the Bridge Financing Warrants that will be exercised automatically upon
the closing of this offering at an exercise price equal to the par value of the common stock. The issuance of additional shares
of capital stock by us will dilute your ownership percentage in the Company and could impair our ability to raise capital in the
future through the sale of equity securities.</P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>Certain stockholders who are also officers and directors
of the Company may have significant control over our management.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Our directors and executive officers
currently own an aggregate 4,477,488 shares of our common stock, which currently constitutes 86.1% of our issued
and outstanding common stock. As a result, directors and executive officers may have a significant influence on our affairs and
management, as well as on all matters requiring member approval, including electing and removing members of our Board of Directors,
causing us to engage in transactions with affiliated entities, causing or restricting our sale or merger, and certain other matters.
Our Chairman and Chief Executive Officer, Mr. Terren Peizer, may be deemed to beneficially own the shares held by Acuitas. Such
concentration of ownership and control could have the effect of delaying, deferring or preventing a change in control of us even
when such a change of control would be in the best interests of our stockholders.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>There is not now, and there may never
be, an active, liquid and orderly trading market for our common stock or warrants, which may make it difficult for you to sell
your shares of our common stock and warrants.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">There is not now, nor has there been
since our inception, any significant volume of trading activity in our common stock or an active market for shares of our common
stock, and the warrants are a new class of securities for which there is no existing market. An active trading market for our
securities may never develop or be sustained after this offering. As a result, investors in our common stock and warrants must
bear the economic risk of holding those securities for an indefinite period of time. Although our common stock is quoted on the
OTCQB Marketplace, or OTCQB, over-the-counter quotation system, trading of our common stock on such system has only recently commenced
and continues to be extremely limited and sporadic and at very low volumes. If an active market for our securities does not
develop, it may be difficult for you to sell the securities you purchase in this offering without depressing the market price
for such securities or at all. Further, an unestablished trading market for our securities may also impair our ability to raise
capital by selling additional equity in the future, and may impair our ability to enter into strategic partnerships or acquire
companies or products by using shares of our common stock as consideration. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>We may, in the future, issue additional
common stock, which would reduce investors&rsquo; percent of ownership and may dilute our share value.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> As of March 2, 2020, our Articles of Incorporation
authorize the issuance of 800,000,000 shares of common stock. As of March 2, 2020, we had 5,199,346 shares of common stock outstanding.
Accordingly, we may issue up to an additional 793,357,588 shares of common stock. The future issuance of common stock may
result in substantial dilution in the percentage of our common stock held by our then existing shareholders. We may value any
common stock in the future on an arbitrary basis. The issuance of common stock for future services or acquisitions or other corporate
actions may have the effect of diluting the value of the shares held by our investors, might have an adverse effect on any trading
market for our common stock and could impair our ability to raise capital in the future through the sale of equity securities.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>We have a large number of restricted shares outstanding,
a portion of which may be sold under Rule 144 which may reduce the market price of our shares.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Of the 5,199,346 shares of common stock
issued and outstanding as of March 2, 2020, 721,858 shares are held by non-affiliates and 4,477,488 are owned by affiliates of
the Company, consisting of our officers and directors or entities controlled by them. The majority of our common stock, including
all of the affiliates&rsquo; securities are deemed &ldquo;restricted securities&rdquo; within the meaning of Rule 144 as promulgated
under the Securities Act.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">It is anticipated that all of the &ldquo;restricted securities&rdquo;
will be eligible for resale under Rule 144. In general, under Rule 144, subject to the satisfaction of certain other conditions,
a person, who is not an affiliate (and who has not been an affiliate for a period of at least three months immediately preceding
the sale) and who has beneficially owned restricted shares of our common stock for at least six months is permitted to sell such
shares without restriction, provided that there is sufficient public information about us as contemplated by Rule 144. An affiliate
who has beneficially owned restricted shares of our common stock for a period of at least one year may sell a number of shares
equal to one percent of our issued and outstanding common stock approximately every three months.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The respective holding periods for certain shares issued to affiliates and non-affiliates holding restricted securities commenced and were issued between
May 17, 2013 and June 30, 2013. The possibility that substantial amounts of our common stock may be sold under Rule 144 into the
public market may adversely affect prevailing market prices for the common stock and could impair our ability to raise capital
in the future through the sale of equity securities.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>
Any failure to maintain effective internal control over financial reporting could harm us. </I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Our management is responsible for establishing and maintaining
adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance
with U.S. generally accepted accounting principles (&ldquo;GAAP&rdquo;). Under standards established
by the Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;), a deficiency in internal control over financial reporting
exists when the design or operation of a control does not allow management or personnel, in the normal course of performing their
assigned functions, to prevent or detect misstatements on a timely basis. The PCAOB defines a material weakness as a deficiency,
or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that
a material misstatement of annual or interim financial statements will not be prevented, or detected and corrected, on a timely
basis.</P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">If we are unable to assert that our internal control over
financial reporting is effective, or when required in the future, if our independent registered public accounting firm is unable
to express an unqualified opinion as to the effectiveness of our internal control over financial reporting, investors may lose
confidence in the accuracy and completeness of our financial reports, the market price of our common stock could be adversely affected
and we could become subject to litigation or investigations by the stock exchange on which our securities are listed, the SEC or
other regulatory authorities, which could require additional financial and management resources.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>The lack of public company experience of our management
team could adversely impact our ability to comply with the reporting requirements of U.S. securities laws, which could have a materially
adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Our officers have limited public company experience, which
could impair our ability to comply with legal and regulatory requirements such as those imposed by Sarbanes-Oxley Act of 2002.
Such responsibilities include complying with federal securities laws and making required disclosures on a timely basis. Any such
deficiencies, weaknesses or lack of compliance could have a materially adverse effect on our ability to comply with the reporting
requirements of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), which is necessary to maintain
our public company status. If we were to fail to fulfill those obligations, our ability to continue as a U.S. public company would
be in jeopardy in which event you could lose your entire investment in our Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>We are considered a smaller reporting company and is
exempt from certain disclosure requirements, which could make our stock less attractive to potential investors.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Rule 12b-2 of the Exchange Act defines a &ldquo;smaller reporting
company&rdquo; as an issuer that is not an investment company, an asset-backed issuer, or a majority-owned subsidiary of a parent
that is not a smaller reporting company and that:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Had a public float of less than $250 million as of the last business day of its most recently completed fiscal quarter, computed by multiplying the aggregate number of worldwide number of shares of its voting and non-voting common equity held by non-affiliates by the price at which the common equity was last sold, or the average of the bid and asked prices of common equity, in the principle market for the common equity; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the case of an initial registration statement under the Securities Act or the Exchange Act for shares of its common equity, had a public float of less than $250 million as of a date within 30 days of the date of the filing of the registration statement, computed by multiplying the aggregate worldwide number of such shares held by non-affiliates before the registration plus, in the case of a Securities Act registration statement, the number of such shares included in the registration statement by the estimated public offering price of the shares; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: justify">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">In the case of an issuer who had annual revenue of less than
        $100 million during the most recently completed fiscal year for which audit financial statements are available, had a public float
        as calculated under paragraph (1) or (2) of this definition that was either zero or less than $700 million.</P>
        </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">As a &ldquo;smaller reporting
company&rdquo; we are not required and may not include a Compensation Discussion and Analysis (&ldquo;CD&amp;A&rdquo;)
section in our proxy statements; we provide only 3 years of business development information; provide fewer years of selected
data; and have other &ldquo;scaled&rdquo; disclosure requirements that are less comprehensive than issuers that are not
&ldquo;smaller reporting companies&rdquo; which could make our stock less attractive to potential investors, which could make
it more difficult for you to sell your shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>We have not held regular annual meetings of stockholders
in the past, and if we are required by the Nevada District Court to hold an annual meeting pursuant to Nevada Revised Statutes
&sect;78.345(1), it could result in the unanticipated expenditure of funds, time and other Company resources.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Section 1 of Article II of our bylaws provides that an annual
meeting of stockholders shall be held each year on a date and at a time designated by our Board of Directors. Section 78.345(1)
of the Nevada Revised Statutes provides that if there is a failure to hold the annual meeting for a period of 18 months after the
last election of directors, stockholders owning at least 15% of the voting power of the outstanding common stock may apply to the
Nevada district court to order the election of directors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>
<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We have not held regular annual meetings
of stockholders in the past because a substantial majority of our stock is owned by a small number of stockholders, making it
easy to obtain written consent in lieu of a meeting when necessary. In light of our historical liquidity constraints, handling
matters by written consent has allowed us to save on financial and administrative resources required to prepare for and hold such
annual meetings. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">To our knowledge, no stockholder or director has requested
our management to hold such an annual meeting and no stockholder or director has applied to the Nevada district court seeking an
order directing us to hold a meeting of stockholders. However, if one or more stockholders or directors were to apply to the Nevada
district court seeking such an order, and if the Nevada district court were to order an annual meeting before we were prepared
to hold one, the preparation for the annual meeting of stockholders and the meeting itself could result in the unanticipated expenditure
of funds, time, and other Company resources.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>We are subject to the periodic reporting requirements
of the Exchange Act, which require us to incur audit fees and legal fees in connection with the preparation of such reports. These
additional costs will negatively affect our ability to earn a profit.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We are required to file periodic reports with the SEC pursuant
to the Exchange Act and the rules and regulations thereunder. In order to comply with such requirements, our independent registered
auditors have to review our financial statements on a quarterly basis and audit our financial statements on&nbsp;an annual basis.
Moreover, our legal counsel has to review and assist in the preparation of such reports. Factors such as the number and type of
transactions that we engage in and the complexity of our reports cannot accurately be determined at this time and may have a major
negative effect on the cost and amount of time to be spent by our auditors and attorneys. However, the incurrence of such costs
is an expense to our operations and thus has a negative effect on our ability to meet our overhead requirements and earn a profit.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>Because we do not intend to pay any cash dividends
on our common stock, our stockholders will not be able to receive a return on their shares unless they sell them.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We intend to retain any future earnings to finance the development
and expansion of our business. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. Unless
we pay dividends, our stockholders will not be able to receive a return on their shares unless they sell them. There is no assurance
that stockholders will be able to sell shares when desired.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0"><B><I>Holders of our
warrants will have no rights as a common stockholder until they acquire our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">Until you acquire shares of our common
stock upon exercise of your warrants, you will have no rights with respect to shares of our common stock issuable upon exercise
of your warrants. Upon exercise of your warrants, you will be entitled to exercise the rights of a common stockholder only as
to matters for which the record date occurs after the exercise date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0"><B><I>The warrants
may not have any value.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">Each warrant will have an exercise price
of $&#8199;&#8199;&#8199;&#8199; (125% of the offering price) and will expire on the fifth anniversary of the date they first
become exercisable. In the event our common stock price does not exceed the exercise price of the warrants during the period when
the warrants are exercisable, the warrants may not have any value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_003"></A>Cautionary
Note Regarding Forward-Looking Statements&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">This prospectus contains &ldquo;forward-looking
statements&rdquo; within the meaning of the federal securities laws, and that involve significant risks and uncertainties. We intend
the forward-looking statements to be covered by the safe harbor for forward-looking statements in these sections. Words such as
&ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo;
&ldquo;continue,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;future,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo;
&ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; and similar expressions, as well as statements in future tense, identify forward-looking
statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate
indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when
those statements are made or management&rsquo;s good faith belief as of that time with respect to future events, and are subject
to significant risks and uncertainties that could cause actual performance or results to differ materially from those expressed
in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited
to:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; text-indent: 0.5in">- our limited operating
history and experience in developing and manufacturing drugs;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; text-indent: 0.5in">- none of our products
are approved for commercial sale;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; text-indent: 0.5in">- our substantial
capital needs;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; text-indent: 0.5in">- product development
risks;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; text-indent: 0.5in">- we do not have
sales and marketing personnel;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; text-indent: 0.5in">- regulatory, competitive
and contractual risks;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; text-indent: 0.5in">- risks related
to our intellectual property rights;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; text-indent: 0.5in">- the absence of
liquidity in our common stock;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; text-indent: 0.5in">- the risk of substantial
dilution from future issuances of our equity securities; and</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; text-indent: 0.5in">- the other risks
set forth herein under the caption &ldquo;Risk Factors.&rdquo;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The foregoing does not represent an
exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced
with. Forward-looking statements necessarily involve risks and uncertainties, and our actual results could differ materially from
those anticipated in the forward-looking statements due to a number of factors, including those set forth above under &ldquo;Risk
Factors&rdquo; and elsewhere in this prospectus. The factors set forth above under &ldquo;Risk Factors&rdquo; and other cautionary
statements made in this prospectus should be read and understood as being applicable to all related forward-looking statements
wherever they appear in this prospectus. The forward-looking statements contained in this prospectus represent our judgment as
of the date of this prospectus. We caution readers not to place undue reliance on such statements. Except as required by law, we
undertake no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available
or other events occur in the future. All subsequent written and oral forward-looking statements attributable to us or persons acting
on our behalf are expressly qualified in their entirety by the cautionary statements contained above and throughout this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_004"></A>Use
of Proceeds</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We estimate that the net proceeds from
the sale of the units we are offering will be approximately $911,000, assuming
all of the securities offered hereby are sold. However, because this is a best efforts offering and there is no minimum offering
amount required as a condition to the closing of this offering, the actual offering amount, placement agent fees and net proceeds
to us are not presently determinable and may be substantially less than the maximum amounts set forth on the cover page of this
prospectus. &ldquo;Net proceeds&rdquo; is what we expect to receive after deducting the placement agent fees and estimated
offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We intend to use the net proceeds of
this offering primarily to fund the Lead-in stage of our planned Phase 2b/3 fund clinical trial of BIV201 and for working capital
and other general corporate purposes, including the mandatory repayment of all accrued principal and interest under the Debenture
upon the closing of this offering, estimated to be approximately $910,000 if this offering is consummated prior to March 31, 2020.
The amounts that we actually spend for any specific purpose may vary significantly, and will depend on a number of factors
including, but not limited to, the pace of progress of our research and development, market conditions, and our ability to qualify
vendors. In addition, we may use a portion of any net proceeds to acquire complementary compounds; however, we do not have plans
for any acquisitions at this time. We will have significant discretion in the use of any net proceeds. Investors will be relying
on the judgment of our management regarding the application of the proceeds of any sale of the units.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><A NAME="a_005"></A><FONT STYLE="text-transform: uppercase"><B>Dividend
Policy</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We have never declared or paid any cash
dividends on our common stock and we do not anticipate paying any cash dividends in the foreseeable future. The payment of dividends,
if any, in the future is within the discretion of our Board of Directors and will depend on our earnings, capital requirements
and financial condition and other relevant facts. We currently intend to retain all future earnings, if any, to finance the development
and growth of our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_006"></A>Capitalization</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The following table sets forth
our cash and capitalization as of December 31, 2019: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on an actual basis; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"> on a pro-forma basis to give effect to the following transactions with
    our controlling stockholder Acuitas: (i) the issuance of 4,422 shares of common stock as interest on the Debenture issued
    in the Bridge Financing in January 2020, (ii) the automatic exercise of the Bridge Financing Warrants upon the closing of
    this offering and the issuance of an aggregate of 5,359,832 shares of common stock upon the closing of this offering pursuant
    to a committed exercise by Acuitas of its purchase option granted in connection with its initial investment in the Company
    and (iii) the related derivative liabilities of approximately $2,674,000 related to the warrants will be relieved to additional
    capital and approximately $573,000 related to the conversion option of the convertible debenture will be relieved through
    the statement of operations; and </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    a pro forma as adjusted basis to give effect to the pro-forma adjustment above, as well as the sale of units in this offering,
    assuming an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per unit, after deducting estimated
    placement agent fees and estimated offering expenses payable by us, and the application of a portion of such net proceeds
    to satisfy all amounts due with respect to the Debenture as of the closing date of this offering.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">You should read the information in this
table together with our financial statements and accompanying notes and &ldquo;Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations&rdquo; appearing elsewhere in this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">As
    of December 31, 2019</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Actual</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Pro Forma As Adjusted</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt">Cash</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: right"> 3,108 </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 11%; text-align: right"> 3,108 </TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt">Stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 0.25in">Common stock,
    $0.0001 par value per share, 800,000,000 shares authorized; 5,183,724, and 11,793,273 and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    shares issued and outstanding actual, pro forma and pro forma as adjusted, respectively</TD>
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 518 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 1,179 </TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 0.25in">Additional paid in capital</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 19,472,373 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 22,146,373 </TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 0.25in">Accumulated deficit</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (21,517,319) </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (20,944,119 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Total
    stockholders&rsquo; (deficit) equity </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"> (2,044,428 </TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,203,443 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_007"></A>Dilution</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">If you purchase units in this offering,
your interest will be diluted immediately to the extent of the difference between the assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
unit and the pro forma as adjusted net tangible book value per share of our common stock immediately upon the consummation of
this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The pro forma net tangible <FONT STYLE="font-size: 10pt">book
value of our common stock as of December 31, 2019 was $_____, or $0.01 per share. Pro forma net tangible book value per
share of our common stock represents our total tangible assets (total assets less intangible assets) less total liabilities divided
by the number of shares of common stock outstanding as of that date, after giving pro-forma effect to the automatic exercise of
the Bridge Financing Warrants and the committed exercise of Acuitas&rsquo; purchase option upon the closing of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Net tangible book value dilution per
share to new investors represents the difference between the amount per share paid by purchasers in this offering and the pro
forma as adjusted net tangible book value per share of common stock immediately after completion of this offering. After giving
effect to our sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock as part of the units sold in this
offering at an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per unit, and after deducting
placement agent fees and estimated offering expenses, our pro forma as adjusted net tangible book value as of December
31, 2019 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share. This represents an immediate increase in net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share to existing stockholders and an immediate dilution in net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share to purchasers of units in this offering, as illustrated in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 78%; padding-left: 10pt; text-align: justify; line-height: 100%; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Assumed
    public offering price per unit</FONT></TD>
    <TD STYLE="width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 106%">&nbsp;</TD>
    <TD STYLE="width: 1%; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; line-height: 106%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-align: justify; line-height: 106%; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Pro
    forma net tangible book value per share as of December 31, 2019 </FONT></TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">0.01</FONT></TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-align: justify; line-height: 106%; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Increase
    in net tangible book value per share attributable to new investors</FONT></TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-align: justify; line-height: 106%; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Pro
    forma adjusted net tangible book value per share as of December 31, 2019, after giving effect to the offering</FONT></TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-align: justify; line-height: 106%; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Dilution
    per share to new investors in the offering</FONT></TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">$</FONT></TD>
    <TD STYLE="text-align: right; line-height: 106%">&nbsp;</TD>
    <TD STYLE="line-height: 106%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The pro forma number of shares
of common stock to be outstanding after this offering is based on 5,183,724 shares of common stock outstanding as of December
31, 2019 and giving pro-forma effect to the automatic exercise of the Bridge Financing Warrants and the issuance of an aggregate
of 5,359,832 shares of common stock pursuant to the committed exercise of Acuitas&rsquo; purchase option upon the closing of this
offering, which does not include:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 3%; line-height: 107%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 94%; line-height: 107%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60,400
    </FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">shares of common stock issuable upon the exercise of outstanding
    stock options as of March 2, 2020, at a weighted average exercise price of $11.62 per share; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 3%; line-height: 107%; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 94%; line-height: 107%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,374,667
    </FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">shares of common stock issuable upon the exercise of outstanding
    and exercisable warrants as of March 2, 2020 (other than the Bridge Financing Warrants), at a weighted average exercise
    price of $9.70 per share.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">To the extent that outstanding exercisable options or warrants
are exercised, you may experience further dilution. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> Given that there is no minimum offering
size, it is possible that we will receive significantly less proceeds than the expected proceeds of $5,000,000. In addition,
we may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient
funds for our current or future operating plans. To the extent that we raise additional capital by issuing equity securities or
convertible debt, your ownership will be further diluted.</P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_008"></A>Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">&nbsp;<I>The following discussion of the Company&rsquo;s
financial condition and the results of operations should be read in conjunction with the Financial Statements and Notes thereto
appearing elsewhere in this prospectus.</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We are a clinical stage biotechnology
company engaged in the discovery, development and commercialization of therapies targeting life-threatening complications of liver
cirrhosis. Our initial disease target is ascites, a serious medical condition affecting about 100,000 Americans and many times
more worldwide. Our therapeutic product candidate BIV201 is based on a drug that is approved in about 40 countries to treat related
complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the US. The active agent
in BIV201, terlipressin, is a potent vasoconstrictor which is in use for various medical conditions around the world. The goal
is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">BioVie accomplished the following
key milestones during the twelve months ended December 31, 2019: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2018, we completed an equity investment with Acuitas and other investors that provided gross proceeds of $3.2 million to BioVie.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2018, the Company announced that BIV201 had been granted an Orphan Drug designation for hepatorenal syndrome.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2019, we completed patient enrollment in our mid-stage (Phase 2a) clinical trial of BIV201 for the treatment of refractory ascites.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    April 2019, we announced top-line results for the Phase 2a clinical trial of BIV201 in six patients.</FONT></TD></TR>


</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    June 18, 2019, we met with representatives of the U.S. Food &amp; Drug Administration (&ldquo;FDA&rdquo;) for a Type C
    Guidance     Meeting to plan our next clinical study following the recently completed Phase 2a clinical trial. We discussed our clinical development efforts with the FDA and proposed trial endpoints. While the FDA has
not provided final guidance nor do we have certainty as to what that guidance would entail, our goal remains to proceed into a
Phase 2b/3 or Phase 3 clinical trial in a manner consistent with what was reviewed with the FDA. We may still need to address certain
risks associated with unvalidated quality of life measures. In July 2019, the FDA provided its meeting minutes for the June 18,
2019 meeting that documented general agreement with the Company proposed randomized study design. The FDA also provided its suggestions
and guidance regarding primary and secondary endpoints and other key aspects of our clinical trial design and the Company is incorporating
those suggestions as it moves forward.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    August 2019, we developed a proprietary novel liquid formulation of terlipressin that is intended to improve convenience for
    outpatient administration and avoid potential formulation errors when pharmacists reconstitute the powder version.</FONT></TD></TR>
    </table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 7px"> &nbsp; </TD>
    <TD STYLE="text-align: justify; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    October 2019, we submitted a Phase 2b/3 randomized, controlled clinical trial protocol to the FDA incorporating the suggestions
    received from the FDA in the Type C Guidance Meeting.</FONT> </TD></TR>
    </table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2019, we announced that the first batch of pre-filled
    syringes containing this liquid formulation had been manufactured and cleared quality control testing.</font></TD></TR>
    </table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <B>Comparison of the six months ended December 31, 2019 to the
six months ended December 31, 2018</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <B><I>Net income (loss)</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The net income for the six months ended
December 31, 2019 was $2.8 million as compared to a net loss of $940,000 for the six months ended December 31, 2018. The increase
in net income of $3.8 million was due to a decrease in fair value of derivative liabilities of $7.8 million offset by an increase
in operating expenses of $424,000 and increase in interest expense of $3.5 million related to the embedded derivative liability
warrants. The change in the fair value of derivative liabilities was due to a decrease in the Company&rsquo;s stock price. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> Total operating expenses for the
six months ended December 31, 2019 were approximately $1.4 million compared to $992,000 for the six months ended December 31,
2018.&nbsp;&nbsp;The net increase of approximately $424,000 was primarily due to activities related to the Phase 2a clinical trials
wrap up and preparation of the protocols for the Phase 2b/3 trials during the six months ended December 31, 2019 and an increase
in selling, general and administrative expenses. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <B><I>Research and Development Expenses</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> Research and development expenses
were approximately $688,000 for the six months ended December 31, 2019, an increase of $287,000, from $401,000 for the six months
ended December 31, 2018. The increase was primarily attributed to the wrapping up of the phase 2a clinical trials and readying
for the next phase of trials including the preparing the protocols and manufacturing of the prefilled syringe which may be used
in the next phase of trials subject to FDA clearance. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <B><I>Selling, General and Administrative Expenses</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> Selling, general and administrative
expenses were approximately $614,000 for the six months ended December 31, 2019, a net increase of approximately $137,000, from
$477,000 for the six months ended December 31, 2018. The net increase was primarily attributed to an increase in the insurance
premiums of approximately $88,000 for increased coverage, increased payroll of approximately $30,000 due the hiring of a half
time chief financial officer that joined in October 2018 and other expenses of approximately $19,000 related to activities of
the Company&rsquo;s capital raise and up listing to the Nasdaq. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><B>Comparison of the Year Ended
June 30, 2019 to the Year Ended June 30, 2018</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Summary of Operating Expenses</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Total operating expenses
for fiscal year ended June 30, 2019 were $2,497,000 compared to $2,372,000 for the year ended June 30, 2018.&nbsp;&nbsp;The net increase of $125,000
was primarily due to an increase in research and development expenses of $637,000 as the Company resumed and completed its Phase
2a clinical trial program during the year and hired 1 full time employee and 1 half time employee in November 2018, who were previously
consultants; offset by a reduction in selling, general and administrative expenses of $512,000 which represented the issuance of
common stock in August 2017 and January 2018 as compensation for professional services.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Research and Development</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Research and development
expenses for the year ended June 30, 2019 increased by $637,000 to $1,008,000 from $371,000 for fiscal year ended June 30, 2018. The increase
was primary attributed to the Phase 2a clinical trial activities which began and was completed during the year and the hiring of
1 full time and 1 half time employee in November 2018, who were previously consultants.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Selling, General and Administrative</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Selling, general and administrative expenses declined
by $513,000 to $1,259,000 for the fiscal year ended June 30, 2019 compared to $1,772,000 for the fiscal year
ended June 30, 2018. The reduction in expense was primarily related to compensation paid in BioVie common stock during the fiscal
year ended June 30, 2018 related to financial and strategic advisory services provided of approximately $642,000 which did not
occur during fiscal year ended June 30, 2019.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <B>Capital Resources and Liquidity</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> At December 31, 2019 the Company
had approximately $3,000 in cash and had completed its Phase 2a clinical trial of the BIV201 therapy. On September 24, 2019, the
Company entered into a Securities Purchase Agreement with its controlling stockholder regarding bridge financing (the "Bridge
Financing") in the form of up to $2.0 million in convertible debt and warrants, of which $886,000 has been drawn to date. Amounts
borrowed under the Bridge Financing must be repaid with the proceeds of our potential public offering of equity securities referred
to below. The availability of additional draws under the Bridge Financing is under discussion with Acuitas in light of delays
in the timing of this potential public offering. As further discussed below, the Company is pursuing various options to raise further
financing to continue the testing and development of its product. If the Company is not successful in raising additional funds
it may reduce its monthly spend and potentially delay the implementation of the larger scale Phase 2b Clinical trial until sufficient
funding is secured. On January 3, 2020, Acuitas provided the Company a short-term interest free advance of $20,000. The short-term
advance along with the $30,000 advances in December 2019 were rolled into the partial draw number 2 of $250,000 received on January
14, 2020. Subsequent partial draws number 2 also included $66,000 advanced on February 25, 2020 and $20,000 on March 9, 2020, totaling $386,000 for draw number 2 to date. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> As of December 31, 2019, the Company
had an accumulated deficit of approximately $21.5 million and as a development stage enterprise, the Company expects substantial
losses in future periods. The accompanying interim financial statements were prepared assuming the Company will continue as a
going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.
The Company's future operations are dependent on the success of the Company's ongoing development and commercialization effort,
as well as continuing to secure additional financing. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We cannot assure you that our drug
candidate will be developed, work, or receive regulatory approval; that we will ever earn revenues sufficient to support our operations
or that we will ever be profitable. Furthermore, since we have no committed source of sufficient financing, we cannot assure you
that we will be able to raise money as and when we need it to continue our operations. If we cannot raise funds as and when we
need them, we may be required to severely curtail, or even to cease, our operations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> Additionally, in April 2019, to
facilitate our planned up listing to the NASDAQ Stock Market and related potential future issuances and sales of our equity securities
for ordinary corporate finance and general corporate purposes and as recommended by our Board of Directors (&ldquo;Board&rdquo;),
our stockholders approved an amendment to our Articles of Incorporation to effect a reverse split of our outstanding Class A common
stock in the range of 50:1 to 200:1, as determined by our Board. On November 22, 2019, the Company effected a reverse stock split
of 125 common stock for every 1 common stock. All share amounts have been updated to reflect the reverse stock split. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> Management intends to attempt to
secure additional required funding primarily through additional equity or debt financings.&nbsp;&nbsp;We may also seek to secure
required funding through sales or out-licensing of intellectual property assets, seeking partnerships with other pharmaceutical
companies or third parties to co-develop and fund research and development efforts, or similar transactions.&nbsp;&nbsp;However,
there can be no assurance that we will be able to obtain required funding.&nbsp;&nbsp;If we are unsuccessful in securing funding
from any of these sources, we will defer, reduce or eliminate certain planned expenditures in our research protocols.&nbsp;&nbsp;If
we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection or other alternatives
that could result in our stockholders losing some or all of their investment in us. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> These circumstances raise substantial
doubt on our ability to continue as a going concern. These financial statements do not include any adjustments relating to the
recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from
this uncertainty.&nbsp; </P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> The Company has no off-balance sheet
arrangements that have or are reasonably likely to have a current or future effect or change on the Company&rsquo;s financial
condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material
to investors. The term &ldquo;off-balance sheet arrangement&rdquo; generally means any transaction, agreement or other contractual
arrangement to which an entity unconsolidated with the Company is a party, under which the Company has (i) any obligation arising
under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred
to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.&nbsp; </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Critical Accounting Policies and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;<I>&nbsp;</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"> For the six-month period ended December
31, 2019, there were no significant changes to the Company&rsquo;s critical accounting policies as identified in the Annual Report
Form 10-K for the fiscal year ended June 30, 2019. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> <B>New Accounting Pronouncements</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> The Company considered the applicability
and impact of recent accounting pronouncements and determined those to be either not applicable or expected to have minimal impact
on our balance sheets or statement of operations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B><A NAME="a_009"></A>BUSINESS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">We are a clinical-stage company
pursuing the discovery, development, and commercialization of innovative drug therapies. We are currently focused on developing
and commercializing BIV201, a novel approach to the treatment of ascites due to chronic liver cirrhosis. Our therapy BIV201 is
based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis (part of the same disease
pathway as ascites), but not yet available in the United States and has never been approved in the United States. BIV201&rsquo;s
active agent is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension in studies around the world. The
goal is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites
patients.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In April 2017, we entered into
a CRADA with the McGuire Research Institute Inc. in Richmond, VA, and began administering BIV201 to patients in September 2017.
In April 2019, we announced top-line results for our Phase 2a clinical trial of BIV201 (continuous infusion terlipressin) in six
patients with refractory ascites due to advanced liver cirrhosis. The following results were observed:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt/normal Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="padding-bottom: 5pt; font: 10pt/normal Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuous
    infusion of terlipressin via portable infusion pump was maintained for 28 days in three patients with refractory ascites,
    and all patients remained hemodynamically stable during treatment.</FONT></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt/normal Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="padding-bottom: 5pt; font: 10pt/normal Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    steady state plasma concentration data characterized terlipressin pharmacokinetics (PK) within the predicted PK model concentrations.</FONT></TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt/normal Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="padding-bottom: 10pt; font: 10pt/normal Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Four
    of the six patients treated with BIV201 experienced an increase in the number of days between paracenteses ranging from 71%
    to 414% compared to prior to initiating therapy.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On June 18, 2019, we met with representatives
of the U.S. Food &amp;Drug Administration ("FDA") for a Type C Guidance Meeting to plan our next clinical study following
the recently completed Phase 2a clinical trial. We discussed our clinical development efforts with the FDA and proposed safety
and efficacy endpoints for our next clinical trial. In July 2019, the FDA provided its meeting minutes for this meeting that documented
general agreement with the Company's proposed randomized clinical study design. The FDA also provided its suggestions and guidance regarding primary and secondary endpoints and other key
aspects of our clinical trial design including appropriate quality of life measures. On October 1, 2019, the Company submitted
a Phase 2b/3 randomized, controlled clinical trial protocol to the FDA incorporating these suggestions. If this trial demonstrates
significant improvement on various measures of patient health status, we believe it could potentially form the basis to submit
a new drug application (NDA) for the eventual marketing of BIV201 in the US. While the FDA has not provided final guidance nor
do we have certainty as to what that guidance would entail, our goal remains to commence the planned Phase 2b/3 trial in the next
several months in a manner consistent with what was reviewed with the FDA. We may still need to address certain risks associated
with yet to be validated quality of life measures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In September 2019, the Company manufactured
the first batch of a novel patent-pending liquid formulation of terlipressin for use in the Phase 2b/3 trial subject to FDA clearance.
This new product format is intended to improve convenience for outpatient administration and avoid potential formulation errors
when pharmacists reconstitute the powder version. In November 2019, the Company announced that the first batch of pre-filled
syringes containing this liquid formulation had been manufactured and cleared quality control testing.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">BIV201 has the potential to
improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis,
NASH, and alcoholism. It is covered by a pending patent application, has FDA Fast-Track status and we have obtained Orphan
Drug designation for it in the U.S. for the treatment of hepatorenal syndrome (received November 21, 2018) and treatment of ascites
due to all etiologies except cancer (received September 8, 2016). Orphan Drug designation for the most common of these complications,
ascites, which represents a significant unmet medical need. The FDA has never approved any drug specifically for treating ascites.
BIV201 also has an Orphan Drug designation for HRS.</P>






<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

    <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The BIV201 development
    program     began at LAT Pharma LLC. On April 11, 2016, we acquired LAT Pharma LLC and the rights to its BIV201 development
    program and     currently own all development and marketing rights to the product candidate. We and PharmaIN, LAT
    Pharma&rsquo;s former partner     focused on the development of new modified product candidates in the same therapeutic field
    but not including BIV201, have     agreed to pay royalties equal to less than 1% of future net sales of each company&rsquo;s
    ascites drug development programs,     or if such program is licensed to a third party, less than 5% of each company&rsquo;s
    net license revenues. On December 24,     2018, we returned our partial ownership rights to the PharmaIN modified
    terlipressin development program and simultaneously     paid the remaining balance due on a related debt. PharmaIN&rsquo;s
    rights to our program remain unchanged. We have a U.S. pending     patent application for the use of BIV201 for the
    treatment of patients diagnosed with ascites due to liver cirrhosis in the     outpatient setting using ambulatory pump
    infusion, and have corresponding patent applications pending in Japan,     Europe, China and Hong Kong.</P>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B>About Ascites and Liver Cirrhosis</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">About 600,000 Americans and millions
worldwide suffer from liver cirrhosis. Cirrhosis is the 8th leading cause of death due to disease in the US, killing more than
30,000 people each year. The condition results primarily from hepatitis, alcoholism, and fatty liver disease linked to obesity.
Ascites is a common complication of advanced liver cirrhosis, involving kidney dysfunction and the accumulation of large amounts
of fluid in the abdominal cavity.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B>The Need for an Ascites Therapy</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">With no medications approved by
the FDA specifically for treating ascites, an estimated 40% of patients die within two years of diagnosis. Certain drugs approved
for other uses such as diuretics may provide initial relief, but patients may fail to respond to treatment as ascites worsens.
This represents a critical unmet medical need. U.S. treatment costs for liver cirrhosis, including ascites and other complications,
are estimated at more than $4 billion annually.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B>The Ascites Development Pathway</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 510px; width: 624px"></P>





<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">Most
experts agree that ascites develops through a sequence of events illustrated by the above diagram. High blood pressure in the vein
that supplies blood to the liver, called &ldquo;portal hypertension,&rdquo; occurs as increasing liver damage (fibrosis) impedes
blood flow through the liver.&nbsp;This causes vasodilation and blood pooling in the central or &ldquo;splanchnic&rdquo; region
of the body and low blood volume in the arteries. The decrease in effective blood volume activates a signaling pathway (&ldquo;neurohormonal
systems&rdquo;) which tells the kidneys to retain large amounts of salt and water in an effort to increase blood volume. Ultimately
the retention of excess sodium and water leads to the formation of ascites as these substances &ldquo;weep&rdquo; from the liver
and lymph system and collect in the patient&rsquo;s abdomen.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B>The BIV201 Mechanism of Action</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">BIV201 is being developed by BioVie
with the goal of alleviating the portal hypertension and correcting splanchnic vasodilation, thereby increasing effective blood
volume and&nbsp;reducing the&nbsp;signals to the kidneys to retain excess salt and water. If successful, BIV201 could halt the
cycle of accelerating fluid generation in ascites patients and reduce the need for the frequent and painful paracentesis procedures
many of these patients currently require.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B>Future Possible BIV201 Indications</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">Based on investigative studies
around the world of the active agent in BIV201, terlipressin, our new product candidate may have potential future applications
in&nbsp;other life-threatening conditions due to liver cirrhosis, such as those listed below. Securing marketing approvals for
any of these new uses will require well-controlled clinical trials to satisfy the FDA and/or other countries&rsquo; regulatory
requirements, none of which have commenced at this time. We may be unable to, or chose not to, pursue the development BIV201 for
these indications.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; padding-bottom: 0pt; font: 10pt/normal Times New Roman, Times"><FONT STYLE="font-family: Symbol; font-size: 10pt; line-height: 107%">&middot;</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; font: 10pt/normal Times New Roman, Times; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 107%">Bleeding
    Esophageal Varices (BEV): The bursting of blood vessels lining the esophagus due to high blood pressure (&ldquo;portal hypertension&rdquo;)
    in the vein which supplies blood to the liver resulting as a result of advanced liver cirrhosis. This situation requires emergency
    treatment to avoid blood loss and death.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; padding-bottom: 0pt; font: 10pt/normal Times New Roman, Times"><FONT STYLE="font-family: Symbol; font-size: 10pt; line-height: 107%">&middot;</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; font: 10pt/normal Times New Roman, Times; text-align: justify">Hepatorenal
    syndrome (HRS): As their disease progresses liver cirrhosis patients&rsquo; kidneys may begin to fail, and this deadly condition
    may set in. It often occurs once a patient no longer responds to (off-label) drugs used to control ascites. The second stage
    is called &ldquo;type 1 HRS&rdquo; and requires hospitalization as multiple organ failure and death may occur. We obtained
    Orphan Drug designation for BIV201 in the U.S. for the treatment of HRS on November 21, 2018.</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"><B>Efflux Pump Antibiotics Program</B></P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Prior to the Merger of Lat Pharma LLC
and NanoAntibiotics Inc. in April 2016, we were exclusively developing novel nanotechnology anti-infective drugs to combat multi-drug
resistant bacteria. We are at an early stage of discovery and development of broad spectrum antibiotics for gram-negative and gram-positive
bacterial infections. Developing this technology in-house is resource-intensive with respect to time, personnel and capital necessary
for scientific discovery. For further development of our nanoantibiotic technology we will need to find and license additional
nanotechnology to complete our planned products. Presently this program is inactive as we are focusing our efforts on BIV201.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">BioVie relies on a combination of patent,
trade secret, other intellectual property laws (such as FDA data exclusivity), nondisclosure agreements, and other measures to
protect our proposed products. We require our employees, consultants, and advisors to execute confidentiality agreements and to
agree to disclose and assign to us all inventions conceived during the workday, using our property, or which relate to our business.
Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products
or to obtain and use information that we regard as proprietary. In July 2017 we announced filing an application for patent
coverage in Japan, and subsequently filed for patent protection in Europe, China and Hong Kong. BioVie has secured Orphan Drug
designations in the U.S. for the treatment of hepatorenal syndrome (received November 21, 2018) and treatment of ascites due to
all etiologies except cancer (received September 8, 2016). We have applied for an additional Orphan Drug designation which could
be granted in 2019.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>
<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Government Regulation</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Government authorities in the United
States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development,
testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution,
post-approval monitoring and reporting, marketing and export and import of products such as those we are developing. Any pharmaceutical
candidate that we develop must be approved by the FDA before it may be legally marketed in the United States and by the appropriate
foreign regulatory agency before it may be legally marketed in foreign countries.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>United States Drug Development
Process</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">In the United States, the FDA regulates
drugs under the Federal Food, Drug and Cosmetic Act, or FDCA, and implementing regulations. Drugs are also subject to other federal,
state and local statutes and regulations. Biologics are subject to regulation by the FDA under the FDCA, the Public Health Service
Act, or the PHSA, and related regulations, and other federal, state and local statutes and regulations. Biological products include,
among other things, viruses, therapeutic serums, vaccines and most protein products. The process of obtaining regulatory approvals
and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure
of substantial time and financial resources. Failure to comply with the applicable United States requirements at any time during
the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions.
FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters,
product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government
contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material
adverse effect on us.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The process required by the FDA before
a drug or biological product may be marketed in the United States generally involves the following:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; padding-bottom: 10pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices or other applicable regulations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; padding-bottom: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission to the FDA of an Investigational New Drug Application, or an IND, which must become effective before human clinical trials may begin;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; padding-bottom: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance of adequate and well-controlled human clinical trials according to the FDA&rsquo;s current good clinical practices, or GCPs, to establish the safety and efficacy of the proposed drug or biologic for its intended use;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission to the FDA of a New Drug Application, or an NDA, for a new drug product, or a Biologics License Application, or a BLA, for a new biological product;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the drug or biologic is to be produced to assess compliance with the FDA&rsquo;s current good manufacturing practice standards, or cGMP, to assure that the facilities, methods and controls are adequate to preserve the drug&rsquo;s or biologic&rsquo;s identity, strength, quality and purity;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the NDA or BLA; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA review and approval of the NDA or BLA.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The lengthy process of seeking required
approvals and the continuing need for compliance with applicable statutes and regulations require the expenditure of substantial
resources. There can be no certainty that approvals will be granted.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>
<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Clinical trials involve the administration
of the drug or biological candidate to healthy volunteers or patients having the disease being studied under the supervision of
qualified investigators, generally physicians not employed by or under the trial sponsor&rsquo;s control. Clinical trials are conducted
under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion
criteria, and the parameters to be used to monitor subject safety. Each protocol must be submitted to the FDA as part of the IND.
Clinical trials must be conducted in accordance with the FDA&rsquo;s good clinical practices requirements. Further, each clinical
trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which
the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers
such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation
to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or
his or her legal representative and must monitor the clinical trial until it is completed.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Human clinical trials prior to approval
are typically conducted in three sequential Phases that may overlap or be combined:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30px">&nbsp;</TD>
    <TD STYLE="width: 18px; padding-bottom: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&bull;</I></FONT></TD>
    <TD STYLE="padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase&nbsp;1.</I>&nbsp;&nbsp;The drug or biologic is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients having the specific disease.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30px">&nbsp;</TD>
    <TD STYLE="width: 18px; padding-bottom: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&bull;</I></FONT></TD>
    <TD STYLE="padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase&nbsp;2.</I>&nbsp;&nbsp;The drug or biologic is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule for patients having the specific disease.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30px">&nbsp;</TD>
    <TD STYLE="width: 18px; padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&bull;</I></FONT></TD>
    <TD STYLE="padding-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase&nbsp;3.</I>&nbsp;&nbsp;Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials, which usually involve more subjects than earlier trials, are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. Generally, at least two adequate and well-controlled Phase&nbsp;3 clinical trials are required by the FDA for approval of an NDA or BLA.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Post-approval studies, or Phase&nbsp;4
clinical trials, may be conducted after initial marketing approval. These studies are used to gain additional experience from the
treatment of patients in the intended therapeutic indication and may be required by the FDA as part of the approval process.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Progress reports detailing the results
of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA
by the investigators for serious and unexpected adverse events or any finding from tests in laboratory animals that suggests a
significant risk for human subjects. Phase&nbsp;1, Phase&nbsp;2 and Phase&nbsp;3 clinical trials may not be completed successfully
within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial
at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable
health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is
not being conducted in accordance with the IRB&rsquo;s requirements or if the drug or biologic has been associated with unexpected
serious harm to patients.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>
<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Concurrent with clinical trials, companies
usually complete additional animal studies and develop additional information about the chemistry and physical characteristics
of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with
cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug or biological
candidate and, among other things, must include methods for testing the identity, strength, quality and purity of the final drug
or biologic. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate
that the drug or biological candidate does not undergo unacceptable deterioration over its shelf life.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>U.S. Review and Approval Processes</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The results of product development,
preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the
chemistry of the drug or biologic, proposed labeling and other relevant information are submitted to the FDA as part of an NDA
or BLA requesting approval to market the product. The submission of an NDA or BLA is subject to the payment of substantial user
fees; a waiver of such fees may be obtained under certain limited circumstances.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The FDA reviews all NDAs and BLAs submitted
before it accepts them for filing and may request additional information rather than accepting an NDA or BLA for filing. Once the
submission is accepted for filing, the FDA begins an in-depth review of the NDA or BLA.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">After the NDA or BLA submission is accepted
for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective for its
intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&rsquo;s
identity, strength, quality and purity. The FDA reviews a BLA to determine, among other things, whether the product is safe, pure
and potent and the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&rsquo;s
continued safety, purity and potency. In addition to its own review, the FDA may refer applications for novel drug or biological
products or drug or biological products which present difficult questions of safety or efficacy to an advisory committee, typically
a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should
be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such
recommendations carefully when making decisions. During the approval process, the FDA also will determine whether a risk evaluation
and mitigation strategy, or REMS, is necessary to assure the safe use of the drug or biologic. If the FDA concludes that a REMS
is needed, the sponsor of the NDA or BLA must submit a proposed REMS; the FDA will not approve the NDA or BLA without a REMS, if
required.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Before approving an NDA or BLA, the
FDA will inspect the facilities at which the product is to be manufactured. The FDA will not approve the product unless it determines
that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production
of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA will typically inspect one
or more clinical sites to assure compliance with cGMP. If the FDA determines the application, manufacturing process or manufacturing
facilities are not acceptable it will outline the deficiencies in the submission and often will request additional testing or information.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The NDA or BLA review and approval process
is lengthy and difficult and the FDA may refuse to approve an NDA or BLA if the applicable regulatory criteria are not satisfied
or may require additional clinical data or other data and information. Even if such data and information is submitted, the FDA
may ultimately decide that the NDA or BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not
always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The
FDA will issue a &ldquo;complete response&rdquo; letter if the agency decides not to approve the NDA or BLA. The complete response
letter usually describes all of the specific deficiencies in the NDA or BLA identified by the FDA. The deficiencies identified
may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally,
the complete response letter may include recommended actions that the applicant might take to place the application in a condition
for approval. If a complete response letter is issued, the applicant may either resubmit the NDA or BLA, addressing all of the
deficiencies identified in the letter, or withdraw the application.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>
<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">If a product receives regulatory approval,
the approval may be limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict
the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included
in the product labeling. In addition, the FDA may require Phase&nbsp;4 testing which involves clinical trials designed to further
assess a product&rsquo;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved
products that have been commercialized.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>Orphan Drug Designation</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Under the Orphan Drug Act, the FDA may
grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease
or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States
and for which there is no reasonable expectation that the cost of developing and making a drug or biological product available
in the United States for this type of disease or condition will be recovered from sales of the product. Orphan product designation
must be requested before submitting an NDA or BLA. After the FDA grants orphan product designation, the identity of the therapeutic
agent and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage
in or shorten the duration of the regulatory review and approval process.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">If a product that has Orphan designation
subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled
to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological
product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to
the product with orphan exclusivity. Competitors, however, may receive approval of different products for the indication for which
the Orphan product has exclusivity or obtain approval for the same product but for a different indication for which the Orphan
product has exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor
obtains approval of the same drug or biological product as defined by the FDA or if our drug or biological candidate is determined
to be contained within the competitor&rsquo;s product for the same indication or disease. If a drug or biological product designated
as an orphan product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan
product exclusivity. Orphan Drug status in the European Union has similar but not identical benefits in the European Union.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>Expedited Development and Review
Programs</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The FDA has a Fast Track program that
is intended to expedite or facilitate the process for reviewing new drug and biological products that meet certain criteria. Specifically,
new drug and biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening
condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the
combination of the product and the specific indication for which it is being studied. Unique to a Fast Track product, the FDA may
consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if (i) the sponsor
provides a schedule for the submission of the sections of the NDA or BLA, (ii) the FDA agrees to accept sections of the NDA or
BLA and determines that the schedule is acceptable, and (iii) the sponsor pays any required user fees upon submission of the first
section of the NDA or BLA.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Any product submitted to the FDA for
marketing approval, including those submitted to a Fast Track program, may also be eligible for other types of FDA programs intended
to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review
if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant
improvement in the treatment, diagnosis or prevention of a disease compared with marketed products. The FDA will attempt to direct
additional resources to the evaluation of an application for a new drug or biological product designated for priority review in
an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Drug or biological products
studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic
benefit over existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate
and well-controlled clinical studies establishing that the product has an effect on a surrogate endpoint that is reasonably likely
to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity.
As a condition of approval, the FDA generally requires that a sponsor of a drug or biological product receiving accelerated approval
perform adequate and well-controlled post-marketing clinical studies to establish safety and efficacy for the approved indication.
Failure to conduct such studies or conducting such studies that do not establish the required safety and efficacy may result in
revocation of the original approval. In addition, the FDA currently requires as a condition for accelerated approval pre-approval
of promotional materials, which could adversely impact the timing of the commercial launch or subsequent marketing of the product.
Fast Track designation, priority review and accelerated approval do not change the standards for approval but may expedite the
development or approval process.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>Post-Approval Requirements</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Any drug or biological products for
which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements,
reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information on an annual
basis or as required more frequently for specific events, product sampling and distribution requirements, complying with certain
electronic records and signature requirements and complying with FDA promotion and advertising requirements, which include, among
others, standards for direct-to-consumer advertising, prohibitions against promoting drugs and biologics for uses or in patient
populations that are not described in the drug&rsquo;s or biologic&rsquo;s approved labeling (known as &ldquo;off-label use&rdquo;),
rules for conducting industry-sponsored scientific and educational activities, and promotional activities involving the internet.
Failure to comply with FDA requirements can have negative consequences, including the immediate discontinuation of noncomplying
materials, adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors,
and civil or criminal penalties. Although physicians may prescribe legally available drugs and biologics for off-label uses, manufacturers
may not market or promote such off-label uses.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We will need to rely on third parties
for the production of our product candidates. Manufacturers of our product candidates are required to comply with applicable FDA
manufacturing requirements contained in the FDA&rsquo;s cGMP regulations. cGMP regulations require among other things, quality
control and quality assurance as well as the corresponding maintenance of comprehensive records and documentation. Drug and biologic
manufacturers and other entities involved in the manufacture and distribution of approved drugs and biologics are also required
to register their establishments and list any products made there with the FDA and comply with related requirements in certain
states, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and
other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control
to maintain cGMP compliance. Discovery of problems with a product after approval may result in serious and extensive restrictions
on a product, manufacturer, or holder of an approved NDA or BLA, including suspension of a product until the FDA is assured that
quality standards can be met, continuing oversight of manufacturing by the FDA under a &ldquo;consent decree,&rdquo; which frequently
includes the imposition of costs and continuing inspections over a period of many years, and possible withdrawal of the product
from the market. In addition, changes to the manufacturing process generally require prior FDA approval before being implemented
and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject
to further FDA review and approval.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The FDA also may require post-marketing
testing, known as Phase&nbsp;4 testing, risk minimization action plans and surveillance to monitor the effects of an approved product
or place conditions on an approval that could otherwise restrict the distribution or use of the product.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Employees</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Our business is managed by our officers.
Our Chairman and Chief Executive Officer, Terren Peizer began devoting part-time efforts to the Company&rsquo;s activities in July
2018. Our President and Chief Operating Officer, Jonathan Adams, began devoting full-time efforts to the Company on July 1, 2017.
Our Chief Financial Officer and Corporate Secretary, Wendy Kim, devotes part-time efforts to the Company&rsquo;s activities. Our
Chief Scientific Officer began devoting full-time efforts and our Chief Medical Officer began devoting part-time efforts to the
Company in November 2018 and previously were each consultants to the Company. We also rely on a team of highly experienced scientific,
medical, and regulatory consultants to conduct its product development activities.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_010"></A>Management</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Directors and Officers</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The following table sets forth certain
information regarding our Board of Directors, our executive officers, and some of our key employees, as of the date of this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt/normal Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%"><B>Name</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; border-bottom: black 1pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%"><B>Age</B></FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%"><B>Director Since</B></FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%"><B>Position</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 26%; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Terren Peizer</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 6%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">60</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 8%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;2018</FONT></TD>
    <TD STYLE="vertical-align: top; width: 3%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 49%; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Chairman &amp; Chief Executive Officer</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Jonathan Adams</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">56</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;2016</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">President &amp; Chief Operating Officer</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Joanne Wendy Kim</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">65</FONT> </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;--</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Chief Financial Officer and Corporate Secretary</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Patrick Yeramian, MD</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">61</FONT> </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;--</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Chief Medical Officer</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Penelope Markham, PhD</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">54</FONT> </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;--</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Chief Scientific Officer</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Jim Lang</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">55</FONT> </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;2016</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Independent Director</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Cuong Do</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">53</FONT> </TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;2016</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Independent Director</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Michael Sherman</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">60</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;2017</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Independent Director</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Richard J. Berman</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">76</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">&nbsp;2019</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 5.4pt; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; line-height: 106%">Independent Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">According to our Bylaws, the directors
shall be elected at the annual meeting of the stockholders and each director shall be elected to serve until his successor shall
be elected and shall qualify. A director need not be a stockholder. Directors shall not receive any stated salary for their services
as directors or as members of committees, but by resolution of the Board of Directors a fixed fee and expenses of attendance may
be allowed for attendance at each meeting. The Bylaws shall not be construed to preclude any director from serving the Company
in any other capacity as an officer, agent or otherwise, and receiving compensation therefor.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">There are no familial relationships
among any of our directors or officers. Mr. Terren Peizer, Chairman of the Board of Directors and Chief Executive Officer, is also
the founder of Catasys, Inc. a U.S. reporting company listed on Nasdaq on whose board Mr. Sherman also serves. Additionally, Jim
Lang currently serves as a director at OptimizeRX, a U.S. reporting company that is listed on the Nasdaq stock exchange. None of
our other directors or officers is or has been a Director or has held any form of directorship in any other U.S. reporting companies.
None of our directors or officers has been affiliated with any Company that has filed for bankruptcy within the last five years.
We are not aware of any proceedings to which any of our officers or directors, or any associate of any such officer or director,
is a party that are adverse to the Company. We are also not aware of any material interest of any of our officers or directors
that is adverse to our own interests.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Information</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Mr. Terren Peizer, Chairman of the Board
of Directors and Chief Executive Officer, is an entrepreneur, investor, and financier with a particular interest in healthcare,
having founded and successfully commercialized several healthcare companies. Mr. Peizer is the founder of Catasys, Inc., a leader
in behavioral and mental health management services, having served as the Chairman of the Board of Directors and CEO of Catasys
since inception in 2004. Mr. Peizer also is the Founder, Chairman and CEO and majority shareholder of NeurMedix, Inc., a biotechnology
Company with a focus on inflammatory, neurological and neuro-degenerative diseases. Mr. Peizer is Chairman of Acuitas Group Holdings,
LLC, his personal holding company that owns his portfolio Company interests. Through Acuitas, he owns Crede Capital Group, LLC,
an industry leader in investing in micro and small capitalization public equities, having invested over $1.2 billion directly into
portfolio companies. Previously he was Chairman of Cray, Inc., the leading supercomputing Company, and held senior executive positions
at various publicly-traded growth companies and with the investment banking firms Goldman Sachs, First Boston, and Drexel Burnham
Lambert. He received his B.S.E. in finance from The Wharton School of Finance and Commerce.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>
<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Mr. Jonathan Adams has served
as the Company&rsquo;s Chief Executive Officer and Chief Financial Officer from the time acquired LAT Pharma LLC on April 11,
2016 until July 2018. In July 2018, he began serving as the Company&rsquo;s President and Chief Operating Officer. He founded
LAT Pharma LLC and served as its Chief Executive Officer prior to its acquisition. Mr. Adams is a co-inventor of the Company&rsquo;s
pending patent application for the use of terlipressin to treat ascites patients. He has over 29 years of biopharmaceutical
industry experience, including corporate finance, company acquisitions and licensing deals, marketing and sales support. At Searle
Pharmaceuticals he was a member of the global launch team for Celebrex, and he has worked on launching numerous new drugs and
medical devices. Mr. Adams earned a BS at Cornell University and an MBA at the Tuck School at Dartmouth.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Joanne Wendy Kim has served as the Company&rsquo;s
Chief Financial Officer since October 2018. Ms. Kim previously served as CFO for several companies throughout her career, most
recently with Landmark Education Enterprises, and she has provided interim CFO services to various organizations through Group
JWK from 2016 to 2018. In her various roles, Ms. Kim oversaw corporate finance and operational groups, closed eight acquisitions,
secured bank financings, developed and implemented new business strategies, managed risk and implemented new financial policies
and procedures. As a CPA, Ms. Kim provided accounting, SEC filing review and other business consultative services to clients serving
as a Director at BDO USA, LLP&rsquo;s National Office SEC Department in 2008-2016 and as a Senior Manager at KPMG in earlier part
of her career. She brings more than 30 years of accounting experience to this position. Ms. Kim earned her BBA in accounting and
finance at California State University, Long Beach.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Dr. Yeramian has served as the Company&rsquo;s
Chief Medical Officer since November 2018. Dr. Yeramian has over 25 years of experience in the pharmaceutical industry. He has
supervised the clinical development of new drugs, biopharmaceuticals, cellular therapy agents, and vaccines as well as having held
a prominent role in the approval of several new drug (metronidazole &ndash; Flagyl MR &reg;), biological (interferon alpha &ndash;
Multiferon&reg;, nafarelin &ndash; Synarel&reg;) and device (Inerpan&reg;) applications in the U.S. in the EC and the granting
of over 20 successful INDs and IMPDs. Dr Yeramian was the Medical Director of the Vaccine and Gene Therapy Institute, Florida from
October 2011 to February 2015 and a consulting Medical Director for Tapimmune Inc. from February 2015 to January 2017 and Kantum
Diagnostics from March 2017 to March 2019. Dr. Yeramian currently serves as the Medical Director of Amylyx Inc. (since March 2019)
and as the General Manager of DLx Therpeutics LLC (since January 2018). Previously he served as Chief Medical Officer at Viragen,
Inc. where he was responsible for development of global clinical and regulatory strategies and for implementation of clinical programs
worldwide. Earlier Dr. Yeramian also served as Director of clinical research at GD Searle where he supervised the clinical programs
for antibiotics, antivirals, sepsis/thrombosis, and cancer vaccines. Dr. Yeramian holds a Medical Degree from the University of
Paris together with a Master of Clinical Science in experimental oncology and a Graduate Degree in molecular virology. He also
earned a Master of Business Administration from Rutgers University. He completed his medical residency in oncology at the Saint-Louis
Hospital in Paris.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Dr. Markham has served as the Company&rsquo;s
Chief Scientific Officer since November 2018. She was previously our Chief Scientist. Dr. Markham served as a Technical Consultant
at LAT Pharma for 7 years prior to our acquisition of LAT Pharma. She has spent 15 years in immunology, infectious disease, bacteriology
and drug discovery research. Dr. Markham was a co-founder and Research Director for Influx, Inc. involved in antibiotic drug discovery.
She has been a member of NIH grant review panels and consulted for several pharmaceutical companies in a variety of therapeutic
areas including Orphan Drug development. Dr. Markham has more than 20 publications in peer-reviewed journals and three patents.
She holds a BS in Biochemistry from the University College Cork, Ireland, a Masters from Strathclyde University, Scotland, and
a PhD from Rush University, Chicago.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Mr. Cuong Do has been President, Global
Strategy Group, at Samsung since February 2015. Mr. Do helps to set the strategic direction for Samsung Group&rsquo;s diverse business
portfolio. He was previously the Chief Strategy Officer for Merck from October 2011 to March 2014, Tyco Electronics, and Lenovo.
Mr. Do is a former senior partner at McKinsey &amp; Company, where he spent 17 years and helped build the healthcare, high tech
and corporate finance practices. He holds a BA from Dartmouth College, and an MBA from the Tuck School of Business at Dartmouth.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Mr. Jim Lang is currently CEO of Water
Street Capital&rsquo;s and JLL Partner&rsquo;s Global Life Sciences Services Platform. He formerly served as the CEO of Decision
Resources Group (DRG), which he transformed into a leading healthcare data and analytics firm. Prior to that, Jim was CEO of IHS
Cambridge Energy Research Associates (IHS CERA), a recognized leader in energy industry subscription information products, and
formerly the President of Strategic Decisions Group (SDG), a leading global strategy consultancy. Mr. Lang holds a BS summa cum
laude in electrical and computer engineering from the University of New Hampshire and an MBA with Distinction from the Tuck School
of Business. Jim Lang currently also serves as a Director at OptimizeRX, a Nasdaq listed Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Richard J. Berman was Chairman of National
Investment Managers, a company with $12 billion pension administration assets from 2006-2011. Mr. Berman is a director of four
other public healthcare companies: Catasys, Inc., Advaxis, Inc., Cryoport Inc. and Immuron Ltd. and a public fintech company, Cuentas,
Inc. From 1998-2000, he was employed by Internet Commerce Corporation (now Easylink Services) as Chairman and CEO, and was a director
from 1998-2012. Previously, Mr. Berman was Senior Vice President of Bankers Trust Company, where he started the M&amp;A and Leveraged
Buyout Departments; created the largest battery company in the world in the 1980&rsquo;s by merging Prestolite, General Battery
and Exide and advised on over $4 billion of M&amp;transactions (completed over 300 deals). He is a past Director of the Stern School
of Business of NYU where he obtained his BS and MBA. He also has US and foreign law degrees from Boston College and The Hague Academy
of International Law, respectively.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Michael Sherman JD retired from his
position as a Managing Director at Barclays Plc in 2018, where he had worked since 2008. Previously he was a Managing Director
at Lehman Brothers, Inc. He has worked in investment banking for 30 years. Mr. Sherman has significant experience in healthcare
finance, most recently assisting on a $450 million convertible transaction for Neurocrine Biosciences. He has worked on successful
financial transactions for Teva Pharmaceutical Industries, Amgen Inc., Cubist Pharmaceuticals, Merck &amp; Co., and Cardinal Health,
among other companies. After graduating from the University of Pennsylvania, Michael Sherman received his JD, cum laude, from the
Harvard Law School.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Terren Peizer&rsquo;s qualifications
to serve on our Board of Directors are primarily based on his experience as an entrepreneur, investor, and financier with a particular
interest in healthcare, having founded and successfully commercialized several healthcare companies. Mr. Peizer is the founder
of Catasys, Inc., a leader in behavioral and mental health management services, having served as the Chairman of the Board of Directors
and CEO of Catasys since inception in 2004. Mr. Peizer also is the Founder, Chairman and CEO and majority shareholder of NeurMedix,
Inc., a biotechnology Company with a focus on inflammatory, neurological and neuro-degenerative diseases. Mr. Peizer is Chairman
of Acuitas Group Holdings, LLC, his personal holding Company that owns his portfolio Company interests. Through Acuitas, he owns
Crede Capital Group, LLC, an industry leader in investing in micro and small capitalization public equities, having invested over
$1.2 billion directly into portfolio companies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Jonathan Adams&rsquo;s qualifications
to serve on our Board of Directors are primarily based on his founding of LAT Pharma LLC and his over 26 years of biopharmaceutical
industry experience. As Chief Executive of LAT Pharma LLC, Mr. Adams was a key contributor to inventing the BIV201 product candidate.
He also helped to secure an Orphan Drug designation for a terlipressin analogue (a prior product candidate which is no longer in
development). Mr. Adams&rsquo;s biopharmaceutical experience includes work in corporate finance, company acquisitions and licensing
deals, marketing and sales support.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Wendy Kim&rsquo;s qualifications to
serve as our Chief Financial Officer are primarily based on her 35 years of accounting experience and having served as CFO for
several companies and the provision of interim CFO services, accounting and business consultative services to various organizations
through Group JWK, BDO USA, LLP and KPMG.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Dr. Yeramian&rsquo;s qualifications
to serve as our Chief Medical Officer are primarily based on his extensive experience in the pharmaceutical industry, including
the supervision of the clinical development of new drugs, biopharmaceuticals, cellular therapy agents, and vaccines as well as
having held a prominent role in the approval of several new drugs and having been Chief Medical Officer responsible for development
of global clinical and regulatory strategies and for implementation of clinical programs worldwide at Viragen.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Dr. Markham&rsquo;s qualifications to
serve as our Scientific Officer are primarily based on her years of experience with LAT Pharma, as well as having been a member
of NIH grant review panels and consulted for several pharmaceutical companies in a variety of therapeutic areas including Orphan
Drug development.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Cuong Do&rsquo;s qualifications to serve
on our Board of Directors are primarily based on his decades of experience as an executive in the pharma, biotech, and other high
technology industries. He was previously the Chief Strategy Officer for Merck, a leading U.S. pharmaceuticals Company, Tyco Electronics,
and Lenovo. Mr. Do is a former senior partner at McKinsey &amp; Company, where he spent 17 years and helped build the healthcare,
high tech and corporate finance practices.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Jim Lang&rsquo;s qualifications to serve
on our Board of Directors are primarily based on his decades of experience as a strategy consultant, broad industry expertise,
and senior-level management experience running several healthcare and information technology companies. This includes his experience
as CEO of Decision Resources Group, CEO of IHS Cambridge Energy Research Associates (IHS CERA), and President of Strategic Decisions
Group (SDG), a leading global strategy consultancy.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Richard J. Berman&rsquo;s qualifications
to serve on our board of directors include his experience in the healthcare industry, and his current and past experience in numerous
private and publicly traded companies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Michael Sherman&rsquo;s qualifications
to serve on our Board of Directors are primarily based on his decades of finance industry experience including as a Managing Director
at Barclays Plc and as a Managing Director at Lehman Brothers, Inc. He has worked in investment banking for 30 years. Mr. Sherman
has significant experience in healthcare finance including having worked on successful financial transactions for several pharmaceutical
and healthcare focused companies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>Committees
of the Board of Directors</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> Our Board of Directors has
three standing committees: an audit committee, a compensation committee and a nominating and corporate governance committee.
Both our audit committee and our compensation committee will be composed solely of independent directors. Subject to phase-in
rules, the rules of Nasdaq and Rule 10A-3 of the Exchange Act require that the audit committee of a listed company be comprised
solely of independent directors, and the rules of Nasdaq require that the compensation committee and the nominating and corporate
governance committee of a listed company be comprised solely of independent directors. Each committee operates under a charter
approved by our Board of Directors and will have the composition and responsibilities described below. The charter of each committee
will be available on our website following the closing of this offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>
<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>AUDIT COMMITTEE</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We have established an audit committee
of the Board of Directors. The members of our audit committee are Michael Sherman, Jim Lang and Richard J. Berman, each of which
is an independent director within the meaning of the Nasdaq rules. Mr. Sherman serves as chairman of the audit committee.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We have adopted an audit committee charter,
detailing the principal functions of the audit committee, including:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assisting
board oversight of&thinsp;(1) the integrity of our financial statements, (2) our compliance with legal and regulatory requirements,
(3) our independent auditor&rsquo;s qualifications and independence, and (4) the performance of our internal audit function and
independent auditors; the appointment, compensation, retention, replacement, and oversight of the work of the independent auditors
and any other independent registered public accounting firm engaged by us;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-approving
all audit and non-audit services to be provided by the independent auditors or any other registered public accounting firm engaged
by us, and establishing pre-approval policies and procedures; reviewing and discussing with the independent auditors all relationships
the auditors have with us in order to evaluate their continued independence;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">setting
clear policies for audit partner rotation in compliance with applicable laws and regulations;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
and reviewing a report, at least annually, from the independent auditors describing (1) the independent auditor&rsquo;s internal
quality-control procedures and (2) any material issues raised by the most recent internal quality-control review, or peer review,
of the audit firm, or by any inquiry or investigation by governmental or professional authorities, within the preceding five years
respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">meeting
to review and discuss our annual audited financial statements and quarterly financial statements with management and the independent
auditor, including reviewing our specific disclosures under &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations&rdquo;; reviewing and approving any related party transaction required to be disclosed pursuant to Item
404 of Regulation S-K promulgated by the SEC prior to us entering into such transaction; and</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
with management, the independent auditors, and our legal advisors, as appropriate, any legal, regulatory or compliance matters,
including any correspondence with regulators or government agencies and any employee complaints or published reports that raise
material issues regarding our financial statements or accounting policies and any significant changes in accounting standards
or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>COMPENSATION COMMITTEE</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We have established a compensation
committee of the Board of Directors. The members of our Compensation Committee are Mr. Berman and Mr. Sherman. Mr. Berman
serves as chairman of the compensation committee.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">We have adopted a compensation
committee charter, which details the principal functions of the compensation committee, including:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer&rsquo;s compensation,
evaluating our Chief Executive Officer&rsquo;s performance in light of such goals and objectives and determining and approving
the remuneration (if any) of our Chief Executive Officer based on such evaluation;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
and making recommendations to our Board of Directors with respect to the compensation, and any incentive-compensation and equity-based
plans that are subject to board approval of all of our other officers;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
our executive compensation policies and plans;</FONT></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementing
and administering our incentive compensation equity-based remuneration plans; assisting management in complying with our proxy
statement and annual report disclosure requirements;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving
all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">producing
a report on executive compensation to be included in our annual proxy statement; and reviewing, evaluating and recommending changes,
if appropriate, to the remuneration for directors.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The charter  also provides that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, independent legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC.</P>
<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B><I>Nominating
and Corporate Governance Committee</I></B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><FONT STYLE="text-transform: uppercase"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We have established a nominating
and corporate governance committee of the Board of Directors. The members of our nominating and corporate governance committee
are Mr. Do and Mr. Lang. Mr. Do serves as chair of the nominating and corporate governance committee.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We have adopted a nominating and
corporate governance committee charter, which details the purpose and responsibilities of the nominating and corporate governance
committee, including:</P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
screening and reviewing individuals qualified to serve as directors, consistent with criteria approved by the Board of Directors,
and recommending to the Board of Directors candidates for nomination for election at the annual meeting of stockholders or to
fill vacancies on the Board of Directors;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
and recommending to the Board of Directors and overseeing implementation of our corporate governance guidelines;</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">coordinating
and overseeing the annual self-evaluation of the Board of Directors, its committees, individual directors and management in the
governance of the company; and</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
on a regular basis our overall corporate governance and recommending improvements as and when necessary.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The charter also provides that the nominating and corporate governance committee may, in its sole discretion, retain or obtain the advice of, and terminate, any search firm to be used to identify director candidates, and will be directly responsible for approving the search firm&rsquo;s fees and other retention terms.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We have not formally established any specific, minimum qualifications
that must be met or skills that are necessary for directors to possess. In general, in identifying and evaluating nominees for
director, the Board of Directors considers educational background, diversity of professional experience, knowledge of our business,
integrity, professional reputation, independence, wisdom, and the ability to represent the best interests of our stockholders.
Prior to our initial business combination, holders of our public shares will not have the right to recommend director candidates
for nomination to our Board of Directors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Compensation Committee Interlocks and Insider Participation</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">None of our officers currently serves, or in the past year
has served, as a member of the compensation committee of any entity that has one or more officers serving on our Board of Directors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>CODE OF ETHICS</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We have adopted a code of conduct and
ethics meeting the requirements of Section 406 of the Sarbanes-Oxley Act of 2002. We believe our code of conduct and ethics is
reasonably designed to deter wrongdoing and promote honest and ethical conduct; provide full, fair, accurate, timely and understandable
disclosure in public reports; comply with applicable laws; ensure prompt internal reporting of violations; and provide accountability
for adherence to the provisions of the code of ethic. Our code of conduct and ethics is available on our website<B>.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>
<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B><A NAME="a_011"></A>EXECUTIVE COMPENSATION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We did not pay any compensation
to any of our executive officers prior to the start of our fiscal year ending June 30, 2019; however, we did accrue salary for
Mr. Adams in accordance with his related employment agreements for all periods subsequent to their effective dates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="27" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Annual Compensation</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Name&nbsp;and&nbsp;Principal Position</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Year</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Salary</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Bonus</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Stock Awards</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Option Awards(1)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">All Other Compensation</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Total</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Terren Peizer</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Chief Executive Officer and
    Chairman(2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 37%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">Jonathan Adams</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">2019</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">250,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">7,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">11,789</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: right">268,789</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.4pt">President and Chief Operating
    Officer(2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2018</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">250,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,978</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">280,978</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The aggregate
grant date fair value of such awards were computed in accordance with Financial Accounting Standards Board ASC Topic 718, Stock
Compensation (ASC Topic 718), and do not take into account estimated forfeitures related to service-based vesting conditions, if
any. The valuation assumptions used in calculating these values are discussed in Note 8 of the Notes to Consolidated Financial
Statements appearing elsewhere herein. These amounts do not represent actual amounts paid or to be realized. Amounts shown are
not necessarily indicative of values to be achieved, which may be more or less than the amounts shown as awards may subject to
time-based vesting.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mr.
Peizer became our Chief Executive Officer and Chairman in July 2018 at which time Mr. Adams became President and Chief Operating
Officer, having previously served as our Chief Executive Officer and Chief Financial Officer, Treasurer and Corporate Secretary.
The stock awards received by Mr. Peizer and Mr. Adams represented 1,600 shares of common stock and vested in full upon grant.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Employment Agreement</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">On April 11, 2016, we entered into
an employment agreement with Mr. Adams, pursuant to which Mr. Adams  was entitled to receive $250,000 as annual salary. The
agreement was effective beginning April 11, 2016 and expired on July 2, 2019.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">On July 9, 2018, Mr. Adams, our
President and Chief Operating Officer, entered into an Accord and Debt Satisfaction Agreement with us, pursuant to which he
agreed to release us from all liabilities (including the original contract dated March 23, 2017 to defer payment of his
accrued salary, the promissory note issued by us to defer payment of accrued salary and subsequent unpaid salary), for an
aggregate amount of $534,722, and received a cash payment of $25,694 in satisfaction. The gain of $509,028 on the settlement
of debt was reflected as additional paid in capital.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>
<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Option/SAR Grants</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">In connection with his employment agreement, on April 11, 2016 Mr. Adams received options to acquire 24,000 shares exercisable at $7.50 per share, the closing price on that date. These options vested and became exercisable as follows: (i) 8,000 shares on April 11, 2017, (ii) 8,000 shares on April 11, 2018, and (iii) 8,000 shares on April 11, 2019.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Between November 16, 2016
and May 19, 2017, we issued options to acquire 8,000 shares exercisable at an average price of $30.00 per share to
consultants and members of our Board of Directors for services provided to us.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Long-Term Incentive Plans and Awards</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Other than the options granted as
described above and our recently adopted 2019 Omnibus Equity Incentive Plan (the &ldquo;2019 Plan&rdquo;), we do not currently have any long-term
incentive plans that provide compensation intended to serve as incentive for performance. Since prior to such grants, no individual
grants or agreements regarding future payouts under non-stock price-based plans had been made to any executive officer or any
director or any employee or consultant since our inception, no future payouts under non-stock price-based plans or agreements
had been granted or entered into or exercised by our officer or director or employees or consultants.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>2019 Omnibus Equity Incentive Plan</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">On April 30, 2019, our Board of Directors and our stockholders approved and adopted the 2019 Plan, subject to complying with the notification requirements of Regulation 14C of the Exchange Act which were complied with effective May 29, 2019. The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and directors. The 2019 Plan allows for the issuance of up to 253,163 shares of common stock pursuant to new awards granted under the 2019 Plan. This description is qualified in its entirety by reference to the actual terms of the 2019 Plan, a copy of which is attached as Appendix D to our Definitive Information Statement on Schedule 14C, filed with the SEC on May 8, 2019.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Compensation of Directors</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">There are no arrangements pursuant
to which our directors are or will be compensated in the future for any services provided to the Company, except that each director
shall receive stock options and common share grants as remuneration for their service in lieu of cash compensation. For the fiscal
year ended June 30, 2019, each director received 800 stock options on the one-year anniversary of his or her service to the Company
with an exercise price equal to the closing stock price on the day of the option grant. The total value of the options granted
to directors for the fiscal year ended June 30, 2019 was $8,804 based on the Black-Scholes option value method. Each director
also receives a stock grant of 1,600 common shares for every year of service. On January 2, 2020, our directors received a combined
grant of 11,200 shares of common stock with a face value of $39,200 based on the closing stock price of $3.50 on
the grant date.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><A NAME="a_012"></A><FONT STYLE="text-transform: uppercase"><B>Principal
Stockholders</B></FONT></P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Based solely upon
information made available to us, the following table sets forth information as of March 2, 2020 regarding the
beneficial ownership of our common stock by:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our named executive officers and directors; and&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: justify; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all our executive officers and directors as a group.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The percentage ownership information
shown in the table is based upon 5,199,346 shares of common stock outstanding as of March 2, 2020. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Beneficial ownership is determined in
accordance with the rules of the SEC and includes voting or investment power with respect to the securities. Except as otherwise
indicated, each person or entity named in the table has sole voting and investment power with respect to all shares of our capital
shown as beneficially owned, subject to applicable community property laws.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">In computing the number and percentage
of shares beneficially owned by a person as of a particular date, shares that may be acquired by such person (for example, upon
the exercise of options or warrants) within 60&nbsp;days of such date are counted as outstanding, while these shares are not counted
as outstanding for computing the percentage ownership of any other person.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The address of each holder listed below,
except as otherwise indicated, is c/o BioVie Inc., 2120 Colorado Avenue, #230, Santa Monica, California 90404.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 8pt; font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Name and Address of Beneficial Owner</TD><TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Common Shares of Beneficial Ownership (1)</TD><TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of Beneficial Ownership</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; font-size: 8pt; text-align: justify; padding-left: 5.4pt"> Terren Peizer(2) </TD><TD STYLE="width: 8%; font-size: 8pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 12%; font-size: 8pt; text-align: right"> 10,868,788 </TD><TD STYLE="width: 1%; font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 8%; font-size: 8pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 12%; font-size: 8pt; text-align: right"> 90.6 </TD><TD STYLE="width: 1%; font-size: 8pt; text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 8pt; text-align: justify; padding-left: 5.4pt"> Jonathan Adams(3) </TD><TD STYLE="font-size: 8pt"> &nbsp; </TD>
    <TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; text-align: right"> 97,037 </TD><TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt"> &nbsp; </TD>
    <TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; text-align: right"> 0.9 </TD><TD STYLE="font-size: 8pt; text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 8pt; text-align: justify; padding-left: 5.4pt"> Joanne Wendy Kim(4) </TD><TD STYLE="font-size: 8pt"> &nbsp; </TD>
    <TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; text-align: right"> 1,600 </TD><TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt"> &nbsp; </TD>
    <TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; text-align: right"> <FONT STYLE="font-size: 8pt">*</FONT> </TD><TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 8pt; text-align: justify; padding-left: 5.4pt"> Patrick Yeramian, MD(4) </TD><TD STYLE="font-size: 8pt"> &nbsp; </TD>
    <TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; text-align: right"> 2,400 </TD><TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt"> &nbsp; </TD>
    <TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; text-align: right"> <FONT STYLE="font-size: 8pt">*</FONT> </TD><TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 8pt; text-align: justify; padding-left: 5.4pt"> Penolope Markham, PhD(5) </TD><TD STYLE="font-size: 8pt"> &nbsp; </TD>
    <TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; text-align: right"> 13,893 </TD><TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt"> &nbsp; </TD>
    <TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; text-align: right"> <FONT STYLE="font-size: 8pt">*</FONT> </TD><TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 8pt; text-align: justify; padding-left: 5.4pt"> Cuong Do(6) </TD><TD STYLE="font-size: 8pt"> &nbsp; </TD>
    <TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; text-align: right"> 170,707 </TD><TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt"> &nbsp; </TD>
    <TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; text-align: right"> 1.4 </TD><TD STYLE="font-size: 8pt; text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 8pt; text-align: justify; padding-left: 5.4pt"> James Lang(7) </TD><TD STYLE="font-size: 8pt"> &nbsp; </TD>
    <TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; text-align: right"> 47,032 </TD><TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt"> &nbsp; </TD>
    <TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; text-align: right"> <FONT STYLE="font-size: 8pt">*</FONT> </TD><TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 8pt; text-align: justify; padding-left: 5.4pt"> Michael Sherman(8) </TD><TD STYLE="font-size: 8pt"> &nbsp; </TD>
    <TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; text-align: right"> 37,485 </TD><TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt"> &nbsp; </TD>
    <TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; text-align: right"> <FONT STYLE="font-size: 8pt">*</FONT> </TD><TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 8pt; text-align: justify; padding-left: 5.4pt"> Richard J. Berman </TD><TD STYLE="font-size: 8pt"> &nbsp; </TD>
    <TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; text-align: right"> 2,400 </TD><TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt"> &nbsp; </TD>
    <TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; text-align: right"> &mdash;&nbsp;&nbsp; </TD><TD STYLE="font-size: 8pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 8pt; font-weight: bold; text-align: justify; padding-left: 5.4pt"> All directors and executive officers
    as a group (ten persons): </TD><TD STYLE="font-size: 8pt; font-weight: bold"> &nbsp; </TD>
    <TD STYLE="font-size: 8pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; font-weight: bold; text-align: right"> 11,241,343 </TD><TD STYLE="font-size: 8pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; font-weight: bold"> &nbsp; </TD>
    <TD STYLE="font-size: 8pt; font-weight: bold; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 8pt; font-weight: bold; text-align: right"> 93.7 </TD><TD STYLE="font-size: 8pt; font-weight: bold; text-align: left"> % </TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 7pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">_________________________________</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">*Less than 1%</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.75pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Beneficial ownership is determined in accordance with the rules of
the SEC and generally includes voting or investment power with respect to securities. In accordance with SEC rules, shares of common
stock issuable upon the exercise of options or warrants which are currently exercisable or which become exercisable within 60 days
following the date of the information in this table are deemed to be beneficially owned by, and outstanding with respect to, the
holder of such option or warrant, however none of the persons listed hereinabove has the right to acquire beneficial ownership
in any other shares of the Company. Subject to community property laws where applicable, to our knowledge, each person listed is
believed to have sole voting and investment power with respect to all shares of common stock owned by such person.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0  0 ">&nbsp;</P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.75pt"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify">All
                                         shares and warrants are held of record by Acuitas Group Holdings, LLC, a limited liability
                                         company 100% owned by Terren S. Peizer, and as to which, Mr. Peizer may be deemed to
                                         beneficially own or control. Mr. Peizer disclaims beneficial ownership of any such securities.
                                         Excludes shares issuable upon conversion of the Debenture, which is expected to be repaid
                                         in cash with the net proceeds of this offering, and includes an aggregate of 6,609,832
                                         shares expected to be issued to Acuitas upon completion of this offering in connection
                                         with the automatic exercise of the Bridge Financing Warrants and the committed exercise
                                         of its purchase option granted in connection with its initial investment in the Company.
                                         After giving effect to such issuance and the completion of this offering, Acuitas is
                                         expected to beneficially own 10,862,765 shares in total, or 73.4% of the outstanding
                                         shares of common stock.</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.75pt"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes
                                         warrants to purchase 8,564 shares of common stock and options to purchase 24,800
                                         shares of common stock, all of which are exercisable within the next 60 days. Common
                                         stock beneficially owned by Mr. Adams includes 1,120 and 1,200 shares of common stock
                                         held of record by Mr. Adams, as custodian for Elliott P. Adams and Jeremy P. Adams, respectively;
                                         and 1,164 shares of common stock held of record by Elliott P. Adams. Each of Elliott
                                         P. Adams and Jeremy P. Adams are family members of Mr. Adams and, as a result, Mr. Adams
                                         may be deemed to beneficially own shares held by (or for the benefit of) such family
                                         members.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.75pt"><FONT STYLE="font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents options to purchase shares of common stock exercisable
in the next 60 days.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.75pt"><FONT STYLE="font-size: 10pt">(5)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes
                                         options to purchase 3,200 shares of common stock exercisable in the next 60 days.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.75pt"><FONT STYLE="font-size: 10pt">(6)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes
                                         warrants to purchase 70,667 shares of common stock and options to purchase 3,200
                                         shares of common stock, all of which are exercisable within the next 60 days. All shares
                                         of common stock, warrants and options are held of record by Do &amp; Rickles Investments,
                                         LLC, a limited liability company 100% owned by Cuong Do and his wife, and as such, Mr.
                                         Do may be deemed to beneficially own or control. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.75pt"><FONT STYLE="font-size: 10pt">(7)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes
                                         warrants to purchase 18,788 shares of common stock and options to purchase 3,200
                                         shares of common stock, all of which are exercisable in the next 60 days.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 18pt"></TD><TD STYLE="width: 24.75pt"> <FONT STYLE="font-size: 10pt">(8)</FONT> </TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes
                                         warrants to purchase 13,606 shares of common stock and options to purchase 3,200
                                         shares of common stock, all of which are exercisable within the next 60 days. Common
                                         stock held by Michael Sherman includes 13,333 shares of the common stock held of record
                                         by Sherman Children&rsquo;s Trust Brian Krisber, Trustee. All shares of common stock,
                                         warrants and options are deemed to be beneficially owned or controlled by Michael Sherman.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><A NAME="a_013"></A><FONT STYLE="text-transform: uppercase"><B>Certain
Relationships and Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">During the period commencing July 1,
2015 and through the date of this prospectus, we have not engaged in any transactions with any officer, director or holder of more
than 5% of our common stock, except as follows:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><I>Purchase of Preferred Stock</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">On July 3, 2018, we entered into
a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with Acuitas Group Holdings, LLC (&ldquo;Acuitas&rdquo;)
and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the &ldquo;Purchasers&rdquo;) pursuant
to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the our Series A Convertible Preferred Stock
(the &ldquo;Preferred Stock&rdquo;) at a price per share of $1.50 per share of Preferred Stock (the &ldquo;Initial Sale&rdquo;)
and (ii) we agreed to issue warrants (the &ldquo;Warrants&rdquo;) to purchase 1,706,666 shares of common stock, each subject to
the terms and conditions set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. We received $160,000
of the $3.2 million in April and May 2018 as prepaid equity. Acuitas also received an additional 6,667 Warrants in connection
with the payoff of a note issued by us in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3,
2018. In addition, Acuitas had the option to purchase up to an additional 1,600,000 shares of common stock at a price per share
of $1.875, and warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing
of the Initial Sale (the &ldquo;Subsequent Sale&rdquo;) in the event that we did not obtain $3,000,000 of funding through various
non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale, less any federal or FDA grant funding
received by the Company. Acuitas is controlled by our Chairman and Chief Executive Officer, Terren Peizer and the Purchasers included
Jonathan Adams, James Lang, Cuong Do and Michael Sherman, who are members of our Board of Directors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The Purchase Agreement contained
customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties,
we also disclosed customary information, including the following: (i) the existence of the Mallinckrodt petition before the PTAB,
(ii) our capitalization, (iii) our obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion
terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement
and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and us, (iv) our obligation to pay a low single digit
royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to
the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy), and (v) certain
recent issuances of common stock by us.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Each share of Preferred Stock
automatically converted into 100 shares of common stock upon the filing with the Secretary of State of the State of Nevada
of a Certificate of Amendment to our Articles of Incorporation (the &ldquo;Amendment&rdquo;) on August 13, 2018 that increased
the number of authorized shares of common stock to 800,000,000. The Amendment was approved by the written consent of the holders
of more than a majority of our issued and outstanding common stock on July 3, 2018 and was filed with the Secretary of State of
the State of Nevada 20 calendar days following the distribution of our Definitive Information Statement on Schedule 14 that was
filed with the SEC on July 13, 2018.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Pursuant to a letter agreement dated June 24, 2019, Acuitas agreed to modify its
existing rights under the Purchase Agreement so that:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">- Acuitas agreed to immediately
exchange its existing 1,606,667 Warrants for common stock such that it will have effectively exercised its Warrants in
full pursuant to a cashless exercise thereof at an assumed current market price of $45.00 per share and, as a result received
an aggregate of 95% of the shares covered thereby, or 1,526,094 shares of common stock;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">- Acuitas agreed to (i) waive its rights
to a 50% adjustment of the purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants and the
price per share in the Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property
rights, and (ii) effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a &ldquo;cashless purchase&rdquo;
at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of our common stock
on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case
not later than November 30, 2019, which will result Acuitas having irrevocably waived its rights to an adjustment in the purchase
price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in
the Subsequent Sale upon the issuance by us of an aggregate of 1,339,958 shares of common stock (the &ldquo;Subsequent Sale Shares&rdquo;)
to Acuitas, which is expected to occur concurrently with the closing of this offering;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">- Acuitas shall in exchange for the
foregoing agreements and waivers have the option to purchase additional shares of common stock and warrants to purchase one share
of common stock for each share of common stock purchased during the period from September 1, 2019 to November 30, 2019 at the
then-effective purchase price of the Preferred Stock in the Initial Sale (the &ldquo;Funding Option&rdquo;), provided that any
shares issued pursuant to any exercise of the Funding Option will reduce share-for-share the amount of shares issued pursuant
to the deemed exercise of its rights to purchase securities in a Subsequent Sale mentioned above. Assuming the closing of this
offering occurs on or prior to September 1, 2019, such option will terminate upon such closing.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">On September 24, 2019, the Company,
entered into a Securities Purchase Agreement (the &ldquo;2019 Purchase Agreement&rdquo;) with Acuitas pursuant to which (i)
Acuitas agreed to purchase a 10% OID Convertible Delayed Draw Debenture (the &ldquo;Debenture&rdquo;) due September 24, 2020 for
an aggregate commitment amount of up to $2.0 million, and (ii) the Company issued 1,125,000 shares (the &ldquo;Commitment Shares&rdquo;)
of the Company&rsquo;s common stock and warrants (the &ldquo;Commitment Warrants&rdquo;) to purchase an equal number of shares,
each subject to the terms and conditions set forth in the 2019 Purchase Agreement. The Debenture accrues additional principal at
the rate of 6% per annum and interest at the rate of 10% per annum, is convertible into shares of common stock at $4.00 per share
prior to the completion of this offering or, subsequent to the closing of this offering, the lower of $4.00 or 80% of the offering
price per unit to the public in this offering and are mandatorily redeemable upon such closing at 100% of the accrued principal
amount and unpaid interest to the date of redemption. The Commitment Warrants are five year warrants, exercisable at an amount
equal to the lower of $4.00 or 80% of the offering price per unit to the public in this offering. Upon entering into the 2019 Purchase
Agreement, the Company drew an initial $500,000 under the Debenture and in accordance with the 2019 Purchase Agreement, Acuitas
received an additional 125,000 warrants (the &ldquo;Bridge Warrants&rdquo;) having the same terms as the Commitment Warrants. Any
future draws under the Debenture, which may be made from and after October 15, 2019, November 15, 2019 and December 15, 2019 in
equal tranches of $500,000 each, will entitle Acuitas to receive additional Bridge Warrants in equal amount upon such funding.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Pursuant to the 2019 Purchase Agreement,
 Acuitas has agreed to further modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company
so that Acuitas&rsquo; previous agreement in June 2019 to waive its rights to a 50% adjustment of the purchase price of the Preferred
Stock in the July 2018 transaction, the exercise price of the warrants in such transaction and the price per share in a Subsequent
Sale in the event of certain reductions in the useful life of our current intellectual property rights, and effectively exercise
its rights to purchase securities in a Subsequent Sale pursuant to a &ldquo;cashless purchase&rdquo; at an assumed current market
price of approximately $11.25 per share, conditioned in each case on the listing of the Company&rsquo;s common stock on Nasdaq
or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November
30, 2019, such that Acuitas will have irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock
in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the
issuance by us of an aggregate of 2,679,916 shares of common stock and 2,679,916 warrants having the same terms as the Commitment
Warrants to Acuitas, which is currently expected with the closing of this offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Pursuant to an amendment to the 2019 Purchase
Agreement dated October 9, 2019, Acuitas agreed to modify its existing rights under the 2019 Purchase Agreement so that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Commitment Warrants (and related warrants
issued upon the first draw under the Debenture) were replaced with warrants having similar terms, but which are automatically
exercised upon the closing of this offering at an exercise price equal to the par value of the common stock; and </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acuitas' existing rights under the Purchase Agreement dated July 3, 2018 with the Company were further amended so that the number of Subsequent Sale Shares would be multiplied by four (in lieu of the changes to the Purchase Agreement originally provided for in the 2019 Purchase Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> In February 2020, the Company entered
into a letter agreement with Acuitas regarding Acuitas&rsquo; previous agreement to modify its existing rights under the Purchase
Agreement dated July 3, 2018 with the Company so that its June 2019 waiver of its rights to a 50% adjustment of the purchase price
applicable to its initial investment in the Company and the exercise price of the warrants received in such transaction and the
price per share should it exercise certain rights to purchase additional securities in the event of certain reductions in the
useful life of the Company&rsquo;s intellectual property rights and commitment to purchase such securities upon the closing of
the Company&rsquo;s planned public offering (the &ldquo;Public Offering&rdquo;) of shares of Class A common stock (the &ldquo;Common
Stock&rdquo;) as described above and commitment to purchase such additional securities would remain effective until April 30,
2020, and accordingly Acuitas shall be entitled to receive an aggregate of 5,359,832 shares of Common Stock at such closing. In
addition, the parties agreed that certain draws under the Company&rsquo;s current bridge financing with Acuitas were to be made
based with respect to the Company&rsquo;s ongoing capital requirements and current market conditions, notwithstanding certain
scheduled availability dates set forth in the 10% OID Convertible Delayed Draw Debenture issued in connection therewith. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Issuance of Shares in Settlement
of Debt</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">During the fiscal year ended June 30,
2019, we settled $1,475,765 of debt including $1,313,765 owed to related parties, by issuing 7,803 shares of common stock
with a fair value of $1,150,135. See Notes 5 and 6 to the financial statements appearing elsewhere in this prospectus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_014"></A>Description
of Capital Stock</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The following description of our
capital stock and provisions of our Articles of Incorporation, bylaws and the Nevada corporations law are summaries and are qualified
in their entirety by reference to our Articles of Incorporation and our bylaws. We have filed copies of these documents with the
SEC as exhibits to the Registration Statement of which this prospectus forms a part. Pursuant to our Articles of Incorporation,
as amended, our authorized capital stock consists of 800,000,000 shares of Class A common stock, par value of $0.0001 per share
(which we refer to as our common stock), and 10,000,000 shares of preferred stock, par value $0.001 per share, to be designated
from time to time by our Board of Directors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We are authorized to issue up to
800,000,000 shares of Class A common stock, par value $0.0001 per share. Each outstanding share of common stock entitles the holder
thereof to one vote per share on all matters. Our bylaws provide that elections for directors shall be by a plurality of votes.
Stockholders do not have preemptive rights to purchase shares in any future issuance of our common stock. Upon our liquidation,
dissolution or winding up, and after payment of creditors and preferred stockholders, if any, our assets will be divided pro-rata
on a share-for-share basis among the holders of the shares of common stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The holders of shares of our common
stock are entitled to dividends out of funds legally available when and as declared by our Board of Directors. Our Board of Directors
has never declared a dividend and does not anticipate declaring a dividend in the foreseeable future.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">All of the issued and outstanding
shares of our common stock are duly authorized, validly issued, fully paid and non-assessable. To the extent that additional shares
of our common stock are issued, the relative interests of existing stockholders will be diluted.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">As of March 2, 2020,
there were 5,199,346 shares of our common stock outstanding.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We are authorized to issue up to
10,000,000 shares of preferred stock, par value $0.001 per share, in one or more classes or series within a class as may be determined
by our Board of Directors, who may establish, from time to time, the number of shares to be included in each class or series,
may fix the designation, powers, preferences and rights of the shares of each such class or series and any qualifications, limitations
or restrictions thereof. Any preferred stock so issued by the Board of Directors may rank senior to the common stock with respect
to the payment of dividends or amounts upon liquidation, dissolution or winding up of us, or both. Moreover, under certain circumstances,
the issuance of preferred stock or the existence of the unissued preferred stock might tend to discourage or render more difficult
a merger or other change of control.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">As of March 2, 2020,
there were no shares of our preferred stock outstanding.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;<A HREF="#toc">Table
                                         of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Warrants to be Issued in this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.45pt; text-indent: 33.1pt; text-align: justify"><I>The following summary of
certain terms and provisions of the warrants that are being offered hereby is not complete and is subject to, and qualified in
its entirety by the provisions of, the warrant. Prospective investors should carefully review the terms and provisions of the
form of warrant&nbsp;for a complete description of the terms and conditions of the warrants.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.45pt; text-indent: 34.55pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 34.55pt; text-align: justify"><I>Exercisability.</I>&nbsp;The warrants
are exercisable beginning on the date of original issuance and at any time up to the date that is five years after their original
issuance. The warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed
exercise notice and, at any time a registration statement registering the issuance of the shares of common stock underlying the
warrants under the Securities Act is effective and available for the issuance of such shares, or an exemption from registration
under the Securities Act is available for the issuance of such shares, by payment in full in immediately available funds for the
number of shares of common stock purchased upon such exercise. If a registration statement registering the issuance of the shares
of common stock underlying the warrants under the Securities Act is not effective or available and an exemption from registration
under the Securities Act is not available for the issuance of such shares, the holder may, in its sole discretion, elect to exercise
the warrant through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of
common stock determined according to the formula set forth in the warrant. No fractional shares of common stock will be issued
in connection with the exercise of a warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal to
the fractional amount multiplied by the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 34.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 34.55pt; text-align: justify"><I>Exercise Limitation.&nbsp;</I>A holder
will not have the right to exercise any portion of the warrant if the holder (together with its affiliates) would beneficially
own in excess of 4.99% (or, upon election of the holder, 9.99%) of the number of shares of our common stock outstanding immediately
after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants.
However, any holder may increase or decrease such percentage, provided that any increase will not be effective until the 61st
day after such election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 34.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 34.55pt; text-align: justify"><I>Exercise Price.</I>&nbsp;The warrants
will have an exercise price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (of 125% of the offering price). The exercise price is subject to appropriate
adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar
events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 34.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 34.55pt; text-align: justify"><I>Transferability.</I>&nbsp;Subject to
applicable laws, the warrants may be offered for sale, sold, transferred or assigned without our consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 34.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 34.55pt; text-align: justify"><I>Exchange Listing.
</I>There is no established trading market for the warrants. We expect the warrants will trade on the OTCQB Marketplace
under the symbol &ldquo;BIVIW.&rdquo; We cannot assure you that an active trading market for the warrants will develop or be sustained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 34.55pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 34.55pt; text-align: justify"><I>Fundamental Transactions.</I>&nbsp;If
a fundamental transaction occurs, then the successor entity will succeed to, and be substituted for us, and may exercise every
right and power that we may exercise and will assume all of our obligations under the warrants with the same effect as if such
successor entity had been named in the warrant itself. If holders of our common stock are given a choice as to the securities,
cash or property to be received in a fundamental transaction, then the holder shall be given the same choice as to the consideration
it receives upon any exercise of the warrant following such fundamental transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 34.55pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 34.55pt; text-align: justify"><I>Rights as a Stockholder</I>. Except
as otherwise provided in the warrants or by virtue of such holder&rsquo;s ownership of shares of our common stock, the holder
of a warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder
exercises the warrant.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Anti-Takeover Effects of Our Articles of Incorporation
and Bylaws</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Our Articles of Incorporation and bylaws contain certain
provisions that may have anti-takeover effects, making it more difficult for or preventing a third party from acquiring control
of us or changing our Board of Directors and management. According to our Articles of Incorporation and bylaws, neither the holders
of our common stock nor the holders of any preferred stock we may issue in the future have cumulative voting rights in the election
of our directors. The combination of the present ownership by a few stockholders of a significant portion of our issued and outstanding
common stock and lack of cumulative voting makes it more difficult for other stockholders to replace our Board of Directors or
for a third party to obtain control of us by replacing our Board of Directors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Anti-Takeover Effects of Nevada Law</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>Business Combinations</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The &ldquo;business combination&rdquo; provisions of Sections
78.411 to 78.444, inclusive, of the Nevada Revised Statutes, or NRS, generally prohibit a Nevada corporation with at least 200
stockholders from engaging in various &ldquo;combination&rdquo; transactions with any interested stockholder for a period of two
years after the date of the transaction in which the person became an interested stockholder, unless the transaction is approved
by the board of directors prior to the date the interested stockholder obtained such status or the combination is approved by the
board of directors and thereafter is approved at a meeting of the stockholders by the affirmative vote of stockholders representing
at least 60% of the outstanding voting power held by disinterested stockholders, and extends beyond the expiration of the two-year
period, unless:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the combination was approved by the board of directors prior
to the person becoming an interested stockholder or the transaction by which the person first became an interested stockholder
was approved by the board of directors before the person became an interested stockholder or the combination is later approved
by a majority of the voting power held by disinterested stockholders; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the consideration to be paid by the interested stockholder is at least equal to the highest of: (a) the highest price per share paid by the interested stockholder within the two years immediately preceding the date of the announcement of the combination or in the transaction in which it became an interested stockholder, whichever is higher, (b) the market value per share of common stock on the date of announcement of the combination and the date the interested stockholder acquired the shares, whichever is higher, or (c) for holders of preferred stock, the highest liquidation value of the preferred stock, if it is higher.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">A &ldquo;combination&rdquo; is generally defined to include
mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or other disposition, in one transaction or
a series of transactions, with an &ldquo;interested stockholder&rdquo; having: (a) an aggregate market value equal to 5% or more
of the aggregate market value of the assets of the corporation, (b) an aggregate market value equal to 5% or more of the aggregate
market value of all outstanding shares of the corporation, (c) 10% or more of the earning power or net income of the corporation,
and (d) certain other transactions with an interested stockholder or an affiliate or associate of an interested stockholder.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">In general, an &ldquo;interested stockholder&rdquo; is a
person who, together with affiliates and associates, owns (or within two years, did own) 10% or more of a corporation&rsquo;s voting
stock. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage
attempts to acquire our Company even though such a transaction may offer our stockholders the opportunity to sell their stock at
a price above the prevailing market price.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>Control Share Acquisitions</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The &ldquo;control share&rdquo; provisions of Sections 78.378
to 78.3793, inclusive, of the NRS apply to &ldquo;issuing corporations&rdquo; that are Nevada corporations with at least 200 stockholders,
including at least 100 stockholders of record who are Nevada residents, and that conduct business directly or indirectly in Nevada.
The control share statute prohibits an acquirer, under certain circumstances, from voting its shares of a target corporation&rsquo;s
stock after crossing certain ownership threshold percentages, unless the acquirer obtains approval of the target corporation&rsquo;s
disinterested stockholders. The statute specifies three thresholds: one-fifth or more but less than one-third, one-third but less
than a majority, and a majority or more, of the outstanding voting power. Generally, once an acquirer crosses one of the above
thresholds, those shares in an offer or acquisition and acquired within 90 days thereof become &ldquo;control shares&rdquo; and
such control shares are deprived of the right to vote until disinterested stockholders restore the right. These provisions also
provide that if control shares are accorded full voting rights and the acquiring person has acquired a majority or more of all
voting power, all other stockholders who do not vote in favor of authorizing voting rights to the control shares are entitled to
demand payment for the fair value of their shares in accordance with statutory procedures established for dissenters&rsquo; rights.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">A corporation may elect to not be governed by, or &ldquo;opt
out&rdquo; of, the control share provisions by making an election in its articles of incorporation or bylaws, provided that the
opt-out election must be in place on the 10th day following the date an acquiring person has acquired a controlling interest, that
is, crossing any of the three thresholds described above. We have not opted out of the control share statutes, and will be subject
to these statutes if we are an &ldquo;issuing corporation&rdquo; as defined in such statutes.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The effect of the Nevada control share statutes is that the
acquiring person, and those acting in association with the acquiring person, will obtain only such voting rights in the control
shares as are conferred by a resolution of the stockholders at an annual or special meeting. The Nevada control share law, if applicable,
could have the effect of discouraging takeovers of our Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Trading Market</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> Our common stock currently trades on the
OTCQB Marketplace under the ticker &ldquo;BIVI&rdquo; We expect our warrants will trade on the OTCQB Marketplace under the symbol
&ldquo;BIVIW&rdquo; after the consummation of this offering. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Our independent stock transfer agent is West Coast Stock
Transfer, Inc., located at 721 N. Vulcan Ave., Suite 205, Encinitas, California 92024. Their phone number is (619) 664-4780.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Disclosure of Commission Position
on Indemnification for Securities Act Liabilities</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing
provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in
the Securities Act and is, therefore, unenforceable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="a_015"></A> <B>plan
of distribution</B> </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"> <FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Pursuant to a placement agency agreement,
we have engaged ThinkEquity, a division of Fordham Financial Management, Inc., or the placement agent, to act as our exclusive
placement agent in connection with this offering of our securities pursuant to this prospectus on a reasonable best efforts basis,
provided that members of our management and/or controlling stockholder will also attempt to assist us in the sales of the securities
pursuant to this prospectus, with no commission or other remuneration payable to them or to ThinkEquity, a division of Fordham
Financial Management, Inc. for any units they may sell. Management and our controlling stockholder will rely on the safe harbor
from broker-dealer registration set forth in Rule 3a4-1 under the Securities Exchange Act of 1934, as amended. The placement
agency agreement does not give rise to any commitment by the placement agent to purchase any of our securities, and the placement
agent will have no authority to bind us by virtue of the placement agency agreement. The placement agent may engage sub-agents
or selected dealers to assist with the offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Only certain institutional investors purchasing
the securities offered hereby will execute a securities purchase agreement with us, the form of which has been filed as an exhibit
to the registration statement of which this prospectus is a part, providing such investors with certain representations, warranties
and covenants from us, which representations, warranties and covenants will not be available to other investors who will not execute
a securities purchase agreement in connection with the purchase of the securities offered pursuant to this prospectus. Therefore,
those investors shall rely solely on this prospectus in connection with the purchase of securities in the offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Neither the placement agent nor our management
or controlling stockholder is required to arrange the purchase or sale of any specific number or dollar amount of securities.
The placement agent has agreed to use reasonable best efforts to arrange for the sale of the securities. There is no required
minimum number of securities that must be sold as a condition to completion of this offering. Further, the placement agent does
not guarantee that it will be able to raise new capital in any prospective offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> We will deliver the securities being issued
to the investors upon receipt of investor funds for the purchase of the securities offered pursuant to this prospectus. We expect
to deliver the securities being offered pursuant to this prospectus on or about March [__], 2020. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> The placement agent may be deemed to be
an underwriter within the meaning of Section 2(a)(11) of the Securities Act, and any commissions received by the placement agent
and any profit realized on the resale of our securities sold by the placement agent while acting as principal might be deemed
to be underwriting discounts or commissions under the Securities Act. As an underwriter, the placement agent would be required
to comply with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule 415(a)(4) under
the Securities Act and Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of
purchases and sales of our securities by the placement agent acting as principal. Under these rules and regulations, the placement
agent: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD STYLE="text-align: justify"> may
                                         not engage in any stabilization activity in connection with our securities; and </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"> <FONT STYLE="font-family: Symbol">&middot;</FONT> </TD><TD STYLE="text-align: justify"> may
                                         not bid for or purchase any of our securities or attempt to induce any person to purchase
                                         any of our securities, other than as permitted under the Exchange Act, until it has completed
                                         its participation in the distribution. </TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> <B>State Blue Sky Information</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> We have applied to register our
securities to offer and sell the units to retail customers in certain states. Accordingly, we will offer and sell the units
to retail customers only in Colorado, Delaware, the District of Columbia, Florida, Georgia, Hawaii, Illinois, Indiana,
Louisiana, Maryland, Minnesota, Missouri, Montana, New Hampshire, New York, Ohio, Oregon, Rhode Island, Tennessee, Texas,
Vermont, Virginia, Wisconsin and Wyoming. In New York and Hawaii, we have relied on exemptions from the state
registration requirements. In the other states, we have applied to have the units registered for sale and will not sell the
units to retail customers in these states unless and until such registration is effective (including in Colorado, pursuant to
11-51-302(6) of the Colorado Revised Statutes). </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> If you are not an institutional investor, you may purchase our securities in this offering only in the jurisdictions
described directly above. Institutional investors in every state may purchase the units in this offering pursuant to exemptions
under the Blue Sky laws of various states. The definition of an &ldquo;institutional investor&rdquo; varies from state to state
but generally includes financial institutions, broker-dealers, banks, insurance companies and other qualified entities. In states
that require registration, we will not sell the units to retail customers in these states until such registration is effective
in each of these states (including in Colorado, pursuant to 11-51-302(6) of the Colorado Revised Statutes). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>
<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> We file periodic and annual reports under the Securities Exchange Act of 1934, as amended. Under the National Securities Markets Improvement Act of 1996 ("NSMIA"), which preempts the states from regulating (i.e., requiring registration or qualification) transactions in certain securities referred to as "covered securities," the resale of the units, and the shares and warrants comprising the units, once they become separately transferable, are exempt from state registration requirements under NSMIA. However, states are permitted to require notice filings and collect fees with regard to these transactions, and a state may suspend the offer and sale of securities within such state if any such required filing is not made or fee is not paid. Absent compliance with such individual state laws, our common stock may not be traded in such jurisdictions. Because the securities registered hereunder have not been registered for resale under the blue sky laws of any state, nor have any required notice filings or fees been submitted for any resale in any state, the holders of such shares and persons who desire to purchase them in any trading market that might develop in the future, should be aware that there may be significant state blue-sky law restrictions upon the ability of investors to sell the securities and of purchasers to purchase the securities. Accordingly, investors may not be able to liquidate their investments and should be prepared to hold the common stock for an indefinite period of time. If any state has not yet adopted a statute relating to NSMIA and any required notice and/or fee filing, adopts such a statute in the future, or if any state amends its existing statutes with respect to its requirements, compliance with those new requirements would be required in order for our securities to continue to be eligible for resale in those jurisdictions. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Aside from the exemption from registration provided by NSMIA, we believe that the units, from and after the effective date, and the common stock and warrants comprising the units, once they become separately transferable, will be eligible for sale on the secondary market basis in various states based on the availability of another applicable exemption from state registration requirements, in certain instances subject to waiting periods, notice filings or fee payments. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> <B>Fees and Expenses</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> We have agreed to pay the placement agent
a total cash fee equal to 7% of the gross proceeds of this offering from units sold by the placement
agent. We will also pay the placement agent a reimbursement for non-accountable expenses equal to 1% of the gross proceeds of this
offering from units sold by the placement agent and reimbursement for the placement agent's legal fees and expenses in the amount
of up to $75,000. In addition, we have also agreed to pay the following expenses of the placement agent relating to the offering:
(a) all fees, expenses and disbursements relating to background checks of our officers and directors in an amount not to exceed
$15,000 in the aggregate; (b) all filing fees and communication expenses associated with the review of this offering by FINRA;
(c) all fees, expenses and disbursements relating to the registration, qualification or exemption of securities offered under the
securities laws of foreign jurisdictions designated by the placement agent, including without limitation, all filing and registration
fees, and we will pay $5,000 to the placement agent&rsquo;s blue sky counsel upon the commencement of blue-sky work by such counsel
and an additional $10,000 at the closing of this offering; (d) $29,500 for the placement agent&rsquo;s use of Ipreo&rsquo;s prospectus
tracking and compliance software for this offering; (e) $2,000 for the costs associated with commemorative mementos and lucite
tombstones, (f) the fees and expenses of the representatives&rsquo; legal counsel incurred in connection with this offering in
an amount up to $75,000; and (g) up to $20,000 of the representative&rsquo;s actual accountable road show expenses for the offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> We estimate the total offering expenses
of this offering that will be payable by us, excluding the placement agent's fees and expenses, will be approximately $[675,000]. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"> <B>Placement Agent Warrants</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> Upon the closing of this offering, we have
agreed to issue to the placement agent warrants, or the Agent&rsquo;s Warrants, to purchase
a number of shares of common stock equal to 5% of the total number of shares of common stock sold as part of the units sold by
the placement agent in this public offering. The Agent&rsquo;s Warrants will be exercisable at a per share exercise price equal
to 125% of the public offering price per unit sold in this offering. The Agent&rsquo;s Warrants are exercisable at any time and
from time to time, in whole or in part, during the four year period commencing one year from the effective date of the registration
statement related to this offering. The Agent&rsquo;s Warrants also provide for one demand registration right of the shares of
common stock underlying the Agent&rsquo;s Warrants, and unlimited &ldquo;piggyback&rdquo; registration rights with respect to the
registration of the shares of common stock underlying the Agent&rsquo;s Warrants and customary antidilution provisions. The demand
registration right provided will not be greater than five years from the effective date of the registration statement related to
this offering in compliance with FINRA Rule 5110(f)(2)(G). The piggyback registration right provided will not be greater than seven
years from the effective date of the registration statement related to this offering in compliance with FINRA Rule 5110(f)(2)(G). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>



<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> The Agent&rsquo;s Warrants and the shares
of common stock underlying the Agent&rsquo;s Warrants, have been deemed compensation by the Financial Industry Regulatory Authority,
or FINRA, and are therefore subject to a 180-day lock-up pursuant to Rule&nbsp;5110(g)(1) of FINRA. The representative, or permitted
assignees under such rule, may not sell, transfer, assign, pledge, or hypothecate the Agent&rsquo;s Warrants or the securities
underlying the Agent&rsquo;s Warrants, nor will the representative engage in any hedging, short sale, derivative, put, or call
transaction that would result in the effective economic disposition of the Agent&rsquo;s Warrants or the underlying shares of
common stock for a period of 180&nbsp;days from the effective date of the registration statement. Additionally, the Agent&rsquo;s
Warrants may not be sold transferred, assigned, pledged or hypothecated for a 180-day period following the effective date of the
registration statement except to any dealer participating in the offering and their bona fide officers or partners. The Agent&rsquo;s
Warrants will provide for adjustment in the number and price of the Agent&rsquo;s Warrants and the shares of common stock underlying
such Agent&rsquo;s Warrants in the event of recapitalization, merger, stock split or other structural transaction, or a future
financing undertaken by us. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <B>Right of First Refusal</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> Until &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2021, 12 months from the effective date of the registration statement of which this prospectus is a part, the placement
agent shall have an irrevocable right of first refusal to act as sole investment banker, sole book-runner and/or sole placement
agent, at the representative sole discretion, for each and every future public and private equity and debt offerings for the Company,
or any successor to or any subsidiary of the Company, including all equity linked financings, on terms customary to the representative.
The representative shall have the sole right to determine whether or not any other broker-dealer shall have the right to participate
in any such offering and the economic terms of any such participation. The representative will not have more than one opportunity
to waive or terminate the right of first refusal in consideration of any payment or fee. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> <B>Lock-up Agreements</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> <B>&nbsp;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; background-color: white"> The Company,
each of its directors and officers and 5% or greater holders of the Company&rsquo;s outstanding shares of common stock as of the
date of this prospectus, have agreed for a period of (i) six months after the date of this prospectus in the case of directors
and officers and (ii) three months after the date of this prospectus in the case of the Company and the 5% or greater holders
of the Company&rsquo;s outstanding common stock, without the prior written consent of the placement agent, not to directly or
indirectly: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"> &nbsp; </TD>
    <TD STYLE="width: 24px; text-align: justify"> &#9679; </TD>
    <TD STYLE="text-align: justify"> issue (in the case of us), offer, pledge, sell, contract to sell, sell any option or contract
    to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer
    or dispose of any shares of common stock or other capital stock or any securities convertible into or exercisable or exchangeable
    for our common stock or other capital stock; or </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"> &nbsp; </TD>
    <TD STYLE="width: 24px; text-align: justify"> &#9679; </TD>
    <TD STYLE="text-align: justify"> in the case of the Company, file or cause the filing of any registration statement under
    the Securities Act with respect to any shares of common stock or other capital stock or any securities convertible into or
    exercisable or exchangeable for our common stock or other capital stock; or </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"> &nbsp; </TD>
    <TD STYLE="width: 24px; text-align: justify"> &#9679; </TD>
    <TD STYLE="text-align: justify"> complete any offering of debt securities of the Company, other than entering into a line
    of credit, term loan arrangement or other debt instrument with a traditional bank; or </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"> &nbsp; </TD>
    <TD STYLE="width: 24px; text-align: justify"> &#9679; </TD>
    <TD STYLE="text-align: justify"> enter into any swap or other agreement, arrangement, hedge or transaction that transfers
    to another, in whole or in part, directly or indirectly, any of the economic consequences of ownership of our common stock
    or other capital stock or any securities convertible into or exercisable or exchangeable for our common stock or other capital
    stock, whether any transaction described in any of the foregoing bullet points is to be settled by delivery of our common
    stock or other capital stock, other securities, in cash or otherwise, or publicly announce an intention to do any of the foregoing. </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> <B>Indemnification</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> We have agreed to indemnify the placement
agent and specified other persons against certain liabilities relating to or arising out of the placement agent's activities under
the engagement agreement and to contribute to payments that the placement agent may be required to make in respect of such liabilities. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> <B>Determination of Offering Price</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> The offering price of the securities
we are offering will be negotiated between us and the investors, in consultation with the placement agent based on the trading
of our securities prior to the offering, among other things. Other factors we will consider in determining the offering price
of the securities we are offering include the history and prospects of the Company, the stage of development of our business,
our business plans for the future and the extent to which they have been implemented, an assessment of our management, general
conditions of the securities markets at the time of the offering and such other factors as were deemed relevant. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> &nbsp; </P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> <B>Other Relationships</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> From time to time, the placement
agent has provided, and may provide in the future, various advisory, investment and commercial banking and other services to us
in the ordinary course of business, for which they have received and may continue to receive customary fees and commissions. However,
except as disclosed in this prospectus, we have no present arrangements with the placement agent for any further services. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> <B>Canada</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"> The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a legal advisor. Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI33-105 regarding underwriter conflicts of interest in connection with this offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><A NAME="a_016"></A><FONT STYLE="text-transform: uppercase"><B>Experts</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
balance sheet of BioVie Inc. as of June 30, 2019 and the related statements of operations, changes in stockholders&rsquo; equity, and cash flow for the year
ended June 30, 2019, have been audited by EisnerAmper LLP, independent registered public accounting firm, as stated in their report
which is incorporated herein, which report includes an explanatory paragraph about the existence of substantial doubt concerning
the Company&rsquo;s ability to continue as a going concern. Such financial statements have been incorporated herein in reliance
on the report of such firm given upon their authority as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The audited balance sheet of BioVie Inc.
as June 30, 2018 and the related statements of operations, changes in stockholders&rsquo; equity and cash flows for the year then
ended, included in this prospectus and elsewhere in the registration statement have been so included in reliance upon the reports
of D. Brooks and Associates CPA&rsquo;s, P.A., independent registered public accountants, upon the authority of said firm as experts
in accounting and auditing.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><A NAME="a_017"></A><FONT STYLE="text-transform: uppercase"><B>Legal
Matters</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Loeb &amp; Loeb LLP, Los Angeles,
California, and New York, New York, will pass upon the validity of the securities offered hereby. Certain matters are being passed
on for the placement agent by Greenberg Traurig, LLP, McLean, Virginia. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_018"></A>Where
You Can Find More Information&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We have filed with the SEC a registration
statement on Form&nbsp;S-1 under the Securities Act with respect to the securities offered by this prospectus. This prospectus,
which constitutes a part of the registration statement, does not contain all of the information set forth in the registration
statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations of the
SEC. For further information with respect to us and our securities, we refer you to the registration statement, including
the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of
any contract or any other document is not necessarily complete. If a contract or document has been filed as an exhibit to the
registration statement, please see the copy of the contract or document that has been filed. Each statement is this prospectus
relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC maintains an
Internet website that contains reports, proxy statements and other information about issuers, like us, that file electronically
with the SEC. The address of that website is <U>www.sec.gov</U>.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We are subject to the information and
reporting requirements of the Securities Exchange Act of 1934, as amended, and, in accordance with this law, file periodic reports,
proxy statements and other information with the SEC. These periodic reports, proxy statements and other information are available
on the website of the SEC referred to above.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><A NAME="a_019"></A><B>Index to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 88%"><A HREF="#a_206"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm &ndash; EisnerAmper LLP</FONT></A></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: right"><A HREF="#a_206"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-indent: 30.75pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top"><A HREF="#a_207"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm &ndash; D Brooks and Associates CPA&rsquo;s, P.A.</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#a_207"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements for the years ended June 30, 2019 and 2018:</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_201"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Sheets</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#a_201"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;F-4</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_202"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Operations</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#a_202"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;F-5</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_203"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Changes in Stockholders&rsquo; Equity</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#a_203"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;F-6</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_204"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Cash Flows</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#a_204"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;F-7</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_205"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Financial Statements</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#a_205"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;F-8</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
    <TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unaudited
    financial statements for the three and six months ended December 31, 2019 and 2018:</FONT> </TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_311"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Sheets</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#a_311"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;F-26</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_312"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Operations</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#a_312"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;F-27</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_313"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Changes in Stockholders&rsquo; Equity</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#a_313"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;F-28</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_314"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Cash Flows</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#a_314"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;F-29</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top; padding-left: 27pt"><A HREF="#a_315"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Financial Statements</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="text-align: right"><A HREF="#a_315"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;F-30</FONT></A></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: right">&nbsp;</P>

<!-- Field: Page; Sequence: 58; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center; text-indent: 0.5in"><B><A NAME="a_206"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">To the Board of Directors and Stockholders
of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">BioVie. Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>Opinion on the Financial Statements </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We have audited the accompanying balance sheet
of BioVie, Inc. (the &ldquo;Company") as of June 30, 2019 and the related statements of operations, changes in stockholders&rsquo;
equity, and cash flows for the year then ended, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of
June 30, 2019, and the results of its operations and its cash flows for the year then ended in conformity with accounting principles
generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; color: blue">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>Going Concern</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; color: blue">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The accompanying financial statements have
been prepared assuming that the Company will continue as a going concern. As discussed in Note&nbsp;2 to the financial statements,
the Company&rsquo;s recurring losses from operations and negative cash flows from operating activities raise substantial doubt
about its ability to continue as a going concern. Management&rsquo;s plans in regard to these matters are also described in Note
2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; color: blue">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B><I>Basis for Opinion </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">These financial statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based
on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB")
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,
nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the
effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Our audit included performing procedures to
assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable
basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">/s/ EisnerAmper LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We have served as the Company&rsquo;s auditor
since 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">EISNERAMPER LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Iselin, New Jersey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">September 25, 2019, except for Note 1 (Reverse
Stock Split) as to which date is November 22, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><B><A NAME="a_207"></A>REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0; text-align: left">To the Board of Directors and<BR>
Stockholders of BioVie, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0; text-align: justify"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0; text-align: justify">We have audited the accompanying balance
sheets of BioVie, Inc. (the Company) as of June 30, 2018, and the related statements of operations, stockholders&rsquo; equity,
and cash flows for each of the year then ended, and the related notes (collectively referred to as the financial statements). In
our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June
30, 2018, and the results of its operations and its cash flows the year ended June 30, 2018, in conformity with accounting principles
generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0; text-align: justify"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0; text-align: justify">These financial statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based
on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0; text-align: justify">We conducted our audit in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,
nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required
to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the
effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0; text-align: justify">Our audit included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made
by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provide a
reasonable basis for our opinion.&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 4.5pt; padding-left: 4.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 82%; padding-right: 4.5pt; padding-left: 4.5pt">
        <P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0">/s/ D. Brooks and Associates CPA&rsquo;s, P.A.</P></TD>
    <TD STYLE="width: 18%; padding-right: 4.5pt; padding-left: 4.5pt; font: 10pt/106% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 4.5pt; padding-left: 4.5pt">
        <P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0">We have served as the Company&rsquo;s auditor since 2017 through
        January 18, 2019.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt/106% Times New Roman, Times, Serif; padding-right: 4.5pt; padding-left: 4.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt/106% Times New Roman, Times, Serif; padding-right: 4.5pt; padding-left: 4.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 4.5pt; padding-left: 4.5pt">
        <P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: left">Palm Beach Gardens, Florida</P>
        <P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: left">October 4, 2018, except for the
        common share, per share and loss per share presentation on a post-reverse split basis dated November 22,
        2019</P>
        <P STYLE="font: 10pt/106% Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD></TR>
</TABLE>

<P STYLE="font: 12pt/107% Times New Roman, Times, Serif; margin: 0 0 0">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B><A NAME="a_201"></A>Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; padding-left: 10pt">Cash</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">339,923</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">45,800</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other Assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">334,150</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total Current Assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">674,073</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">45,800</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">OTHER&nbsp;&nbsp;ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Intangible Assets, Net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,554,603</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,783,980</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt">Goodwill</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">345,711</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">345,711</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total Other Assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,900,314</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,129,691</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4.5pt; padding-left: 5.4pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">2,574,387</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">2,175,491</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts Payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">443,480</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">884,207</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accrued Payroll</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">354,167</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total Current Liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">443,480</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,238,374</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">LONG-TERM LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Demand Promissory Note</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Notes Payable, Related Parties</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">575,918</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">&nbsp;Total Long-Term Liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">825,918</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">TOTAL LIABILITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">443,480</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,064,292</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Commitments and contingencies (Note 7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">STOCKHOLDERS' EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 10pt; padding-left: 10pt">Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt; padding-left: 10pt">Common stock, $0.0001 par value; 800,000,000 and 300,000,000 shares authorized at June 30, 2019 and June 30, 2018, respectively; 4,058,442 and 788,026 shares issued and outstanding at June 30, 2019 and June 30, 2018, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">406</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 10pt; padding-left: 10pt">Additional paid in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,392,573</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,880,246</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 10pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,262,072</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,769,126</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total Stockholders' Equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,130,907</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">111,199</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4.5pt; padding-left: 5.4pt">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">2,574,387</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">2,175,491</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>The accompanying notes are an integral part
of the financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B><A NAME="a_202"></A>Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Year ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Year ended</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 5.4pt">REVENUE</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 11pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">OPERATING EXPENSES:</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; padding-left: 10pt">Amortization</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">229,377</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">229,377</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,008,100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">370,852</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Selling, general and administrative expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,259,096</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,771,937</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">TOTAL OPERATING EXPENSES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,496,573</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,372,166</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 11pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">LOSS FROM OPERATIONS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,496,573</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,372,166</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 11pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">OTHER EXPENSE (INCOME):</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Gain on settlement of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(51,400</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">273</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,960</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Interest income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,159</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">TOTAL OTHER EXPENSE (INCOME), NET</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(52,286</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">40,956</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 11pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4.5pt; padding-left: 5.4pt">NET LOSS</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">(2,444,287</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">(2,413,122</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividend related to ratchet adjustment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">48,659</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">20,995</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4.5pt; padding-left: 5.4pt">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">(2,492,946</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">(2,434,117</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4.5pt; padding-left: 5.4pt">NET LOSS PER SHARE BASIC AND DILUTED</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">(0.98</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">(3.18</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 5.4pt">WEIGHTED AVERAGE NUMBER OF</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4.5pt; padding-left: 10pt">COMMON&nbsp;&nbsp;SHARES OUTSTANDING BASIC AND DILUTED</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">2,539,611</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">766,065</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>The accompanying notes are an integral part
of the financial statements.<BR STYLE="clear: both">
</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B><A NAME="a_203"></A>Statements of Changes in Stockholders&rsquo;
Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Preferred</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Preferred</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Common</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Common</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Additional</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Total</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Paid in</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Stockholders'</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 37%; padding-bottom: 4.5pt; padding-left: 5.4pt">Balance, June 30, 2017</TD><TD STYLE="width: 2%; padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; border-bottom: Black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="width: 5%; border-bottom: Black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; border-bottom: Black 4.5pt double; text-align: right">735,400</TD><TD STYLE="width: 1%; padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="width: 5%; border-bottom: Black 4.5pt double; text-align: right">74</TD><TD STYLE="width: 1%; padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="width: 5%; border-bottom: Black 4.5pt double; text-align: right">3,492,254</TD><TD STYLE="width: 1%; padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="width: 5%; border-bottom: Black 4.5pt double; text-align: right">(2,335,009</TD><TD STYLE="width: 1%; padding-bottom: 4.5pt; text-align: left">)</TD><TD STYLE="width: 2%; padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="width: 5%; border-bottom: Black 4.5pt double; text-align: right">1,157,319</TD><TD STYLE="width: 1%; padding-bottom: 4.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Issuance of shares and warrants for cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,838</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">444,998</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">444,999</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">Issuance of shares for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,988</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">642,846</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">642,850</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Options vested</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">238,165</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">238,165</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">Exercise of options for cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Issuance of warrants for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,469</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,469</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Issuance of warrants with debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,519</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,519</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Deemed dividends for ratchet adjustment to warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,995</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,995</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,413,122</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,413,122</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4.5pt; padding-left: 5.4pt">Balance, June 30, 2018</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">788,026</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">79</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">4,880,246</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">(4,769,126</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">111,199</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Issuance of preferred stock in a private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,133,332</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,200,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Conversion of preferred stock to common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,133,332</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,200,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,706,666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">171</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(171</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Issuance of shares in exchange for debt settlement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,804</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,150,134</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,150,135</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">Issuance of shares for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,999</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Stock option compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,860</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,860</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">Cashless exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,544,746</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">154</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(154</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Deemed dividends for ratchet adjustment to warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,659</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(48,659</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,444,287</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,444,287</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4.5pt; padding-left: 5.4pt">Balance, June 30, 2019</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">4,058,442</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">406</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">9,392,573</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">(7,262,072</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">2,130,907</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>The accompanying notes are an integral part
of the financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B><A NAME="a_204"></A>Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Year ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Year ended</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-left: 10pt">Net loss</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(2,444,287</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(2,413,122</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Adjustments to reconcile net loss to net cash to cash used in operating activities:</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Common shares issued for service</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">655,319</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Amortization of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229,377</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">229,377</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;Amortization of debt discount</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,519</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Stock based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,860</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">238,165</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Gain on settlement of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Changes in operating assets and liabilities</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(334,150</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(117,777</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">413,234</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accrued payroll</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">229,167</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,501,577</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(621,341</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Repayment of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(244,300</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Proceeds from issuance of preferred shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,040,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Proceeds from issuance of common stock and warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">446,999</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,795,700</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">661,999</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Net increase in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">294,123</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,658</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 5.4pt">Cash, beginning of period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">45,800</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,140</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4.5pt; padding-left: 5.4pt">Cash, end of period</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">339,923</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">45,800</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">SUPPLEMENTAL CASH FLOW INFORMATION:</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4.5pt; padding-left: 10pt">&nbsp;&nbsp;Cash paid for interest</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4.5pt; padding-left: 10pt">&nbsp;&nbsp;Cash paid for taxes</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 11pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 5.4pt">SCHEDULE OF NON-CASH FINANCING ACTIVITIES:</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4.5pt; padding-left: 10pt">&nbsp;&nbsp;&nbsp;Conversion of preferred shares to common stock</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">3,200,000</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4.5pt; padding-left: 10pt">&nbsp;&nbsp;&nbsp;Settlement of debt by issuance of common stock and forgiveness of debt</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">1,150,135</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4.5pt; padding-left: 10pt">&nbsp;&nbsp;&nbsp;Cashless exercise of warrants</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">19,309</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4.5pt; padding-left: 10pt">&nbsp;&nbsp;&nbsp;Deemed dividends for ratchet adjustments to warrants</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">48,659</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><I>The accompanying notes are an integral part
of the financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B><A NAME="a_205"></A>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Background Information
    and Reverse Stock Split</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><I>Background Information</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">We are a
clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. We are
currently focused on developing and commercializing BIV201 (continuous infusion terlipressin), a novel approach to the
treatment of ascites due to chronic liver cirrhosis. Our therapy BIV201 is based on a drug that is approved in about 40
countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet
available in the United States. BIV201&rsquo;s active agent is a potent vasoconstrictor and has shown efficacy for reducing
portal hypertension in studies around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby
halting the cycle of accelerating fluid generation in ascites patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In April 2017, we entered into a CRADA
with the McGuire Research Institute Inc. in Richmond, VA, and began administering BIV201 to patients in September 2017. In April
2019, we announced top-line results for our Phase 2a clinical trial of BIV201 (continuous infusion terlipressin) in six patients
with refractory ascites due to advanced liver cirrhosis. On June 18, 2019, we met with representatives of the FDA for Type C Guidance
Meeting to plan our next clinical study following the recently completed Phase 2a clinical trial. We discussed our clinical development
efforts with the FDA and proposed trial endpoints. While the FDA has not provided final guidance nor do we have certainty as to
what that guidance would entail, our goal remains to proceed into a Phase 2b/3 or Phase 3 clinical trial in a manner consistent
with what was reviewed with the FDA. We may still need to address certain risks associated with unvalidated quality of life measures.
In July 2019, the FDA provided meeting minutes for the June 18, 2019 meeting that documented general agreement with the Company
proposed randomized study design. The FDA also provided its suggestions and guidance regarding primary and secondary endpoints
and other key aspects of our clinical trial design and the Company is incorporating those suggestions as it moves forward. We are
developing a proprietary novel liquid formulation of terlipressin that is intended to improve convenience for outpatient administration
and avoid potential formulation errors when pharmacists reconstitute the powder version.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">BIV201 has the potential to improve
the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic
steatohepatitis (NASH), and alcoholism. It has FDA Fast-Track status and Orphan Drug designation for the most common of these complications,
ascites, which represents a significant unmet medical need. The FDA has never approved any drug specifically for treating ascites.
The Company has secured a US Patent covering the use of BIV201 for the treatment of ascites patients in the outpatient setting
using ambulatory pump infusion, and has filed patent applications for its product candidate in Japan, and Europe, Hong Kong, and
China. BIV201 also received Orphan Drug designation for hepatorenal syndrome (&ldquo;HRS&rdquo;) in November 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The BIV201 development program began
at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The
Company currently owns all development and marketing rights to its drug candidate. The Company and PharmaIN, Corp. (&ldquo;PharmaIN&rdquo;),
LAT Pharma&rsquo;s former partner focused on the development of new modified drug candidates in the same therapeutic field but
not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development
programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24,
2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously
paid the remaining balance due on a related debt. PharmaIN, Corp.&rsquo;s rights to our program remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company&rsquo;s activities are
subject to significant risks and uncertainties including failure to secure additional funding to properly execute the Company&rsquo;s
business plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><I>Reverse Stock Split</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On November 21, 2019,
the Company effected a 1:125 reverse stock split of the Company&rsquo;s common stock. The reverse split combined each
125 shares of the Company&rsquo;s issued and outstanding common stock into 1 share of the common stock. No fractional shares
were issued in connection with the reverse split, and any fractional shares resulting from the reverse split were rounded up
to the nearest whole share. Unless the context otherwise requires, all references in these financial statements to shares of
the Company&rsquo;s common stock, options and warrants, including prices per share of its common stock reflect the
Reverse Stock Split.</P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity and Going Concern</B></FONT></td>
        </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company&rsquo;s operations are
subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not
limited to: the results of clinical testing and trial activities of the Company&rsquo;s products, the Company&rsquo;s ability to
obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other
companies, the price of, and demand for, Company products, the Company&rsquo;s ability to negotiate favorable licensing or other
manufacturing and marketing agreements for its products, and the Company&rsquo;s ability to raise capital. The Company&rsquo;s
financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization
of assets and the satisfaction of liabilities in the normal course of business. The Company has experienced losses since inception
and has an accumulated deficit of approximately $7.3 million at June 30, 2019. In addition, the Company has not generated any revenues
and no revenues are anticipated in the foreseeable future. The Company&rsquo;s future operations are dependent on the success of
the Company&rsquo;s ongoing development and commercialization efforts, as well as continuing to secure additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In July 2018, the Company completed
a capital raise from Acuitas Group Holding, LLC (&ldquo;Acuitas&rdquo;) and other purchasers and received net proceeds of $3.2
million ( see note 8 &ldquo;Equity Transactions&rdquo;) and resumed further clinical development of BIV201 and completed its Phase
2a clinic trial program. The Company is pursuing various options to raise further financing to continue the testing and development
of its product. If the Company is not successful in raising additional funds it may reduce its monthly spend and potentially delay
the implementation of the larger scale Phase 2b Clinical trial until sufficient funding is secured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Additionally, in April 2019, to
facilitate our planned uplisting to the NASDAQ Stock Market and related potential future issuances and sales of our equity securities
for ordinary corporate finance and general corporate purposes and as recommended by our Board of Directors (&ldquo;Board&rdquo;),
our stockholders approved an amendment to our Articles of Incorporation to effect a reverse split of our outstanding Class A common
stock in the range of 50:1 to 200:1, as determined by our Board. Following that approval, we filed a Registration Statement on
Form S-1 (Registration No. 333-231136) (the S-1 Registration Statement) pursuant to which we anticipate completing an offering
of our equity securities with proceeds sufficient to enable the launch and completion of the BIV201 Phase 2b study and fund our
internal operations for at least the next twelve months. There can be no assurance, however, that we will achieve effectiveness
of the S-1 Registration Statement or successfully complete an offering thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The future viability of the Company
is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources
of funding may include sales of equity, obtaining loans, or other strategic transactions. Although management continues to pursue
these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to
the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company&rsquo;s ability
to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this
uncertainty.</P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significant Accounting Policies</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Basis of Presentation </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.05pt 0 0; text-align: justify">The Company&rsquo;s financial
statements have been prepared in accordance with accounting principles generally accepted in the United States (&ldquo;GAAP&rdquo;)
and include all adjustments necessary for the fair presentation of the Company&rsquo;s financial position for the periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Use of Estimates</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 6.95pt 0 0; text-align: justify">The preparation of financial
statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the
financial statements and accompanying notes. The Company bases its estimates on historical experience and on various assumptions
that are believed to be reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&rsquo;s
balance sheet and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions,
which are used <FONT STYLE="letter-spacing: -0.15pt">for, </FONT>but not limited to, accounting for share-based compensation, accounting
for derivatives and accounting for income taxes. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Cash</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers all highly liquid instruments with original
maturities of three months or less to be cash equivalents. Cash is maintained at one financial institution and, at times, balances
may exceed federally insured limits. The Company has never experienced any losses related to these balances. All of the Company&rsquo;s
cash balances were fully insured at June 30, 2019.<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Other Assets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Other Assets consists of direct cost related to capital raise and
filing of the registration statement legal fees and investment banking fees incurred to raise capital. The costs will be expensed
once the Company raises the capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Fair Value of Financial Instruments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.15pt 0 0; text-align: justify">Fair value is defined as the
price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants
at the measurement date. When determining the fair value for applicable assets and liabilities, we consider the principal or most
advantageous market in which we would transact and we consider assumptions market participants would use when pricing the asset
or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. This guidance also establishes a fair value
hierarchy to prioritize inputs used in measuring fair value as follows:</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0.2pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.05pt">&#9679;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Level 1: Observable inputs such as quoted prices in active markets&#894;</FONT></TD></TR></TABLE>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0.45pt 0 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.05pt">&#9679;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Level 2: Inputs, other than quoted prices in active markets, that are observable either directly
or indirectly&#894; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 26pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.05pt">&#9679;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting
entity to develop its own assumptions</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s financial instruments include cash, accounts payable, related party loans and a demand promissory note. The carrying
amounts of cash and accounts payable approximate their fair value, due to the short-term nature of these items.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significant Accounting Policies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Long-Term Notes Payable</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company&rsquo;s long-term notes
payable include accrued payroll to officers and accrued payments to third party consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Research and Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.05pt 7.25pt 0 0; text-align: justify">Research and development
expenses consist primarily of costs associated with the preclinical and/ or clinical trials of drug candidates, compensation and
other expenses for research and development, personnel, supplies and development materials, costs for consultants and related contract
research and facility costs. Expenditures relating to research and development are expensed as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Income Taxes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7pt 0 0; text-align: justify">The Company uses the asset and
liability method of accounting for deferred income taxes. Deferred income taxes are measured by applying enacted statutory rates
to net operating loss carryforwards and to the differences between the financial reporting and tax bases of assets and liabilities.
Deferred tax assets are reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all
of the deferred tax assets will not be realized.</P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0.15pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 7.05pt 0 0; text-align: justify">The Company recognizes uncertainty
in income taxes in the financial statements using a recognition threshold and measurement attribute of a tax position taken or
expected to be taken in a tax return. The Company applies the &ldquo;more-likely-than-not&rdquo; recognition threshold to all tax
positions, commencing at the adoption date of the applicable accounting guidance, which resulted in no unrecognized tax benefits
as of such date. Additionally, there have been no unrecognized tax benefits subsequent to adoption. The Company has opted to classify
interest and penalties that would accrue, if any, according to the provisions of relevant tax law as general and administrative
expenses, in the statements of operations. For the years ended June 30, 2019 and 2018 there was no such interest or penalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Net Loss per Common Share</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Basic net loss per common share
is computed by dividing the net loss before deemed dividend by the weighted average number of shares of common stock outstanding
during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares
of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution
that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures.
Due to the net loss for the period, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The table below shows the number
of outstanding stock options and warrants as of June 30, 2019 and June 30, 2018:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 4.5in; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">June 30, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">June 30, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Stock Options</TD><TD STYLE="width: 8%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 25%; text-align: right">58,000</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 25%; text-align: right">41,200</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 5.4pt">Warrants</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">124,667</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">38,193</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 5.4pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4.5pt double; font-weight: bold; text-align: right">182,667</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4.5pt double; font-weight: bold; text-align: right">79,393</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significant Accounting Policies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Stock-based Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The Company has accounted for stock-based compensation
under the provisions of FASB ASC 718 &ndash; &ldquo;Stock Compensation&rdquo; which requires the use of the fair-value based method
to determine compensation for all arrangements under which employees and others receive shares of stock or equity instruments (stock
options and common stock purchase warrants). For employee awards, the fair value of each stock option award is estimated on the
date of grant using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected
term, and the risk-free interest rate. For non-employees, the fair value of each stock option award is estimated on the measurement
date using the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term,
and the risk-free interest rate. For non-employees, the Company utilizes the graded vesting attribution method under which the
entity treats each separately vesting portion (tranche) as a separate award and recognizes compensation cost for each tranche over
its separate vesting schedule. Expected volatilities are based on historical volatility of peer companies and other factors estimated
over the expected term of the stock options. For employee awards, the expected term of options granted is derived using the &ldquo;simplified
method&rdquo; which computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free
rate is based on the U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. We recognize
forfeitures as they occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Goodwill</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Goodwill is recorded when the purchase price
paid for an acquisition exceeds the fair value of net identified tangible and intangible assets acquired. The Company performs
an annual impairment test of goodwill and further periodic tests to the extent indicators of impairment develop between annual
impairment tests. The Company&rsquo;s impairment review process compares the fair value of the reporting unit to its carrying value,
including the goodwill related to the reporting unit. To determine the fair value of the reporting unit, the Company may use various
approaches including an asset or cost approach, market approach or income approach or any combination thereof. These approaches
may require the Company to make certain estimates and assumptions including future cash flows, revenue and expenses. These estimates
and assumptions are reviewed each time the Company tests goodwill for impairment and are typically developed as part of the Company&rsquo;s
routine business planning and forecasting process. While the Company believes its estimates and assumptions are reasonable, variations
from those estimates could produce materially different results. The Company did not recognize any goodwill impairments for the
years ended June 30th, 2018 and June 30th, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Impairment of Long-Lived Assets</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Long-lived assets, including intangible
assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may
not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset
to estimated undiscounted future cash flows expected to be generated by the asset.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">If the carrying amount of an asset
exceeds its undiscounted estimated future cash flows, an impairment review is performed. An impairment charge is recognized in
the amount by which the carrying amount of the asset exceeds the fair value of the asset. Generally, fair value is determined using
valuation techniques such as expected discounted cash flows or appraisals, as appropriate. Assets to be disposed of would be separately
presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer
depreciated or amortized. The assets and liabilities of a disposed group classified as held for sale would be presented separately
in the appropriate asset and liability sections of the balance sheet.</P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Significant Accounting Policies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Reclassifications</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Certain prior year amounts have been reclassified
for consistency with current year presentation. These reclassifications had no effect on the reported results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Recent accounting pronouncements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The Company considers the applicability and
impact of all Accounting Standard Updates (&ldquo;ASU&rsquo;s&rdquo;). ASU&rsquo;s not discussed below were assessed and determined
to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">In June 2018, the FASB issued ASU 2018-07,
&ldquo;Compensation &ndash; Stock Compensation (Topic 718): Improvements to Non-employee share based accounting&rdquo;, which simplifies
the accounting for non-employee share-based payment transactions. The amendments specify that Topic 718 applies to all share-based
payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor&rsquo;s own operations by
issuing share-based payment awards. The standard will be effective for the Company in the first quarter of fiscal year 2020, although
early adoption is permitted (but no sooner than the adoption of Topic 606). The Company does not expect that the adoption of this
ASU will have a significant impact on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">In July 2017, the FASB issued Accounting Standards
Update (&ldquo;ASU&rdquo;) No. 2017-11. &ldquo;Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480);
Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement
of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily
Redeemable Noncontrolling Interests with a Scope Exception. ASU 2017-11 revises the guidance for instruments with down round features
in Subtopic 815-40, Derivatives and Hedging &ndash; Contracts in Entity&rsquo;s Own Equity, which is considered in determining
whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. An entity still is required
to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they
qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified
as liabilities. ASU 2017-11 is effective for annual and interim periods beginning December 15, 2018, and early adoption is permitted,
including adoption in an interim period. ASU 2017-11 provides that upon adoption, an entity may apply this standard retrospectively
to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the opening balance
of retaining earnings in the fiscal year and interim period adopted. The Company is currently in the process of assessing the impact
of this ASU on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intangible
Assets</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; background-color: white">Intellectual
property, stated at cost, less accumulated amortization consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-left: 5.4pt">Intellectual Property</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,293,770</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,293,770</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Less Accumulated Amortization</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(739,167</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(509,790</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4.5pt; padding-left: 5.4pt">Intellectual Property, Net</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">1,554,603</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">1,783,980</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify; background-color: white">Amortization
expense amounted to $229,377 and $229,377 for the years ended June 30, 2019 and 2018, respectively. The Company amortizes intellectual
property over the expected original useful lives of 10 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify; background-color: white">Estimated future
amortization expense is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 11pt Times New Roman, Times, Serif; width: 4.5in; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="white-space: nowrap; width: 68%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ending June 30,</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;229,377 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;229,377 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;229,377 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;229,377 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;229,377 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;407,718 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-top: Black 1.5pt solid; border-bottom: Black 4.25pt double; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,554,603 </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Renegotiated Debt</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On July 19, 2018, Geis-Hides Consulting
LLC entered into an Accord and Debt Satisfaction Agreement with the Company in which the consulting firm agreed to release the
Company from all liabilities arising from the Original Contract and Debt Repayment Plan dated December 15, 2013 totaling $132,000
and received cash of $65,000 and 2,080 common shares in satisfaction. The common shares were valued at the market price
on the date of settlement at $7.50 per common share. The gain of $51,400 on the settlement of debt was reflected on the
Statements of Operations as &ldquo;other income&rdquo; for the year ended June 30, 2019.</P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Related Party Transactions</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; background-color: white">On March 23, 2017,
Barrett Ehrlich agreed to defer the payment of his consulting fee debt of $173,333 until&nbsp;December 31, 2019, through the issuance
of a Promissory note.&nbsp; The promissory note does not carry any interest charge as long as the amount is paid in full before&nbsp;December
31, 2019.&nbsp; The consulting fee debt was reclassified from a current liability to a long-term liability on the balance sheet.&nbsp;Any
portion of the balance due under the note that remains unpaid after&nbsp;December 31, 2019&nbsp;will accrue interest at a rate
of 5% per annum until paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On August 8, 2018, Barrett Ehrlich
(Independent contractor, related party to Elliot Ehrlich and shareholder) on behalf of The Barrett Edge Inc. (&ldquo;Barrett&rdquo;)
entered into an Accord and Debt Satisfaction Agreement with the Company in which Barrett agreed to release the Company from all
liabilities including the original contract to defer payment of accrued consulting fees dated March 23, 2017, the promissory note
issued by the Company to defer payment of accrued consulting fees; loan to the Company for $14,000, and subsequent unpaid consulting
fees, totaling $543,014, and received cash of $131,333 and 3,947 common shares in satisfaction. The common shares were
valued at the market price on the date of settlement at $16.25 per common share. The gain of $361,548 on the settlement
of debt was reflected in the additional paid in capital for the year ended June 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; background-color: white">On March 23, 2017,
Elliot Ehrlich agreed to forgive 50% of his salary debt of $444,056.&nbsp; The adjusted salary debt is $222,028.&nbsp; Elliot Ehrlich
also agreed to defer the payment of his salary debt of $222,028 until&nbsp;December 31, 2019, through the issuance of a Promissory
note.&nbsp; The promissory note does not carry any interest charge as long as the amount is paid in full before&nbsp;December 31,
2019.&nbsp; The salary debt was reclassified from a current liability to a long-term liability on the balance sheet and the salary
debt forgiven had been reflected on the income statement as other income.&nbsp;Any portion of the balance due under the note that
remains unpaid after&nbsp;December 31, 2019&nbsp;will accrue interest at a rate of 5% per annum until paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On July 9, 2018, Elliot Ehrlich (former
CEO and shareholder) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release the
Company from all liabilities including the original contract to defer payment of accrued salary dated March 23, 2017, totaling
the amount of $222,028 the promissory note issued by the Company to defer payment of accrued salary; and received cash of $22,273
and 1,777 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at
$7.50 per common share. The gain of $186,503 on the settlement of debt was reflected in the additional paid in capital
for the year ended June 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; background-color: white">On March 23, 2017,
Jonathan Adams agreed to defer the payment of his salary debt of $180,555 until&nbsp;December 31, 2019, through the issuance of
a Promissory note.&nbsp; The promissory note does not carry any interest charge as long as the amount is paid in full before&nbsp;December
31, 2019.&nbsp; The salary debt was reclassified from a current liability to a long-term liability on the balance sheet.&nbsp;Any
portion of the balance due under the note that remains unpaid after&nbsp;December 31, 2019&nbsp;will accrue interest at a rate
of 5% per annum until paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; background-color: white">On July 9, 2018, Jonathan
Adams (COO) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from
all liabilities including the original contract to defer payment of his accrued salary dated March 23, 2017, the promissory note
issued by the Company to defer payment of accrued salary; and subsequent unpaid salary, totaling the amount of $534,722, and received
cash of $25,694 in satisfaction. The gain of $509,028 on the settlement of debt was reflected in the additional paid in capital
for the year ended June 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; background-color: white">The outstanding balance
of the long-term note payable at June 30, 2019 and 2018 was $0 and $575,918, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">See note 8 &ldquo;Equity Transactions&rdquo;, for other related
party transactions with Acuitas Group Holdings, LLC (&ldquo;Acuitas&rdquo;) and board of director members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commitments and Contingencies</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Office
Lease</I></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On October 1, 2018, the Company
executed a lease agreement with Acuitas Group Holdings, LLC (related party) for the Company&rsquo;s Corporate office space at the
Acuitas&rsquo; offices at 11100 Wilshire Boulevard, Los Angeles, CA 90025. The lease is a month-to-month lease that may be cancelled
upon 30 days&rsquo; written notice and requires monthly payments of $1,000. On July 1, 2019, the Company&rsquo;s office moved with
Acuitas&rsquo; new offices to 2120 Colorado Avenue Ste 230, Santa Monica, CA 90404.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Challenge to US Patent</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">On April 30, 2018, we received notice that
Mallinckrodt had petitioned the U.S. Patent and Trademark Office (&ldquo;USPTO&rdquo;) to institute an Inter Partes Review of our
U.S. Patent No. 9,655,945 titled &ldquo;Treatment of Ascites&rdquo; (the &ldquo;&rsquo;945 patent&rdquo;). Inter Partes Review
is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more
claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents
and printed publications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">On August 15, 2018, we submitted a Preliminary
Response to the PTAB providing a rationale as to why, in our opinion, Mallinckrodt&rsquo;s request to institute the IPR should
not be granted. On November 14, 2018, the PTAB granted institution of the IPR challenge after determining that there was a reasonable
likelihood of success in proving that at least one of our 14 claims was unpatentable. On March 7, 2019, we submitted a Patent Owner&rsquo;s
Response and a Patent Owner&rsquo;s Contingent Motion to Amend our patent claims, and Declaration of Dr. Jaime Bosch, MD, PhD,
our medical expert. On June 26 and June 28, 2019, we submitted a Patent Owner&rsquo;s Reply In Support Of Its Contingent Motion
To Amend Under 37 C.F.R.&sect; 42.121 to amend our patent claims and a Patent Sur-Reply supported by the Supplemental Declaration
of Dr. Jaime Bosch to the Reply and the Opposition to Motion to Amend, filed by Petitioner Mallinckrodt, filed June 6, 2019. On
July 29, 2019, we submitted a Patent Owner&rsquo;s Opposition to Petitioner&rsquo;s Motion to Strike. On July 17, 2019, we received
from the PTAB an Order Oral Hearing in response to our request of an Oral Hearing which was held on August 12, 2019 at 1:00PM EST.
We are actively defending the &rsquo;945 patent and we are exploring the possibility of settlement with Mallinckrodt. However,
there can be no assurance that a favorable outcome will result, or if settlement is reached that the PTAB will accept it. A reasonable
estimate cannot be made at this time. Although the PTAB encourages settlement, in view of public-interest considerations, the PTAB
may continue the proceeding to a final written decision even if the parties settle. If the IPR is not terminated due to settlement,
the PTAB is statutorily required to issue its final written decision in this case before November 14, 2019 (within one year from
the date of institution). At June 30, 2019, no adjustments or accruals have been reflected in our financial statements related
to this matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Royalty Agreements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Pursuant to the Agreement and Plan
of Merger entered into on April 11, 2016 between LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single
digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation;
and The Barrett Edge, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company and PharmaIN Corporation,
LAT Pharma&rsquo;s former partner focused on the development of new modified drug candidates in the same therapeutic field but
not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development
programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24,
2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously
paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Pursuant to the Technology Transfer
Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single
digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped
at a maximum of $200,000 per year.</P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity Transactions</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><I>Stock Options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The following table summarizes the
activity relating to the Company&rsquo;s stock options for the years ended June 30, 2018 and 2019:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average Exercise Price</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Remaining Average Contractual Term</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; padding-left: 5.4pt">Outstanding at June 30, 2017</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">32,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">12.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5.9</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">142,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Options Exercised</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(800</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.50</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">Outstanding at June 30, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">15.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">142,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">131,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Options Exercised or Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4.5pt; padding-left: 5.4pt">Outstanding at June 30, 2019</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">58,000</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">12.50</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">5.2</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">273,000</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4.5pt; padding-left: 5.4pt">Exercisable at June 30, 2019</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">58,000</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">12.50</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">5.2</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The fair value of each option grant
on the date of grant is estimated using the Black-Scholes Option &ndash; Pricing model reflecting the following weighted-average
assumptions:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-left: 5.4pt">Expected life of options (In years)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69.77</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">103.13</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.60</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.28</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Dividend Yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Expected volatility is based on
the historical volatilities of three comparable companies of the daily closing price of their respective common stock and the expected
life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as
they are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company recorded stock-based
compensation expense of $64,860 for the year ended June 30, 2019 and $238,165 for the year ended June 30, 2018.</P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity Transactions (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The following is a summary of stock
options outstanding and exercisable by exercise price as of June 30, 2019:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-size: 11pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 11pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Weighted Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Contract Life</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">3.75</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 19%; text-align: right">5,600</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 19%; text-align: right">4.6</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 19%; text-align: right">5,600</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,800</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">800</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,600</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">26.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">27.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">800</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">28.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,600</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">31.25</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.4</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">58,000</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 11pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt; font-size: 11pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">58,000</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><I>Issuance of Shares for Cash</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In July 2017 and August 2017, the Company
sold and issued an aggregate of 7,091 shares of common stock and warrants to purchase 3,546 shares of common stock
in a private placement transaction for aggregate gross proceeds of approximately $195,000. The purchase price for the common stock
and warrants was $27.50 per share. The warrants are exercisable at an exercise price of $75.00 at any time from
date of issuance until 5 years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Between July 2017 and September 2017,
the Company sold an aggregate of 2,000 shares of common stock in transactions under the Aspire Equity Line for aggregate
gross proceeds of $50,000. The average purchase price for the common stock was $25.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In October 2017, the Company sold and
issued an aggregate of 1,273 shares of common stock and warrants to purchase 637 shares of common stock in a private
placement transaction for aggregate gross proceeds of approximately $35,000. The purchase price for the common stock and warrants
was $27.50 per share. The warrants are exercisable at an exercise price of $75.00 at any time from date of issuance
until 5 years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In November 2017, the Company also
sold and issued an aggregate of 546 shares of common stock and warrants to purchase 273 shares of common stock in
a private placement transaction for aggregate gross proceeds of approximately $15,000. The purchase price for the common stock
and warrants was $27.50 per share. The warrants are exercisable at an exercise price of $75.00 at any time from
date of issuance until 5 years from the date of issuance.</P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity Transactions (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In January 2018, the Company sold an
aggregate of 2,667 shares of common stock and warrants to purchase 2,667 shares of common stock to a member of its
board of directors for aggregate gross proceeds of $50,000. The purchase price for the common stock and warrants was $18.75
per share. The warrants are exercisable at an exercise price of $18.75 at any time from date of issuance until 7 years
from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">On July 3, 2018, we entered into a Securities
Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with Acuitas Group Holdings, LLC (&ldquo;Acuitas&rdquo;)and certain
other purchasers identified in the Purchase Agreement (together with Acuitas, the &ldquo;Purchasers&rdquo;) pursuant to which
(i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the our Series A Convertible Preferred Stock
(the &ldquo;Preferred Stock&rdquo;) at a price per share of $1.50 per share of Preferred Stock (the &ldquo;Initial Sale&rdquo;)
and (ii) we agreed to issue warrants (the &ldquo;Warrants&rdquo;) to purchase 1,706,666 shares of common stock, each subject
to the terms and conditions set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. We received $160,000
of the $3.2 million in April and May 2018 as prepaid equity. Acuitas also received an additional 6,667 Warrants in connection
with the payoff of a note issued by us in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3,
2018. In addition, Acuitas had the option to purchase up to an additional 1,600,000 shares of common stock at a price per
share of $1.875, and warrants on the same terms as the Warrants, within two weeks following the one year anniversary of
the closing of the Initial Sale (the &ldquo;Subsequent Sale&rdquo;) in the event that we did not obtain $3,000,000 of funding
through various non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale, less any federal or
FDA grant funding received by the Company. Acuitas is controlled by our Chairman and Chief Executive Officer, Terren Peizer and
the Purchasers included Jonathan Adams, James Lang, Cuang Do and Michael Sherman, who are members of our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The Purchase Agreement contained customary
representations and warranties. In connection with the disclosure schedule associated with the representations and warranties,
we also disclosed customary information, including the following: (i) the existence of the Mallinckrodt petition before the U.S.
Patent Trial and Appeal Board, (ii) our capitalization, (iii) our obligation to pay a low single digit royalty on the net sales
of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge,
Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and us, (iv) our obligation
to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000
per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy),
and (v) certain recent issuances of common stock by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Each share of Preferred Stock automatically
converted into 1 shares of common stock upon the filing with the Secretary of State of the State of Nevada of a Certificate of
Amendment to our Articles of Incorporation (the &ldquo;Amendment&rdquo;) on August 13, 2018 that increased the number of authorized
shares of common stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a
majority of our issued and outstanding common stock on July 3, 2018 and was filed with the Secretary of State of the State of
Nevada 20 calendar days following the distribution of our Definitive Information Statement on Schedule 14 that was filed with
the SEC on July 13, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Pursuant to the Purchase Agreement,
Terren Peizer, the Chairman of Acuitas, was appointed as a member of the Company&rsquo;s Board of Directors (the &ldquo;Board&rdquo;)
and as the Chief Executive Officer of the Company, effective July 3, 2018. The issuance of the Preferred Stock, the Warrants and
the underlying common stock under the Purchase Agreement is exempt from registration under the Securities Act of 1933, as amended
(the &ldquo;Securities Act&rdquo;), pursuant to the exemption for transactions by an issuer not involving any public offering under
Section 4(a)(2) of the Securities Act.</P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity Transactions (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Pursuant to a letter agreement dated June 24,
2019, Acuitas has agreed to modify its existing rights under the Purchase Agreement so that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acuitas
                                         agreed to immediately exchange its existing 1,606,667 Warrants for common stock
                                         such that it will have effectively exercised its Warrants in full pursuant to a cashless
                                         exercise thereof at an assumed current market price of $45.00 per share and, as
                                         a result received an aggregate of 95% of the shares covered thereby, or 1,526,333
                                         shares of common stock;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31.5pt; text-align: justify; text-indent: -9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 9pt"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acuitas
                                         agreed to (i) waive its rights to a 50% adjustment of the purchase price of the Preferred
                                         Stock in the Initial Sale, the exercise price of the Warrants and the price per share
                                         in the Subsequent Sale in the event of certain reductions in the useful life of our current
                                         intellectual property rights, and (ii) effectively exercise its rights to purchase securities
                                         in a Subsequent Sale pursuant to a &ldquo;cashless purchase&rdquo; at an assumed current
                                         market price of approximately $11.25 per share, conditioned in each case on the
                                         listing of our common stock on NASDAQ or the raising of $2.0 million in additional funds
                                         in the form of another securities offering, in either case not later than November 30,
                                         2019, which will result Acuitas having irrevocably waived its rights to an adjustment
                                         in the purchase price of the Preferred Stock in the Initial Sale and the exercise price
                                         of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance
                                         by us of an aggregate of 1,339,958 shares of common stock (the &ldquo;Subsequent
                                         Sale Shares&rdquo;) to Acuitas.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><I>Issuance of Warrants for Cash
and Cashless Exercise of Warrants </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In December 2017, the Company issued
warrants for cash to purchase 20,000 shares of common stock in a private placement transaction for aggregate gross proceeds
of $100,000. The purchase price for the warrants were $5.00 per warrant. The warrants are exercisable at an exercise price
of $25.00 at any time from date of issuance until 7 years from the date of issuance. As a result of the conversion of the
Series A Preferred Stock in July 2018, the exercise of warrants to purchase 20,000 shares of common stock was reduced from
$18.75 per share to $1.875 per share. On August 4, 2018, the Company issued 17,936 shares of common stock
pursuant to a cashless exercise of warrants to purchase 20,000 shares at an exercise price of $1.875 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On May 13, 2019, the Company issued
479 shares of common stock pursuant to a cashless exercise of warrants to purchase 479 shares at an exercise price
of $13.75 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On June 24, 2019, the Company issued
1,526,094 shares of common stock pursuant to a cashless exercise of warrants to purchase 1,606,667 shares at an
exercise price of $45.00 per share.</P>

<P STYLE="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><I>Issuance of Warrants Services</I></P>

<P STYLE="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In January 2018, the Company
issued warrants to purchase 840 shares of common stock in exchange for services. The warrants are exercisable at an exercise
price of $18.75 any time from the date of issuance until 7 years from the date of issuance. The warrants were valued at
$9,444. The fair value of the warrants granted was estimated using the Black Scholes Method and the following assumptions: volatility
&ndash; 166.7%; Term &ndash; 7 years; Risk Free Rate &ndash; 2.48%; dividend rate &ndash; 0.00%</P>

<P STYLE="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In February 2018, the Company
issued warrants to purchase 840 shares of common stock in a termination agreement. The warrants are exercisable at an exercise
price of $18.75 any time from the date of issuance until 7 years from the date of issuance. The warrants were valued at
$3,025. The fair value of the warrants granted was estimated using the Black Scholes Method and the following assumptions: volatility
&ndash; 166.7%; Term &ndash; 7 years; Risk Free Rate &ndash; 2.81%; dividend rate &ndash; 0.00%</P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity Transactions (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><I>Issuance of Shares for Services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">In August 2017, the Company issued 12,000
shares of common stock to Aspire Capital in exchange for services. The shares were valued at $27.50 per share which was
the trading price on date of issuance, and the value of the services were $330,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">In November 2017, the Company issued 1,200
shares of common in exchange for services. The shares were valued at $28.75 per share which was the trading price on
date of issuance, and the value of the services were $34,500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">In January 2018, The Company issued 240
shares of common stock in exchange for services. The shares were valued at $16.25 per share which was the trading price
on date of issuance, and the value of the services were $3,900.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">In January 2018, the Company issued 11,200
shares of common stock as compensation for the Board of Directors. The shares were valued at $18.75 per share which
was the trading price on date of issuance, and the value of the compensation was $210,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In February 2018, the Company issued 4,800 shares
of common stock in exchange for services. The shares were valued at $5.94 per share which was the trading price on date
of issuance, and the value of the services were $28,500.</P>

<P STYLE="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In April 2018, the Company issued
2,400 shares of common in exchange for services. The shares were valued at $5.63 per share, and the value of the
services were $13,500. In April 2018, the Company issued 1,200 shares of common in exchange for services. The shares were
valued at $3.00 per share which was the trading price on date of issuance, and the value of the services were $3,600.</P>

<P STYLE="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In May 2018, the Company issued
2,000 shares of common in exchange for services. The shares were valued at $2.25 per share which was the trading
price on date of issuance, and the value of the services were $4,500.</P>

<P STYLE="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In May 2018, the Company issued
548 shares of common in exchange for services. The shares were valued at $12.50 per share which was the trading price on
date of issuance, and the value of the services were $6,850.</P>

<P STYLE="font: 10pt/10.7pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In June 2018, the Company issued
2,400 shares of common in exchange for services. The shares were valued at $3.13 per share which was the trading
price on date of issuance, and the value of the services were $7,500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On January 2, 2019, the Company issued
11,200 shares of common stock as part of the annual board of director compensation. The share price on date of issuance
was $4.38 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Issuance of Shares in Settlement of Debt</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">During the year ended June 30, 2019,
the Company settled $1,475,765 of debt and accrued compensation including $1,313,765 owed to related parties, by issuing 7,803
shares of common stock with a fair value of $1,150,135. See notes 5 and 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Issuance of Stock Options </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In November 2017, the Company extended
the maturity date of stock options to acquire 6,400 shares at exercise prices ranging from $26.25 to $31.25
issued to the board of directors between November 2016 and December 2016 by 3 years. The Company recorded an incremental expense
of $79,491 based on the increase in fair value of the options.</P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity Transactions (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In June 2018, 800 shares of
stock options were exercised for $2,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On October 1, 2018, the Company issued
stock options to purchase 800 shares of common stock to the Chief Financial Officer as part of her compensation. The stock
options were issued and are exercisable at an exercise price of $8.75 at any time from date of issuance and expire in 5
years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On October 13, 2018, the Company issued
stock options to purchase 800 shares of common stock as part of their annual board of director compensation. The stock
options were issued and are exercisable at $6.25 at any time from date of issuance and expire in 5 years from the date
of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On October 27, 2018, the Company issued
stock options to purchase 800 shares of common stock as part of their annual board of director compensation. The stock
options were issued and are exercisable at $6.25 at any time from date of issuance and expire in 5 years from the date
of issuance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On November 10, 2018, the Company issued
stock options to purchase 800 shares of common stock as part of their annual board of director compensation. The stock
options are exercisable at an exercise price of $6.25 at any time from date of issuance and expire in 5 years from the
date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On January 19, 2019, the Company issued
stock options to purchase 800 shares of common stock to each of five key employees or consultants and two company directors
as part of his or her annual compensation, for an aggregate total of 5,600 stock options. The stock options are exercisable
at an exercise price of $3.125 at any time from date of issuance until 5 years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On March 11, 2019, the Company issued
stock options to purchase 8,000 shares of common stock to an investor relations (IR) consultant. The stock options were
issued and are exercisable at $6.25 at any time from date of issuance and expire in 5 years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><I>Warrant Price Adjustment</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In December 2017, the Company issued
warrants to purchase 20,000 shares of common stock in a private placement transaction for aggregate gross proceeds of $100,000.
The warrants were exercisable at an exercise price of $25.00 at any time from date of issuance until 7 years from the date
of issuance. The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower price.
In January 2018, the Company sold shares at $18.75, which therefore triggered the reduction in the strike price. The Company
calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded
$20,995 as a deemed dividend. In July 2018, the Company sold shares at $1.88, which therefore triggered the reduction in
the strike price. The Company calculated the difference in fair value of the warrants between the stated exercise price and the
reduced exercise price and recorded $44,889 as a deemed dividend. The fair value of the warrants granted was estimated using the
Black Scholes Method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In January and February 2018, the Company
issued warrants to purchase 1,680 shares of common stock in exchange for banking services which was recognized at fair
value. The warrants were exercisable at an exercise price of $18.75 at any time from date of issuance until 7 years from
the date of issuance. The warrants have a down round feature that reduces the exercise price if the Company sells stock for a
lower price. In July 2018, the Company sold shares at $1.88, which therefore triggered the reduction in the strike price.
The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise
price and recorded $3,770 as a deemed dividend. The fair value of the warrants granted was estimated using the Black Scholes Method.</P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity Transactions (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The following table summarizes
the warrants that have been issued:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Aggregate</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Remaining</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Intrinsic</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Life (Years)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; padding-left: 5.4pt">Outstanding at June 30, 2017</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">49,391</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">62.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">0.5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,802</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">27.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 5.4pt">Expired</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(40,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">62.50</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">Outstanding at June 30, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,193</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">36.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,713,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">45.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,159,988</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 5.4pt">Exercised</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,626,859</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">45.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Outstanding and exercisable at June 30, 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">124,667</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">45.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5.6</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,202,678</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Of the above warrants, 9,391
expire in fiscal year ending June 30, 2022, 4,815 expire in fiscal year ending June 30, 2023 and 110,461 expire
in fiscal year ended June 30, 2025.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income Taxes </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Deferred income taxes reflect the net tax effects
of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts
used for income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">At June 30, 2018, the Company has a Net Operating
Loss (&ldquo;NOL&rdquo;) carryforward of approximately $1,800,000. The NOL expires during the years 2032 to 2037. Realization of
any portion of the $832,186 of net deferred tax assets at June 30, 2018 is not considered more likely than not by management; accordingly,
a valuation allowance has been established for the full amount. The valuation allowance as of June 30, 2018 was $832,186. The change
in the valuation allowance from June 30, 2017 to June 30, 2018 amounted to $357,231.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">At June 30, 2019, the Company had a Net Operating
Loss (&ldquo;NOL&rdquo;) carryforward of approximately $5,700,000. NOL&rsquo;s generated prior to 2018 will expire during the years
2032 to 2037. Realization of any portion of the $1,680,613 deferred tax assets at June 30, 2019 is not considered more likely than
not by management; accordingly, a valuation allowance has been established for the full amount, which as of June 30, 2019 was $1,680,613.
The change in the valuation allowance during the year ended June 30, 2019 amounted to $848,427. The Company does not have any uncertain
tax positions or events leading to uncertainty in a tax position. The Company&rsquo;s 2016, 2017 and 2018 Corporate Income Tax
Returns are subject to Internal Revenue Service examination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">On December 22, 2017, the Tax Cuts and Jobs
Act (the &ldquo;Act&rdquo;) was signed into law. The Act decreases the U.S. corporate federal income tax rate from a maximum of
35% to a flat 21% effective January 1, 2018. The Act also includes a number of other provisions including, among others, the elimination
of net operating loss carrybacks and limitations on the use of future losses, NOL&rsquo;s generated in 2018 and later having an
indefinite life, the repeal of the Alternative Minimum Tax regime, and the repeal of the domestic production activities deduction.
The impact on the Company&rsquo;s financial statements is immaterial, primarily because the Company has a valuation allowance on
deferred tax assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income Taxes (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Given the significant complexity of the Act
and anticipated additional implementation guidance from the Internal Revenue Service, further implications of the Act may be identified
in future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Significant components of the Company&rsquo;s
deferred tax assets are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Deferred tax assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-left: 5.4pt">Tax loss carryforward</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,624,887</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">555,064</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">36,917</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,277</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,809</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">257,845</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Valuation Allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,680,613</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(832,186</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Net deferred tax assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since
management of the Company believes that it is more likely than not that the net deferred tax assets will not provide future benefit,
the Company has established a 100 percent valuation allowance on the net deferred tax assets as of June 30, 2019 and 2018.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s NOL carryover up to the date of the July 2018 financing will be subject to Section 382 usage limitations since
a greater than 50% ownership change took place from the financing event. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Reconciliation of the differences between income
tax benefit computed at the federal and state statutory tax rates and the provision for income tax benefit for the years ended
June 30, 2019 and 2018 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 11pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 11pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-left: 5.4pt">Income tax expense (benefit) at federal statutory rate</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">21</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">34</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">State taxes, net of federal benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-29</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-39</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 11pt; padding-bottom: 4.5pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsequent Events</B></FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On September 24, 2019, BioVie Inc.,
a Nevada corporation (the &ldquo;Company&rdquo;), entered into a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;)
with Acuitas Group Holdings, LLC (&ldquo;Acuitas&rdquo;) pursuant to which (i) Acuitas agreed to purchase a 10% OID Convertible
Delayed Draw Debenture (the &ldquo;Debenture&rdquo;) due September 20, 2020 in aggregate commitment amount of up to $2.0 million,
and (ii) the Company issued 1,125,000 shares (the &ldquo;Commitment Shares&rdquo;) of the Company&rsquo;s Class A Common Stock
(the &ldquo;Common Stock&rdquo;) and warrants (the &ldquo;Commitment Warrants&rdquo;) to purchase an equal number of shares, each
subject to the terms and conditions set forth in the Purchase Agreement. The Debentures accrue additional principal at the rate
of 6% per annum and interest at the rate of 10% per annum, are convertible into shares of Common Stock $4.00 per share or, subsequent
to the closing of the Company&rsquo;s planned public offering of shares of Common Stock (the &ldquo;Public Offering&rdquo;) as
described in its Registration Statement on Form S-1 (File No. 333-231136), the lower of $4.00 or 80% of the offering price to
the public in the Public Offering and are mandatorily redeemable upon such closing at 100% of the accrued principal amount and
unpaid interest to the date of redemption. The Commitment Warrants are five year warrants, exercisable upon the earlier of the effectiveness of the Company&rsquo;s currently pending reverse stock split and December 1,
2019 at the lower of $4.00 or 80% of the offering price to the public in the Public Offering. Upon entering into the Purchase Agreement, the Company drew
an initial $500,000 under the Debenture and in accordance with the Purchase Agreement, Acuitas received an additional 125,000
warrants (the &ldquo;Bridge Warrants&rdquo;) having the same terms as the Commitment Warrants. Any future draws under the Debenture,
which may be made from and after October 15, 2019, November 15, 2019 and December 15, 2019 in equal tranches of $500,000 each,
will entitle Acuitas to receive additional Bridge Warrants in equal amount upon such funding.</P>
<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Notes to Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>For the Years Ended June 30, 2019 and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Subsequent Events (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-indent: 0.5in">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Pursuant to the Purchase Agreement,
Acuitas has agreed to further modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company so that
Acuitas&rsquo; previous agreement in June 2019 to waive its rights to a 50% adjustment of the purchase price of the Preferred
Stock in the July 2018 transaction, the exercise price of the warrants in such transaction and the price per share in a purchase
option triggered on July 3, 2019 (any such purchase, a &ldquo;Subsequent Sale&rdquo;) in the event of certain reductions in the
useful life of our current intellectual property rights, and effectively exercise its rights to purchase securities in a Subsequent
Sale pursuant to a &ldquo;cashless purchase&rdquo; at an assumed current market price of approximately $11.25 per share,
conditioned in each case on the listing of the Company&rsquo;s common stock on NASDAQ or the raising of $2.0 million in additional
funds in the form of another securities offering, in either case not later than November 30, 2019, such that Acuitas will have
irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise
price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 2,679,916
shares of Common Stock and 2,679,916 warrants having the same terms as the Commitment Warrants to Acuitas, which is
currently expected with the closing of the Public Offering. In addition, the Purchase Agreement provides that, should the underwriters
in the Public Offering exercise their option to purchase additional securities during the 45 days following closing and the issuance
of such securities would result in Acuitas&rsquo; beneficial ownership (on a fully diluted basis) of shares of Common Stock being
below 60%, Acuitas shall be issued a number of additional shares of Common Stock and warrants having the same terms as the Commitment
Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of Common Stock equalling 60%.</P>





<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B><A NAME="a_311"></A>Condensed Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">June 30,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">(Unaudited)</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; padding-left: 10pt">Cash</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3,108</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">339,923</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">550,810</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">334,150</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">553,918</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">674,073</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">OTHER&nbsp;&nbsp;ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Intangible assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,439,915</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,554,603</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt">Goodwill</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">345,711</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">345,711</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total other assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,785,626</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,900,314</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,339,544</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,574,387</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,085,177</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">443,480</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Derivative liability - warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,674,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Derivative liability - conversion option on convertible debenture</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">573,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Loan payable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Convertible debenture - related party, net of discount $478,405 and $0 at December 31, 2019 and 2018, respectively</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">21,595</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,383,972</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">443,480</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Commitments and contingencies (Note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">STOCKHOLDERS' (DEFICIT) EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Common stock, $0.0001 par value; 800,000,000 shares authorized at December 31, 2019 and June 30, 2019, respectively; 5,183,724 and 4,058,724 shares issued and outstanding at December 31, 2019 and June 30, 2019, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">518</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">406</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Additional paid in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,472,373</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,392,573</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(21,517,319</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,262,072</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total stockholders' (deficit) equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,044,428</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,130,907</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,339,544</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,574,387</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B>See accompanying notes to unaudited
condensed financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><A NAME="a_312"></A><B>Condensed Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Three Months Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Three Months Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Six Months Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Six Months Ended</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">OPERATING EXPENSES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; padding-left: 10pt">Amortization</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">57,344</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">57,344</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">114,689</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">114,689</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">346,514</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">206,019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">688,015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,540</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Selling, general and administrative expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">306,589</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">237,507</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">613,961</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">477,069</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">TOTAL OPERATING EXPENSES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">710,447</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">500,870</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,416,665</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">992,298</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">LOSS FROM OPERATIONS</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(710,447</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(500,870</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,416,665</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(992,298</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">OTHER (INCOME) EXPENSE :</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Change in fair value of derivative liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,396,192</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,758,778</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Gain on settlement of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(51,400</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,920</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,498,535</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">271</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Interest income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(213</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(360</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(233</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(788</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">TOTAL OTHER (INCOME) EXPENSE, NET</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(7,375,485</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(360</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,260,476</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(51,917</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">NET INCOME (LOSS)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,665,038</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(500,510</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,843,811</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(940,381</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deemed dividends for commitment shares and rachet adjustments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">17,099,058</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">48,659</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,665,038</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(500,510</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(14,255,247</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(989,040</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">NET INCOME (LOSS) PER COMMON SHARE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 10pt">- Basic</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1.29</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.20</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3.06</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.40</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 10pt">- Diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1.29</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.20</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(3.06</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.40</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">WEIGHTED AVERAGE NUMBER OF COMMON&nbsp;&nbsp;SHARES OUTSTANDING</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">- Basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,183,724</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,520,429</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,661,183</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,497,457</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">- Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,183,724</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,520,429</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,661,183</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,497,457</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 10pt; text-align: center">See accompanying notes to unaudited
condensed financial statements</P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: center"><B><A NAME="a_314"></A>Condensed Statements
of Changes in Stockholders&rsquo; (Deficit) Equity </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the periods July 1, 2018 through December
31, 2018 and July 1, 2019 through December 31, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><B>(Unaudited)</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center"><B>Total</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center"><B>Additional</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center"><B>Stockholders&rsquo;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center"><B>Preferred Stock</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center"><B>Common Stock</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center"><B>Paid in</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center"><B>Accumulated</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center"><B>Equity</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>Shares</B></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>Amount</B></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>Shares</B></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>Amount</B></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>Capital</B></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>Deficit</B></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>(Deficit)</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%">Balance, June 30, 2018</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">$</TD>
    <TD STYLE="width: 5%; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: right">788,026</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">$</TD>
    <TD STYLE="width: 5%; text-align: right">79</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">$</TD>
    <TD STYLE="width: 5%; text-align: right">4,880,246</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">$</TD>
    <TD STYLE="width: 5%; text-align: right">(4,769,126</TD>
    <TD STYLE="width: 1%">)</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">$</TD>
    <TD STYLE="width: 5%; text-align: right">111,199</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Issuance of preferred stock in a private placement</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2,133,332</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3,200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3,200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3,200,000</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Conversion of preferred stock to common stock</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">(2,133,332</TD>
    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">(3,200,000</TD>
    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1,706,666</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">171</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">(171</TD>
    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Issuance of shares in exchange for debt settlement</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">7,804</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1,150,134</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1,150,135</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Stock option compensation</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3,412</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">3,412</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Cashless exercise of warrants</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">17,935</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">(2</TD>
    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Deemed dividends for ratchet adjustment to warrants</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">48,659</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">(48,659</TD>
    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Net loss for the three months ended September 30, 2018</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">(439,871</TD>
    <TD STYLE="padding-bottom: 1.5pt">)</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">(439,871</TD>
    <TD STYLE="padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Balance, September 30, 2018</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">2,520,431</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">253</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">9,282,278</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">(5,257,656</TD>
    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4,024,875</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Stock option compensation</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">16,285</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">16,285</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Net loss for the three months ended December 31, 2018</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">(500,510</TD>
    <TD STYLE="padding-bottom: 1.5pt">)</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">(500,510</TD>
    <TD STYLE="padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Balance, December 31, 2018</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">$</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right">2,520,431</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">$</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right">253</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">$</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right">9,298,563</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">$</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right">(5,758,166</TD>
    <TD STYLE="padding-bottom: 4pt">)</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">$</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right">3,540,650</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Balance June 30, 2019</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>$</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">4,058,724</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">406</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">9,392,573</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>$</TD>
    <TD STYLE="text-align: right">(7,262,072</TD>
    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD>$</TD>
    <TD STYLE="text-align: right">2,130,907</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Issuance of commitment shares</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1,125,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">112</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">10,068,638</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">10,068,750</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Deemed dividend for commitment shares</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">(17,099,058</TD>
    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">(17,099,058</TD>
    <TD>)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Net loss for the three months ended September 30, 2019</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">(3,821,227</TD>
    <TD STYLE="padding-bottom: 1.5pt">)</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">(3,821,227</TD>
    <TD STYLE="padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Balance, September 30, 2019</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">5,183,724</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">518</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">19,461,211</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">(28,182,357</TD>
    <TD>)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">(8,720,628</TD>
    <TD>)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Stock option compensation</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">11,162</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>$</TD>
    <TD STYLE="text-align: right">11,162</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Net income for the three months ended December 31, 2019</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">6,665,038</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">6,665,038</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Balance, December 31, 2019</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">$</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right">5,183,724</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">$</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right">518</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">$</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right">19,472,373</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">$</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right">(21,517,319</TD>
    <TD STYLE="padding-bottom: 4pt">)</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">$</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right">(2,044,428</TD>
    <TD STYLE="padding-bottom: 4pt">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 10pt; text-align: center">See accompanying notes to unaudited
condensed financial statements</P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: center"><B><A NAME="a_313"></A>Condensed Statements of Cash
Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><B>(Unaudited)</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Six Months Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Six Months Ended</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-left: 10pt">Net income (loss)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,843,811</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(940,381</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Adjustments to reconcile net loss to net cash to cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Amortization of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">114,689</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">114,689</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Stock based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,162</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,697</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Gain on settlement of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Interest expense from convertible debenture</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,497,264</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Change in fair value of derivative liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,758,778</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Changes in operating assets and liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(216,660</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Accounts payable and accrued expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">641,697</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(456,422</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(866,815</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,211,017</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Repayment of debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(244,300</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Proceeds from issuance of preferred shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,040,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Proceeds from loan payable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Proceeds from convertible debenture - related party</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">500,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">530,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,795,700</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net (decrease) increase in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(336,815</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,584,683</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Cash, beginning of period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">339,923</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">45,800</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt">Cash, end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,108</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,630,483</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">SUPPLEMENTAL CASH FLOW INFORMATION:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">&nbsp;&nbsp;Cash paid for interest</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,272</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">&nbsp;&nbsp;Cash paid for taxes</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">SCHEDULE OF NON-CASH FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">&nbsp;&nbsp;&nbsp;Conversion of preferred shares to common stock</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,200,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">&nbsp;&nbsp;&nbsp;Settlement of debt by issuance of common stock and forgiveness of debt</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,150,135</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 10pt">&nbsp;&nbsp;&nbsp;Cashless exercise of warrants</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">224</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">&nbsp;&nbsp;&nbsp;Deemed dividends for ratchet adjustments to warrants</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">48,659</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">&nbsp;&nbsp;&nbsp;Deemed dividends for commitment shares</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">17,099,058</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">&nbsp;&nbsp;&nbsp;Stock warrants classified as derivative liability</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,530,308</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 10pt; text-align: center">See accompanying notes to unaudited
condensed financial statements</P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B><A NAME="a_315"></A>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Six Months Ended December 31, 2019
and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><B>1.</B></TD>
    <TD STYLE="width: 98%"><B>Background Information</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">BioVie Inc. (the &ldquo;Company&rdquo;)
is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. We are currently
focused on developing and commercializing BIV201 (continuous infusion terlipressin), a novel approach to the treatment of ascites
due to chronic liver cirrhosis. Our therapy BIV201 is based on a drug that is approved in about 40 countries to treat related complications
of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the United States. BIV201&rsquo;s active
agent is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension in studies around the world. The goal
is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">BioVie began administering BIV201 to
patients in a Phase 2a clinical trial in patients with refractory ascites due to advanced liver cirrhosis at the McGuire Research
Institute Inc. in Richmond, VA in September 2017. In April 2019, we announced top-line results and in June met with representatives
of the FDA for a Type C Guidance Meeting to discuss the study results and plan our next clinical study. In July 2019, the FDA provided
meeting minutes that documented general agreement with the Company&rsquo;s proposed randomized and controlled study design. The
FDA also provided its suggestions and guidance regarding primary and secondary endpoints, quality of life measures and other key
aspects of the clinical trial design. In October 2019, BioVie announced the submission of a Phase 2b/3 clinical trial protocol
to the FDA. We are developing a patent-pending novel liquid formulation of terlipressin for use in this study that is intended
to improve convenience for outpatient administration and avoid potential formulation errors that may occur when pharmacists reconstitute
the powder version.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify; background-color: white"><FONT STYLE="color: #201F1E">BIV201
has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis
due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. It has FDA Fast-Track status and Orphan Drug designation
for the most common of these complications, ascites, which represents a significant unmet medical need. </FONT>An Orphan drug that
is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). <FONT STYLE="color: #201F1E">The
FDA has never approved any drug specifically for treating ascites.&nbsp;</FONT>In addition, the Company has a pending patent application
directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2b/3 trial, subject to FDA clearance,
which could eventually provide up to 20 years of patent coverage in each country in which the Company seeks patent protection,
such as the United States, if a patent issues according to the patent laws of the issuing country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The BIV201 development program began
at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The
Company currently owns all development and marketing rights to its drug candidate. The Company and PharmaIN, Corp. (&ldquo;PharmaIN&rdquo;),
LAT Pharma&rsquo;s former partner focused on the development of new modified drug candidates in the same therapeutic field but
not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development
programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24,
2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously
paid the remaining balance due on a related debt. PharmaIN, Corp.&rsquo;s rights to our program remain unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company&rsquo;s activities are subject
to significant risks and uncertainties including failure to secure additional funding to properly execute the Company&rsquo;s business
plan.</P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Six Months Ended December 31, 2019
and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><B>2.</B></TD>
    <TD STYLE="width: 98%"><B>Liquidity and Going Concern</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company&rsquo;s operations are subject
to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited
to: the results of clinical testing and trial activities of the Company&rsquo;s products, the Company&rsquo;s ability to obtain
regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies,
the price of, and demand for, Company products, the Company&rsquo;s ability to negotiate favorable licensing or other manufacturing
and marketing agreements for its products, and the Company&rsquo;s ability to raise capital. The Company&rsquo;s financial statements
have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the
satisfaction of liabilities in the normal course of business. As of December 31, 2019, the Company had an accumulated deficit of
approximately $21.5 million and as a development stage enterprise, the Company expects substantial losses in future periods. The
accompanying interim financial statements were prepared assuming the Company will continue as a going concern, which contemplates
the realization of assets and the satisfaction of liabilities in the normal course of business. The Company&rsquo;s future operations
are dependent on the success of the Company&rsquo;s ongoing development and commercialization effort, as well as continuing to
secure additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On September 24, 2019, the Company entered
into a Securities Purchase Agreement with its controlling stockholder regarding bridge financing (the &ldquo;Bridge Financing&rdquo;)
in the form of up to $2.0 million in convertible debt and warrants, of which $500,000 has been drawn as of December 31, 2019. In
December 2019, Acuitas provided the Company, a short-term interest free advance of $30,000. Amounts borrowed under the Bridge Financing
must be repaid with the proceeds of our potential public offering of equity securities referred to below. The availability of additional
draws under the Bridge Financing is under further discussion with the controlling stockholder in light of delays in the timing
of the potential public offering. As further discussed below, the Company is pursuing various options to raise further financing
to continue the testing and development of its product. If the Company is not successful in raising additional funds it may reduce
its monthly spend and potentially delay the implementation of the larger scale Phase 2b/3 clinical trial until sufficient funding
is secured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Additionally, in April 2019, to facilitate
our planned up listing to the NASDAQ Stock Market and related potential future issuances and sales of our equity securities for
ordinary corporate finance and general corporate purposes and as recommended by our Board of Directors (&ldquo;Board&rdquo;), our
stockholders approved an amendment to our Articles of Incorporation to effect a reverse split of our outstanding Class A common
stock in the range of 50:1 to 200:1, as determined by our Board. On November 22, 2019, the Company effected the reverse stock split
of 125 common stock for every 1 common stock. All share amounts have been updated to reflect the reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The future viability of the Company
is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources
of funding may include sales of equity, obtaining loans, or other strategic transactions. Although management continues to pursue
these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to
the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company&rsquo;s ability
to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this
uncertainty.</P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Six Months Ended December 31, 2019
and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><B>3.</B></TD>
    <TD STYLE="width: 98%"><B>Significant Accounting Policies</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Basis of Presentation &ndash; Interim Financial Information</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The accompanying unaudited interim financial
statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State
of America (&ldquo;U.S. GAAP&rdquo;) for interim financial information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect
all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair
presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for
the full year. The condensed balance sheet at June 30, 2019 was derived from audited annual financial statements but does not contain
all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included
under the heading: &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo; should
be read in conjunction with our Company&rsquo;s audited financial statements and related notes included in our Company&rsquo;s
Form 10-K for the year ended June 30, 2019 filed with the SEC on September 27, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">For a summary of significant accounting
policies, see the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 filed with the SEC on September
27, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Net income (loss) per Common Share</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Basic net income (loss) per common
share is computed by dividing the net income (loss) before deemed dividend by the weighted average number of shares of common
stock outstanding during the period. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Diluted net income (loss) per common
share is computed by dividing by the weighted average number of shares of common stock outstanding and potentially outstanding
shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through
stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the six months ended December
31, 2019 and 2018 as such amounts were excluded from the diluted loss since their effect was considered anti-dilutive. For the
three months ended December 31, 2019, all potential securities were anti-dilutive as a result of the effect of the change in fair
value of the derivative liabilities and assumed conversion of debenture in determining the amount of net income (loss) attributable
to common stockholders. Due to the net loss for the three months ended December 31, 2018, amounts were excluded from the diluted
loss since their effect was considered anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The table below shows the number of
outstanding stock options and warrants as of December 31, 2019 and 2018:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center"><B>December 31, 2019</B></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center"><B>December 31, 2018</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>Number of Shares</B></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>Number of Shares</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 18%; padding-bottom: 1.5pt; padding-left: 5.4pt">Stock Options</TD>
    <TD STYLE="width: 33%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: right">60,400</TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 9%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: right">44,400</TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 5.4pt">Warrants</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">1,374,667</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right">1,731,525</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 5.4pt"><B>Total</B></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><B>1,435,067</B></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><B>1,775,925</B></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Six Months Ended December 31, 2019
and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><B>3.</B></TD>
    <TD STYLE="width: 98%"><B>Significant Accounting Policies (continued)</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Recent accounting pronouncements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company considers the applicability
and impact of all Accounting Standard Updates (&ldquo;ASU&rsquo;s&rdquo;). ASU&rsquo;s not discussed below were assessed and determined
to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In June 2018, the FASB issued ASU 2018-07,
&ldquo;Compensation &ndash; Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting&rdquo;. This guidance
aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions
with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning
of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption
date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal
years. Early adoption is permitted. The Company has adopted this ASU as of July 1, 2019. There has been no impact on the financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2018, the FASB issued ASU 2018-13,
&ldquo;Fair value measurement (Topic 820): Disclosure Framework &ndash; Changes to the Disclosure Requirements for Fair Value Measurement&rdquo;.
The new guidance modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for fiscal years beginning
after December 15, 2019. Early adoption is permitted. The Company does not expect ASU 2018-13 to have a significant impact to its
condensed consolidated financial statements and related disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><B>4.</B></TD>
    <TD STYLE="width: 98%"><B>Intangible Assets</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company&rsquo;s
intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated useful
lives. The following is a summary of the intangible assets as of December 31, 2019 and June 30, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30, 2019</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-left: 5.4pt">Intellectual Property</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,293,770</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,293,770</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Less Accumulated Amortization</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(853,855</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(739,167</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 5.4pt">Intellectual Property, Net</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,439,915</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,554,603</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Amortization expense
for the three-month period ended December 31, 2019 and 2018 was $57,344 and $57,344 respectively Amortization expense for the six-month
period ended December 31, 2019 and 2018 was $114,689 and $114,689 respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Estimated future amortization
expense is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; width: 68%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Year ending June 30, 2020 (Remaining six months)</TD>
    <TD STYLE="white-space: nowrap; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;114,689 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2021</TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;229,377 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2022</TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;229,377 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2023</TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;229,377 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2024</TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;229,377 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2025</TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;229,377 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Thereafter</TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;178,341 </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-top: Black 1.5pt solid; border-bottom: Black 4pt double; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1,439,915 </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Six Months Ended December 31, 2019
and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><B>5.</B></TD>
    <TD STYLE="width: 98%"><B>Related Party Transactions</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Equity Transactions with Acuitas </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On July 3, 2018, we entered into a Securities
Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with Acuitas Group Holding, LLC (&ldquo;Acuitas&rdquo;) and certain other
purchasers identified in the Purchase Agreement (together with Acuitas, the &ldquo;Purchasers&rdquo;) pursuant to which (i) the
Purchasers agreed to purchase an aggregate of 2,133,332 shares of the our Series A Convertible Preferred Stock (the &ldquo;Preferred
Stock&rdquo;) at a price per share of $1.50 per share of Preferred Stock (the &ldquo;Initial Sale&rdquo;) and (ii) we agreed to
issue warrants (the &ldquo;Warrants&rdquo;) to purchase 1,706,666 shares of common stock, each subject to the terms and conditions
set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. We received $160,000 of the $3.2 million in
April and May 2018 as prepaid equity. Acuitas also received an additional 6,667 Warrants in connection with the payoff of a note
issued by us in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas
had the option to purchase up to an additional 1,600,000 shares of common stock at a price per share of $1.88, and warrants on
the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale (the &ldquo;Subsequent
Sale&rdquo;) in the event that we did not obtain $3,000,000 of funding through various non-dilutive grants prior to the one year
anniversary of the closing of the Initial Sale, less any federal or FDA grant funding received by the Company. Acuitas is controlled
by our Chairman and Chief Executive Officer, Terren Peizer and the Purchasers included Jonathan Adams, James Lang, Cuong Do and
Michael Sherman, who are members of our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Purchase Agreement contained customary
representations and warranties. In connection with the disclosure schedule associated with the representations and warranties,
we also disclosed customary information, including the following: (i) the existence of the Mallinckrodt petition before the U.S.
Patent Trial and Appeal Board, (ii) our capitalization, (iii) our obligation to pay a low single digit royalty on the net sales
of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge,
Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and us, (iv) our obligation
to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000
per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy),
and (v) certain recent issuances of common stock by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Each share of Preferred Stock automatically
converted into 100 shares of common stock (prior to reverse split) upon the filing with the Secretary of State of the State of
Nevada of a Certificate of Amendment to our Articles of Incorporation (the &ldquo;Amendment&rdquo;) on August 13, 2018 that increased
the number of authorized shares of common stock to 800,000,000. The Amendment was approved by the written consent of the holders
of more than a majority of our issued and outstanding common stock on July 3, 2018 and was filed with the Secretary of State of
the State of Nevada 20 calendar days following the distribution of our Definitive Information Statement on Schedule 14 that was
filed with the SEC on July 13, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Pursuant to a letter agreement dated
June 24, 2019, Acuitas agreed to modify its existing rights under the Purchase Agreement so that:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; padding-bottom: 10pt; text-align: right">-</TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt; text-align: justify">Acuitas agreed to immediately exchange its existing 1,606,667 Warrants for common stock such that it will have effectively exercised its Warrants in full pursuant to a cashless exercise thereof at an assumed current market price of $45.00 per share and, as a result received an aggregate of 95% of the shares covered thereby, or 1,526,094 shares of common stock;</TD></TR>
</TABLE>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Six Months Ended December 31, 2019
and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><B>5.</B></TD>
    <TD STYLE="width: 98%"><B>Related Party Transactions (continued)</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; padding-bottom: 10pt; text-align: right">-</TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt; text-align: justify">Acuitas agreed to (i) waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants and the price per share in the Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and (ii) effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a &ldquo;cashless purchase&rdquo; at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of our common stock on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, which will result Acuitas having irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 1,339,958 shares of common stock (the &ldquo;Subsequent Sale Shares&rdquo;) to Acuitas, which is expected to occur concurrently with the closing of our potential public offering and listing on Nasdaq;</TD></TR>
</TABLE>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20px; padding-bottom: 10pt; text-align: right">-</TD>
    <TD STYLE="width: 7px">&nbsp;</TD>
    <TD STYLE="padding-bottom: 10pt; text-align: justify">Acuitas shall in exchange for the foregoing agreements and waivers have the option to purchase additional shares of common stock and warrants to purchase one share of common stock for each share of common stock purchased during the period from September 1, 2019 to November 30, 2019 at the then-effective purchase price of the Preferred Stock in the Initial Sale (the &ldquo;Funding Option&rdquo;), provided that any shares issued pursuant to any exercise of the Funding Option will reduce share-for-share the amount of shares issued pursuant to the deemed exercise of its rights to purchase securities in a Subsequent Sale mentioned above.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Convertible Debenture Transaction with Acuitas</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 24, 2019, the Company
entered into a Securities Purchase Agreement (the &ldquo;2019 Purchase Agreement&rdquo;) with Acuitas pursuant to which (i)
Acuitas agreed to purchase a 10% OID Convertible Delayed Draw Debenture (the &ldquo;Debenture&rdquo;) due September 24, 2020
for an aggregate commitment amount of up to $2.0 million, and (ii) the Company issued 1,125,000 shares (the &ldquo;Commitment
Shares&rdquo;) of the Company&rsquo;s common stock and warrants (the &ldquo;Commitment Warrants&rdquo;) to purchase an equal
number of shares, each subject to the terms and conditions set forth in the 2019 Purchase Agreement. The Debenture accrues
additional principal at the rate of 6% per annum and interest at the rate of 10% per annum, is convertible into shares of
common stock at $4.00 per share prior to the completion of the company&rsquo;s planned public offering of units (the
&ldquo;Public Offering&rdquo;) or, subsequent to the closing of the Public Offering, the lower of $4.00 or 80% of the
offering price per unit to the public in the Public Offering and are mandatorily redeemable upon such closing at 100% of the
accrued principal amount and unpaid interest to the date of redemption. The Commitment Warrants are five-year warrants,
exercisable upon the earlier of the effectiveness of the Company&rsquo;s current reverse stock split or December 1, 2019, at
an amount equal to the lower of $4.00 or 80% of the offering price per unit to the public in the Public Offering. Upon
entering into the 2019 Purchase Agreement, the Company drew an initial $500,000 under the Debenture and in accordance with
the 2019 Purchase Agreement, Acuitas received an additional 125,000 warrants (the &ldquo;Bridge Warrants&rdquo;) having the
same terms as the Commitment Warrants. Any future draws under the Debenture, which may be made from and after October 15,
2019, November 15, 2019 and December 15, 2019 in equal tranches of $500,000 each, will entitle Acuitas to receive additional
Bridge Warrants in equal amount upon such funding. In addition, the 2019 Purchase Agreement provides that, should the
underwriters in the Public Offering exercise their option to purchase additional securities during the 45 days
following closing and the issuance of such securities would result in Acuitas' beneficial ownership (on a fully diluted
basis) of shares of common stock being below 60%, Acuitas shall be issued a number of additional shares of common stock and
warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of
shares of common stock equaling 60%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The issuance of 1,125,000 shares of the Company&rsquo;s
commons stock and warrants to purchase an equal amount number of shares, to its controlling stockholder for the Bridge Financing
was accounted for as a deemed dividend due to its related party nature and $17.1 million representing the excess of the fair value
of the consideration given for the financing, net of debt discount; was recorded in accumulated deficit for the six months ended
December 31, 2019, accordingly. (See accompanied Condensed Statements of Changes in Stockholders&rsquo; (Deficit) Equity). A debt
discount of $500,000 against the debenture was recorded which will be amortized over the term of the debenture using the effective
interest method. The Company recognized amortization of this discount in the amount of $21,595 for the six-month period ended December
31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company received partial draws of draw
number two of&nbsp;the Debenture of $25,000 and $5,000 on December 5, 2019 and December 13,<SUP>&nbsp;</SUP>2019 respectively.&nbsp;&nbsp;Acuitas
and the Company continue to discuss the need and timing for some or&nbsp;all of&nbsp;the remaining draws under the Agreement. &nbsp;(See
subsequent events).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Six Months Ended December 31, 2019
and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><B>5.</B></TD>
    <TD STYLE="width: 98%"><B>Related Party Transactions (continued)</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Pursuant to the 2019 Purchase Agreement,
Acuitas has agreed to further modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company so that
Acuitas&rsquo; previous agreement in June 2019 to waive its rights to a 50% adjustment of the purchase price of the Preferred Stock
in the July 2018 transaction, the exercise price of the warrants in such transaction and the price per share in a Subsequent Sale
in the event of certain reductions in the useful life of our current intellectual property rights, and effectively exercise its
rights to purchase securities in a Subsequent Sale pursuant to a &ldquo;cashless purchase&rdquo; at an assumed current market price
of approximately $11.25 per share, conditioned in each case on the listing of the Company&rsquo;s common stock on Nasdaq or the
raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November
30, 2019, such that Acuitas will have irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock
in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the
issuance by us of an aggregate of 2,679,916 shares of common stock and 2,679,916 warrants having the same terms as the Commitment
Warrants to Acuitas, upon the closing of the Public Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Pursuant to an amendment to the 2019
Purchase Agreement dated October 9, 2019, Acuitas agreed to modify its existing rights under the 2019 Purchase Agreement so that:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif; line-height: 115%">-</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="line-height: 115%">The Commitment Warrants (and related warrants issued upon the first draw under the Debenture) were replaced with warrants having similar terms, but which are automatically exercised upon the closing of the offering at an exercise price equal to the par value of the common stock;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif; line-height: 115%">-</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="line-height: 115%">Acuitas' existing rights under the Purchase Agreement dated July 3, 2018 with the Company were further amended so that the number of Subsequent Sale Shares would be multiplied by four (in lieu of the changes to the Purchase Agreement originally provided for in the 2019 Purchase Agreement); and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; line-height: 115%"><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif; line-height: 115%">-</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="line-height: 115%">The provisions of the 2019 Purchase Agreement providing that, should the underwriters in the offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas&rsquo; beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%, Acuitas will be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60% have been modified such that, upon the exercise of such option by the underwriters, the Company will issue to Acuitas a number of securities that will result in Acuitas&rsquo; fully diluted beneficial ownership after the exercise of such option being the same as prior thereto. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Six Months Ended December 31, 2019
and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><B>6.</B></TD>
    <TD STYLE="width: 98%"><B>Fair Value Measurements</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">At December 31, 2019, the estimated fair value of derivative
liabilities measured on a recurring basis are as follows:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="15" STYLE="font-weight: bold; text-align: center">Fair Value Measurements at</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="15" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2019</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Level 1</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Level 2</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Level 3</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">Total</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; padding-left: 5.4pt">Derivative liability - Warrants</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,674,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">2,674,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Derivative liability -Conversion option on convertible debenture</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">573,200</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">573,200</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;Total derivatives</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,247,200</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,247,200</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The following table presents the activity for liabilities
measured at fair value using unobservable inputs for the six months ended December 31, 2019:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Derivative liabilities - Warrants</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Derivative liability - Conversion Option on Convertible Debenture</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">Beginning balance at July 1, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: left; padding-left: 5.4pt">Additions to level 3 liabilities</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">8,367,012</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">2,638,966</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Change in in fair value of level 3 liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(257,288</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(105,298</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Transfer in and/or out of Level 3</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">Balance at September 30, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,109,724</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,533,668</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Additions to level 3 liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Change in in fair value of level 3 liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,435,724</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,960,468</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Transfer in and/or out of Level 3</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 5.4pt">Balance at December 31, 2019</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,674,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">573,200</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Derivative liability &ndash; Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company accounts for stock purchase
warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under
applicable accounting guidance, stock warrants that are precluded from being indexed to the Company&rsquo;s own stock because of
full-rachet anti-dilution provisions or the adjustments to the strike price due to an occurrence of a future event; are accounted
for as derivative financial instruments. The stock warrants issued September 24, 2019 were not considered indexed to the Company&rsquo;s
own stock&nbsp;because of the adjustment to strike price,&nbsp;an occurrence of a future event such as the Company&rsquo;s pending
capital raise.</P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Six Months Ended December 31, 2019
and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><B>6.</B></TD>
    <TD STYLE="width: 98%"><B>Fair Value Measurements (continued)</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The warrants associated with the level
3 liability were issued on September 24, 2019 and were valued using the Black-Scholes-Merton model with the following assumptions:
stock price of $8.95, exercise price of $4.00, term of 5 years expiring September 2024, volatility of 71.44%, dividend yield of
0%, and risk-free interest rate of 1.52%. The valuation at December 31, 2019 used the following assumptions: stock price of $3.50,
exercise price of $4.00, term of 5 year expiring September 2024, volatility of 80.79%, dividend yield of 0%, and risk-free interest
rate of 1.69%. (See note 5 &ldquo;Related Party Transactions &ndash; Convertible debenture transactions<I>&rdquo;</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify"><I>Derivative liability &ndash; Conversion
option in convertible debenture</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company valued the conversion
option of the $2 million 10% OID Convertible Delayed Draw Debenture which may be convertible into shares of common stock at
$4.00 per share prior to the completion of an offering or, subsequent to the closing of the offering, the lower of $4.00 or
80% of the offering price per unit to the public in  such offering and are mandatorily redeemable upon such closing at 100%
of the accrued principal amount and unpaid interest to the date of redemption. (See note 5 &ldquo;Related Party Transactions
&ndash; <I>Convertible debenture transactions with Acuitas</I>&rdquo; as of September 24, 2019). The conversion option was
valued on September 24, 2019 using the Black Scholes-Mertons model with the following assumptions: stock price of $8.95,
conversion price of $4.00, term of 1 year expiring September 2020, volatility of 75.48%, dividend yield of 0%, and risk-free
interest rate of 1.78%. The valuation at December 31, 2019 used the following assumptions: stock price of $3.50, conversion
price of $4.00, term of 1 year expiring September 2020, volatility of 109.83%, dividend yield of 0%, and risk-free interest
rate of 1.59%.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><B>7.</B></TD>
    <TD STYLE="width: 98%"><B>Equity Transactions</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Stock Options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the activity
relating to the Company&rsquo;s stock options for the six months ended December 31, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average Exercise Price</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Remaining Average Contractual Term</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; padding-left: 5.4pt">Outstanding at June 30, 2019</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">58,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">12.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5.2</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">87,480</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Options Exercised or Forfeited</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 5.4pt">Outstanding at December 31, 2019</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">60,400</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">12.29</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4.5</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,100</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 5.4pt">Exercisable at December 31, 2019</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">60,400</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">12.29</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4.5</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,100</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Six Months Ended December 31, 2019
and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><B>7.</B></TD>
    <TD STYLE="width: 98%"><B>Equity Transactions (continued)</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The fair value of each option grant
on the date of grant is estimated using the Black-Scholes option. The pricing model reflected the following weighted-average assumptions
for the six months ended December 31, 2019:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31 2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-left: 5.4pt">Expected life of options (In years)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">5</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71.55</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67.91</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Risk free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.61</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.98</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Dividend Yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Expected volatility is based on the
historical volatilities of three comparable companies of the daily closing price of their respective common stock and the expected
life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as
they are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company recorded stock-based compensation expense of $0 and $11,162 for the three- and six- month
periods ended December 31, 2019, respectively, and $16,285 and $19,697 for the three- and six- month periods ended December 31,
2018, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The following is a summary of stock
options outstanding and exercisable by exercise price as of December 31, 2019:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercise Price</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Contract Life</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">3.75</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 19%; text-align: right">5,600</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 19%; text-align: right">4.1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 19%; text-align: right">5,600</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,200</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,600</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,600</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.1</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">25.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,600</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">26.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.3</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,400</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">27.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">800</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">28.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,600</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">31.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.9</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 10pt"><I>Stock Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the warrants
activity during the six months ended December 31, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Life (Years)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate Intrinsic Value</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; padding-left: 5.4pt">Outstanding and exercisable at June 30, 2019</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">124,667</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">45.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">5.6</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">716,653</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 5.4pt">Expired</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">Outstanding and exercisable at December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,374,667</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7.72</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4.7</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">139,498</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Of the above warrants, 9,391 expire
in fiscal year ending June 30, 2022, 4,455 expire in fiscal year ending June 30, 2023, and 1,360,821 expire in fiscal year ending
June 30, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Six Months Ended December 31, 2019
and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><B>7.</B></TD>
    <TD STYLE="width: 98%"><B>Equity Transactions (continued)</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Offerings of Common Stock and Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Issuance of Stock Options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On October 1, 2019, the Company issued
stock options to purchase 800 shares of common stock to the Chief Financial Officer as part of her compensation. The stock options
were issued and are exercisable at an exercise price of $8.75 at any time from date of issuance and expire in 5 years from the
date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On October 13, 2019, the Company issued
stock options to purchase 800 shares of common stock as part of their annual board of director compensation. The stock options
were issued and are exercisable at $7.50 at any time from date of issuance and expire in 5 years from the date of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On November 10, 2019, the Company issued
stock options to purchase 800 shares of common stock as part of their annual board of director compensation. The stock options
were issued and are exercisable at $6.25 at any time from date of issuance and expire in 5 years from the date of issuance.&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><B>8.</B></TD>
    <TD STYLE="width: 98%"><B>Commitments and Contingencies</B>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Office Lease&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On July 1, 2019, the Company&rsquo;s
office moved with Acuitas&rsquo; new offices to 2120 Colorado Avenue Ste 230, Santa Monica, CA 90404. There is no lease agreement
for the new premises and the Company continues to accrue monthly lease payments of $1,000 for the new office under the terms of
the previous month-to-month lease for the previous premises which may be cancelled upon 30 days&rsquo; written notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Challenge to US Patent</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 30, 2018, we received notice that
Mallinckrodt had petitioned the U.S. Patent and Trademark Office (&ldquo;USPTO&rdquo;) to institute an Inter Partes Review of our
U.S. Patent No. 9,655,945 titled &ldquo;Treatment of Ascites&rdquo; (the &ldquo;&rsquo;945 patent&rdquo;). Inter Partes Review
is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more
claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents
and printed publications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">On November 13, 2019, the Patent Trial
and Appeal Board of the United States Patent and Trademark Office (the &ldquo;Board&rdquo;) issued a written decision in the <I>inter
partes</I> review (&ldquo;IPR&rdquo;) action that was brought by Mallinckrodt Pharmaceuticals Ireland Limited (&ldquo;Mallinckrodt&rdquo;)
against BioVie Inc. (&ldquo;BioVie&rdquo; or &ldquo;Company&rdquo;). In that action, Mallinckrodt sought to invalidate BioVie&rsquo;s
patent (U.S. Pat. No. 9,655,945, &ldquo;Treatment of Ascites&rdquo;) (the &ldquo;&rsquo;945 Patent&rdquo;). In its decision, the
Board determined that all claims of the &lsquo;945 Patent were not patentable because they were either anticipated or obvious in
light of prior art. The Board also denied BioVie&rsquo;s Motion to Amend the claims on similar grounds. The result of the Board&rsquo;s
decision is that the &lsquo;945 patent is no longer valid or enforceable. Acuitas Group Holdings, LLC was aware of this patent
challenge when it purchased a majority ownership interest in the company in July 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This ruling is unrelated to the Company&rsquo;s
Orphan drug designations for ascites and hepatorenal syndrome (&ldquo;HRS&rdquo;), which remain unchanged. An Orphan drug that
is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). In addition,
the ruling does not affect the Company&rsquo;s rights in its pending patent application directed to proprietary liquid formulations
of terlipressin for use in its planned Phase 2b/3 trial, subject to FDA clearance, which could eventually provide up to 20 years
of patent coverage in each country in which the Company seeks patent protection, such as the United States, if a patent issues
from a patent application according to the patent laws of each issuing country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<B>BIOVIE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Notes to Condensed Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Six Months Ended December 31, 2019
and 2018</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><B>8.</B></TD>
    <TD STYLE="width: 98%"><B>Commitments and Contingencies (continued)</B>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><I>Royalty Agreements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Pursuant to the Agreement and Plan of
Merger entered into on April 11, 2016 between our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated
to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members,
PharmaIn Corporation, and The Barrett Edge, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The Company and PharmaIN Corporation,
LAT Pharma&rsquo;s former partner focused on the development of new modified drug candidates in the same therapeutic field but
not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development
programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24,
2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously
paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged. Additionally the Company
obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT
Pharma LLC members, and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between
LAT Pharma LLC. The Company has an obligation to pay a low single digit royalty on net sales of all terlipressin products covered
by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by
and between us and the University of Padova (Italy).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">Pursuant to the Technology Transfer
Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single
digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped
at a maximum of $200,000 per year.&nbsp;<B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><B>9.</B></TD>
    <TD STYLE="width: 98%"><B>Subsequent Events</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On January 2, 2020, the Company issued 11,200 shares of common stock
as part of the annual board of director compensation. The share price on date of issuance was $3.50.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">On January 3, 2020, the Company received a third partial draw of
$20,000 and on January 14, 2020 a fourth&nbsp;partial draw of $250,000 of draw number two of&nbsp;the Debenture.&nbsp;&nbsp; The
total of the partial draw received under draw number two of&nbsp;the Debenture was $300,000 at February 12, 2020. Acuitas and the
Company continue to discuss the need and timing for some or&nbsp;all&nbsp;the remaining draws under the Debenture Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 11, 2020, the Company entered into
a letter agreement dated February 10, 2020 with Acuitas regarding Acuitas&rsquo; previous agreement to modify its existing rights
under the Purchase Agreement dated July 3, 2018 with the Company so that its June 2019 waiver of its rights to a 50% adjustment
of the purchase price applicable to its initial investment in the Company and the exercise price of the warrants received in such
transaction and the price per share should it exercise certain rights to purchase additional securities in the event of certain
reductions in the useful life of the Company&rsquo;s intellectual property rights and commitment to purchase such securities upon
the closing of the Company&rsquo;s planned public offering (the &ldquo;Public Offering&rdquo;) of shares of Class A common stock
(the &ldquo;Common Stock&rdquo;) as described in its Registration Statement on Form S-1 (File No. 333-231136) and commitment to
purchase such additional securities would remain effective until April 30, 2020, and accordingly Acuitas shall be entitled to receive
an aggregate of 5,359,832 shares of Common Stock at such closing. In addition, the parties agreed that certain draws under the
Company&rsquo;s current bridge financing with Acuitas were to be made based with respect to the Company&rsquo;s ongoing capital
requirements and current market conditions, notwithstanding certain scheduled availability dates set forth in the 10% OID Convertible
Delayed Draw Debenture issued in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 98 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 14pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Units</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><IMG SRC="image_003.jpg" ALT="CzAwX4YXEAAAOf2 (1)" STYLE="height: 62px; width: 179px"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: center"><B></B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 8pt 0 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 2in; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%; border-top: Black 1pt solid; font: 11pt/107% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 11pt/107% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 11pt/107% Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt/normal Times New Roman, Times, Serif; margin: 48pt 0 0; text-align: center"><B>ThinkEquity</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>a division of Fordham Financial Management,
Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 1in 0 0; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 9pt 0 0; text-align: center">&nbsp;&nbsp; , 2020 </P>

<P STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin: 47pt 0 0; text-align: justify"><FONT STYLE="font-size: 10pt">Through
and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 (the 25</FONT><FONT STYLE="font-size: 6pt"><SUP>th
</SUP></FONT><FONT STYLE="font-size: 10pt">day after the date of this offering), all dealers effecting transactions in these securities,
whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&rsquo;s
obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>


<DIV STYLE="page-break-before: always; border-top: black 1.5pt solid; margin-top: 6pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>PART II &ndash; INFORMATION NOT REQUIRED
IN PROSPECTUS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Item 13. Other Expenses of Issuance and Distribution</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The following table sets forth the expenses
in connection with this registration statement. All of such expenses are estimates, other than the filing fees payable to the Securities
and Exchange Commission and to FINRA.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; border-bottom: 1.5pt solid">Amount<BR> to be paid</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: left">SEC registration fee</TD><TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 08%; text-align: right">3,638</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">FINRA filing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,567</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Transfer agent and registrar fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Blue sky qualification fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">35,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Printing expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Miscellaneous expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: 1.5pt solid; text-align: right"> 120,794 </TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: black 4.5pt double; text-align: right"> 645,000 </TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Item 14. Indemnification of Directors and Officers</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">We are a Nevada corporation and generally governed by the
Nevada Private Corporations Code, Title 78 of the Nevada Revised Statutes, or NRS.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Section 78.138 of the NRS provides that, unless the corporation&rsquo;s
articles of incorporation provide otherwise, a director or officer will not be individually liable unless it is proven that (i)
the director&rsquo;s or officer&rsquo;s acts or omissions constituted a breach of his or her fiduciary duties, and (ii) such breach
involved intentional misconduct, fraud or a knowing violation of the law.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Section 78.7502 of the NRS permits a Nevada corporation to
indemnify its directors and officers against expenses, judgments, fines, and amounts paid in settlement actually and reasonably
incurred in connection with a threatened, pending, or completed action, suit, or proceeding, except an action by or on behalf of
the corporation, if the officer or director (i) is not liable pursuant to NRS 78.138, or (ii) acted in good faith and in a manner
the officer or director reasonably believed to be in or not opposed to the best interests of the corporation and, if a criminal
action or proceeding, had no reasonable cause to believe the conduct of the officer or director was unlawful. Section 78.7502 of
the NRS also requires a corporation to indemnify its officers and directors if they have been successful on the merits or otherwise
in defense of any claim, issue, or matter resulting from their service as a director or officer.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Section 78.751 of the NRS permits a Nevada corporation to
indemnify its officers and directors against expenses incurred by them in defending a civil or criminal action, suit, or proceeding
as they are incurred and in advance of final disposition thereof, upon determination by the stockholders, the disinterested board
members, or by independent legal counsel. Section 78.751 of NRS requires a corporation to advance expenses as incurred upon receipt
of an undertaking by or on behalf of the officer or director to repay the amount if it is ultimately determined by a court of competent
jurisdiction that such officer or director is not entitled to be indemnified by the corporation if so provided in the corporation&rsquo;s
articles of incorporation, bylaws, or other agreement. Section 78.751 of the NRS further permits the corporation to grant its directors
and officers additional rights of indemnification under its articles of incorporation, bylaws or other agreement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Section 78.752 of the NRS provides that a Nevada corporation
may purchase and maintain insurance or make other financial arrangements on behalf of any person who is or was a director, officer,
employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or
agent of another company, partnership, joint venture, trust or other enterprise, for any liability asserted against him and liability
and expenses incurred by him in his capacity as a director, officer, employee or agent, or arising out of his status as such, whether
or not the corporation has the authority to indemnify him against such liability and expenses.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Our Articles of Incorporation and bylaws implement the indemnification
and insurance provisions permitted by Chapter 78 of the NRS by providing that:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 18px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 18px; line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We shall indemnify our directors and officers to the fullest extent permitted by the NRS against expense, liability and loss reasonably incurred or suffered by them in connection with their service as an officer or director; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 18px; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 18px; line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="line-height: 107%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may purchase and maintain insurance, or make other financial arrangements, on behalf of any person who holds or who has held a position as a director, officer, or representative against liability, cost, payment, or expense incurred by such person.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">At the present time, there is no pending litigation or proceeding
involving a director, officer, employee or other agent of ours in which indemnification would be required or permitted. We are
not aware of any threatened litigation or proceeding which may result in a claim for such indemnification.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>Item 15. Recent Sales of Unregistered Securities</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The Company has not sold any within the past three years
which were not registered under the Securities Act except as follows:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><I>Acuitas Group Transaction</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">On July 3, 2018, the registrant,
entered into a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with Acuitas Group Holdings, LLC (&ldquo;Acuitas&rdquo;)
and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the &ldquo;Purchasers&rdquo;) pursuant
to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the Company&rsquo;s newly created Series A
Convertible Preferred Stock (the &ldquo;Preferred Stock&rdquo;) at a price per share of $1.50 per share of Preferred Stock (the
&ldquo;Initial Sale&rdquo;) and (ii) the registrant agreed to issue associated warrants (the &ldquo;Warrants&rdquo;) to purchase
1,706,666 shares of the registrant&rsquo;s Class A Common Stock (the &ldquo;Common Stock&rdquo;), each subject to the terms and
conditions set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. The registrant received $160,000
of the $3.2 million in April and May 2018 as prepaid equity. Acuitas also received an additional 6,667 Warrants in connection
with the payoff of a note issued by the registrant in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred
on July 3, 2018. In addition, Acuitas had the option to purchase up to an additional 1,600,000 shares of Common Stock at a price
per share of $1.88, and associated warrants on the same terms as the Warrants, within two weeks following the one year
anniversary of the closing of the Initial Sale (the &ldquo;Subsequent Sale&rdquo;) in the event that the registrant had not obtained
$3,000,000 of funding through various non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale,
less any federal or FDA grant funding received by the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Each share of Preferred Stock automatically
converted into 100 shares of Common Stock upon the filing with the Secretary of State of the State of Nevada of a Certificate
of Amendment to the registrant&rsquo;s Articles of Incorporation (the &ldquo;Amendment&rdquo;) on August 13, 2018 that increased
the number of authorized shares of Common Stock to 800,000,000. The Amendment was approved by the written consent of the holders
of more than a majority of the registrant&rsquo;s issued and outstanding Common Stock on July 3, 2018 and was filed with the Secretary
of State of the State of Nevada 20 calendar days following the distribution of the registrant&rsquo;s Definitive Information that
was filed with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Pursuant to a letter agreement dated June 24, 2019, Acuitas has agreed to modify its existing rights under the Purchase Agreement so that:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">- Acuitas agreed to immediately
exchange its existing Warrants for common stock such that it will have effectively exercised its Warrants in full pursuant to
a cashless exercise thereof at an assumed current market price of $45.00 per share and, as a result received an aggregate of 95%
of the shares covered thereby, or 1,526,094 shares of common stock, on June 24, 2019;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">- Acuitas agreed to (i) waive its rights
to a 50% adjustment of the purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants and the
price per share in the Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property
rights, and (ii) effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a &ldquo;cashless purchase&rdquo;
at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of our common
stock on NASDAQ or the raising of $2.0 million in additional funds in the form of another securities offering, in either case
not later than November 30, 2019, which will result Acuitas having irrevocably waived its rights to an adjustment in the purchase
price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in
the Subsequent Sale upon the issuance by us of an aggregate of 1,339,958 shares of common stock (the &ldquo;Subsequent
Sale Shares&rdquo;) to Acuitas, which is expected concurrently with the closing of this offering;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">- Acuitas shall in exchange for the
foregoing agreements and waivers have the option to purchase additional shares of common stock and warrants to purchase one share
of common stock for each share of common stock purchased during the period from September 1, 2019 to November 30, 2019 at the
then-effective purchase price of the Preferred Stock in the Initial Sale (the &ldquo;Funding Option&rdquo;), provided that any
shares issued pursuant to any exercise of the Funding Option will reduce share-for-share the amount of shares issued pursuant
to the deemed exercise of its rights to purchase securities in a Subsequent Sale mentioned above. Assuming the closing of this
offering occurs on or prior to September 1, 2019, such option will terminate upon such closing. In the event such closing
occurs subsequent to September 1, 2019 and prior to November 30, 2019, we anticipate that Acuitas may elect to continue to fund
our on-going clinical trials and operations by means of exercising such Funding Option, with any shares so purchased being deducted
from the amount of Subsequent Sale Shares deliverable at closing as described above.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">On September 24, 2019, the registrant
entered into a Securities Purchase Agreement (the &ldquo;2019 Purchase Agreement&rdquo;) with Acuitas pursuant to which (i) Acuitas
agreed to purchase a 10% OID Convertible Delayed Draw Debenture (the &ldquo;Debenture&rdquo;) due September 24, 2020 for an aggregate
commitment amount of up to $2.0 million, and (ii) the Company issued 1,125,000 shares (the &ldquo;Commitment Shares&rdquo;) of
the Company&rsquo;s common stock and warrants (the &ldquo;Commitment Warrants&rdquo;) to purchase an equal number of shares, each
subject to the terms and conditions set forth in the 2019 Purchase Agreement. The Debenture accrues additional principal at the
rate of 6% per annum and interest at the rate of 10% per annum, is convertible into shares of common stock at $4.00 per share
prior to the completion of the registrant&rsquo;s planned public offering of units (the &ldquo;Public Offering&rdquo;) as described
in this Registration Statement on Form S-1 or, subsequent to the closing of the Public Offering, the lower of $4.00 or 80% of
the offering price per unit to the public in the Public Offering and are mandatorily redeemable upon such closing at 100% of the
accrued principal amount and unpaid interest to the date of redemption. The Commitment Warrants are five year warrants, exercisable
at an amount equal to the lower of $4.00 or 80% of the offering price per unit to the public in the Public Offering. Upon
entering into the 2019 Purchase Agreement, the Company drew an initial $500,000 under the Debenture and in accordance with the
2019 Purchase Agreement, Acuitas received an additional 125,000 warrants (the &ldquo;Bridge Warrants&rdquo;) having the same terms
as the Commitment Warrants. Any future draws under the Debenture, which may be made from and after October 15, 2019, November
15, 2019 and December 15, 2019 in equal tranches of $500,000 each, will entitle Acuitas to receive additional Bridge Warrants
in equal amount upon such funding. In addition, the 2019 Purchase Agreement provides that, should the underwriters in the Public
Offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such
securities would result in Acuitas' beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%,
Acuitas shall be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants
to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60%.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Pursuant to the 2019 Purchase Agreement,
Acuitas has agreed to further modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company so that
Acuitas&rsquo; previous agreement in June 2019 to waive its rights to a 50% adjustment of the purchase price of the Preferred
Stock in the July 2018 transaction, the exercise price of the warrants in such transaction and the price per share in a, a Subsequent
Sale in the event of certain reductions in the useful life of our current intellectual property rights, and effectively exercise
its rights to purchase securities in a Subsequent Sale pursuant to a &ldquo;cashless purchase&rdquo; at an assumed current market
price of approximately $11.25 per share, conditioned in each case on the listing of the Company&rsquo;s common stock on
Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later
than November 30, 2019, such that Acuitas will have irrevocably waived its rights to an adjustment in the purchase price of the
Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent
Sale upon the issuance by us of an aggregate of 2,679,916 shares of Common Stock and 2,679,916 warrants having the
same terms as the Commitment Warrants to Acuitas, which is currently expected with the closing of this public offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Pursuant to an amendment to the 2019 Purchase Agreement dated October 9, 2019, the Registrant and Acuitas have agreed to the following amendments
thereto:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Commitment Warrants (and related warrants issued upon the first draw under the Debenture) were replaced with warrants having similar
terms, but which are automatically exercised upon the closing of the Public Offering as described in this Registration Statement
at an exercise price equal to the par value of the Common Stock;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acuitas has agreed to further modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company so that
the number of Subsequent Sale Shares would be multiplied by four (in lieu of the changes to the Purchase Agreement originally provided
for in the 2019 Purchase Agreement); and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The provisions of the 2019 Purchase Agreement providing that, should the underwriters in the Public Offering exercise their option to
purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas&rsquo;
beneficial ownership (on a fully diluted basis) of shares of Common Stock being below 60%, Acuitas will be issued a number of additional
shares of Common Stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on
a fully diluted basis) of shares of Common Stock equaling 60% have been modified such that, upon the exercise of such option by
the underwriters, the Company will issue to Acuitas a number of securities that will result in Acuitas&rsquo; fully diluted beneficial
ownership after the exercise of such option being the same as prior thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2020, the Company entered into a letter agreement with Acuitas regarding Acuitas' previous agreement to modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company so that its June 2019 waiver of its rights to a 50% adjustment of the purchase price applicable to its initial investment in the Company and the exercise price of the warrants received in such transaction and the price per share should it exercise certain rights to purchase additional securities in the event of certain reductions in the useful life of the Company's intellectual property rights and commitment to purchase such securities upon the closing of the Company's planned public offering (the "Public Offering") of shares of Class A common stock (the "Common Stock") as described above and commitment to purchase such additional securities would remain effective until April 30, 2020, and accordingly Acuitas shall be entitled to receive an aggregate of 5,359,832 shares of Common Stock at such closing. In addition, the parties agreed that certain draws under the Company's current bridge financing with Acuitas were to be made based with respect to the Company's ongoing capital requirements and current market conditions, notwithstanding certain scheduled availability dates set forth in the 10% OID Convertible Delayed Draw Debenture issued in connection therewith.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The issuance of the Preferred Stock, the Warrants
and the underlying common stock under the Purchase Agreement and the 2019 Purchase Agreement is exempt from registration under the
Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), pursuant to the exemption for transactions by an issuer
not involving any public offering under Section 4(a)(2) of the Securities Act. The exchange of the replacement warrants pursuant
to the amendment to the 2019 Purchase Agreement was made in reliance on Section 3(a)(9) of the Securities Act, which exempts any
security exchanged by the issuer with its existing security holders exclusively where no commission or other remuneration is paid
or given directly or indirectly for soliciting such exchange.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>
<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><I>Aspire Capital Transaction</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">On January 4, 2017, the registrant entered into a Common
Stock Purchase Agreement, or the Purchase Agreement, with Aspire Capital Fund, LLC, an Illinois limited liability company, or Aspire
Capital, which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is
committed to purchase up to an aggregate of $12.0 million of shares of the registrant&rsquo;s common stock (the &ldquo;Purchase
Shares&rdquo;) over the 30-month term of the Purchase Agreement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Upon execution of the Purchase Agreement,
the registrant issued 19,200 shares of its common stock to Aspire Capital in consideration for entering into the Purchase Agreement,
and sold an additional 8,000 shares and warrants relating to 4,000 shares for aggregate proceeds of $200,000. The Purchase Shares
may be sold by the registrant to Aspire Capital on any business day the registrant selects in two ways: (1)&nbsp;through a regular
purchase of up to 800 shares at a known price based on the market price of our common stock prior to the time of each sale, and
(2)&nbsp;through a VWAP purchase on the terms and conditions set forth in the Purchase Agreement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The issuance of the 19,200 Commitment
Shares, 8,000 Initial Purchase Shares and all other shares of common stock that may be issued from time to time to Aspire Capital
under the Purchase Agreement is exempt from registration under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
pursuant to the exemption for transactions by an issuer not involving any public offering under Section&nbsp;4(a)(2) of the Securities
Act.</P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify"><I>Aspire Capital Transaction</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">In the second quarter of the registrant&rsquo;s
fiscal year ending June 30, 2017, the registrant sold 4,600 shares to a number of accredited investors for $25.00 per share, for
aggregate gross proceeds of $115,000. The registrant also issued warrants to purchase 2,300 shares to such investors, which warrants
expire five years following issuance and are exercisable for $62.50 per share. Mr. James Lang, who joined the registrant&rsquo;s Board
of Directors on December 7, 2016, purchased 2,000 shares and received warrants to purchase 1,000 shares on November 11, 2016.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The issuance of the shares and warrants to the accredited
investors was exempt from registration under the Securities Act pursuant to Rule 506(b) of Regulation D under the Securities Act.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Item 16. Exhibits</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The following is a list of exhibits filed as a part of this
registration statement:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 7%; border-bottom: black 1.5pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 92%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description of Document</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="bivi-20200311_s1a9ex1z1.htm">Form of Placement Agency Agreement (including form of Placement Agent Warrant)</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%">1.2</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%">Form of Securities Purchase Agreement * * </TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013816000847/nnab-20160415_8kex2z1.htm">Agreement and Plan of Merger, dated April 11, 2016, among the Company, LAT Acquisition Corp and LAT Pharma, LLC (incorporated by reference to Exhibit 2.1 the Company&rsquo;s Current Report on Form 8-K filed on April 15, 2016).</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000154823313000011/nano0813ex-3.1.htm">Articles of Incorporation of the Company as filed with the Secretary of State of Nevada (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s registration statement on Form S-1 filed on August 15, 2013, File No. 333-190635).</A></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013816001063/nnab-20160722_8kex3z1.htm">Certificate of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K filed on July 22, 2016).</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013818000151/bivi-20180713_def14c.htm">Certificate of Amendment to Articles of Incorporation (incorporated by reference to Appendix A to the Company&rsquo;s Information Statement on Schedule 14C filed on July 13, 2018).</A></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013818000134/biovie-20180703_8kex3z1.htm">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company&rsquo;s Current Report on Form 8-K filed on July 3, 2018).</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000154823313000011/nano0813ex-3.2.htm">Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company&rsquo;s registration statement on Form S-1 filed on August 15, 2013, File No. 333-190635).</A></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%">3.6</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000485/bivi-20191122_s1a8ex3z6.htm">Certificate
    of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.6 to the Company&rsquo;s registration
    statement on Form S-1/A filed on November 11, 2019, File No. 333-231136).</A> *</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000127/bivi-20190426_s1ex4z1.htm">Specimen Certificate representing shares of Class A Common Stock.</A> *</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000379/bivi-20191009_8kex4z1.htm" STYLE="-sec-extract: exhibit">Form of Warrant (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on October 9, 2019).</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013817000006/bivi-20170105_8kex4z1.htm">Form
    of 10% OID Convertible Delayed Draw Debenture (incorporated by reference to Exhibit 4.1 the Company&rsquo;s Current Report
    on Form 8-K filed on September 25, 2019).</A></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%">4.4</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%">Warrant Agency Agreement and Form of Warrant offered
    hereby. * * </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000360/bivi-20191001_s1a4ex5z1.htm">Opinion of Loeb &amp; Loeb LLP.</A> *</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013817000006/bivi-20170105_8kex10z1.htm">Common Stock Purchase Agreement, dated January 4, 2017, between the Company and Aspire Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed on January 5, 2017).</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013818000134/biovie-20180703_8kex10z1.htm">Securities
    Purchase Agreement, dated as of July 3, 2018, by and among BioVie Inc., Acuitas Group Holdings, LLC and the Purchasers
    identified therein (incorporated by reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed
on July 3, 2018).</A></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000127/bivi-20190426_s1ex10z3.htm">Employment Agreement between Jonathan Adams and the Company dated, April 11, 2016.</A> *</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000127/bivi-20190426_s1ex10z4.htm">Amendment No. 1 to Employment Agreement between Jonathan Adams and the Company dated July 3, 2018.</A> *</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%">10.5</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000217/bivi-20190628_s1ex10z5.htm" STYLE="-sec-extract: exhibit">Letter Agreement between Acuitas Group Holdings, LLC and the Company dated June 24, 2019.</A> *</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%">10.6</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000134/bivi_14cdef.htm">BioVie Inc.2019 Omnibus Equity Incentive Plan (incorporated by reference to Appendix D to the Definitive Information Statement on Schedule 14C, filed on May 8, 2019).</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%">10.7</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000330/bivi-20190924_8kex10z1.htm">Securities
    Purchase Agreement dated as of September 24, 2019 by and among BioVie Inc. and Acuitas Group Holdings, LLC (incorporated by
    reference to Exhibit 10.1 to the Company&rsquo;s Current Report on Form 8-K filed on September 25, 2019).</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%">10.8</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000379/bivi-20191009_8kex10z1.htm" STYLE="-sec-extract: exhibit">Amendment to Securities Purchase Agreement, dated
    as of October 9, 2019, by and between the Company and Acuitas Group Holdings, LLC (incorporated by reference to Exhibit 10.1
    to the Company's Current Report on Form 8-K filed on October 9, 2019)</a></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%">10.9</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013820000056/bivi-20191231_10qex10z1.htm" STYLE="-sec-extract: exhibit">BioVie, Inc. Letter Agreement with Acuitas Group Holdings, LLC dated as of February 10, 2020 (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on February 13, 2020).</a></TD></TR>

<TR STYLE="background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000217/bivi-20190628_s1ex14z1.htm" STYLE="-sec-extract: exhibit">Code of Conduct and Ethics of BioVie Inc</A>. *</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="bivi-20200311_s1a9ex23z1.htm">Consent of D. Brooks and Associates CPA&rsquo;s, P.A., Independent Registered Public Accounting Firm.</A></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000360/bivi-20191001_s1a4ex5z1.htm" STYLE="-sec-extract: exhibit">Consent of Loeb &amp; Loeb LLP.</A> *</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%">23.3</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><A HREF="bivi-20200311_s1a9ex23z3.htm">Consent of EisnerAmper LLP, Independent Registered Public Accounting Firm.</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="white-space: nowrap; vertical-align: top; line-height: 107%">24.1</TD>
    <TD STYLE="vertical-align: bottom; line-height: 107%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 107%"><A HREF="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000127/bivi-20190426_s1.htm#a_020" STYLE="-sec-extract: exhibit">Powers of Attorney (included on signature page to this registration statement).</A> *</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px">&nbsp;</TD>
    <TD STYLE="line-height: 107%; width: 24px">*</TD>
    <TD STYLE="text-align: justify; line-height: 107%">Previously filed.
</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px"> &nbsp; </TD>
    <TD STYLE="line-height: 107%; width: 24px"> ** </TD>
    <TD STYLE="text-align: justify; line-height: 107%"> To be filed by amendment. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Undertakings</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">1. For purposes of determining any liability
under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) the information omitted from the form of prospectus
filed as part of this registration statement in reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the
registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration
statement as of the time it was declared effective.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">2. For the purpose of determining any
liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">3. To provide to the underwriters at
the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required
by the underwriters to permit prompt delivery to each purchaser.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Insofar as indemnification for liabilities
arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to
the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid
by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will,
unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed
by the final adjudication of such issue.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 2.5pt; margin-bottom: 2.5pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;<A HREF="#toc">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center"><B>Signatures</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Pursuant to the requirements
of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Los Angeles, State of California, on March 11, 2020. </P>





<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIOVIE INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; line-height: 107%">/s/ Terren Peizer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 62%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 3%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 5%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 30%; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terren Peizer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">Pursuant to the requirements of the
Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the
dates indicated.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 29%; border-bottom: black 1.5pt solid; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Person</B></FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 49%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capacity</B></FONT></TD>
    <TD STYLE="width: 1%; line-height: 107%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 20%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%; text-align: left; vertical-align: bottom">/s/ Terren Peizer</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief
    Executive Officer </FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"> March 11, 2020 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terren Peizer</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">(Principal Executive Officer)</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%; text-align: left; vertical-align: bottom">/s/ Joanne Wendy
    Kim</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Corporate Secretary </FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"> March 11, 2020 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joanne Wendy Kim</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">(Principal Financial Officer)</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">/s/ Jonathan Adams</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief
    Operating Officer and Director</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"> March 11, 2020 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan Adams</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">*</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"> March
    11, 2020 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cuong Do</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">*</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"> March
    11, 2020 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jim Lang</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">*</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"> March
    11, 2020 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Sherman</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">*</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"> March
    11, 2020 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard J. Berman</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 107%">*By: /s/ Terren Peizer</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attorney-in-fact</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%"> March
    11, 2020 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terren Peizer</FONT></TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="line-height: 107%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 107%">&nbsp;</TD></TR>
</TABLE>

<!-- Field: Page; Sequence: 106; Options: Last -->
    <DIV STYLE="margin-top: 2.5pt; margin-bottom: 2.5pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>bivi-20200311_s1a9ex1z1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>PLACEMENT AGENCY AGREEMENT</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>between</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>and</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>THINKEQUITY</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>A DIVISION OF FORDHAM FINANCIAL MANAGEMENT,
INC.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>as Placement Agent</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>&nbsp;</B></P>


<DIV STYLE="page-break-before: always; border-top: black 1.5pt solid; margin-top: 0pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></DIV>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: center"><B>BIOVIE INC.</B></P>

<P STYLE="font: bold 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><U>PLACEMENT AGENCY AGREEMENT</U></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: right">New York, New York<BR>
March ___, 2020</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">ThinkEquity</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">A Division of Fordham Financial Management, Inc.<BR>
17 State Street, 22<SUP>nd</SUP> Floor</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">New York, NY 10004</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0">Ladies and Gentlemen:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">The undersigned,
BioVie Inc., a corporation formed under the laws of the State of Nevada (the &#8220;<B>Company</B>&#8221;), hereby confirms its
agreement (this &#8220;<B>Agreement</B>&#8221;) with ThinkEquity, a division of Fordham Financial Management, Inc., (hereinafter
referred to as &#8220;you&#8221; (including its correlatives) or the &#8220;<B>Placement Agent</B>&#8221;) as follows:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 16pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-weight: normal">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; font-weight: normal"><U>Agreement to Act as Placement Agent; Purchase
and Sale of Securities</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Units</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">1.1.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Nature
and Purchase of Units</U>. On the basis of the representations and warranties herein contained, but subject to the terms and
conditions herein set forth, the Company agrees to issue and sell to certain investors (each an &#8220;<B>Investor</B>&#8221;
and, collectively, the &#8220;<B>Investors</B>&#8221;) up to a maximum offering amount of $[&#8226;] of units
(&#8220;<B>Units</B>&#8221;) at a purchase price of $[&#8226;] per Unit, each consisting of one (1) share of the
Company&#8217;s Class A common stock, par value $0.0001 per share (the &#8220;<B>Common Stock</B>&#8221;) and one half of one
warrant (each a &#8220;<B>Warrant</B>&#8221; and collectively, the &#8220;<B>Warrants</B>&#8221;), where each whole Warrant
is exercisable to purchase one share of Common Stock. The shares of Common Stock issuable upon exercise of the Warrants are
hereinafter referred to as the &#8220;<B>Warrant Shares</B>.&#8221; The Units and the Warrant Shares are hereinafter referred
to together as the &#8220;<B>Public&nbsp;Securities</B>.&#8221; Each Warrant will be exercisable for a period of five (5)
years at an exercise price of $[&#8226;] per share, subject to adjustment as provided in the Warrants. The Warrants shall be
issued pursuant to, and shall have the rights and privileges set forth in, a warrant agent agreement, dated on or before the
Closing Date, between the Company and West Coast Transfer, Inc., as warrant agent (the &#8220;<B>Warrant Agent
Agreement</B>&#8221;).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">1.1.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Unit Payment and Delivery.</U></P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 11pt; font-weight: normal">(i)</FONT><FONT STYLE="font-size: 7pt; font-weight: normal">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 11pt; font-weight: normal">The Closing shall be held on [____], 2020, or such other time not later
than ten Business Days after such date as shall be agreed upon by the Placement Agent and the Company (such date of payment and
delivery being herein called the &#8220;</FONT><FONT STYLE="font-size: 11pt">Closing Date<FONT STYLE="font-weight: normal">&#8221;),
at 10:00 a.m. eastern time at the offices of Greenberg Traurig, LLP (&#8220;</FONT>Placement Agent Counsel<FONT STYLE="font-weight: normal">&#8221;)
located at 1750 Tysons Blvd., Suite 1000, McLean, VA 22102, or at such other place (or remotely by facsimile or other electronic
transmission) as shall be agreed upon by the Placement Agent and the Company. All such actions taken at the Closing shall be deemed
to have occurred simultaneously.&nbsp;&nbsp;No Units which the Company has agreed to sell pursuant to this Agreement, or any other
document the Placement Agent determines as necessary to consummate the Offering, shall be deemed to have been purchased and paid
for, or sold by the Company, until such Units shall have been delivered to the Investor thereof against payment therefore by such
Investor.&nbsp;&nbsp;If the Company shall default in its obligations to deliver the Units to an Investor whose offer it has accepted
and whose payment was collected, the Company shall indemnify and hold the Placement</FONT></FONT></P>


<DIV STYLE="page-break-before: always; border-top: black 1.5pt solid; margin-top: 12pt"><P STYLE="margin: 0pt; font: 12pt Times New Roman, Times, Serif">&nbsp;</P></DIV>


<P STYLE="font: 11pt Times New Roman, Serif; margin: 0 0 0 0; text-align: justify">Agent harmless against any loss,
claim or damage incurred by the Placement Agent arising from or as a result of such default by the Company.</P>

<P STYLE="font: bold 12pt Times New Roman, Serif; margin: 12pt 0 0 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 11pt; font-weight: normal">(ii)</FONT><FONT STYLE="font-size: 7pt; font-weight: normal">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 11pt; font-weight: normal">On the Closing Date, the Company shall deliver the certificates (in form
and substance satisfactory to the Placement Agent) representing the Units (or through the facilities of DTC) to the Investors.
The Units shall be registered in such name or names and in such authorized denominations as the Placement Agent may request in
writing at least two (2) full Business Days prior to the Closing Date. The Company shall not be obligated to sell or deliver the
Units except upon tender of payment by the Placement Agent for all of the Units. The term &#8220;</FONT><FONT STYLE="font-size: 11pt">Business
Day<FONT STYLE="font-weight: normal">&#8221; shall mean any day other than a Saturday, a Sunday or a legal holiday or a day on
which banking institutions are authorized or obligated by law to close in New York, New York.</FONT></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Agreement to Act as Placement Agent</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">1.2.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>On the basis of the representations, warranties and agreements of the Company herein contained, and subject to all the terms
and conditions of this Agreement, the Placement Agent shall be the Company&#8217;s exclusive placement agent on a reasonable efforts
basis, in connection with the offering and sale by the Company of the Units to the Investors, with the terms of such offering (the
&#8220;<B>Offering</B>&#8221;) to be subject to market conditions and negotiations between the Company, the Placement Agent and
the prospective Investors.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">1.2.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As compensation for services rendered, and provided that any of the Units are sold to Investors in the Offering, on the
Closing Date (as defined below) of the Offering, the Company shall pay to the Placement Agent an amount equal to 7% of the gross
proceeds (the &#8220;<B>Placement Fee</B>&#8221;) received by the Company from the sale of Units at the Closing, other than any
gross proceeds received from a Referred Investor (as defined below). The Company will enter into any subscription, purchase or
other customary agreements as the Placement Agent or the Investors deem necessary or appropriate to consummate the Offering, all
of which will be in form and substance reasonably acceptable to the Placement Agent and the Investors.&nbsp;&nbsp;The Company shall
have the sole right to accept offers to purchase the Units and may reject any such offer in whole or in part.&nbsp;&nbsp;Notwithstanding
the foregoing, it is understood and agreed that the Placement Agent or any of their respective affiliates may, solely at their
discretion and without any obligation to do so, purchase Units as principal; provided, however, that any such purchases by the
Placement Agent (or their respective affiliates) shall be fully disclosed to the Company and approved by the Company in accordance
with the previous sentence.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">1.2.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Agreement shall not give rise to any commitment by the Placement Agent to purchase any of the Units, and the Placement
Agent shall have no authority to bind the Company.&nbsp;&nbsp;The Placement Agent shall act on a reasonable efforts basis and does
not guarantee that it will be able to raise new capital in the Offering.&nbsp;&nbsp;The Placement Agent may retain other brokers
or dealers to act as sub-agents on its behalf in connection with the Offering, the fees of which shall be paid out of the Placement
Fee.&nbsp;&nbsp;Prior to the earlier of (i) the date on which this Agreement is terminated and (ii) the Closing Date (as defined
below), the Company shall not, without the prior written consent of the Placement Agent, solicit or accept offers to purchase Units
of the Company (other than pursuant to the grant of options or restricted stock awards under the Company's equity compensation
plans or the exercise of options or warrants to purchase shares of Common Stock that are outstanding at the date hereof) otherwise
than through the Placement Agent in accordance herewith; <B><I>provided however</I></B> that Acuitas Group Holdings, LLC may refer
potential investors to the Company (&#8220;Referred Investors&#8221;).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">1.2.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company acknowledges and agrees that the Placement Agent shall act as an independent contractor, and not as a fiduciary,
and any duties of the Placement Agent with respect to investment banking services to the Company, including the offering of the
Units contemplated hereby (including in connection with determining the terms of the Offering), shall be contractual in nature,
as</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify">expressly set forth herein, and shall
be owed solely to the Company.&nbsp;&nbsp;Each party disclaims any intention to impose any fiduciary or similar duty on the other.
Additionally, the Placement Agent has not advised, nor is advising, the Company or any other person as to any legal, tax, investment,
accounting or regulatory matters in any jurisdiction with respect to the transactions contemplated hereby.&nbsp;&nbsp;The Company
shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation
and appraisal of the transactions contemplated hereby, and the Placement Agent shall have no responsibility or liability to the
Company with respect thereto.&nbsp;&nbsp;Any review by the Placement Agent of the Company, the transactions contemplated hereby
or other matters relating to such transactions has been and will be performed solely for the benefit of the Placement Agent and
has not been and shall not be on behalf of the Company or any other person.&nbsp;&nbsp;It is understood that the Placement Agent
has not and will not be rendering an opinion to the Company as to the fairness of the terms of the Offering. Notwithstanding anything
in this Agreement to the contrary, the Company acknowledges that the Placement Agent may have financial interests in the success
of the Offering contemplated hereby that are not limited to the Placement Fee.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Placement Agent&#8217;s Warrants</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">1.3.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Purchase Warrants</U>. The Company hereby agrees to issue and sell to the Placement Agent (and/or its designees) on the
Closing Date an option (&#8220;<B>Placement Agent&#8217;s Warrant</B>&#8221;) for the purchase of an aggregate of [&#8226;] shares
of Common Stock, representing 5% of the Units purchased by Investors other than Referred Investors, for an aggregate purchase price
of $100.00. The Placement Agent&#8217;s Warrant agreement, in the form attached hereto as <U>Exhibit&nbsp;A</U> (the &#8220;<B>Placement
Agent&#8217;s Warrant Agreement</B>&#8221;), shall be exercisable, in whole or in part, commencing on the first anniversary of
the Effective Date and expiring on the five-year anniversary of the Effective Date at an initial exercise price per share of Common
Stock of $[&#8226;], which is equal to 125% of the initial public offering price per Unit. The Placement Agent&#8217;s Warrant
Agreement and the shares of Common Stock issuable upon exercise thereof are hereinafter referred to together as the &#8220;<B>Placement
Agent&#8217;s Securities</B>.&#8221; The Placement Agent understands and agrees that there are significant restrictions pursuant
to FINRA Rule 5110 against transferring the Placement Agent&#8217;s Warrant Agreement and the underlying shares of Common Stock
during the one hundred eighty (180) days after the effective date of the Registration Statement (as defined below) (the &#8220;<B>Effective
Date</B>&#8221;) and by its acceptance thereof shall agree that it will not sell, transfer, assign, pledge or hypothecate the Placement
Agent&#8217;s Warrant Agreement, or any portion thereof, or be the subject of any hedging, short sale, derivative, put or call
transaction that would result in the effective economic disposition of such securities for a period of one hundred eighty (180)
days following the Effective Date to anyone other than (i) a selected dealer in connection with the Offering, or (ii) a bona fide
officer or partner of the Placement Agent or of any such selected dealer; and only if any such transferee agrees to the foregoing
lock-up restrictions.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">1.3.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery</U>. Delivery of the Placement Agent&#8217;s Warrant Agreement shall be made on the Closing Date and shall be
issued in the name or names and in such authorized denominations as the Placement Agent may request.</P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt; font-weight: normal">2.</FONT><FONT STYLE="font-size: 7pt; font-weight: normal">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 11pt; font-weight: normal"><U>Representations and Warranties of the Company</U>. The Company represents
and warrants to the Placement Agent as of the Applicable Time (as defined below) and as of the Closing Date, as follows:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Filing of Registration Statement</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.1.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Pursuant to the Securities Act</U>. The Company has filed with the U.S. Securities and Exchange Commission (the &#8220;<B>Commission</B>&#8221;)
a registration statement, and an amendment or amendments thereto, on Form S-1 (File No. 333-231136), including any related prospectus
or prospectuses, for the registration of the Public Securities and the Placement Agent&#8217;s Securities under the Securities
Act of 1933, as amended (the &#8220;<B>Securities Act</B>&#8221;), which registration statement and amendment</P>


<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">or amendments have been prepared by
the Company in all material respects in conformity with the requirements of the Securities Act and the rules and regulations of
the Commission under the Securities Act (the &#8220;<B>Securities Act Regulations</B>&#8221;) and will contain all material statements
that are required to be stated therein in accordance with the Securities Act and the Securities Act Regulations. Except as the
context may otherwise require, such registration statement, as amended, on file with the Commission at the time the registration
statement became effective (including the Preliminary Prospectus included in the registration statement, financial statements,
schedules, exhibits and all other documents filed as a part thereof or incorporated therein and all information deemed to be a
part thereof as of the Effective Date pursuant to paragraph (b) of Rule 430A of the Securities Act Regulations (the &#8220;<B>Rule
430A Information</B>&#8221;)), is referred to herein as the &#8220;<B>Registration Statement</B>.&#8221; If the Company files
any registration statement pursuant to Rule 462(b) of the Securities Act Regulations, then after such filing, the term &#8220;Registration
Statement&#8221; shall include such registration statement filed pursuant to Rule 462(b). The Registration Statement has been
declared effective by the Commission on the date hereof.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">Each prospectus
used prior to the effectiveness of the Registration Statement, and each prospectus that omitted the Rule 430A Information that
was used after such effectiveness and prior to the execution and delivery of this Agreement, is herein called a &#8220;<B>Preliminary
Prospectus</B>.&#8221; The Preliminary Prospectus, subject to completion, dated [March [&#8226;], 2020], that was included in the
Registration Statement immediately prior to the Applicable Time is hereinafter called the &#8220;<B>Pricing Prospectus</B>.&#8221;
The final prospectus in the form first furnished to the Placement Agent for use in the Offering is hereinafter called the &#8220;Prospectus.&#8221;
Any reference to the &#8220;most recent Preliminary Prospectus&#8221; shall be deemed to refer to the latest Preliminary Prospectus
included in the Registration Statement.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">&#8220;<B>Applicable
Time</B>&#8221; means 5:00 p.m., Eastern time, on the date of this Agreement.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0 0.5in; text-align: justify; text-indent: 0in">&#8220;<B>Bona
Fide Electronic Road Show</B>&#8221; means a &#8220;<I>bona fide</I> electronic road show,&#8221; as defined in Rule 433 of the
Securities Act Regulations.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">&#8220;<B>Issuer
Free Writing Prospectus</B>&#8221; means any &#8220;issuer free writing prospectus,&#8221; as defined in Rule 433 of the Securities
Act Regulations (&#8220;<B>Rule 433</B>&#8221;), including without limitation any &#8220;free writing prospectus&#8221; (as defined
in Rule 405 of the Securities Act Regulations) relating to the Public Securities that is (i)&nbsp;required to be filed with the
Commission by the Company, (ii)&nbsp;a &#8220;road show that is a written communication&#8221; within the meaning of Rule 433(d)(8)(i),
whether or not required to be filed with the Commission, or (iii)&nbsp;exempt from filing with the Commission pursuant to Rule
433(d)(5)(i) because it contains a description of the Public Securities or of the Offering that does not reflect the final terms,
in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained
in the Company&#8217;s records pursuant to Rule 433(g).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0in">&#9;&#8220;<B>Pricing
Disclosure Package</B>&#8221; the Pricing Prospectus and the information included on Schedule 1-A hereto, all considered together.&#9;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Stop Orders, etc</U>. Neither the Commission nor, to the Company&#8217;s knowledge, any state regulatory authority
has issued any order preventing or suspending the use of the Registration Statement, any Preliminary Prospectus or the Prospectus
or has instituted or, to the Company&#8217;s knowledge, threatened to institute, any proceedings with respect to such an order.
The Company has complied with each request (if any) from the Commission for additional information.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosures in Registration Statement</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.3.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance with Securities Act and 10b-5 Representation</U>.</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 11pt; font-weight: normal">(i)</FONT><FONT STYLE="font-size: 7pt; font-weight: normal">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 11pt; font-weight: normal">Each of the Registration Statement and any post-effective amendment thereto,
at the time it became effective, complied in all material respects with the requirements of the Securities Act and the Securities
Act Regulations. Each Preliminary Prospectus, including the prospectus filed as part of the Registration Statement as originally
filed or as part of any amendment or supplement thereto, and the Prospectus, at the time each was filed with the Commission, complied
in all material respects with the requirements of the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus
delivered to the Placement Agent for use in connection with this Offering and the Prospectus was or will be identical to the electronically
transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 11pt; font-weight: normal">(ii)</FONT><FONT STYLE="font-size: 7pt; font-weight: normal">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 11pt; font-weight: normal">Neither the Registration Statement nor any amendment thereto, at its
effective time, as of the Applicable Time, at the Closing Date, contained, contains or will contain an untrue statement of a material
fact or omitted, omits or will omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading. </FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-size: 11pt; font-weight: normal">(iii)</FONT><FONT STYLE="font-size: 7pt; font-weight: normal">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-weight: normal">The Pricing Disclosure Package, as of the Applicable Time, at the Closing Date, did not,
does not and will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that this
representation and warranty shall not apply to statements made or statements omitted in reliance upon and in conformity with written
information furnished to the Company with respect to the Placement Agent expressly for use in the Registration Statement, the Pricing
Prospectus or the Prospectus or any amendment thereof or supplement thereto. <FONT STYLE="font-size: 11pt">The parties hereto acknowledge
and agree that, for all purposes of this Agreement, the Placement Agent&#8217;s information consists solely of the following information
in the Prospectus: the information in the [____] paragraph under the heading &#8220;Plan of Distribution&#8221; (&#8220;the &#8220;Placement
Agent&#8217;s Information&#8221;).</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 1.5in"><FONT STYLE="font-size: 11pt; font-weight: normal">(iv)</FONT><FONT STYLE="font-size: 7pt; font-weight: normal">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-weight: normal">Neither the Prospectus nor any amendment or supplement thereto (including any prospectus
wrapper), as of its issue date, at the time of any filing with the Commission pursuant to Rule 424(b), at the Closing Date, includes
or will include an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances under which they were made, not misleading. <FONT STYLE="font-size: 11pt">provided,
however, that this representation and warranty shall not apply to the Placement Agent&#8217;s Information</FONT></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.3.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure of Agreements</U>. The agreements and documents described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus conform in all material respects to the descriptions thereof contained therein and there are no agreements
or other documents required by the Securities Act and the Securities Act Regulations to be described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus or to be filed with the Commission as exhibits to the Registration Statement,
that have not been so described or filed. Each agreement or other instrument (however characterized or described) to which the
Company is a party or by which it is or may be bound or affected and (i)&nbsp;that is referred to in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, or (ii)&nbsp;is material to the Company&#8217;s business, has been duly authorized
and validly executed by the Company, is in full force and effect in all material respects and is enforceable against the Company
and, to the Company&#8217;s knowledge, the other parties thereto, in accordance with its terms, except (x)&nbsp;as such enforceability
may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&#8217; rights generally, (y)&nbsp;as
enforceability of any indemnification or contribution provision may be limited under the federal and state securities laws, and
(z)&nbsp;that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">defenses and to the discretion of
the court before which any proceeding therefor may be brought. None of such agreements or instruments has been assigned by the
Company, and neither the Company nor, to the Company&#8217;s knowledge, any other party is in default thereunder and, to the Company&#8217;s
knowledge, no event has occurred that, with the lapse of time or the giving of notice, or both, would constitute a default thereunder.
To the best of the Company&#8217;s knowledge, performance by the Company of the material provisions of such agreements or instruments
will not result in a violation of any existing applicable law, rule, regulation, judgment, order or decree of any governmental
agency or court, domestic or foreign, having jurisdiction over the Company or any of its assets or businesses (each, a &#8220;<B>Governmental
Entity</B>&#8221;), including, without limitation, those relating to environmental laws and regulations.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.3.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Prior Securities Transactions</U>. No securities of the Company have been sold by the Company or by or on behalf of,
or for the benefit of, any person or persons controlling, controlled by or under common control with the Company, except as disclosed
in the Registration Statement, the Pricing Disclosure Package and the Preliminary Prospectus.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.3.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Regulations</U>. The disclosures in the Registration Statement, the Pricing Disclosure Package and the Prospectus concerning
the effects of federal, state, local and all foreign regulation on the Offering and the Company&#8217;s business as currently contemplated
are correct in all material respects and no other such regulations are required to be disclosed in the Registration Statement,
the Pricing Disclosure Package and the Prospectus which are not so disclosed.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Changes After Dates in Registration Statement</U><I>.</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.4.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Material Adverse Change</U>. Since the respective dates as of which information is given in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, except as otherwise specifically stated therein: (i)&nbsp;there has been no
material adverse change in the financial position or results of operations of the Company, nor any change or development that,
singularly or in the aggregate, would involve a material adverse change or a prospective material adverse change, in or affecting
the condition (financial or otherwise), results of operations, business, assets or prospects of the Company (a &#8220;<B>Material
Adverse Change</B>&#8221;); (ii)&nbsp;there have been no material transactions entered into by the Company, other than as contemplated
pursuant to this Agreement; and (iii)&nbsp;no officer or director of the Company has resigned from any position with the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.4.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Recent Securities Transactions, etc</U>. Subsequent to the respective dates as of which information is given in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, and except as may otherwise be indicated or contemplated herein or
disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not: (i)&nbsp;issued
any securities or incurred any liability or obligation, direct or contingent, for borrowed money; or (ii)&nbsp;declared or paid
any dividend or made any other distribution on or in respect to its capital stock.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Independent Accountants</U>. To the knowledge of the Company, D. Brooks and Associates CPA&#8217;s, P.A. (&#8220;<B>Brooks</B>&#8221;),
whose report is filed with the Commission as part of the Registration Statement, the Pricing Disclosure Package and the Prospectus,
is an independent registered public accounting firm as required by the Securities Act and the Securities Act Regulations and the
Public Company Accounting Oversight Board. To the knowledge of the Company, EisnerAmper LLP (&#8220;<B>Eisner</B>&#8221; and together
with Brooks, the &#8220;<B>Auditors</B>&#8221; and each an &#8220;<B>Auditor</B>&#8221;), who has reviewed certain of the financial
statements filed with the Commission as part of the Registration Statement, the Pricing Disclosure Package and the Prospectus,
is an independent registered public accounting firm as required by the Securities Act and the Securities Act Regulations and the
Public Company Accounting Oversight Board. Neither Auditor has, during the periods covered by the financial statements included
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, provided to the Company any non-audit services,
as such term is used in Section 10A(g) of the Exchange Act.</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Financial Statements, etc</U>. The financial statements, including the notes thereto and supporting schedules included
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, fairly present the financial position and the
results of operations of the Company at the dates and for the periods to which they apply; and such financial statements have been
prepared in conformity with U.S. generally accepted accounting principles (&#8220;<B>GAAP</B>&#8221;), consistently applied throughout
the periods involved (provided that unaudited interim financial statements are subject to year-end audit adjustments that are not
expected to be material in the aggregate and do not contain all footnotes required by GAAP); and the supporting schedules included
in the Registration Statement present fairly the information required to be stated therein. Except as included therein, no historical
or pro forma financial statements are required to be included in the Registration Statement, the Pricing Disclosure Package or
the Prospectus under the Securities Act or the Securities Act Regulations. The pro forma and pro forma as adjusted financial information
and the related notes, if any, included in the Registration Statement, the Pricing Disclosure Package and the Prospectus have been
properly compiled and prepared in accordance with the applicable requirements of the Securities Act and the Securities Act Regulations
and present fairly the information shown therein, and the assumptions used in the preparation thereof are reasonable and the adjustments
used therein are appropriate to give effect to the transactions and circumstances referred to therein. All disclosures contained
in the Registration Statement, the Pricing Disclosure Package or the Prospectus regarding &#8220;non-GAAP financial measures&#8221;
(as such term is defined by the rules and regulations of the Commission), if any, comply with Regulation G of the Exchange Act
and Item 10 of Regulation S-K of the Securities Act, to the extent applicable. Each of the Registration Statement, the Pricing
Disclosure Package and the Prospectus discloses all material off-balance sheet transactions, arrangements, obligations (including
contingent obligations), and other relationships of the Company with unconsolidated entities or other persons that may have a material
current or future effect on the Company&#8217;s financial condition, changes in financial condition, results of operations, liquidity,
capital expenditures, capital resources, or significant components of revenues or expenses. Except as disclosed in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, (a) the Company has not incurred any material liabilities or obligations,
direct or contingent, or entered into any material transactions other than in the ordinary course of business, (b) the Company
has not declared or paid any dividends or made any distribution of any kind with respect to its capital stock, (c) there has not
been any change in the capital stock of the Company, or, other than in the course of business, any grants under any stock compensation
plan, and (d) there has not been any material adverse change in the Company&#8217;s long-term or short-term debt.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authorized Capital; Options, etc</U>. The Company had, at the date or dates indicated in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, the duly authorized, issued and outstanding capitalization as set forth therein.
Based on the assumptions stated in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company will
have on the Closing Date the adjusted stock capitalization set forth therein. Except as set forth in, or contemplated by, the Registration
Statement, the Pricing Disclosure Package and the Prospectus, on the Effective Date, as of the Applicable Time and on the Closing
Date, there will be no stock options, warrants, or other rights to purchase or otherwise acquire any authorized, but unissued shares
of Common Stock of the Company or any security convertible or exercisable into shares of Common Stock of the Company, or any contracts
or commitments to issue or sell shares of Common Stock or any such options, warrants, rights or convertible securities.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Valid Issuance of Securities, etc</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.8.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Outstanding Securities</U>. All issued and outstanding securities of the Company issued prior to the transactions contemplated
by this Agreement have been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof have
no rights of rescission with respect thereto, and are not subject to personal liability by reason of being such holders; and none
of such</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">securities were issued in violation
of the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the Company. The
authorized shares of Common Stock conform in all material respects to all statements relating thereto contained in the Registration
Statement, the Pricing Disclosure Package and the Prospectus. The offers and sales of the outstanding shares of Common Stock were
at all relevant times either registered under the Securities Act and the applicable state securities or &#8220;blue sky&#8221;
laws or, based in part on the representations and warranties of the purchasers of such Shares, exempt from such registration requirements.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.8.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Securities Sold Pursuant to this Agreement</U>. The Public Securities and Placement Agent&#8217;s Securities have been
duly authorized for issuance and sale and, when issued and paid for, will be validly issued, fully paid and non-assessable; the
holders thereof are not and will not be subject to personal liability by reason of being such holders; the Public Securities and
Placement Agent&#8217;s Securities are not and will not be subject to the preemptive rights of any holders of any security of the
Company or similar contractual rights granted by the Company; and all corporate action required to be taken for the authorization,
issuance and sale of the Public Securities and Placement Agent&#8217;s Securities has been duly and validly taken. The Public Securities
and Placement Agent&#8217;s Securities conform in all material respects to all statements with respect thereto contained in the
Registration Statement, the Pricing Disclosure Package and the Prospectus. All corporate action required to be taken for the authorization,
issuance and sale of the Warrants and the Placement Agent&#8217;s Warrant Agreement has been duly and validly taken; the Warrant
Shares and the shares of Common Stock issuable upon exercise of the Placement Agent&#8217;s Warrant have been duly authorized and
reserved for issuance by all necessary corporate action on the part of the Company and when paid for and issued in accordance with
the Warrants and the Warrant Agent Agreement or the Placement Agent&#8217;s Warrant and the Placement Agent&#8217;s Warrant Agreement,
as applicable, such shares of Common Stock will be validly issued, fully paid and non-assessable; the holders thereof are not and
will not be subject to personal liability by reason of being such holders; and such shares of Common Stock are not and will not
be subject to the preemptive rights of any holders of any security of the Company or similar contractual rights granted by the
Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Registration Rights of Third Parties</U>. Except as set forth in the Registration Statement, the Pricing Disclosure Package
and the Prospectus, no holders of any securities of the Company or any rights exercisable for or convertible or exchangeable into
securities of the Company have the right to require the Company to register any such securities of the Company under the Securities
Act or to include any such securities in a registration statement to be filed by the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Validity and Binding Effect of Agreements</U>. This Agreement, the Warrants, the Warrant Agent Agreement and the Placement
Agent&#8217;s Warrant Agreement have been duly and validly authorized by the Company, and, when executed and delivered, will constitute,
the valid and binding agreements of the Company, enforceable against the Company in accordance with their respective terms, except:
(i)&nbsp;as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&#8217;
rights generally; (ii)&nbsp;as enforceability of any indemnification or contribution provision may be limited under the federal
and state securities laws; and (iii)&nbsp;that the remedy of specific performance and injunctive and other forms of equitable relief
may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Conflicts, etc</U>. The execution, delivery and performance by the Company of this Agreement, the Placement Agent&#8217;s
Warrant Agreement and all ancillary documents, the consummation by the Company of the transactions herein and therein contemplated
and the compliance by the Company with the terms hereof and thereof do not and will not, with or without the giving of notice or
the lapse of time or both: (i)&nbsp;result in a material breach of, or conflict with any of the terms and provisions of, or constitute
a material default under, or result in the creation, modification, termination or imposition of any</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">lien, charge or encumbrance upon any
property or assets of the Company pursuant to the terms of any agreement or instrument to which the Company is a party; (ii)&nbsp;result
in any violation of the provisions of the Company&#8217;s Articles of Incorporation (as the same may be amended or restated from
time to time, the &#8220;<B>Charter</B>&#8221;) or the by-laws of the Company; or (iii)&nbsp;violate any existing applicable law,
rule, regulation, judgment, order or decree of any Governmental Entity as of the date hereof.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Defaults; Violations</U>. No material default exists in the due performance and observance of any term, covenant or
condition of any material license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other agreement
or instrument evidencing an obligation for borrowed money, or any other material agreement or instrument to which the Company is
a party or by which the Company may be bound or to which any of the properties or assets of the Company is subject. The Company
is not in violation of any term or provision of its Charter or by-laws, or in violation of any franchise, license, permit, applicable
law, rule, regulation, judgment or decree of any Governmental Entity.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Corporate Power; Licenses; Consents</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.13.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Conduct of Business</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
the Company has all requisite corporate power and authority, and has all necessary authorizations, approvals, orders, licenses,
certificates and permits of and from all governmental regulatory officials and bodies that it needs as of the date hereof to conduct
its business purpose as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.13.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Transactions Contemplated Herein</U>. The Company has all corporate power and authority to enter into this Agreement,
the Warrants, the Warrant Agent Agreement and the Placement Agent&#8217;s Warrant Agreement and to carry out the provisions and
conditions hereof and thereof, and all consents, authorizations, approvals and orders required in connection therewith have been
obtained. No consent, authorization or order of, and no filing with, any court, government agency or other body is required for
the valid issuance, sale and delivery of the Public Securities and the consummation of the transactions and agreements contemplated
by this Agreement, the Warrants, the Warrant Agent Agreement and the Placement Agent&#8217;s Warrant Agreement and as contemplated
by the Registration Statement, the Pricing Disclosure Package and the Prospectus, except with respect to applicable federal and
state securities laws and the rules and regulations of the Financial Industry Regulatory Authority, Inc. (&#8220;<B>FINRA</B>&#8221;).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>D&amp;O Questionnaires</U>. To the Company&#8217;s knowledge, all information contained in the questionnaires (the &#8220;<B>Questionnaires</B>&#8221;)
completed by each of the Company&#8217;s directors and officers immediately prior to the Offering (the &#8220;<B>Insiders</B>&#8221;)
as supplemented by all information concerning the Company&#8217;s directors, officers and principal shareholders as described in
the Registration Statement, the Pricing Disclosure Package and the Prospectus, as well as in the Lock-Up Agreement (as defined
in Section 2.23 below), provided to the Placement Agent, is true and correct in all material respects and the Company has not become
aware of any information which would cause the information disclosed in the Questionnaires to become materially inaccurate and
incorrect.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Litigation; Governmental Proceedings</U>. There is no action, suit, proceeding, inquiry, arbitration, investigation,
litigation or governmental proceeding pending or, to the Company&#8217;s knowledge, threatened against, or involving the Company
or, to the Company&#8217;s knowledge, any executive officer or director which has not been disclosed in the Registration Statement,
the Pricing Disclosure Package and the Prospectus.</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Good Standing</U>. The Company has been duly organized and is validly existing as a corporation and is in good standing
under the laws of the State of Nevada as of the date hereof, and is duly qualified to do business and is in good standing in each
other jurisdiction in which its ownership or lease of property or the conduct of business requires such qualification, except where
the failure to qualify, singularly or in the aggregate, would not have or reasonably be expected to result in a Material Adverse
Change.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.17<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Insurance</U>. The Company carries or is entitled to the benefits of insurance, with reputable insurers, in such amounts
and covering such risks which the Company believes are adequate, including, but not limited to, directors and officers insurance
coverage at least equal to $5,000,000 and the Company has included each Placement Agent as an additional insured party to the directors
and officers insurance coverage and all such insurance is in full force and effect. The Company has no reason to believe that it
will not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage
from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would
not result in a Material Adverse Change.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.18<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transactions Affecting Disclosure to FINRA</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.18.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Finder&#8217;s Fees</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
there are no claims, payments, arrangements, agreements or understandings relating to the payment of a finder&#8217;s, consulting
or origination fee by the Company or any Insider with respect to the sale of the Public Securities hereunder or any other arrangements,
agreements or understandings of the Company or, to the Company&#8217;s knowledge, any of its shareholders that may affect the Placement
Agent&#8217;s compensation, as determined by FINRA.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.18.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Payments Within Twelve (12) Months</U>. Except as described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus, the Company has not made any direct or indirect payments (in cash, securities or otherwise) to: (i)&nbsp;any
person, as a finder&#8217;s fee, consulting fee or otherwise, in consideration of such person raising capital for the Company or
introducing to the Company persons who raised or provided capital to the Company; (ii) any FINRA member; or (iii)&nbsp; any person
or entity that has any direct or indirect affiliation or association with any FINRA member, within the twelve (12) months prior
to the Effective Date, other than the payment to the Placement Agent as provided hereunder in connection with the Offering.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.18.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Use of Proceeds</U>. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA
member or its affiliates, except as specifically authorized herein.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.18.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
</FONT><U>FINRA Affiliation</U>. There is no (i) officer or director of the Company, (ii) beneficial owner of 5% or more of any
class of the Company's securities or (iii) beneficial owner of the Company's unregistered equity securities which were acquired
during the 180-day period immediately preceding the filing of the Registration Statement that is an affiliate or associated person
of a FINRA member participating in the Offering (as determined in accordance with the rules and regulations of FINRA).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.18.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Information</U>. All information provided by the Company in its FINRA questionnaire to Placement Agent Counsel specifically
for use by Placement Agent Counsel in connection with its Public Offering System filings (and related disclosure) with FINRA is
true, correct and complete in all material respects.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.19<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Foreign Corrupt Practices Act</U>. None of the Company or, to the Company&#8217;s knowledge, any director, officer, agent,
employee or affiliate of the Company or any other person acting on behalf of the Company, has, directly or indirectly, given or
agreed to give any money, gift or similar benefit (other</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">than legal price concessions to customers
in the ordinary course of business) to any customer, supplier, employee or agent of a customer or supplier, or official or employee
of any governmental agency or instrumentality of any government (domestic or foreign) or any political party or candidate for office
(domestic or foreign) or other person who was, is, or may be in a position to help or hinder the business of the Company (or assist
it in connection with any actual or proposed transaction) that (i)&nbsp;might subject the Company to any damage or penalty in any
civil, criminal or governmental litigation or proceeding, (ii)&nbsp;if not given in the past, might have had a Material Adverse
Change or (iii)&nbsp;if not continued in the future, might adversely affect the assets, business, operations or prospects of the
Company. The Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the
Company to comply in all material respects with the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.20<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance with OFAC</U>. None of the Company or, to the Company&#8217;s knowledge, any director, officer, agent, employee
or affiliate of the Company or any other person acting on behalf of the Company, is currently subject to any U.S. sanctions administered
by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#8220;<B>OFAC</B>&#8221;), and the Company will
not, directly or indirectly, use the proceeds of the Offering hereunder, or lend, contribute or otherwise make available such proceeds
to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of any person currently
subject to any U.S. sanctions administered by OFAC.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.21<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Money Laundering Laws</U>. The operations of the Company are and have been conducted at all times in compliance with
applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules,
regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &#8220;<B>Money Laundering
Laws</B>&#8221;); and no action, suit or proceeding by or before any Governmental Entity involving the Company with respect to
the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.22<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Officers&#8217; Certificate</U>. Any certificate signed by any duly authorized officer of the Company and delivered to
you or to Placement Agent Counsel shall be deemed a representation and warranty by the Company to the Placement Agent as to the
matters covered thereby.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.23<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Lock-Up Agreements.</U> Schedule 2 hereto contains a complete and accurate list of the Company&#8217;s officers, directors
and each owner of at least 5% of the Company&#8217;s outstanding shares of Common Stock (or securities convertible or exercisable
into shares of Common Stock) (collectively, the &#8220;<B>Lock-Up Parties</B>&#8221;). The Company has caused each of the Lock-Up
Parties (i) who are directors and officers of the Company to deliver to the Placement Agent an executed Lock-Up Agreement, in the
form attached hereto as <U>Exhibit B-1</U> (the &#8220;<B>D&amp;O Lock-Up Agreement</B>&#8221;) and (ii) who are holders of 5%
or more of the Company&#8217;s outstanding securities to deliver to the Placement Agent an executed Lock-Up Agreement, in the form
attached hereto as <U>Exhibit B-2</U> (the &#8220;<B>Shareholder Lock-Up Agreement</B>&#8221; and, together with the D&amp;O Lock-Up
Agreement, the &#8220;<B>Lock-Up Agreements</B>&#8221;), prior to the execution of this Agreement.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.24<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subsidiaries</U>. The Company has no direct or indirect subsidiaries.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.25<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Related Party Transactions</U>. There are no business relationships or related party transactions involving the Company
or any other person required to be described in the Registration Statement, the Pricing Disclosure Package and the Prospectus that
have not been described as required.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.26<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Board of Directors</U>. The board of directors of the Company is comprised of the persons set forth under the heading
of the Pricing Prospectus and the Prospectus captioned &#8220;Management.&#8221; The qualifications of the persons serving as board
members and the overall composition of the board comply</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">with the Exchange Act, the Exchange
Act Regulations, the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder (the &#8220;<B>Sarbanes-Oxley Act</B>&#8221;)
applicable to the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.27<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Sarbanes-Oxley Compliance</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.27.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure Controls</U>. The Company has developed and currently maintains disclosure controls and procedures that will
comply with Rule 13a-15 or 15d-15 under the Exchange Act Regulations, and such controls and procedures are effective to ensure
that all material information concerning the Company will be made known on a timely basis to the individuals responsible for the
preparation of the Company&#8217;s Exchange Act filings and other public disclosure documents.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">2.27.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance</U>. The Company is, or at the Applicable Time and on the Closing Date will be, in material compliance with
the provisions of the Sarbanes-Oxley Act applicable to it, and has implemented or will implement such programs and taken reasonable
steps to ensure the Company&#8217;s future compliance (not later than the relevant statutory and regulatory deadlines therefor)
with all of the material provisions of the Sarbanes-Oxley Act.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.28<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Accounting Controls</U>. The Company maintains systems of &#8220;internal control over financial reporting&#8221; (as
defined under Rules 13a-15 and 15d-15 under the Exchange Act Regulations) that comply with the requirements of the Exchange Act
and have been designed by, or under the supervision of, their respective principal executive and principal financial officers,
or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with GAAP, including, but not limited to, internal accounting
controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management&#8217;s general
or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management&#8217;s
general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. Except as disclosed in the Registration Statement, the
Pricing Disclosure Package and the Prospectus, the Company is not aware of any material weaknesses in its internal controls. The
Company&#8217;s Auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i) all significant
deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are known to
the Company&#8217;s management and that have adversely affected or are reasonably likely to adversely affect the Company&#8217;
ability to record, process, summarize and report financial information; and (ii) any fraud known to the Company&#8217;s management,
whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal
controls over financial reporting.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.29<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Investment Company Status</U>. The Company is not and, after giving effect to the Offering and the application of
the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be,
required to register as an &#8220;investment company,&#8221; as defined in the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.30<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Labor Disputes</U>. No labor dispute with the employees of the Company exists or, to the knowledge of the Company,
is imminent.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.31<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Intellectual Property Rights</U>. The Company owns or possesses or has valid rights to use all patents, patent applications,
trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, inventions,
trade secrets and similar rights (&#8220;<B>Intellectual Property Rights</B>&#8221;) necessary for the conduct of the business
of the Company as currently carried on and as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.
To the</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">knowledge of the Company, no action
or use by the Company necessary for the conduct of its business as currently carried on and as described in the Registration Statement
and the Prospectus will involve or give rise to any infringement of, or license or similar fees for, any Intellectual Property
Rights of others. The Company has not received any notice alleging any such infringement, fee or conflict with asserted Intellectual
Property Rights of others except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus.
Except as would not reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change (i) to the
knowledge of the Company, there is no infringement, misappropriation or violation by third parties of any of the Intellectual Property
Rights owned by the Company; (ii) except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus
there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by others challenging the
rights of the Company in or to any such Intellectual Property Rights, and the Company is unaware of any facts which would form
a reasonable basis for any such claim, that would, individually or in the aggregate, together with any other claims in this Section
2.31, reasonably be expected to result in a Material Adverse Change; (iii) the Intellectual Property Rights owned by the Company
and, to the knowledge of the Company, the Intellectual Property Rights licensed to the Company have not been adjudged by a court
of competent jurisdiction invalid or unenforceable, in whole or in part, and except as disclosed in the Registration Statement,
the Pricing Disclosure Package and the Prospectus there is no pending or, to the Company&#8217;s knowledge, threatened action,
suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property Rights, and the Company
is unaware of any facts which would form a reasonable basis for any such claim that would, individually or in the aggregate, together
with any other claims in this Section 2.31, reasonably be expected to result in a Material Adverse Change; (iv) except as disclosed
in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no pending or, to the Company&#8217;s
knowledge, threatened action, suit, proceeding or claim by others that the Company infringes, misappropriates or otherwise violates
any Intellectual Property Rights or other proprietary rights of others, the Company has not received any written notice of such
claim and the Company is unaware of any other facts which would form a reasonable basis for any such claim that would, individually
or in the aggregate, together with any other claims in this Section 2.31, reasonably be expected to result in a Material Adverse
Change; and (v) to the Company&#8217;s knowledge, no employee of the Company is in or has ever been in violation in any material
respect of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement,
non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis of
such violation relates to such employee&#8217;s employment with the Company, or actions undertaken by the employee while employed
with the Company and could reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change. To
the Company&#8217;s knowledge, all material technical information developed by and belonging to the Company which has not been
patented has been kept confidential. The Company is not a party to or bound by any options, licenses or agreements with respect
to the Intellectual Property Rights of any other person or entity that are required to be set forth in the Registration Statement,
the Pricing Disclosure Package and the Prospectus and are not described therein. The Registration Statement, the Pricing Disclosure
Package and the Prospectus contain in all material respects the same description of the matters set forth in the preceding sentence.
None of the technology employed by the Company has been obtained or is being used by the Company in violation of any contractual
obligation binding on the Company or, to the Company&#8217;s knowledge, any of its officers, directors or employees, or otherwise
in violation of the rights of any persons.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.32<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Taxes</U>. The Company has filed all material returns (as hereinafter defined) required to be filed with taxing authorities
prior to the date hereof or has duly obtained extensions of time for the filing thereof. The Company has paid all material taxes
(as hereinafter defined) shown as due on such returns that were filed and has paid all taxes imposed on or assessed against the
Company. The provisions for taxes payable, if any, shown on the financial statements filed with or as part of the Registration
Statement are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">including the dates of such consolidated
financial statements. Except as disclosed in writing to the Placement Agent, (i) no issues have been raised (and are currently
pending) by any taxing authority in connection with any of the returns or taxes asserted as due from the Company, and (ii) no waivers
of statutes of limitation with respect to the returns or collection of taxes have been given by or requested from the Company.
The term &#8220;taxes&#8221; means all federal, state, local, foreign and other net income, gross income, gross receipts, sales,
use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll, employment, excise,
severance, stamp, occupation, premium, property, windfall profits, customs, duties or other taxes, fees, assessments or charges
of any kind whatever, together with any interest and any penalties, additions to tax or additional amounts with respect thereto.
The term &#8220;returns&#8221; means all returns, declarations, reports, statements and other documents required to be filed in
respect to taxes.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.33<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>ERISA Compliance</U>. The Company and any &#8220;employee benefit plan&#8221; (as defined under the Employee Retirement
Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &#8220;<B>ERISA</B>&#8221;))
established or maintained by the Company or its ERISA Affiliates (as defined below) are in compliance in all material respects
with ERISA. &#8220;<B>ERISA Affiliate</B>&#8221; means, with respect to the Company, any member of any group of organizations described
in Sections 414(b),(c),(m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations
thereunder (the &#8220;<B>Code</B>&#8221;) of which the Company is a member. No &#8220;reportable event&#8221; (as defined under
ERISA) has occurred or is reasonably expected to occur with respect to any &#8220;employee benefit plan&#8221; established or maintained
by the Company or any of its ERISA Affiliates. No &#8220;employee benefit plan&#8221; established or maintained by the Company
or any of its ERISA Affiliates, if such &#8220;employee benefit plan&#8221; were terminated, would have any &#8220;amount of unfunded
benefit liabilities&#8221; (as defined under ERISA). Neither the Company nor any of its ERISA Affiliates has incurred or reasonably
expects to incur any material liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any &#8220;employee
benefit plan&#8221; or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each &#8220;employee benefit plan&#8221; established
or maintained by the Company or any of its ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is
so qualified and, to the knowledge of the Company, nothing has occurred, whether by action or failure to act, which would cause
the loss of such qualification.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.34<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance with Laws</U>. The Company: (i) is and at all times has been in compliance with all statutes, rules, or regulations
applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling,
promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company
(&#8220;<B>Applicable Laws</B>&#8221;), except as could not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Change; (ii) has not received any warning letter, untitled letter or other correspondence or notice from any other
governmental authority alleging or asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances,
authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (&#8220;<B>Authorizations</B>&#8221;);
(iii) possesses all material Authorizations and such Authorizations are valid and in full force and effect and are not in material
violation of any term of any such Authorizations; (iv) has not received notice of any claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action from any governmental authority or third party alleging that any product
operation or activity is in violation of any Applicable Laws or Authorizations and has no knowledge that any such governmental
authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (v)
has not received notice that any governmental authority has taken, is taking or intends to take action to limit, suspend, modify
or revoke any Authorizations and has no knowledge that any such governmental authority is considering such action; (vi) has filed,
obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and
supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices,</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">applications, records, claims, submissions
and supplements or amendments were complete and correct on the date filed (or were corrected or supplemented by a subsequent submission);
and (vii) has not, either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or
issued, any recall, market withdrawal or replacement, safety alert, post-sale warning, &#8220;dear doctor&#8221; letter, or other
notice or action relating to the alleged lack of safety or efficacy of any product or any alleged product defect or violation and,
to the Company&#8217;s knowledge, no third party has initiated, conducted or intends to initiate any such notice or action.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.35<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tests and Preclinical and Clinical Trials</U>. The preclinical studies and clinical trials conducted by or, to the Company&#8217;s
knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
as applicable, and are intended to be submitted to the U.S. Food and Drug Administration (the &#8220;<B>FDA</B>&#8221;) or other
comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental
protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable
Laws, including, without limitation, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and
regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies
and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company&#8217;s
knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except
to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware
of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described
or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which
such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement,
the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from
the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted
by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the
design and implementation of such trials, copies of which communications have been made available to you.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.36<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance with Health Care Laws</U>. The Company is and at all times has been, in compliance with all applicable Health
Care Laws except to the extent that any&nbsp;non-compliance&nbsp;would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Change. For purposes of this Agreement, &#8220;<B>Health Care Laws</B>&#8221; means: (i)&nbsp;the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301 et seq.) and the regulations promulgated thereunder; (ii)&nbsp;all applicable
federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute
(42 U.S.C.&nbsp;Section&nbsp;1320a-7b(b)),&nbsp;the U.S. Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal
False Statements Law (42 U.S.C.&nbsp;Section&nbsp;1320a-7b(a)),&nbsp;18 U.S.C. Sections 286, 287 and the health care fraud criminal
provisions under HIPAA (42 U.S.C. Section&nbsp;1320d et seq.), the civil monetary penalties law (42 U.S.C.&nbsp;Section&nbsp;1320a-7a),&nbsp;the
exclusion law (42 U.S.C.&nbsp;Section&nbsp;1320a-7),&nbsp;the Physician Payments Sunshine Act (42 U.S.C.&nbsp;Section&nbsp;1320a-7h),&nbsp;and
the laws governing government funded or sponsored healthcare programs including, but not limited to, Medicare (Title XVIII of the
Social Security Act) and Medicaid (Title XIX of the Social Security Act); (iii) HIPAA, as amended by the HITECH Act (42 U.S.C.
Section&nbsp;17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education
Reconciliation Act of 2010; (v) all other applicable local, state, federal, national, supranational and foreign laws, relating
to the regulation of the Company; and (vi)&nbsp;the directives and regulations promulgated pursuant to such statutes and any state
or&nbsp;non-U.S.&nbsp;counterpart thereof. The Company has not received written notice of any claim, action, suit, proceeding,
hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority
or third party alleging that any product operation or activity is in</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">violation of any Health Care Laws nor,
to the Company&#8217;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration
or other action threatened, except in each case as would not, individually or in the aggregate, have a Material Adverse Change.
The Company has filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims,
submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material
respects (or were corrected or supplemented by a subsequent submission). The Company is not a party to any corporate integrity
agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental
or regulatory authority. Additionally, neither the Company, nor to the knowledge of the Company, any of their respective employees,
officers, directors, contractors or agents has been excluded, suspended or debarred from participation in any U.S. federal health
care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation,
proceeding, or other similar action that would reasonably be expected to result in debarment, suspension, or exclusion.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.37<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Ineligible Issuer</U>.&nbsp; At the time of filing the Registration Statement and any post-effective amendment thereto,
at the time of effectiveness of the Registration Statement and any amendment thereto, at the earliest time thereafter that the
Company or another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the Securities Act Regulations)
of the Public Securities and at the date hereof, the Company was and is an &#8220;ineligible issuer,&#8221; as defined in Rule
405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company
be considered an ineligible issuer.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.38<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Real Property</U>. Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
the Company has good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items of real or
personal property which are material to the business of the Company, in each case free and clear of all liens, encumbrances, security
interests, claims and defects that do not, singly or in the aggregate, materially affect the value of such property and do not
interfere with the use made and proposed to be made of such property by the Company; and all of the leases and subleases material
to the business of the Company and under which the Company holds properties described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, are in full force and effect, and the Company has not received any notice of any material
claim of any sort that has been asserted by anyone adverse to the rights of the Company under any of the leases or subleases mentioned
above, or affecting or questioning the rights of the Company to the continued possession of the leased or subleased premises under
any such lease or sublease.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.39<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Contracts Affecting Capital</U>. There are no transactions, arrangements or other relationships between and/or among
the Company, any of its affiliates (as such term is defined in Rule 405 of the Securities Act Regulations) and any unconsolidated
entity, including, but not limited to, any structured finance, special purpose or limited purpose entity that could reasonably
be expected to materially affect the Company&#8217;s liquidity or the availability of or requirements for their capital resources
required to be described or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus
which have not been described or incorporated by reference as required.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.40<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Loans to Directors or Officers</U>. There are no outstanding loans, advances (except normal advances for business expenses
in the ordinary course of business) or guarantees or indebtedness by the Company to or for the benefit of any of the officers or
directors of the Company or any of their respective family members, except as disclosed in the Registration Statement, the Pricing
Disclosure Package and the Prospectus.</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.41<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Smaller Reporting Company</U>.&nbsp; As of the time of filing of the Registration Statement, the Company was a &#8220;smaller
reporting company,&#8221; as defined in Rule&nbsp;12b-2 of the Exchange Act Regulations.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.42<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Industry Data</U>.&nbsp; The statistical and market-related data included in each of the Registration Statement, the
Pricing Disclosure Package and the Prospectus are based on or derived from sources that the Company reasonably and in good faith
believes are reliable and accurate or represent the Company&#8217;s good faith estimates that are made on the basis of data derived
from such sources.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.43<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reverse Stock Split</U>. The Company has effectuated a reverse stock split of its shares of Common Stock .</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.44<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Emerging Growth Company</U>. From the time of the initial filing of the Registration Statement to the Commission (or,
if earlier, the first date on which the Company engaged directly in or through any Person authorized to act on its behalf in any
Testing-the Waters Communication) through June 30, 2019, the Company was an &#8220;emerging growth company,&#8221; as defined in
Section 2(a) of the Securities Act (an &#8220;Emerging Growth Company&#8221;). &#8220;<B>Testing-the-Waters Communication</B>&#8221;
means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Securities Act.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.45<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Testing-the-Waters Communications</U>. The Company has not (i) alone engaged in any Testing-the-Waters Communications
and (ii) authorized anyone to engage in Testing-the-Waters Communications.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.46<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Electronic Road Show</U>. The Company has made available a Bona Fide Electronic Road Show in compliance with Rule&nbsp;433(d)(8)(ii)
of the Securities Act Regulations such that no filing of any &#8220;road show&#8221; (as defined in Rule&nbsp;433(h) of the Securities
Act Regulations) is required in connection with the Offering.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">2.47<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Margin Securities</U>. The Company owns no &#8220;margin securities&#8221; as that term is defined in Regulation U of
the Board of Governors of the Federal Reserve System (the &#8220;<B>Federal Reserve Board</B>&#8221;), and none of the proceeds
of Offering will be used, directly or indirectly, for the purpose of purchasing or carrying any margin security, for the purpose
of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for any other
purpose which might cause any of the shares of Common Stock to be considered a &#8220;purpose credit&#8221; within the meanings
of Regulation T, U or X of the Federal Reserve Board.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 16pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-weight: normal">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; font-weight: normal"><U>Covenants of the Company</U>. The Company
covenants and agrees as follows:</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendments to Registration Statement</U>. The Company shall deliver to the Placement Agent, prior to filing, any amendment
or supplement to the Registration Statement or Prospectus proposed to be filed after the Effective Date and not file any such amendment
or supplement to which the Placement Agent shall reasonably object in writing.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Federal Securities Laws</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">3.2.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance</U>. The Company, subject to Section 3.2.2, shall comply with the requirements of Rule 430A of the Securities
Act Regulations, and will notify the Placement Agent promptly, and confirm the notice in writing, (i)&nbsp;when any post-effective
amendment to the Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have been
filed; (ii)&nbsp;of the receipt of any comments from the Commission; (iii)&nbsp;of any request by the Commission for any amendment
to the Registration Statement or any amendment or supplement to the Prospectus or for additional information; (iv)&nbsp;of the
issuance by the Commission of any stop order suspending the</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">effectiveness of the Registration
Statement or any post-effective amendment or of any order preventing or suspending the use of any Preliminary Prospectus or the
Prospectus, or of the suspension of the qualification of the Public Securities and Placement Agent&#8217;s Securities for offering
or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes or of any examination
pursuant to Section&nbsp;8(d) or 8(e) of the Securities Act concerning the Registration Statement and (v)&nbsp;if the Company becomes
the subject of a proceeding under Section&nbsp;8A of the Securities Act in connection with the Offering of the Public Securities
and Placement Agent&#8217;s Securities. The Company shall effect all filings required under Rule 424(b) of the Securities Act Regulations,
in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and shall take such steps
as it deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received
for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company shall use its
best efforts to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the
lifting thereof at the earliest possible moment.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">3.2.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Continued Compliance</U>. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange
Act and the Exchange Act Regulations so as to permit the completion of the distribution of the Public Securities as contemplated
in this Agreement and in the Registration Statement, the Pricing Disclosure Package and the Prospectus. If at any time when a prospectus
relating to the Public Securities is (or, but for the exception afforded by Rule 172 of the Securities Act Regulations (&#8220;<B>Rule
172</B>&#8221;), would be) required by the Securities Act to be delivered in connection with sales of the Public Securities, any
event shall occur or condition shall exist as a result of which it is necessary, in the opinion of counsel for the Placement Agent
or for the Company, to (i)&nbsp;amend the Registration Statement in order that the Registration Statement will not include an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading; (ii)&nbsp;amend or supplement the Pricing Disclosure Package or the Prospectus in order that the Pricing
Disclosure Package or the Prospectus, as the case may be, will not include any untrue statement of a material fact or omit to state
a material fact necessary in order to make the statements therein not misleading in the light of the circumstances existing at
the time it is delivered to a purchaser or (iii)&nbsp;amend the Registration Statement or amend or supplement the Pricing Disclosure
Package or the Prospectus, as the case may be, in order to comply with the requirements of the Securities Act or the Securities
Act Regulations, the Company will promptly (A)&nbsp;give the Placement Agent notice of such event; (B)&nbsp;prepare any amendment
or supplement as may be necessary to correct such statement or omission or to make the Registration Statement, the Pricing Disclosure
Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use, furnish
the Placement Agent with copies of any such amendment or supplement and (C)&nbsp;file with the Commission any such amendment or
supplement; provided that the Company shall not file or use any such amendment or supplement to which the Placement Agent or counsel
for the Placement Agent shall reasonably object. The Company will furnish to the Placement Agent such number of copies of such
amendment or supplement as the Placement Agent may reasonably request. The Company has given the Placement Agent notice of any
filings made pursuant to the Exchange Act or the Exchange Act Regulations within 48 hours prior to the Applicable Time. The Company
shall give the Placement Agent notice of its intention to make any such filing from the Applicable Time until the Closing Date
and will furnish the Placement Agent with copies of the related document(s) a reasonable amount of time prior to such proposed
filing, as the case may be, and will not file or use any such document to which the Placement Agent or counsel for the Placement
Agent shall reasonably object.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">3.2.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exchange Act Registration</U>. For a period of three (3) years after the date of this Agreement, the Company shall use
its best efforts to maintain the registration of the shares of Common Stock under the Exchange Act. The Company shall not deregister
the shares of Common Stock under the Exchange Act during such period without the prior written consent of the Placement Agent.</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">3.2.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Free Writing Prospectuses</U>. The Company agrees that it shall not make any offer relating to the Public Securities
that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &#8220;free writing prospectus,&#8221;
or a portion thereof, required to be filed by the Company with the Commission or retained by the Company under Rule 433.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">3.2.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reserved</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery to the Placement Agent of Registration Statements</U>. The Company has delivered or made available or shall
deliver or make available to the Placement Agent and counsel for the Placement Agent, without charge, signed copies of the Registration
Statement as originally filed and each amendment thereto (including exhibits filed therewith) and signed copies of all consents
and certificates of experts.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery to the Placement Agent of Prospectuses</U>. The Company has delivered or made available or will deliver or make
available to the Placement Agent, without charge, as many copies of each Preliminary Prospectus as the Placement Agent reasonably
requested, and the Company hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company
will furnish to the Placement Agent, without charge, during the period when a prospectus relating to the Public Securities is (or,
but for the exception afforded by Rule 172, would be) required to be delivered under the Securities Act, such number of copies
of the Prospectus (as amended or supplemented) as the Placement Agent may reasonably request. The Prospectus and any amendments
or supplements thereto furnished to the Placement Agent will be identical to the electronically transmitted copies thereof filed
with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effectiveness and Events Requiring Notice to the Placement Agent</U>. The Company shall use its best efforts to cause
the Registration Statement to remain effective with a current prospectus for at least nine (9) months after the Applicable Time,
and shall notify the Placement Agent immediately and confirm the notice in writing: (i)&nbsp;of the effectiveness of the Registration
Statement and any amendment thereto; (ii)&nbsp;of the issuance by the Commission of any stop order or of the initiation, or the
threatening, of any proceeding for that purpose; (iii)&nbsp;of the issuance by any state securities commission of any proceedings
for the suspension of the qualification of the Public Securities for offering or sale in any jurisdiction or of the initiation,
or the threatening, of any proceeding for that purpose; (iv)&nbsp;of the mailing and delivery to the Commission for filing of any
amendment or supplement to the Registration Statement or Prospectus; (v)&nbsp;of the receipt of any comments or request for any
additional information from the Commission; and (vi)&nbsp;of the happening of any event during the period described in this Section
3.5 that, in the judgment of the Company, makes any statement of a material fact made in the Registration Statement, the Pricing
Disclosure Package or the Prospectus untrue or that requires the making of any changes in (A) the Registration Statement in order
to make the statements therein not misleading, or (B) in the Pricing Disclosure Package or the Prospectus in order to make the
statements therein, in light of the circumstances under which they were made, not misleading. If the Commission or any state securities
commission shall enter a stop order or suspend such qualification at any time, the Company shall make every reasonable effort to
obtain promptly the lifting of such order.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Review of Financial Statements.</U> For a period of five (5) years after the date of this Agreement, the Company, at
its expense, shall cause its regularly engaged independent registered public accounting firm to review (but not audit) the Company&#8217;s
financial statements for each of the three fiscal quarters immediately preceding the announcement of any quarterly financial information.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Financial Public Relations Firm</U>. As of the Effective Date, the Company shall have retained a financial public relations
firm reasonably acceptable to the Placement Agent and the Company, which shall initially be Tailwinds Research Group, which firm
shall be experienced in assisting issuers in initial public offerings of securities and in their relations with their security
holders, and shall retain such</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">firm or another firm reasonably acceptable
to the Placement Agent for a period of not less than two (2) years after the Effective Date.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reports to the Placement Agent</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">3.8.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Periodic Reports, etc</U>. For a period of three (3) years after the date of this Agreement, the Company shall furnish
or make available to the Placement Agent copies of such financial statements and other periodic and special reports as the Company
from time to time furnishes generally to holders of any class of its securities and also promptly furnish to the Placement Agent:
(i) a copy of each periodic report the Company shall be required to file with the Commission under the Exchange Act and the Exchange
Act Regulations; (ii) a copy of every press release and every news item and article with respect to the Company or its affairs
which was released by the Company; (iii) a copy of each Form 8-K prepared and filed by the Company; (iv) five copies of each registration
statement filed by the Company under the Securities Act; and (v) such additional documents and information with respect to the
Company and the affairs of any future subsidiaries of the Company as the Placement Agent may from time to time reasonably request;
provided the Placement Agent shall sign, if requested by the Company, a Regulation FD compliant confidentiality agreement which
is reasonably acceptable to the Placement Agent and Placement Agent Counsel in connection with the Placement Agent&#8217;s receipt
of such information. Documents filed with the Commission pursuant to its EDGAR system shall be deemed to have been delivered to
the Placement Agent pursuant to this Section 3.9.1.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">3.8.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transfer Agent; Transfer Sheets</U>. For a period of three (3) years after the date of this Agreement, the Company shall
retain a transfer agent and registrar acceptable to the Placement Agent (the&nbsp;&#8220;<B>Transfer Agent</B>&#8221;) and shall
furnish to the Placement Agent at the Company&#8217;s sole cost and expense such transfer sheets of the Company&#8217;s securities
as the Placement Agent may reasonably request, including the daily and monthly consolidated transfer sheets of the Transfer Agent
and DTC. West Coast Stock Transfer, Inc. is acceptable to the Placement Agent to act as Transfer Agent for the shares of Common
Stock.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Payment of Expenses</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">3.9.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>General Expenses Related to the Offering</U>. The Company hereby agrees to pay on the Closing Date all expenses incident
to the performance of the obligations of the Company under this Agreement, including, but not limited to: (i) all filing fees and
communication expenses relating to the registration of the shares of Common Stock to be sold in the Offering with the Commission;
(ii) all Public Filing System filing fees associated with the review of the Offering by FINRA; (iii) all fees and expenses relating
to the listing of such Public Securities on such other stock exchanges as the Company and the Placement Agent together determine;
(iv) all fees, expenses and disbursements relating to background checks of the Company&#8217;s officers and directors in an amount
not to exceed $15,000 in the aggregate; (v) all fees, expenses and disbursements relating to the registration or qualification
of the Public Securities under the &#8220;blue sky&#8221; securities laws of such states and other jurisdictions as the Placement
Agent may reasonably designate (including, without limitation, all filing and registration fees, it being agreed that if the Offering
is commenced on the Over-the-Counter Bulletin Board, the Company shall make a payment of $15,000 to such counsel upon the commencement
of &#8220;blue sky&#8221; work by such counsel and an additional $10,000 at Closing); (vi) all fees, expenses and disbursements
relating to the registration, qualification or exemption of the Public Securities under the securities laws of such foreign jurisdictions
as the Placement Agent may reasonably designate; (vii) the costs of all mailing and printing of the placement documents (including,
without limitation, this Agreement, any Blue Sky Surveys and, if appropriate, any Agreement with the Placement Agent, Selected
Dealers&#8217; Agreement, Placement Agent&#8217;s Questionnaire and Power of Attorney), Registration Statements, Prospectuses and
all amendments, supplements and exhibits thereto and as many preliminary and final Prospectuses as the Placement Agent may reasonably
deem necessary; (viii) the costs and expenses of a public relations firm; (ix) the costs of</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">preparing, printing and delivering
certificates representing the Public Securities; (x) fees and expenses of the transfer agent for the shares of Common Stock;
(xi) stock transfer and/or stamp taxes, if any, payable upon the transfer of securities from the Company to the Placement Agent;
(xii) to the extent approved by the Company in writing, the costs associated with post-Closing advertising the Offering in the
national editions of the Wall Street Journal and New York Times; (xiii) $2,000 for the costs associated with commemorative mementos
and lucite tombstones, each of which the Company or its designee shall provide within a reasonable time after the Closing Date
in such quantities as the Placement Agent may reasonably request; (xiv) the fees and expenses of the Company&#8217;s accountants;
(xv) the fees and expenses of the Company&#8217;s legal counsel and other agents and the Placement Agent; (xvi) fees and expenses
of the Placement Agent&#8217;s legal counsel not to exceed $75,000; (q) the $29,500 cost associated with the Placement Agent&#8217;s
use of Ipreo&#8217;s book-building, prospectus tracking and compliance software for the Offering; and (xvii) up to $20,000 of the
Placement Agent&#8217;s actual accountable &#8220;road show&#8221; expenses for the Offering. The Placement Agent may deduct from
the net proceeds of the Offering payable to the Company on the Closing Date the expenses set forth herein to be paid by the Company
to the Placement Agent.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">3.9.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-accountable Expenses</U>. The Company further agrees that, in addition to the expenses payable pursuant to Section
3.9.1, on the Closing Date it shall pay to the Placement Agent, by deduction from the net proceeds of the Offering contemplated
herein, a non-accountable expense allowance equal to one percent (1%) of the gross proceeds received by the Company from the sale
of the Units, less the Advance (as such term is defined in Section 7.3 hereof), provided, however, that in the event that the Offering
is terminated, the Company agrees to reimburse the Placement Agent pursuant to Section 7.3 hereof.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Application of Net Proceeds</U>. The Company shall apply the net proceeds from the Offering received by it in a manner
consistent with the application thereof described under the caption &#8220;Use of Proceeds&#8221; in the Registration Statement,
the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Earnings Statements to Security Holders</U>. The Company shall make generally available to its security holders
as soon as practicable, but not later than the first day of the fifteenth (15<SUP>th</SUP>) full calendar month following the date
of this Agreement, an earnings statement (which need not be certified by independent registered public accounting firm unless required
by the Securities Act or the Securities Act Regulations, but which shall satisfy the provisions of Rule 158(a) under Section 11(a)
of the Securities Act) covering a period of at least twelve (12) consecutive months beginning after the date of this Agreement.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stabilization</U>. Neither the Company nor, to its knowledge, any of its employees, directors or shareholders (without
the consent of the Placement Agent) has taken or shall take, directly or indirectly, any action designed to or that has constituted
or that might reasonably be expected to cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization
or manipulation of the price of any security of the Company to facilitate the sale or resale of the Public Securities.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Internal Controls</U>. The Company shall maintain a system of internal accounting controls sufficient to provide reasonable
assurances that: (i)&nbsp;transactions are executed in accordance with management&#8217;s general or specific authorization; (ii)&nbsp;transactions
are recorded as necessary in order to permit preparation of financial statements in accordance with GAAP and to maintain accountability
for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&#8217;s general or specific authorization;
and (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action
is taken with respect to any differences.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Accountants</U>. As of the date of this Agreement, the Company shall retain an independent registered public accounting
firm reasonably acceptable to the Placement Agent, and the Company shall</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">continue to retain a nationally recognized
independent registered public accounting firm for a period of at least three (3) years after the date of this Agreement. The Placement
Agent acknowledges that Eisner is acceptable to the Placement Agent.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>FINRA</U>. The Company shall advise the Placement Agent (who shall make an appropriate filing with FINRA) if it is or
becomes aware that (i) any officer or director of the Company, (ii) any beneficial owner of 5% or more of any class of the Company's
securities or (iii) any beneficial owner of the Company's unregistered equity securities which were acquired during the 180 days
immediately preceding the filing of the Registration Statement is or becomes an affiliate or associated person of a FINRA member
participating in the Offering (as determined in accordance with the rules and regulations of FINRA).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Fiduciary Duties</U>. The Company acknowledges and agrees that the Placement Agent&#8217;s responsibility to the Company
is solely contractual in nature and that none of the Placement Agent or their affiliates or any selling agent shall be deemed to
be acting in a fiduciary capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with
the Offering and the other transactions contemplated by this Agreement.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.17<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Company Lock-Up Agreements</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">3.17.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Restriction on Sales of Capital Stock</U>. The Company, on behalf of itself and any successor entity, agrees that, without
the prior written consent of the Placement Agent, it will not, for a period of 90 days after the date of this Agreement (the &#8220;<B>Lock-Up
Period</B>&#8221;), (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly,
any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital
stock of the Company; (ii) file or caused to be filed any registration statement with the Commission relating to the offering of
any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital
stock of the Company; (iii) complete any offering of debt securities of the Company, other than entering into a line of credit
with a traditional bank or (iv) enter into any swap or other arrangement that transfers to another, in whole or in part, any of
the economic consequences of ownership of capital stock of the Company, whether any such transaction described in clause (i), (ii),
(iii) or (iv) above is to be settled by delivery of shares of capital stock of the Company or such other securities, in cash or
otherwise.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0in">The restrictions contained
in this Section 3.17.1 shall not apply to (i) the shares of Common Stock to be sold hereunder, (ii) the issuance by the Company
of shares of Common Stock upon the exercise of a stock option or warrant or the conversion of a security outstanding on the date
hereof, of which the Placement Agent has been advised in writing, (iii) the issuance by the Company of shares of Common Stock or
warrants to purchase shares of Common Stock to Acuitas Group Holdings, LLC, in the manner and as disclosed in the Registration
Statement, Pricing Disclosure Package and the Prospectus pursuant to that certain Letter Agreement, dated June 24, 2019, between
the Company and Acuitas Group Holdings, LLC or (iv) the issuance by the Company of stock options or shares of capital stock of
the Company under any equity compensation plan of the Company, provided that in each of (ii), (iii) and (iv) above, the underlying
shares shall be restricted from sale during the entire Lock-Up Period.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">3.17.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Restriction on Continuous Offerings</U>. Notwithstanding the restrictions contained in Section 3.17.1, the Company, on
behalf of itself and any successor entity, agrees that, without the prior written consent of the Placement Agent, it will not,
for a period of twelve (12) months after the date of this Agreement, directly or indirectly in any &#8220;at-the-market&#8221;
or continuous equity transaction, offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of shares
of capital stock of the</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">Company or any securities convertible
into or exercisable or exchangeable for shares of capital stock of the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.18<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Release of D&amp;O Lock-up Period</U>. If the Placement Agent, in its sole discretion, agrees to release or waive the
restrictions set forth in the Lock-Up Agreements described in Section 2.23 hereof for an officer or director of the Company and
provide the Company with notice of the impending release or waiver at least three (3) Business Days before the effective date of
the release or waiver, the Company agrees to announce the impending release or waiver by a press release substantially in the form
of <U>Exhibit C</U> hereto through a major news service at least two (2) Business Days before the effective date of the release
or waiver.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.19<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Blue Sky Qualifications</U>. The Company shall use its best efforts, in cooperation with the Placement Agent, if necessary,
to qualify the Public Securities for offering and sale under the applicable securities laws of such states and other jurisdictions
(domestic or foreign) as the Placement Agent may designate and to maintain such qualifications in effect so long as required to
complete the distribution of the Public Securities; provided, however, that the Company shall not be obligated to file any general
consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which
it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise
so subject.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">3.20<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reporting Requirements</U>. The Company, during the period when a prospectus relating to the Public Securities is (or,
but for the exception afforded by Rule 172, would be) required to be delivered under the Securities Act, will file all documents
required to be filed with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and
Exchange Act Regulations. Additionally, the Company shall report the use of proceeds from the issuance of the Public Securities
as may be required under Rule 463 under the Securities Act Regulations.</P>

<P STYLE="font: 16pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt; font-weight: normal">4.</FONT><FONT STYLE="font-size: 7pt; font-weight: normal">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 11pt; font-weight: normal"><U>Conditions of Placement Agent&#8217;s Obligations</U>. The obligations
of the Placement Agent hereunder shall be subject to (i) the continuing accuracy of the representations and warranties of the Company
as of the date hereof and as of the Closing Date; (ii) the accuracy of the statements of officers of the Company made pursuant
to the provisions hereof; (iii) the performance by the Company of its obligations hereunder; and (iv) the following conditions:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Regulatory Matters.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">4.1.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effectiveness of Registration Statement; Rule 430A Information</U>. The Registration Statement has become effective not
later than 5:00 p.m., Eastern time, on the date of this Agreement or such later date and time as shall be consented to in writing
by you, and, at the Closing Date, no stop order suspending the effectiveness of the Registration Statement or any post-effective
amendment thereto has been issued under the Securities Act, no order preventing or suspending the use of any Preliminary Prospectus
or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company&#8217;s
knowledge, contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional
information. The Prospectus containing the Rule 430A Information shall have been filed with the Commission in the manner and within
the time frame required by Rule 424(b) (without reliance on Rule 424(b)(8)) or a post-effective amendment providing such information
shall have been filed with, and declared effective by, the Commission in accordance with the requirements of Rule 430A.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">4.1.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>FINRA Clearance</U>. On or before the date of this Agreement, the Placement Agent shall have received clearance from
FINRA as to the amount of compensation allowable or payable to the Placement Agent as described in the Registration Statement.</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Company Counsel Matters</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">4.2.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing Date Opinion of Counsel</U>. On the Closing Date, the Placement Agent shall have received the favorable opinion
or opinions of Loeb &amp; Loeb LLP, counsel to the Company, dated the Closing Date and addressed to the Placement Agent, with respect
to the matters contained in <U>Exhibit D</U> attached hereto.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">4.2.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Opinion of Special Intellectual Property Counsel for the Company</U>. On the Closing Date, the Placement Agent shall
have received the opinion of McDonnell Boehnen Hulbert &amp; Berghoff LLP, special intellectual property counsel for the Company,
dated the Closing Date, addressed to the Placement Agent substantially in the form of <U>Exhibit E</U> attached hereto.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">4.2.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reliance</U>. In rendering such opinions, such counsel may rely: (i)&nbsp;as to matters involving the application of
laws other than the laws of the United States and jurisdictions in which they are admitted, to the extent such counsel deems proper
and to the extent specified in such opinion, if at all, upon an opinion or opinions (in form and substance reasonably satisfactory
to the Placement Agent) of other counsel reasonably acceptable to the Placement Agent, familiar with the applicable laws; and (ii)&nbsp;as
to matters of fact, to the extent they deem proper, on certificates or other written statements of officers of the Company and
officers of departments of various jurisdictions having custody of documents respecting the corporate existence or good standing
of the Company, provided that copies of any such statements or certificates shall be delivered to Placement Agent Counsel if requested.
The opinion of Loeb &amp; Loeb LLP and any opinion relied upon by Loeb &amp; Loeb LLP shall include a statement to the effect that
it may be relied upon by Placement Agent Counsel in its opinion delivered to the Placement Agent.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">4.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Comfort Letters</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">4.3.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cold Comfort Letter</U>. At the time this Agreement is executed you shall have received cold comfort letters containing
statements and information of the type customarily included in accountants&#8217; comfort letters with respect to the financial
statements and certain financial information contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus,
addressed to the Placement Agent and in form and substance satisfactory in all respects to you and to the Auditors, dated as of
the date of this Agreement.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">4.3.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Bring-down Comfort Letter</U>. At the Closing Date, the Placement Agent shall have received from Eisner a letter, dated
as of the Closing Date, to the effect that Eisner reaffirms the statements made in the letter furnished pursuant to Section 4.3.1,
except that the specified date referred to shall be a date not more than three (3) business days prior to the Closing Date.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">4.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Officers&#8217; Certificates</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">4.4.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Officers&#8217; Certificate</U>. The Company shall have furnished to the Placement Agent a certificate, dated the Closing
Date, of its Chief Executive Officer, its President and its Chief Financial Officer stating that (i) such officers have carefully
examined the Registration Statement, the Pricing Disclosure Package, any Issuer Free Writing Prospectus and the Prospectus and,
in their opinion, the Registration Statement and each amendment thereto, as of the Applicable Time and as of the Closing Date did
not include any untrue statement of a material fact and did not omit to state a material fact required to be stated therein or
necessary to make the statements therein not misleading, and the Pricing Disclosure Package, as of the Applicable Time and as of
the Closing Date, any Issuer Free Writing Prospectus as of its date and as of the Closing Date, the Prospectus and each amendment
or supplement thereto, as of the respective date thereof and as of the Closing Date, did not include any untrue statement of a
material fact and did not omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances in which they were made, not misleading, (ii) since the effective</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">date of the Registration Statement,
no event has occurred which should have been set forth in a supplement or amendment to the Registration Statement, the Pricing
Disclosure Package or the Prospectus, (iii) to the best of their knowledge after reasonable investigation, as of the Closing Date,
the representations and warranties of the Company in this Agreement are true and correct and the Company has complied with all
agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date and
(iv) there has not been, subsequent to the date of the most recent audited financial statements included or incorporated by reference
in the Pricing Disclosure Package, any material adverse change in the financial position or results of operations of the Company,
or any change or development that, singularly or in the aggregate, would involve a material adverse change or a prospective material
adverse change, in or affecting the condition (financial or otherwise), results of operations, business, assets or prospects of
the Company, except as set forth in the Prospectus.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">4.4.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Secretary&#8217;s Certificate</U>. At the Closing Date, the Placement Agent shall have received a certificate of the
Company signed by the Secretary of the Company, dated the Closing Date, as the case may be, respectively, certifying: (i)&nbsp;that
each of the Charter and Bylaws is true and complete, has not been modified and is in full force and effect; (ii)&nbsp;that the
resolutions of the Company&#8217;s Board of Directors relating to the Offering are in full force and effect and have not been modified;
(iii) as to the accuracy and completeness of all correspondence between the Company or its counsel and the Commission; and (iv)&nbsp;as
to the incumbency of the officers of the Company. The documents referred to in such certificate shall be attached to such certificate.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">4.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Material Changes</U>. Prior to and on the Closing Date: (i)&nbsp;there shall have been no material adverse change
or development involving a prospective material adverse change in the condition or prospects or the business activities, financial
or otherwise, of the Company from the latest dates as of which such condition is set forth in the Registration Statement, the Pricing
Disclosure Package and the Prospectus; (ii)&nbsp;no action, suit or proceeding, at law or in equity, shall have been pending or
threatened against the Company or any Insider before or by any court or federal or state commission, board or other administrative
agency wherein an unfavorable decision, ruling or finding may materially adversely affect the business, operations, prospects or
financial condition or income of the Company, except as set forth in the Registration Statement, the Pricing Disclosure Package
and the Prospectus; (iii)&nbsp;no stop order shall have been issued under the Securities Act and no proceedings therefor shall
have been initiated or threatened by the Commission; and (iv)&nbsp;the Registration Statement, the Pricing Disclosure Package and
the Prospectus and any amendments or supplements thereto shall contain all material statements which are required to be stated
therein in accordance with the Securities Act and the Securities Act Regulations and shall conform in all material respects to
the requirements of the Securities Act and the Securities Act Regulations, and neither the Registration Statement, the Pricing
Disclosure Package nor the Prospectus nor any amendment or supplement thereto shall contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">4.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Agreements</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">4.6.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Lock-Up Agreements</U>. On or before the date of this Agreement, the Company shall have delivered to the Placement Agent
executed copies of the Lock-Up Agreements from each of the persons listed in Schedule 2 hereto.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">4.6.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Warrant Agent Agreement</U>. On or before the Closing Date, the Company shall have delivered to the Placement Agent executed
copies of the Warrant Agent Agreement.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">4.6.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Placement Agent&#8217;s Warrant Agreement</U>. On the Closing Date, the Company shall have delivered to the Placement
Agent executed copies of the Placement Agent&#8217;s Warrant Agreement.</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">4.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Additional Documents</U>. At the Closing Date, Placement Agent Counsel shall have been furnished with such documents
and opinions as they may require for the purpose of enabling Placement Agent Counsel to deliver an opinion to the Placement Agent,
or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of any of the conditions,
herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Public Securities and
the Placement Agent&#8217;s Securities as herein contemplated shall be satisfactory in form and substance to the Placement Agent
and Placement Agent Counsel.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 16pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-weight: normal">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; font-weight: normal"><U>Indemnification</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification of the Placement Agent</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">5.1.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>General</U>. Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless the Placement
Agent, its affiliates and each of its respective directors, officers, members, employees, representatives, partners, shareholders,
affiliates, counsel, and agents and each person, if any, who controls any such Placement Agent within the meaning of Section 15
of the Securities Act or Section 20 of the Exchange Act (collectively the &#8220;<B>Placement Agent Indemnified Parties</B>,&#8221;
and each a &#8220;<B>Placement Agent Indemnified Party</B>&#8221;), against any and all loss, liability, claim, damage and expense
whatsoever (including but not limited to any and all legal or other expenses reasonably incurred in investigating, preparing or
defending against any litigation, commenced or threatened, or any claim whatsoever, whether arising out of any action between any
of the Placement Agent Indemnified Parties and the Company or between any of the Placement Agent Indemnified Parties and any third
party, or otherwise) to which they or any of them may become subject under the Securities Act, the Exchange Act or any other statute
or at common law or otherwise or under the laws of foreign countries (a &#8220;<B>Claim</B>&#8221;), (i) arising out of or based
upon any untrue statement or alleged untrue statement of a material fact contained in (A) the Registration Statement, the Pricing
Disclosure Package, any Preliminary Prospectus, the Prospectus, or in any Issuer Free Writing Prospectus or in any Written Testing-the-Waters
Communication (as from time to time each may be amended and supplemented); (B) any materials or information provided to investors
by, or with the approval of, the Company in connection with the marketing of the Offering, including any &#8220;road show&#8221;
or investor presentations made to investors by the Company (whether in person or electronically); or (C) any application or other
document or written communication (in this Section 5, collectively called &#8220;application&#8221;) executed by the Company or
based upon written information furnished by the Company in any jurisdiction in order to qualify the Public Securities and Placement
Agent&#8217;s Securities under the securities laws thereof or filed with the Commission, any state securities commission or agency,
or any other national securities exchange; or the omission or alleged omission therefrom of a material fact required to be stated
therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading,
unless such statement or omission was made in reliance upon, and in conformity with, the Placement Agent&#8217;s Information or
(ii) otherwise arising in connection with or allegedly in connection with the Offering. The Company also agrees that it will reimburse
the Placement Agent Indemnified Party for all fees and expenses (including but not limited to any and all legal or other expenses
reasonably incurred in investigating, preparing or defending against any litigation, commenced or threatened, or any claim whatsoever,
whether arising out of any action between any of the Placement Agent Indemnified Parties and the Company or between any of the
Placement Agent Indemnified Parties and any third party, or otherwise) (collectively, the &#8220;<B>Expenses</B>&#8221;), and further
agrees wherever and whenever possible to advance payment of Expenses as they are incurred by a Placement Agent Indemnified Party
in investigating, preparing, pursuing or defending any Claim.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">5.1.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Procedure</U>. If any action is brought against a Placement Agent Indemnified Party in respect of which indemnity may
be sought against the Company pursuant to Section 5.1.1, such Placement Agent Indemnified Party shall promptly notify the Company
in writing of the institution of</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">such action and the Company shall
assume the defense of such action, including the employment and fees of counsel (subject to the approval of such Placement Agent
Indemnified Party) and payment of actual expenses if a Placement Agent Indemnified Party requests that the Company do so. Such
Placement Agent Indemnified Party shall have the right to employ its or their own counsel in any such case, but the fees and expenses
of such counsel shall be at the expense of the Company, and shall be advanced by the Company. The Company shall not be liable for
any settlement of any action effected without its consent (which shall not be unreasonably withheld). In addition, the Company
shall not, without the prior written consent of the Placement Agent, settle, compromise or consent to the entry of any judgment
in or otherwise seek to terminate any pending or threatened action in respect of which advancement, reimbursement, indemnification
or contribution may be sought hereunder (whether or not such Placement Agent Indemnified Party is a party thereto) unless such
settlement, compromise, consent or termination (i) includes an unconditional release of each Placement Agent Indemnified Party,
acceptable to such Placement Agent Indemnified Party, from all liabilities, expenses and claims arising out of such action for
which indemnification or contribution may be sought and (ii) does not include a statement as to or an admission of fault, culpability
or a failure to act, by or on behalf of any Placement Agent Indemnified Party.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification of the Company</U>. The Placement Agent agrees to indemnify and hold harmless the Company, its directors,
its officers who signed the Registration Statement and persons who control the Company within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the
foregoing indemnity from the Company to the Placement Agent, as incurred, but only with respect to untrue statements or omissions,
or alleged untrue statements or omissions made in the Registration Statement, any Preliminary Prospectus, the Pricing Disclosure
Package or Prospectus or any amendment or supplement thereto or in any application, in reliance upon, and in strict conformity
with, the Placement Agent&#8217;s Information. In case any action shall be brought against the Company or any other person so indemnified
based on any Preliminary Prospectus, the Registration Statement, the Pricing Disclosure Package or Prospectus or any amendment
or supplement thereto or any application, and in respect of which indemnity may be sought against the Placement Agent, the Placement
Agent shall have the rights and duties given to the Company, and the Company and each other person so indemnified shall have the
rights and duties given to the Placement Agent by the provisions of Section 5.1.2. The Company agrees promptly to notify the Placement
Agent of the commencement of any litigation or proceedings against the Company or any of its officers, directors or any person,
if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, in connection
with the issuance and sale of the Public Securities or in connection with the Registration Statement, the Pricing Disclosure Package,
the Prospectus, or any Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Contribution</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">5.3.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Contribution Rights</U>. If the indemnification provided for in this Section 5 shall for any reason be unavailable to
or insufficient to hold harmless an indemnified party under Section 5.1 or 5.2 in respect of any loss, claim, damage or liability,
or any action in respect thereof, referred to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified
party, contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability,
or action in respect thereof, (i) in such proportion as shall be appropriate to reflect the relative benefits received by the Company,
on the one hand, and the Placement Agent, on the other, from the Offering of the Public Securities, or (ii) if the allocation provided
by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in clause (i) above but also the relative fault of the Company, on the one hand, and the Placement Agent, on the other,
with respect to the statements or omissions that resulted in such loss, claim, damage or liability, or action</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">in respect thereof, as well as any
other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Placement Agent,
on the other, with respect to such Offering shall be deemed to be in the same proportion as the total net proceeds from the Offering
of the Public Securities purchased under this Agreement (before deducting expenses) received by the Company, as set forth in the
table on the cover page of the Prospectus, on the one hand, and the total Placement Fee received by the Placement Agent with
respect to the Public Securities purchased under this Agreement, as set forth in the table on the cover page of the Prospectus,
on the other hand. The relative fault shall be determined by reference to whether the untrue or alleged untrue statement of a material
fact or omission or alleged omission to state a material fact relates to information supplied by the Company or the Placement Agent,
the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such statement
or omission. The Company and the Placement Agent agree that it would not be just and equitable if contributions pursuant to this
Section 5.3.1 were to be determined by pro rata allocation or by any other method of allocation that does not take into account
the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim,
damage or liability, or action in respect thereof, referred to above in this Section 5.3.1 shall be deemed to include, for purposes
of this Section 5.3.1, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating
or defending any such action or claim. Notwithstanding the provisions of this Section 5.3.1 in no event shall the Placement Agent
be required to contribute any amount in excess of the amount by which the total Placement Fee received by the Placement Agent with
respect to the Offering of the Public Securities exceeds the amount of any damages that the Placement Agent has otherwise been
required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person
who was not guilty of such fraudulent misrepresentation.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 1in">5.3.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Contribution Procedure</U>. Within fifteen (15) days after receipt by any party to this Agreement (or its representative)
of notice of the commencement of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof
is to be made against another party (&#8220;<B>contributing party</B>&#8221;), notify the contributing party of the commencement
thereof, but the failure to so notify the contributing party will not relieve it from any liability which it may have to any other
party other than for contribution hereunder. In case any such action, suit or proceeding is brought against any party, and such
party notifies a contributing party or its representative of the commencement thereof within the aforesaid fifteen (15) days, the
contributing party will be entitled to participate therein with the notifying party and any other contributing party similarly
notified. Any such contributing party shall not be liable to any party seeking contribution on account of any settlement of any
claim, action or proceeding affected by such party seeking contribution on account of any settlement of any claim, action or proceeding
affected by such party seeking contribution without the written consent of such contributing party. The contribution provisions
contained in this Section 5.3.2 are intended to supersede, to the extent permitted by law, any right to contribution under the
Securities Act, the Exchange Act or otherwise available.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 16pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-weight: normal">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; font-weight: normal"><U>Additional Covenants</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Board Composition and Board Designations</U>. The Company shall ensure that: (i)&nbsp;the qualifications of the persons
serving as members of the Board of Directors and the overall composition of the Board comply with the Sarbanes-Oxley Act, with
the Exchange Act and with the listing rules of the any national securities exchange, as the case may be, in the event the Company
seeks to have its Public Securities listed on another exchange or quoted on an automated quotation system, and (ii)&nbsp;if applicable,
at least one member of the Audit Committee of the Board of Directors qualifies as an &#8220;audit committee financial expert,&#8221;
as such term is defined under Regulation S-K and the listing rules of such exchange.</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Prohibition on Press Releases and Public Announcements</U>. The Company shall not issue press releases or engage in any
other publicity, without the Placement Agent&#8217;s prior written consent, which shall not be unreasonably withheld, for a period
ending at 5:00 p.m., Eastern time, on the first (1<SUP>st</SUP>) Business Day following the forty-fifth (45<SUP>th</SUP>) day after
the Closing Date, other than normal and customary releases issued in the ordinary course of the Company&#8217;s business.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Right of First Refusal</U>. Provided that the Units are sold in accordance with the terms of this Agreement, the Placement
Agent shall have an irrevocable right of first refusal (the &#8220;<B>Right of First Refusal</B>&#8221;), for a period of twelve
(12) months after the date the Offering is completed, to act as sole and exclusive investment banker, sole and exclusive book-runner,
sole and exclusive financial advisor, sole and exclusive underwriter and/or sole and exclusive placement agent, at the Placement
Agent&#8217;s sole and exclusive discretion, for each and every future public and private equity and debt offering, including all
equity linked financings (each, a &#8220;<B>Subject Transaction</B>&#8221;), during such twelve (12) month period, of the Company,
or any successor to or subsidiary of the Company, on terms and conditions customary to the Placement Agent for such Subject Transactions.
For the avoidance of any doubt, the Company shall not retain, engage or solicit any additional investment banker, book-runner,
financial advisor, underwriter and/or placement agent in a Subject Transaction without the express written consent of the Placement
Agent.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company shall notify
the Placement Agent of its intention to pursue a Subject Transaction, including the material terms thereof, by providing written
notice thereof by registered mail or overnight courier service addressed to the Placement Agent.&nbsp; If the Placement Agent fails
to exercise its Right of First Refusal with respect to any Subject Transaction within ten (10) Business Days after the mailing
of such written notice, then the Placement Agent shall have no further claim or right with respect to the Subject Transaction.
The Placement Agent may elect, in its sole and absolute discretion, not to exercise its Right of First Refusal with respect to
any Subject Transaction; provided that any such election by the Placement Agent shall not adversely affect the Placement Agent&#8217;s
Right of First Refusal with respect to any other Subject Transaction during the twelve (12) month period agreed to above.&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 16pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-weight: normal">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; font-weight: normal"><U>Effective Date of this Agreement and Termination
Thereof</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">7.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effective Date</U>. This Agreement shall become effective when both the Company and the Placement Agent have executed
the same and delivered counterparts of such signatures to the other party.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">7.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination</U>. The Placement Agent shall have the right to terminate this Agreement at any time prior to any Closing
Date, (i)&nbsp;if any domestic or international event or act or occurrence has materially disrupted, or in your opinion will in
the immediate future materially disrupt, general securities markets in the United States; or (ii)&nbsp;if trading on the New York
Stock Exchange or any other exchange shall have been suspended or materially limited, or minimum or maximum prices for trading
shall have been fixed, or maximum ranges for prices for securities shall have been required by FINRA or by order of the Commission
or any other government authority having jurisdiction; or (iii)&nbsp;if the United States shall have become involved in a new war
or an increase in major hostilities; or (iv)&nbsp;if a banking moratorium has been declared by a New York State or federal authority;
or (v)&nbsp;if a moratorium on foreign exchange trading has been declared which materially adversely impacts the United States
securities markets; or (vi)&nbsp;if the Company shall have sustained a material loss by fire, flood, accident, hurricane, earthquake,
theft, sabotage or other calamity or malicious act which, whether or not such loss shall have been insured, will, in your opinion,
make it inadvisable to proceed with the delivery of the Units; or (vii)&nbsp;if the Company is in material breach of any of its
representations, warranties or covenants hereunder; or (viii)&nbsp;if the Placement Agent shall have become aware after the date
hereof of such a material adverse change in the conditions or prospects of the Company, or such adverse material change in general
market conditions as in the Placement Agent&#8217;s judgment would make it impracticable to proceed with the offering, sale</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">and/or delivery of the Public Securities
or to enforce contracts made by the Placement Agent for the sale of the Public Securities.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">7.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Expenses</U>. Notwithstanding anything to the contrary in this Agreement, in the event that this Agreement shall not
be carried out for any reason whatsoever, within the time specified herein or any extensions thereof pursuant to the terms herein,
the Company shall be obligated to pay to the Placement Agent their actual and accountable out-of-pocket expenses related to the
transactions contemplated herein then due and payable (including the fees and disbursements of Placement Agent Counsel) up to $100,000,
inclusive of the $35,000 advance for accountable expenses previously paid by the Company to the Placement Agent (the &#8220;<B>Advance</B>&#8221;)
and upon demand the Company shall pay the full amount thereof to the Placement Agent on behalf of the Placement Agent; <FONT STYLE="font-family: Times New Roman, Times, Serif; letter-spacing: 0pt"><B><I>provided,
however, that such expense cap in no way limits or impairs the indemnification and contribution provisions of this Agreement</I></B></FONT>.
Notwithstanding the foregoing, any advance received by the Placement Agent will be reimbursed to the Company to the extent not
actually incurred in compliance with FINRA Rule 5110(f)(2)(C).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">7.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification</U>. Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any
termination of this Agreement, and whether or not this Agreement is otherwise carried out, the provisions of Section 5 shall remain
in full force and effect and shall not be in any way affected by, such election or termination or failure to carry out the terms
of this Agreement or any part hereof.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">7.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations, Warranties, Agreements to Survive</U>. All representations, warranties and agreements contained in this
Agreement or in certificates of officers of the Company submitted pursuant hereto, shall remain operative and in full force and
effect regardless of (i)&nbsp;any investigation made by or on behalf of the Placement Agent or its Affiliates or selling agents,
any person controlling the Placement Agent, its officers or directors or any person controlling the Company or (ii)&nbsp;delivery
of and payment for the Public Securities.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 16pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt; font-weight: normal">8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 11pt; font-weight: normal"><U>Miscellaneous</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">8.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. All communications hereunder, except as herein otherwise specifically provided, shall be in writing and
shall be mailed (registered or certified mail, return receipt requested), personally delivered or sent by facsimile transmission
and confirmed and shall be deemed given when so delivered or faxed and confirmed or if mailed, two (2) days after such mailing.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 12pt 0.5in">If to the Placement Agent:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">ThinkEquity</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">17 State Street, 22<SUP>nd</SUP> Floor</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">New York, NY 10004<BR>
Attn: Mr. Eric Lord, Head of Investment Banking</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">E-mail: el@think-equity.com</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Fax: (212) 349-2550</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.1pt"><BR>
Greenberg Traurig, LLP</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.1pt">1750 Tysons Blvd., Suite 1000</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.1pt">McLean, Virginia 22102</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.1pt">Attn: Jason Simon</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.1pt">E-mail: simonj@gtlaw.com</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 35.1pt">Fax No.:&nbsp;(703) 749-1301</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">If to the Company:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">BioVie Inc.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">2120 Colorado Avenue, Suite 230</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Santa Monica, California 90404</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Attention: Terren S. Peizer, Chief Executive Officer</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">E-mail: Terren@acuitasgh.com</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Loeb &amp; Loeb LLP</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">345 Park Avenue</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">New York, New York 10154</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Attention: Mitchell S. Nussbaum</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Email: <U>mnussbaum@loeb.com</U></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Fax No: (212) 504-3013</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">8.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Headings</U>. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any
way limit or affect the meaning or interpretation of any of the terms or provisions of this Agreement.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">8.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendment</U>. This Agreement may only be amended by a written instrument executed by each of the parties hereto.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">8.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entire Agreement</U>. This Agreement (together with the other agreements and documents being delivered pursuant to or
in connection with this Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof
and thereof, and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject
matter hereof. Notwithstanding anything to the contrary set forth herein, it is understood and agreed by the parties hereto that
all other terms and conditions of that certain engagement letter between the Company and ThinkEquity, a division of Fordham Financial
Management, Inc., dated March 20, 2019, as amended, shall remain in full force and effect, <B><I>provided that</I></B> the solicitation
of and any subscription by any Referred Investor shall not violate any of the terms or provisions thereof.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">8.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Binding Effect</U>. This Agreement shall inure solely to the benefit of and shall be binding upon the Placement Agent,
the Company and the controlling persons, directors and officers referred to in Section 5 hereof, and their respective successors,
legal representatives, heirs and assigns, and no other person shall have or be construed to have any legal or equitable right,
remedy or claim under or in respect of or by virtue of this Agreement or any provisions herein contained. The term &#8220;successors
and assigns&#8221; shall not include a purchaser, in its capacity as such, of securities from the Placement Agent.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">8.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law; Consent to Jurisdiction; Trial by Jury</U>. This Agreement shall be governed by and construed and enforced
in accordance with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company
hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be
brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern
District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives
any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any such process or summons
to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested,
postage prepaid, addressed to it at the address set forth in Section 8.1 hereof. Such mailing shall be</P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify">deemed personal service and shall be
legal and binding upon the Company in any action, proceeding or claim. The Company agrees that the prevailing party(ies) in any
such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys&#8217; fees and expenses relating
to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf and, to the
extent permitted by applicable law, on behalf of its stockholders and affiliates) and the Placement Agent hereby irrevocably waive,
to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or
relating to this Agreement or the transactions contemplated hereby.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">8.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Execution in Counterparts</U>. This Agreement may be executed in one or more counterparts, and by the different parties
hereto in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute
one and the same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto
and delivered to each of the other parties hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf
transmission shall constitute valid and sufficient delivery thereof.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in">8.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waiver, etc</U>. The failure of any of the parties hereto to at any time enforce any of the provisions of this Agreement
shall not be deemed or construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement
or any provision hereof or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement.
No waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless
set forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought;
and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or
subsequent breach, non-compliance or non-fulfillment.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in">[<I>SIGNATURE PAGE
FOLLOWS</I>]</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">If the foregoing
correctly sets forth the understanding between the Placement Agent and the Company, please so indicate in the space provided below
for that purpose, whereupon this letter shall constitute a binding agreement between us.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0 222.3pt">Very truly yours,</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0 222.3pt">BIOVIE INC.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 24pt 0 0 222.3pt">By: <U>___________________________________</U></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 222.3pt">&#9;Name:&#9;<BR>
&#9;Title:&#9;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 204pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 204pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 204pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 276.9pt 0 0">Confirmed as of the date first written above mentioned,
on behalf of itself and as Placement Agent:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0">THINKEQUITY</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0">A Division of Fordham Financial Management, Inc.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 24pt 0 0">By: <U>___________________________________</U></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">Name:&#9;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">Title:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">[SIGNATURE PAGE]</P><P STYLE="font: 8pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">BIOVIE INC. - PLACEMENT AGENCY AGREEMENT</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B><U>SCHEDULE 1-A</U></B><U><BR>
<BR>
</U></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B>Pricing Information</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">Number of Units: [&#8226;]</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">Public Offering Price per Unit: $[&#8226;]</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt">Exercise Price per Warrant: $[&#8226;]</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Proceeds to Company per Unit (before expenses): $[&#8226;]</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>SCHEDULE 1-B</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Issuer General Use Free Writing Prospectuses</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">None.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>SCHEDULE 1-C</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Written Testing-the-Waters Communications</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">None.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<!-- Field: Page; Sequence: 33; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. 1-1</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>SCHEDULE 2</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>List of Lock-Up Parties</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<UL STYLE="margin-top: 0in; list-style-type: disc">

<LI STYLE="margin: 0 0 6pt; font-size: 11pt">Terren Peizer (as Chairman and Chief Executive Officer)</LI>

<LI STYLE="margin: 0 0 6pt; font-size: 11pt">Terren Peizer (as owner of at least 5% of the Company&#8217;s outstanding shares of
Common Stock)</LI>

<LI STYLE="margin: 0 0 6pt; font-size: 11pt">Jonathan Adams</LI>

<LI STYLE="margin: 0 0 6pt; font-size: 11pt">Joanne Wendy Kim</LI>

<LI STYLE="margin: 0 0 6pt; font-size: 11pt">Patrick Yeramian</LI>

<LI STYLE="margin: 0 0 6pt; font-size: 11pt">Penelope Markham</LI>

<LI STYLE="margin: 0 0 6pt; font-size: 11pt">Jim Lang</LI>

<LI STYLE="margin: 0 0 6pt; font-size: 11pt">Cuong Do</LI>

<LI STYLE="margin: 0 0 6pt; font-size: 11pt">Hari Kumar</LI>

<LI STYLE="margin: 0 0 6pt; font-size: 11pt">Michael Sherman</LI>

<LI STYLE="margin: 0 0 6pt; font-size: 11pt">Richard J. Berman</LI>

</UL>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. 2-1</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form of Placement Agent&#8217;s Warrant Agreement</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt/13.75pt Times New Roman, Times, Serif; margin: 4.65pt 0 0; text-align: justify; text-indent: 0.2pt">THE REGISTERED
HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT
EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE
OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE
OTHER THAN (I) THINKEQUITY, A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC., OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING,
OR (II) A BONA FIDE OFFICER OR PARTNER OF THINKEQUITY, A DIVISION OF FORDHAM FINANCIAL MANAGEMENT, INC., OR OF ANY SUCH SELECTED
DEALER.</P>

<P STYLE="font: 11pt/13.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/13.5pt Times New Roman, Times, Serif; margin: 1pt 0 0; text-align: justify; text-indent: 0.2pt">THIS PURCHASE
WARRANT IS NOT EXERCISABLE PRIOR TO [________________] [<B>DATE THAT IS [ONE YEAR] FROM THE EFFECTIVE DATE OF THE OFFERING</B>].
VOID AFTER 5:00 P.M., EASTERN TIME, [___________________] [<B>DATE THAT IS FIVE YEARS FROM THE EFFECTIVE DATE OF THE OFFERING</B>].</P>

<P STYLE="font: 11pt/13.5pt Times New Roman, Times, Serif; margin: 1pt 0 0; text-align: justify; text-indent: 0.2pt">&nbsp;</P>

<P STYLE="font: 11pt/13.5pt Times New Roman, Times, Serif; margin: 1pt 0 0; text-align: justify; text-indent: 0.2pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WARRANT TO PURCHASE CLASS A COMMON STOCK
</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>BioVie Inc.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">Warrant Shares: _______</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: right">Initial Exercise Date: ______, 20__</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">THIS WARRANT TO PURCHASE
COMMON STOCK (the &#8220;<U>Warrant</U>&#8221;) certifies that, for value received, _____________ or its assigns (the &#8220;<U>Holder</U>&#8221;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on
or after ____, 20__ (the &#8220;<U>Initial Exercise Date</U>&#8221;) and, in accordance with FINRA Rule 5110(f)(2)(G)(i), prior
to at 5:00 p.m. (New York time) on the date that is five (5) years following the Effective Date (the &#8220;<U>Termination Date</U>&#8221;)
but not thereafter, to subscribe for and purchase from BioVie Inc., a Nevada corporation (the &#8220;<U>Company</U>&#8221;), up
to ______ shares of Class A common stock, par value $0.0001 per share, of the Company (the &#8220;<U>Warrant Shares</U>&#8221;),
as subject to adjustment hereunder. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Affiliate</U>&#8221;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Business
Day</U>&#8221; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to
close.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Commission</U>&#8221;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Effective
Date</U>&#8221; means the effective date of the registration statement on Form S-1 (File No. 333-231136), including any related
prospectus or prospectuses, for the registration of the Company&#8217;s Class A common stock, par value $0.0001 per share and the
Warrant Shares under the Securities Act, that the Company has filed with the Commission.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Exchange
Act</U>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Person</U>&#8221;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Rule
144</U>&#8221; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Securities
Act</U>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Trading
Day</U>&#8221; means a day on which the New York Stock Exchange is open for trading.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>Trading
Market</U>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: OTCQB Marketplace, the NYSE American, The Nasdaq Capital Market, The Nasdaq Global Market, The Nasdaq Global
Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&#8220;<U>VWAP</U>&#8221;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market,
the volume weighted average price of a share of Common Stock for such date (or the nearest preceding date) on the OTCQB or OTCQX
as applicable, (c) if Common Stock is not then listed or quoted for trading on the OTCQB or OTCQX and if prices for Common Stock
are then reported in the &#8220;Pink Sheets&#8221; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of Common Stock so reported, or (d)&nbsp;in all other
cases, the fair market value of the Common Stock as determined by an independent appraiser selected in good faith by the Holder
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after
the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the
Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of
the Company) of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise Form annexed hereto. Within two
(2) Trading Days following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares
specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the
cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice
of Exercise form be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been
exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within five (5) Trading
Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number
of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and
the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall
deliver any objection to any Notice of Exercise Form within two (2) Business Days of receipt of such notice. <B>The Holder and
any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any
given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Exercise Price</U>. The exercise price per share of the Common Stock under this Warrant shall be <B>$_______</B><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>[1]</SUP></FONT>,
subject to adjustment hereunder (the &#8220;<U>Exercise Price</U>&#8221;).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Cashless Exercise</U>. If at any time on or after the Initial Exercise Date, there is no effective registration statement registering,
or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may
also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be
entitled to receive the number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 99pt; text-align: justify; text-indent: -27pt">(A) = as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise
is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and
delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined
in Rule 600(b)(64) of Regulation NMS promulgated under the federal securities laws) on such Trading</P>


<HR ALIGN="LEFT" SIZE="1" STYLE="width: 33%; margin-left:0.5in">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 6pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><SUP>[1]</SUP></FONT>
125% of the public offering price per share of common stock and warrant in the offering.</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 99pt; text-align: justify">Day, (ii) the VWAP on the Trading
Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular
trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the
close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of
the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed
and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in">(B) = the Exercise
Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -31.5pt">(X) = the
number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a &#8220;cashless exercise,&#8221; the parties acknowledge and agree that in accordance with
Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised,
and the holding period of the Warrants being exercised may be tacked on to the holding period of the Warrant Shares.&nbsp;&nbsp;The
Company agrees not to take any position contrary to this Section 2(c).</FONT>&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by its transfer agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with
The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<U>DWAC</U>&#8221;) if the Company is
then a participant in such system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the
Warrant Shares to or resale of the Warrant Shares by Holder, or (B) the Warrant Shares are eligible for resale by the Holder without
volume or manner-of-sale limitations pursuant to Rule 144 and, in either case, the Warrant Shares have been sold by the Holder
prior to the Warrant Share Delivery Date (as defined below), and otherwise by physical delivery of a certificate, registered in
the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder
is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is two
(2)&nbsp;Trading Days after the delivery to the Company of the Notice of Exercise (such date, the &#8220;<U>Warrant Share Delivery
Date</U>&#8221;). If the Warrant Shares can be delivered via DWAC, the transfer agent shall have received from the Company, at
the expense of the Company, any legal opinions or other documentation required by it to deliver such Warrant Shares without legend
(subject to receipt by the Company of reasonable back up documentation from the Holder, including with respect to affiliate status)
and, if applicable and requested by the Company prior to the Warrant Share Delivery Date, the transfer agent shall have received
from the Holder a confirmation of sale of the Warrant Shares (provided the requirement of the Holder to provide a confirmation
as to</P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">the sale of Warrant Shares shall
not be applicable to the issuance of unlegended Warrant Shares upon a cashless exercise of this Warrant if the Warrant Shares are
then eligible for resale pursuant to Rule 144(b)(1)). The Warrant Shares shall be deemed to have been issued, and Holder or any
other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes,
as of the date the Warrant has been exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if permitted)
and all taxes required to be paid by the Holder, if any, pursuant to Section&nbsp;2(d)(vi) prior to the issuance of such shares,
having been paid. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise
by the second Trading Day following the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated
damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock
on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading
Day after such liquidated damages begin to accrue) for each Trading Day after the second Trading Day following such Warrant Share
Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder
a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which
new Warrant shall in all other respects be identical with this Warrant.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
iii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Rescission Rights</U>. If the Company fails to cause
its transfer agent to deliver to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date,
then the Holder will have the right to rescind such exercise; <U>provided</U>, <U>however</U>, that the Holder shall be required
to return any Warrant Shares or Common Stock subject to any such rescinded exercise notice concurrently with the return to Holder
of the aggregate Exercise Price paid to the Company for such Warrant Shares and the restoration of Holder&#8217;s right to acquire
such Warrant Shares pursuant to this Warrant (including, issuance of a replacement warrant certificate evidencing such restored
right).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
iv.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Compensation for Buy-In on Failure to Timely Deliver Warrant
Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if the Company fails to cause its transfer agent
to transmit to the Holder the Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery Date, and if after
such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#8217;s brokerage
firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which
the Holder anticipated receiving upon such exercise (a &#8220;<U>Buy-In</U>&#8221;), then the Company shall (A) pay in cash to
the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage commissions, if any) for
the shares of</P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder
in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was
executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares
for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number
of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations
hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect
to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000,
under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall
provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the
Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available
to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with
respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant
to the terms hereof.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
v.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>No Fractional Shares or Scrip</U>. No fractional shares
or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which
the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment
in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next
whole share.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
vi.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares
shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance
of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in
the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>, that in the
event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise
shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all transfer
agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another
established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
vii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Closing of Books</U>. The Company will not close its
stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
viii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Signature</U>. This Section 2 and the exercise form
attached hereto set forth the totality of the procedures required of the Holder in order to exercise this Purchase Warrant.&nbsp;
Without limiting the preceding sentences, no ink-original exercise form shall be required, nor shall any medallion guarantee (or
other type of guarantee or notarization) of any exercise form be required in order to exercise this Purchase Warrant.&nbsp; No
additional legal opinion, other information or instructions shall be required of the Holder to exercise this Purchase Warrant.&nbsp;
The Company shall honor exercises of this Purchase Warrant and shall deliver Shares underlying this Purchase Warrant in accordance
with the terms, conditions and time periods set forth herein.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Holder&#8217;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have
the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to
such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates,
and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates), would beneficially own
in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence, the number of
shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable
upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of
Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned
by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other
securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion
or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates.&nbsp; Except
as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder
that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act
and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation
contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities
owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion
of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this
Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion
of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation
to verify or confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above
shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.
For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number
of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with
the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Company&#8217;s transfer agent setting forth the number of shares of Common Stock outstanding.&nbsp; Upon the
written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder the
number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be
determined after giving effect to the conversion or exercise of securities of the</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Company, including this Warrant,
by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The
&#8220;<U>Beneficial Ownership Limitation</U>&#8221; shall be 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to
the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial
Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section
2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP>
day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner
otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which
may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a
successor holder of this Warrant.&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a)
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.
For the purposes of clarification, the Exercise Price of this Warrant will not be adjusted in the event that the Company sells
or grants any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer,
sale, grant or any option to purchase or other disposition) any Common Stock or Common Stock Equivalents, at an effective price
per share less than the Exercise Price then in effect.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[RESERVED]</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &#8220;<U>Purchase Rights</U>&#8221;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of</P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the
Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such
Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined
for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder&#8217;s right to participate
in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not
be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result
of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such
time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend
(other than cash dividends) or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common
Stock, by way of return of capital or otherwise (including, without limitation, any distribution of shares or other securities,
property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar
transaction) (a &quot;<U>Distribution</U>&quot;), at any time after the issuance of this Warrant, then, in each such case, the
Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to
any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, to the extent
that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any
shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial
Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the time of such Distribution,
such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised this Warrant.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the
outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more
related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons</P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">whereby such other Person or group
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person
or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share
purchase agreement or other business combination) (each a &#8220;<U>Fundamental Transaction</U>&#8221;), then, upon any subsequent
exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon
such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard
to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<U>Alternate Consideration</U>&#8221;)
receivable by holders of Common Stock as a result of such Fundamental Transaction for each share of Common Stock for which this
Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the
exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in
a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder
shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental
Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the &#8220;<U>Successor Entity</U>&#8221;) to assume in writing all of the obligations of the Company under this Warrant in accordance
with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder
and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder,
deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such
Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an
exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such
number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance
to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted
for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &#8220;Company&#8221;
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the
obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as
of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notice to Holder</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Adjustment to Exercise Price</U>. Whenever the Exercise
Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly mail to the Holder a notice setting forth
the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief
statement of the facts requiring such adjustment.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Notice to Allow Exercise by Holder</U>. If (A) the Company
shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special
nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders
of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights,
(D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock,
any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of
the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or
(E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
then, in each case, the Company shall cause to be mailed a notice to the Holder at its last address as it shall appear upon the
Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified,
stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend,
distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that
holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure
to provide such notice or any defect therein shall not affect the validity of the corporate action required to be specified in
such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding
the Company, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The
Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective
date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: -1.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Transferability</U>. Pursuant to FINRA Rule 5110(g)(1), neither this Warrant nor any Warrant Shares issued upon exercise of
this Warrant shall be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative,
put, or call</P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">transaction that would result in
the effective economic disposition of the securities by any person for a period of 180 days immediately following the date of effectiveness
or commencement of sales of the offering pursuant to which this Warrant is being issued, except the transfer of any security:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i.
by operation of law or by reason of reorganization of the Company;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii.
to any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred remain
subject to the lock-up restriction in this Section 4(a) for the remainder of the time period;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii.
if the aggregate amount of securities of the Company held by the Holder or related person do not exceed 1% of the securities being
offered;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv.
that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member
manages or otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10% of the
equity in the fund; or</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;v.
the exercise or conversion of any security, if all securities received remain subject to the lock-up restriction in this Section
4(a) for the remainder of the time period.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -1in"><I>&nbsp;</I>&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">Subject to the
foregoing restriction, any applicable securities laws and the conditions set forth in Section 4(d), this Warrant and all rights
hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this
Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially
in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes
payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver
a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified
in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned,
and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder
shall surrender this Warrant to the Company within three (3) Trading Days of the date the Holder delivers an assignment form to
the Company assigning this Warrant full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder
for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed
by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants
to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the</P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">initial issuance date of this Warrant
and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose
(the &#8220;<U>Warrant Register</U>&#8221;), in the name of the record Holder hereof from time to time. The Company may deem and
treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution
to the Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a
view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable
state securities law, except pursuant to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Registration
Rights</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Demand
Registration</U>. The Company, upon written demand (a &#8220;<U>Demand Notice</U>&#8221;) of the Holder(s) of at least 51% of the
Warrants and/or the Warrant Shares (the &#8220;<U>Majority Holders</U>&#8221;), agrees to register, on one occasion, all or any
portion of the Warrant Shares underlying the Warrant (the &#8220;<U>Registrable Securities</U>&#8221;). On such occasion, the Company
will file a registration statement with the Commission covering the Registrable Securities within sixty (60) days after receipt
of a Demand Notice and use its reasonable best efforts to have the registration statement declared effective promptly thereafter,
subject to compliance with review by the Commission;&nbsp;<U>provided</U>,&nbsp;<U>however</U>, that the Company shall not be required
to comply with a Demand Notice if the Company has filed a registration statement with respect to which the Holder is entitled to
piggyback registration rights pursuant to&nbsp;Section 5 b)&nbsp;hereof and either: (i) the Holder has elected to participate in
the offering covered by such registration statement or (ii) if such registration statement relates to an underwritten primary offering
of securities of the Company, until the offering covered by such registration statement has been withdrawn or until thirty (30)
days after such offering is consummated. The demand for registration may be made at any time beginning on the Initial Exercise
Date and expiring on the fifth anniversary of the Effective Date. The Company covenants and agrees to give written notice of its
receipt of any Demand Notice by any Holder(s) to all other registered Holders of the Purchase Warrants and/or the Registrable Securities
within ten (10) days after the date of the receipt of any such Demand Notice.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font-size: 11pt">i)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 11pt"><U>Terms</U>. The Company shall bear all fees and expenses attendant to the registration of
the Registrable Securities pursuant to Section 5 a), but the Holders shall pay any and all underwriting commissions and the expenses
of any legal counsel selected by the Holders to represent them in connection with the sale of the Registrable Securities. The Company
agrees to use its reasonable best efforts to cause the filing required herein to become effective promptly and to qualify or register
the Registrable Securities in such States as are reasonably requested by the Holder(s); <U>provided</U>, <U>however</U>, that in
no event shall the Company be required to register the Registrable Securities in a State in which such registration would cause:
(i) the Company to be obligated to register or license to do business in such State or submit to general service of process in
such State, or (ii) the principal shareholders of the Company to be obligated to escrow their shares of capital stock of the Company.
The Company shall cause any registration statement filed pursuant</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">to the demand right granted under Section
5 a) to remain effective for a period of at least twelve (12) consecutive months after the date that the Holders of the Registrable
Securities covered by such registration statement are first given the opportunity to sell all of such securities. The Holders shall
only use the prospectuses provided by the Company to sell the Warrant Shares covered by such registration statement, and will immediately
cease to use any prospectus furnished by the Company if the Company advises the Holder that such prospectus may no longer be used
due to a material misstatement or omission. Notwithstanding the provisions of this Section 5 a) i), the Holder shall be entitled
to a demand registration under this Section 5 a) i) on only one (1) occasion and such demand registration right shall terminate
on the fifth anniversary of the date of the Underwriting Agreement (as defined below) in accordance with FINRA Rule 5110(f)(2)(G)(iv).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&#8220;Piggy-back&#8221;
Registration</U>. In addition to the demand right of registration described in&nbsp;Section 5.1&nbsp;hereof, the Holder shall have
the right, for a period of no more than two (2) years form the Initial Exercise Date in accordance with FINRA Rule 5110(f)(2)(G)(v),
to include the Registrable Securities as part of any other registration of securities filed by the Company (other than in connection
with a transaction contemplated by Rule 145(a) promulgated under the Act or pursuant to Form S-8 or any equivalent form);&nbsp;<U>provided</U>,&nbsp;<U>however</U>,
that if, solely in connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s)
thereof shall, in its reasonable discretion, impose a limitation on the number of shares of common stock which may be included
in the registration statement because, in such underwriter(s)&#8217; judgment, marketing or other factors dictate such limitation
is necessary to facilitate public distribution, then the Company shall be obligated to include in such registration statement only
such limited portion of the Registrable Securities with respect to which the Holder requested inclusion hereunder as the underwriter
shall reasonably permit. Any exclusion of Registrable Securities shall be made pro rata among the Holders seeking to include Registrable
Securities in proportion to the number of Registrable Securities sought to be included by such Holders;&nbsp;<U>provided</U>,&nbsp;<U>however</U>,
that the Company shall not exclude any Registrable Securities unless the Company has first excluded all outstanding securities,
the holders of which are not entitled to inclusion of such securities in such Registration Statement or are not entitled to pro
rata inclusion with the Registrable Securities.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-size: 11pt"><U>Terms</U>. The Company shall bear all fees and expenses attendant to registering the Registrable
Securities pursuant to&nbsp;Section 5 b) hereof, but the Holders shall pay any and all underwriting commissions and the expenses
of any legal counsel selected by the Holders to represent them in connection with the sale of the Registrable Securities. In the
event of such a proposed registration, the Company shall furnish the then Holders of outstanding Registrable Securities with not
less than thirty (30) days written notice prior to the proposed date of filing of such registration statement. Such notice to the
Holders shall continue to be given for each registration statement filed by the Company during the two (2) year period following
the Initial Exercise Date until such time as all of the Registrable Securities have been sold by the Holder. The holders of the
Registrable Securities shall exercise the &#8220;piggy-back&#8221; rights provided for herein by giving written notice, within
ten (10) days of the receipt of the Company&#8217;s notice of its intention to file a registration statement. Except as otherwise
provided in this Warrant, there shall be no limit on the number of times the Holder may request registration under this&nbsp;Section
5 b) i); <U>provided</U>, <U>however</U>, that such registration rights shall terminate on the second anniversary of the Initial
Exercise Date in accordance with FINRA Rule 5110(f)(2)(G).</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>.
The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration statement hereunder
and each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section 20(a) of the
Exchange Act, against all loss, claim, damage, expense or liability (including all reasonable attorneys&#8217; fees and other expenses
reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which any of them may become subject
under the Securities Act, the Exchange Act or otherwise, arising from such registration statement but only to the same extent and
with the same effect as the provisions pursuant to which the Company has agreed to indemnify the Placement Agent contained in Section
5 of that certain Placement Agency Agreement (the &#8220;<U>Placement Agency Agreement</U>&#8221;), dated [&#9679;], 2020, by and
between the Company and ThinkEquity, a division of Fordham Financial Management, Inc., as placement agent (the &#8220;<U>Placement
Agent</U>&#8221;). The Holder(s) of the Registrable Securities to be sold pursuant to such registration statement, and their successors
and assigns, shall severally, and not jointly, indemnify the Company, against all loss, claim, damage, expense or liability (including
all reasonable attorneys&#8217; fees and other expenses reasonably incurred in investigating, preparing or defending against any
claim whatsoever) to which they may become subject under the Act, the Exchange Act or otherwise, arising from information furnished
by or on behalf of such Holders, or their successors or assigns, in writing, for specific inclusion in such registration statement
to the same extent and with the same effect as the provisions contained in Section 5 of the Placement Agency Agreement pursuant
to which the Placement Agent has agreed to indemnify the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise
of Warrants</U>. Nothing contained in this Warrant shall be construed as requiring the Holder(s) to exercise their Warrants prior
to or after the initial filing of any registration statement or the effectiveness thereof.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Documents
Delivered to Holders</U>. The Company shall furnish to each Holder participating in any of the foregoing offerings and to each
underwriter of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of: (i) an opinion of
counsel to the Company, dated the effective date of such registration statement (and, if such registration includes an underwritten
public offering, an opinion dated the date of the closing under any underwriting agreement related thereto), and (ii) a &#8220;cold
comfort&#8221; letter dated the effective date of such registration statement (and, if such registration includes an underwritten
public offering, a letter dated the date of the closing under the underwriting agreement) signed by the independent registered
public accounting firm which has issued a report on the Company&#8217;s financial statements included in such registration statement,
in each case covering substantially the same matters with respect to such registration statement (and the prospectus included therein)
and, in the case of such accountants&#8217; letter, with respect to events subsequent to the date of such financial statements,
as are customarily covered in opinions of issuer&#8217;s counsel and in accountants&#8217; letters delivered to underwriters in
underwritten public offerings of securities. The Company shall also deliver promptly to each Holder participating in the offering
requesting the correspondence and memoranda described below and to the managing underwriter, if any, copies of all correspondence
between the Commission and the Company, its counsel or auditors and all memoranda relating to discussions with the Commission or
its staff with respect to the registration statement and permit each Holder and underwriter to do such investigation, upon reasonable
advance notice, with respect to information contained in or omitted from the registration statement as it deems reasonably necessary
to comply with applicable securities laws or rules of FINRA. Such investigation shall include access to books, records and properties
and opportunities to discuss the business of the Company with its officers and independent auditors,</P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">all to such reasonable extent and
at such reasonable times as any such Holder shall reasonably request.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;<FONT STYLE="font-size: 11pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Underwriting
Agreement</U>. The Company shall enter into an underwriting agreement with the managing underwriter(s), if any, selected by any
Holders whose Registrable Securities are being registered pursuant to this&nbsp;Section 5, which managing underwriter shall be
reasonably satisfactory to the Company. Such agreement shall be reasonably satisfactory in form and substance to the Company, each
Holder and such managing underwriters, and shall contain such representations, warranties and covenants by the Company and such
other terms as are customarily contained in agreements of that type used by the managing underwriter. The Holders shall be parties
to any underwriting agreement relating to an underwritten sale of their Registrable Securities and may, at their option, require
that any or all the representations, warranties and covenants of the Company to or for the benefit of such underwriters shall also
be made to and for the benefit of such Holders. Such Holders shall not be required to make any representations or warranties to
or agreements with the Company or the underwriters except as they may relate to such Holders, their Shares and their intended methods
of distribution.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Documents
to be Delivered by Holder(s)</U>. Each of the Holder(s) participating in any of the foregoing offerings shall furnish to the Company
a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security holders.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Damages</U>.
Should the registration or the effectiveness thereof required by&nbsp;Section 5 a)&nbsp;and&nbsp;Section 5 b)&nbsp;hereof be delayed
by the Company or the Company otherwise fails to comply with such provisions, the Holder(s) shall, in addition to any other legal
or other relief available to the Holder(s), be entitled to obtain specific performance or other equitable (including injunctive)
relief against the threatened breach of such provisions or the continuation of any such breach, without the necessity of proving
actual damages and without the necessity of posting bond or other security.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 6</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>No Rights as Stockholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other
rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated,
the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of
such Warrant or stock certificate.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next
succeeding Trading Day.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Authorized Shares</U>.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 1in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be
listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance
herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by
the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such
issue).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 1in">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its
certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be
necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the
generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor
upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise
Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any
public regulatory body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be determined in accordance with the provisions of the Underwriting Agreement.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies. Without limiting
any other provision of this Warrant or the Underwriting Agreement, if the Company willfully and knowingly fails to comply with
any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including
those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing
any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notices</U>. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company
shall be delivered in accordance with the notice provisions of the Placement Agency Agreement.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability
of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted
by the Company or by creditors of the Company.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be
adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to
waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant
and shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and the Holder.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or
the remaining provisions of this Warrant.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">********************</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;<BR STYLE="clear: both">
</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 11pt; text-transform: uppercase"><B>Biovie inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; font: 12pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">By:__________________________________________</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">Name:</P>
        <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">Title:</P></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="text-transform: uppercase">TO:&#9;biovie
Inc.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">_________________________</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(1)&nbsp;&nbsp; The undersigned
hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(2)&nbsp;&nbsp; Payment shall
take the form of (check applicable box):</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">[ ] in lawful money of the United
States; or</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">[ ] if permitted the cancellation
of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this
Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth
in subsection 2(c).</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(3)&nbsp;&nbsp; Please register
and issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">_______________________________</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Warrant Shares shall be delivered to the
following DWAC Account Number or by physical delivery of a certificate to:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">_______________________________</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">_______________________________</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">_______________________________</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(4)&nbsp;&nbsp; <U>Accredited
Investor</U>. If the Warrant is being exercised via cash exercise, the undersigned is an &#8220;accredited investor&#8221; as defined
in Regulation D promulgated under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt/200% Times New Roman, Times, Serif; margin: 0">Name of Investing Entity: _______________________________________________________________</P>

<P STYLE="font: 11pt/200% Times New Roman, Times, Serif; margin: 0"><I>Signature of Authorized Signatory of Investing Entity</I>:
________________________________________</P>

<P STYLE="font: 11pt/200% Times New Roman, Times, Serif; margin: 0">Name of Authorized Signatory: ___________________________________________________________</P>

<P STYLE="font: 11pt/200% Times New Roman, Times, Serif; margin: 0">Title of Authorized Signatory: ____________________________________________________________</P>

<P STYLE="font: 11pt/200% Times New Roman, Times, Serif; margin: 0">Date: ______________________________________________________________________________</P>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->




<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center">(To assign the foregoing warrant, execute<BR>
this form and supply required information.<BR>
Do not use this form to exercise the warrant.)</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">FOR VALUE RECEIVED, [____]
all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">_______________________________________________
whose address is</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">_______________________________________________________________.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">_______________________________________________________________</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">Dated: ______________,
_______</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">Holder&#8217;s Signature: _____________________________</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">Holder&#8217;s Address: _____________________________</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: 0.5in">_____________________________</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE: The signature to this Assignment Form
must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever.
Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority
to assign the foregoing Warrant.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 22.7pt 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EXHIBIT B-1</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>D&amp;O Lock-Up Agreement<BR>
<BR>
</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right; text-indent: 0.5in">March [&#8226;], 2020</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">ThinkEquity</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">A Division of Fordham Financial Management, Inc.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">17 State Street, 22<SUP>nd</SUP> Floor</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">New York, NY 10004<BR>
<BR>
</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The undersigned
understands that ThinkEquity, a Division of Fordham Financial Management, Inc. (the &#8220;<B>Placement Agent</B>&#8221;), proposes
to enter into a Placement Agency Agreement (the &#8220;<B>Placement Agency Agreement</B>&#8221;) with BioVie Inc., a Nevada corporation
(the &#8220;<B>Company</B>&#8221;), providing for the public offering (the &#8220;<B>Public Offering</B>&#8221;) of shares of the
Company&#8217;s Class A common stock, par value $0.0001 per share, of the Company (the &#8220;<B>Common Shares</B>&#8221;), and
warrants to purchase Common Shares.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; text-indent: 0.5in">To induce the Placement
Agent to continue its efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written
consent of the Placement Agent, the undersigned will not, during the period commencing on the date hereof and ending 180 days after
the date of the Placement Agency Agreement relating to the Public Offering (the &#8220;<B>Lock-Up Period</B>&#8221;), (1) offer,
pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, any Common Shares or
any securities convertible into or exercisable or exchangeable for Common Shares, whether now owned or hereafter acquired by the
undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (collectively, the &#8220;<B>Lock-Up
Securities</B>&#8221;); (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the
economic consequences of ownership of the Lock-Up Securities, whether any such transaction described in clause (1) or (2) above
is to be settled by delivery of Lock-Up Securities, in cash or otherwise; (3) make any demand for or exercise any right with respect
to the registration of any Lock-Up Securities; or (4) publicly disclose the intention to make any offer, sale, pledge or disposition,
or to enter into any transaction, swap, hedge or other arrangement relating to any Lock-Up Securities. Notwithstanding the foregoing,
and subject to the conditions below, the undersigned may transfer Lock-Up Securities without the prior written consent of the Placement
Agent in connection with (a) transactions relating to Lock-Up Securities acquired in open market transactions after the completion
of the Public Offering; <U>provided</U> that no filing under Section 13 or Section&nbsp;16(a) of the Securities Exchange Act of
1934, as amended (the &#8220;<B>Exchange Act</B>&#8221;), or other public announcement shall be required or shall be voluntarily
made in connection with subsequent sales of Lock-Up Securities acquired in such open market transactions; (b) transfers of Lock-Up
Securities as a <I>bona fide</I> gift, by will or intestacy or to a family member or trust for the benefit of the undersigned or
a family member (for purposes of this lock-up agreement, &#8220;family member&#8221; means any relationship by blood, marriage
or adoption, not more remote than first cousin); (c) transfers of Lock-Up Securities to a charity or educational institution; (d)
if the undersigned is a corporation, partnership, limited liability company or other business entity, (i) any transfers of Lock-Up
Securities to another corporation, partnership or other business entity that controls, is controlled by or is under common control
with the undersigned or (ii) distributions of Lock-Up Securities to members, partners, stockholders, subsidiaries or affiliates
(as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned; (e) if the undersigned is
a trust, to a trustee or beneficiary of the trust; <U>provided</U> that in the case of any transfer pursuant to the foregoing clauses&nbsp;(b),
(c) (d) or (e), (i) any such transfer shall not involve a disposition for value, (ii) each transferee shall sign and deliver to
the Placement Agent a lock&#45;up agreement substantially in the form of this lock-up agreement and (iii) no</P>


<DIV STYLE="page-break-before: always; border-top: black 1.5pt solid; margin-top: 12pt"><P STYLE="margin: 0pt; font: 12pt Times New Roman, Times, Serif">&nbsp;</P></DIV>


<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">filing under Section 13 or Section&nbsp;16(a)
of the Exchange Act or other public announcement shall be required or shall be voluntarily made; (f) the receipt by the undersigned
from the Company of Common Shares upon the vesting of restricted stock awards or stock units or upon the exercise of options to
purchase the Company&#8217;s Common Shares issued under an equity incentive plan of the Company or an employment arrangement described
in the Pricing Prospectus (as defined in the Placement Agency Agreement) (the &#8220;<B>Plan Shares</B>&#8221;) or the transfer
of Common Shares or any securities convertible into Common Shares to the Company upon a vesting event of the Company&#8217;s securities
or upon the exercise of options to purchase the Company&#8217;s securities, in each case on a &#8220;cashless&#8221; or &#8220;net
exercise&#8221; basis or to cover tax obligations of the undersigned in connection with such vesting or exercise, but only to the
extent such right expires during the Lock-up Period, <U>provided</U> that no filing under Section 13 or Section 16(a) of the Exchange
Act or other public announcement shall be required or shall be voluntarily made within 180 days after the date of the Placement
Agency Agreement, and after such 180<SUP>th</SUP> day, if the undersigned is required to file a report under Section 13 or Section
16(a) of the Exchange Act reporting a reduction in beneficial ownership of Common Shares during the Lock-Up Period, the undersigned
shall include a statement in such schedule or report to the effect that the purpose of such transfer was to cover tax withholding
obligations of the undersigned in connection with such vesting or exercise and, <U>provided further</U>, that the Plan Shares shall
be subject to the terms of this lock-up agreement; (g) the transfer of Lock-Up Securities pursuant to agreements described in the
Pricing Prospectus under which the Company has the option to repurchase such securities or a right of first refusal with respect
to the transfer of such securities, <U>provided</U> that if the undersigned is required to file a report under Section 13 or Section
16(a) of the Exchange Act reporting a reduction in beneficial ownership of Common Shares during the Lock-Up Period, the undersigned
shall include a statement in such schedule or report describing the purpose of the transaction; (h) the establishment of a trading
plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of Lock-Up Securities, <U>provided</U> that (i) such plan
does not provide for the transfer of Lock-Up Securities during the Lock-Up Period and (ii) to the extent a public announcement
or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the undersigned or the Company
regarding the establishment of such plan, such public announcement or filing shall include a statement to the effect that no transfer
of Lock-Up Securities may be made under such plan during the Lock-Up Period; (i) the transfer of Lock-Up Securities that occurs
by operation of law, such as pursuant to a qualified domestic order or in connection with a divorce settlement, <U>provided</U>
that the transferee agrees to sign and deliver a lock-up agreement substantially in the form of this lock-up agreement for the
balance of the Lock-Up Period, and <U>provided further</U>, that any filing under Section 13 or Section 16(a) of the Exchange Act
that is required to be made during the Lock-Up Period as a result of such transfer shall include a statement that such transfer
has occurred by operation of law; and (j) the transfer of Lock-Up Securities <FONT STYLE="font-size: 11pt">pursuant to a bona fide
third party tender offer, merger, consolidation or other similar transaction made to all holders of the Common Shares involving
a change of control (as defined below) of the Company after the closing of the Public Offering and approved by the Company&#8217;s
board of directors; <U>provided</U> that in the event that the </FONT>tender offer, merger, consolidation or other such transaction
<FONT STYLE="font-size: 11pt">is not completed, the Lock-Up Securities owned by the undersigned shall remain subject to the restrictions
contained in this lock-up agreement. For purposes of clause (k) above, &#8220;change of control&#8221; shall mean the consummation
of any bona fide third party tender offer, merger, amalgamation, consolidation or other similar transaction the result of which
is that any &#8220;person&#8221; (as defined in Section 13(d)(3) of the Exchange Act), or group of persons, becomes the beneficial
owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of a majority of total voting power of the voting stock of the
Company. The undersigned also agrees and consents to the entry of stop transfer instructions with the Company&#8217;s transfer
agent and registrar against the transfer of the undersigned&#8217;s Lock-Up Securities except in compliance with this lock-up agreement.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: justify; text-indent: 0.5in">The undersigned
agrees that, prior to engaging in any transaction or taking any other action that is subject to the terms of this lock-up agreement
during the period from the date hereof to and including the</P>


<!-- Field: Page; Sequence: 56; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">expiration of the Lock-Up Period, the
undersigned will give notice thereof to the Company and will not consummate any such transaction or take any such action unless
it has received written confirmation from the Company that the Lock-Up Period has expired.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the undersigned is an
officer or director of the Company, (i) the undersigned agrees that the foregoing restrictions shall be equally applicable to any
issuer-directed or &#8220;friends and family&#8221; Securities that the undersigned may purchase in the Public Offering; (ii) the
Placement Agent agrees that, at least three (3) business days before the effective date of any release or waiver of the foregoing
restrictions in connection with a transfer of Lock-Up Securities, the Placement Agent will notify the Company of the impending
release or waiver; and (iii) the Company has agreed in the Placement Agency Agreement to announce the impending release or waiver
by press release through a major news service at least two (2) business days before the effective date of the release or waiver.
Any release or waiver granted by the Placement Agent hereunder to any such officer or director shall only be effective two (2)
business days after the publication date of such press release. The provisions of this paragraph will not apply if (a) the release
or waiver is effected solely to permit a transfer of Lock-Up Securities not for consideration and (b) the transferee has agreed
in writing to be bound by the same terms described in this lock-up agreement to the extent and for the duration that such terms
remain in effect at the time of such transfer.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The undersigned
understands that the Company and the Placement Agent are relying upon this lock-up agreement in proceeding toward consummation
of the Public Offering. The undersigned further understands that this lock-up agreement is irrevocable and shall be binding upon
the undersigned&#8217;s heirs, legal representatives, successors and assigns.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The undersigned
understands that if the Placement Agency Agreement (other than the provisions thereof which survive termination) shall terminate
or be terminated prior to payment for and delivery of the Common Shares to be sold thereunder, then this lock-up agreement shall
be void and of no further force or effect.</P>


<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Whether or not the
Public Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only be made
pursuant to the Private Placement Agreement, the terms of which are subject to negotiation between the Company, the Placement Agent
and the Investors.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 3.5in; border-collapse: collapse; font-size: 11pt; margin: 0 0 0 3in">
<TR STYLE="vertical-align: middle">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif">Very truly yours,</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle; width: 50%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom; width: 50%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif">(Name - Please Print)</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif">&nbsp;(Signature)</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif">(Name of Signatory, in the case of entities - Please Print)</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif">(Title of Signatory, in the case of entities - Please Print)</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 3.5in; border-collapse: collapse; font-size: 11pt; margin: 0 0 0 3in">
<TR STYLE="vertical-align: middle">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 20%">Address:</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 80%; border-bottom: Black 1pt solid"></TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle; border-bottom: Black 1pt solid"></TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle; border-bottom: Black 1pt solid"></TD></TR>
</TABLE>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 31.2pt 0 0; text-align: justify; text-indent: 0.5in">&#9;</P>


<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. B-1-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EXHIBIT B-2</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Shareholder Lock-Up Agreement<BR>
<BR>
</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right; text-indent: 0.5in">November [&#8226;],
2019</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">ThinkEquity</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">A Division of Fordham Financial Management, Inc.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">17 State Street, 22<SUP>nd</SUP> Floor</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">New York, NY 10004<BR>
<BR>
</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The undersigned
understands that ThinkEquity, a Division of Fordham Financial Management, Inc. (the &#8220;<B>Placement Agent</B>&#8221;), proposes
to enter into a Placement Agency Agreement (the &#8220;<B>Placement Agency Agreement</B>&#8221;) with BioVie Inc., a Nevada corporation
(the &#8220;<B>Company</B>&#8221;), providing for the public offering (the &#8220;<B>Public Offering</B>&#8221;) of shares of the
Company&#8217;s Class A common stock, par value $0.0001 per share, of the Company (the &#8220;<B>Common Shares</B>&#8221;), and
warrants to purchase Common Shares.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0 0; text-align: justify; text-indent: 0.5in">To induce the Placement
Agent to continue its efforts in connection with the Public Offering, the undersigned hereby agrees that, without the prior written
consent of the Placement Agent, the undersigned will not, during the period commencing on the date hereof and ending 90 days after
the date of the Placement Agency Agreement relating to the Public Offering (the &#8220;<B>Lock-Up Period</B>&#8221;), (1) offer,
pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, directly or indirectly, any Common Shares or
any securities convertible into or exercisable or exchangeable for Common Shares, whether now owned or hereafter acquired by the
undersigned or with respect to which the undersigned has or hereafter acquires the power of disposition (collectively, the &#8220;<B>Lock-Up
Securities</B>&#8221;); (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the
economic consequences of ownership of the Lock-Up Securities, whether any such transaction described in clause (1) or (2) above
is to be settled by delivery of Lock-Up Securities, in cash or otherwise; (3) make any demand for or exercise any right with respect
to the registration of any Lock-Up Securities; or (4) publicly disclose the intention to make any offer, sale, pledge or disposition,
or to enter into any transaction, swap, hedge or other arrangement relating to any Lock-Up Securities. Notwithstanding the foregoing,
and subject to the conditions below, the undersigned may transfer Lock-Up Securities without the prior written consent of the Placement
Agent in connection with (a) transactions relating to Lock-Up Securities acquired in open market transactions after the completion
of the Public Offering; <U>provided</U> that no filing under Section 13 or Section&nbsp;16(a) of the Securities Exchange Act of
1934, as amended (the &#8220;<B>Exchange Act</B>&#8221;), or other public announcement shall be required or shall be voluntarily
made in connection with subsequent sales of Lock-Up Securities acquired in such open market transactions; (b) transfers of Lock-Up
Securities as a <I>bona fide</I> gift, by will or intestacy or to a family member or trust for the benefit of the undersigned or
a family member (for purposes of this lock-up agreement, &#8220;family member&#8221; means any relationship by blood, marriage
or adoption, not more remote than first cousin); (c) transfers of Lock-Up Securities to a charity or educational institution; (d)
if the undersigned is a corporation, partnership, limited liability company or other business entity, (i) any transfers of Lock-Up
Securities to another corporation, partnership or other business entity that controls, is controlled by or is under common control
with the undersigned or (ii) distributions of Lock-Up Securities to members, partners, stockholders, subsidiaries or affiliates
(as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned; (e) if the undersigned is
a trust, to a trustee or beneficiary of the trust; <U>provided</U> that in the case of any transfer pursuant to the foregoing clauses&nbsp;(b),
(c) (d) or (e), (i) any such transfer shall not involve a disposition for value, (ii) each transferee shall sign and deliver to
the Placement Agent a lock&#45;up agreement substantially in the form of this lock-up agreement and (iii) no</P>


<DIV STYLE="page-break-before: always; border-top: black 1.5pt solid; margin-top: 12pt"><P STYLE="margin: 0pt; font: 12pt Times New Roman, Times, Serif">&nbsp;</P></DIV>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">filing under Section 13 or Section&nbsp;16(a)
of the Exchange Act or other public announcement shall be required or shall be voluntarily made; (f) the receipt by the undersigned
from the Company of Common Shares upon the vesting of restricted stock awards or stock units or upon the exercise of options to
purchase the Company&#8217;s Common Shares issued under an equity incentive plan of the Company or an employment arrangement described
in the Pricing Prospectus (as defined in the Placement Agency Agreement) (the &#8220;<B>Plan Shares</B>&#8221;) or the transfer
of Common Shares or any securities convertible into Common Shares to the Company upon a vesting event of the Company&#8217;s securities
or upon the exercise of options to purchase the Company&#8217;s securities, in each case on a &#8220;cashless&#8221; or &#8220;net
exercise&#8221; basis or to cover tax obligations of the undersigned in connection with such vesting or exercise, but only to the
extent such right expires during the Lock-up Period, <U>provided</U> that no filing under Section 13 or Section 16(a) of the Exchange
Act or other public announcement shall be required or shall be voluntarily made within 90 days after the date of the Placement
Agency Agreement, and after such 90<SUP>th</SUP> day, if the undersigned is required to file a report under Section 13 or Section
16(a) of the Exchange Act reporting a reduction in beneficial ownership of Common Shares during the Lock-Up Period, the undersigned
shall include a statement in such schedule or report to the effect that the purpose of such transfer was to cover tax withholding
obligations of the undersigned in connection with such vesting or exercise and, <U>provided further</U>, that the Plan Shares shall
be subject to the terms of this lock-up agreement; (g) the transfer of Lock-Up Securities pursuant to agreements described in the
Pricing Prospectus under which the Company has the option to repurchase such securities or a right of first refusal with respect
to the transfer of such securities, <U>provided</U> that if the undersigned is required to file a report under Section 13 or Section
16(a) of the Exchange Act reporting a reduction in beneficial ownership of Common Shares during the Lock-Up Period, the undersigned
shall include a statement in such schedule or report describing the purpose of the transaction; (h) the establishment of a trading
plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of Lock-Up Securities, <U>provided</U> that (i) such plan
does not provide for the transfer of Lock-Up Securities during the Lock-Up Period and (ii) to the extent a public announcement
or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the undersigned or the Company
regarding the establishment of such plan, such public announcement or filing shall include a statement to the effect that no transfer
of Lock-Up Securities may be made under such plan during the Lock-Up Period, (i) the transfer of Lock-Up Securities that occurs
by operation of law, such as pursuant to a qualified domestic order or in connection with a divorce settlement, <U>provided</U>
that the transferee agrees to sign and deliver a lock-up agreement substantially in the form of this lock-up agreement for the
balance of the Lock-Up Period, and <U>provided further</U>, that any filing under Section 13 or Section 16(a) of the Exchange Act
that is required to be made during the Lock-Up Period as a result of such transfer shall include a statement that such transfer
has occurred by operation of law; and (j) the transfer of Lock-Up Securities <FONT STYLE="font-size: 11pt">pursuant to a bona fide
third party tender offer, merger, consolidation or other similar transaction made to all holders of the Common Shares involving
a change of control (as defined below) of the Company after the closing of the Public Offering and approved by the Company&#8217;s
board of directors; provided that in the event that the tender offer, merger, consolidation or other such transaction is not completed,
the Lock-Up Securities owned by the undersigned shall remain subject to the restrictions contained in this lock-up agreement. For
purposes of clause (k) above, &#8220;change of control&#8221; shall mean the consummation of any bona fide third party tender offer,
merger, amalgamation, consolidation or other similar transaction the result of which is that any &#8220;person&#8221; (as defined
in Section 13(d)(3) of the Exchange Act), or group of persons, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5
of the Exchange Act) of a majority of total voting power of the voting stock of the Company. The undersigned also agrees and consents
to the entry of stop transfer instructions with the Company&#8217;s transfer agent and registrar against the transfer of the undersigned&#8217;s
Lock-Up Securities except in compliance with this lock-up agreement.</FONT></P>


<!-- Field: Page; Sequence: 59; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The undersigned
agrees that, prior to engaging in any transaction or taking any other action that is subject to the terms of this lock-up agreement
during the period from the date hereof to and including the expiration of the Lock-Up Period, the undersigned will give notice
thereof to the Company and will not consummate any such transaction or take any such action unless it has received written confirmation
from the Company that the Lock-Up Period has expired.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If the undersigned is an
officer or director of the Company, (i) the undersigned agrees that the foregoing restrictions shall be equally applicable to any
issuer-directed or &#8220;friends and family&#8221; Securities that the undersigned may purchase in the Public Offering; (ii) the
Placement Agent agrees that, at least three (3) business days before the effective date of any release or waiver of the foregoing
restrictions in connection with a transfer of Lock-Up Securities, the Placement Agent will notify the Company of the impending
release or waiver; and (iii) the Company has agreed in the Placement Agency Agreement to announce the impending release or waiver
by press release through a major news service at least two (2) business days before the effective date of the release or waiver.
Any release or waiver granted by the Placement Agent hereunder to any such officer or director shall only be effective two (2)
business days after the publication date of such press release. The provisions of this paragraph will not apply if (a) the release
or waiver is effected solely to permit a transfer of Lock-Up Securities not for consideration and (b) the transferee has agreed
in writing to be bound by the same terms described in this lock-up agreement to the extent and for the duration that such terms
remain in effect at the time of such transfer.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The undersigned
understands that the Company and the Placement Agent are relying upon this lock-up agreement in proceeding toward consummation
of the Public Offering. The undersigned further understands that this lock-up agreement is irrevocable and shall be binding upon
the undersigned&#8217;s heirs, legal representatives, successors and assigns.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">The undersigned
understands that, if the Placement Agency Agreement (other than the provisions thereof which survive termination) shall terminate
or be terminated prior to payment for and delivery of the Common Shares to be sold thereunder, then this lock-up agreement shall
be void and of no further force or effect.</P>


<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in">Whether or not the
Public Offering actually occurs depends on a number of factors, including market conditions. Any Public Offering will only be made
pursuant to a Placement Agency Agreement, the terms of which are subject to negotiation between the Company, the Placement Agent
and the Investors.</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 3.5in; border-collapse: collapse; font-size: 11pt; margin: 0 0 0 3in">
<TR STYLE="vertical-align: middle">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif">Very truly yours,</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle; width: 50%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom; width: 50%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif">(Name - Please Print)</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif">&nbsp;(Signature)</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif">(Name of Signatory, in the case of entities - Please Print)</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: middle">
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif">(Title of Signatory, in the case of entities - Please Print)</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle">&nbsp;</TD>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 3.5in; border-collapse: collapse; font-size: 11pt; margin: 0 0 0 3in">
<TR STYLE="vertical-align: middle">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 20%">Address:</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 80%; border-bottom: Black 1pt solid"></TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle; border-bottom: Black 1pt solid"></TD></TR>
<TR>
    <TD STYLE="font-family: Calibri, Helvetica, Sans-Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; vertical-align: middle; border-bottom: Black 1pt solid"></TD></TR>
</TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Ex. B-2-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0 0 0; text-align: center"><B><U>EXHIBIT C</U></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>Form of Press Release</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>BioVie Inc.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B><BR>
[Date]</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BioVie Inc. (the &#8220;Company&#8221;) announced
today that ThinkEquity, a division of Fordham Financial Management, Inc., acting as Placement Agent in the Company&#8217;s recent
public offering of&nbsp; _______ shares of the Company&#8217;s Class A common stock, is [waiving] [releasing] a lock-up restriction
with respect to _________&nbsp; shares of the Company&#8217;s common stock held by [certain officers or directors] [an officer
or director] of the Company.&nbsp; The [waiver] [release] will take effect on&nbsp; _________, 20___, and the shares may be sold
on or after such date.&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><B>This press release is not an offer
or sale of the securities in the United States or in any other jurisdiction where such offer or sale is prohibited, and such securities
may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act
of 1933, as amended.</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 62; Options: NewSection Last; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>bivi-20200311_s1a9ex23z1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<DIV STYLE="width: 6.5in; margin:0 auto">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Exhibit 23.1</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;<IMG SRC="image_004.jpg" ALT=""></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></DIV>

<DIV STYLE="width: 6.5in; margin: 0 auto"><P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>


<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt; line-height: 115%">We
consent to the inclusion in this Registration Statement of BioVie, Inc. on Form S-1/A to be filed on or about March 11, 2020,
of our audit report dated October 4, 2018, except for common share presentation on a post-reverse split basis dated November 19,
2019, with respect to the financial statements of Biovie, Inc. for the year ended June 30, 2018. We also consent to the
reference to our firm under the caption &ldquo;Experts&rdquo; in this Registration Statement.</FONT></P>


<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 6pt 0; text-align: justify"><IMG SRC="image_010.jpg" ALT="" STYLE="height: 70px; width: 368px"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">D. Brooks and Associates CPA&rsquo;s, P.A.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">Palm Beach Gardens, FL</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">March 11, 2020</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>


</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>4
<FILENAME>bivi-20200311_s1a9ex23z3.htm
<DESCRIPTION>EXHIBIT 23.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><B>CONSENT OF INDEPENDENT REGISTE<FONT STYLE="letter-spacing: -0.05pt">RE</FONT>D
<FONT STYLE="letter-spacing: -0.05pt">PU</FONT><FONT STYLE="letter-spacing: 0.05pt">B</FONT><FONT STYLE="letter-spacing: -0.05pt">LI</FONT>C
A<FONT STYLE="letter-spacing: -0.05pt">CCOU</FONT>N<FONT STYLE="letter-spacing: -0.05pt">TIN</FONT>G <FONT STYLE="letter-spacing: -0.05pt">FIRM</FONT></B></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">We consent to the inclusion in this Amendment
No.9  to the Registration Statement of BioVie, Inc. on Form S-1A to be filed on or about March 11, 2020, of our report dated
September 25, 2019, except for Note 1 (Reverse Stock Split) as to which date is November 22, 2019, on our audit of the financial
statements as of June 30, 2019 and for the year ended June 30, 2019. Our report includes an explanatory paragraph about the existence
of substantial doubt concerning the Company&rsquo;s ability to continue as a going concern. We also consent to the reference to
our firm under the caption &ldquo;Experts&rdquo; in this Registration Statement.</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">/s/ EISNERAMPER LLP</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">Iselin, New Jersey</P>

<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify">March 11, 2020</P>



<P STYLE="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1"  R )$# 2(  A$! Q$!_\0
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M%)+8W&K2C$FI3M-T_AZ*/R%=)FA;%SCRR<1:*3-(6 ZT$#J*8LBMT.?QIV:
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MR^^R,!B/K0 KM]MUZ-(SF.R4L[?[;< ?E6H>E06EG#8P"&!<+U)/)8^I-3T
M<QJ4BZ-XNMM1<[;>^@:"8]@RY93^614W@^%Y-/GU28?O=2G:8^R]%'Y"KOB#
M0X=?TPV4[M&-P8.G52/2K]K EM;1V\:A4B4*H'H*E1:9T2J1=)+KM\D2USVC
M_P#(W:]]8?\ T&NAJA::6EKJ=[?K(S/>;-RGHNT8XILSA)*,EW0NLV1U#1KN
MS'!FB91]<<54\,ZFNHZ)!D[;B!?)GC/5'7@YK8-8.H^%EN+YM0TZ]ETZ\;[[
MQ<K)_O+T-#TU'!Q<>26ANYI1FL73-*UJVO!-?ZW]KC"D>4L(0$^IK;H1G))/
M1W%HHHIB"BBB@ HHHH **** "BBB@ I*** "EHHH 2FT44T =OQIU%%(E;B=
+Z=110-!1110,_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '^ G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XWQ!X@U&T\5Q:
M5;:CIVGP&S-P9KU,@MNQM'S#M5;3O%VJ7S^'#+'#"E[=7$,Q1<K,B*2KIGD
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBJ\-_:7%J]U#<Q20)NW2*P*C;U
MY]J +%%06=Y;7]I%=VDR36\J[DD0Y5AZ@U/0 4456.H6BZBNGFYC%XT9E6'=
M\Q0'&['IF@"S115&VUC3[R[:UM[E))UW[D7/&TA6_(G'USZ4 7J*KW=_:V"Q
M-=3I$)9%B0L?O.>@'N:L4 %%%% !115>YOK6S>!+F=(FN)!%$&/WW/0#WXH
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MK.)1L'XT 7J*P]#\0IK>IZK# 89+6T>(131/N$@9-Q_(\5N4 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%&1ZTC,%4LQ 4#))[4 <]XQU_\
ML/1R(6_TRXS'"/3U;\/YXKR2-<#)))/))[UI^(M7;7M=FN@2;=/W< ]%'?\
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M* "BBB@ HHHH **** "BBB@ HHHH *\\\?>)YFG_ .$=TM\32#_2I5/W%/\
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MUX3(,H:]?\&W!N/"6GL3DK'L/_ 21_2@#=HHHH **** "BBB@ HHHH ****
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M6=C@ 5J>-Y[31YA?W,JI'*F#GJ6'&!ZFO%/$7B.[UN?RV_=6B-\D(/ZL>YH
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M)B.GF-_,U[M<R"*UFD)P$1F)^@KP6 Y7=W/- $U%%% !124M "'H:]"^&?\
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M?#NE-HN@VMC)())D4M*XZ,[$LQ_,FM2B@ HHHH **** "BBB@ HHHH ****
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M80Z7IT%E ,1PH%'OZG\30!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH K3ZA:VUU!;33JDTYQ&AZM]*AO]:T_3)DBO+CRY'4NJA&8E1U/ /
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M>2KC(HMK:"TA$-O$D48Z*@P*EHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "HXH(H%811J@9B[;1C+'J?K4E% !1110 4444 %%%% !1110 54M],L
M;2=YK>TABE?.61 #SUJW10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
0 !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  ^ +,# 2(  A$! Q$!_\0
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3Q6Y1132L9SDI.Z5@HHHIDG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !A E@# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WUW5%+,0
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M)ZX Q4YK)>[#JAY'0J0<YR5DR>BBBO(/H@HHHH **** "BBB@ HHHH ****
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M -%&K'PX53\&M*! P;"3(_%J):<WD):V\SI/#WB;3_$GAJWUZT<I:31ESYN
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M-9\GC^[OKS4X?#7AV;6(],D,-U-]J2!3(!DK&#DN1]!65\+O^1M^()_ZB_\
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M/Y).0IZYSG'.*[B)_,B1_P"\ :\9DC\;_"C3VV>3XD\'P@@QD;9[>(_S'/\
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MV\^:-I$4(Q!5<9^;&!U'!.31TL'6YQLW@/6;_3?[$U3Q;/=Z&0JR1&T1;B5
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M.<)'=*O"B08.<#C(P<<9J:Y\*VTVISW]M=W5C+=1+#=+;,H6=%!"[@0<, 2
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MH;[P)((8'N"#49\(QG6-*U)=5U 2Z;&\:*S(XEWXWER5)); Z$8QQBFFNO\
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3.]*:**.@!VH'2BB@!:***8'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !& 7 # 2(  A$! Q$!_\0
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M-&GZN\MS]@U"$6NH 9\O.4E _BC/<>W446NKH+]S5HHSSBBI&%%%% !1110
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $A J<# 2(  A$! Q$!_\0
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MP< .5*L.A!'(-8/@SP+:>';>&\O$6XUK85DN3(TF 2>%W=!C H YG5+3Q/\
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M34;-V"BX16/9_E/ZU:!!&0<BFO&D@PZ*P]&&:JG38D.ZV=[=O^F9^7_OD\4
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MJ"K*<.C=5/H:FJI=6[AQ=6P_?H,%>TB^A_I4\$Z7,*RQGY6]>H/H: )****
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M!O\ Z]7* "BBB@ HHHH *IW_ .\>U@QD22@M]%Y_F!5RJ<ISJULO]V)V_D*
M+E%%9&K^((-(O;6UDMIY7N$>3=$!A$3&YFR1P <T :]>=ZE8>)KQ]4MV6^?S
M4NUD_>@0/$5/D+&,\-G;GI_%GJ*VK7QW97J1BVL;R2>:14@A"KF0,I;=G.!A
M5)()R./6I+;QM875NLT=O<A6-L!N49'GDA>_;'- %74-&N(XO"PBBO7BLI0)
MUAE^908R 3R,@,<'V)K!L]*\4Z;H\%M:"]2(VL33Q[P2C"4[UCY&#LQP"/KF
MMNT\>0QZ<DEY!<S-';)/-/%$J(-[%4&"QP21C'XUJ#Q9:G0O[4^RW.W[0ML8
M0HW;RP48YP1DCD'% '/I!XI2YLS!+?SL;5U'V@")(F^?:S88AS]P$-ST.>M7
M=%L==G\.ZE!<7E_#=R(OD-. &CE"\D-N8E2V/0=<<5;;QO91I;M+:7$>^X:V
ME#,F89 X0@C=EN2.5SQS3)?'5K#IK:A)IUXMJ)7CWL8UW;"0S*"V6 (/3DT
M9,MKXFNHHKZ87=M<W$%RS+$%D:U),8C11D=E8\'N>^*J76EZ]>V?F7-E>C:E
MF[1QS[I&V3N7PQ.2=NUL$\<=Q73S>,K2&WNKHVETUG#+Y"7 "A99=P7:H)SU
M/4@#@U ?'MB%5OL5X5""29MJXB4R&/)YY^;TSD'- $OAY-6CUW4Q>"\DM&.Z
M&6X;&.3A F2.!CYAC/<9KIJXY?'B002/>Z=,CF[GAA2-E)=8CAFZ]1P,=R>*
MDO/&<4D=VEDLD,EN\ \R:,'(=T'$98-C#_>QCKZ4 =;163HNO0:VUV(89(OL
MTIC82%0Q()'*@Y7IW [5K4 4M/\ D^T0?\\ICCZ'YOZU=JG#QJETOJB-_,?T
MJY0 4444 %%%% !5.]_>3VD&,AI-[?11G^>*N53<%M7A]%A8_F1_A0!<HHHH
M "0.II-R\?,.>G/6N+\=V0U#5_#%I(LQMY;UTF$3,N4,9R"1T!Z5R&M:8+?7
M]4L[V9K(((DTJ3[)-.R1*HVB HV 0>H/)H ]CW ,%R,GH*S/$&N0^'M'FU&:
M)YDB*@QQD;CN8+W^M>7^)9VFUJYEAL6BU.SNX ;G$QGE *@R*!\B1D'IWY[U
M!XAA@EC\2KJ%K=R^(/[0#6[>5(P6VW+M*D<!<9_&@#VD," <]:I:OJ?]E:7-
M>K:7%X8R!Y-LNYVR0.!^->7>(=/,C>--0$5Q]LM+NV:TE0N#'D*&*8]NXINN
MZ?\ V6GBRQTZ">*T-E9RK&F\@R&0;B/?UH ]3&LV)O9[,RE;BW@6XE1@1L1L
MXR>F>#Q4NGZC:ZGIT%_:R;[:=!(CD8RI]CTKS+4=(TU_&FMP7>GL\UWIR26/
M[MR'FV,6((XSD#K65%%#_P (OX<,,9CT]'8:L)+:5T%QL&TRH,%AUZ<9H ]K
M+ #)( ]:S-#UN+7(;N2*&2(6UW):L'QRR'!(QVKS0P00V^@+J-Q<WOAG[5<E
M\6TJ(K$?NUV'+% <[<UUGPVB$.BZDBPRPQ_VG.8TE4JP3C;D'GI0!V=%%% %
M/3ODBE@S_JI64?3J/YU<JG;?+J-XH[[&_,8_I5R@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JG=<7]D3_><?^.U
M<JGJ&$%M,>D<ZD_0_+_6@"Y117C7Q8ED3Q3;!)9%'V1>%<C^)JSJU/9QYCNR
M[!?7:_L>:VC=]]CV6BOF#SKD#/FW&,9SO;IZTGVB?_GO-_W\;_&N7ZY_=/?_
M -5G_P _?P_X)]056U"Q@U/3KBQN0QAG0HVTX(![@]C7S1]HG_Y[S?\ ?QO\
M:/M$_P#SWF_[^-_C1]<_NA_JJ_\ G[^'_!/?5\$Z0B3JHG7SHH8F(DZ"(@@C
MCJ2HR>^*D7PCIZW33^;=',T\RH9!M1IE*OCCH<D_6OG_ ,^XQGSYL>OF-_C2
M?:)_^>\W_?P_XT?7/[H?ZJO_ )^_A_P3Z8L+.+3M/MK* L8K>)8DW')PHP,_
ME5BOF S7*G#33COR["D^T3_\]YO^_C?XT?7/[H?ZK/\ Y^_A_P $^H**^8!/
M<'I/,?I(W^-)]HG_ .>\W_?QO\:/KG]T/]57_P _?P_X)]045Y%\(I9)-;U(
M/([@6R\,Q/\ %[UZ[752J>TCS'S^88/ZG7='FO:VNVY4/.KI[0'_ -"%6ZIP
M_/JER^>$1$_'DG^8JY6AQ!1110 4444 %4Y.-8@/8PN/U6KE4[S*7=G+VWE#
M_P "'^(% %RJ5Q96%S>PW<Z(\T*/&A9N KXW#'0YP.M7:^9]6)_MK4/F;_CY
ME[G^^:PK5O96TN>ME66?7Y27-R\MNE]SWH>&-$6V6W"2".-P\7^E29B(! "'
M=E1@D8'&#4%CX/T6TMK))<SS6J1J)3(5WF,Y0LH."1DXSZUX!D_WF_,T9/\
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MG5J*G&[.[+\!+'572@TG:^I[+17SE_PE?B'_ *#E_P#]_C1_PE?B'_H.7_\
MW^-<_P!<CV/:_P!5J_\ S\7W,^C:*^<O^$K\0_\ 0<O_ /O\:/\ A*_$/_0<
MO_\ O\:/KD>P?ZK5_P#GXON9]&T5\Y?\)7XA_P"@Y?\ _?\ -'_"5^(?^@Y?
M_P#?\T?7(]@_U6K_ //Q?<SZ-HKYR_X2OQ"?^8Y?_P#?\T?\)7XA_P"@Y?\
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M[\G/I5M/%.DI=:5>7EV;BZB<!S;+((T3RBH<QOP'4D?=]ZXS^P=9_P"@1?\
M_@,_^%']@ZS_ - B_P#_  &?_"A5)KH$L%A92<G4WOUCU37Z_@C;&IPVECK,
M,GB"34IY[-8X)2L@PXEW;06YZ<YX&:VYO%&ERZU?W U+<M_91QPO*DN+5EV[
ME;;@@-CDKZ<UQ/\ 8.L_] B__P# 9_\ "C^P=9_Z!%__ . S_P"%)3FNGYCG
MA,--W<U?UCY?Y+^F=A!XFL9;J^74-3@-I(R%FM8YX97*Q[0T;9))[8?KUKS_
M .G3WK0_L'6?^@1?_P#@,_\ A2-H>KJ,MI5ZHSC+6[#^E3)RENC?#T\/0;Y)
MK6W5=/F=E\)YDM]5U260X5;9>G?YNE>L6<+C?<3C$TO4?W%[+7FGPNT>[M=7
MO);ZQGA'DC898RH)W>]>G7%W';D)AI)6^[&G+'_ >]>AAE:FCXG/Y*6.DXN^
MB_(L5!->VT#;9)5#_P!T<M^0YJ'[/<W7-S*8D/\ RRB./S;K^56(;:"W&(8E
M3Z#FN@\8@^W._P#J;.X<'N0%'ZFE\^]/2R4?68?X5;HH IFYNUY:P8_[DBG^
M>*/[2B7B:.:#WD0X_,9%7** &1RQS('C=74]U.13ZJRZ? [>8@,,O]^([3^/
MK4?GW-G_ ,?*^=#_ ,]HQR/]Y?ZB@">ZM_/C4J=LL;;HV]#_ (=J^;M6#?VS
M?;@ QN)"0.WS&OI:.1)8P\;!D89!!R#7B>I?#[Q)<ZI=SQV(,<DSNI\U.022
M.]<F+C*25D?2\-UZ5&=1U9*-TMW;JSB",@CUKM8/&EK#-:S"*\^66W=H=PV0
M")"I$7/\6>>GXU0C\ >)9BX33U)0X8&9 1^&:D_X5SXJ_P"@8/\ O^G^-<D8
MU8[)_<?25Z^ KI*I4CI_>74B\-^(;72)[FXO$NYYI90QVOE77!!# D9//4Y^
ME6X_%=F+>VB=;P2I:O;&XCPC0@J I1=V"PQ][Y20?6H?^%<^*O\ H&#_ +_I
M_C1_PKGQ5_T#!_W_ $_QII54K6_ SG++IS<Y5%=_WEZ?U_2%B\46\=HUKYFH
M;6M)[=I]P\PL\@=6///3!Y[U<?QK;R7=O,J30QKG?"L"L$S&$*J=P.#CMMQQ
MWJE_PKGQ5_T#!_W_ $_QH_X5SXJ_Z!@_[_I_C3_?=OP):RUN[J1_\"11AUN.
MW;7/(%S&FH*%B'FDE?W@;YCGGY<C/O6O=^+=.NC<R_9[M966[CB4;=NV8#EN
M>"".@JM_PKGQ5_T#!_W_ $_QH_X5SXJ_Z!@_[_I_C22JK2WX%SGETGS.HK_X
MEY+]"Y/XSLIA=E8KV+S?M($:%=DGFH%#/SU7'OQ7$@8 %=5_PKGQ5_T#!_W_
M $_QJ.3P!XEB9%?3U#.<*HF0D_AFE*-66Z_ NA7P%!-0J1U_O(R=##'7].V
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MM/\ 1KF2S/W,>9#_ +O<?@?YU>JEJ(\N)+I?O0-O/^[T;]*N@@C(Z4 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1[:;5[6.UOV7,L,;[E4Y]?IBM"L_1+6_LM'MK;4[[[;>(N)+@)MWG/I]*T*
M"J>G?)'/#G_53,H^A^8?SJY5.U&V_O1ZLC?^._\ UJ +E%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1^%5$_TS4#)UAM\JO^TYZG\!Q^-7J],_/PHHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %, G # 2(  A$! Q$!_\0
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M5+5]0&E:1=WYC,@MXS(4!QNQVS2Z3?C5=(M+\1F,7$2R;"<[<CIF@"Y1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'U- &MYB?WU_.CS$_OK^=9.X^IHW'U- &MYB?WU_.CS$_OK^=9.X^IHW'U-
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MU [T27=M#*D4MQ$DC_=1G +?0=Z\^33K.+P'<W:0(+B&]/E38^>/;/M4*>H
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M?IWK3M]2,^MWECL016\$4RR@_>WY_3BI;?5M-NI7BM]0M970%F5)02 .I^E
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MXO*EACDC_N.H(_*I** &>5'L5/+78N,+C@8Z4NQ2X?:-P& V.<4ZB@ HHHH
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M$0#[XB;(<>O'.:W=-ACM?&VJQ01K%&]I!(RH, MEQG'K@"@#HB<4UGVJ68@
M#)-.-9&NSM]G2TC;$ERVT^R]S2D[*XXQYI6*%NYN[F:_?_EH=L8/9!T_.F2+
MN<L:MA B!%& H  J-DKBFN8]"+2*3(6X[59@G>$!<92G>63VILS06R;YY%5?
MYUGR7*;3T+$BP2@2 #(YS69+J$]WNCL4P@X:X?A1]/6D9Y]34Q6Z-%:G[TI&
M"P]!7&W5[=-<,$EV1(WEK$/Y5:CR*XZ5/VC<8O8VII%"&"!_D4\NW5F/5O\
M"B\>"VM((I9%5Y 6(SR.@'Z5AZA')'?&*3S(Y!C;&H/S9'ZU9N]%U/>C2V;S
ML4!!!X7V/I67U=R;E+5['3&G3CRWE;J:\ /DFYB;#(0S'\.OZ52N+!=3OS-8
M30^>X^:-S@J?;UK-@U2:".2T .P+M=Z72+6<:E;) DAF$H9FP<!>Y)^E.A3Y
M;1_K^K%2IRI\T^:SZ>AVEE8?8-,@M-VXJ?F;U/4U:MDQ$3_>8FIY1U/H*=&F
MV-1[5Z$8KVM^R/ G-RAKNV,VT;:))HHYHH7<*\N=@/\ %BI=M;F!%M]J-M2[
M:J7]V+2'@;I7.(T'4FDW97948N3LBG?9N[J.PCZ9WS$=E]*N+#]LU&"S4?N8
M<22_A]T57@C_ +-M&FE_>7,IYQU9CT K<TFQ:SMBTO-Q*=\K>_I^%<BO4GS,
M[W:E3Y4:.*=24M=!RA6=>_\ 'Q_P$5HUG7O_ !\?\!% %?Z\"N<_X26Y-B^K
M+I@;2$8YE\[]Z4!P9 F,;?;.<5T9 ((/0\&N6.B:PNBR:!&UI]@?=&+HL?,6
M(G)79C&[!QG- !:)<7OCJ[EN((WBM8HS"PN&_=JP)#!<8);OGI[U)XF$MQJ>
MEVHM;ZXM\2RRI:,4+$ !06R .I/)K2LM.DM=:OKK*^1-##'&,_,-@(.?S%+J
M":JEW!<Z<\4D:J4EM)FV*^>C!@#@B@"AI>J:/I^F2./MENB7'E317&^62.3'
M0]3C'/I3O#GB6#68%C>3-X6D)58F5=H8@<D8Z8[U<T6PN+)[R[NWC-Y>3>;(
M(L[$  "J,]< =:LZ=8QZ99"UA=VC#N^7/.68L?U- %#4V8>)_#ZJS!6>?(!X
M/R#KZUBG4;S[#HATR )'-J$B-')<M\Y!?Y2<$[3@GVP!717EC+<:WI-XA3RK
M1I3(">3N7 Q62NA:C;Z1I\<!MWN[.^>Y"NY".I+<9QP<-0!8N/$%Q]JO([&S
M@FBLFV3-+<B-G<#)5 1SCU..::WB2>YO;2VTFP6Z^U6@NU>27RPJ[L'/!_\
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MYG74+E"H'^HB/\(_O'W-;@44@P.*>.E:QCRJQSSFY.[#%%%%42%9U[_Q\?\
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M0!S5E*=7\6KJ-M!/':V]HT+2RQ-'YC,P.T!@"0,'GU-)XK@O(IK/4-.A>2X
MDM&"#)"R# 8^RL%-=-10!QECHTMGXD@TJ.W<:9;/]O20CY2WEA-N?7=N;%0)
M;W-OX9LI7MI_]&UEKB5%C)81^<_S;>I&"#]*[JB@#GM.C:7QCJ%[Y+B*2RMQ
M'(Z%<Y+DCGOTR*Q],L[F.'P\K6TJB'4;EF!0C8I\S!/H.1^==S10!Q0L)AX%
MU^$6LGG37%TZIL.Y\N=I [\8Q786V1:P[L[MBYSZXJ6B@##MH91XVOYC&XB:
MRA4.5^4D,^1GUJ;Q)9O>:+*T.!<VS+<P$]G0[A^>"/QK6JAJNF_VK:_9FNYX
M(6.)5A(!D4CE22,@'VP: .2GLKO6/#%UJ\44OGW]U%=>4@!?R(V&U0#P3M&[
M'<FK,/F.;W5+";4K[4(;)XXEN[;RT))SMQM7<<CI78QQI#$D4:A8T4*JCH .
M@IU '"V/GWGB/3;H2ZG=*MO.)9;FW\I$8J/E5=HQ^O:M7P])'H7@.TFNH9(A
M!!ODCV8;))XQZDFNEJ.:"*YB\N:-9$)!VL,C(.1^HH >IW*#@C(S@]12T44
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M37:)B>9561LGD+G''XFHI]+L[F_AOI(S]IA4HKJY7Y3V('4?6M86+]ROY_\
MUJ7[$_J/S_\ K4 8_P#9%C_9L&G^3_HL#(T:;CP5.5YZ]:AO/#VF7US)<3V[
M;Y<"79*R++C^\ <-^-;WV)_4?G_]:C[$_J/S_P#K4 4?)B\CR/+7RMNS9CY=
MN,8QZ8K*3POI"","WD81,&B#S.PB(.1MR?E_"NC^Q/ZC\_\ ZU'V)_4?G_\
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M6@!:**0L%ZD#)QS0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ Y
MHYHHH 3%4[^P%\L(W[/+D$F<9SCM5VBDU?0:;3NBE_9X_O\ Z4?V>/[_ .E7
M:*GV<>Q?M9]RE_9X_O\ Z4?V>/[_ .E7:*/9Q[![67<I?V>/[_Z4?V>/[_Z5
M=HH]G'L'M9=RE_9X_O\ Z4?V>/[_ .E7:*/9Q[![6?<SY-,WQ.@EP6!&<=/U
MJU:VXM;6*!3D1J%SCK4U%-12V)E.4M&'-'-%%42'-'-%% !S1S110 <T<T44
M '-'-%% !S1S110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %Y IX# 2(  A$! Q$!_\0
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M2]X=H'6OXN\/]/MA/TA8?TJ+_A,-"7A7=_\ MFW^%<J=+9?^8@@_X&HI#IX
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M:G#XJ\'ZYX,NW (C9X"W.$?J0/\ 9?#?\"%5/C=KL6F1:-X1L<""UA6:11V
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M^^C:G_X!R?\ Q-/F7<7++L4 D6?N(/PS3R(0.Y]E&*L/H6O9R-%U/_P#D_\
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M:,>S'[WT;\Q6M/%)Z3/+QW#,H)SPKOY/?Y/K\['O&:*H:3JUCK=A'?:?<+/
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M\B=&O77)/^XIZ#W/Y#K7EUQ<37=P]Q<S233.<O)(Q9F^I/)KEJ8J,=(ZGTN
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M(XD+-^0KKM.^%?BB_4-);P6:'O<2\_DH)_/%<WM:U3X?P/H?[-RK!+]]:_\
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M^.$5U6E?&6QE94U73IK8GK) WF+]2."/PS7,7WPC\2VJEK<V=X/[L<I5OR8
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M0Y/>CL?:Y3G,<8OJV)2YG]TO^#^9ZYX.\7VOBO3?-0"*\BP+B#/W3ZCU4_\
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MB=#<,.H_W1W/<\>M>Y1Q)#&D<:*D:*%55& H'0 =A6%'#\_O3V/9S?.UA?\
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MKK_AEXMO=;TBPL+S2=81XK%7;4[R,^5<L,#*N?O$YS] :SG1E%-]$RE-/0]
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M04445L>4%4;W6=+TZXAM[[4K.UFF_P!5'/.J-)_N@G)_"KQZ5X0VF6/B2_\
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M;ZJ*Y.YMIK*[FM;A=D\#M'(OHP.#7T1X&\-_\(UX:AM9%'VN4^=<G_;(^[^
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M/2J>HZA;:7I\][>2B*W@7>[GL/ZD] *!I.326[./^*GB!=*\,-81/BZU',0
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M6F3C6K@#T,*_XU/!\&-)4@W&J7T@](PB9_,&E["L_P#AS7^V<JCJEK_@_P"
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MS%1$HD&7W,5&/7)!'UK';P9-/ID=E=ZL95MK1K.T*6X01*RA"S#<=S[/ESD
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MH **** "BBB@ H-%% '/7_BN*QU.2Q_LZ\G:.2*)I(O+V[Y1\@Y8'DC&>@J
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M6C);3J8KTR KPP#(%R KN -JGD9KI[-C%X]EW0WQ,E@D<DS6\WE&4$L<.5V
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M)IS/)<LNU)FMI5S&0>$WE0.W(QWI+B3Q1-8SRQ0ZLCC[-Y<'"M*1&X==P/R
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M%I<Z9'#++-!$?+NO, $L<D@.=@S@(!CWZX S3MO&EQ<2QS1VI9KN*V6WM7G
MC6222522X3<!B//?L /5^\+0UO\ A&YTU<:A!>QJW]H-=E&A)!1H5B9.&'/R
MY#>_0UT58WA6^NM2T"*ZO'W3M+,K'C@+*Z@<  X  SWQ6S4L:"BBBD,****
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ME)"N\:GH3@CS!UX/;/-.P&S10**0!1110 4444 %%%% !1110 4444 %%%%
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MT,:J5+)DL1$T6<YZ%6S_ %YI!X9A5X668@1@(R8959=L:D85AS^Z7KD>QXH
ML31Z/Y=I;/.D:PN(+=8[ED*MMX4%2#G;VJ<QZ;97,LS2112E2S[Y<;5)&XX)
MPN3MR1C)QFJ:Z-#97%O.MRD;(8D7<@ <@R\=1R?-;\1GGI3[_1H[F6287!AF
MDEC=&Y'*J5 .UE)&">A'- #[BVTX?NMS&2&,(L4<YW1@C:"%S@'!^]C-2O%I
MEQ?)(TD37 8(%6;&XK\P!4'#$9W#(..M9,>@R"^$*KY5G$&*.47))*' .XDC
MY,<@8&!SQBXGAVW16 ?!98U+*@!^21I.ON7/\Z- )XX-*2*5!,CK<_N',EP7
M+XR-F22>"Q&!T)/K3Y;?3+B9KN1HG:WPLC^;PFW)&X9QQD]>F3ZU0A\,116C
M0M/N8P20B3:2<,$ /S,>0(UZ8'L,5;32I8[.Y@2\*&5]T>Q2%C&<X'S9P>^"
M.O&V@ AL])B:#R716QYD;+<-N90JCKNRRX5..0<"GI::8^R6,QGR\;724\;"
MW<'L78'_ 'B#5-/#42VQB-P6<G)D*9)_UG<G/_+0]_YTLOAX%Y6AN1$)0R,O
ME C:4B7 Y&#^Z'/N>.AH EO[O2[>.6:;;)^]S)Y9W$/$ID&<'@@1YQ]*D&EZ
M6J)"J@*Q&U/.;#!>B8SRHY^7[H]*HS^&#<27+S:A(S3 KDJ3M!29>Y_Z;=L#
MY1P,U;L].DBOIKDJJ*T[%$< E4PQ.,="SLS?0@<=@"I;P:19PLCK+.820\OE
M2,I894J#R.KL-H[D]P:=%%H2[KH(^8HVD8R>:2HC9=QP>X,:>YVCK5LZ0S03
MVC7"-9RNTGEM%E@6?>1G."N2>,=^M5Y?#-K-%+%(4>,Q2Q0AH@3"'.>"?0YQ
M[8]* -I&5URK!ADC(/?O3JC@B,494E3\S-E5V]23^?/7OUJ2D,**** "BBB@
M HHHH **** "BBB@ HHHH *J7C,L]D%8@-/A@#U&QC_2K=4=181M9RMPB7 W
M'T!5E!_,B@"26]6!V#PS[5ZNL99?TY_2IXY4FC62-U=&&593D$4^J&FXS>&/
M_4FX;R\=.@W8_P"!;OUH M0SI/$)(SE22 <8Z'!_E4!U&(NRPQS3[#M8Q)E0
M>XST/X57M?-_L&7R,^;B;9CKNW-BK=AY)T^W-OCR?+79CTQ0 Z"ZBN59HFSM
M.&5@593Z$'D4RWO8+J:YBC8^9;R>7*I4@J< CKU!!!S47!U\>7VMCYV/]X;,
M_P#D2J-]_P 2SQ':WXX@O@+.X] _)B;\RR?\"6DW8TIP4[KKT_KTN/UB>6:^
ML=+MI7CDG?SIG0X*0H06Y'3<Q5?H3Z5H"]@_M V.\_:!$)BNT_<)QG/3J*R]
M _T^6[UMN1>,$MCZ6Z9"D?[Q+/\ 1AZ4J_\ (]2?]@Q?_1K5*?7N:R@M8?RI
M_?I?[MOD:-_J5KIL:/<R$>8VR-$4N\C>BJH))XSP.U4H_$-KYL<=U!=V?F,$
M1[F$JC,>@W<@$]@2":HZ@EXWC2W,$]M$_P!A80&XA:0$[_WFW#+@X\O/7C\:
ML7VF:SJ-A<65Q>Z8T,\9C<?8I.A&/^>M%WK8:ITXJ//U5[WV^5M;>?X&\.]+
M4%G')#:0Q32F:5(U5Y2,;V Y/X]:GJSE:L[!1110 4444 %%%% !1110 444
M4 %%%!Z4 -D++&S(F]@"0N<9/I7-1Z;JUI#Y:,LC22I.YA)C5I"#Y@8E\A2=
MIRN><_*>0=7=JWF'Y+3R_/P.N?*]>OWO;I_*JZ:A=S>(/L8\L6\;R[B#AB%2
M(@<@YYD/IT'N"Q%<Q:TD%R(DE9G\Y8RTP#;F V.?F( !!^[CKG:*?]@U,S>9
M]IG_ -9(^WSOE_UV8^/3RR1CIZY(!#%UBZBO)O-0/F9HHHD<;<>9'&"25!!R
M^3U[^PJRNL7$FH16HM8T)N#$X>1@P7:Q#@;<$'8<'.#Z@Y -0*<%KK:>29WE
ME<3J9 'VQG'WGR)-V#V&,<?<YS6A+:R/K\%RL!5(P0\C; ""I'!'SYR1PWRX
M&>H%5HO$$NYUFM8QY<K*Y27.$\YHE(! W'*G(_7) JQ<ZQ-%?-:PV8E/F>4&
M:4*"_EF3G@X&%(SZXXQD@U SYK+53=32B.1WQ(F_S\ JTJE=@#*1A!@\KDCO
MU+8DUB:WEMY+B1YH8(C(86!/G,JADSN7IM9C\P.)1C! JU_PDL3RA(;<R>8J
M-%\Q7.YT0AB5P,&09VENAZ'@PQ>)'5)4>W::=;N2W4*#R0TA P%)P$3&[')^
MA(-0+-[;ZI)#:B'<KB @A)N(Y_EVLQ."Z#YLCG.?NGLU=+EBL8HU$Q9-0>X*
MK<-DJ9&/7=Z$$C..O>KVFWLMYYQFC2(K*R(H?+%1CDC P>><9J_0!RHTS6K:
MTM;:WGD$2PQ"3#[F60*0Q7YE 4$*<9QUX/(JS/:ZP);8PNS$W;R2NTQP(_-&
MT8W 8\O/8\XXSR.AHHN%CDK9]5^P6TRSS++<+$B++('+NRL&<#L%!1\<?ZMN
M!G)U-1LYYYVAB4'S8%B5Y 6"IN_>YY')7:.N3^%;-%%QG/0V^LV\:6R[2JB.
M-)%8!%5';D@DGE"GKT/3C+8].OR\4X-S%,GE!_,N V\B0&0\'E2N[ X'/0'&
M.CHHN!S-I9ZK"UK=7OGW$\+-O2.3:"Q498#>05)'0XQGA16AK5M)=K#"MF9X
MR3YCH$+H..%W$8)_O#)&.F2"-:BE<#FSHTLHO4DMHP)(9T9LC%RSON0GOA1D
M?-_>('')MW6G0R7#7-U:H\45J5^107=F!5O?(48'^^:V:*=P.<U+3]2N)+*5
M$22X@B4HQ*[/-R"WF?Q;<JN"G/7.1Q3[[3+R\@39-/$PT^2!BQC+NYVX#9##
MG!R0:Z"BBX',R:'*+F>9X6E2<21ND1174$+@@G&X?)@JQ(Y';-7;2&_M].F6
M.!8[CRB(5^4)NW-M+*O ;D%B.#VK9HI7"QS<&FZE8_9K6$E[>&8E3&=BE#@D
MME\[@V\@?,#G! X(?:Q:Q%'"C)*P9D#,\PRH$@+%@6;DKN&%)''\.<#H:*=P
ML<XFGZPD09;N7[0(HR#)-N02'<)"1W&-G'3C(P<DNLK;5DFLVG,[*'8R*\F%
M08'<2,6YR0#N'/\ !VZ&BBX6,6^TQY;F\FBA1O.2WW D9E\N0EE.?5>.>.?K
M4;65[%I4$,,;JOVB1W@AD",(V+E5#=/E)3(![$<C@[U%*X')B/6-.19&^2*"
MW11$LN?.D7RPJ+EB,L/,7A5Y(^]P:T[*VU&&]F\Z5Y5,"@2NWR^9@9VJ&/&=
MQY (Z9(QMV:*=Q'.VNFW\EU8RW1FVP2J["2X+$OY<BNPP<%22F%XQSP,XJ:^
MTN:XUDRCSA"ZQ999R NTON &>"0R\@9Z\@UN447&<Q'9Z\599KJ0/Y"*KHPZ
M[5#9.[&[=O.=G<<]@V[35K>[8@3"T:1(PL<Y+. Z@89F."4W9.%YZD\-74T4
M7%8P+$ZBMZL$DC2K$$DE'F E2V5"$]P%^<]R1GN,[]%%(84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %-=%D1D=0R,,%2,@BG44
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %Y IX# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#PHH#T- CX
MK4CTB.3[L\I^D=3MH\4:Y9IF/N HKK]C+L<CK1[F)M*G/-,+9-;GV2VX C ]
MRY)JS'IT)7(4+[D4_8/N+V\5T.<6)W^ZC'Z"I5M)VZ1-6\; $X6X4>RJ6J9+
M QC=]L9/<@+_ #IJAW$\1V.=-C=#K _X#-1FVG7K#)_WS73>3"#S>S/_ +BY
MIXV1'(64C_IKM7-/V"[D_6'V.2Z'!X/H:6NHN+Z!UVO!"P';&:I,8)3E;!3]
M%Q4NCYEJNGT,3-'6MU#(G^KLT!]D'^%2BXO^BP!?^ "CV/F'MET1SXC<]$8_
M0&G>3+_SR?\ [Y-=$MUJ>.K ?\!%3I/?GJ5_%_\  4U17<EUWV.9%M<'I!*?
MHAIQ@N$^]!*/JAKJ!<SJ?WD\"?5__KT[^U(8_OWB-[(F?ZU7L4NHO;-]#E#%
M(3C8X/H0:4V\X&?)?'^Z:ZK_ (2&%/N1/*?? I__  D=\ZXAL8A[MN-'LEW%
M[5]CD!%*3_JG_P"^33Q;SGI#)_WP:ZAM3UE^=T,(]HP/YU$;Z[ZRZHV?1 #1
M[(?MCGULKM_N6LS?2,FIAI6I8S]AN />,BMEM49.L][(?^NFT5 VL7!/R!1_
MOLSG]31[-+J+VC?0H)IFHDX^R2?B,5:CT2_/)\J+_>DQ_*D?5+]^//D^B(!_
M*H-]X^<M+^+4TD@<F=!9MK>GX$6O)&!_")68?D1BNHL?%U[;@?;YK6=!_$@V
MG^=>="WNI.6=@/4DTXPK&/GO 1W"FK3,VDSU;_A.M,"_ZN9F_NH5/\R*AD^(
M5G&F5TV]+>C% /SR:\NW6PZ3W&?J*>EQ&O2ZN%_6G<GE/11\3K?.#I,W_@0O
M^%7+?XD:;*VV2RNH_H\;?S(KS/[1;.-KS[Q_M0#(_$4OEV$HQY@'_?0_GFBX
M[(]DMO%NDW &V:13Z21$?RR*T$UFS;&)UKPF2SMU4-%.0?9J1;4L.+Y/HTF/
MZT[L5D>_)J-LYP)E)JVDH8?*0?I7SQ]BN.JW:D^TW/\ .I5M]4C(,<]QGL4D
M;^E%V*R[GT,'(ZTX2>]> QZKXDLONZK?1@?WG8C]:O0^./$T(VG58G_ZZQ*3
M_*BX<OF>YB2GB3WKQ.+Q[XA P\VGR?[_ !_(BKL/Q!U$ ":RLY/>*<C^IIW!
MH]A$H]14@DKRR'X@6A'[^RGC/JLBL/YBK0^(&E#I]I'_ 'S_ (T$GIBRT\2F
MO.8O'FEOTDN1]%!_D:D_X3G2PVUFNQ[F(_XT >BB;WIXF]Z\['CC2,#,]S^$
M+&IH?&>CR-C[7+'[R0LH_/%%AW9Z )J<)JXY/$>F-C;K%FQ]!<*3^6:MP:XD
MQQ!-YY](QN/Z4K(?,SJ/.I?.]ZYM]3OE.U=/N21ZQ$?TJ-KW7I/]5ILJY]86
M-*T1WD=1YWO2>=[URID\3GD6DH'_ %[G_"H)KGQ*HYMYU]Q;'_"E:([R.P,U
M-\ZN#;5-?B)#&X!]X?\ ZU1?VWKBMG?*?8P\?RJK(ER9WYFIAFKA1XDUA#\T
M*N/>$BK*>+)L?O;"3WV@T60KLZ\S5&9:YZ#Q+!.^PQ21D_WQ@5=&H(PR,X]J
M8C2,OO3#+6>U\G^U^51G4$]#0!H&2FF2L\W\??</PJ-M1B'<G\* -$R4PO67
M)JL:_=#-5635I#]U0/UH VS)Q49>L(ZG,3]\?]\T?VI+TRA_"@#:+TPO61_:
M<O=5-,?4Y".%4&@#7+TPO6&]]<-_RTQ]*A:YF/\ RU;\Z -\O32]<\UQ*>LC
M?G3#-)_ST;\Z .A+TTO7/&>3_GHWYTTW,Q&/,;'UH Z$O3"]8 NIU'$K?G3&
MNIB>96_.@#H"]-+USQNIO^>K?G33<2_\]&_.@#H"]-+US_VF7_GH_P"='VN<
M?\M6H WB]-+UB"_N!_'GZBI5U+^^GXB@#4+TTO5$:A$W4D?44X7,3=)%_.@"
MT7IN^H?,!Z&D+^] 'G#O: X:65_96)_E2![0#,=E*Y]9.*J-+= ?*BI[D#^M
M5Y#<2??N0/8-4.1JHW-,W,BCY8H8A[MBJKW1W9>\A'LB%C_*J/V56Y:7)_$U
MN:!I]K))-YL*2@*,>8@;'/O6-:LZ=-S:V.S X)8K$1H1=G+_ ";_ $,YKZ+&
M#-=2^V @I!J*(<QVD8]W;<:VM9TVV7[/Y,$<?WL[% S]W&<502PB _U8/UHH
M5'6@IK2X9AA%@L1+#RU:[>>I6.JSL/N0J/09J%KB9SD+$/HF?YUK+9P+SY:G
M\:E5(U^[;@_K6_*^K.+G2V1BJMVWW6Q]!BITM+UNMSMQ[UJX8#Y80/QI KH?
MO1(?< T<J%SLS_L-RWWKML?[Q_I4JZ0/O/*[CZG-7&N%7[UXF?15!-/348DZ
MSM^/%/E0<TBB;"%1_JYS]$)J-K!6^[;S,/\ :(6KLNH6I;+32'_=-0_VI:J?
MDBF/ON-&@ES%?^RWZBS7_@3YIRZ9.?\ EG GU!-61JT1Z6;L?<FI1J5T1^YT
M\CW(-%D.\BL--N0,B>-1[#%*-.<\O=$GT )J5KK5)>&V*/3"U(D.H-R]P /9
ML?RIV%=D*:9'G[LKGU\O_&I?L"="S1CT+@?RJP+*9ER\Y<>^3_.F&&TBYF:+
MZ-@4"U*_V*T4_,P8_P"]NII6%/N0I]2P%/:ZTY#@0I)Z;%-1BZ4-E+5E3K\P
M"_K1H&H,[L-JA!].:8L,Y.0\GX "GB_0-EBF/0.3_(4?;[,'/D*Q]<M_C1<=
MF1/;?,1,)G(]6 IT=FIY2T!]V8G^E$FI0,,+:J?]XG_&F?VC,0 L4:J.@R?Z
M4M U)C;RJ,"&%?\ /TIHM9O2,?@3_2F?;KH]D'_;1_\ &D-Y=_WT'_ V/]:+
MAJ6DM)F( =,^FTG^E78M.O&'^MB5?4KBL87]TIS]K"?[H-+_ &M=+_S$I/P2
MBZ!1;-[[#(G,MQG_ '0*0I;Q_>>Y;_=A!_I7/OJ]T>FH71^C8J(ZI>M_R_71
M_P"VAHNA\K.C-Y;)G;;WY_[9+_6F'4)CQ':70'^UL']*YQKN\DX-U.?JYI-M
MU)_RU8_5Z5PY3J8I+UN397FT]T9#_2K,:QX8RV&J9]1#&1_.N/%K>]G;\)/_
M *]/%O?C@2R_@YHN^P<J[G;1K9[<M:ZSGH=D" '_ ,>J>";3[<$K8:QN[Y@C
M(_G7GS6]Z#RTN?<FF^1>^LN/]XT<S[!RKN>CG4_+7$>GZD5_Z:6J'_V:HAKD
M49)>PN5]?] !_P#9JX!8K\?=:8?1C4JR:Q$/EN+Q1[2-1S>0<J[G>#Q58Q\>
M=<P'WL%%.7Q/HLA'G:I=$=P+'!_/=7##6-;C&UK^[QZ,Y;^=1MJM\WWY$?\
MWXU/]*=PY3TZW\3>%47"ZSJ<1]?LW^ JT_B#PI*H*>)KV-N^ZW!S^&VO)/M\
MI^]%"?\ @&/Y4W[2'ZP)^!(HW%8]A3Q!X>CY@\8,),?>DTY6_I4T>N22,&@\
M8Z5(!T\VP /ZUXR'!_Y9@?\  ZD4 X^1A]&I<H7L>ZVOBVZ@(>?7M%G"\9-N
MRX_(UOP?$&PEC^;6](B*CD%9/TKYUAC9B,/*/^ $UJ06<SKG[0Q'I]D9_P"E
M1*C&1<:TD>^?\)]I00%==TV7G!"N5/\ X]BLM_BI:!RJ7NGD=B23_P"S5Y%#
MIMNY DCGF;^['9E3^I%61X>TR8'=:W4![EBO'X%Z2H0ZC]O/H>J_\)Y+>@>3
M=Z/]#.03^IJO+XMU.(9SIS#U\R0C]%->;V?@S2[I\"[!). JH6(]SLW58N?
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MB8Z[=+$HB\T%/,(#/@$9( R.O<5HP_##PSX=\-PZGXWU>6TEFQ^[@.W82,[
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M0N]6L[614$<]Q'$VU<'#, <?G79_%CPEIG@K5-*@TPW#174;O+Y[[R-K*.,
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M,\O0<4SSY?6IM$J\AIC<=5--P>]2&>0]6%1[V]:3MT&K]0R:4,PZ9'T-)O\
M84;\=*5[!8?O?U-(6;VI/,8^GY4%F/I^5.X6%$A':I!/C_EF*ARWH:7/KG\J
M=V)I,Z,RA1\UV@^@%1FZMU.6N'/T%8>'[&E"M6OM7V,?9+N;!U*!/N^:?P K
M7T&^%W-,H1@%4'+-GO7(A#71>%5VW%QG^X/YURXV4G0E_75'L9!"*S*EZO\
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M?QM<WNCI;R:??SF1YC,!]G8_ZS<#R?FW?=SUQQBLY\KJ-29K#F]DG%%?XO\
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M7/C3I6Y9Q2C3@/O.:+2>Z"\5U/2_A)HVA2ZC%XEU/Q):6,MA=,J6<TB(TOR
MA\LV<9<CI_#UK"^+.N6'B'Q]=76G3">VCB2 2J/E8KG)'J,GK7+1V4&?FW&K
MBP1*/DC_ #J52;ES-E.LE'E0MAXO\3Z9:K:V&MZA!;K]V-)F"CZ"J.HWVK:S
M<_:=1NKF\FQC?,Y<@>V:U%.P?*%'_ :5I+C^%PH^HJ_9+<AUF5=)UCQ)HBO'
MI6I7UFCG+)#(5!_"C5+[7]<D1]6U"ZNR@POVB4L%^@/U-/EW8S+<D_C4#-!U
M,SFCV<5J+VLF3:1?ZUH4DCZ5JMQ8M* )/(E*[L=,TZXN-2O-3&J7FJSR7W!^
MTM(?,X&!SUXJI]HMU/1FI&O8U^[$H^O-'+!:ASS9TY\7>)6A,;^*-5D4C!43
MGD5C+#%O,FR1G)W;G.23ZYK-.I2#A3CZ"HGO)'^\Y_.FG!; U.6YV?\ PF7B
MA;5;5-9O5@5=@43G[O3%5I-<U"[T^"QO-0>6U@_U4,LN53 QP/I7(%]WWF-(
M/+[L:FZZ(?*WNSI#>01?Q0_@<UHVWC_6-/@6WM=9O8H5Z)'(<#Z5Q@,']XTA
M,9Z$TW*X*-NYT5]XLFN[AKB>:YN)VZO*^2:=/X]UBYT^/3YYY9K2(*(X9)"5
M7:,+@>PKFMJGI2B,'O4W;*LD;\OCS7Y=-733>O\ 85 "P$Y08.1Q]:AD\:^(
M9-,_LTZI<"Q_Y]PV$Z[NGUYK)$*'JPJ1;:-OX\4N60<T47=/\6^(-),IT[5K
MNU\W&_RI"-V,XS^9_.JVF:YJNC7;76F7L]I<,AC,L+E6*D@D9],@?E3H["-O
M^7E%^M6!IT:]+N$_C3]FWN'M$MC/N+^\N[V2]N)I)+N1_,>8L=Y;USZUM'Q[
MXN:$Q'Q%J9C(VE?M#=*9'9QKR9[<CZU<A>QBX>&!Z?LB?;,Y<22B;SQ)()MV
M[S QW9]<]<UNW/C'Q5J%I):7/B#49;>1=KQM.2&'H:VH+G1/X],5C_LMBKGV
MW2@F(]('_?0I^S0>V9REWKNO:GIL>G7NKW4]E%MV02R$JNT8&!["I+S5];U7
M3X-/O]5N;FS@*F*"1R50J"HP/8$C\:VI[NW.?*TO:?4XJ&-KN=ML=O#'GU%-
M4XKH2ZLGU,!;&0#.TD?[M;*>+/$-MIPT]=9OA9B,Q>1YAV[,8VX],5IKHNIR
MIE[D*I[*E:5CX(ENE#R0:A(#_'&AP?TIM1ZDJ4NAR8\2ZLVC#13<SOIG'^B%
MB(_O;NG^]S]:MP>)M0MM%.DF>8::00;7S3Y9!.X\?7FNHN?!,5L &MIQGIYH
M(S6SI/PCEO[9;IX8%B<94-+R1^ -)N"6I2YY.R.!T_QUJ.D0R6^F@P02G,B1
ML0'.,<_A5O2?'NIZ,6?2])CA=UVL\>X9'H<5WEY\';B-L6:(<]PXX_.L:[\"
MWFES&"ZU!86 !Q@=*$X2T3!J4=6CD[KQQX@GN#*;2WBD9BY81G).<YSGK5A_
MB1XZEB$:ZL\2XQ\@ /YUT\O@BPA"-?7['>NY?G&"/PJ2'0/#,>%\V-B.Y>GR
MI[BYVMCSPZEXAN+CSY-1N#-N#[R_.[.<U8OYO$FN212ZE?W5VT0(C:5R=N>N
M/R%>E+I>AVZ;HWC_  -9MY?:?&2B,O'I3Y4+F9QFK2ZYK?E?VQJ-U>F'<(_.
M);9NQG'UP/RJU>7&M:TL*ZIJ=[=+$28_/D)"YZXK?BU&T8[1&[D_W5S5ES:%
M-SVDQX_B %'*NP<S?4PX&OETEM).L70TYLAK5')0Y.3Q[GFG6&GR:7<K=:9+
M=P3CI)&Q4_I3[S7H;/Y8+(@CH2!60_B74+A_E.Q?J!19"NSKWU/Q)<PM%<ZA
M>S1-]Y9)C@U39C"H#!$ [ 5@_P!LRB/]]=,#[,:SKG7(P>"\GUHLEL#;>YTL
MNK10@[<,WYU@WVKW\[;8591ZXQ67)X@?HD8'U-4Y-9NF_B 'M1S(I0;-+[#?
M77,L[ >F:1M.CB^_*2?]ZL5]3G;K(WYU"UX[=6)J?:1*]E(VI&CB&$(_$U2D
M8NV<_E6?]H'O2?:3VS2]K$?LI&@&V4AN@.K8K-::1NIIF_UJ76[%*CW-5;N-
M3S@TY]1AQQ$*R-Y[4AD:I=9E*BB^U\I/$8 IGVP?W15+>WK2;CZU/M9%>RB7
M3>'L*8UU(?2JF3ZTN3ZTG4;*]G%%CS7([4;W]15;)]:7)]:7,'*;'VQO[WY4
MW[8_8G\Z!I&I]M-O\_\ 7L_^%']BZF?O6%]_X"O_ (5M[1F7LD--W(>Y_"I[
M+5Y;*1VC"LS#!W@D?H13/[&U/&/[.O /7[,_^%/31-2[:;=G_MW?_"IG::Y9
M;&E&<Z$U4I.TELPU#4Y=2\OSA&OEYQY8(ZXZY)]*HC:3C)S5TZ/JJG_D%WQ/
MM;O_ (4T:5J0.7TN^S_U[/\ X5,5&"Y8Z(JM5JUYNI4;<GU*P49Z$_C01C^$
MXJ=M*U-FXTR^'_;J_P#A3QI6J;<?V9?G_MV?_"KYD9.#*V_T-&]C4XTG5@?^
M05?8_P"O9_\ "G?V7JA_YA-Y^-N_^%',@Y'V*P)/45(L8;J/YU/_ &5K&>-,
MO!_V[O\ X5(NE:N?^8?>?^ [_P"%4FB'&1 (0/X#_P!\TX(/[JCZFK:Z1JG?
M3[W_ ,!W_P *E72=0'73KW_P&?\ PJU8S:D4TC0]6'_ 5J011_W7/XXJW]@U
M(<#3;S_P'?\ PH&GZC_T#[S_ ,!W_P *=T*TBN(XL_<0?7FG%(0.>?\ =%/?
M3M3'(T^\_P# =_\ "J[VFKC@:9>_^ S_ .%)R2ZC4)/H3J(!_P LS^-+YMNH
M_P!6@K/>QUAC_P @V_\ _ 9_\*B.EZN?^8;?_P#@,_\ A4NK$M49&D;J,?=*
MK3#=QX^:7-9YTK5_^@9??^ S_P"%(=)U;_H&7W_@,_\ A4^V17L&76NX.F]C
M]*A-U#G^(_4U7_LG5O\ H&7W_@,_^%']D:M_T#+[_P !G_PI>V'[ L"]@7HF
M?K2-J /0 ?A5?^R-6_Z!=]_X#/\ X4O]CZM_T"[[_P !G_PI>V'[ D^VMV8C
MZ"FF[8]9#^=,_L?5O^@9??\ @._^%']C:M_T"[[_ ,!W_P */:A[%"FY!_B)
M_&FF?/>E_L75L_\ (+OO_ =_\*7^Q-6[Z9??^ [_ .%+VK8_9(A+YZM^M)GW
MJQ_8FJ?] R^_\!G_ ,*7^Q=3_P"@7??^ S_X4<P^0J_C2'CO5S^Q=4_Z!=]_
MX#O_ (4O]BZI_P! R]_\!W_PHN%BEFDZU>&CZH/^87>_^ S_ .%!TG53TTN]
M_P# 9_\ "BZ"S*6,]J3:*N?V-JQ_YAE]_P" S_X4HT75.^EWW_@,_P#A2N@L
MRF%%/"^U6O[&U/\ Z!=]_P" S_X4?V-JG_0,OO\ P'?_  IIH&F0!4[DTN8E
M[9J?^Q]4_P"@9??^ [_X4HT?5/\ H&7W_@._^%5S(GD97\R+^Y^M*'A[J?SJ
MT-&U0_\ ,,O?_ =_\*D&AZD?^89>_P#@._\ A5)D-%+,!Z _G2A(O4BM!/#F
MJ/TT^[7ZP/\ X5,/"^ICK9W7_?A_\*HDR_*3LQJ1$8=)%'UK57PUJ'>PO3_V
MP?\ PJS'X;N!]_3KW_OP_P#A35B7<R$A)ZW./I4J*4/_ !\''UK;'ATJ,M87
MO_?E_P#"F+8+;ODZ/?R ?].[_P"%.Z%9]BBEQ(.(\R&I1J6HVWS(JI]5J[+.
M57;#H6H(?7[*W^%1*AGXN--U,?2V?^@HYH]PY)=B'_A+-;3@7" ?[@KH-*^+
MOBW3+1;6*2TGC7A?.@)*_0@C]:Q_LUK$<II6I,?>VD_PICWMW&,0:'>X][5_
M\*F3@UJ7%33]U&Q?_$CQAJZ;)YX$CSG;' %'^/ZTRR\:^,+-U-OJ[1J#G9L!
M7\B*YZ:[UF3.W2+T?]NS_P"%5'_MML_\2N^_\!G_ ,*GFIVL/DJ-W.\F^)7C
M:3DZTL?M';1C^E8.HZUJ^MSK+J6JSW#H,*7(&![ 5S30ZVW_ ##+[_P&?_"H
MVM=</33K\?2V?_"DITUL4Z=66YU,$=N<&ZO6*CMO-7SJGARSBP%5G ZYR:X%
MM-UES\VG7Y^MN_\ A3/[&U;_ *!=]_X#/_A0ZRZ L.^K.EO/$MB['RHB!]:I
MIXI6!LQVRD^XK%_L75?^@7??^ S_ .%+_8VJ?] N^_\  9_\*EUF7[!&Z?'-
MZH_=00)[D$U4N/&>L7"D&Y"*>R*!6;_8^J?] N^_\!G_ ,*/[(U3_H%7W_@,
M_P#A4^UEW*]E'L,FU*[G;,DS,?<U$+N<=)"*G.CZM_T"K[_P&?\ PI/['U;_
M *!=]_X#/_A4\[[E<B[$#74[=9&/XTS>YZL:M?V/JW_0+OO_  &?_"D_L?5O
M^@7??^ S_P"%+F\Q\OD5OF[M03ZM5C^Q]6_Z!=]_X#/_ (4?V-JO_0+OO_ 9
M_P#"ES!RLJ$CM29JY_8VJ_\ 0+OO_ 9_\*/[&U7_ *!=]_X#/_A2N5RE+-&:
MN_V-JO\ T"[[_P !G_PH_L;5?^@7??\ @,_^%%PL4\FDJ[_8VJ_] N^_\!G_
M ,*/[&U7_H%WW_@,_P#A1<+,I4E7O[&U7_H%WW_@,_\ A1_8VJ_] J^_\!G_
M ,*+A9E'FC!J_P#V-JW_ $"K[_P&?_"D_L;5O^@7??\ @,_^% 692I*N_P!B
MZM_T"[[_ ,!G_P */[&U7_H%WW_@,_\ A1<+,I4F:O?V+JW_ $"[[_P&?_"D
M_L75O^@5?_\ @,_^%*X[,^YJ*6BL382BEHH 2BEQ10 E%+10 E%+10 448HQ
M0 448HQ0 E%+BC% "44M% "44M% "44N** $Q2XHHH ,4E+1B@!**7%&* $H
MI:* $HI:* $HI:* $HI:* $I:** "DI:* "DI:* "BBC% !111B@ HHQ1B@
MHHQ10 4E+10 E%+10 E%+BB@!,48I:* $Q2XHHH ,4F*6B@!**6B@!,44M%
M!24M% "44M% "44M% "44M% "44M% "44M% "4N*** "BBB@!,T9I:* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HI,TN: "BDS1F@!:*3-+F@ HI,YI: "BBB@ HHHH *
M*** "BBB@ HHHH **** "BC-&: "BC-)F@!:*,T9H **** "BBB@ HHHH **
M** "BBB@ HHI,T +11FDS0 M%)FES0 449HH **** "BBB@ HHHH **** "B
MBB@ HI** %HI!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %&*** .*U=-3M=:DTBTN9?)UEPT<AE.;;',NWGC*
MC@#UJJD$\_C*_M,:C/;0>0H:._,:P@J>2"WS9QV]/>NWEL;:>[@NY85:>WSY
M3GJN1@_I5.X\.Z3<WK7DUFC7#$%GW$$XZ=#0!0D\W5-9U)H[M[:"S@^S)*IX
M21AN=N>,@8&>W-<V\]U;Z?>RV-_>?V9<7-O;Q3RS%GP3B212>5!]:[A='L18
M3V1AW03NTDJLQ)=F.22>O6H8/#6C6T4T45A&(YDV2*22&7KCDT <X1?"U\0Z
M?::G<1PV3ADE9B[A3'N,88G(YQSV%0WEQ=W.G>';2%[JYFFM&DD@CN#$TF$&
M&,A/8GIWKK!H&EBP:Q%F@MV;>R GYF]2<Y-1MX:T=K6.V-BGE1DL@W'*YZX.
M<]AQ0 WPO=->^&M/N)+AKAVB&Z5A@L?>MBHK>WAM;=(+>-8XHQM5%& !4M !
M1110 4444 %%%% !1110 4444 %9/B*SN+K2G:SG>&[@/G1,KD E>=IQU!Z8
MK6I'571D895A@CU% 'G6HW=]>^%-1\0&>XA-U+'';PQS$>5&KA3C!X)(.36R
M&N-,\-7!CANX+ZZD$$,=S=^>P=N%(8$XZD_A6\VB:<VE#3#:(;('(AYQUW?S
MYJ*#P_IEM)$\-ML,4GFH-[$;L$9P3Z$_G0!SVNV#6IM;2SU.\;4"D<=I DQ5
M4"D;Y'QU!&<Y^E4KB\O!)?:H;ZX^UVVK):1PB0B-H_E^79TYR>?:NMO/#>D7
M]TUU=6223L "Y8Y(_.I3H6F&_2]-G&;E,8?Z# /U'KUH PX5U&/QO>PMJ#S&
M2P>2%#Q'&=X"C;TR/6J/A@ZFGB);6?[7OAMR=0,UR)4:0D;2N"=O?CCBNI&@
MZ8NH_P!H"U'VO=N\W<<Y_.K%GI]K8+(MK"L8D<R.1R68]R3UH LCI1110 44
M44 %%%% !1110 4444 (RAE*GH1@UQ-I%J3ZXGAR2ZG-M92FZ:?SCOEBXV(3
MU/).?H*[>JZV-JE_)?+"HN9$"-)W*CM0!Q?A-+B\U*:XN%OW2.YEVW#7W[OC
MHOE[LGKZ8J\NV^TW4=7N]2GLK6><$/&Y!\B/@!?3<<G(Y.16NGAG2(I6FBLQ
M'*VX[T=@06!!(YZ\U-/H>FW6GPV$]JKVL&/+C).!@8% ''V@OII-)TZ\N[R&
MRO)[B5%,Q$HB"DQHS Y! YQFF?:);OPQ;376I7QN TUO:00RE6N) Y".2,$X
M &2>.]=?_P (WH_V3[+]A3R=_F!<GAO4'.127'AG1KKR?.L(F$*>7& 2 J]<
M#!]Z .1OY+\1:FUUJ4ZW>E6$#Q>5*55I,99B!][)&*[VSD>:R@ED&'>-68>A
M(JF_AW2)3 7L8F\A0L><\ '(!]1GUK3QB@ HHHH **** "BBB@ I,T&N8UGQ
M;%:EH+$++,.#(>57Z>M5"$I.R(G.,%>1T<]S#;1F2>5(T'\3G K N_&>GPY6
M!9+AO4#:OZ\_I7$75[<WTIDN9FD8^IZ52EN88>'<9]!R:ZXX9+XF<D\5)_"=
M=-XWNV/[JVB0>^2:K'QCJI/!@ ]/+_\ KUR+:G&/NQLWU.*9_:C?\\1_WU6O
MLJ?8Q=:IW.VC\:Z@OWXH'_ BM.U\;V[D+<VSQ_[2'=^E><+J@S\T1'T-3QWL
M$G&_:?1N*3H0?0:KU%U/7[/5++4%S:W"2'^[T8?@>:MYKQ^.1XW#QN58<AE-
M=/I'B^: K#J&98^@D'WE^OK7//#-:QU.BGBD]):'=45#;W$5U"LT,BO&W(93
M4U<QUA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% #)21"Y!P0*<.@^E,F_U#_[IIZ_='TH$+1110,**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@",D^<@SQ@_TJ2HV_UZ?[I_I4E !1110
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MB1GY6 !&",#IP<9%,G0O6EW%J%C;WD.[RID#KN&#@^M#4EE9IIVGV]E$S-'
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M45?0 5YCX?MC=:Y:QXR V]OH.?Z5ZA7'BGJD=V$6C84445RG6%%%% !1110
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M!6ME\'7]3&[^/I^AV]+4<4B31)+&X9' 96!X(/0U)61L%%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>bivi-20191231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: 2.xfr; Date: 2020%2D03%2D10T17:55:00Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nanoantibiotics.com/role/DocumentAndEntityInformation" xlink:href="bivi-20191231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BalanceSheets" xlink:href="bivi-20191231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BalanceSheetsParenthetical" xlink:href="bivi-20191231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfOperations" xlink:href="bivi-20191231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" xlink:href="bivi-20191231.xsd#StatementsOfChangesInStockholdersDeficitEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfCashFlows" xlink:href="bivi-20191231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BackgroundInformationAndReverseStockSplit" xlink:href="bivi-20191231.xsd#BackgroundInformationAndReverseStockSplit" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/Liquidity" xlink:href="bivi-20191231.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPolicies" xlink:href="bivi-20191231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssets" xlink:href="bivi-20191231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/RenegotiatedDebt" xlink:href="bivi-20191231.xsd#RenegotiatedDebt" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/RelatedPartyTransactions" xlink:href="bivi-20191231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/FairValueMeasurements" xlink:href="bivi-20191231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/CommitmentsAndContingencies" xlink:href="bivi-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactions" xlink:href="bivi-20191231.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxes" xlink:href="bivi-20191231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SubsequentEvents" xlink:href="bivi-20191231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" xlink:href="bivi-20191231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" xlink:href="bivi-20191231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsTables" xlink:href="bivi-20191231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/FairValueMeasurementsTables" xlink:href="bivi-20191231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsTables" xlink:href="bivi-20191231.xsd#EquityTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesTables" xlink:href="bivi-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BackgroundInformationAndReverseStockSplitDetailsNarrative" xlink:href="bivi-20191231.xsd#BackgroundInformationAndReverseStockSplitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" xlink:href="bivi-20191231.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails" xlink:href="bivi-20191231.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" xlink:href="bivi-20191231.xsd#IntangibleAssetsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetailsNarrative" xlink:href="bivi-20191231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/FairValueMeasurementsDetails" xlink:href="bivi-20191231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/FairValueMeasurementsDetails2" xlink:href="bivi-20191231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails" xlink:href="bivi-20191231.xsd#EquityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails2" xlink:href="bivi-20191231.xsd#EquityTransactionsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails3" xlink:href="bivi-20191231.xsd#EquityTransactionsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails4" xlink:href="bivi-20191231.xsd#EquityTransactionsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails5" xlink:href="bivi-20191231.xsd#EquityTransactionsDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetails" xlink:href="bivi-20191231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetails2" xlink:href="bivi-20191231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetailsNarrative" xlink:href="bivi-20191231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" xlink:title="00000005 - Statement - Condensed Statements of Changes in Stockholders&apos; (Deficit) Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_IssuanceOfPreferredStockInPrivatePlacement" xlink:label="loc_biviIssuanceOfPreferredStockInPrivatePlacement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfPreferredStockInPrivatePlacement_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_IssuanceOfPreferredStockInPrivatePlacementShares" xlink:label="loc_biviIssuanceOfPreferredStockInPrivatePlacementShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfPreferredStockInPrivatePlacementShares_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ConversionOfPreferredStockToCommonStock" xlink:label="loc_biviConversionOfPreferredStockToCommonStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviConversionOfPreferredStockToCommonStock_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ConversionOfPreferredStockToCommonStockInShares" xlink:label="loc_biviConversionOfPreferredStockToCommonStockInShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviConversionOfPreferredStockToCommonStockInShares_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_SettlementOfDebtByIssuanceOfCommonStock" xlink:label="loc_biviSettlementOfDebtByIssuanceOfCommonStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSettlementOfDebtByIssuanceOfCommonStock_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_SettlementOfDebtByIssuanceOfCommonStockShares" xlink:label="loc_biviSettlementOfDebtByIssuanceOfCommonStockShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSettlementOfDebtByIssuanceOfCommonStockShares_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_IssuanceOfWarrantsInPrivatePlacement" xlink:label="loc_biviIssuanceOfWarrantsInPrivatePlacement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfWarrantsInPrivatePlacement_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_OptionsVested" xlink:label="loc_biviOptionsVested_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviOptionsVested_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_CashlessExerciseOfWarrants" xlink:label="loc_biviCashlessExerciseOfWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviCashlessExerciseOfWarrants_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_CashlessExerciseOfWarrantsShares" xlink:label="loc_biviCashlessExerciseOfWarrantsShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviCashlessExerciseOfWarrantsShares_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_IssuanceOfWarrantsWithDebt" xlink:label="loc_biviIssuanceOfWarrantsWithDebt_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfWarrantsWithDebt_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DeemedDividend" xlink:label="loc_biviDeemedDividend_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviDeemedDividend_60" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DeemedDividendsForRatchetAdjustmentsToWarrants" xlink:label="loc_biviDeemedDividendsForRatchetAdjustmentsToWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviDeemedDividendsForRatchetAdjustmentsToWarrants_60" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss_60" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BackgroundInformationAndReverseStockSplit" xlink:title="00000007 - Disclosure - Background Information and Reverse Stock Split" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/Liquidity" xlink:title="00000008 - Disclosure - Liquidity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssets" xlink:title="00000010 - Disclosure - Intangible Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/RenegotiatedDebt" xlink:title="00000011 - Disclosure - Renegotiated Debt" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/RelatedPartyTransactions" xlink:title="00000012 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/FairValueMeasurements" xlink:title="00000013 - Disclosure - Fair Value Measurements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/CommitmentsAndContingencies" xlink:title="00000014 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactions" xlink:title="00000015 - Disclosure - Equity Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" xlink:title="00000019 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsTables" xlink:title="00000020 - Disclosure - Intangible Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/FairValueMeasurementsTables" xlink:title="00000021 - Disclosure - Fair Value Measurements (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsTables" xlink:title="00000022 - Disclosure - Equity Transactions (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesTables" xlink:title="00000023 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BackgroundInformationAndReverseStockSplitDetailsNarrative" xlink:title="00000024 - Disclosure - Background Information and Reverse Stock Split (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" xlink:title="00000025 - Disclosure - Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetails" xlink:title="00000026 - Disclosure - Intangible Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" xlink:title="00000027 - Disclosure - Intangible Assets (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000028 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/FairValueMeasurementsDetails" xlink:title="00000029 - Disclosure - Fair Value Measurements (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DerivativeLiabilityWarrantsMember" xlink:label="loc_biviDerivativeLiabilityWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember" xlink:label="loc_biviDerivativeLiabilityConversionOptionOnConvertibleDebentureMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityConversionOptionOnConvertibleDebentureMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/FairValueMeasurementsDetails2" xlink:title="00000030 - Disclosure - Fair Value Measurements (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DerivativeLiabilityWarrantsMember" xlink:label="loc_biviDerivativeLiabilityWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember" xlink:label="loc_biviDerivativeLiabilityConversionOptionOnConvertibleDebentureMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityConversionOptionOnConvertibleDebentureMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails" xlink:title="00000031 - Disclosure - Equity Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails2" xlink:title="00000032 - Disclosure - Equity Transactions (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails3" xlink:title="00000033 - Disclosure - Equity Transactions (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionOneMember" xlink:label="loc_biviStockOptionOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionTwoMember" xlink:label="loc_biviStockOptionTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionThreeMember" xlink:label="loc_biviStockOptionThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionFourMember" xlink:label="loc_biviStockOptionFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionFiveMember" xlink:label="loc_biviStockOptionFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFiveMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionSixMember" xlink:label="loc_biviStockOptionSixMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSixMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionSevenMember" xlink:label="loc_biviStockOptionSevenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSevenMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionEightMember" xlink:label="loc_biviStockOptionEightMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionEightMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionNineMember" xlink:label="loc_biviStockOptionNineMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionNineMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionTenMember" xlink:label="loc_biviStockOptionTenMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionTenMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_220" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails4" xlink:title="00000034 - Disclosure - Equity Transactions (Details 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionOneMember" xlink:label="loc_biviStockOptionOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionTwoMember" xlink:label="loc_biviStockOptionTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionThreeMember" xlink:label="loc_biviStockOptionThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionFourMember" xlink:label="loc_biviStockOptionFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionFiveMember" xlink:label="loc_biviStockOptionFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFiveMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionSixMember" xlink:label="loc_biviStockOptionSixMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSixMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionSevenMember" xlink:label="loc_biviStockOptionSevenMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSevenMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionEightMember" xlink:label="loc_biviStockOptionEightMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionEightMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionNineMember" xlink:label="loc_biviStockOptionNineMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionNineMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionTenMember" xlink:label="loc_biviStockOptionTenMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionTenMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_210" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails5" xlink:title="00000035 - Disclosure - Equity Transactions (Details 5)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_40" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesDetails" xlink:title="00000036 - Disclosure - Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesDetails2" xlink:title="00000037 - Disclosure - Income Taxes (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000038 - Disclosure - Income Taxes (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>bivi-20191231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: 2.xfr; Date: 2020%2D03%2D10T17:55:00Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Capital in Excess of Par Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionOneMember" xlink:label="bivi_StockOptionOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionOneMember" xlink:to="bivi_StockOptionOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_StockOptionOneMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionTwoMember" xlink:label="bivi_StockOptionTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionTwoMember" xlink:to="bivi_StockOptionTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_StockOptionTwoMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionThreeMember" xlink:label="bivi_StockOptionThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionThreeMember" xlink:to="bivi_StockOptionThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_StockOptionThreeMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionFourMember" xlink:label="bivi_StockOptionFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionFourMember" xlink:to="bivi_StockOptionFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_StockOptionFourMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionFiveMember" xlink:label="bivi_StockOptionFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionFiveMember" xlink:to="bivi_StockOptionFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_StockOptionFiveMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionSixMember" xlink:label="bivi_StockOptionSixMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionSixMember" xlink:to="bivi_StockOptionSixMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_StockOptionSixMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionSevenMember" xlink:label="bivi_StockOptionSevenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionSevenMember" xlink:to="bivi_StockOptionSevenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_StockOptionSevenMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_2_lbl" xml:lang="en-US">Additional Paid-In Capital</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionEightMember" xlink:label="bivi_StockOptionEightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionEightMember" xlink:to="bivi_StockOptionEightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_StockOptionEightMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionNineMember" xlink:label="bivi_StockOptionNineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionNineMember" xlink:to="bivi_StockOptionNineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_StockOptionNineMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionTenMember" xlink:label="bivi_StockOptionTenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionTenMember" xlink:to="bivi_StockOptionTenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_StockOptionTenMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DerivativeLiabilityWarrantsMember" xlink:label="bivi_DerivativeLiabilityWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DerivativeLiabilityWarrantsMember" xlink:to="bivi_DerivativeLiabilityWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DerivativeLiabilityWarrantsMember_lbl" xml:lang="en-US">Derivative liability - Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember" xlink:label="bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember" xlink:to="bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_lbl" xml:lang="en-US">Derivative Liability - Conversion Option on Convertible Debenture [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">OTHER ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DerivativeLiabilitiesWarrantCurrent" xlink:label="bivi_DerivativeLiabilitiesWarrantCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DerivativeLiabilitiesWarrantCurrent" xlink:to="bivi_DerivativeLiabilitiesWarrantCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DerivativeLiabilitiesWarrantCurrent_lbl" xml:lang="en-US">Derivative liability - warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DerivativeLiabilitiesConversionOptionCurrent" xlink:label="bivi_DerivativeLiabilitiesConversionOptionCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DerivativeLiabilitiesConversionOptionCurrent" xlink:to="bivi_DerivativeLiabilitiesConversionOptionCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DerivativeLiabilitiesConversionOptionCurrent_lbl" xml:lang="en-US">Derivative liability - conversion option on convertible debenture</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Loan payable - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ConvertibleDebentureRelatedParty" xlink:label="bivi_ConvertibleDebentureRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ConvertibleDebentureRelatedParty" xlink:to="bivi_ConvertibleDebentureRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ConvertibleDebentureRelatedParty_lbl" xml:lang="en-US">Convertible debenture - related party, net of discount $498,466 and $0 at September 30, 2019 and 2018, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Payroll</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Demand Promissory Note</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl" xml:lang="en-US">Notes Payable, Related Parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Long Term Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 800,000,000, 800,000,000 and 300,000,000 shares authorized at December 31, 2019, June 30, 2019 and June 30, 2018, respectively; 5,183,724, 4,058,442 and 788,026 shares issued and outstanding at December 31, 2019, June 30, 2019 and June 30, 2018, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">REVENUE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">TOTAL OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US">OTHER EXPENSE (INCOME)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="us-gaap_GainLossOnSaleOfDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDerivatives" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_lbl" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on settlement of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInterestAndDividendIncome" xlink:label="us-gaap_OtherInterestAndDividendIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInterestAndDividendIncome" xlink:to="us-gaap_OtherInterestAndDividendIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherInterestAndDividendIncome_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_TotalOtherExpenseIncome" xlink:label="bivi_TotalOtherExpenseIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_TotalOtherExpenseIncome" xlink:to="bivi_TotalOtherExpenseIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="bivi_TotalOtherExpenseIncome_lbl" xml:lang="en-US">TOTAL OTHER EXPENSE (INCOME)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DeemedDividend" xlink:label="bivi_DeemedDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DeemedDividend" xlink:to="bivi_DeemedDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DeemedDividend_lbl" xml:lang="en-US">Deemed dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="us-gaap_IncomeLossAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossAttributableToParent_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO COMPANY STOCKHOLDERS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">NET LOSS PER COMMON SHARE, BASIC AND DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">NET LOSS PER COMMON SHARE, BASIC</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">NET LOSS PER COMMON SHARE, DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, DILUTED</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning Balance, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of shares and warrants for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of shares and warrants for cash, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of commitment shares, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_IssuanceOfPreferredStockInPrivatePlacement" xlink:label="bivi_IssuanceOfPreferredStockInPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfPreferredStockInPrivatePlacement" xlink:to="bivi_IssuanceOfPreferredStockInPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_IssuanceOfPreferredStockInPrivatePlacement_lbl" xml:lang="en-US">Issuance of preferred stock in a private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_IssuanceOfPreferredStockInPrivatePlacementShares" xlink:label="bivi_IssuanceOfPreferredStockInPrivatePlacementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfPreferredStockInPrivatePlacementShares" xlink:to="bivi_IssuanceOfPreferredStockInPrivatePlacementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_IssuanceOfPreferredStockInPrivatePlacementShares_lbl" xml:lang="en-US">Issuance of preferred stock in a private placement, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ConversionOfPreferredStockToCommonStock" xlink:label="bivi_ConversionOfPreferredStockToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ConversionOfPreferredStockToCommonStock" xlink:to="bivi_ConversionOfPreferredStockToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ConversionOfPreferredStockToCommonStock_lbl" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ConversionOfPreferredStockToCommonStockInShares" xlink:label="bivi_ConversionOfPreferredStockToCommonStockInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ConversionOfPreferredStockToCommonStockInShares" xlink:to="bivi_ConversionOfPreferredStockToCommonStockInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ConversionOfPreferredStockToCommonStockInShares_lbl" xml:lang="en-US">Conversion of preferred stock to common stock (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_SettlementOfDebtByIssuanceOfCommonStock" xlink:label="bivi_SettlementOfDebtByIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SettlementOfDebtByIssuanceOfCommonStock" xlink:to="bivi_SettlementOfDebtByIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SettlementOfDebtByIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of shares in exchange for debt settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_SettlementOfDebtByIssuanceOfCommonStockShares" xlink:label="bivi_SettlementOfDebtByIssuanceOfCommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SettlementOfDebtByIssuanceOfCommonStockShares" xlink:to="bivi_SettlementOfDebtByIssuanceOfCommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SettlementOfDebtByIssuanceOfCommonStockShares_lbl" xml:lang="en-US">Issuance of shares in exchange for debt settlement, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_IssuanceOfWarrantsInPrivatePlacement" xlink:label="bivi_IssuanceOfWarrantsInPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfWarrantsInPrivatePlacement" xlink:to="bivi_IssuanceOfWarrantsInPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_IssuanceOfWarrantsInPrivatePlacement_lbl" xml:lang="en-US">Issuance of warrants in a private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of shares for services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of shares for services, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_OptionsVested" xlink:label="bivi_OptionsVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_OptionsVested" xlink:to="bivi_OptionsVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_OptionsVested_lbl" xml:lang="en-US">Options vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options for cash, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock option compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_CashlessExerciseOfWarrants" xlink:label="bivi_CashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_CashlessExerciseOfWarrants" xlink:to="bivi_CashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_CashlessExerciseOfWarrants_lbl" xml:lang="en-US">Cashless exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_CashlessExerciseOfWarrantsShares" xlink:label="bivi_CashlessExerciseOfWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_CashlessExerciseOfWarrantsShares" xlink:to="bivi_CashlessExerciseOfWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_CashlessExerciseOfWarrantsShares_lbl" xml:lang="en-US">Cashless exercise of warrants, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of warrants for services</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_IssuanceOfWarrantsWithDebt" xlink:label="bivi_IssuanceOfWarrantsWithDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfWarrantsWithDebt" xlink:to="bivi_IssuanceOfWarrantsWithDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_IssuanceOfWarrantsWithDebt_lbl" xml:lang="en-US">Issuance of warrants with debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DeemedDividend" xlink:to="bivi_DeemedDividend_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DeemedDividend_2_lbl" xml:lang="en-US">Deemed dividend for commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DeemedDividendsForRatchetAdjustmentsToWarrants" xlink:label="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants" xlink:to="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants_lbl" xml:lang="en-US">Deemed dividends for ratchet adjustment to warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Ending Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending Balance, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash to cash used by operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xml:lang="en-US">Common shares issued for service</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Gain on settlement of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_InterestExpenseFromConvertibleDebenture" xlink:label="bivi_InterestExpenseFromConvertibleDebenture" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_InterestExpenseFromConvertibleDebenture" xlink:to="bivi_InterestExpenseFromConvertibleDebenture_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_InterestExpenseFromConvertibleDebenture_lbl" xml:lang="en-US">Interest expense from convertible debenture</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued Payroll</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used by operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xml:lang="en-US">Repayment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Proceeds from issuance of preferred shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from loan payable - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ProceedsFromConvertibleDebentureRelatedParty" xlink:label="bivi_ProceedsFromConvertibleDebentureRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ProceedsFromConvertibleDebentureRelatedParty" xlink:to="bivi_ProceedsFromConvertibleDebentureRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ProceedsFromConvertibleDebentureRelatedParty_lbl" xml:lang="en-US">Proceeds from convertible debenture - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net decrease in cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">NON-CASH INVESTING AND FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ConversionOfPreferredSharesToCommonStock" xlink:label="bivi_ConversionOfPreferredSharesToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ConversionOfPreferredSharesToCommonStock" xlink:to="bivi_ConversionOfPreferredSharesToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ConversionOfPreferredSharesToCommonStock_lbl" xml:lang="en-US">Conversion of preferred shares to common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SettlementOfDebtByIssuanceOfCommonStock" xlink:to="bivi_SettlementOfDebtByIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_SettlementOfDebtByIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Settlement of debt by issuance of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants" xlink:to="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants_2_lbl" xml:lang="en-US">Deemed dividends for ratchet adjustments to warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DeemedDividend" xlink:to="bivi_DeemedDividend_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bivi_DeemedDividend_3_lbl" xml:lang="en-US">Deemed dividends for commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockWarrantsClassifiedAsDerivativeLiability" xlink:label="bivi_StockWarrantsClassifiedAsDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockWarrantsClassifiedAsDerivativeLiability" xlink:to="bivi_StockWarrantsClassifiedAsDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockWarrantsClassifiedAsDerivativeLiability_lbl" xml:lang="en-US">Stock warrants classified as derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_NotesToFinancialStatementsAbstract" xlink:label="bivi_NotesToFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_NotesToFinancialStatementsAbstract" xlink:to="bivi_NotesToFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_NotesToFinancialStatementsAbstract_lbl" xml:lang="en-US">Notes to Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Background Information and Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_LiquidityTextBlock" xlink:label="bivi_LiquidityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_LiquidityTextBlock" xlink:to="bivi_LiquidityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_LiquidityTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DemandNoteTextBlock" xlink:label="bivi_DemandNoteTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DemandNoteTextBlock" xlink:to="bivi_DemandNoteTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DemandNoteTextBlock_lbl" xml:lang="en-US">Renegotiated Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Equity Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_OtherAssetPolicyTextBlock" xlink:label="bivi_OtherAssetPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_OtherAssetPolicyTextBlock" xlink:to="bivi_OtherAssetPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_OtherAssetPolicyTextBlock_lbl" xml:lang="en-US">Other Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">Long-Term Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Reclassifications" xlink:label="us-gaap_Reclassifications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Reclassifications" xlink:to="us-gaap_Reclassifications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Reclassifications_lbl" xml:lang="en-US">Reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent accounting pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureSignificantAccountingPoliciesTablesAbstract" xlink:label="bivi_DisclosureSignificantAccountingPoliciesTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureSignificantAccountingPoliciesTablesAbstract" xlink:to="bivi_DisclosureSignificantAccountingPoliciesTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DisclosureSignificantAccountingPoliciesTablesAbstract_lbl" xml:lang="en-US">Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Dilutive securities were excluded from the computation of diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureIntangibleAssetsTablesAbstract" xlink:label="bivi_DisclosureIntangibleAssetsTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureIntangibleAssetsTablesAbstract" xlink:to="bivi_DisclosureIntangibleAssetsTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DisclosureIntangibleAssetsTablesAbstract_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Future expected Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Fair Value of Derivative Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Liabilities Measured at Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureStockOptionsTablesAbstract" xlink:label="bivi_DisclosureStockOptionsTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureStockOptionsTablesAbstract" xlink:to="bivi_DisclosureStockOptionsTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DisclosureStockOptionsTablesAbstract_lbl" xml:lang="en-US">Notes to Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of option outstanding and exercisable by exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureIncomeTaxesTablesAbstract" xlink:label="bivi_DisclosureIncomeTaxesTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureIncomeTaxesTablesAbstract" xlink:to="bivi_DisclosureIncomeTaxesTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DisclosureIncomeTaxesTablesAbstract_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Income tax Benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureSubsequentEventsDetailsNarrativeAbstract" xlink:label="bivi_DisclosureSubsequentEventsDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureSubsequentEventsDetailsNarrativeAbstract" xlink:to="bivi_DisclosureSubsequentEventsDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DisclosureSubsequentEventsDetailsNarrativeAbstract_lbl" xml:lang="en-US">Background Information And Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse Stock Split</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Dilutive Securities excluded from the Computation of Diluted Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureIntangibleAssetsDetailsAbstract" xlink:label="bivi_DisclosureIntangibleAssetsDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureIntangibleAssetsDetailsAbstract" xlink:to="bivi_DisclosureIntangibleAssetsDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DisclosureIntangibleAssetsDetailsAbstract_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Intellectual Property</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intellectual Property, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureIntangibleAssetsDetails2Abstract" xlink:label="bivi_DisclosureIntangibleAssetsDetails2Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureIntangibleAssetsDetails2Abstract" xlink:to="bivi_DisclosureIntangibleAssetsDetails2Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DisclosureIntangibleAssetsDetails2Abstract_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix" xlink:label="bivi_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix" xlink:to="bivi_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureIntangibleAssetsDetailsNarrativeAbstract" xlink:label="bivi_DisclosureIntangibleAssetsDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureIntangibleAssetsDetailsNarrativeAbstract" xlink:to="bivi_DisclosureIntangibleAssetsDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DisclosureIntangibleAssetsDetailsNarrativeAbstract_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_3_lbl" xml:lang="en-US">Amortization Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Useful Life of Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Total derivatives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilities_2_lbl" xml:lang="en-US">Beginning balance at July 1, 2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_lbl" xml:lang="en-US">Additions to level 3 liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl" xml:lang="en-US">Change in in fair value of level 3 liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xml:lang="en-US">Transfer in and/or out of Level 3</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilities_3_lbl" xml:lang="en-US">Balance at September 30, 2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Option Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Option Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Option Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Option Outstanding at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Option Excersiable at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding Weighted Average Exercise Price at the beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding Weighted Average Exercise Price at the end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Excersiable Weighted Average Exercise Price at the end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term at the beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term, Excerised</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term at the end</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Excersiable Weighted Average Remaining Contractual Term at the end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Options Exercised or Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value Outstanding at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (In years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend Yield</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Option Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Weighted Average Contractual Life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2_lbl" xml:lang="en-US">Option Excersiable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Warrant Outstanding at the beginning of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Warrant Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Warrant Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Warrant Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Warrant Outstanding at the end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xml:lang="en-US">Weighted Average Exercise Price at the beginning of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2_lbl" xml:lang="en-US">Weighted Average Exercise Price at the end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted Average Remaining Life at the beginning of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_lbl" xml:lang="en-US">Weighted Average Remaining Life, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3_lbl" xml:lang="en-US">Weighted Average Remaining Life at the end of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureIncomeTaxesDetailsAbstract" xlink:label="bivi_DisclosureIncomeTaxesDetailsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureIncomeTaxesDetailsAbstract" xlink:to="bivi_DisclosureIncomeTaxesDetailsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DisclosureIncomeTaxesDetailsAbstract_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred tax assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xml:lang="en-US">Tax loss carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureIncomeTaxesDetails2Abstract" xlink:label="bivi_DisclosureIncomeTaxesDetails2Abstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureIncomeTaxesDetails2Abstract" xlink:to="bivi_DisclosureIncomeTaxesDetails2Abstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DisclosureIncomeTaxesDetails2Abstract_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income tax expense (benefit) at federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income Tax Expense Benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureIncomeTaxesDetailsNarrativeAbstract" xlink:label="bivi_DisclosureIncomeTaxesDetailsNarrativeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureIncomeTaxesDetailsNarrativeAbstract" xlink:to="bivi_DisclosureIncomeTaxesDetailsNarrativeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_DisclosureIncomeTaxesDetailsNarrativeAbstract_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net Operating Loss Carry Forwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_CashlessExerciseOfWarrants" xlink:to="bivi_CashlessExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_CashlessExerciseOfWarrants_doc" xml:lang="en-US">Cashless Exercise of Warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_CashlessExerciseOfWarrantsShares" xlink:to="bivi_CashlessExerciseOfWarrantsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_CashlessExerciseOfWarrantsShares_doc" xml:lang="en-US">Cashless Exercise of Warrants Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ConversionOfPreferredSharesToCommonStock" xlink:to="bivi_ConversionOfPreferredSharesToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_ConversionOfPreferredSharesToCommonStock_doc" xml:lang="en-US">Conversion Of Preferred Shares To Common Stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ConversionOfPreferredStockToCommonStock" xlink:to="bivi_ConversionOfPreferredStockToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_ConversionOfPreferredStockToCommonStock_doc" xml:lang="en-US">Conversion Of Preferred Stock To Common Stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ConversionOfPreferredStockToCommonStockInShares" xlink:to="bivi_ConversionOfPreferredStockToCommonStockInShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_ConversionOfPreferredStockToCommonStockInShares_doc" xml:lang="en-US">Conversion Of Preferred Stock To Common Stock (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ConvertibleDebentureRelatedParty" xlink:to="bivi_ConvertibleDebentureRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_ConvertibleDebentureRelatedParty_doc" xml:lang="en-US">Convertible debenture - related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DeemedDividend" xlink:to="bivi_DeemedDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_DeemedDividend_doc" xml:lang="en-US">Deemed Dividend</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants" xlink:to="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants_doc" xml:lang="en-US">Deemed Dividends for Ratchet Adjustments to Warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DemandNoteTextBlock" xlink:to="bivi_DemandNoteTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_DemandNoteTextBlock_doc" xml:lang="en-US">Demand Note [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DerivativeLiabilitiesConversionOptionCurrent" xlink:to="bivi_DerivativeLiabilitiesConversionOptionCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_DerivativeLiabilitiesConversionOptionCurrent_doc" xml:lang="en-US">Derivative liability - conversion option on convertible debenture</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DerivativeLiabilitiesWarrantCurrent" xlink:to="bivi_DerivativeLiabilitiesWarrantCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_DerivativeLiabilitiesWarrantCurrent_doc" xml:lang="en-US">Derivative liability - warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember" xlink:to="bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_doc" xml:lang="en-US">Derivative Liability - Conversion Option on Convertible Debenture [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DerivativeLiabilityWarrantsMember" xlink:to="bivi_DerivativeLiabilityWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_DerivativeLiabilityWarrantsMember_doc" xml:lang="en-US">Derivative liability - Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix" xlink:to="bivi_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix_doc" xml:lang="en-US">Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the sixth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_InterestExpenseFromConvertibleDebenture" xlink:to="bivi_InterestExpenseFromConvertibleDebenture_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_InterestExpenseFromConvertibleDebenture_doc" xml:lang="en-US">Interest expense from convertible debenture</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfPreferredStockInPrivatePlacement" xlink:to="bivi_IssuanceOfPreferredStockInPrivatePlacement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_IssuanceOfPreferredStockInPrivatePlacement_doc" xml:lang="en-US">Issuance Of Preferred Stock In Private Placement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfPreferredStockInPrivatePlacementShares" xlink:to="bivi_IssuanceOfPreferredStockInPrivatePlacementShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_IssuanceOfPreferredStockInPrivatePlacementShares_doc" xml:lang="en-US">Issuance Of Preferred Stock In Private Placement, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfWarrantsInPrivatePlacement" xlink:to="bivi_IssuanceOfWarrantsInPrivatePlacement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_IssuanceOfWarrantsInPrivatePlacement_doc" xml:lang="en-US">Issuance of Warrants in Private Placement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfWarrantsWithDebt" xlink:to="bivi_IssuanceOfWarrantsWithDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_IssuanceOfWarrantsWithDebt_doc" xml:lang="en-US">Issuance of Warrant with Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_LiquidityTextBlock" xlink:to="bivi_LiquidityTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_LiquidityTextBlock_doc" xml:lang="en-US">Liquidity [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_OptionsVested" xlink:to="bivi_OptionsVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_OptionsVested_doc" xml:lang="en-US">Options Vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_OtherAssetPolicyTextBlock" xlink:to="bivi_OtherAssetPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_OtherAssetPolicyTextBlock_doc" xml:lang="en-US">Other Assets [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ProceedsFromConvertibleDebentureRelatedParty" xlink:to="bivi_ProceedsFromConvertibleDebentureRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_ProceedsFromConvertibleDebentureRelatedParty_doc" xml:lang="en-US">Proceeds From Convertible Debenture Related Party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SettlementOfDebtByIssuanceOfCommonStock" xlink:to="bivi_SettlementOfDebtByIssuanceOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_SettlementOfDebtByIssuanceOfCommonStock_doc" xml:lang="en-US">Settlement Of Debt By Issuance Of Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SettlementOfDebtByIssuanceOfCommonStockShares" xlink:to="bivi_SettlementOfDebtByIssuanceOfCommonStockShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_SettlementOfDebtByIssuanceOfCommonStockShares_doc" xml:lang="en-US">Settlement of Debt by Issuance of Common Stock, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue_doc" xml:lang="en-US">Per share weighted average intrinsic value of equity-based compensation awards excersied. Excludes stock and unit options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_doc" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted, Weighted Average Remaining Contractual Terms</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3_doc" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3_doc" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Excerised, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4_doc" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionEightMember" xlink:to="bivi_StockOptionEightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionEightMember_doc" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionFiveMember" xlink:to="bivi_StockOptionFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionFiveMember_doc" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionFourMember" xlink:to="bivi_StockOptionFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionFourMember_doc" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionNineMember" xlink:to="bivi_StockOptionNineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionNineMember_doc" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionOneMember" xlink:to="bivi_StockOptionOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionOneMember_doc" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionSevenMember" xlink:to="bivi_StockOptionSevenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionSevenMember_doc" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionSixMember" xlink:to="bivi_StockOptionSixMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionSixMember_doc" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionTenMember" xlink:to="bivi_StockOptionTenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionTenMember_doc" xml:lang="en-US">Stock Option Ten [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionThreeMember" xlink:to="bivi_StockOptionThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionThreeMember_doc" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionTwoMember" xlink:to="bivi_StockOptionTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockOptionTwoMember_doc" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockWarrantsClassifiedAsDerivativeLiability" xlink:to="bivi_StockWarrantsClassifiedAsDerivativeLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_StockWarrantsClassifiedAsDerivativeLiability_doc" xml:lang="en-US">Stock warrants classified as derivative liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_TotalOtherExpenseIncome" xlink:to="bivi_TotalOtherExpenseIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bivi_TotalOtherExpenseIncome_doc" xml:lang="en-US">Total Other Expense Income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionOneMember" xlink:to="bivi_StockOptionOneMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionOneMember_3_lbl" xml:lang="en-US">StockOptionOneMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionTwoMember" xlink:to="bivi_StockOptionTwoMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionTwoMember_3_lbl" xml:lang="en-US">StockOptionTwoMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionThreeMember" xlink:to="bivi_StockOptionThreeMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionThreeMember_3_lbl" xml:lang="en-US">StockOptionThreeMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionFourMember" xlink:to="bivi_StockOptionFourMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionFourMember_3_lbl" xml:lang="en-US">StockOptionFourMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionFiveMember" xlink:to="bivi_StockOptionFiveMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionFiveMember_3_lbl" xml:lang="en-US">StockOptionFiveMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionSixMember" xlink:to="bivi_StockOptionSixMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionSixMember_3_lbl" xml:lang="en-US">StockOptionSixMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionSevenMember" xlink:to="bivi_StockOptionSevenMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionSevenMember_3_lbl" xml:lang="en-US">StockOptionSevenMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionEightMember" xlink:to="bivi_StockOptionEightMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionEightMember_3_lbl" xml:lang="en-US">StockOptionEightMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionNineMember" xlink:to="bivi_StockOptionNineMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionNineMember_3_lbl" xml:lang="en-US">StockOptionNineMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionTenMember" xlink:to="bivi_StockOptionTenMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionTenMember_3_lbl" xml:lang="en-US">StockOptionTenMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDerivatives" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_2_lbl" xml:lang="en-US">Gain (Loss) on Sale of Derivatives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInterestAndDividendIncome" xlink:to="us-gaap_OtherInterestAndDividendIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherInterestAndDividendIncome_2_lbl" xml:lang="en-US">Other Interest and Dividend Income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_2_lbl" xml:lang="en-US">Interest Income, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_TotalOtherExpenseIncome" xlink:to="bivi_TotalOtherExpenseIncome_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_TotalOtherExpenseIncome_3_lbl" xml:lang="en-US">TotalOtherExpenseIncome</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossAttributableToParent_2_lbl" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_2_lbl" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_OtherAssetPolicyTextBlock" xlink:to="bivi_OtherAssetPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_OtherAssetPolicyTextBlock_3_lbl" xml:lang="en-US">OtherAssetPolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>bivi-20191231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: 2.xfr; Date: 2020%2D03%2D10T17:55:00Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nanoantibiotics.com/role/DocumentAndEntityInformation" xlink:href="bivi-20191231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BalanceSheets" xlink:href="bivi-20191231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BalanceSheetsParenthetical" xlink:href="bivi-20191231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfOperations" xlink:href="bivi-20191231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" xlink:href="bivi-20191231.xsd#StatementsOfChangesInStockholdersDeficitEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfCashFlows" xlink:href="bivi-20191231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BackgroundInformationAndReverseStockSplit" xlink:href="bivi-20191231.xsd#BackgroundInformationAndReverseStockSplit" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/Liquidity" xlink:href="bivi-20191231.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPolicies" xlink:href="bivi-20191231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssets" xlink:href="bivi-20191231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/RenegotiatedDebt" xlink:href="bivi-20191231.xsd#RenegotiatedDebt" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/RelatedPartyTransactions" xlink:href="bivi-20191231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/FairValueMeasurements" xlink:href="bivi-20191231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/CommitmentsAndContingencies" xlink:href="bivi-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactions" xlink:href="bivi-20191231.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxes" xlink:href="bivi-20191231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SubsequentEvents" xlink:href="bivi-20191231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" xlink:href="bivi-20191231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" xlink:href="bivi-20191231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsTables" xlink:href="bivi-20191231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/FairValueMeasurementsTables" xlink:href="bivi-20191231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsTables" xlink:href="bivi-20191231.xsd#EquityTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesTables" xlink:href="bivi-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BackgroundInformationAndReverseStockSplitDetailsNarrative" xlink:href="bivi-20191231.xsd#BackgroundInformationAndReverseStockSplitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" xlink:href="bivi-20191231.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails" xlink:href="bivi-20191231.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" xlink:href="bivi-20191231.xsd#IntangibleAssetsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetailsNarrative" xlink:href="bivi-20191231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/FairValueMeasurementsDetails" xlink:href="bivi-20191231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/FairValueMeasurementsDetails2" xlink:href="bivi-20191231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails" xlink:href="bivi-20191231.xsd#EquityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails2" xlink:href="bivi-20191231.xsd#EquityTransactionsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails3" xlink:href="bivi-20191231.xsd#EquityTransactionsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails4" xlink:href="bivi-20191231.xsd#EquityTransactionsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails5" xlink:href="bivi-20191231.xsd#EquityTransactionsDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetails" xlink:href="bivi-20191231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetails2" xlink:href="bivi-20191231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetailsNarrative" xlink:href="bivi-20191231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DerivativeLiabilitiesWarrantCurrent" xlink:label="loc_biviDerivativeLiabilitiesWarrantCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_biviDerivativeLiabilitiesWarrantCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DerivativeLiabilitiesConversionOptionCurrent" xlink:label="loc_biviDerivativeLiabilitiesConversionOptionCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_biviDerivativeLiabilitiesConversionOptionCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ConvertibleDebentureRelatedParty" xlink:label="loc_biviConvertibleDebentureRelatedParty" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_biviConvertibleDebentureRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapNotesPayableRelatedPartiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="loc_us-gaapOtherExpensesAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaapGainLossOnSaleOfDerivatives" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfDerivatives" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInterestAndDividendIncome" xlink:label="loc_us-gaapOtherInterestAndDividendIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapOtherInterestAndDividendIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_TotalOtherExpenseIncome" xlink:label="loc_biviTotalOtherExpenseIncome" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_biviTotalOtherExpenseIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DeemedDividend" xlink:label="loc_biviDeemedDividend" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_biviDeemedDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="loc_us-gaapIncomeLossAttributableToParent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossAttributableToParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" xlink:title="00000005 - Statement - Condensed Statements of Changes in Stockholders&apos; (Deficit) Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_IssuanceOfPreferredStockInPrivatePlacement" xlink:label="loc_biviIssuanceOfPreferredStockInPrivatePlacement" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfPreferredStockInPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_IssuanceOfPreferredStockInPrivatePlacementShares" xlink:label="loc_biviIssuanceOfPreferredStockInPrivatePlacementShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfPreferredStockInPrivatePlacementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ConversionOfPreferredStockToCommonStock" xlink:label="loc_biviConversionOfPreferredStockToCommonStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviConversionOfPreferredStockToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ConversionOfPreferredStockToCommonStockInShares" xlink:label="loc_biviConversionOfPreferredStockToCommonStockInShares" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviConversionOfPreferredStockToCommonStockInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_SettlementOfDebtByIssuanceOfCommonStock" xlink:label="loc_biviSettlementOfDebtByIssuanceOfCommonStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSettlementOfDebtByIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_SettlementOfDebtByIssuanceOfCommonStockShares" xlink:label="loc_biviSettlementOfDebtByIssuanceOfCommonStockShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSettlementOfDebtByIssuanceOfCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_IssuanceOfWarrantsInPrivatePlacement" xlink:label="loc_biviIssuanceOfWarrantsInPrivatePlacement" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfWarrantsInPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_OptionsVested" xlink:label="loc_biviOptionsVested" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviOptionsVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_CashlessExerciseOfWarrants" xlink:label="loc_biviCashlessExerciseOfWarrants" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_CashlessExerciseOfWarrantsShares" xlink:label="loc_biviCashlessExerciseOfWarrantsShares" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviCashlessExerciseOfWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_IssuanceOfWarrantsWithDebt" xlink:label="loc_biviIssuanceOfWarrantsWithDebt" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfWarrantsWithDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DeemedDividend" xlink:label="loc_biviDeemedDividend" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviDeemedDividend" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DeemedDividendsForRatchetAdjustmentsToWarrants" xlink:label="loc_biviDeemedDividendsForRatchetAdjustmentsToWarrants" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviDeemedDividendsForRatchetAdjustmentsToWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_InterestExpenseFromConvertibleDebenture" xlink:label="loc_biviInterestExpenseFromConvertibleDebenture" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_biviInterestExpenseFromConvertibleDebenture" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaapGainLossOnSaleOfDerivatives" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfDerivatives" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfDebt" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRepaymentsOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ProceedsFromConvertibleDebentureRelatedParty" xlink:label="loc_biviProceedsFromConvertibleDebentureRelatedParty" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_biviProceedsFromConvertibleDebentureRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ConversionOfPreferredSharesToCommonStock" xlink:label="loc_biviConversionOfPreferredSharesToCommonStock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_biviConversionOfPreferredSharesToCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_SettlementOfDebtByIssuanceOfCommonStock" xlink:label="loc_biviSettlementOfDebtByIssuanceOfCommonStock" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_biviSettlementOfDebtByIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_CashlessExerciseOfWarrants" xlink:label="loc_biviCashlessExerciseOfWarrants" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_biviCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DeemedDividendsForRatchetAdjustmentsToWarrants" xlink:label="loc_biviDeemedDividendsForRatchetAdjustmentsToWarrants" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_biviDeemedDividendsForRatchetAdjustmentsToWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DeemedDividend" xlink:label="loc_biviDeemedDividend" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_biviDeemedDividend" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockWarrantsClassifiedAsDerivativeLiability" xlink:label="loc_biviStockWarrantsClassifiedAsDerivativeLiability" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_biviStockWarrantsClassifiedAsDerivativeLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BackgroundInformationAndReverseStockSplit" xlink:title="00000007 - Disclosure - Background Information and Reverse Stock Split">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_NotesToFinancialStatementsAbstract" xlink:label="loc_biviNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviNotesToFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/Liquidity" xlink:title="00000008 - Disclosure - Liquidity">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_NotesToFinancialStatementsAbstract" xlink:label="loc_biviNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_LiquidityTextBlock" xlink:label="loc_biviLiquidityTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviNotesToFinancialStatementsAbstract" xlink:to="loc_biviLiquidityTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssets" xlink:title="00000010 - Disclosure - Intangible Assets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/RenegotiatedDebt" xlink:title="00000011 - Disclosure - Renegotiated Debt">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_NotesToFinancialStatementsAbstract" xlink:label="loc_biviNotesToFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DemandNoteTextBlock" xlink:label="loc_biviDemandNoteTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviNotesToFinancialStatementsAbstract" xlink:to="loc_biviDemandNoteTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/RelatedPartyTransactions" xlink:title="00000012 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/FairValueMeasurements" xlink:title="00000013 - Disclosure - Fair Value Measurements">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/CommitmentsAndContingencies" xlink:title="00000014 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactions" xlink:title="00000015 - Disclosure - Equity Transactions">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_OtherAssetPolicyTextBlock" xlink:label="loc_biviOtherAssetPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_biviOtherAssetPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsGoodwillPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Reclassifications" xlink:label="loc_us-gaapReclassifications" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReclassifications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" xlink:title="00000019 - Disclosure - Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureSignificantAccountingPoliciesTablesAbstract" xlink:label="loc_biviDisclosureSignificantAccountingPoliciesTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureSignificantAccountingPoliciesTablesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsTables" xlink:title="00000020 - Disclosure - Intangible Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureIntangibleAssetsTablesAbstract" xlink:label="loc_biviDisclosureIntangibleAssetsTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsTablesAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsTablesAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/FairValueMeasurementsTables" xlink:title="00000021 - Disclosure - Fair Value Measurements (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsTables" xlink:title="00000022 - Disclosure - Equity Transactions (Tables)">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureStockOptionsTablesAbstract" xlink:label="loc_biviDisclosureStockOptionsTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureStockOptionsTablesAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureStockOptionsTablesAbstract" xlink:to="loc_us-gaapShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureStockOptionsTablesAbstract" xlink:to="loc_us-gaapScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesTables" xlink:title="00000023 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureIncomeTaxesTablesAbstract" xlink:label="loc_biviDisclosureIncomeTaxesTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIncomeTaxesTablesAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIncomeTaxesTablesAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BackgroundInformationAndReverseStockSplitDetailsNarrative" xlink:title="00000024 - Disclosure - Background Information and Reverse Stock Split (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureSubsequentEventsDetailsNarrativeAbstract" xlink:label="loc_biviDisclosureSubsequentEventsDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureSubsequentEventsDetailsNarrativeAbstract" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" xlink:title="00000025 - Disclosure - Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract" xlink:label="loc_biviDisclosureSignificantAccountingPoliciesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureSignificantAccountingPoliciesDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetails" xlink:title="00000026 - Disclosure - Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureIntangibleAssetsDetailsAbstract" xlink:label="loc_biviDisclosureIntangibleAssetsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetailsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" xlink:title="00000027 - Disclosure - Intangible Assets (Details 2)">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureIntangibleAssetsDetails2Abstract" xlink:label="loc_biviDisclosureIntangibleAssetsDetails2Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetails2Abstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetails2Abstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetails2Abstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetails2Abstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetails2Abstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix" xlink:label="loc_biviFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetails2Abstract" xlink:to="loc_biviFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetails2Abstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetails2Abstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000028 - Disclosure - Intangible Assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureIntangibleAssetsDetailsNarrativeAbstract" xlink:label="loc_biviDisclosureIntangibleAssetsDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetailsNarrativeAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIntangibleAssetsDetailsNarrativeAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/FairValueMeasurementsDetails" xlink:title="00000029 - Disclosure - Fair Value Measurements (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DerivativeLiabilityWarrantsMember" xlink:label="loc_biviDerivativeLiabilityWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember" xlink:label="loc_biviDerivativeLiabilityConversionOptionOnConvertibleDebentureMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityConversionOptionOnConvertibleDebentureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/FairValueMeasurementsDetails2" xlink:title="00000030 - Disclosure - Fair Value Measurements (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DerivativeLiabilityWarrantsMember" xlink:label="loc_biviDerivativeLiabilityWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember" xlink:label="loc_biviDerivativeLiabilityConversionOptionOnConvertibleDebentureMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityConversionOptionOnConvertibleDebentureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails" xlink:title="00000031 - Disclosure - Equity Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureStockOptionsDetailsAbstract" xlink:label="loc_biviDisclosureStockOptionsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureStockOptionsDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails2" xlink:title="00000032 - Disclosure - Equity Transactions (Details 2)">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureEquityTransactionsDetails2Abstract" xlink:label="loc_biviDisclosureEquityTransactionsDetails2Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureEquityTransactionsDetails2Abstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails3" xlink:title="00000033 - Disclosure - Equity Transactions (Details 3)">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureStockOptionsDetailsAbstract" xlink:label="loc_biviDisclosureStockOptionsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureStockOptionsDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionOneMember" xlink:label="loc_biviStockOptionOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionOneMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionTwoMember" xlink:label="loc_biviStockOptionTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionTwoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionThreeMember" xlink:label="loc_biviStockOptionThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionThreeMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionFourMember" xlink:label="loc_biviStockOptionFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFourMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionFiveMember" xlink:label="loc_biviStockOptionFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFiveMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionSixMember" xlink:label="loc_biviStockOptionSixMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSixMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionSevenMember" xlink:label="loc_biviStockOptionSevenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSevenMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionEightMember" xlink:label="loc_biviStockOptionEightMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionEightMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionNineMember" xlink:label="loc_biviStockOptionNineMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionNineMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionTenMember" xlink:label="loc_biviStockOptionTenMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionTenMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails4" xlink:title="00000034 - Disclosure - Equity Transactions (Details 4)">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureStockOptionsDetailsAbstract" xlink:label="loc_biviDisclosureStockOptionsDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureStockOptionsDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionOneMember" xlink:label="loc_biviStockOptionOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionOneMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionTwoMember" xlink:label="loc_biviStockOptionTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionTwoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionThreeMember" xlink:label="loc_biviStockOptionThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionThreeMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionFourMember" xlink:label="loc_biviStockOptionFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFourMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionFiveMember" xlink:label="loc_biviStockOptionFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionFiveMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionSixMember" xlink:label="loc_biviStockOptionSixMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSixMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionSevenMember" xlink:label="loc_biviStockOptionSevenMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionSevenMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionEightMember" xlink:label="loc_biviStockOptionEightMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionEightMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionNineMember" xlink:label="loc_biviStockOptionNineMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionNineMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_StockOptionTenMember" xlink:label="loc_biviStockOptionTenMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionTenMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails5" xlink:title="00000035 - Disclosure - Equity Transactions (Details 5)">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureStockholdersEquityDetails3Abstract" xlink:label="loc_biviDisclosureStockholdersEquityDetails3Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureStockholdersEquityDetails3Abstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesDetails" xlink:title="00000036 - Disclosure - Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureIncomeTaxesDetailsAbstract" xlink:label="loc_biviDisclosureIncomeTaxesDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIncomeTaxesDetailsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesDetails2" xlink:title="00000037 - Disclosure - Income Taxes (Details 2)">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureIncomeTaxesDetails2Abstract" xlink:label="loc_biviDisclosureIncomeTaxesDetails2Abstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIncomeTaxesDetails2Abstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIncomeTaxesDetails2Abstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIncomeTaxesDetails2Abstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIncomeTaxesDetails2Abstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000038 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DisclosureIncomeTaxesDetailsNarrativeAbstract" xlink:label="loc_biviDisclosureIncomeTaxesDetailsNarrativeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureIncomeTaxesDetailsNarrativeAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>17
<FILENAME>bivi-20191231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: 2.xfr; Date: 2020%2D03%2D10T17:55:00Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:bivi="http://nanoantibiotics.com/20191231">
    <link:schemaRef xlink:href="bivi-20191231.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2017-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-06-30_custom_StockOptionOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_StockOptionOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-06-30_custom_StockOptionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_StockOptionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-06-30_custom_StockOptionThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_StockOptionThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-06-30_custom_StockOptionFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_StockOptionFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-06-30_custom_StockOptionFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_StockOptionFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-06-30_custom_StockOptionSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_StockOptionSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-06-30_custom_StockOptionSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_StockOptionSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-06-30_us-gaap_StockOptionMember128077054">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_StockOptionEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-06-30_custom_StockOptionEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_StockOptionNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-06-30_custom_StockOptionNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_StockOptionTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-06-30_custom_StockOptionTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2019-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-07-01to2018-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-07-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-31to2019-11-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-31</xbrli:startDate>
        <xbrli:endDate>2019-11-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2018-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2018-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_DerivativeLiabilityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_StockOptionOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-12-31_custom_StockOptionOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_StockOptionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-12-31_custom_StockOptionTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_StockOptionThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-12-31_custom_StockOptionThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_StockOptionFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-12-31_custom_StockOptionFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_StockOptionFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-12-31_custom_StockOptionFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_StockOptionSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-12-31_custom_StockOptionSixMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionSixMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_StockOptionSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-12-31_custom_StockOptionSevenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionSevenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_StockOptionEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-12-31_custom_StockOptionEightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionEightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_StockOptionNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-12-31_custom_StockOptionNineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionNineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_StockOptionTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-12-31_custom_StockOptionTenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionTenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2018-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2018-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2018-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-09-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-01to2019-12-31_custom_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-01to2019-09-30_custom_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <us-gaap:AssetsCurrent contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">45800</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">674073</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">553918</us-gaap:AssetsCurrent>
    <us-gaap:Assets contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">2175491</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">2574387</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">2339544</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">884207</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">443480</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1085177</us-gaap:AccountsPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">1238374</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">443480</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">4383972</us-gaap:LiabilitiesCurrent>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">4880246</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">9392573</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">19472373</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">111199</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">2130907</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">-2044428</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">2175491</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">2574387</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">2339544</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2018-06-30" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2018-06-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2018-06-30" unitRef="Shares" decimals="INF">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2018-06-30" unitRef="Shares" decimals="INF">788026</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">4058442</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">5183724</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">-2501577</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">-621341</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">-866815</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">-1211017</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">2795700</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">661999</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">530000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">2795700</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CommonStockValue contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">79</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">406</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">518</us-gaap:CommonStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2018-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2019-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2018-06-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-06-30" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2019-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2018-06-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2018-06-30" unitRef="Shares" decimals="INF">788026</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-06-30" unitRef="Shares" decimals="INF">4058442</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-12-31" unitRef="Shares" decimals="INF">5183724</us-gaap:CommonStockSharesIssued>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">-117777</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">413234</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">641697</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">-456422</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">294123</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">40658</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">-336815</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">1584683</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:Cash contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">5140</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">45800</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">339923</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">3108</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">1630483</us-gaap:Cash>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2018-06-30" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-06-30" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2019-12-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">354167</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2019-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="From2018-07-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">229167</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">-4769126</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">-7262072</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">-21517319</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">1783980</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">1554603</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1439915</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">345711</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">345711</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">345711</us-gaap:Goodwill>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">2129691</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">1900314</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1785626</us-gaap:AssetsNoncurrent>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">229377</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">229377</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">114689</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">114689</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">57344</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">57344</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">1008100</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">370852</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">688015</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">400540</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">346514</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">206019</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">1259096</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">1771937</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">613961</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">477069</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">306589</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">237507</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">2496573</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">2372166</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">1416665</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">992298</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">710447</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">500870</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">-2496573</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">-2372166</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">-1416665</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">-992298</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-710447</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">-500870</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">273</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">40960</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">3498535</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">271</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">20920</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2018-10-01to2018-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestIncomeOther contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">1159</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">4</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">233</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">788</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">213</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">360</us-gaap:InterestIncomeOther>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2018-07-01to2019-06-30" unitRef="USDPShares" decimals="INF">-0.98</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-07-01to2018-06-30" unitRef="USDPShares" decimals="INF">-3.18</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2018-07-01to2019-06-30" unitRef="Shares" decimals="INF">2539611</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2017-07-01to2018-06-30" unitRef="Shares" decimals="INF">766065</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">58000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-06-30_custom_StockOptionOneMember" unitRef="Shares" decimals="INF">5600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-06-30_custom_StockOptionTwoMember" unitRef="Shares" decimals="INF">10400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-06-30_custom_StockOptionThreeMember" unitRef="Shares" decimals="INF">24800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-06-30_custom_StockOptionFourMember" unitRef="Shares" decimals="INF">800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-06-30_custom_StockOptionFiveMember" unitRef="Shares" decimals="INF">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-06-30_custom_StockOptionSixMember" unitRef="Shares" decimals="INF">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-06-30_custom_StockOptionSevenMember" unitRef="Shares" decimals="INF">4400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">41200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-06-30_custom_StockOptionEightMember" unitRef="Shares" decimals="INF">800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-06-30_custom_StockOptionNineMember" unitRef="Shares" decimals="INF">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-06-30_custom_StockOptionTenMember" unitRef="Shares" decimals="INF">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">32000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">60400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_custom_StockOptionOneMember" unitRef="Shares" decimals="INF">5600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_custom_StockOptionTwoMember" unitRef="Shares" decimals="INF">11200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_custom_StockOptionThreeMember" unitRef="Shares" decimals="INF">25600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_custom_StockOptionFourMember" unitRef="Shares" decimals="INF">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_custom_StockOptionFiveMember" unitRef="Shares" decimals="INF">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_custom_StockOptionSixMember" unitRef="Shares" decimals="INF">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_custom_StockOptionSevenMember" unitRef="Shares" decimals="INF">4400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_custom_StockOptionEightMember" unitRef="Shares" decimals="INF">800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_custom_StockOptionNineMember" unitRef="Shares" decimals="INF">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2019-12-31_custom_StockOptionTenMember" unitRef="Shares" decimals="INF">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">12.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">15.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">12.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">12.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_StockOptionOneMember" unitRef="USDPShares" decimals="INF">3.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_StockOptionTwoMember" unitRef="USDPShares" decimals="INF">6.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_StockOptionThreeMember" unitRef="USDPShares" decimals="INF">7.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_StockOptionFourMember" unitRef="USDPShares" decimals="INF">8.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_StockOptionFiveMember" unitRef="USDPShares" decimals="INF">12.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_StockOptionSixMember" unitRef="USDPShares" decimals="INF">25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_StockOptionSevenMember" unitRef="USDPShares" decimals="INF">26.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_StockOptionEightMember" unitRef="USDPShares" decimals="INF">27.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_StockOptionNineMember" unitRef="USDPShares" decimals="INF">28.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2019-12-31_custom_StockOptionTenMember" unitRef="USDPShares" decimals="INF">31.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2018-07-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">446999</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">49000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">642850</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2018-07-01to2019-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-07-01to2018-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2018-07-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2018-07-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">48999</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-07-01to2018-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">642846</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2018-07-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2017-07-01to2018-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <dei:EntityRegistrantName contextRef="From2019-07-01to2019-12-31">BIOVIE INC.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2019-07-01to2019-12-31">0001580149</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2019-07-01to2019-12-31">S-1/A</dei:DocumentType>
    <dei:AmendmentFlag contextRef="From2019-07-01to2019-12-31">true</dei:AmendmentFlag>
    <dei:EntityFilerCategory contextRef="From2019-07-01to2019-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">825918</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2019-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherInterestAndDividendIncome contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">51400</us-gaap:OtherInterestAndDividendIncome>
    <us-gaap:OtherInterestAndDividendIncome contextRef="From2017-07-01to2018-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:Liabilities contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">2064292</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">443480</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">4383972</us-gaap:Liabilities>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">575918</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="AsOf2019-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">-2444287</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">-2413122</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2018-07-01to2019-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2017-07-01to2018-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-07-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-07-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2017-07-01to2018-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-07-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-2444287</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2017-07-01to2018-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-2413122</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">2843811</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">-940381</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">6665038</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">-500510</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-10-01to2019-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-10-01to2018-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-07-01to2019-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-10-01to2018-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-07-01to2019-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-10-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-07-01to2019-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2018-07-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProfitLoss contextRef="From2019-10-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">6665038</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2018-10-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-500510</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-07-01to2019-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-3821227</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2018-07-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-439871</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2019-07-01to2019-09-30" unitRef="USD" decimals="0">-3821227</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="From2018-07-01to2018-09-30" unitRef="USD" decimals="0">-439871</us-gaap:ProfitLoss>
    <bivi:DeemedDividend contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">48659</bivi:DeemedDividend>
    <bivi:DeemedDividend contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">20995</bivi:DeemedDividend>
    <bivi:DeemedDividend contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">17099058</bivi:DeemedDividend>
    <bivi:DeemedDividend contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">48659</bivi:DeemedDividend>
    <bivi:DeemedDividend contextRef="From2019-10-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividend contextRef="From2018-10-01to2018-12-31" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividend contextRef="From2019-07-01to2019-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividend contextRef="From2019-07-01to2019-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividend contextRef="From2019-07-01to2019-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividend contextRef="From2019-07-01to2019-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-17099058</bivi:DeemedDividend>
    <bivi:DeemedDividend contextRef="From2019-07-01to2019-09-30" unitRef="USD" decimals="0">-17099058</bivi:DeemedDividend>
    <us-gaap:Revenues contextRef="From2018-07-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:Revenues contextRef="From2017-07-01to2018-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">4058724</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-06-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2019-06-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2018-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">788026</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2017-06-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2017-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">735400</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">5183724</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2520431</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2019-09-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2018-09-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">5183724</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2520431</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-06-30" unitRef="USD" decimals="0">1157319</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">111199</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">406</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">9392573</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-7262072</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">79</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4880246</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-4769126</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">74</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3492254</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2017-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-2335009</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">2130907</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">-2044428</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">3540650</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">518</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">253</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">19472373</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">9298563</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-21517319</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-5758166</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">518</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">253</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">19461211</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">9282278</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-28182357</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-5257656</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2019-09-30" unitRef="USD" decimals="0">-8720628</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="AsOf2018-09-30" unitRef="USD" decimals="0">4024875</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">26519</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-07-01to2019-06-30" unitRef="Shares" decimals="INF">182667</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">41200</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">38193</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-07-01to2019-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">124667</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-07-01to2019-06-30_us-gaap_StockOptionMember128077054" unitRef="Shares" decimals="INF">58000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-07-01to2018-06-30" unitRef="Shares" decimals="INF">79393</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-07-01to2019-12-31" unitRef="Shares" decimals="INF">1435067</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-07-01to2018-12-31" unitRef="Shares" decimals="INF">1775925</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-07-01to2019-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">60400</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-07-01to2018-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">44400</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2019-07-01to2019-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">1374667</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-07-01to2018-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">1731525</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">1783980</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">1554603</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">1439915</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">509790</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">739167</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">853855</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">2293770</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">2293770</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">2293770</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">58000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-06-30_custom_StockOptionOneMember" unitRef="Shares" decimals="INF">5600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-06-30_custom_StockOptionTwoMember" unitRef="Shares" decimals="INF">10400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-06-30_custom_StockOptionThreeMember" unitRef="Shares" decimals="INF">24800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-06-30_custom_StockOptionFourMember" unitRef="Shares" decimals="INF">800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-06-30_custom_StockOptionFiveMember" unitRef="Shares" decimals="INF">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-06-30_custom_StockOptionSixMember" unitRef="Shares" decimals="INF">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-06-30_custom_StockOptionSevenMember" unitRef="Shares" decimals="INF">4400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-06-30_custom_StockOptionEightMember" unitRef="Shares" decimals="INF">800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-06-30_custom_StockOptionNineMember" unitRef="Shares" decimals="INF">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-06-30_custom_StockOptionTenMember" unitRef="Shares" decimals="INF">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">60400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-12-31_custom_StockOptionOneMember" unitRef="Shares" decimals="INF">5600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-12-31_custom_StockOptionTwoMember" unitRef="Shares" decimals="INF">11200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-12-31_custom_StockOptionThreeMember" unitRef="Shares" decimals="INF">25600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-12-31_custom_StockOptionFourMember" unitRef="Shares" decimals="INF">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-12-31_custom_StockOptionFiveMember" unitRef="Shares" decimals="INF">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-12-31_custom_StockOptionSixMember" unitRef="Shares" decimals="INF">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-12-31_custom_StockOptionSevenMember" unitRef="Shares" decimals="INF">4400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-12-31_custom_StockOptionEightMember" unitRef="Shares" decimals="INF">800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-12-31_custom_StockOptionNineMember" unitRef="Shares" decimals="INF">1600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="AsOf2019-12-31_custom_StockOptionTenMember" unitRef="Shares" decimals="INF">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-06-30_custom_StockOptionOneMember">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-06-30_custom_StockOptionTwoMember">P4Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-06-30_custom_StockOptionThreeMember">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-06-30_custom_StockOptionFourMember">P4Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-06-30_custom_StockOptionFiveMember">P3Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-06-30_custom_StockOptionSixMember">P3Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-06-30_custom_StockOptionSevenMember">P2Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-06-30_us-gaap_StockOptionMember128077054">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-06-30_custom_StockOptionEightMember">P2Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-06-30_custom_StockOptionNineMember">P3Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-06-30_custom_StockOptionTenMember">P2Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2019-07-01to2019-12-31_us-gaap_StockOptionMember">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2019-07-01to2019-12-31_custom_StockOptionOneMember">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2019-07-01to2019-12-31_custom_StockOptionTwoMember">P4Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2019-07-01to2019-12-31_custom_StockOptionThreeMember">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2019-07-01to2019-12-31_custom_StockOptionFourMember">P4Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2019-07-01to2019-12-31_custom_StockOptionFiveMember">P3Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2019-07-01to2019-12-31_custom_StockOptionSixMember">P2Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2019-07-01to2019-12-31_custom_StockOptionSevenMember">P2Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2019-07-01to2019-12-31_custom_StockOptionEightMember">P2Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2019-07-01to2019-12-31_custom_StockOptionNineMember">P2Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2019-07-01to2019-12-31_custom_StockOptionTenMember">P10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4 contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember">P5Y9M18D</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4 contextRef="From2018-07-01to2019-06-30_us-gaap_StockOptionMember128077054">P5Y2M12D</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4 contextRef="From2019-07-01to2019-12-31_us-gaap_StockOptionMember">P4Y1M6D</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2018-07-01to2019-06-30_us-gaap_StockOptionMember128077054">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2019-07-01to2019-12-31_us-gaap_StockOptionMember">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2018-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">38193</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2019-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">124667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2017-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">49391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2019-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">1374667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="AsOf2018-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">36.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="AsOf2019-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">45.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="AsOf2017-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">62.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="AsOf2019-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">7.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3 contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember">P5Y6M</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3 contextRef="From2018-07-01to2019-06-30_us-gaap_WarrantMember">P5Y7M6D</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3 contextRef="From2019-07-01to2019-12-31_us-gaap_WarrantMember">P4Y8M12D</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">28802</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2018-07-01to2019-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">1713332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2019-07-01to2019-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">27.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue contextRef="From2018-07-01to2019-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">45.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue contextRef="From2019-07-01to2019-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">4.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">62.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember">P5Y3M18D</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="From2018-07-01to2019-06-30_us-gaap_WarrantMember">P5Y7M6D</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="From2019-07-01to2019-12-31_us-gaap_WarrantMember">P4Y8M12D</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2017-07-01to2018-06-30_us-gaap_WarrantMember">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2018-07-01to2019-06-30_us-gaap_WarrantMember">P5Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2019-07-01to2019-12-31_us-gaap_WarrantMember">P5Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">3040000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">250000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="From2019-07-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">3040000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <bivi:ConversionOfPreferredSharesToCommonStock contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">3200000</bivi:ConversionOfPreferredSharesToCommonStock>
    <bivi:ConversionOfPreferredSharesToCommonStock contextRef="From2017-07-01to2018-06-30" unitRef="USD" xsi:nil="true" />
    <bivi:ConversionOfPreferredSharesToCommonStock contextRef="From2019-07-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <bivi:ConversionOfPreferredSharesToCommonStock contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">3200000</bivi:ConversionOfPreferredSharesToCommonStock>
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">1150135</bivi:SettlementOfDebtByIssuanceOfCommonStock>
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2017-07-01to2018-06-30" unitRef="USD" xsi:nil="true" />
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2018-07-01to2019-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2018-07-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1</bivi:SettlementOfDebtByIssuanceOfCommonStock>
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2018-07-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1150134</bivi:SettlementOfDebtByIssuanceOfCommonStock>
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2018-07-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2019-07-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">1150135</bivi:SettlementOfDebtByIssuanceOfCommonStock>
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1</bivi:SettlementOfDebtByIssuanceOfCommonStock>
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2018-07-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1150134</bivi:SettlementOfDebtByIssuanceOfCommonStock>
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2018-07-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:SettlementOfDebtByIssuanceOfCommonStock contextRef="From2018-07-01to2018-09-30" unitRef="USD" decimals="0">1150135</bivi:SettlementOfDebtByIssuanceOfCommonStock>
    <bivi:CashlessExerciseOfWarrants contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">19309</bivi:CashlessExerciseOfWarrants>
    <bivi:CashlessExerciseOfWarrants contextRef="From2017-07-01to2018-06-30" unitRef="USD" xsi:nil="true" />
    <bivi:CashlessExerciseOfWarrants contextRef="From2018-07-01to2019-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:CashlessExerciseOfWarrants contextRef="From2018-07-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">154</bivi:CashlessExerciseOfWarrants>
    <bivi:CashlessExerciseOfWarrants contextRef="From2018-07-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-154</bivi:CashlessExerciseOfWarrants>
    <bivi:CashlessExerciseOfWarrants contextRef="From2018-07-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:CashlessExerciseOfWarrants contextRef="From2019-07-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <bivi:CashlessExerciseOfWarrants contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">224</bivi:CashlessExerciseOfWarrants>
    <bivi:CashlessExerciseOfWarrants contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:CashlessExerciseOfWarrants contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2</bivi:CashlessExerciseOfWarrants>
    <bivi:CashlessExerciseOfWarrants contextRef="From2018-07-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-2</bivi:CashlessExerciseOfWarrants>
    <bivi:CashlessExerciseOfWarrants contextRef="From2018-07-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:CashlessExerciseOfWarrants contextRef="From2018-07-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestPaidNet contextRef="From2018-07-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestPaidNet contextRef="From2017-07-01to2018-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestPaidNet contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">1272</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2018-07-01to2018-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaidNet contextRef="From2018-07-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaidNet contextRef="From2017-07-01to2018-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaidNet contextRef="From2019-07-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaidNet contextRef="From2018-07-01to2018-12-31" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfPreferredStockInPrivatePlacement contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">3200000</bivi:IssuanceOfPreferredStockInPrivatePlacement>
    <bivi:IssuanceOfPreferredStockInPrivatePlacement contextRef="From2018-07-01to2019-06-30_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">3200000</bivi:IssuanceOfPreferredStockInPrivatePlacement>
    <bivi:IssuanceOfPreferredStockInPrivatePlacement contextRef="From2018-07-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfPreferredStockInPrivatePlacement contextRef="From2018-07-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3200000</bivi:IssuanceOfPreferredStockInPrivatePlacement>
    <bivi:IssuanceOfPreferredStockInPrivatePlacement contextRef="From2018-07-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfPreferredStockInPrivatePlacement contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">3200000</bivi:IssuanceOfPreferredStockInPrivatePlacement>
    <bivi:IssuanceOfPreferredStockInPrivatePlacement contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfPreferredStockInPrivatePlacement contextRef="From2018-07-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3200000</bivi:IssuanceOfPreferredStockInPrivatePlacement>
    <bivi:IssuanceOfPreferredStockInPrivatePlacement contextRef="From2018-07-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfPreferredStockInPrivatePlacement contextRef="From2018-07-01to2018-09-30" unitRef="USD" decimals="0">3200000</bivi:IssuanceOfPreferredStockInPrivatePlacement>
    <bivi:ConversionOfPreferredStockToCommonStock contextRef="From2018-07-01to2019-06-30" unitRef="USD" xsi:nil="true" />
    <bivi:ConversionOfPreferredStockToCommonStock contextRef="From2018-07-01to2019-06-30_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">-3200000</bivi:ConversionOfPreferredStockToCommonStock>
    <bivi:ConversionOfPreferredStockToCommonStock contextRef="From2018-07-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">171</bivi:ConversionOfPreferredStockToCommonStock>
    <bivi:ConversionOfPreferredStockToCommonStock contextRef="From2018-07-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-171</bivi:ConversionOfPreferredStockToCommonStock>
    <bivi:ConversionOfPreferredStockToCommonStock contextRef="From2018-07-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:ConversionOfPreferredStockToCommonStock contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="USD" decimals="0">-3200000</bivi:ConversionOfPreferredStockToCommonStock>
    <bivi:ConversionOfPreferredStockToCommonStock contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">171</bivi:ConversionOfPreferredStockToCommonStock>
    <bivi:ConversionOfPreferredStockToCommonStock contextRef="From2018-07-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-171</bivi:ConversionOfPreferredStockToCommonStock>
    <bivi:ConversionOfPreferredStockToCommonStock contextRef="From2018-07-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:ConversionOfPreferredStockToCommonStock contextRef="From2018-07-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <bivi:ConversionOfPreferredStockToCommonStockInShares contextRef="From2018-07-01to2019-06-30_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">-2133332</bivi:ConversionOfPreferredStockToCommonStockInShares>
    <bivi:ConversionOfPreferredStockToCommonStockInShares contextRef="From2018-07-01to2019-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1706666</bivi:ConversionOfPreferredStockToCommonStockInShares>
    <bivi:ConversionOfPreferredStockToCommonStockInShares contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">-2133332</bivi:ConversionOfPreferredStockToCommonStockInShares>
    <bivi:ConversionOfPreferredStockToCommonStockInShares contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1706666</bivi:ConversionOfPreferredStockToCommonStockInShares>
    <us-gaap:ShareBasedCompensation contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">64860</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">238165</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-07-01to2019-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-07-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-07-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">64860</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-07-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">11162</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">19697</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">11162</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">16285</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-10-01to2019-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-10-01to2018-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2019-10-01to2019-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-10-01to2018-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2019-10-01to2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">11162</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-10-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">16285</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-07-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3412</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2019-10-01to2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-10-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-07-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensation contextRef="From2018-07-01to2018-09-30" unitRef="USD" decimals="0">3412</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2019-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">12.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2019-06-30_custom_StockOptionOneMember" unitRef="USDPShares" decimals="INF">3.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2019-06-30_custom_StockOptionTwoMember" unitRef="USDPShares" decimals="INF">6.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2019-06-30_custom_StockOptionThreeMember" unitRef="USDPShares" decimals="INF">7.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2019-06-30_custom_StockOptionFourMember" unitRef="USDPShares" decimals="INF">8.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2019-06-30_custom_StockOptionFiveMember" unitRef="USDPShares" decimals="INF">12.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2019-06-30_custom_StockOptionSixMember" unitRef="USDPShares" decimals="INF">25.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2019-06-30_custom_StockOptionSevenMember" unitRef="USDPShares" decimals="INF">26.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2019-06-30_custom_StockOptionEightMember" unitRef="USDPShares" decimals="INF">27.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2019-06-30_custom_StockOptionNineMember" unitRef="USDPShares" decimals="INF">28.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2019-06-30_custom_StockOptionTenMember" unitRef="USDPShares" decimals="INF">31.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="AsOf2019-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">12.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:IncomeLossAttributableToParent contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">-2492946</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">-2434117</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">-14255247</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">-989040</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">6665038</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">-500510</us-gaap:IncomeLossAttributableToParent>
    <bivi:TotalOtherExpenseIncome contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">-52286</bivi:TotalOtherExpenseIncome>
    <bivi:TotalOtherExpenseIncome contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">40956</bivi:TotalOtherExpenseIncome>
    <bivi:TotalOtherExpenseIncome contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">-4260476</bivi:TotalOtherExpenseIncome>
    <bivi:TotalOtherExpenseIncome contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">-51917</bivi:TotalOtherExpenseIncome>
    <bivi:TotalOtherExpenseIncome contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">-7375485</bivi:TotalOtherExpenseIncome>
    <bivi:TotalOtherExpenseIncome contextRef="From2018-10-01to2018-12-31" unitRef="USD" decimals="0">-360</bivi:TotalOtherExpenseIncome>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">250000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="AsOf2019-06-30" unitRef="USD" xsi:nil="true" />
    <dei:EntitySmallBusiness contextRef="From2019-07-01to2019-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2019-07-01to2019-12-31">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2018-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromRepaymentsOfDebt contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">-244300</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:ProceedsFromRepaymentsOfDebt contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">-35000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:ProceedsFromRepaymentsOfDebt contextRef="From2019-07-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromRepaymentsOfDebt contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">-244300</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2018-07-01to2019-06-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2017-07-01to2018-06-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2018-07-01to2019-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">11200</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">37988</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <bivi:SettlementOfDebtByIssuanceOfCommonStockShares contextRef="From2018-07-01to2019-06-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <bivi:SettlementOfDebtByIssuanceOfCommonStockShares contextRef="From2018-07-01to2019-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">7804</bivi:SettlementOfDebtByIssuanceOfCommonStockShares>
    <bivi:SettlementOfDebtByIssuanceOfCommonStockShares contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <bivi:SettlementOfDebtByIssuanceOfCommonStockShares contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">7804</bivi:SettlementOfDebtByIssuanceOfCommonStockShares>
    <bivi:CashlessExerciseOfWarrantsShares contextRef="From2018-07-01to2019-06-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <bivi:CashlessExerciseOfWarrantsShares contextRef="From2018-07-01to2019-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1544746</bivi:CashlessExerciseOfWarrantsShares>
    <bivi:CashlessExerciseOfWarrantsShares contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <bivi:CashlessExerciseOfWarrantsShares contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">17935</bivi:CashlessExerciseOfWarrantsShares>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2018-07-01to2019-06-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 5%"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 95%"&gt;&lt;b&gt;Background Information and Reverse Stock Split&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Background Information&lt;/i&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;We are a clinical-stage company pursuing the discovery, development, and commercialization&#13;of innovative drug therapies. We are currently focused on developing and commercializing BIV201 (continuous infusion terlipressin),&#13;a novel approach to the treatment of ascites due to chronic liver cirrhosis. Our therapy BIV201 is based on a drug that is approved&#13;in about 40 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not&#13;yet available in the United States. BIV201&amp;#8217;s active agent is a potent vasoconstrictor and has shown efficacy for reducing&#13;portal hypertension in studies around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby halting&#13;the cycle of accelerating fluid generation in ascites patients.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In April 2017, we entered into a CRADA with the McGuire Research Institute Inc. in Richmond,&#13;VA, and began administering BIV201 to patients in September 2017. In April 2019, we announced top-line results for our Phase 2a&#13;clinical trial of BIV201 (continuous infusion terlipressin) in six patients with refractory ascites due to advanced liver cirrhosis.&#13;On June 18, 2019, we met with representatives of the FDA for Type C Guidance Meeting to plan our next clinical study following&#13;the recently completed Phase 2a clinical trial. We discussed our clinical development efforts with the FDA and proposed trial&#13;endpoints. While the FDA has not provided final guidance nor do we have certainty as to what that guidance would entail, our goal&#13;remains to proceed into a Phase 2b/3 or Phase 3 clinical trial in a manner consistent with what was reviewed with the FDA. We&#13;may still need to address certain risks associated with unvalidated quality of life measures. In July 2019, the FDA provided meeting&#13;minutes for the June 18, 2019 meeting that documented general agreement with the Company proposed randomized study design. The&#13;FDA also provided its suggestions and guidance regarding primary and secondary endpoints and other key aspects of our clinical&#13;trial design and the Company is incorporating those suggestions as it moves forward. We are developing a proprietary novel liquid&#13;formulation of terlipressin that is intended to improve convenience for outpatient administration and avoid potential formulation&#13;errors when pharmacists reconstitute the powder version.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;BIV201 has the potential to improve the health of thousands of patients suffering from&#13;life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. It has&#13;FDA Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which represents a significant&#13;unmet medical need. The FDA has never approved any drug specifically for treating ascites. The Company has secured a US Patent&#13;covering the use of BIV201 for the treatment of ascites patients in the outpatient setting using ambulatory pump infusion, and&#13;has filed patent applications for its product candidate in Japan, and Europe, Hong Kong, and China. BIV201 also received Orphan&#13;Drug designation for hepatorenal syndrome (&amp;#8220;HRS&amp;#8221;) in November 2018.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company&#13;acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development and marketing&#13;rights to its drug candidate. The Company and PharmaIN, Corp. (&amp;#8220;PharmaIN&amp;#8221;), LAT Pharma&amp;#8217;s former partner focused&#13;on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties&#13;equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed&#13;to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial&#13;ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on&#13;a related debt. PharmaIN, Corp.&amp;#8217;s rights to our program remain unchanged.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company&amp;#8217;s activities are subject to significant risks and uncertainties including&#13;failure to secure additional funding to properly execute the Company&amp;#8217;s business plan.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On November 21, 2019, the Company effected a 1:125 reverse stock split of the Company&amp;#8217;s&#13;common stock. The reverse split combined each 125 shares of the Company&amp;#8217;s issued and outstanding common stock into 1 share&#13;of the common stock. No fractional shares were issued in connection with the reverse split, and any fractional shares resulting&#13;from the reverse split were rounded up to the nearest whole share. Unless the context otherwise requires, all references in these&#13;financial statements to shares of the Company&amp;#8217;s common stock, options and warrants, including prices per share of its&#13;common stock reflect the Reverse Stock Split.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2019-07-01to2019-12-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 99%"&gt;&lt;b&gt;Background Information&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;BioVie Inc. (the &amp;#8220;Company&amp;#8221;) is a clinical-stage company pursuing the discovery,&#13;development, and commercialization of innovative drug therapies. We are currently focused on developing and commercializing BIV201&#13;(continuous infusion terlipressin), a novel approach to the treatment of ascites due to chronic liver cirrhosis. Our therapy BIV201&#13;is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis (part of the same&#13;disease pathway as ascites), but not yet available in the United States. BIV201&amp;#8217;s active agent is a potent vasoconstrictor&#13;and has shown efficacy for reducing portal hypertension in studies around the world. The goal is for BIV201 to interrupt the ascites&#13;disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;BioVie began administering BIV201 to patients in a Phase 2a clinical trial in patients&#13;with refractory ascites due to advanced liver cirrhosis at the McGuire Research Institute Inc. in Richmond, VA in September 2017.&#13;In April 2019, we announced top-line results and in June met with representatives of the FDA for a Type C Guidance Meeting to&#13;discuss the study results and plan our next clinical study. In July 2019, the FDA provided meeting minutes that documented general&#13;agreement with the Company&amp;#8217;s proposed randomized and controlled study design. The FDA also provided its suggestions and&#13;guidance regarding primary and secondary endpoints, quality of life measures and other key aspects of the clinical trial design.&#13;In October 2019, BioVie announced the submission of a Phase 2b/3 clinical trial protocol to the FDA. We are developing a patent-pending&#13;novel liquid formulation of terlipressin for use in this study that is intended to improve convenience for outpatient administration&#13;and avoid potential formulation errors that may occur when pharmacists reconstitute the powder version.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;BIV201 has the potential to improve the health of thousands of patients suffering from&#13;life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. It has&#13;FDA Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which represents a significant&#13;unmet medical need. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States&#13;for the designated use(s). The FDA has never approved any drug specifically for treating ascites.&amp;#160;In addition, the Company&#13;has a pending patent application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2b/3&#13;trial, subject to FDA clearance, which could eventually provide up to 20 years of patent coverage in each country in which the&#13;Company seeks patent protection, such as the United States, if a patent issues according to the patent laws of the issuing country.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company&#13;acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development and marketing&#13;rights to its drug candidate. The Company and PharmaIN, Corp. (&amp;#8220;PharmaIN&amp;#8221;), LAT Pharma&amp;#8217;s former partner focused&#13;on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties&#13;equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed&#13;to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial&#13;ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on&#13;a related debt. PharmaIN, Corp.&amp;#8217;s rights to our program remain unchanged.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company&amp;#8217;s activities are subject to significant risks and uncertainties including&#13;failure to secure additional funding to properly execute the Company&amp;#8217;s business plan.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <bivi:LiquidityTextBlock contextRef="From2018-07-01to2019-06-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 5%"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 95%"&gt;&lt;b&gt;Liquidity and Going Concern&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company&amp;#8217;s operations are subject to a number of factors that can affect its&#13;operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and&#13;trial activities of the Company&amp;#8217;s products, the Company&amp;#8217;s ability to obtain regulatory approval to market its products,&#13;competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products,&#13;the Company&amp;#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products,&#13;and the Company&amp;#8217;s ability to raise capital. The Company&amp;#8217;s financial statements have been prepared assuming the Company&#13;will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal&#13;course of business. The Company has experienced losses since inception and has an accumulated deficit of approximately $7.3 million&#13;at June 30, 2019. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future.&#13;The Company&amp;#8217;s future operations are dependent on the success of the Company&amp;#8217;s ongoing development and commercialization&#13;efforts, as well as continuing to secure additional financing.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In July 2018, the Company completed a capital raise from Acuitas Group Holding, LLC&#13;(&amp;#8220;Acuitas&amp;#8221;) and other purchasers and received net proceeds of $3.2 million ( see note 8 &amp;#8220;Equity Transactions&amp;#8221;)&#13;and resumed further clinical development of BIV201 and completed its Phase 2a clinic trial program. The Company is pursuing various&#13;options to raise further financing to continue the testing and development of its product. If the Company is not successful in&#13;raising additional funds it may reduce its monthly spend and potentially delay the implementation of the larger scale Phase 2b&#13;Clinical trial until sufficient funding is secured.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Additionally, in April 2019, to facilitate our planned uplisting to the NASDAQ Stock&#13;Market and related potential future issuances and sales of our equity securities for ordinary corporate finance and general corporate&#13;purposes and as recommended by our Board of Directors (&amp;#8220;Board&amp;#8221;), our stockholders approved an amendment to our Articles&#13;of Incorporation to effect a reverse split of our outstanding Class A common stock in the range of 50:1 to 200:1, as determined&#13;by our Board. Following that approval, we filed a Registration Statement on Form S-1 (Registration No. 333-231136) (the S-1 Registration&#13;Statement) pursuant to which we anticipate completing an offering of our equity securities with proceeds sufficient to enable&#13;the launch and completion of the BIV201 Phase 2b study and fund our internal operations for at least the next twelve months. There&#13;can be no assurance, however, that we will achieve effectiveness of the S-1 Registration Statement or successfully complete an&#13;offering thereunder.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The future viability of the Company is largely dependent upon its ability to raise additional&#13;capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans,&#13;or other strategic transactions. Although management continues to pursue these plans, there is no assurance that the Company will&#13;be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations.&#13;These circumstances raise substantial doubt on the Company&amp;#8217;s ability to continue as a going concern. The financial statements&#13;do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;</bivi:LiquidityTextBlock>
    <bivi:LiquidityTextBlock contextRef="From2019-07-01to2019-12-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 99%"&gt;&lt;b&gt;Liquidity and Going Concern&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company&amp;#8217;s operations are subject&#13;to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited&#13;to: the results of clinical testing and trial activities of the Company&amp;#8217;s products, the Company&amp;#8217;s ability to obtain&#13;regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies,&#13;the price of, and demand for, Company products, the Company&amp;#8217;s ability to negotiate favorable licensing or other manufacturing&#13;and marketing agreements for its products, and the Company&amp;#8217;s ability to raise capital. The Company&amp;#8217;s financial statements&#13;have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the&#13;satisfaction of liabilities in the normal course of business. As of December 31, 2019, the Company had an accumulated deficit of&#13;approximately $21.5 million and as a development stage enterprise, the Company expects substantial losses in future periods. The&#13;accompanying interim financial statements were prepared assuming the Company will continue as a going concern, which contemplates&#13;the realization of assets and the satisfaction of liabilities in the normal course of business. The Company&amp;#8217;s future operations&#13;are dependent on the success of the Company&amp;#8217;s ongoing development and commercialization effort, as well as continuing to&#13;secure additional financing.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On September 24, 2019, the Company entered&#13;into a Securities Purchase Agreement with its controlling stockholder regarding bridge financing (the &amp;#8220;Bridge Financing&amp;#8221;)&#13;in the form of up to $2.0 million in convertible debt and warrants, of which $500,000 has been drawn as of December 31, 2019. In&#13;December 2019, Acuitas provided the Company, a short-term interest free advance of $30,000. Amounts borrowed under the Bridge Financing&#13;must be repaid with the proceeds of our potential public offering of equity securities referred to below. The availability of additional&#13;draws under the Bridge Financing is under further discussion with the controlling stockholder in light of delays in the timing&#13;of the potential public offering. As further discussed below, the Company is pursuing various options to raise further financing&#13;to continue the testing and development of its product. If the Company is not successful in raising additional funds it may reduce&#13;its monthly spend and potentially delay the implementation of the larger scale Phase 2b/3 clinical trial until sufficient funding&#13;is secured.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Additionally, in April 2019, to facilitate&#13;our planned up listing to the NASDAQ Stock Market and related potential future issuances and sales of our equity securities for&#13;ordinary corporate finance and general corporate purposes and as recommended by our Board of Directors (&amp;#8220;Board&amp;#8221;), our&#13;stockholders approved an amendment to our Articles of Incorporation to effect a reverse split of our outstanding Class A common&#13;stock in the range of 50:1 to 200:1, as determined by our Board. On November 22, 2019, the Company effected the reverse stock split&#13;of 125 common stock for every 1 common stock. All share amounts have been updated to reflect the reverse stock split.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The future viability of the Company&#13;is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources&#13;of funding may include sales of equity, obtaining loans, or other strategic transactions. Although management continues to pursue&#13;these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to&#13;the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company&amp;#8217;s ability&#13;to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this&#13;uncertainty.&lt;/p&gt;</bivi:LiquidityTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2018-07-01to2019-06-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 5%"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 95%"&gt;&lt;b&gt;Significant Accounting Policies&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Basis of Presentation &lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company&amp;#8217;s financial statements have been prepared in accordance with accounting&#13;principles generally accepted in the United States (&amp;#8220;GAAP&amp;#8221;) and include all adjustments necessary for the fair presentation&#13;of the Company&amp;#8217;s financial position for the periods presented.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity with GAAP requires management&#13;to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company&#13;bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances.&#13;The amounts of assets and liabilities reported in the Company&amp;#8217;s balance sheet and the amounts of expenses reported for each&#13;of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, accounting for share-based&#13;compensation, accounting for derivatives and accounting for income taxes. Actual results could differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company considers all highly liquid instruments with original maturities of three&#13;months or less to be cash equivalents. Cash is maintained at one financial institution and, at times, balances may exceed federally&#13;insured limits. The Company has never experienced any losses related to these balances. All of the Company&amp;#8217;s cash balances&#13;were fully insured at June 30, 2019.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Other Assets&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Other Assets consists of direct cost related to capital raise and filing of the registration&#13;statement legal fees and investment banking fees incurred to raise capital. The costs will be expensed once the Company raises&#13;the capital.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Fair value is defined as the price that would be received from selling an asset or paid&#13;to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair&#13;value for applicable assets and liabilities, we consider the principal or most advantageous market in which we would transact&#13;and we consider assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer&#13;restrictions, and risk of nonperformance. This guidance also establishes a fair value hierarchy to prioritize inputs used in measuring&#13;fair value as follows:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 35px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td&gt;Level 1: Observable inputs such as quoted prices in active markets&amp;#894;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 35px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td&gt;Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly&amp;#894; and&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 35px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop&#13;    its own assumptions&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company&amp;#8217;s financial instruments include cash, accounts payable, related party&#13;loans and a demand promissory note. The carrying amounts of cash and accounts payable approximate their fair value, due to the&#13;short-term nature of these items.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Long-Term Notes Payable&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company&amp;#8217;s long-term notes payable include accrued payroll to officers and&#13;accrued payments to third party consultants.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Research and development expenses consist primarily of costs associated with the preclinical&#13;and/ or clinical trials of drug candidates, compensation and other expenses for research and development, personnel, supplies&#13;and development materials, costs for consultants and related contract research and facility costs. Expenditures relating to research&#13;and development are expensed as incurred.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company uses the asset and liability method of accounting for deferred income taxes.&#13;Deferred income taxes are measured by applying enacted statutory rates to net operating loss carryforwards and to the differences&#13;between the financial reporting and tax bases of assets and liabilities. Deferred tax assets are reduced, if necessary, by a valuation&#13;allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company recognizes uncertainty in income taxes in the financial statements using&#13;a recognition threshold and measurement attribute of a tax position taken or expected to be taken in a tax return. The Company&#13;applies the &amp;#8220;more-likely-than-not&amp;#8221; recognition threshold to all tax positions, commencing at the adoption date of&#13;the applicable accounting guidance, which resulted in no unrecognized tax benefits as of such date. Additionally, there have been&#13;no unrecognized tax benefits subsequent to adoption. The Company has opted to classify interest and penalties that would accrue,&#13;if any, according to the provisions of relevant tax law as general and administrative expenses, in the statements of operations.&#13;For the years ended June 30, 2019 and 2018 there was no such interest or penalty.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Net Loss per Common Share&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Basic net loss per common share is computed by dividing the net loss before deemed dividend&#13;by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed&#13;by dividing net loss by the weighted average number of shares of common stock outstanding and potentially outstanding shares of&#13;common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options,&#13;warrants, convertible preferred stock and convertible debentures. Due to the net loss for the period, such amounts were excluded&#13;from the diluted loss since their effect was considered anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The table below shows the number of outstanding stock options and warrants as of June&#13;30, 2019 and June 30, 2018:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;June 30, 2019&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;June 30, 2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Number of Shares&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 56%; text-align: left; padding-left: 5.4pt"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;58,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;41,200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;124,667&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;38,193&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold; padding-left: 5.4pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double"&gt;182,667&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double"&gt;79,393&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company has accounted for stock-based compensation under the provisions of FASB&#13;ASC 718 &amp;#8211; &amp;#8220;Stock Compensation&amp;#8221; which requires the use of the fair-value based method to determine compensation&#13;for all arrangements under which employees and others receive shares of stock or equity instruments (stock options and common&#13;stock purchase warrants). For employee awards, the fair value of each stock option award is estimated on the date of grant using&#13;the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free&#13;interest rate. For non-employees, the fair value of each stock option award is estimated on the measurement date using the Black-Scholes&#13;valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.&#13;For non-employees, the Company utilizes the graded vesting attribution method under which the entity treats each separately vesting&#13;portion (tranche) as a separate award and recognizes compensation cost for each tranche over its separate vesting schedule. Expected&#13;volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the stock&#13;options. For employee awards, the expected term of options granted is derived using the &amp;#8220;simplified method&amp;#8221; which&#13;computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the&#13;U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. We recognize forfeitures as they&#13;occur.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Goodwill is recorded when the purchase price paid for an acquisition exceeds the fair&#13;value of net identified tangible and intangible assets acquired. The Company performs an annual impairment test of goodwill and&#13;further periodic tests to the extent indicators of impairment develop between annual impairment tests. The Company&amp;#8217;s impairment&#13;review process compares the fair value of the reporting unit to its carrying value, including the goodwill related to the reporting&#13;unit. To determine the fair value of the reporting unit, the Company may use various approaches including an asset or cost approach,&#13;market approach or income approach or any combination thereof. These approaches may require the Company to make certain estimates&#13;and assumptions including future cash flows, revenue and expenses. These estimates and assumptions are reviewed each time the&#13;Company tests goodwill for impairment and are typically developed as part of the Company&amp;#8217;s routine business planning and&#13;forecasting process. While the Company believes its estimates and assumptions are reasonable, variations from those estimates&#13;could produce materially different results. The Company did not recognize any goodwill impairments for the years ended June 30th,&#13;2018 and June 30th, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Long-lived assets, including intangible assets, are reviewed for impairment whenever&#13;events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets&#13;to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows&#13;expected to be generated by the asset.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;If the carrying amount of an asset exceeds its undiscounted estimated future cash flows,&#13;an impairment review is performed. An impairment charge is recognized in the amount by which the carrying amount of the asset&#13;exceeds the fair value of the asset. Generally, fair value is determined using valuation techniques such as expected discounted&#13;cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented in the balance sheet and reported&#13;at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated or amortized. The assets and&#13;liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability&#13;sections of the balance sheet.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Certain prior year amounts have been reclassified for consistency with current year&#13;presentation. These reclassifications had no effect on the reported results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Recent accounting pronouncements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company considers the applicability and impact of all Accounting Standard Updates&#13;(&amp;#8220;ASU&amp;#8217;s&amp;#8221;). ASU&amp;#8217;s not discussed below were assessed and determined to be either not applicable or expected&#13;to have minimal impact on our balance sheets or statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In June 2018, the FASB issued ASU 2018-07, &amp;#8220;Compensation &amp;#8211; Stock Compensation&#13;(Topic 718): Improvements to Non-employee share based accounting&amp;#8221;, which simplifies the accounting for non-employee share-based&#13;payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor&#13;acquires goods or services to be used or consumed in a grantor&amp;#8217;s own operations by issuing share-based payment awards. The&#13;standard will be effective for the Company in the first quarter of fiscal year 2020, although early adoption is permitted (but&#13;no sooner than the adoption of Topic 606). The Company does not expect that the adoption of this ASU will have a significant impact&#13;on its financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In July 2017, the FASB issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2017-11.&#13;&amp;#8220;Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815):&#13;I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily&#13;Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with&#13;a Scope Exception. ASU 2017-11 revises the guidance for instruments with down round features in Subtopic 815-40, Derivatives and&#13;Hedging &amp;#8211; Contracts in Entity&amp;#8217;s Own Equity, which is considered in determining whether an equity-linked financial&#13;instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments&#13;would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception.&#13;If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017-11 is&#13;effective for annual and interim periods beginning December 15, 2018, and early adoption is permitted, including adoption in an&#13;interim period. ASU 2017-11 provides that upon adoption, an entity may apply this standard retrospectively to outstanding financial&#13;instruments with a down round feature by means of a cumulative-effect adjustment to the opening balance of retaining earnings&#13;in the fiscal year and interim period adopted. The Company is currently in the process of assessing the impact of this ASU on&#13;its financial statements.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2019-07-01to2019-12-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 99%"&gt;&lt;b&gt;Significant Accounting Policies&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Basis of Presentation &amp;#8211; Interim Financial Information&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The accompanying unaudited interim financial&#13;statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State&#13;of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of&#13;Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information&#13;and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect&#13;all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair&#13;presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for&#13;the full year. The condensed balance sheet at June 30, 2019 was derived from audited annual financial statements but does not contain&#13;all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included&#13;under the heading: &amp;#8220;Management&amp;#8217;s Discussion and Analysis of Financial Condition and Results of Operations&amp;#8221; should&#13;be read in conjunction with our Company&amp;#8217;s audited financial statements and related notes included in our Company&amp;#8217;s&#13;Form 10-K for the year ended June 30, 2019 filed with the SEC on September 27, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;For a summary of significant accounting&#13;policies, see the Company&amp;#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 filed with the SEC on September&#13;27, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Net income (loss) per Common Share&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Basic net income (loss) per common share&#13;is computed by dividing the net income (loss) before deemed dividend by the weighted average number of shares of common stock outstanding&#13;during the period.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Diluted net income (loss) per common&#13;share is computed by dividing by the weighted average number of shares of common stock outstanding and potentially outstanding&#13;shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through&#13;stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the six months ended December&#13;31, 2019 and 2018 as such amounts were excluded from the diluted loss since their effect was considered anti-dilutive. For the&#13;three months ended December 31, 2019, all potential securities were anti-dilutive as a result of the effect of the change in fair&#13;value of the derivative liabilities and assumed conversion of debenture in determining the amount of net income (loss) attributable&#13;to common stockholders. Due to the net loss for the three months ended December 31, 2018, amounts were excluded from the diluted&#13;loss since their effect was considered anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The table below shows the number of&#13;outstanding stock options and warrants as of December 31, 2019 and 2018:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;December 31, 2018&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 18%; padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Stock Options&lt;/td&gt;&#13;    &lt;td style="width: 34%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;60,400&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;44,400&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Warrants&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,374,667&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,731,525&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;b&gt;1,435,067&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;b&gt;1,775,925&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Recent accounting pronouncements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company considers the applicability&#13;and impact of all Accounting Standard Updates (&amp;#8220;ASU&amp;#8217;s&amp;#8221;). ASU&amp;#8217;s not discussed below were assessed and determined&#13;to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In June 2018, the FASB issued ASU 2018-07,&#13;&amp;#8220;Compensation &amp;#8211; Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting&amp;#8221;. This guidance&#13;aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions&#13;with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning&#13;of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption&#13;date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal&#13;years. Early adoption is permitted. The Company has adopted this ASU as of July 1, 2019. There has been no impact on the financial&#13;statements.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In August 2018, the FASB issued ASU 2018-13,&#13;&amp;#8220;Fair value measurement (Topic 820): Disclosure Framework &amp;#8211; Changes to the Disclosure Requirements for Fair Value Measurement&amp;#8221;.&#13;The new guidance modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for fiscal years beginning&#13;after December 15, 2019. Early adoption is permitted. The Company does not expect ASU 2018-13 to have a significant impact to its&#13;condensed consolidated financial statements and related disclosures.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2018-07-01to2019-06-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 5%"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 95%"&gt;&lt;b&gt;Intangible Assets&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Intellectual property, stated at cost, less accumulated amortization consists of the&#13;following:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;June 30, 2019&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;June 30, 2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 56%; text-align: left; padding-left: 5.4pt"&gt;Intellectual Property&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,293,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,293,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; padding-bottom: 1pt"&gt;Less Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(739,167&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(509,790&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; padding-bottom: 2.5pt"&gt;Intellectual Property, Net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;1,554,603&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;1,783,980&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Amortization expense amounted to $229,377 and $229,377 for the years ended June 30,&#13;2019 and 2018, respectively. The Company amortizes intellectual property over the expected original useful lives of 10 years.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Estimated future amortization expense is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;Year ending June 30,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 70%; text-align: center; padding-left: 5.4pt"&gt;2020&lt;/td&gt;&lt;td style="width: 10%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;229,377&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;2021&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;2022&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;2023&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;2024&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;407,718&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;1,554,603&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2019-07-01to2019-12-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 99%"&gt;&lt;b&gt;Intangible Assets&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company&amp;#8217;s&#13;intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated useful&#13;lives. The following is a summary of the intangible assets as of December 31, 2019 and June 30, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;June 30, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 58%; padding-left: 5.4pt"&gt;Intellectual Property&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;2,293,770&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;2,293,770&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Less Accumulated Amortization&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(853,855&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(739,167&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 4pt; padding-left: 5.4pt"&gt;Intellectual Property, Net&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;1,439,915&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;1,554,603&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Amortization expense&#13;for the three-month period ended December 31, 2019 and 2018 was $57,344 and $57,344 respectively Amortization expense for the six-month&#13;period ended December 31, 2019 and 2018 was $114,689 and $114,689 respectively.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Estimated future amortization&#13;expense is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="white-space: nowrap; width: 69%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year ending June 30, 2020 (Remaining six months)&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 31%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;114,689 &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;2021&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;229,377 &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;2022&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;229,377 &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;2023&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;229,377 &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;2024&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;229,377 &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;2025&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;229,377 &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Thereafter&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;178,341 &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid; border-bottom: black 4.5pt double; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,439,915 &lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <bivi:DemandNoteTextBlock contextRef="From2018-07-01to2019-06-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 5%"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 95%"&gt;&lt;b&gt;Renegotiated Debt&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On July 19, 2018, Geis-Hides Consulting LLC entered into an Accord and Debt Satisfaction&#13;Agreement with the Company in which the consulting firm agreed to release the Company from all liabilities arising from the Original&#13;Contract and Debt Repayment Plan dated December 15, 2013 totaling $132,000 and received cash of $65,000 and 2,080 common shares&#13;in satisfaction. The common shares were valued at the market price on the date of settlement at $7.50 per common share. The gain&#13;of $51,400 on the settlement of debt was reflected on the Statements of Operations as &amp;#8220;other income&amp;#8221; for the year&#13;ended June 30, 2019.&lt;/p&gt;</bivi:DemandNoteTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2018-07-01to2019-06-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 5%"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 95%"&gt;&lt;b&gt;Related Party Transactions&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On March 23, 2017, Barrett Ehrlich agreed to defer the payment of his consulting fee&#13;debt of $173,333 until&amp;#160;December 31, 2019, through the issuance of a Promissory note.&amp;#160; The promissory note does not carry&#13;any interest charge as long as the amount is paid in full before&amp;#160;December 31, 2019.&amp;#160; The consulting fee debt was reclassified&#13;from a current liability to a long-term liability on the balance sheet.&amp;#160;Any portion of the balance due under the note that&#13;remains unpaid after&amp;#160;December 31, 2019&amp;#160;will accrue interest at a rate of 5% per annum until paid in full.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On August 8, 2018, Barrett Ehrlich (Independent contractor, related party to Elliot&#13;Ehrlich and shareholder) on behalf of The Barrett Edge Inc. (&amp;#8220;Barrett&amp;#8221;) entered into an Accord and Debt Satisfaction&#13;Agreement with the Company in which Barrett agreed to release the Company from all liabilities including the original contract&#13;to defer payment of accrued consulting fees dated March 23, 2017, the promissory note issued by the Company to defer payment of&#13;accrued consulting fees; loan to the Company for $14,000, and subsequent unpaid consulting fees, totaling $543,014, and received&#13;cash of $131,333 and 3,947 common shares in satisfaction. The common shares were valued at the market price on the date of settlement&#13;at $16.25 per common share. The gain of $361,548 on the settlement of debt was reflected in the additional paid in capital for&#13;the year ended June 30, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On March 23, 2017, Elliot Ehrlich agreed to forgive 50% of his salary debt of $444,056.&amp;#160;&#13;The adjusted salary debt is $222,028.&amp;#160; Elliot Ehrlich also agreed to defer the payment of his salary debt of $222,028 until&amp;#160;December&#13;31, 2019, through the issuance of a Promissory note.&amp;#160; The promissory note does not carry any interest charge as long as the&#13;amount is paid in full before&amp;#160;December 31, 2019.&amp;#160; The salary debt was reclassified from a current liability to a long-term&#13;liability on the balance sheet and the salary debt forgiven had been reflected on the income statement as other income.&amp;#160;Any&#13;portion of the balance due under the note that remains unpaid after&amp;#160;December 31, 2019&amp;#160;will accrue interest at a rate&#13;of 5% per annum until paid in full.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On July 9, 2018, Elliot Ehrlich (former CEO and shareholder) entered into an Accord&#13;and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all liabilities including the&#13;original contract to defer payment of accrued salary dated March 23, 2017, totaling the amount of $1,777 the promissory note&#13;issued by the Company to defer payment of accrued salary; and received cash of $22,273 and 222,028 common shares in satisfaction.&#13;The common shares were valued at the market price on the date of settlement at $7.50 per common share. The gain of $186,503 on&#13;the settlement of debt was reflected in the additional paid in capital for the year ended June 30, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On March 23, 2017, Jonathan Adams agreed to defer the payment of his salary debt of&#13;$180,555 until&amp;#160;December 31, 2019, through the issuance of a Promissory note.&amp;#160; The promissory note does not carry any&#13;interest charge as long as the amount is paid in full before&amp;#160;December 31, 2019.&amp;#160; The salary debt was reclassified from&#13;a current liability to a long-term liability on the balance sheet.&amp;#160;Any portion of the balance due under the note that remains&#13;unpaid after&amp;#160;December 31, 2019&amp;#160;will accrue interest at a rate of 5% per annum until paid in full.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On July 9, 2018, Jonathan Adams (COO) entered into an Accord and Debt Satisfaction Agreement&#13;with the Company in which he agreed to release the Company from all liabilities including the original contract to defer payment&#13;of his accrued salary dated March 23, 2017, the promissory note issued by the Company to defer payment of accrued salary; and&#13;subsequent unpaid salary, totaling the amount of $534,722, and received cash of $25,694 in satisfaction. The gain of $509,028&#13;on the settlement of debt was reflected in the additional paid in capital for the year ended June 30, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The outstanding balance of the long-term note payable at June 30, 2019 and 2018 was&#13;$0 and $575,918, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;See note 8 &amp;#8220;Equity Transactions&amp;#8221;, for other related party transactions with&#13;Acuitas Group Holdings, LLC (&amp;#8220;Acuitas&amp;#8221;) and board of director members.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2019-07-01to2019-12-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 99%"&gt;&lt;b&gt;Related Party Transactions&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Equity Transactions with Acuitas &lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On July 3, 2018, we entered into a Securities Purchase Agreement (the &amp;#8220;Purchase&#13;Agreement&amp;#8221;) with Acuitas Group Holding, LLC (&amp;#8220;Acuitas&amp;#8221;) and certain other purchasers identified in the Purchase&#13;Agreement (together with Acuitas, the &amp;#8220;Purchasers&amp;#8221;) pursuant to which (i) the Purchasers agreed to purchase an aggregate&#13;of 2,133,332 shares of the our Series A Convertible Preferred Stock (the &amp;#8220;Preferred Stock&amp;#8221;) at a price per share of&#13;$1.50 per share of Preferred Stock (the &amp;#8220;Initial Sale&amp;#8221;) and (ii) we agreed to issue warrants (the &amp;#8220;Warrants&amp;#8221;)&#13;to purchase 1,706,666 shares of common stock, each subject to the terms and conditions set forth in the Purchase Agreement, for&#13;an aggregate consideration of $3.2 million. We received $160,000 of the $3.2 million in April and May 2018 as prepaid equity.&#13;Acuitas also received an additional 6,667 Warrants in connection with the payoff of a note issued by us in favor of Acuitas. The&#13;Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas had the option to purchase up to an additional&#13;1,600,000 shares of common stock at a price per share of $1.88, and warrants on the same terms as the Warrants, within two weeks&#13;following the one year anniversary of the closing of the Initial Sale (the &amp;#8220;Subsequent Sale&amp;#8221;) in the event that we&#13;did not obtain $3,000,000 of funding through various non-dilutive grants prior to the one year anniversary of the closing of the&#13;Initial Sale, less any federal or FDA grant funding received by the Company. Acuitas is controlled by our Chairman and Chief Executive&#13;Officer, Terren Peizer and the Purchasers included Jonathan Adams, James Lang, Cuong Do and Michael Sherman, who are members of&#13;our Board.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Purchase Agreement contained customary representations and warranties. In connection&#13;with the disclosure schedule associated with the representations and warranties, we also disclosed customary information, including&#13;the following: (i) the existence of the Mallinckrodt petition before the U.S. Patent Trial and Appeal Board, (ii) our capitalization,&#13;(iii) our obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared&#13;among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated&#13;April 11, 2016, by and between LAT Pharma LLC and us, (iv) our obligation to pay a low single digit royalty on net sales of all&#13;terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement,&#13;dated July 25, 2016, by and between us and the University of Padova (Italy), and (v) certain recent issuances of common stock&#13;by us.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Each share of Preferred Stock automatically converted into 100 shares of common stock&#13;(prior to reverse split) upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to our&#13;Articles of Incorporation (the &amp;#8220;Amendment&amp;#8221;) on August 13, 2018 that increased the number of authorized shares of common&#13;stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of our issued and&#13;outstanding common stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar days following&#13;the distribution of our Definitive Information Statement on Schedule 14 that was filed with the SEC on July 13, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Pursuant to a letter agreement dated June 24, 2019, Acuitas agreed to modify its existing&#13;rights under the Purchase Agreement so that:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 20px; text-align: right; vertical-align: top"&gt;&amp;#8211;&lt;/td&gt;&#13;    &lt;td style="width: 7px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;Acuitas agreed to immediately exchange its existing 1,606,667 Warrants&#13;    for common stock such that it will have effectively exercised its Warrants in full pursuant to a cashless exercise thereof&#13;    at an assumed current market price of $45.00 per share and, as a result received an aggregate of 95% of the shares covered&#13;    thereby, or 1,526,094 shares of common stock;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 20px; text-align: right; vertical-align: top"&gt;&amp;#8211;&lt;/td&gt;&#13;    &lt;td style="width: 7px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;Acuitas agreed to (i) waive its rights to a 50% adjustment of the purchase&#13;    price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants and the price per share in the Subsequent&#13;    Sale in the event of certain reductions in the useful life of our current intellectual property rights, and (ii) effectively&#13;    exercise its rights to purchase securities in a Subsequent Sale pursuant to a &amp;#8220;cashless purchase&amp;#8221; at an assumed&#13;    current market price of approximately $11.25 per share, conditioned in each case on the listing of our common stock on Nasdaq&#13;    or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than&#13;    November 30, 2019, which will result Acuitas having irrevocably waived its rights to an adjustment in the purchase price of&#13;    the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the&#13;    Subsequent Sale upon the issuance by us of an aggregate of 1,339,958 shares of common stock (the &amp;#8220;Subsequent Sale Shares&amp;#8221;)&#13;    to Acuitas, which is expected to occur concurrently with the closing of our potential public offering and listing on Nasdaq;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 20px; text-align: right; vertical-align: top"&gt;&amp;#8211;&lt;/td&gt;&#13;    &lt;td style="width: 7px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;Acuitas shall in exchange for the foregoing agreements and waivers have&#13;    the option to purchase additional shares of common stock and warrants to purchase one share of common stock for each share&#13;    of common stock purchased during the period from September 1, 2019 to November 30, 2019 at the then-effective purchase price&#13;    of the Preferred Stock in the Initial Sale (the &amp;#8220;Funding Option&amp;#8221;), provided that any shares issued pursuant to&#13;    any exercise of the Funding Option will reduce share-for-share the amount of shares issued pursuant to the deemed exercise&#13;    of its rights to purchase securities in a Subsequent Sale mentioned above.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Convertible Debenture Transaction with Acuitas&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On September 24, 2019, the Company entered into a Securities Purchase Agreement (the&#13;&amp;#8220;2019 Purchase Agreement&amp;#8221;) with Acuitas pursuant to which (i) Acuitas agreed to purchase a 10% OID Convertible Delayed&#13;Draw Debenture (the &amp;#8220;Debenture&amp;#8221;) due September 24, 2020 for an aggregate commitment amount of up to $2.0 million,&#13;and (ii) the Company issued 1,125,000 shares (the &amp;#8220;Commitment Shares&amp;#8221;) of the Company&amp;#8217;s common stock and warrants&#13;(the &amp;#8220;Commitment Warrants&amp;#8221;) to purchase an equal number of shares, each subject to the terms and conditions set forth&#13;in the 2019 Purchase Agreement. The Debenture accrues additional principal at the rate of 6% per annum and interest at the rate&#13;of 10% per annum, is convertible into shares of common stock at $4.00 per share prior to the completion of the company&amp;#8217;s&#13;planned public offering of units (the &amp;#8220;Public Offering&amp;#8221;) or, subsequent to the closing of the Public Offering, the&#13;lower of $4.00 or 80% of the offering price per unit to the public in the Public Offering and are mandatorily redeemable upon&#13;such closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. The Commitment Warrants are&#13;five-year warrants, exercisable upon the earlier of the effectiveness of the Company&amp;#8217;s current reverse stock split or December&#13;1, 2019, at an amount equal to the lower of $4.00 or 80% of the offering price per unit to the public in the Public Offering.&#13;Upon entering into the 2019 Purchase Agreement, the Company drew an initial $500,000 under the Debenture and in accordance with&#13;the 2019 Purchase Agreement, Acuitas received an additional 125,000 warrants (the &amp;#8220;Bridge Warrants&amp;#8221;) having the same&#13;terms as the Commitment Warrants. Any future draws under the Debenture, which may be made from and after October 15, 2019, November&#13;15, 2019 and December 15, 2019 in equal tranches of $500,000 each, will entitle Acuitas to receive additional Bridge Warrants&#13;in equal amount upon such funding. In addition, the 2019 Purchase Agreement provides that, should the underwriters in the Public&#13;Offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such&#13;securities would result in Acuitas' beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%,&#13;Acuitas shall be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants&#13;to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60%.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The issuance of 1,125,000 shares of the Company&amp;#8217;s commons stock and warrants to&#13;purchase an equal amount number of shares, to its controlling stockholder for the Bridge Financing was accounted for as a deemed&#13;dividend due to its related party nature and $17.1 million representing the excess of the fair value of the consideration given&#13;for the financing, net of debt discount; was recorded in accumulated deficit for the six months ended December 31, 2019, accordingly.&#13;(See accompanied Condensed Statements of Changes in Stockholders&amp;#8217; (Deficit) Equity). A debt discount of $500,000 against&#13;the debenture was recorded which will be amortized over the term of the debenture using the effective interest method. The Company&#13;recognized amortization of this discount in the amount of $21,595 for the six-month period ended December 31, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company received partial draws of draw number two of&amp;#160;the Debenture of $25,000&#13;and $5,000 on December 5, 2019 and December 13,&amp;#160;2019 respectively.&amp;#160;&amp;#160;Acuitas and the Company continue to discuss&#13;the need and timing for some or&amp;#160;all of&amp;#160;the remaining draws under the Agreement. &amp;#160;(See subsequent events).&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&#13;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Pursuant to the 2019 Purchase Agreement, Acuitas has agreed to further modify its existing&#13;rights under the Purchase Agreement dated July 3, 2018 with the Company so that Acuitas&amp;#8217; previous agreement in June 2019&#13;to waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the July 2018 transaction, the exercise&#13;price of the warrants in such transaction and the price per share in a Subsequent Sale in the event of certain reductions in the&#13;useful life of our current intellectual property rights, and effectively exercise its rights to purchase securities in a Subsequent&#13;Sale pursuant to a &amp;#8220;cashless purchase&amp;#8221; at an assumed current market price of approximately $11.25 per share, conditioned&#13;in each case on the listing of the Company&amp;#8217;s common stock on Nasdaq or the raising of $2.0 million in additional funds in&#13;the form of another securities offering, in either case not later than November 30, 2019, such that Acuitas will have irrevocably&#13;waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of&#13;the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 2,679,916 shares&#13;of common stock and 2,679,916 warrants having the same terms as the Commitment Warrants to Acuitas, upon the closing of the Public&#13;Offering.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Pursuant to an amendment to the 2019 Purchase Agreement dated October 9, 2019, Acuitas&#13;agreed to modify its existing rights under the 2019 Purchase Agreement so that:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; vertical-align: top"&gt;&amp;#8211;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;The Commitment Warrants (and related warrants issued upon the first draw under the Debenture)&#13;    were replaced with warrants having similar terms, but which are automatically exercised upon the closing of the offering at&#13;    an exercise price equal to the par value of the common stock;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; vertical-align: top"&gt;&amp;#8211;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;Acuitas' existing rights under the Purchase Agreement dated July 3, 2018 with the Company&#13;    were further amended so that the number of Subsequent Sale Shares would be multiplied by four (in lieu of the changes to the&#13;    Purchase Agreement originally provided for in the 2019 Purchase Agreement); and&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px; vertical-align: top"&gt;&amp;#8211;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;The provisions of the 2019 Purchase Agreement providing that, should the underwriters in the&#13;    offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of&#13;    such securities would result in Acuitas&amp;#8217; beneficial ownership (on a fully diluted basis) of shares of common stock being&#13;    below 60%, Acuitas will be issued a number of additional shares of common stock and warrants having the same terms as the&#13;    Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60%&#13;    have been modified such that, upon the exercise of such option by the underwriters, the Company will issue to Acuitas a number&#13;    of securities that will result in Acuitas&amp;#8217; fully diluted beneficial ownership after the exercise of such option being&#13;    the same as prior thereto. &lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2018-07-01to2019-06-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 5%"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 95%"&gt;&lt;b&gt;Commitments and Contingencies&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Office Lease&lt;/i&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On October 1, 2018, the Company executed a&#13;lease agreement with Acuitas Group Holdings, LLC (related party) for the Company&amp;#8217;s Corporate office space at the Acuitas&amp;#8217;&#13;offices at 11100 Wilshire Boulevard, Los Angeles , CA 90025. The lease is a month-to-month lease that may be cancelled upon 30&#13;days&amp;#8217; written notice and requires monthly payments of $1,000. On July 1, 2019, the Company&amp;#8217;s office moved with Acuitas&amp;#8217;&#13;new offices to 2120 Colorado Avenue Ste 230, Santa Monica, CA 90404.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Challenge to US Patent&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On April 30, 2018, we received notice that&#13;Mallinckrodt had petitioned the U.S. Patent and Trademark Office (&amp;#8220;USPTO&amp;#8221;) to institute an Inter Partes Review of&#13;our U.S. Patent No. 9,655,945 titled &amp;#8220;Treatment of Ascites&amp;#8221; (the &amp;#8220;&amp;#8217;945 patent&amp;#8221;). Inter Partes Review&#13;is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more&#13;claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents&#13;and printed publications.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On August 15, 2018, we submitted a Preliminary&#13;Response to the PTAB providing a rationale as to why, in our opinion, Mallinckrodt&amp;#8217;s request to institute the IPR should&#13;not be granted. On November 14, 2018, the PTAB granted institution of the IPR challenge after determining that there was a reasonable&#13;likelihood of success in proving that at least one of our 14 claims was unpatentable. On March 7, 2019, we submitted a Patent&#13;Owner&amp;#8217;s Response and a Patent Owner&amp;#8217;s Contingent Motion to Amend our patent claims, and Declaration of Dr. Jaime Bosch,&#13;MD, PhD, our medical expert. On June 26 and June 28, 2019, we submitted a Patent Owner&amp;#8217;s Reply In Support Of Its Contingent&#13;Motion To Amend Under 37 C.F.R.&amp;#167; 42.121 to amend our patent claims and a Patent Sur-Reply supported by the Supplemental Declaration&#13;of Dr. Jaime Bosch to the Reply and the Opposition to Motion to Amend, filed by Petitioner Mallinckrodt, filed June 6, 2019. On&#13;July 29, 2019, we submitted a Patent Owner&amp;#8217;s Opposition to Petitioner&amp;#8217;s Motion to Strike. On July 17, 2019, we received&#13;from the PTAB an Order Oral Hearing in response to our request of an Oral Hearing which was held on August 12, 2019 at 1:00PM&#13;EST. We are actively defending the &amp;#8217;945 patent and we are exploring the possibility of settlement with Mallinckrodt. However,&#13;there can be no assurance that a favorable outcome will result, or if settlement is reached that the PTAB will accept it. A reasonable&#13;estimate cannot be made at this time. Although the PTAB encourages settlement, in view of public-interest considerations, the&#13;PTAB may continue the proceeding to a final written decision even if the parties settle. If the IPR is not terminated due to settlement,&#13;the PTAB is statutorily required to issue its final written decision in this case before November 14, 2019 (within one year from&#13;the date of institution). At June 30, 2019, no adjustments or accruals have been reflected in our financial statements related&#13;to this matter.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Royalty Agreements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Pursuant to the Agreement and Plan of Merger&#13;entered into on April 11, 2016 between LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit&#13;royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation;&#13;and The Barrett Edge, Inc.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company and PharmaIN Corporation, LAT&#13;Pharma&amp;#8217;s former partner focused on the development of new modified drug candidates in the same therapeutic field but not&#13;including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development&#13;programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24,&#13;2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously&#13;paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Pursuant to the Technology Transfer Agreement&#13;entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit&#13;royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped at&#13;a maximum of $200,000 per year.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2019-07-01to2019-12-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 99%"&gt;&lt;b&gt;Commitments and Contingencies&lt;/b&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Office Lease&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On July 1, 2019, the Company&amp;#8217;s office moved with Acuitas&amp;#8217; new offices to&#13;2120 Colorado Avenue Ste 230, Santa Monica, CA 90404. There is no lease agreement for the new premises and the Company continues&#13;to accrue monthly lease payments of $1,000 for the new office under the terms of the previous month-to-month lease for the previous&#13;premises which may be cancelled upon 30 days&amp;#8217; written notice.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Challenge to US Patent&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On April 30, 2018, we received notice that Mallinckrodt had petitioned the U.S. Patent&#13;and Trademark Office (&amp;#8220;USPTO&amp;#8221;) to institute an Inter Partes Review of our U.S. Patent No. 9,655,945 titled &amp;#8220;Treatment&#13;of Ascites&amp;#8221; (the &amp;#8220;&amp;#8217;945 patent&amp;#8221;). Inter Partes Review is a trial proceeding conducted with the USPTO Patent&#13;Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds&#13;of novelty and obviousness on the basis of prior art consisting of patents and printed publications.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On November 13, 2019, the Patent Trial and Appeal Board of the United States Patent&#13;and Trademark Office (the &amp;#8220;Board&amp;#8221;) issued a written decision in the &lt;i&gt;inter partes&lt;/i&gt; review (&amp;#8220;IPR&amp;#8221;)&#13;action that was brought by Mallinckrodt Pharmaceuticals Ireland Limited (&amp;#8220;Mallinckrodt&amp;#8221;) against BioVie Inc. (&amp;#8220;BioVie&amp;#8221;&#13;or &amp;#8220;Company&amp;#8221;). In that action, Mallinckrodt sought to invalidate BioVie&amp;#8217;s patent (U.S. Pat. No. 9,655,945, &amp;#8220;Treatment&#13;of Ascites&amp;#8221;) (the &amp;#8220;&amp;#8217;945 Patent&amp;#8221;). In its decision, the Board determined that all claims of the &amp;#8216;945&#13;Patent were not patentable because they were either anticipated or obvious in light of prior art. The Board also denied BioVie&amp;#8217;s&#13;Motion to Amend the claims on similar grounds. The result of the Board&amp;#8217;s decision is that the &amp;#8216;945 patent is no longer&#13;valid or enforceable. Acuitas Group Holdings, LLC was aware of this patent challenge when it purchased a majority ownership interest&#13;in the company in July 2018.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;This ruling is unrelated to the Company&amp;#8217;s Orphan drug designations for ascites&#13;and hepatorenal syndrome (&amp;#8220;HRS&amp;#8221;), which remain unchanged. An Orphan drug that is first-to-market typically receives&#13;7 years of market exclusivity in the United States for the designated use(s). In addition, the ruling does not affect the Company&amp;#8217;s&#13;rights in its pending patent application directed to proprietary liquid formulations of terlipressin for use in its planned Phase&#13;2b/3 trial, subject to FDA clearance, which could eventually provide up to 20 years of patent coverage in each country in which&#13;the Company seeks patent protection, such as the United States, if a patent issues from a patent application according to the&#13;patent laws of each issuing country.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Royalty Agreements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016 between&#13;our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net&#13;sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett&#13;Edge, Inc.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company and PharmaIN Corporation, LAT Pharma&amp;#8217;s former partner focused on the&#13;development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties&#13;equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed&#13;to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial&#13;ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on&#13;a related debt. PharmaIN, Corp. rights to our program remain unchanged. Additionally the Company obligation to pay a low single&#13;digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, and The&#13;Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC. The Company&#13;has an obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up&#13;to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the&#13;University of Padova (Italy).&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Pursuant to the Technology Transfer Agreement entered into on July 25, 2016 between&#13;BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit royalty on net sales of all terlipressin&#13;products covered by US patent no. 9,655,645 and any future foreign issuances capped at a maximum of $200,000 per year.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2018-07-01to2019-06-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 5%"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 95%"&gt;&lt;b&gt;Equity Transactions&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The following table summarizes the activity&#13;relating to the Company&amp;#8217;s stock options for the years ended June 30, 2018 and 2019:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Weighted-Average Exercise Price&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Weighted Remaining Average Contractual Term&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Aggregate Intrinsic Value&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 44%; padding-left: 5.4pt"&gt;Outstanding at June 30, 2017&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;32,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;12.50&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;5.9&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;142,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Granted&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;10,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;18.75&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5.0&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 1pt"&gt;Options Exercised&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(800&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;2.50&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Outstanding at June 30, 2018&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;41,200&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;15.00&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5.8&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;142,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Granted&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;16,800&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4.5&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;131,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 1pt"&gt;Options Exercised or Forfeited&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 2.5pt"&gt;Outstanding at June 30, 2019&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;58,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;12.50&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;5.2&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;273,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 2.5pt"&gt;Exercisable at June 30, 2019&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;58,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;12.50&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;5.2&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The fair value of each option grant&#13;on the date of grant is estimated using the Black-Scholes Option &amp;#8211; Pricing model reflecting the following weighted-average&#13;assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;June 30,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 56%; text-align: left; padding-left: 5.4pt"&gt;Expected life of options (In years)&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69.77&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;103.13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.60&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.28&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Dividend Yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Expected volatility is based on the&#13;historical volatilities of three comparable companies of the daily closing price of their respective common stock and the expected&#13;life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as&#13;they are incurred.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company recorded stock-based compensation&#13;expense of $64,860 for the year ended June 30, 2019 and $238,165 for the year ended June 30, 2018.&lt;/p&gt;&#13;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The following is a summary of stock&#13;options outstanding and exercisable by exercise price as of June 30, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Outstanding&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Contract Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Exercisable&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;3.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;5,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;4.6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;5,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.7&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;25.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;26.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.8&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;27.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.7&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;28.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.1&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;31.25&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.4&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;Total&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;58,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;58,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Issuance of Shares for Cash&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In July 2017 and August 2017, the Company&#13;sold and issued an aggregate of 7,091 shares of common stock and warrants to purchase 3,546 shares of common stock in a private&#13;placement transaction for aggregate gross proceeds of approximately $195,000. The purchase price for the common stock and warrants&#13;was $27.50 per share. The warrants are exercisable at an exercise price of $75.00 at any time from date of issuance until 5 years&#13;from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Between July 2017 and September 2017,&#13;the Company sold an aggregate of 2,000 shares of common stock in transactions under the Aspire Equity Line for aggregate gross&#13;proceeds of $50,000. The average purchase price for the common stock was $25.00 per share.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In October 2017, the Company sold and&#13;issued an aggregate of 1,273 shares of common stock and warrants to purchase 637 shares of common stock in a private placement&#13;transaction for aggregate gross proceeds of approximately $35,000. The purchase price for the common stock and warrants was $27.50&#13;per share. The warrants are exercisable at an exercise price of $75.00 at any time from date of issuance until 5 years from the&#13;date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In November 2017, the Company also sold and issued an aggregate of 546 shares of common&#13;stock and warrants to purchase 273 shares of common stock in a private placement transaction for aggregate gross proceeds of approximately&#13;$15,000. The purchase price for the common stock and warrants was $27.50 per share. The warrants are exercisable at an exercise&#13;price of $75.00 at any time from date of issuance until 5 years from the date of issuance.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In January 2018, the Company sold an&#13;aggregate of 2,667 shares of common stock and warrants to purchase 2,667 shares of common stock to a member of its board of directors&#13;for aggregate gross proceeds of $50,000. The purchase price for the common stock and warrants was $18.75 per share. The warrants&#13;are exercisable at an exercise price of $18.75 at any time from date of issuance until 7 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On July 3, 2018, we entered into a Securities&#13;Purchase Agreement (the &amp;#8220;Purchase Agreement&amp;#8221;) with Acuitas Group Holdings, LLC (&amp;#8220;Acuitas&amp;#8221;)and certain other&#13;purchasers identified in the Purchase Agreement (together with Acuitas, the &amp;#8220;Purchasers&amp;#8221;) pursuant to which (i) the&#13;Purchasers agreed to purchase an aggregate of 2,133,332 shares of the our Series A Convertible Preferred Stock (the &amp;#8220;Preferred&#13;Stock&amp;#8221;) at a price per share of $1.50 per share of Preferred Stock (the &amp;#8220;Initial Sale&amp;#8221;) and (ii) we agreed&#13;to issue warrants (the &amp;#8220;Warrants&amp;#8221;) to purchase 1,706,666 shares of common stock, each subject to the terms and conditions&#13;set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. We received $160,000 of the $3.2 million in&#13;April and May 2018 as prepaid equity. Acuitas also received an additional 6,667 Warrants in connection with the payoff of a note&#13;issued by us in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas&#13;had the option to purchase up to an additional 1,600,000 shares of common stock at a price per share of $1.875, and warrants on&#13;the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale (the &amp;#8220;Subsequent&#13;Sale&amp;#8221;) in the event that we did not obtain $3,000,000 of funding through various non-dilutive grants prior to the one year&#13;anniversary of the closing of the Initial Sale, less any federal or FDA grant funding received by the Company. Acuitas is controlled&#13;by our Chairman and Chief Executive Officer, Terren Peizer and the Purchasers included Jonathan Adams, James Lang, Cuang Do and&#13;Michael Sherman, who are members of our Board of Directors.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Purchase Agreement contained customary&#13;representations and warranties. In connection with the disclosure schedule associated with the representations and warranties,&#13;we also disclosed customary information, including the following: (i) the existence of the Mallinckrodt petition before the U.S.&#13;Patent Trial and Appeal Board, (ii) our capitalization, (iii) our obligation to pay a low single digit royalty on the net sales&#13;of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge,&#13;Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and us, (iv) our obligation&#13;to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000&#13;per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy),&#13;and (v) certain recent issuances of common stock by us.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Each share of Preferred Stock automatically&#13;converted into 1 shares of common stock upon the filing with the Secretary of State of the State of Nevada of a Certificate of&#13;Amendment to our Articles of Incorporation (the &amp;#8220;Amendment&amp;#8221;) on August 13, 2018 that increased the number of authorized&#13;shares of common stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of&#13;our issued and outstanding common stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar&#13;days following the distribution of our Definitive Information Statement on Schedule 14 that was filed with the SEC on July 13,&#13;2018.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Pursuant to the Purchase Agreement, Terren Peizer, the Chairman of Acuitas, was appointed&#13;as a member of the Company&amp;#8217;s Board of Directors (the &amp;#8220;Board&amp;#8221;) and as the Chief Executive Officer of the Company,&#13;effective July 3, 2018. The issuance of the Preferred Stock, the Warrants and the underlying common stock under the Purchase Agreement&#13;is exempt from registration under the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;), pursuant to the exemption&#13;for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Pursuant to a letter agreement dated June 24,&#13;2019, Acuitas has agreed to modify its existing rights under the Purchase Agreement so that:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 30px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="margin: 0; text-align: justify; width: 12px"&gt;&amp;#8226;&lt;/td&gt;&#13;    &lt;td style="margin: 0; text-align: justify"&gt;Acuitas agreed to immediately exchange its existing 1,606,667 Warrants for common stock such that it will have effectively exercised its Warrants in full pursuant to a cashless exercise thereof at an assumed current market price of $45.00 per share and, as a result received an aggregate of 95% of the shares covered thereby, or 1,526,333 shares of common stock;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 30px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="margin: 0; text-align: justify; width: 12px"&gt;&amp;#8226;&lt;/td&gt;&#13;    &lt;td style="margin: 0; text-align: justify"&gt;Acuitas agreed to (i) waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants and the price per share in the Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and (ii) effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a &amp;#8220;cashless purchase&amp;#8221; at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of our common stock on NASDAQ or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, which will result Acuitas having irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 1,339,958 shares of common stock (the &amp;#8220;Subsequent Sale Shares&amp;#8221;) to Acuitas.&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Issuance of Warrants for Cash and&#13;Cashless Exercise of Warrants &lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In December 2017, the Company issued&#13;warrants for cash to purchase 20,000 shares of common stock in a private placement transaction for aggregate gross proceeds of&#13;$100,000. The purchase price for the warrants were $25.00 per warrant. The warrants are exercisable at an exercise price of $5.00&#13;at any time from date of issuance until 7 years from the date of issuance. As a result of the conversion of the Series A Preferred&#13;Stock in July 2018, the exercise of warrants to purchase 20,000 shares of common stock was reduced from $18.75 per share to $1.875&#13;per share. On August 4, 2018, the Company issued 17,936 shares of common stock pursuant to a cashless exercise of warrants to purchase&#13;20,000 shares at an exercise price of $1.875 per share.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On May 13, 2019, the Company issued&#13;479 shares of common stock pursuant to a cashless exercise of warrants to purchase 478 shares at an exercise price of $13.75 per&#13;share.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On June 24, 2019, the Company issued&#13;1,526,094 shares of common stock pursuant to a cashless exercise of warrants to purchase 1,606,667 shares at an exercise price&#13;of $45.00 per share.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Issuance of Warrants Services&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In January 2018, the Company&#13;issued warrants to purchase 840 shares of common stock in exchange for services. The warrants are exercisable at an exercise price&#13;of $18.75 any time from the date of issuance until 7 years from the date of issuance. The warrants were valued at $9,444. The fair&#13;value of the warrants granted was estimated using the Black Scholes Method and the following assumptions: volatility &amp;#8211; 166.7%;&#13;Term &amp;#8211; 7 years; Risk Free Rate &amp;#8211; 2.48%; dividend rate &amp;#8211; 0.00%&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In February 2018, the Company&#13;issued warrants to purchase 840 shares of common stock in a termination agreement. The warrants are exercisable at an exercise&#13;price of $18.75 any time from the date of issuance until 7 years from the date of issuance. The warrants were valued at $3,025.&#13;The fair value of the warrants granted was estimated using the Black Scholes Method and the following assumptions: volatility &amp;#8211;&#13;166.7%; Term &amp;#8211; 7 years; Risk Free Rate &amp;#8211; 2.81%; dividend rate &amp;#8211; 0.00%&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Issuance of Shares for Services&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In August 2017, the Company issued 12,000 shares&#13;of common stock to Aspire Capital in exchange for services. The shares were valued at $27.50 per share which was the trading price&#13;on date of issuance, and the value of the services were $330,000.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In November 2017, the Company issued 1,200&#13;shares of common in exchange for services. The shares were valued at $28.75 per share which was the trading price on date of issuance,&#13;and the value of the services were $34,500.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In January 2018, The Company issued 240 shares&#13;of common stock in exchange for services. The shares were valued at $16.25 per share which was the trading price on date of issuance,&#13;and the value of the services were $3,900.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In January 2018, the Company issued 11,200&#13;shares of common stock as compensation for the Board of Directors. The shares were valued at $18.75 per share which was the trading&#13;price on date of issuance, and the value of the compensation was $210,000.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In February 2018, the Company issued 4,800 shares of common&#13;stock in exchange for services. The shares were valued at $5.94 per share which was the trading price on date of issuance, and&#13;the value of the services were $28,500.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In April 2018, the Company issued&#13;2,400 shares of common in exchange for services. The shares were valued at $5.63 per share, and the value of the services were&#13;$13,500. In April 2018, the Company issued 1,200 shares of common in exchange for services. The shares were valued at $3.00 per&#13;share which was the trading price on date of issuance, and the value of the services were $3,600.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In May 2018, the Company issued&#13;2,000 shares of common in exchange for services. The shares were valued at $2.25 per share which was the trading price on date&#13;of issuance, and the value of the services were $4,500.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In May 2018, the Company issued&#13;548 shares of common in exchange for services. The shares were valued at $12.50 per share which was the trading price on date of&#13;issuance, and the value of the services were $6,850.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In June 2018, the Company issued&#13;2,400 shares of common in exchange for services. The shares were valued at $3.13 per share which was the trading price on date&#13;of issuance, and the value of the services were $7,500.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On January 2, 2019, the Company issued&#13;11,200 shares of common stock as part of the annual board of director compensation. The share price on date of issuance was $4.38&#13;per share.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Issuance of Shares in Settlement of Debt&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;During the year ended June 30, 2019,&#13;the Company settled $1,475,765 of debt and accrued compensation including $1,313,765 owed to related parties, by issuing 7,803&#13;shares of common stock with a fair value of $1,150,135. See notes 5 and 6.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Issuance of Stock Options &lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In November 2017, the Company extended the maturity date of stock options to acquire&#13;6,400 shares at exercise prices ranging from $26.25 to $31.25 issued to the board of directors between November 2016 and December&#13;2016 by 3 years. The Company recorded an incremental expense of $79,491 based on the increase in fair value of the options.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In June 2018, 800 shares of stock options were exercised for $2,000.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On October 1, 2018, the Company issued&#13;stock options to purchase 800 shares of common stock to the Chief Financial Officer as part of her compensation. The stock options&#13;were issued and are exercisable at an exercise price of $8.75 at any time from date of issuance and expire in 5 years from the&#13;date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On October 13, 2018, the Company issued&#13;stock options to purchase 800 shares of common stock as part of their annual board of director compensation. The stock options&#13;were issued and are exercisable at $6.25 at any time from date of issuance and expire in 5 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On October 27, 2018, the Company issued&#13;stock options to purchase 800 shares of common stock as part of their annual board of director compensation. The stock options&#13;were issued and are exercisable at $6.25 at any time from date of issuance and expire in 5 years from the date of issuance&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On November 10, 2018, the Company issued&#13;stock options to purchase 800 shares of common stock as part of their annual board of director compensation. The stock options&#13;are exercisable at an exercise price of $6.25 at any time from date of issuance and expire in 5 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On January 19, 2019, the Company issued&#13;stock options to purchase 800 shares of common stock to each of five key employees or consultants and two company directors as&#13;part of his or her annual compensation, for an aggregate total of 5,600 stock options. The stock options are exercisable at an&#13;exercise price of $3.125 at any time from date of issuance until 5 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On March 11, 2019, the Company issued&#13;stock options to purchase 8,000 shares of common stock to an investor relations (IR) consultant. The stock options were issued&#13;and are exercisable at $6.25 at any time from date of issuance and expire in 5 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Warrant Price Adjustment&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In December 2017, the Company issued&#13;warrants to purchase 20,000 shares of common stock in a private placement transaction for aggregate gross proceeds of $100,000.&#13;The warrants were exercisable at an exercise price of $25.00 at any time from date of issuance until 7 years from the date of issuance.&#13;The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In January&#13;2018, the Company sold shares at $18.75, which therefore triggered the reduction in the strike price. The Company calculated the&#13;difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $20,995&#13;as a deemed dividend. In July 2018, the Company sold shares at $1.88, which therefore triggered the reduction in the strike price.&#13;The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise&#13;price and recorded $44,889 as a deemed dividend. The fair value of the warrants granted was estimated using the Black Scholes Method.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In January and February 2018, the Company&#13;issued warrants to purchase 1,680 shares of common stock in exchange for banking services which was recognized at fair value.&#13;The warrants were exercisable at an exercise price of $18.75 at any time from date of issuance until 7 years from the date of issuance.&#13;The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In July 2018,&#13;the Company sold shares at $1.88, which therefore triggered the reduction in the strike price. The Company calculated the difference&#13;in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $3,770 as a deemed&#13;dividend. The fair value of the warrants granted was estimated using the Black Scholes Method.&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The following table summarizes&#13;the warrants that have been issued:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Aggregate&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Intrinsic&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Shares&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Life (Years)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Value&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 40%; padding-left: 5.4pt"&gt;Outstanding at June 30, 2017&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;49,391&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;62.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,802&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;27.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(40,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;62.50&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Outstanding at June 30, 2018&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,193&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;36.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.5&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,713,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;45.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,159,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(1,626,859&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;45.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; padding-bottom: 1pt"&gt;Outstanding and exercisable at June 30, 2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;124,667&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;45.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;5.6&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;1,202,678&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Of the above warrants, 9,391&#13;expire in fiscal year ending June 30, 2022, 4,815 expire in fiscal year ending June 30, 2023 and 110,461 expire in fiscal&#13;year ended June 30, 2025.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2019-07-01to2019-12-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 99%"&gt;&lt;b&gt;Equity Transactions&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The following table summarizes the activity relating to the Company&amp;#8217;s stock options&#13;for the six months ended December 31, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted-Average Exercise Price&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted Remaining Average Contractual Term&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Aggregate Intrinsic Value&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 44%; padding-left: 5.4pt"&gt;Outstanding at June 30, 2019&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;58,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;12.50&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;5.2&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;87,480&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Granted&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,400&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;7.42&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4.1&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Options Exercised or Forfeited&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 4pt; padding-left: 5.4pt"&gt;Outstanding at December 31, 2019&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;60,400&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;12.29&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;4.5&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;2,100&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 4pt; padding-left: 5.4pt"&gt;Exercisable at December 31, 2019&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;60,400&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;12.29&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;4.5&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;2,100&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The fair value of each option grant on the date of grant is estimated using the Black-Scholes&#13;option. The pricing model reflected the following weighted-average assumptions for the six months ended December 31, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31 2019&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31 2018&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 58%; padding-left: 5.4pt"&gt;Expected life of options (In years)&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;5&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;5&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Expected volatility&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;71.55&lt;/td&gt;&#13;    &lt;td&gt;%&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;67.91&lt;/td&gt;&#13;    &lt;td&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Risk free interest rate&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.61&lt;/td&gt;&#13;    &lt;td&gt;%&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.98&lt;/td&gt;&#13;    &lt;td&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Dividend Yield&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td&gt;%&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Expected volatility is based on the historical volatilities of three comparable companies&#13;of the daily closing price of their respective common stock and the expected life of options is based on historical data with&#13;respect to employee exercise periods. The Company accounts for forfeitures as they are incurred.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company recorded stock-based compensation expense of $0 and $11,162 for the three-&#13;and six- month periods ended December 31, 2019, respectively, and $16,285 and $19,697 for the three- and six- month periods ended&#13;December 31, 2018, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The following is a summary of stock options outstanding and exercisable by exercise&#13;price as of December 31, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average Contract Life&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;3.75&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;5,600&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;4.1&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;5,600&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6.25&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11,200&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4.2&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11,200&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;7.50&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;25,600&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6.2&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;25,600&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;8.75&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4.3&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12.50&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3.1&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;25.00&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.8&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;26.25&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,400&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.3&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,400&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;27.50&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;800&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.2&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;800&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;28.75&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.6&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;31.25&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.9&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Stock Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The following table summarizes the warrants activity during the six months ended December&#13;31, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average Remaining Life (Years)&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Aggregate Intrinsic Value&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 44%; padding-left: 5.4pt"&gt;Outstanding and exercisable at June 30, 2019&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;124,667&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;45.00&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;5.6&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;716,653&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Granted&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,250,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4.00&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4.7&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Expired&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Outstanding and exercisable at December 31, 2019&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,374,667&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;7.72&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;4.7&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;139,498&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Of the above warrants, 9,391 expire in fiscal year ending June 30, 2022, 4,455 expire&#13;in fiscal year ending June 30, 2023, and 1,360,821 expire in fiscal year ending June 30, 2025.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Offerings of Common Stock and Warrants&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Issuance of Stock Options&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On October 1, 2019, the Company issued stock options to purchase 800 shares of common&#13;stock to the Chief Financial Officer as part of her compensation. The stock options were issued and are exercisable at an exercise&#13;price of $8.75 at any time from date of issuance and expire in 5 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On October 13, 2019, the Company issued stock options to purchase 800 shares of common&#13;stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $7.50 at any&#13;time from date of issuance and expire in 5 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On November 10, 2019, the Company issued stock options to purchase 800 shares of common&#13;stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $6.25 at any&#13;time from date of issuance and expire in 5 years from the date of issuance.&amp;#160;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-07-01to2019-06-30_us-gaap_StockOptionMember128077054" unitRef="Shares" decimals="INF">16800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2019-07-01to2019-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">2400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">18.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2018-07-01to2019-06-30_us-gaap_StockOptionMember128077054" unitRef="USDPShares" decimals="INF">5.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2019-07-01to2019-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">7.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">800</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2018-07-01to2019-06-30_us-gaap_StockOptionMember128077054" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-07-01to2018-06-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">800</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2019-07-01to2019-12-31_us-gaap_StockOptionMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">2.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2018-07-01to2019-06-30_us-gaap_StockOptionMember128077054" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2019-07-01to2019-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" xsi:nil="true" />
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember">P5Y</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2018-07-01to2019-06-30_us-gaap_StockOptionMember128077054">P4Y6M0D</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease contextRef="From2018-07-01to2019-06-30_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-1626859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue contextRef="From2018-07-01to2019-06-30_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">45.00</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2019-06-30_us-gaap_StockOptionMember" unitRef="USD" decimals="0">87480</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2018-06-30_us-gaap_StockOptionMember" unitRef="USD" decimals="0">142000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2019-06-30_us-gaap_WarrantMember" unitRef="USD" decimals="0">716653</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2017-06-30_us-gaap_StockOptionMember" unitRef="USD" decimals="0">142000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2019-12-31_us-gaap_StockOptionMember" unitRef="USD" decimals="0">2100</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2019-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">139498</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="From2018-07-01to2019-06-30_us-gaap_WarrantMember" unitRef="USD" decimals="0">1159988</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="From2018-07-01to2019-06-30_us-gaap_StockOptionMember128077054" unitRef="USD" decimals="0">131000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="From2019-07-01to2019-12-31_us-gaap_StockOptionMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2018-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">334150</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">550810</us-gaap:OtherAssetsCurrent>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">-334150</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">-216660</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2018-07-01to2018-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">12469</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2017-07-01to2018-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2017-07-01to2018-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">12469</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2017-07-01to2018-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="From2018-07-01to2019-06-30_us-gaap_StockOptionMember128077054" unitRef="USD" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="From2019-07-01to2019-12-31_us-gaap_StockOptionMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2019-06-30_us-gaap_StockOptionMember" unitRef="USD" decimals="0">273000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2019-12-31_us-gaap_StockOptionMember" unitRef="USD" decimals="0">2100</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2018-07-01to2019-06-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 5%"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 95%"&gt;&lt;b&gt;Subsequent Events&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On September 24, 2019, BioVie Inc., a Nevada corporation (the &amp;#8220;Company&amp;#8221;),&#13;entered into a Securities Purchase Agreement (the &amp;#8220;Purchase Agreement&amp;#8221;) with Acuitas Group Holdings, LLC (&amp;#8220;Acuitas&amp;#8221;)&#13;pursuant to which (i) Acuitas agreed to purchase a 10% OID Convertible Delayed Draw Debenture (the &amp;#8220;Debenture&amp;#8221;) due&#13;September 20, 2020 in aggregate commitment amount of up to $2.0 million, and (ii) the Company issued 1,125,000 shares (the &amp;#8220;Commitment&#13;Shares&amp;#8221;) of the Company&amp;#8217;s Class A Common Stock (the &amp;#8220;Common Stock&amp;#8221;) and warrants (the &amp;#8220;Commitment&#13;Warrants&amp;#8221;) to purchase an equal number of shares, each subject to the terms and conditions set forth in the Purchase Agreement.&#13;The Debentures accrue additional principal at the rate of 6% per annum and interest at the rate of 10% per annum, are convertible&#13;into shares of Common Stock $4.00 per share or, subsequent to the closing of the Company&amp;#8217;s planned public offering of shares&#13;of Common Stock (the &amp;#8220;Public Offering&amp;#8221;) as described in its Registration Statement on Form S-1 (File No. 333-231136),&#13;the lower of $4.00 or 80% of the offering price to the public in the Public Offering and are mandatorily redeemable upon such&#13;closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. The Commitment Warrants are five&#13;year warrants, exercisable upon the earlier of the effectiveness of the Company's currently pending reverse stock split and December&#13;1, 2019 at the lower of $4.00 or 80% of the offering price to the public in the Public Offering. Upon entering into the Purchase&#13;Agreement, the Company drew an initial $500,000 under the Debenture and in accordance with the Purchase Agreement, Acuitas received&#13;an additional 125,000 warrants (the &amp;#8220;Bridge Warrants&amp;#8221;) having the same terms as the Commitment Warrants. Any future&#13;draws under the Debenture, which may be made from and after October 15, 2019, November 15, 2019 and December 15, 2019 in equal&#13;tranches of $500,000 each, will entitle Acuitas to receive additional Bridge Warrants in equal amount upon such funding.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Pursuant to the Purchase Agreement, Acuitas has agreed to further modify its existing&#13;rights under the Purchase Agreement dated July 3, 2018 with the Company so that Acuitas&amp;#8217; previous agreement in June 2019&#13;to waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the July 2018 transaction, the exercise&#13;price of the warrants in such transaction and the price per share in a purchase option triggered on July 3, 2019 (any such purchase,&#13;a &amp;#8220;Subsequent Sale&amp;#8221;) in the event of certain reductions in the useful life of our current intellectual property rights,&#13;and effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a &amp;#8220;cashless purchase&amp;#8221;&#13;at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of the Company&amp;#8217;s&#13;common stock on NASDAQ or the raising of $2.0 million in additional funds in the form of another securities offering, in either&#13;case not later than November 30, 2019, such that Acuitas will have irrevocably waived its rights to an adjustment in the purchase&#13;price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in&#13;the Subsequent Sale upon the issuance by us of an aggregate of 2,679,916 shares of Common Stock and 2,679,916 warrants having&#13;the same terms as the Commitment Warrants to Acuitas, which is currently expected with the closing of the Public Offering. In&#13;addition, the Purchase Agreement provides that, should the underwriters in the Public Offering exercise their option to purchase&#13;additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas&amp;#8217;&#13;beneficial ownership (on a fully diluted basis) of shares of Common Stock being below 60%, Acuitas shall be issued a number of&#13;additional shares of Common Stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership&#13;(on a fully diluted basis) of shares of Common Stock equalling 60%.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2019-07-01to2019-12-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 99%"&gt;&lt;b&gt;Subsequent Events&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;On January 2, 2020, the Company issued 11,200 shares of common stock as part of the annual board of director&#13;compensation. The share price on date of issuance was $3.50.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On January 3, 2020, the Company received a third partial draw of $20,000 and on January&#13;14, 2020 a fourth&amp;#160;partial draw of $250,000 of draw number two of&amp;#160;the Debenture.&amp;#160;&amp;#160; The total of the partial&#13;draw received under draw number two of&amp;#160;the Debenture was $300,000 at February 12, 2020. Acuitas and the Company continue&#13;to discuss the need and timing for some or&amp;#160;all&amp;#160;the remaining draws under the Debenture Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On February 11, 2020, the Company entered into a letter agreement dated February 10,&#13;2020 with Acuitas regarding Acuitas&amp;#8217; previous agreement to modify its existing rights under the Purchase Agreement dated&#13;July 3, 2018 with the Company so that its June 2019 waiver of its rights to a 50% adjustment of the purchase price applicable&#13;to its initial investment in the Company and the exercise price of the warrants received in such transaction and the price per&#13;share should it exercise certain rights to purchase additional securities in the event of certain reductions in the useful life&#13;of the Company&amp;#8217;s intellectual property rights and commitment to purchase such securities upon the closing of the Company&amp;#8217;s&#13;planned public offering (the &amp;#8220;Public Offering&amp;#8221;) of shares of Class A common stock (the &amp;#8220;Common Stock&amp;#8221;)&#13;as described in its Registration Statement on Form S-1 (File No. 333-231136) and commitment to purchase such additional securities&#13;would remain effective until April 30, 2020, and accordingly Acuitas shall be entitled to receive an aggregate of 5,359,832 shares&#13;of Common Stock at such closing. In addition, the parties agreed that certain draws under the Company&amp;#8217;s current bridge financing&#13;with Acuitas were to be made based with respect to the Company&amp;#8217;s ongoing capital requirements and current market conditions,&#13;notwithstanding certain scheduled availability dates set forth in the 10% OID Convertible Delayed Draw Debenture issued in connection&#13;therewith.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">114689</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">407718</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">178341</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2018-07-01to2019-06-30">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 5%"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 95%"&gt;&lt;b&gt;Income Taxes &lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the&#13;carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;At June 30, 2018, the Company has a Net Operating Loss (&amp;#8220;NOL&amp;#8221;) carryforward&#13;of approximately $1,800,000. The NOL expires during the years 2032 to 2037. Realization of any portion of the $832,186 of net&#13;deferred tax assets at June 30, 2018 is not considered more likely than not by management; accordingly, a valuation allowance&#13;has been established for the full amount. The valuation allowance as of June 30, 2018 was $832,186. The change in the valuation&#13;allowance from June 30, 2017 to June 30, 2018 amounted to $357,231.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;At June 30, 2019, the Company had a Net Operating Loss (&amp;#8220;NOL&amp;#8221;) carryforward&#13;of approximately $5,700,000. NOL&amp;#8217;s generated prior to 2018 will expire during the years 2032 to 2037. Realization of any&#13;portion of the $1,680,613 deferred tax assets at June 30, 2019 is not considered more likely than not by management; accordingly,&#13;a valuation allowance has been established for the full amount, which as of June 30, 2019 was $1,680,613. The change in the valuation&#13;allowance during the year ended June 30, 2019 amounted to $848,427. The Company does not have any uncertain tax positions or events&#13;leading to uncertainty in a tax position. The Company&amp;#8217;s 2016, 2017 and 2018 Corporate Income Tax Returns are subject to&#13;Internal Revenue Service examination.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;On December 22, 2017, the Tax Cuts and Jobs Act (the &amp;#8220;Act&amp;#8221;) was signed into&#13;law. The Act decreases the U.S. corporate federal income tax rate from a maximum of 35% to a flat 21% effective January 1, 2018.&#13;The Act also includes a number of other provisions including, among others, the elimination of net operating loss carrybacks and&#13;limitations on the use of future losses, NOL&amp;#8217;s generated in 2018 and later having an indefinite life, the repeal of the&#13;Alternative Minimum Tax regime, and the repeal of the domestic production activities deduction. The impact on the Company&amp;#8217;s&#13;financial statements is immaterial, primarily because the Company has a valuation allowance on deferred tax assets.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Given the significant complexity of the Act and anticipated additional implementation&#13;guidance from the Internal Revenue Service, further implications of the Act may be identified in future periods.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Significant components of the Company&amp;#8217;s deferred tax assets are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;&lt;b&gt;June 30, 2019&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;&lt;b&gt;June 30, 2018&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Deferred tax assets:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 58%; padding-left: 5.4pt"&gt;Tax loss carryforward&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;1,624,887&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;555,064&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Intangible assets&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;36,917&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;19,277&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Stock based compensation&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;18,809&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;257,845&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 1pt"&gt;Valuation Allowance&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(1,680,613&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(832,186&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Since management of the Company believes that it is more likely than not that the net&#13;deferred tax assets will not provide future benefit, the Company has established a 100 percent valuation allowance on the net&#13;deferred tax assets as of June 30, 2019 and 2018.&amp;#160;&amp;#160;The Company&amp;#8217;s NOL carryover up to the date of the July 2018&#13;financing will be subject to Section 382 usage limitations since a greater than 50% ownership change took place from the financing&#13;event.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Reconciliation of the differences between income tax benefit computed at the federal&#13;and state statutory tax rates and the provision for income tax benefit for the years ended June 30, 2019 and 2018 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 56%; text-align: left; padding-left: 5.4pt"&gt;Income tax expense (benefit) at federal statutory rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;State taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;-29&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;-39&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <bivi:IssuanceOfWarrantsWithDebt contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">26519</bivi:IssuanceOfWarrantsWithDebt>
    <bivi:IssuanceOfWarrantsWithDebt contextRef="From2017-07-01to2018-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfWarrantsWithDebt contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfWarrantsWithDebt contextRef="From2017-07-01to2018-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">26519</bivi:IssuanceOfWarrantsWithDebt>
    <bivi:IssuanceOfWarrantsWithDebt contextRef="From2017-07-01to2018-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-07-01to2018-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-07-01to2018-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-07-01to2018-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:OptionsVested contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">238165</bivi:OptionsVested>
    <bivi:OptionsVested contextRef="From2017-07-01to2018-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:OptionsVested contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:OptionsVested contextRef="From2017-07-01to2018-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">238165</bivi:OptionsVested>
    <bivi:OptionsVested contextRef="From2017-07-01to2018-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-07-01to2018-06-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">13838</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-07-01to2018-06-30" unitRef="USD" decimals="0">444999</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-07-01to2018-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-07-01to2018-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">444998</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-07-01to2018-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <bivi:IssuanceOfPreferredStockInPrivatePlacementShares contextRef="From2018-07-01to2019-06-30_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">2133332</bivi:IssuanceOfPreferredStockInPrivatePlacementShares>
    <bivi:IssuanceOfPreferredStockInPrivatePlacementShares contextRef="From2018-07-01to2019-06-30_us-gaap_CommonStockMember" unitRef="Shares" xsi:nil="true" />
    <bivi:IssuanceOfPreferredStockInPrivatePlacementShares contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="Shares" decimals="INF">2133332</bivi:IssuanceOfPreferredStockInPrivatePlacementShares>
    <bivi:IssuanceOfPreferredStockInPrivatePlacementShares contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">51400</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2019-07-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">51400</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2019-10-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2018-10-01to2018-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Basis of Presentation &lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company&amp;#8217;s financial statements have been prepared in accordance with accounting&#13;principles generally accepted in the United States (&amp;#8220;GAAP&amp;#8221;) and include all adjustments necessary for the fair presentation&#13;of the Company&amp;#8217;s financial position for the periods presented.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2019-07-01to2019-12-31">&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Basis of Presentation &amp;#8211; Interim Financial Information&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The accompanying unaudited interim financial&#13;statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State&#13;of America (&amp;#8220;U.S. GAAP&amp;#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of&#13;Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information&#13;and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect&#13;all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair&#13;presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for&#13;the full year. The condensed balance sheet at June 30, 2019 was derived from audited annual financial statements but does not contain&#13;all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included&#13;under the heading: &amp;#8220;Management&amp;#8217;s Discussion and Analysis of Financial Condition and Results of Operations&amp;#8221; should&#13;be read in conjunction with our Company&amp;#8217;s audited financial statements and related notes included in our Company&amp;#8217;s&#13;Form 10-K for the year ended June 30, 2019 filed with the SEC on September 27, 2019.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;For a summary of significant accounting&#13;policies, see the Company&amp;#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 filed with the SEC on September&#13;27, 2019.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity with GAAP requires management&#13;to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company&#13;bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances.&#13;The amounts of assets and liabilities reported in the Company&amp;#8217;s balance sheet and the amounts of expenses reported for each&#13;of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, accounting for share-based&#13;compensation, accounting for derivatives and accounting for income taxes. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company considers all highly liquid instruments with original maturities of three&#13;months or less to be cash equivalents. Cash is maintained at one financial institution and, at times, balances may exceed federally&#13;insured limits. The Company has never experienced any losses related to these balances. All of the Company&amp;#8217;s cash balances&#13;were fully insured at June 30, 2019.&amp;#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <bivi:OtherAssetPolicyTextBlock contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Other Assets&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Other Assets consists of direct cost related to capital raise and filing of the registration&#13;statement legal fees and investment banking fees incurred to raise capital. The costs will be expensed once the Company raises&#13;the capital.&lt;/p&gt;</bivi:OtherAssetPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Fair value is defined as the price that would be received from selling an asset or paid&#13;to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair&#13;value for applicable assets and liabilities, we consider the principal or most advantageous market in which we would transact&#13;and we consider assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer&#13;restrictions, and risk of nonperformance. This guidance also establishes a fair value hierarchy to prioritize inputs used in measuring&#13;fair value as follows:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 35px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td&gt;Level 1: Observable inputs such as quoted prices in active markets&amp;#894;&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 35px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td&gt;Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly&amp;#894; and&lt;/td&gt;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 35px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#9679;&lt;/td&gt;&#13;    &lt;td&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop&#13;    its own assumptions&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company&amp;#8217;s financial instruments include cash, accounts payable, related party&#13;loans and a demand promissory note. The carrying amounts of cash and accounts payable approximate their fair value, due to the&#13;short-term nature of these items.&amp;#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:LongTermDebtTextBlock contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Long-Term Notes Payable&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company&amp;#8217;s long-term notes payable include accrued payroll to officers and&#13;accrued payments to third party consultants.&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Research and development expenses consist primarily of costs associated with the preclinical&#13;and/ or clinical trials of drug candidates, compensation and other expenses for research and development, personnel, supplies&#13;and development materials, costs for consultants and related contract research and facility costs. Expenditures relating to research&#13;and development are expensed as incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company uses the asset and liability method of accounting for deferred income taxes.&#13;Deferred income taxes are measured by applying enacted statutory rates to net operating loss carryforwards and to the differences&#13;between the financial reporting and tax bases of assets and liabilities. Deferred tax assets are reduced, if necessary, by a valuation&#13;allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company recognizes uncertainty in income taxes in the financial statements using&#13;a recognition threshold and measurement attribute of a tax position taken or expected to be taken in a tax return. The Company&#13;applies the &amp;#8220;more-likely-than-not&amp;#8221; recognition threshold to all tax positions, commencing at the adoption date of&#13;the applicable accounting guidance, which resulted in no unrecognized tax benefits as of such date. Additionally, there have been&#13;no unrecognized tax benefits subsequent to adoption. The Company has opted to classify interest and penalties that would accrue,&#13;if any, according to the provisions of relevant tax law as general and administrative expenses, in the statements of operations.&#13;For the years ended June 30, 2019 and 2018 there was no such interest or penalty.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Net Loss per Common Share&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Basic net loss per common share is computed by dividing the net loss before deemed dividend&#13;by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed&#13;by dividing net loss by the weighted average number of shares of common stock outstanding and potentially outstanding shares of&#13;common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options,&#13;warrants, convertible preferred stock and convertible debentures. Due to the net loss for the period, such amounts were excluded&#13;from the diluted loss since their effect was considered anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The table below shows the number of outstanding stock options and warrants as of June&#13;30, 2019 and June 30, 2018:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;June 30, 2019&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;June 30, 2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Number of Shares&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 56%; text-align: left; padding-left: 5.4pt"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;58,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;41,200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;124,667&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;38,193&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold; padding-left: 5.4pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double"&gt;182,667&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double"&gt;79,393&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2019-07-01to2019-12-31">&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Net income (loss) per Common Share&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Basic net income (loss) per common share&#13;is computed by dividing the net income (loss) before deemed dividend by the weighted average number of shares of common stock outstanding&#13;during the period.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Diluted net income (loss) per common&#13;share is computed by dividing by the weighted average number of shares of common stock outstanding and potentially outstanding&#13;shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through&#13;stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the six months ended December&#13;31, 2019 and 2018 as such amounts were excluded from the diluted loss since their effect was considered anti-dilutive. For the&#13;three months ended December 31, 2019, all potential securities were anti-dilutive as a result of the effect of the change in fair&#13;value of the derivative liabilities and assumed conversion of debenture in determining the amount of net income (loss) attributable&#13;to common stockholders. Due to the net loss for the three months ended December 31, 2018, amounts were excluded from the diluted&#13;loss since their effect was considered anti-dilutive.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The table below shows the number of&#13;outstanding stock options and warrants as of December 31, 2019 and 2018:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;December 31, 2018&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 18%; padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Stock Options&lt;/td&gt;&#13;    &lt;td style="width: 34%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;60,400&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;44,400&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Warrants&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,374,667&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,731,525&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;b&gt;1,435,067&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;b&gt;1,775,925&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company has accounted for stock-based compensation under the provisions of FASB&#13;ASC 718 &amp;#8211; &amp;#8220;Stock Compensation&amp;#8221; which requires the use of the fair-value based method to determine compensation&#13;for all arrangements under which employees and others receive shares of stock or equity instruments (stock options and common&#13;stock purchase warrants). For employee awards, the fair value of each stock option award is estimated on the date of grant using&#13;the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free&#13;interest rate. For non-employees, the fair value of each stock option award is estimated on the measurement date using the Black-Scholes&#13;valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.&#13;For non-employees, the Company utilizes the graded vesting attribution method under which the entity treats each separately vesting&#13;portion (tranche) as a separate award and recognizes compensation cost for each tranche over its separate vesting schedule. Expected&#13;volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the stock&#13;options. For employee awards, the expected term of options granted is derived using the &amp;#8220;simplified method&amp;#8221; which&#13;computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the&#13;U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. We recognize forfeitures as they&#13;occur.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Goodwill is recorded when the purchase price paid for an acquisition exceeds the fair&#13;value of net identified tangible and intangible assets acquired. The Company performs an annual impairment test of goodwill and&#13;further periodic tests to the extent indicators of impairment develop between annual impairment tests. The Company&amp;#8217;s impairment&#13;review process compares the fair value of the reporting unit to its carrying value, including the goodwill related to the reporting&#13;unit. To determine the fair value of the reporting unit, the Company may use various approaches including an asset or cost approach,&#13;market approach or income approach or any combination thereof. These approaches may require the Company to make certain estimates&#13;and assumptions including future cash flows, revenue and expenses. These estimates and assumptions are reviewed each time the&#13;Company tests goodwill for impairment and are typically developed as part of the Company&amp;#8217;s routine business planning and&#13;forecasting process. While the Company believes its estimates and assumptions are reasonable, variations from those estimates&#13;could produce materially different results. The Company did not recognize any goodwill impairments for the years ended June 30th,&#13;2018 and June 30th, 2019.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Long-lived assets, including intangible assets, are reviewed for impairment whenever&#13;events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets&#13;to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows&#13;expected to be generated by the asset.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;If the carrying amount of an asset exceeds its undiscounted estimated future cash flows,&#13;an impairment review is performed. An impairment charge is recognized in the amount by which the carrying amount of the asset&#13;exceeds the fair value of the asset. Generally, fair value is determined using valuation techniques such as expected discounted&#13;cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented in the balance sheet and reported&#13;at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated or amortized. The assets and&#13;liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability&#13;sections of the balance sheet.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:Reclassifications contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;Certain prior year amounts have been reclassified for consistency with current year&#13;presentation. These reclassifications had no effect on the reported results of operations.&lt;/p&gt;</us-gaap:Reclassifications>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Recent accounting pronouncements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company considers the applicability and impact of all Accounting Standard Updates&#13;(&amp;#8220;ASU&amp;#8217;s&amp;#8221;). ASU&amp;#8217;s not discussed below were assessed and determined to be either not applicable or expected&#13;to have minimal impact on our balance sheets or statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In June 2018, the FASB issued ASU 2018-07, &amp;#8220;Compensation &amp;#8211; Stock Compensation&#13;(Topic 718): Improvements to Non-employee share based accounting&amp;#8221;, which simplifies the accounting for non-employee share-based&#13;payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor&#13;acquires goods or services to be used or consumed in a grantor&amp;#8217;s own operations by issuing share-based payment awards. The&#13;standard will be effective for the Company in the first quarter of fiscal year 2020, although early adoption is permitted (but&#13;no sooner than the adoption of Topic 606). The Company does not expect that the adoption of this ASU will have a significant impact&#13;on its financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In July 2017, the FASB issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2017-11.&#13;&amp;#8220;Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815):&#13;I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily&#13;Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with&#13;a Scope Exception. ASU 2017-11 revises the guidance for instruments with down round features in Subtopic 815-40, Derivatives and&#13;Hedging &amp;#8211; Contracts in Entity&amp;#8217;s Own Equity, which is considered in determining whether an equity-linked financial&#13;instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments&#13;would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception.&#13;If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017-11 is&#13;effective for annual and interim periods beginning December 15, 2018, and early adoption is permitted, including adoption in an&#13;interim period. ASU 2017-11 provides that upon adoption, an entity may apply this standard retrospectively to outstanding financial&#13;instruments with a down round feature by means of a cumulative-effect adjustment to the opening balance of retaining earnings&#13;in the fiscal year and interim period adopted. The Company is currently in the process of assessing the impact of this ASU on&#13;its financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2019-07-01to2019-12-31">&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Recent accounting pronouncements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company considers the applicability&#13;and impact of all Accounting Standard Updates (&amp;#8220;ASU&amp;#8217;s&amp;#8221;). ASU&amp;#8217;s not discussed below were assessed and determined&#13;to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In June 2018, the FASB issued ASU 2018-07,&#13;&amp;#8220;Compensation &amp;#8211; Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting&amp;#8221;. This guidance&#13;aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions&#13;with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning&#13;of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption&#13;date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal&#13;years. Early adoption is permitted. The Company has adopted this ASU as of July 1, 2019. There has been no impact on the financial&#13;statements.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;In August 2018, the FASB issued ASU 2018-13,&#13;&amp;#8220;Fair value measurement (Topic 820): Disclosure Framework &amp;#8211; Changes to the Disclosure Requirements for Fair Value Measurement&amp;#8221;.&#13;The new guidance modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for fiscal years beginning&#13;after December 15, 2019. Early adoption is permitted. The Company does not expect ASU 2018-13 to have a significant impact to its&#13;condensed consolidated financial statements and related disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;Intellectual property, stated at cost, less accumulated amortization consists of the&#13;following:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;June 30, 2019&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;June 30, 2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 56%; text-align: left; padding-left: 5.4pt"&gt;Intellectual Property&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,293,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,293,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; padding-bottom: 1pt"&gt;Less Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(739,167&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(509,790&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; padding-bottom: 2.5pt"&gt;Intellectual Property, Net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;1,554,603&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;1,783,980&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2019-07-01to2019-12-31">&lt;p style="margin: 0; text-align: justify"&gt;The following is a summary of the intangible assets as of December 31, 2019 and June 30, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;June 30, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 58%; padding-left: 5.4pt"&gt;Intellectual Property&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;2,293,770&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;2,293,770&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Less Accumulated Amortization&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(853,855&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;(739,167&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 4pt; padding-left: 5.4pt"&gt;Intellectual Property, Net&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;1,439,915&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;1,554,603&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;Estimated future amortization expense is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;Year ending June 30,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 70%; text-align: center; padding-left: 5.4pt"&gt;2020&lt;/td&gt;&lt;td style="width: 10%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;229,377&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;2021&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;2022&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;2023&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; padding-left: 5.4pt"&gt;2024&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;229,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;407,718&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;1,554,603&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2019-07-01to2019-12-31">&lt;p style="margin: 0; text-align: justify"&gt;Estimated future amortization&#13;expense is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="white-space: nowrap; width: 69%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Year ending June 30, 2020 (Remaining six months)&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; width: 31%; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;114,689 &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;2021&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;229,377 &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;2022&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;229,377 &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;2023&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;229,377 &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;2024&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;229,377 &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;2025&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;229,377 &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;Thereafter&lt;/td&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;178,341 &lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-top: black 1.5pt solid; border-bottom: black 4.5pt double; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt"&gt;&amp;#160;$&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;1,439,915 &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;Significant components of the Company&amp;#8217;s deferred tax assets are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;&lt;b&gt;June 30, 2019&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;&lt;b&gt;June 30, 2018&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Deferred tax assets:&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 58%; padding-left: 5.4pt"&gt;Tax loss carryforward&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;1,624,887&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;555,064&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Intangible assets&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;36,917&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;19,277&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Stock based compensation&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;18,809&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;257,845&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 1pt"&gt;Valuation Allowance&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(1,680,613&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(832,186&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;Reconciliation of the differences between income tax benefit computed at the federal&#13;and state statutory tax rates and the provision for income tax benefit for the years ended June 30, 2019 and 2018 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 56%; text-align: left; padding-left: 5.4pt"&gt;Income tax expense (benefit) at federal statutory rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;34&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;State taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;-29&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;-39&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2018-07-01to2019-06-30">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember" unitRef="Pure" decimals="INF">1.0313</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-07-01to2019-06-30_us-gaap_StockOptionMember128077054" unitRef="Pure" decimals="INF">0.6977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2019-07-01to2019-12-31_us-gaap_StockOptionMember" unitRef="Pure" decimals="INF">.7155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-07-01to2018-12-31_us-gaap_StockOptionMember" unitRef="Pure" decimals="INF">.6791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember" unitRef="Pure" decimals="INF">0.0228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2018-07-01to2019-06-30_us-gaap_StockOptionMember128077054" unitRef="Pure" decimals="INF">0.0260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2019-07-01to2019-12-31_us-gaap_StockOptionMember" unitRef="Pure" decimals="INF">.0161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2018-07-01to2018-12-31_us-gaap_StockOptionMember" unitRef="Pure" decimals="INF">.0298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2018-07-01to2019-06-30_us-gaap_StockOptionMember128077054" unitRef="Pure" decimals="INF">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2019-07-01to2019-12-31_us-gaap_StockOptionMember" unitRef="Pure" decimals="INF">.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2018-07-01to2018-12-31_us-gaap_StockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-07-01to2018-06-30_us-gaap_StockOptionMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-07-01to2019-06-30_us-gaap_StockOptionMember128077054">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-07-01to2019-12-31_us-gaap_StockOptionMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-07-01to2018-12-31_us-gaap_StockOptionMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">555064</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">1624887</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">19277</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">36917</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">257845</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">18809</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">832186</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">1680613</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2018-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2019-06-30" unitRef="USD" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2018-07-01to2019-06-30" unitRef="Pure" decimals="INF">.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2017-07-01to2018-06-30" unitRef="Pure" decimals="INF">.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2018-07-01to2019-06-30" unitRef="Pure" decimals="INF">.08</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2017-07-01to2018-06-30" unitRef="Pure" decimals="INF">.05</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2018-07-01to2019-06-30" unitRef="Pure" decimals="INF">-.29</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2017-07-01to2018-06-30" unitRef="Pure" decimals="INF">-.39</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2018-07-01to2019-06-30" unitRef="Pure" decimals="INF">.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2017-07-01to2018-06-30" unitRef="Pure" decimals="INF">.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">1800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2019-06-30" unitRef="USD" decimals="0">5700000</us-gaap:OperatingLossCarryforwards>
    <dei:EntityTaxIdentificationNumber contextRef="From2019-07-01to2019-12-31">46-2510769</dei:EntityTaxIdentificationNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="From2019-07-01to2019-12-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="From2019-07-01to2019-12-31">2120 Colorado Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2019-07-01to2019-12-31">Suite 230</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="From2019-07-01to2019-12-31">Santa Monica</dei:EntityAddressAddressLine3>
    <dei:EntityAddressStateOrProvince contextRef="From2019-07-01to2019-12-31">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2019-07-01to2019-12-31">90404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2019-07-01to2019-12-31">312</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2019-07-01to2019-12-31">283-5793</dei:LocalPhoneNumber>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;The table below shows the number of outstanding stock options and warrants as of June&#13;30, 2019 and June 30, 2018:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;June 30, 2019&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;June 30, 2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Number of Shares&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Number of Shares&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 56%; text-align: left; padding-left: 5.4pt"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;58,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;41,200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;124,666&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;38,192&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="font-weight: bold; padding-left: 5.4pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double"&gt;182,666&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double"&gt;79,392&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2019-07-01to2019-12-31">&lt;p style="margin: 0; text-align: justify"&gt;The table below shows the number of outstanding stock options and warrants as of December&#13;31, 2019 and 2018:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;December 31, 2018&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 18%; padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Stock Options&lt;/td&gt;&#13;    &lt;td style="width: 34%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;60,400&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;44,400&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Warrants&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,374,667&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,731,525&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 4pt; padding-left: 5.4pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;b&gt;1,435,067&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;b&gt;1,775,925&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2019-10-31to2019-11-01">On November 21, 2019, the Company effected a 1:125 reverse stock split of the  Company's common stock. The reverse split combined each 125 shares of the Company's issued and outstanding  common stock into 1 share of the common stock. No fractional shares were issued in connection with the reverse split, and  any fractional shares resulting from the reverse split were rounded up to the nearest whole share. Unless the context otherwise requires,  all references in these financial statements to shares of the Company's common stock, including prices per share of its  common stock reflect the Reverse Stock Split.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;The following table summarizes the activity&#13;relating to the Company&amp;#8217;s stock options for the years ended June 30, 2018 and 2019:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Weighted-Average Exercise Price&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Weighted Remaining Average Contractual Term&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Aggregate Intrinsic Value&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 44%; padding-left: 5.4pt"&gt;Outstanding at June 30, 2017&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;32,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;12.50&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;5.9&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;142,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Granted&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;10,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;18.75&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5.0&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 1pt"&gt;Options Exercised&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(800&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;)&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;2.50&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Outstanding at June 30, 2018&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;41,200&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;15.00&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5.8&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;142,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Granted&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;16,800&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4.5&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;131,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 1pt"&gt;Options Exercised or Forfeited&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 2.5pt"&gt;Outstanding at June 30, 2019&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;58,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;12.50&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;5.2&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;273,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 2.5pt"&gt;Exercisable at June 30, 2019&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;58,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;12.50&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;5.2&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The fair value of each option grant&#13;on the date of grant is estimated using the Black-Scholes Option &amp;#8211; Pricing model reflecting the following weighted-average&#13;assumptions:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;June 30,&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2019&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"&gt;2018&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 56%; text-align: left; padding-left: 5.4pt"&gt;Expected life of options (In years)&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69.77&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;103.13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.60&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.28&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Dividend Yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2019-07-01to2019-12-31">&lt;p style="margin: 0; text-align: justify"&gt;The following table summarizes the activity relating to the Company&amp;#8217;s stock options&#13;for the six months ended December 31, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted-Average Exercise Price&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted Remaining Average Contractual Term&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Aggregate Intrinsic Value&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 44%; padding-left: 5.4pt"&gt;Outstanding at June 30, 2019&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;58,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;12.50&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;5.2&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;87,480&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Granted&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,400&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;7.42&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4.1&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Options Exercised or Forfeited&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 4pt; padding-left: 5.4pt"&gt;Outstanding at December 31, 2019&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;60,400&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;12.29&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;4.5&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;2,100&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 4pt; padding-left: 5.4pt"&gt;Exercisable at December 31, 2019&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;60,400&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;12.29&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;4.5&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;2,100&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The pricing model reflected the following weighted-average assumptions for the six months&#13;ended December 31, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31 2019&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31 2018&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 58%; padding-left: 5.4pt"&gt;Expected life of options (In years)&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;5&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;5&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Expected volatility&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;71.55&lt;/td&gt;&#13;    &lt;td&gt;%&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;67.91&lt;/td&gt;&#13;    &lt;td&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Risk free interest rate&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.61&lt;/td&gt;&#13;    &lt;td&gt;%&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.98&lt;/td&gt;&#13;    &lt;td&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Dividend Yield&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td&gt;%&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;0&lt;/td&gt;&#13;    &lt;td&gt;%&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;The following is a summary of stock&#13;options outstanding and exercisable by exercise price as of June 30, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Weighted Average&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Outstanding&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Contract Life&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Exercisable&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;3.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;5,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;4.6&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 19%; text-align: right"&gt;5,600&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;6.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;7.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.7&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;8.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;25.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;26.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.8&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;27.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.7&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;800&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;28.75&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.1&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;31.25&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.4&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;4,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;Total&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;58,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 2.5pt double"&gt;58,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock contextRef="From2019-07-01to2019-12-31">&lt;p style="margin: 0; text-align: justify"&gt;The following is a summary of stock&#13;options outstanding and exercisable by exercise price as of December 31, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average Contract Life&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;3.75&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;5,600&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;4.1&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 5%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 19%; text-align: right"&gt;5,600&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6.25&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11,200&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4.2&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;11,200&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;7.50&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;25,600&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;6.2&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;25,600&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;8.75&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4.3&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;12.50&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;3.1&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;25.00&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.8&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;26.25&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,400&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.3&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,400&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;27.50&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;800&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.2&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;800&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;28.75&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2.6&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,600&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;31.25&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1.9&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="From2018-07-01to2019-06-30">&lt;p style="margin: 0; text-align: justify"&gt;The following table summarizes&#13;the warrants that have been issued:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Weighted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Aggregate&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Remaining&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center"&gt;Intrinsic&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Shares&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Exercise Price&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Life (Years)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"&gt;Value&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="width: 40%; padding-left: 5.4pt"&gt;Outstanding at June 30, 2017&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;49,391&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;62.50&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28,802&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;27.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(40,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;62.50&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Outstanding at June 30, 2018&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,193&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;36.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.5&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,713,333&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;45.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.6&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,159,988&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-left: 5.4pt; padding-bottom: 1pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;(1,626,859&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;45.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: left; padding-left: 5.4pt; padding-bottom: 1pt"&gt;Outstanding and exercisable at June 30, 2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;124,667&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;45.00&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;5.6&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; border-bottom: Black 1pt solid"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom: Black 1pt solid"&gt;1,202,678&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="From2019-07-01to2019-12-31">&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Stock Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The following table summarizes the warrants activity during the six months ended December&#13;31, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Number of Shares&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average Remaining Life (Years)&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Aggregate Intrinsic Value&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 44%; padding-left: 5.4pt"&gt;Outstanding and exercisable at June 30, 2019&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;124,667&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;45.00&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;5.6&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;716,653&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Granted&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;1,250,000&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4.00&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;4.7&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Expired&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Outstanding and exercisable at December 31, 2019&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;1,374,667&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;7.72&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;4.7&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;139,498&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <dei:AmendmentDescription contextRef="From2019-07-01to2019-12-31">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant to Section 8(a), may determine.</dei:AmendmentDescription>
    <bivi:InterestExpenseFromConvertibleDebenture contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">3497264</bivi:InterestExpenseFromConvertibleDebenture>
    <bivi:InterestExpenseFromConvertibleDebenture contextRef="From2018-07-01to2018-12-31" unitRef="USD" xsi:nil="true" />
    <bivi:StockWarrantsClassifiedAsDerivativeLiability contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">7530308</bivi:StockWarrantsClassifiedAsDerivativeLiability>
    <bivi:StockWarrantsClassifiedAsDerivativeLiability contextRef="From2018-07-01to2018-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-07-01to2019-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-07-01to2019-09-30_us-gaap_CommonStockMember" unitRef="USD" decimals="0">112</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-07-01to2019-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">10068638</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-07-01to2019-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2019-07-01to2019-09-30" unitRef="USD" decimals="0">10068750</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2019-07-01to2019-09-30_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2019-07-01to2019-09-30_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1125000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2019-07-01to2019-12-31">&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="width: 99%"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;At December 31, 2019, the estimated fair value of derivative&#13;liabilities measured on a recurring basis are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="text-align: center"&gt;&lt;b&gt;Fair Value Measurements at&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 44%; padding-left: 5.4pt"&gt;Derivative liability - Warrants&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;2,674,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;2,674,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Derivative liability -Conversion option on convertible debenture&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;573,200&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;573,200&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;Total derivatives&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;3,247,200&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;3,247,200&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The following table presents the activity for liabilities&#13;measured at fair value using unobservable inputs for the six months ended December 31, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Derivative liabilities - Warrants&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Derivative liability - Conversion Option on Convertible Debenture&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Beginning balance at July 1, 2019&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 58%; padding-left: 5.4pt"&gt;Additions to level 3 liabilities&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;8,367,012&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;2,638,966&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Change in in fair value of level 3 liability&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(257,288&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(105,298&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Transfer in and/or out of Level 3&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Balance at September 30, 2019&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;8,109,724&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,533,668&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Additions to level 3 liabilities&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Change in in fair value of level 3 liability&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(5,435,724&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(1,960,468&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Transfer in and/or out of Level 3&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 4pt; padding-left: 5.4pt"&gt;Balance at December 31, 2019&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;2,674,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;573,200&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Derivative liability &amp;#8211; Warrants&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company accounts for stock purchase&#13;warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under&#13;applicable accounting guidance, stock warrants that are precluded from being indexed to the Company&amp;#8217;s own stock because of&#13;full-rachet anti-dilution provisions or the adjustments to the strike price due to an occurrence of a future event; are accounted&#13;for as derivative financial instruments. The stock warrants issued September 24, 2019 were not considered indexed to the Company&amp;#8217;s&#13;own stock&amp;#160;because of the adjustment to strike price,&amp;#160;an occurrence of a future event such as the Company&amp;#8217;s pending&#13;capital raise.&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The warrants associated with the level&#13;3 liability were issued on September 24, 2019 and were valued using the Black-Scholes-Merton model with the following assumptions:&#13;stock price of $8.95, exercise price of $4.00, term of 5 years expiring September 2024, volatility of 71.44%, dividend yield of&#13;0%, and risk-free interest rate of 1.52%. The valuation at December 31, 2019 used the following assumptions: stock price of $3.50,&#13;exercise price of $4.00, term of 5 year expiring September 2024, volatility of 80.79%, dividend yield of 0%, and risk-free interest&#13;rate of 1.69%. (See note 5 &amp;#8220;Related Party Transactions &amp;#8211; Convertible debenture transactions&lt;i&gt;&amp;#8221;&lt;/i&gt;)&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&lt;i&gt;Derivative liability &amp;#8211; Conversion&#13;option in convertible debenture&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;The Company valued the conversion option&#13;of the $2 million 10% OID Convertible Delayed Draw Debenture which may be convertible into shares of common stock at $4.00 per&#13;share prior to the completion of an offering or, subsequent to the closing of the offering, the lower of $4.00 or 80% of the offering&#13;price per unit to the public in such offering and are mandatorily redeemable upon such closing at 100% of the accrued principal&#13;amount and unpaid interest to the date of redemption. (See note 5 &amp;#8220;Related Party Transactions &amp;#8211; &lt;i&gt;Convertible debenture&#13;transactions with Acuitas&lt;/i&gt;&amp;#8221; as of September 24, 2019). The conversion option was valued on September 24, 2019 using the&#13;Black Scholes-Mertons model with the following assumptions: stock price of $8.95, conversion price of $4.00, term of 1 year expiring&#13;September 2020, volatility of 75.48%, dividend yield of 0%, and risk-free interest rate of 1.78%. The valuation at December 31,&#13;2019 used the following assumptions: stock price of $3.50, conversion price of $4.00, term of 1 year expiring September 2020, volatility&#13;of 109.83%, dividend yield of 0%, and risk-free interest rate of 1.59%.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <bivi:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">229377</bivi:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">3247200</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-12-31_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">2674000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-12-31_custom_DerivativeLiabilityWarrantsMember" unitRef="USD" decimals="0">573200</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-12-31_custom_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">573200</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-12-31_custom_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember" unitRef="USD" decimals="0">2674000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-12-31_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">573200</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-06-30_custom_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-09-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">8109724</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities contextRef="AsOf2019-09-30_custom_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">2533668</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases contextRef="From2019-07-01to2019-09-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">8367012</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases contextRef="From2019-07-01to2019-09-30_custom_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">2638966</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease contextRef="From2019-10-01to2019-12-31_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-5435724</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease contextRef="From2019-07-01to2019-09-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-257288</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease contextRef="From2019-10-01to2019-12-31_custom_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-1960468</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease contextRef="From2019-07-01to2019-09-30_custom_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-105298</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet contextRef="From2019-07-01to2019-09-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet contextRef="From2019-07-01to2019-09-30_custom_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_us-gaap_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2018-07-01to2019-06-30" unitRef="USD" decimals="0">48659</bivi:DeemedDividendsForRatchetAdjustmentsToWarrants>
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2017-07-01to2018-06-30" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2018-07-01to2019-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2017-07-01to2018-06-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2018-07-01to2019-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2017-07-01to2018-06-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2018-07-01to2019-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">48659</bivi:DeemedDividendsForRatchetAdjustmentsToWarrants>
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2017-07-01to2018-06-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">20995</bivi:DeemedDividendsForRatchetAdjustmentsToWarrants>
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2018-07-01to2019-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-48659</bivi:DeemedDividendsForRatchetAdjustmentsToWarrants>
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2017-07-01to2018-06-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-20995</bivi:DeemedDividendsForRatchetAdjustmentsToWarrants>
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2019-07-01to2019-12-31" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2018-07-01to2018-12-31" unitRef="USD" decimals="0">48659</bivi:DeemedDividendsForRatchetAdjustmentsToWarrants>
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2018-07-01to2018-09-30_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2018-07-01to2018-09-30_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2018-07-01to2018-09-30_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">48659</bivi:DeemedDividendsForRatchetAdjustmentsToWarrants>
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2018-07-01to2018-09-30_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-48659</bivi:DeemedDividendsForRatchetAdjustmentsToWarrants>
    <bivi:DeemedDividendsForRatchetAdjustmentsToWarrants contextRef="From2018-07-01to2018-09-30" unitRef="USD" xsi:nil="true" />
    <bivi:ConvertibleDebentureRelatedParty contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">21595</bivi:ConvertibleDebentureRelatedParty>
    <bivi:DerivativeLiabilitiesConversionOptionCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">573200</bivi:DerivativeLiabilitiesConversionOptionCurrent>
    <bivi:DerivativeLiabilitiesWarrantCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">2674000</bivi:DerivativeLiabilitiesWarrantCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="AsOf2019-12-31" unitRef="USD" decimals="0">30000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2019-07-01to2019-12-31" unitRef="Shares" decimals="INF">4661183</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2018-07-01to2018-12-31" unitRef="Shares" decimals="INF">2497457</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2019-10-01to2019-12-31" unitRef="Shares" decimals="INF">5183724</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2018-10-01to2018-12-31" unitRef="Shares" decimals="INF">2520429</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2019-07-01to2019-12-31" unitRef="Shares" decimals="INF">4661183</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2018-07-01to2018-12-31" unitRef="Shares" decimals="INF">2497457</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2019-10-01to2019-12-31" unitRef="Shares" decimals="INF">5183724</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2018-10-01to2018-12-31" unitRef="Shares" decimals="INF">2520429</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted contextRef="From2019-07-01to2019-12-31" unitRef="USDPShares" decimals="INF">-3.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2018-07-01to2018-12-31" unitRef="USDPShares" decimals="INF">-0.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2019-10-01to2019-12-31" unitRef="USDPShares" decimals="INF">1.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="From2018-10-01to2018-12-31" unitRef="USDPShares" decimals="INF">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic contextRef="From2019-07-01to2019-12-31" unitRef="USDPShares" decimals="INF">-3.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2018-07-01to2018-12-31" unitRef="USDPShares" decimals="INF">-0.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2019-10-01to2019-12-31" unitRef="USDPShares" decimals="INF">1.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="From2018-10-01to2018-12-31" unitRef="USDPShares" decimals="INF">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:GainLossOnSaleOfDerivatives contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">7758778</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainLossOnSaleOfDerivatives contextRef="From2018-07-01to2018-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:GainLossOnSaleOfDerivatives contextRef="From2019-10-01to2019-12-31" unitRef="USD" decimals="0">7396192</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainLossOnSaleOfDerivatives contextRef="From2018-10-01to2018-12-31" unitRef="USD" xsi:nil="true" />
    <bivi:ProceedsFromConvertibleDebentureRelatedParty contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">500000</bivi:ProceedsFromConvertibleDebentureRelatedParty>
    <bivi:ProceedsFromConvertibleDebentureRelatedParty contextRef="From2018-07-01to2018-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="From2019-07-01to2019-12-31" unitRef="USD" decimals="0">30000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="From2018-07-01to2018-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2019-07-01to2019-12-31">&lt;p style="margin: 0; text-align: justify"&gt;At December 31, 2019, the estimated fair value of derivative&#13;liabilities measured on a recurring basis are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="text-align: center"&gt;&lt;b&gt;Fair Value Measurements at&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="15" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 44%; padding-left: 5.4pt"&gt;Derivative liability - Warrants&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;2,674,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;$&lt;/td&gt;&#13;    &lt;td style="width: 10%; text-align: right"&gt;2,674,000&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Derivative liability -Conversion option on convertible debenture&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;573,200&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;573,200&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 4pt; padding-left: 5.4pt"&gt;&amp;#160;&amp;#160;&amp;#160;Total derivatives&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;3,247,200&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;3,247,200&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2019-07-01to2019-12-31">&lt;p style="margin: 0; text-align: justify"&gt;The following table presents the activity for liabilities&#13;measured at fair value using unobservable inputs for the six months ended December 31, 2019:&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Derivative liabilities - Warrants&lt;/b&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Derivative liability - Conversion Option on Convertible Debenture&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="3"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Beginning balance at July 1, 2019&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;$&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 58%; padding-left: 5.4pt"&gt;Additions to level 3 liabilities&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;8,367,012&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 8%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;2,638,966&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Change in in fair value of level 3 liability&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(257,288&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(105,298&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Transfer in and/or out of Level 3&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Balance at September 30, 2019&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;8,109,724&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;2,533,668&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Additions to level 3 liabilities&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-left: 5.4pt"&gt;Change in in fair value of level 3 liability&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(5,435,724&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;(1,960,468&lt;/td&gt;&#13;    &lt;td&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; padding-left: 5.4pt"&gt;Transfer in and/or out of Level 3&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="padding-bottom: 4pt; padding-left: 5.4pt"&gt;Balance at December 31, 2019&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;2,674,000&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double"&gt;$&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;573,200&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 4pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>bivi-20191231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: 2.xfr; Date: 2020%2D03%2D10T17:55:00Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /6Ips7xRiXgen8uHZH0sSaCPGbPtzpN2GekhtWpzfXnavywjKSa5nyauE1+2YZUF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:bivi="http://nanoantibiotics.com/20191231" elementFormDefault="qualified" targetNamespace="http://nanoantibiotics.com/20191231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://nanoantibiotics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Balance Sheets (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" id="StatementsOfChangesInStockholdersDeficitEquity">
	  <link:definition>00000005 - Statement - Condensed Statements of Changes in Stockholders' (Deficit) Equity (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/BackgroundInformationAndReverseStockSplit" id="BackgroundInformationAndReverseStockSplit">
	  <link:definition>00000007 - Disclosure - Background Information and Reverse Stock Split</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/Liquidity" id="Liquidity">
	  <link:definition>00000008 - Disclosure - Liquidity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IntangibleAssets" id="IntangibleAssets">
	  <link:definition>00000010 - Disclosure - Intangible Assets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/RenegotiatedDebt" id="RenegotiatedDebt">
	  <link:definition>00000011 - Disclosure - Renegotiated Debt</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000012 - Disclosure - Related Party Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/FairValueMeasurements" id="FairValueMeasurements">
	  <link:definition>00000013 - Disclosure - Fair Value Measurements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000014 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/EquityTransactions" id="EquityTransactions">
	  <link:definition>00000015 - Disclosure - Equity Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000016 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000017 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
	  <link:definition>00000018 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
	  <link:definition>00000019 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
	  <link:definition>00000020 - Disclosure - Intangible Assets (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
	  <link:definition>00000021 - Disclosure - Fair Value Measurements (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/EquityTransactionsTables" id="EquityTransactionsTables">
	  <link:definition>00000022 - Disclosure - Equity Transactions (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000023 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/BackgroundInformationAndReverseStockSplitDetailsNarrative" id="BackgroundInformationAndReverseStockSplitDetailsNarrative">
	  <link:definition>00000024 - Disclosure - Background Information and Reverse Stock Split (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" id="SignificantAccountingPoliciesDetails">
	  <link:definition>00000025 - Disclosure - Significant Accounting Policies (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails" id="IntangibleAssetsDetails">
	  <link:definition>00000026 - Disclosure - Intangible Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" id="IntangibleAssetsDetails2">
	  <link:definition>00000027 - Disclosure - Intangible Assets (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
	  <link:definition>00000028 - Disclosure - Intangible Assets (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
	  <link:definition>00000029 - Disclosure - Fair Value Measurements (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/FairValueMeasurementsDetails2" id="FairValueMeasurementsDetails2">
	  <link:definition>00000030 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails" id="EquityTransactionsDetails">
	  <link:definition>00000031 - Disclosure - Equity Transactions (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails2" id="EquityTransactionsDetails2">
	  <link:definition>00000032 - Disclosure - Equity Transactions (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails3" id="EquityTransactionsDetails3">
	  <link:definition>00000033 - Disclosure - Equity Transactions (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails4" id="EquityTransactionsDetails4">
	  <link:definition>00000034 - Disclosure - Equity Transactions (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails5" id="EquityTransactionsDetails5">
	  <link:definition>00000035 - Disclosure - Equity Transactions (Details 5)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
	  <link:definition>00000036 - Disclosure - Income Taxes (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
	  <link:definition>00000037 - Disclosure - Income Taxes (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000038 - Disclosure - Income Taxes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="bivi-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="bivi-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="bivi-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="bivi-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
    <element id="bivi_DeemedDividend" name="DeemedDividend" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ConversionOfPreferredSharesToCommonStock" name="ConversionOfPreferredSharesToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SettlementOfDebtByIssuanceOfCommonStock" name="SettlementOfDebtByIssuanceOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_CashlessExerciseOfWarrants" name="CashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_IssuanceOfPreferredStockInPrivatePlacement" name="IssuanceOfPreferredStockInPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ConversionOfPreferredStockToCommonStock" name="ConversionOfPreferredStockToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ConversionOfPreferredStockToCommonStockInShares" name="ConversionOfPreferredStockToCommonStockInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_TotalOtherExpenseIncome" name="TotalOtherExpenseIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SettlementOfDebtByIssuanceOfCommonStockShares" name="SettlementOfDebtByIssuanceOfCommonStockShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_CashlessExerciseOfWarrantsShares" name="CashlessExerciseOfWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_LiquidityTextBlock" name="LiquidityTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DemandNoteTextBlock" name="DemandNoteTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_IssuanceOfWarrantsWithDebt" name="IssuanceOfWarrantsWithDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_OptionsVested" name="OptionsVested" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_IssuanceOfPreferredStockInPrivatePlacementShares" name="IssuanceOfPreferredStockInPrivatePlacementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_OtherAssetPolicyTextBlock" name="OtherAssetPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_InterestExpenseFromConvertibleDebenture" name="InterestExpenseFromConvertibleDebenture" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockWarrantsClassifiedAsDerivativeLiability" name="StockWarrantsClassifiedAsDerivativeLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix" name="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DeemedDividendsForRatchetAdjustmentsToWarrants" name="DeemedDividendsForRatchetAdjustmentsToWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ConvertibleDebentureRelatedParty" name="ConvertibleDebentureRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DerivativeLiabilitiesConversionOptionCurrent" name="DerivativeLiabilitiesConversionOptionCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DerivativeLiabilitiesWarrantCurrent" name="DerivativeLiabilitiesWarrantCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ProceedsFromConvertibleDebentureRelatedParty" name="ProceedsFromConvertibleDebentureRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionOneMember" name="StockOptionOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionTwoMember" name="StockOptionTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionThreeMember" name="StockOptionThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionFourMember" name="StockOptionFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionFiveMember" name="StockOptionFiveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionSixMember" name="StockOptionSixMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionSevenMember" name="StockOptionSevenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionEightMember" name="StockOptionEightMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionNineMember" name="StockOptionNineMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionTenMember" name="StockOptionTenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DerivativeLiabilityWarrantsMember" name="DerivativeLiabilityWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember" name="DerivativeLiabilityConversionOptionOnConvertibleDebentureMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_IssuanceOfWarrantsInPrivatePlacement" name="IssuanceOfWarrantsInPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureSignificantAccountingPoliciesTablesAbstract" name="DisclosureSignificantAccountingPoliciesTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureIntangibleAssetsTablesAbstract" name="DisclosureIntangibleAssetsTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureStockOptionsTablesAbstract" name="DisclosureStockOptionsTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureIncomeTaxesTablesAbstract" name="DisclosureIncomeTaxesTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureSubsequentEventsDetailsNarrativeAbstract" name="DisclosureSubsequentEventsDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureSignificantAccountingPoliciesDetailsAbstract" name="DisclosureSignificantAccountingPoliciesDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureIntangibleAssetsDetailsAbstract" name="DisclosureIntangibleAssetsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureIntangibleAssetsDetails2Abstract" name="DisclosureIntangibleAssetsDetails2Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureIntangibleAssetsDetailsNarrativeAbstract" name="DisclosureIntangibleAssetsDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureStockOptionsDetailsAbstract" name="DisclosureStockOptionsDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm3" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureEquityTransactionsDetails2Abstract" name="DisclosureEquityTransactionsDetails2Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureStockholdersEquityDetails3Abstract" name="DisclosureStockholdersEquityDetails3Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureIncomeTaxesDetailsAbstract" name="DisclosureIncomeTaxesDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureIncomeTaxesDetails2Abstract" name="DisclosureIncomeTaxesDetails2Abstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureIncomeTaxesDetailsNarrativeAbstract" name="DisclosureIncomeTaxesDetailsNarrativeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>bivi-20191231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: 2.xfr; Date: 2020%2D03%2D10T17:55:00Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://nanoantibiotics.com/role/DocumentAndEntityInformation" xlink:href="bivi-20191231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BalanceSheets" xlink:href="bivi-20191231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BalanceSheetsParenthetical" xlink:href="bivi-20191231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfOperations" xlink:href="bivi-20191231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" xlink:href="bivi-20191231.xsd#StatementsOfChangesInStockholdersDeficitEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/StatementsOfCashFlows" xlink:href="bivi-20191231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BackgroundInformationAndReverseStockSplit" xlink:href="bivi-20191231.xsd#BackgroundInformationAndReverseStockSplit" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/Liquidity" xlink:href="bivi-20191231.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPolicies" xlink:href="bivi-20191231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssets" xlink:href="bivi-20191231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/RenegotiatedDebt" xlink:href="bivi-20191231.xsd#RenegotiatedDebt" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/RelatedPartyTransactions" xlink:href="bivi-20191231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/FairValueMeasurements" xlink:href="bivi-20191231.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/CommitmentsAndContingencies" xlink:href="bivi-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactions" xlink:href="bivi-20191231.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxes" xlink:href="bivi-20191231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SubsequentEvents" xlink:href="bivi-20191231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" xlink:href="bivi-20191231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" xlink:href="bivi-20191231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsTables" xlink:href="bivi-20191231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/FairValueMeasurementsTables" xlink:href="bivi-20191231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsTables" xlink:href="bivi-20191231.xsd#EquityTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesTables" xlink:href="bivi-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/BackgroundInformationAndReverseStockSplitDetailsNarrative" xlink:href="bivi-20191231.xsd#BackgroundInformationAndReverseStockSplitDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" xlink:href="bivi-20191231.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails" xlink:href="bivi-20191231.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" xlink:href="bivi-20191231.xsd#IntangibleAssetsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IntangibleAssetsDetailsNarrative" xlink:href="bivi-20191231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/FairValueMeasurementsDetails" xlink:href="bivi-20191231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/FairValueMeasurementsDetails2" xlink:href="bivi-20191231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails" xlink:href="bivi-20191231.xsd#EquityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails2" xlink:href="bivi-20191231.xsd#EquityTransactionsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails3" xlink:href="bivi-20191231.xsd#EquityTransactionsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails4" xlink:href="bivi-20191231.xsd#EquityTransactionsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/EquityTransactionsDetails5" xlink:href="bivi-20191231.xsd#EquityTransactionsDetails5" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetails" xlink:href="bivi-20191231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetails2" xlink:href="bivi-20191231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://nanoantibiotics.com/role/IncomeTaxesDetailsNarrative" xlink:href="bivi-20191231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DerivativeLiabilitiesWarrantCurrent" xlink:label="loc_biviDerivativeLiabilitiesWarrantCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_biviDerivativeLiabilitiesWarrantCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DerivativeLiabilitiesConversionOptionCurrent" xlink:label="loc_biviDerivativeLiabilitiesConversionOptionCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_biviDerivativeLiabilitiesConversionOptionCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ConvertibleDebentureRelatedParty" xlink:label="loc_biviConvertibleDebentureRelatedParty" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_biviConvertibleDebentureRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="loc_us-gaapNotesPayableRelatedPartiesNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapNotesPayableRelatedPartiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_TotalOtherExpenseIncome" xlink:label="loc_biviTotalOtherExpenseIncome" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInterestAndDividendIncome" xlink:label="loc_us-gaapOtherInterestAndDividendIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biviTotalOtherExpenseIncome" xlink:to="loc_us-gaapOtherInterestAndDividendIncome" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biviTotalOtherExpenseIncome" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biviTotalOtherExpenseIncome" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaapGainLossOnSaleOfDerivatives" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biviTotalOtherExpenseIncome" xlink:to="loc_us-gaapGainLossOnSaleOfDerivatives" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biviTotalOtherExpenseIncome" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_biviTotalOtherExpenseIncome" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="loc_us-gaapIncomeLossAttributableToParent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossAttributableToParent" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_DeemedDividend" xlink:label="loc_biviDeemedDividend" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossAttributableToParent" xlink:to="loc_biviDeemedDividend" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity" xlink:title="00000005 - Statement - Condensed Statements of Changes in Stockholders&apos; (Deficit) Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="loc_us-gaapProceedsFromRepaymentsOfDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRepaymentsOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaapProceedsFromRelatedPartyDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromRelatedPartyDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_ProceedsFromConvertibleDebentureRelatedParty" xlink:label="loc_biviProceedsFromConvertibleDebentureRelatedParty" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_biviProceedsFromConvertibleDebentureRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BackgroundInformationAndReverseStockSplit" xlink:title="00000007 - Disclosure - Background Information and Reverse Stock Split" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/Liquidity" xlink:title="00000008 - Disclosure - Liquidity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssets" xlink:title="00000010 - Disclosure - Intangible Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/RenegotiatedDebt" xlink:title="00000011 - Disclosure - Renegotiated Debt" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/RelatedPartyTransactions" xlink:title="00000012 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/FairValueMeasurements" xlink:title="00000013 - Disclosure - Fair Value Measurements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/CommitmentsAndContingencies" xlink:title="00000014 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactions" xlink:title="00000015 - Disclosure - Equity Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxes" xlink:title="00000016 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SubsequentEvents" xlink:title="00000017 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000018 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables" xlink:title="00000019 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsTables" xlink:title="00000020 - Disclosure - Intangible Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/FairValueMeasurementsTables" xlink:title="00000021 - Disclosure - Fair Value Measurements (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsTables" xlink:title="00000022 - Disclosure - Equity Transactions (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesTables" xlink:title="00000023 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/BackgroundInformationAndReverseStockSplitDetailsNarrative" xlink:title="00000024 - Disclosure - Background Information and Reverse Stock Split (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails" xlink:title="00000025 - Disclosure - Significant Accounting Policies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetails" xlink:title="00000026 - Disclosure - Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetails2" xlink:title="00000027 - Disclosure - Intangible Assets (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20191231.xsd#bivi_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix" xlink:label="loc_biviFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_biviFiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000028 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/FairValueMeasurementsDetails" xlink:title="00000029 - Disclosure - Fair Value Measurements (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/FairValueMeasurementsDetails2" xlink:title="00000030 - Disclosure - Fair Value Measurements (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails" xlink:title="00000031 - Disclosure - Equity Transactions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails2" xlink:title="00000032 - Disclosure - Equity Transactions (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails3" xlink:title="00000033 - Disclosure - Equity Transactions (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails4" xlink:title="00000034 - Disclosure - Equity Transactions (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/EquityTransactionsDetails5" xlink:title="00000035 - Disclosure - Equity Transactions (Details 5)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesDetails" xlink:title="00000036 - Disclosure - Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesDetails2" xlink:title="00000037 - Disclosure - Income Taxes (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://nanoantibiotics.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000038 - Disclosure - Income Taxes (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6776067024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">REVENUE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">$ 57,344<span></span>
</td>
<td class="nump">$ 57,344<span></span>
</td>
<td class="nump">$ 114,689<span></span>
</td>
<td class="nump">$ 114,689<span></span>
</td>
<td class="nump">229,377<span></span>
</td>
<td class="nump">229,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">346,514<span></span>
</td>
<td class="nump">206,019<span></span>
</td>
<td class="nump">688,015<span></span>
</td>
<td class="nump">400,540<span></span>
</td>
<td class="nump">1,008,100<span></span>
</td>
<td class="nump">370,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">306,589<span></span>
</td>
<td class="nump">237,507<span></span>
</td>
<td class="nump">613,961<span></span>
</td>
<td class="nump">477,069<span></span>
</td>
<td class="nump">1,259,096<span></span>
</td>
<td class="nump">1,771,937<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
<td class="nump">710,447<span></span>
</td>
<td class="nump">500,870<span></span>
</td>
<td class="nump">1,416,665<span></span>
</td>
<td class="nump">992,298<span></span>
</td>
<td class="nump">2,496,573<span></span>
</td>
<td class="nump">2,372,166<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(710,447)<span></span>
</td>
<td class="num">(500,870)<span></span>
</td>
<td class="num">(1,416,665)<span></span>
</td>
<td class="num">(992,298)<span></span>
</td>
<td class="num">(2,496,573)<span></span>
</td>
<td class="num">(2,372,166)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>OTHER EXPENSE (INCOME)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfDerivatives', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(7,396,192)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,758,778)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on settlement of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(51,400)<span></span>
</td>
<td class="num">(51,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInterestAndDividendIncome', window );">Other Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,400)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="nump">20,920<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,498,535<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="nump">40,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="num">(213)<span></span>
</td>
<td class="num">(360)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="num">(788)<span></span>
</td>
<td class="num">(1,159)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_TotalOtherExpenseIncome', window );">TOTAL OTHER EXPENSE (INCOME)</a></td>
<td class="num">(7,375,485)<span></span>
</td>
<td class="num">(360)<span></span>
</td>
<td class="num">(4,260,476)<span></span>
</td>
<td class="num">(51,917)<span></span>
</td>
<td class="num">(52,286)<span></span>
</td>
<td class="nump">40,956<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS</a></td>
<td class="nump">6,665,038<span></span>
</td>
<td class="num">(500,510)<span></span>
</td>
<td class="nump">2,843,811<span></span>
</td>
<td class="num">(940,381)<span></span>
</td>
<td class="num">(2,444,287)<span></span>
</td>
<td class="num">(2,413,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividend', window );">Deemed dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,099,058<span></span>
</td>
<td class="nump">48,659<span></span>
</td>
<td class="nump">48,659<span></span>
</td>
<td class="nump">20,995<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">NET LOSS ATTRIBUTABLE TO COMPANY STOCKHOLDERS</a></td>
<td class="nump">$ 6,665,038<span></span>
</td>
<td class="num">$ (500,510)<span></span>
</td>
<td class="num">$ (14,255,247)<span></span>
</td>
<td class="num">$ (989,040)<span></span>
</td>
<td class="num">$ (2,492,946)<span></span>
</td>
<td class="num">$ (2,434,117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">NET LOSS PER COMMON SHARE, BASIC AND DILUTED</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="num">$ (3.18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,539,611<span></span>
</td>
<td class="nump">766,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">NET LOSS PER COMMON SHARE, BASIC</a></td>
<td class="nump">$ 1.29<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (3.06)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">NET LOSS PER COMMON SHARE, DILUTED</a></td>
<td class="nump">$ 1.29<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (3.06)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC</a></td>
<td class="nump">5,183,724<span></span>
</td>
<td class="nump">2,520,429<span></span>
</td>
<td class="nump">4,661,183<span></span>
</td>
<td class="nump">2,497,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, DILUTED</a></td>
<td class="nump">5,183,724<span></span>
</td>
<td class="nump">2,520,429<span></span>
</td>
<td class="nump">4,661,183<span></span>
</td>
<td class="nump">2,497,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_TotalOtherExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Other Expense Income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_TotalOtherExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInterestAndDividendIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after discount, accretion and premium amortization, of interest income and dividend income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInterestAndDividendIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6635262704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 1%"><b>6.</b></td>
    <td style="width: 99%"><b>Fair Value Measurements</b></td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">At December 31, 2019, the estimated fair value of derivative
liabilities measured on a recurring basis are as follows:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="15" style="text-align: center"><b>Fair Value Measurements at</b></td></tr>
<tr>
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="15" style="border-bottom: black 1.5pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><b>Level 1</b></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><b>Level 2</b></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><b>Level 3</b></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><b>Total</b></td></tr>
<tr>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr>
    <td style="width: 44%; padding-left: 5.4pt">Derivative liability - Warrants</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">&#8212;&#160;&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">&#8212;&#160;&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">2,674,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">2,674,000</td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Derivative liability -Conversion option on convertible debenture</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">573,200</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">573,200</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 4pt; padding-left: 5.4pt">&#160;&#160;&#160;Total derivatives</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">3,247,200</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">3,247,200</td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The following table presents the activity for liabilities
measured at fair value using unobservable inputs for the six months ended December 31, 2019:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Derivative liabilities - Warrants</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Derivative liability - Conversion Option on Convertible Debenture</b></td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3">&#160;</td>
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Beginning balance at July 1, 2019</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#8212;&#160;&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#8212;&#160;&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="width: 58%; padding-left: 5.4pt">Additions to level 3 liabilities</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">8,367,012</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">2,638,966</td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Change in in fair value of level 3 liability</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(257,288</td>
    <td>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(105,298</td>
    <td>)</td></tr>
<tr>
    <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Transfer in and/or out of Level 3</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Balance at September 30, 2019</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">8,109,724</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,533,668</td>
    <td>&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Additions to level 3 liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;&#160;&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;&#160;&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Change in in fair value of level 3 liability</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(5,435,724</td>
    <td>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(1,960,468</td>
    <td>)</td></tr>
<tr>
    <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Transfer in and/or out of Level 3</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 4pt; padding-left: 5.4pt">Balance at December 31, 2019</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">2,674,000</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">573,200</td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Derivative liability &#8211; Warrants</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company accounts for stock purchase
warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under
applicable accounting guidance, stock warrants that are precluded from being indexed to the Company&#8217;s own stock because of
full-rachet anti-dilution provisions or the adjustments to the strike price due to an occurrence of a future event; are accounted
for as derivative financial instruments. The stock warrants issued September 24, 2019 were not considered indexed to the Company&#8217;s
own stock&#160;because of the adjustment to strike price,&#160;an occurrence of a future event such as the Company&#8217;s pending
capital raise.</p>



<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The warrants associated with the level
3 liability were issued on September 24, 2019 and were valued using the Black-Scholes-Merton model with the following assumptions:
stock price of $8.95, exercise price of $4.00, term of 5 years expiring September 2024, volatility of 71.44%, dividend yield of
0%, and risk-free interest rate of 1.52%. The valuation at December 31, 2019 used the following assumptions: stock price of $3.50,
exercise price of $4.00, term of 5 year expiring September 2024, volatility of 80.79%, dividend yield of 0%, and risk-free interest
rate of 1.69%. (See note 5 &#8220;Related Party Transactions &#8211; Convertible debenture transactions<i>&#8221;</i>)</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Derivative liability &#8211; Conversion
option in convertible debenture</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company valued the conversion option
of the $2 million 10% OID Convertible Delayed Draw Debenture which may be convertible into shares of common stock at $4.00 per
share prior to the completion of an offering or, subsequent to the closing of the offering, the lower of $4.00 or 80% of the offering
price per unit to the public in such offering and are mandatorily redeemable upon such closing at 100% of the accrued principal
amount and unpaid interest to the date of redemption. (See note 5 &#8220;Related Party Transactions &#8211; <i>Convertible debenture
transactions with Acuitas</i>&#8221; as of September 24, 2019). The conversion option was valued on September 24, 2019 using the
Black Scholes-Mertons model with the following assumptions: stock price of $8.95, conversion price of $4.00, term of 1 year expiring
September 2020, volatility of 75.48%, dividend yield of 0%, and risk-free interest rate of 1.78%. The valuation at December 31,
2019 used the following assumptions: stock price of $3.50, conversion price of $4.00, term of 1 year expiring September 2020, volatility
of 109.83%, dividend yield of 0%, and risk-free interest rate of 1.59%.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636303280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_LiquidityTextBlock', window );">Liquidity</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 1%"><b>2.</b></td>
    <td style="width: 99%"><b>Liquidity and Going Concern</b></td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company&#8217;s operations are subject
to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited
to: the results of clinical testing and trial activities of the Company&#8217;s products, the Company&#8217;s ability to obtain
regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies,
the price of, and demand for, Company products, the Company&#8217;s ability to negotiate favorable licensing or other manufacturing
and marketing agreements for its products, and the Company&#8217;s ability to raise capital. The Company&#8217;s financial statements
have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the
satisfaction of liabilities in the normal course of business. As of December 31, 2019, the Company had an accumulated deficit of
approximately $21.5 million and as a development stage enterprise, the Company expects substantial losses in future periods. The
accompanying interim financial statements were prepared assuming the Company will continue as a going concern, which contemplates
the realization of assets and the satisfaction of liabilities in the normal course of business. The Company&#8217;s future operations
are dependent on the success of the Company&#8217;s ongoing development and commercialization effort, as well as continuing to
secure additional financing.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On September 24, 2019, the Company entered
into a Securities Purchase Agreement with its controlling stockholder regarding bridge financing (the &#8220;Bridge Financing&#8221;)
in the form of up to $2.0 million in convertible debt and warrants, of which $500,000 has been drawn as of December 31, 2019. In
December 2019, Acuitas provided the Company, a short-term interest free advance of $30,000. Amounts borrowed under the Bridge Financing
must be repaid with the proceeds of our potential public offering of equity securities referred to below. The availability of additional
draws under the Bridge Financing is under further discussion with the controlling stockholder in light of delays in the timing
of the potential public offering. As further discussed below, the Company is pursuing various options to raise further financing
to continue the testing and development of its product. If the Company is not successful in raising additional funds it may reduce
its monthly spend and potentially delay the implementation of the larger scale Phase 2b/3 clinical trial until sufficient funding
is secured.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Additionally, in April 2019, to facilitate
our planned up listing to the NASDAQ Stock Market and related potential future issuances and sales of our equity securities for
ordinary corporate finance and general corporate purposes and as recommended by our Board of Directors (&#8220;Board&#8221;), our
stockholders approved an amendment to our Articles of Incorporation to effect a reverse split of our outstanding Class A common
stock in the range of 50:1 to 200:1, as determined by our Board. On November 22, 2019, the Company effected the reverse stock split
of 125 common stock for every 1 common stock. All share amounts have been updated to reflect the reverse stock split.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The future viability of the Company
is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources
of funding may include sales of equity, obtaining loans, or other strategic transactions. Although management continues to pursue
these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to
the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company&#8217;s ability
to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this
uncertainty.</p><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 5%"><b>2.</b></td>
    <td style="width: 95%"><b>Liquidity and Going Concern</b></td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company&#8217;s operations are subject to a number of factors that can affect its
operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and
trial activities of the Company&#8217;s products, the Company&#8217;s ability to obtain regulatory approval to market its products,
competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products,
the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products,
and the Company&#8217;s ability to raise capital. The Company&#8217;s financial statements have been prepared assuming the Company
will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal
course of business. The Company has experienced losses since inception and has an accumulated deficit of approximately $7.3 million
at June 30, 2019. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future.
The Company&#8217;s future operations are dependent on the success of the Company&#8217;s ongoing development and commercialization
efforts, as well as continuing to secure additional financing.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In July 2018, the Company completed a capital raise from Acuitas Group Holding, LLC
(&#8220;Acuitas&#8221;) and other purchasers and received net proceeds of $3.2 million ( see note 8 &#8220;Equity Transactions&#8221;)
and resumed further clinical development of BIV201 and completed its Phase 2a clinic trial program. The Company is pursuing various
options to raise further financing to continue the testing and development of its product. If the Company is not successful in
raising additional funds it may reduce its monthly spend and potentially delay the implementation of the larger scale Phase 2b
Clinical trial until sufficient funding is secured.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Additionally, in April 2019, to facilitate our planned uplisting to the NASDAQ Stock
Market and related potential future issuances and sales of our equity securities for ordinary corporate finance and general corporate
purposes and as recommended by our Board of Directors (&#8220;Board&#8221;), our stockholders approved an amendment to our Articles
of Incorporation to effect a reverse split of our outstanding Class A common stock in the range of 50:1 to 200:1, as determined
by our Board. Following that approval, we filed a Registration Statement on Form S-1 (Registration No. 333-231136) (the S-1 Registration
Statement) pursuant to which we anticipate completing an offering of our equity securities with proceeds sufficient to enable
the launch and completion of the BIV201 Phase 2b study and fund our internal operations for at least the next twelve months. There
can be no assurance, however, that we will achieve effectiveness of the S-1 Registration Statement or successfully complete an
offering thereunder.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The future viability of the Company is largely dependent upon its ability to raise additional
capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans,
or other strategic transactions. Although management continues to pursue these plans, there is no assurance that the Company will
be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations.
These circumstances raise substantial doubt on the Company&#8217;s ability to continue as a going concern. The financial statements
do not include any adjustments that might result from the outcome of this uncertainty.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_LiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_LiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6638910896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 1%"><b>9.</b></td>
    <td style="width: 99%"><b>Subsequent Events</b></td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0">On January 2, 2020, the Company issued 11,200 shares of common stock as part of the annual board of director
compensation. The share price on date of issuance was $3.50.</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0; text-align: justify">On January 3, 2020, the Company received a third partial draw of $20,000 and on January
14, 2020 a fourth&#160;partial draw of $250,000 of draw number two of&#160;the Debenture.&#160;&#160; The total of the partial
draw received under draw number two of&#160;the Debenture was $300,000 at February 12, 2020. Acuitas and the Company continue
to discuss the need and timing for some or&#160;all&#160;the remaining draws under the Debenture Agreement.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On February 11, 2020, the Company entered into a letter agreement dated February 10,
2020 with Acuitas regarding Acuitas&#8217; previous agreement to modify its existing rights under the Purchase Agreement dated
July 3, 2018 with the Company so that its June 2019 waiver of its rights to a 50% adjustment of the purchase price applicable
to its initial investment in the Company and the exercise price of the warrants received in such transaction and the price per
share should it exercise certain rights to purchase additional securities in the event of certain reductions in the useful life
of the Company&#8217;s intellectual property rights and commitment to purchase such securities upon the closing of the Company&#8217;s
planned public offering (the &#8220;Public Offering&#8221;) of shares of Class A common stock (the &#8220;Common Stock&#8221;)
as described in its Registration Statement on Form S-1 (File No. 333-231136) and commitment to purchase such additional securities
would remain effective until April 30, 2020, and accordingly Acuitas shall be entitled to receive an aggregate of 5,359,832 shares
of Common Stock at such closing. In addition, the parties agreed that certain draws under the Company&#8217;s current bridge financing
with Acuitas were to be made based with respect to the Company&#8217;s ongoing capital requirements and current market conditions,
notwithstanding certain scheduled availability dates set forth in the 10% OID Convertible Delayed Draw Debenture issued in connection
therewith.</p><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 5%"><b>10.</b></td>
    <td style="width: 95%"><b>Subsequent Events</b></td></tr>
</table>
<p style="margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="margin: 0; text-align: justify">On September 24, 2019, BioVie Inc., a Nevada corporation (the &#8220;Company&#8221;),
entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Acuitas Group Holdings, LLC (&#8220;Acuitas&#8221;)
pursuant to which (i) Acuitas agreed to purchase a 10% OID Convertible Delayed Draw Debenture (the &#8220;Debenture&#8221;) due
September 20, 2020 in aggregate commitment amount of up to $2.0 million, and (ii) the Company issued 1,125,000 shares (the &#8220;Commitment
Shares&#8221;) of the Company&#8217;s Class A Common Stock (the &#8220;Common Stock&#8221;) and warrants (the &#8220;Commitment
Warrants&#8221;) to purchase an equal number of shares, each subject to the terms and conditions set forth in the Purchase Agreement.
The Debentures accrue additional principal at the rate of 6% per annum and interest at the rate of 10% per annum, are convertible
into shares of Common Stock $4.00 per share or, subsequent to the closing of the Company&#8217;s planned public offering of shares
of Common Stock (the &#8220;Public Offering&#8221;) as described in its Registration Statement on Form S-1 (File No. 333-231136),
the lower of $4.00 or 80% of the offering price to the public in the Public Offering and are mandatorily redeemable upon such
closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. The Commitment Warrants are five
year warrants, exercisable upon the earlier of the effectiveness of the Company's currently pending reverse stock split and December
1, 2019 at the lower of $4.00 or 80% of the offering price to the public in the Public Offering. Upon entering into the Purchase
Agreement, the Company drew an initial $500,000 under the Debenture and in accordance with the Purchase Agreement, Acuitas received
an additional 125,000 warrants (the &#8220;Bridge Warrants&#8221;) having the same terms as the Commitment Warrants. Any future
draws under the Debenture, which may be made from and after October 15, 2019, November 15, 2019 and December 15, 2019 in equal
tranches of $500,000 each, will entitle Acuitas to receive additional Bridge Warrants in equal amount upon such funding.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Pursuant to the Purchase Agreement, Acuitas has agreed to further modify its existing
rights under the Purchase Agreement dated July 3, 2018 with the Company so that Acuitas&#8217; previous agreement in June 2019
to waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the July 2018 transaction, the exercise
price of the warrants in such transaction and the price per share in a purchase option triggered on July 3, 2019 (any such purchase,
a &#8220;Subsequent Sale&#8221;) in the event of certain reductions in the useful life of our current intellectual property rights,
and effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a &#8220;cashless purchase&#8221;
at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of the Company&#8217;s
common stock on NASDAQ or the raising of $2.0 million in additional funds in the form of another securities offering, in either
case not later than November 30, 2019, such that Acuitas will have irrevocably waived its rights to an adjustment in the purchase
price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in
the Subsequent Sale upon the issuance by us of an aggregate of 2,679,916 shares of Common Stock and 2,679,916 warrants having
the same terms as the Commitment Warrants to Acuitas, which is currently expected with the closing of the Public Offering. In
addition, the Purchase Agreement provides that, should the underwriters in the Public Offering exercise their option to purchase
additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas&#8217;
beneficial ownership (on a fully diluted basis) of shares of Common Stock being below 60%, Acuitas shall be issued a number of
additional shares of Common Stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership
(on a fully diluted basis) of shares of Common Stock equalling 60%.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6639123696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureIncomeTaxesDetailsNarrativeAbstract', window );"><strong>Disclosure Income Taxes Details Narrative Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net Operating Loss Carry Forwards</a></td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureIncomeTaxesDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureIncomeTaxesDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6764336032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details 4) - Stock Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">11,200<span></span>
</td>
<td class="nump">10,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">11,200<span></span>
</td>
<td class="nump">10,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">25,600<span></span>
</td>
<td class="nump">24,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">25,600<span></span>
</td>
<td class="nump">24,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 8.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 26.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 28.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 31.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>27
<FILENAME>0001520138-20-000106-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001520138-20-000106-xbrl.zip
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M++8G:J>64S[Z,A,KOSWWM,IR=><-$32:4ZG(>A,K>])8V7$0T+I&? T!U8>
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M?;?'3R>31@=??=VY[UTLK3[T/2^][L0/*(RSQ[WW7:\^ZX,*X-7G?D PUM'
M$ZDC67HX*#96T\86RL<^!>).2E%U\G(U]6P#5W?4 5VM BUR'3UM UBO.QX-
M*U&IEA#V=!C9=<O7[KW[[J,0,Z$=9)4$@$<#[.68\_:2"Y?NB=T>C_M5+%RZ
M"_805F[C\-C=UR[=BKXJ;!>P%E8QY\);V[K[Z%8'5YT66L'R6VM%%:Q=B02N
M (YM.'>5=ZLT]RZTN&*P7S$]<K&W^9OK7E]!]()3O(P4K"(E;^N(>F5]8'\T
M[/0R66/FPEM!5M(+JX#;"U8.N789)^RJ4H;1J&W.NJOF0++5:(=$2G;M;9#2
M[2]7A>^,E)(^J8HIY>G6+N.367$@?7O4W0O?V!FR3K_3[G7MZFFEE/Y2-5=Y
MLK7+*$Z'II6=(=N"5O#U=X$W%6'TZ:^%&S^>^W)>[B7.. S\LS@.W>M%C+'H
M;P'&GP'T,*")22H'8@V7W-26/SV@N1IP#K?)0N/2X)^E3,$CVN-NB:V]=C:!
M\(BWOGTJY;@[[J2F%1T[*K8QMI;&Q1\;$O:6A'Z0(ZLWM+LEFP^/F,%6E[#=
M0UMK*6/[B%&QE3-^.!C;G2-&0DG;]HGO;1EK..?>9JM$COB<MK^WW=ZXT^D_
M(U1LE8K5[?;;[2/FXX6F[MG=]C@U>_;H-ED@X0JL4,SW.]Y=%IK8U0?;9JF:
M\X@VN8\4MKT?R9% 6SI-+%.=<OQW9\NM=_I';23OD*F5=AJ->\-.]Y@=!CME
MK:5])YWQJ#\X8E14D"MVTK'[]K'[2BO(3!OV1ZE!V\>&A'VD3N_5'#\B:$OG
MQ#PGF;O+UH]<YNZ0C925N0.[8V=;<1P1+G;*C<[(W%&G,SSB&U%%<EAG9(\Z
MW?X16^M5)#?W._WAH'_\,G?]+D?#3GMPW"Z+S;OLM3N]4:H[W5XV>3;#W_Z+
M^K-=W'P4U_%'-YH$"S\&!6+F+F:5I&,/^J8VO''-)2#]V)WB<&GW7ER)R2*D
M3@&?ON/VQ12!PC9SL'%^8W:4.*RWR!3A[S+[&QC-8& PFDJ@.]B6UU7E$HGM
M-&;R^>#BGPYV*RP\'J4[LL?=8\7#NA+RDGBP.[TCOASK$+%T.>S.J#T<MON]
M FEHZ='RQX64]=Q^5=;LN'N\]V%]U<\JRN]U^^WG0?K+(955>QX.^V.S\>MQ
M[3GGG"N<^GE<N,@Y_YWT@MX1XV(=7925A]WA<Q&(6:HHBXEAU^[OG5=\=@$,
M\2N\<@HFC^/?NF ,G461B*,O8ON\X.&H.S;[HZU?9G>@BN0GV/U^;]#N'A*H
M @6PO>YX;/?W -399+*8+:C!FFE ;MW[K3T>CHN=Z(J5]P-[D9,?=L>VR5/J
M _MF AGUNZ-^,?K8'?9?PFP-?9D6C)UQ%_3[0J#20E4 5B@QZ6D *] H:U?
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MEW;V5$2Z1O_= ;]K=.'.\$ VQKI]UA?;VS#<.EC*QXGM;=CQ.FR_*&1+'K8
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M#6%[TP6R0H)C'H2QXUEWCW,1PHOHY ":*%Y,$2<.7R@$[B$(O>FI]0W^>!O
M3V!U?)M$/2#/Q5YCX6(>T^/Z&-,8:=&9B>M'@,Z+%13X@\GC!#"!!# !_@SG
MBM]:-]["G5JP7?J @5.OAE>Z*"1.ZW>ASWWK;!ZZGH6F4LMZ$):@3FQ3Q%(
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M(";F!4AX0 Y*;%3_XB%8>%.D:.!?+8(>.0)!$=)<'/KAG!U7BN(E*J[?=JU
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M^4$ '<LU7"K2]P4]DIB+J3U(=1<0MOPN=O+HZP(ZS/+O>4'R!L**B[GBB+[
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MKC4#!&B72<RNPFZ;X\[DK\LU^72*M7002Y-2Z4H$BA\8?T<A"4B>N'-Z6.(
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M"-7L]8"^!,;+:-#JM[N6U,>JDZ)KA^/6\W9E:>D_8&_ BN N3)U95%YR$1R
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MZ;(:@?YY2A<(=!Z0+=4KU@B DX6"9JD2[UB0KQJA6L1W04C=\[*H80<DH14
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MLA1]*C.)2CA]/!J8Z==#J%>X?^0L%,M$*:Q,(B*RRA/<?,;^C/3)QPBZ+SH
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MHTLPAXV2PL6!U".2<KB!/'"-$Y+?ND)2\ZL*D$T?N !3M$>!#2# ^X:GZJZ
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MTS?0]XYR=&D8]H_/YH-J)SX/($V/?T((Q2%P.N0I-8K31W+9'_F8$(@#8'3
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M37HG:58@EN\0?4Q=*:6I..@6NJ)B; )%+\A>^S ]U*0*)*>M_5GO_8E*'LT
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MIV&JIE+88>!J+OOOJ SFD#+'/U(EK'^ECF%7"F3;0G B&&L$4-[" Q/!2!-
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M4A,=[QAP$.&IDN2M@2IQ0>=X\4NB.^&2#V!\)<DP4%NEP:2TE9GL$!<O,95
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M1J-O^;?$K#DIQD6Q(OE8Y8O);9?YFFB7+GG5/O4/?-X(!Y<_<"DCV1'=DC.
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M-O6:F!-K"S9O=RNO_1(MQZIM N&#&F)!V1(?J3)2?P#$G.\#A0L_9&LT4W%
M4<-/EELD++GH$O\KU%/_@9DJC*=+2F-AS9^PC7Y<4U?9.9PRZKXNCZ5E)3Q6
M2A1Z3M01''406'';6-N>F+U1L7^Y=<&$"J=A;<]W!?ZNK;W5E6A\,H2U+X3=
M#V'7?=<7PC9"V/Z%L T0-I4]4D1MRJ>D9+E"[)H(-)9'_[9_*NNLJW5=[X[,
MT5J&3"G&+1NI^8*C7@>)&U8TMIJPE YMA342)RNUPHB+VF&)'6.6S],#G-H5
M[@S?]X.GT%DJHVXXT5SY(<\#S.0+I)((:IAM5/MMO/G"%J+V+!E15L';6 9T
MSZH#=.:,7N667;^(?UD62*KQQ-CX--0]E]T9*&MO[6/S[&6]_$O[EU I6\H;
M]H4W+KQ1P!L5?-L7WGBAO-&_\,:%-PIXHT(@\<(;+Y$W\EU0%PXY\+^LT=CL
M]:TC<LBV7L55L,Q-1*D0QF\4X+,V=54^2!&#'-%5=CM_+Z:Z?W.^\Q6O_9G6
M]NQ N0E?M6)P[-,=^+(/65$7_YF<1K]ROJM\<NJ@\J)<9DV$&)JNU6VR,!=W
MJ9J0?2;8-31<NTCJOE^_.#\64Z JI78)C&AS'!O<Z90@KZTM5$AO!X%N>$$D
M)N7,@Q#;Y%30$]N4[&V90[MOCL<5<E_/)+U],,!YL%6\ 7M,;L_)Z4U7;C5S
MZRH0+)](O2&H4R4\T4X184U,>[05U$V=(V]VMCX.]<C':8W-<7=R:L=I#T;F
MN%_BF]GK>187</]-#2:Y1C68^L[M5TFJE%%2541N60 /+\6X:PZM+?+'<RO?
MCTJFG9BS&KW&/=NTQL.&J+47ADZ233ZQ59Z]5Q_X[9)XMDC9V>VLUM96EJ^=
M[VLX$"$NY-R2$-K]\,J=/34=,L5^G7?*BW([OZ%9DK"@\ W]PGPV=U<'\NW@
MY#9_"N [R6P#I@89XN (.5=4S+S$&W['033$P."9G,@[9S,<T$7G@FT"J-D=
M_7>\"L)G^FZHQC"F!KR+]O%K6Y0,0M3Z$= LQ$MQ3!7=)KDG:UW;=O*\5.P!
M5^'YJ]?-KCU 7UK3-;A;&UK3*6$DDS[?"*GTEGH6<V&GB3<4;86,N[\&;A6N
M>H5.;NMU2E7W?WVJ./?6"S*VQ?G@C;B$RX FMSK?<>R,:/(MV5*PZO:7>"\E
M)\7%"159Z[C@#W8#OP7MVJ2%R)MDX\R-9%:JD^>2:-S$KM[M;IMCJO187]G%
M"D9U\(KEWKF0J;</,NVYA*BE_?1V NH0MO0^X;\0]= 57%NX&++>BN*\EC\B
M-H^]W]PYJ^R6^&QU_Y% 667I-><)3DZA:2[Z/)CK,,1W#$<$_/*<?.0S'ZUR
MC5%5G/% (QY@@WA!XQ&B#V(<S]\"')J" X:^H":5@\U(PV;,L?FG .F?%+&Y
MI15_IP9[/Q@Q($9?_QR'[ =CQJ8XY2?ZZP\WGS[^\+/5Z?:LGG9:^\>I)63,
M88IB,EKVN#L:=0?]3?3L=H:3T>@ETC.GVG%[MNR,K,'@)5)QG+K<NU)Q.)I8
MYT/%+V[TY\>0,3D=]" "LMOIVO9X3T3,PZ@5)-R7<.S:P^Y+HV6S@K%K#?=U
MI5M+P6:%8M>>G,U]EE+XO8O37?W9H40B_&?/[XJ.42M(N#>1^ )IV;!(?($4
M;%0D(A,>FX!WFS>\J[/A-Q8NK-U%X<^?!__(D&8OD!Z7)EO*MI=!G'K"ZF70
MI)[X.19-UE*CWCE+=^5XOP41_#.I<HA2*%Y'M_-$-FBR\X^O[W71V?WAY\%@
MT!WV$]0J;]@HI),*D%I#NS\>C_8!ZJ]!,,.YQ]?^6K7AMG2U)O:H#-:2+9L&
MMPIQ>\.)M2]PX1_R=\)5GKHU_DQXSJ/\9_M=$*VV/05[,!KW!R5X-0#;L?"O
M=&?&X^[DR.BK['R5G+_M:8Y[MC4>EJ"SOE5#T%633^/N4 ]$- $>YH%7I];W
MR/W1=[V__K *8]"1_[+M\@7H;EK^@QRXK4)CJ"NGDV&O5Q]Y+LU7F>&5^G#5
MV-<F@\K6/$P-@'4@3',4^XV8]OI'QY0RIC!G.Y@ZGOH<BYHZS.ZX'HI%\.P;
MMVV.KSLX'FX\7>G&KRL4MS_*JXX]J8=O#1B/0((M3ORJTSLV"=X!(JX?N_[]
M[1(D 5DAC=W5[B;D\G9O%NZM[F$C<(N_^/>-V6?6N)MV#A9OL1LP552<P:@V
M,#/F_O@!"+=Z!C+>S, 0IJ8G2+U/,<U/K-IVN#^\L@=6=S2$Z[-QU?7M\2S#
M91 F4O1=$/NK\/E=,*OJX?WAYT]_TS<O77,=A.O9+&11)/[G-]=G5;TU8,E8
M=M=X%WBPV2PPKA^9'S,=E)RUJP!@5P;@:^R"TF+WNN6[VE5V[57?U0%KT_@]
M\.%TRS?N%6Y,!W,;?L:JJ (YGKOWN^N<'3.+%6[Z&4PCQ_O_W&4M]IIT^]U^
MSJZIU?0]W^%G0N;4VJ5GV7P/_=OZJJ1<?'X(?%;SCMKCWM5@-.GQY;/+%)?N
M70.R,]>+4>A^9=,XI,*_#]^G7CQC,]SQ'57%T46[G7]P0NQ:'7UF(1FF^Z_H
MPUF_O"SMCL%;:T0/P5-$-70^IU P-X)X!:?$&VU'U'<@X!X^JJ8#J1@ZOAH!
MC.5VE)*9*KE+-<5YR=5V>>F=)6BUI*B-=EAOV]16Z/916U=R<#LEV^=@V'2;
MJXIUB]MVOOJD! 7)K.CEHGK\,D3>%H9'>(H/HN65=H.Q"<KXUM5VU6%H*P'Z
MEFGO@P '+Z:1U_GO0D<X]QHHR^Z;P^&PTJH[@W@F-.N-36NR/IZO00B;9/N2
M-ZQB6=FW "R>7=[([>JA-KR,#91(;=BAWH2KL5UZD8Z"S4L\B-'$[)7<SGTA
M4[EPK2D#^S@F?"-CR!HWX=^S*24'<3/>RG3.>1&]F.N9Y]4Z2UGUQ$6-MBB>
M:#TL#\Z0AT;+WR4WJ=W@-M0MN9UGE]N'/]6I?Q.Y<HW/HQWNH?"I>_KZW/!<
MK+<PGDMWZO6+=MK>N-SZF\73TH==LY^V*3<:N(TB57@>K:)2O[]W*M5EZ)I,
MG&=J[T4F5)0#C2]8W&"\-T+KNT*#\68P/SOZC> ='E09475HEB\?/2/?D\2P
MWO)1W&'Z3O%XG>97+#I 10B<4H.MYT>')L;Y$G0T&I@3<37V0M!6V+RH_SR
M$<_"Z,._8NP;P![AWXS^\'7IN:M\(];J@N$JC5@+#-H??K[UC4_!(U?O;6&-
MF/H$((-1,A*V@S6L'RU[8(1\,V&?1K2=Z# KO_1_,,-GL0A\_J&.@;:O^IX
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M5NG=K43G1:M" [/?&VP6 BU2AD '[IK]39?_H@Z]J(?[0M4VJ4.5XJ>:CM1
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M.7FV@\@5X:DBV\; K8$2IYOVR) DQ^^>M7G>48KH:EO@9(2L]H:;(15GM2.
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M].SEI: E.B8JDSZZQ,[^^B4E.=&-%]F6R!3;AR:Q.:-OYAL.1R0E?OI]O?#
M(_(#3,E)9W#0[P!$'.IB\G#2^7;7'=^=7EQT0!!"XD*/$G32(;3S^S_^^A?
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MW^*34,P)%]62U*-D9) 2;5.,,G)*2;KI^7K)K=Z"&J$*/8X.;>1(X9;FR4H
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M9]![OW;-H\A/OK&18X-[,-/(OYA FZM"'3HZ]*RIY7B60;BS[)(V7>S2U1)
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M=G]T$ J#H(X)0NGXT59"C997-HV29!7$U_@AS50DZHJYYHX(9)\R;1E03!$
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MJ<Z,1)&*$CE7;:V$6;>[4 @$!U3(N.>W2EG4%?9"CILTI@]41LG=9[)8S:)
M9)M(R!4MY !K3O 2( @AA<7E6&T$42WIA0I7&::$Q*0YV#5%^BA\-ETLA+,
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ME])[%WH55SPR!5^S22</@E.&(/O,8FK=93A31%33?V:F=JI_^02P(^1XWBP
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M O<E'#[N(8+6>KZC_;/W>8(<$Y_RE JAL)*"T:W7NY.CHLBBVU5!\V#.TJM
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MI.W@\U>#RIL_5?@[TVOO!'MJW-&2+I3^S@YNIPNR)"*8([)8&N4Y+H2MJ=:
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M5^?,5IP?YA,^.L.0E2/J)4.4#Z[[#&B4JE^5)9$YS .>TSE*NTSZ>[3N=P'
M?D>?1>H_C$$S(!=-C)KEN&);G)_!93.CQ2.,75G@^LF&!JCZ1!V['Z)68B:Z
M E@_GG(QU.,I \?1MFJ@RB053I-KNF#)R+J'W5KYDJ2W.<X>::U,$K).(3\3
M[A$MUNF-,X@-^BDO4;H[J"QA4.^ WP'3_79HG*IKMKY6ITH+45"T.NKNMV]I
MH,+T@1U]6.W6*O1\;,YJS1#MQ4J5@"ZCM8#W\'FC]<BW3E+2CIAIVSR:D^&*
MOBYB-PO:O& _\Z%M*T(\,]JT5#!.>C!35"ZY?(&H+ 71YTEQ"*2?"&V^PAE[
M28FPJWP7=_049.%T5>1DH1/2IYJMNLRPWW#:>W91/9V.-.0'X/2I'5BEZEYI
MV;'2=5'LX@%^QMD\RFEI]$G?ZG]B])!%<R#1O&OOTWJJN%4EUVD<GZ<9K2C+
MX<FZ/#^CTH9FBP<CR\+@])<M+5#UC?JAU(&&'8,3M>I.AUV<AD+-RSF:Q@CA
M$9I$!^BT7X<7_NV;]O;6 F=DF4O E9N_HR1L+8.M]S>M2O.UO;F!R;+=38NB
M #K-3? KHQBJ\E@Z08@G:65*SC2AZ^WIHNG(U?G&"4[P(BKLYPNV)7J;,6QF
MNG3.8%<<P ZPJ0WJPV3F[@O2!:HB'$1]]O*=G>$BB.+\DDYAZ)&"X2:B<2D^
MMA0M311M,!H6X9VHV^$V?.AYM)N'G@=RV!30?1J'!%Z9^[B"RGY@0&6=VT33
MJ0,V-Z7C:/5JWGEJCY6/EP=*P"UC/T=+&D8MJ:Z!RG;ZL/60U=%Y WN(@L%T
MA"&MZ7>5)D1X7; @.OBT&QU\5D4'LWOYY#/#7,BWC@ZN1JS-PH,Y90#QP1*#
M# *$>YI@]SA,4.])B+ BUNU31CJ&+ I!J^8TL,30B$Z0B$8'C-\T!"K@&XYC
M/"]608RNLO0!9V""IN06C>;SU7+%4EBT R+MJT9:$!!>:@PU9*JD%#?<_;'D
M;H+OZ/=%CG-K"_JD;DEW F;!\_H22U^AU2@!X6O+ $-N$@VG/K1(BR#>D(5K
MK$9N]  1!5\3Q>.M9HK'$*>*G$GF<\7C_9PL]F'O_VQ1<"?B$C\7])29+.-F
M3SA^Q)_3I+C?8$II4S80?VE?':9#OG'!^S"#M;:FWU&.CXZ/]K%O5!;^%0?9
M["D=I.+Z1<+M"6+C-^\ W?+VE/="(P1T?[?O="<H\. U5A:Z'Y1O5\ PI*<E
MO@+:M\P0$/]XSXE_3FIYZ"HKR]P+VK?-'X3UM,#])WW+"@'GW^\[YXG*X#7&
MRMP/SK?,'X;S1.45<'YMA8#S'W:TL[(QW)OH6;3(WZX\9[LO0YC=[,=L4YAW
MW@YE@8"SO]UC/SU:%#C;A;/N%0S>8PLK8FNWW2G5>Q\8W)1^9YC=XPP'5-#7
M!KEE9*=Y*7 VS&TB.TV+V*\-=-, 3ZN-]%T&B;4Z%8VG[AHEC/Y2:OSZWNWA
M&HU$5!VN&:+E#G3;68\J9P/^K.-+CA>K^"):V(^6;548XR%OC-F(M];;@S&-
M RMX/)@(("I!0P,AG;D)LRQ):D BZY)I2KAM:@D%P7!)A8Z;\M#( Q0V&K[&
MF"VK_MAIY3\0#&EX4P19H1I7U%"YZQSX+DIHV#"Z#6*:$X"F*/J/5?R"WAT@
MVK]@=.DFAU.528GFN/DY*NZY?$UY-V%3-[M3^0 QJ??[()=ZA-U\RDO6L!U4
MEC!KV(#? >/.=F@<-Z4+PX@EMJ')G&+Z3"=ZC^)UYWU]79!YLDDR)^O>')_A
M\I\.&D+RW7WMG,IJW%5/%7[T579;E:7]/GQZ3_X71E%"_[.@*?X>ZUR<_1X-
M):9\N)J:94&2+\B"5Q&TNZNO[6G?%579CGIL^U.OL9\*[./6&Y4([9Q!$KY-
M,YJEBF7I+#OG?JX_W.YHE>N/<:*\N* &RE\F;]8<-Z2J\/*6M-'[(T@K#W$2
MM1'-YG3'6'ORLA:Y"E[HG\J,:F6RPE;^J,L5M4]2<3OXCO\4?0-4DSY-WQ8?
M@;A^WY61_;Y7I<&<MK/U%>BVV0\@SK%$_#KZX2>6?FV2E+,ZU4W-G7QIG_JB
MHJJ&[(V"SX"9GNS.-DDW9 KJO("[9 Q-F%%F)CQ;T=E5B;O,#]I.O3NNDG>&
M0D)8E^)J!]7\XN46-DA:MA'TU;;[.3+[V%O7S&UW9Z39V(R3\+6-RC_AG-YC
M3L)Q]:K/+*5_&J]3!N]TTFS^^7T:OVTK=<B.;/KM5S/26QHL'23F.,LCEB/[
M=?;TEB_[&4=W][32'G$6W.%Z@+RB^<!W[WK57]^G?FY9I3L:KU6??N7K:P/3
MN?[>&M)K=53I-U-%Q$J@CH FX=K?)7ENM4K:A5L8$@$HUS!\U5JYA^$^OS\3
M@<%M[OL&C3\X,-DDV*/>7UOGU0%8@M@K'[!1!0_J!JP0O!Y/L(G9UL[@%>TK
M09V]ONX]*"/3!YB_OL+%K'[1[V&-NRTH4&.;DP9PN_'U.L8^%]70=SKMW;$]
M=SJW^JJ]M:M:N4>_QLL@HAL'IVG";ORM@GB&L^4[5=L# >C<&0&Q6^*80*"#
MY:0@58EV\MX4@%HE(%K$#G?Y)-?!P=3><:]YP:%S=GT=DM%K#P0,FG?W [,^
MMO ]@^TH0O<T[T&WY/MOT=.\A^MIW(;5P_<TLNA]*T_#UG"Z[<K7X&L^@&[+
M#]^BK_D U]=\^(>O$=;' "LJG+SNC1_YGAJ0C9^- +Z"C9\M&L;!QL\&Z+S[
M*+!58K53;>2R7LVN=?ETZR3)BVS%#LVGQ,)L=A\D56.,[NXR=B%C0BHC2O)H
MSBX$M\:,H5DP"*2]<% #5OX@+FD /&!C2?W6!Y=,IE9$C29BJOMUT]-EI9:C
M I0FKM&\:C_3K7*O+J:$LO]3G$'L[WN3_8HXM0W+8VD(N[6QH[ (LT_O4P2.
M364.&6=C\EU8G=F-L>*+9?DZ3!2E&3I/LP6.-!WZ-8TSD.>S4*-+?=?'QC/:
MU[1Z[CJ ,AM6N^)VM96G^N!>S$B-*V[(K3;YUV -1;LTT;S;MHK:\U[:9+$;
MY?EJ65=4M;6XBPUW@P_N12\UKKA!>JGV:_O?2TU-Y#>L2QD45XG\TVK>^-TD
M02\XR/+? .JCFTRE537S4QJ38FA.UFOBJ(:>Q-M\>2^6?O95.<C*S_RSL/JQ
M$UNE'?JQD7Z%'?@ZRK^>9YA.13!IN\)5]Q5_=V\[KZH:=]9U11]]G1U786F_
MVU)1M""R**J$44:D7V'7K1W46?08A63)[GKD[7YW;[NNJAIW/NJV/_HZNZ["
MTG[7K4707R,<[^MM_%=WH=;M[JKB=49@]<'/%]O79_>4O9YRE/J_*+![V_2I
M2??M+.E;N[4+TQ/"JAMMN'D[8I.^>;FGCG(O4L/")*Q+R_598O>4?WN0].E5
M#NI&%F\^-=R#K0AMA,)EFCRR?KJ;C./VW]^+K8E-JW60GFW[<; AY Z-YV8Z
M ?U4T8^EX5*2T#_0\\#7[@:Z65R=-UK_\Z_#"8@KU8T/Z'Y[_P?WS0R6=?O7
M$>"MK9,F\-5;QQ8@>!U]6UJU;KHW]_EOH(?+;)9U<K+LC++7W\FMGA5W#^-U
M='?S1\==8_@&.K[5D^3KWK^GB<+W:VT)]3J'4^,M5I?5;8UO84W9U-9N[QIN
MCN-U#$V::G;L%CQ>282S]61T57&3=["^S>THS_Y##>9U.!&3"O>Q<>71G>SR
MA'2(6GCE[VAMNTVPRNC]<:^.0X'D=7@-;54[W0SC87P#:V.=[1L\L#7(KIDJ
M7^U.*J**$M&L-GR!<)M]UD<%=Y/,ND0 95;@U?IOYR&]_5X0?YO[99)*V'!)
M_ WMH=E']^;.6WDCC*]C KQ%\[AQ0QL _ 8FS9O7BD6"=AHOO]--/.=3[ VJ
MK9\*!B3"5S YWZ9I',S<-X'GW0_!K1-++^3DP2LH=21_] H0PF_3XT@>OP(#
M[Q\>1UHG&\Y[#%=J$._+OIX<WS O%GJL"..<C;L>.,^B?!ZG^2HC>.?I$L^"
M9YR?X2*(XGQTF[.>*'(19GK.!AD;,QK7;Z($A;BV@/L$*Q40TX"Q8W6&%SC+
M<$@@C?(<%_DE+B2,,U-QN9]C K[M>%7RWL=\"Y!<"IY*!17!,PJ8TD>@]#H-
M'J(BB"_2G/QKEKTLTHPZ=-EFI86^5^+IS%*R4*8,EY(:Q'U^$CU$/&:.YBUA
MH 3]E*;A4Q3'HX0>5A KHML8ES^9UHZR"*\T-3!.R52%/ERRZD'SPW0M5GE3
MH%PE_U+_C:;62'+<F4<GX0E.\"(J<O%2\C3-C<?X03[EE?L#5I:RCPSP';A]
M:3CC^GWNIDCG7Q%;Z:%Y2P5HUZ/+PM+F.$Z?@F0NBRHTTO3:,>2F*'G.J[FA
M[8\E;1.V4%?&,YA#[I.Q$42-)% >DL6!Q3K"__+,=%GFU 46]%DI*R:M$?:I
M0WY!(;\>\[!Q=+SISM$QL*TCSA"CO:/CO=L\ZB.&OWLT7BSPO(@>U\;01,'7
MF+9V%$>EKRW.<8BS(+XI@F)%@+QTA"4];I"273J[ :NB[1L'*!;,;'(X6R0]
M@[I;7$Y+T7>WY4ST-_0(:E&6B?*Z4$#9Y4UJA58&)K/K"P(C;CF.+2I:7B2T
M7J,SWK:[R,K;JWZB,8)?7=%3K8)*'*"$3%'21=,IJHZR/[WA])Z>#TZ2S1=E
M@W\%6I_9H(ILNY'%)_:J9]G;U>]L90DH2M!CLXX,8*TCQ15!@SZB9!4E=],'
MXAK82;I538H+\-\Y5(;I>2_2!DYI!63YJ@)56WKH9)@188,UZR5-F$*MV73M
M*B@ Q!I6:IC16I;3WILUK0PY_+5MU7&2.].S:I6"2Q>H!]YV>7)I,"Y."U&T
M!]<H(:J%F!I] )[I.8Y!9+WD-,CO8YPWC]I/%U5VJ)QS!7+17\-T[JQ-R+=8
M=!T;/D0=7XN3FQE5"NO[?&0=4NM\#ZM5V F63=N4"OO20AVT5NV$2E4OK47O
MD68Y,7:ZN,JJ"7H)9Y:>ILLE71BG\Z]\JQDJ FL].]1<*S;J:+I 30%5^Z%9
MBLHR$"O$3_<36DCA;-*>G-X^-*<,M'%KLH/S/6K,22)SK7;Z>]FX/?!;-3+Z
M+DI0SHI3OE*^V_8N:)S4&;XEE4-6 -<XIL?R5T%6O$@:6*X L46U:,5-R-10
M6.NA0Y25JNB!ZOIHKC.,E^L7/?GU9^=G6$TAQ,9'05,A5$OYKV*:D^DZ*.;W
MN!B%_[O*"W95999*Y_UVZI";R!"[I@ES1!9ZJ"H'M0I"1>IWV7"&ET$27J8%
MGN'GXB06S5$$,M":3 :0;Q<JB:@H^H4*(R;]/WZJ/HL>V9;2113<1G%41#AO
MC;[L MCIB@R;B6"3S4(96F-9(^=;L2X"Q549+V1@FJ_G'&GYT![YSUPTBH%I
M[JKO6[5R5V</&E<(V+!-GRKG"*/%7OH\G2:BR=5GW$]C/T1YT%MZ$V,4++AH
ML:"]FFAZ=GM^VI2.?BG+!^+17^K!W9P270WPC2Z$:]BYFXTXGXUV'B510>QY
MQ-RMFM$R)?SZ.ZN.ZDCQ.HU) 7=_Q4%V$SUS[;E-8;":>@!+N%OIRW25L(B=
MH%5"$^A&I\AEC/$!^=L\7K%7)A91$B3S*(BKWQ"=O]U5-Z$.4!S,OU*QA_N7
M/)K3R+C5+4T),<?H*2KN44 +((80WBTP^Q1]MY=.NV\Q6<G.T[LD^COY0Y2P
M] YY]$R4LM(:5#SAF%!VF2;%/9W"T] ']G<B2=? >8%N@YA]++_'N/B>GLN0
MH@I"]R4#&B0)?6FZS%J8HZ=[G#2_UW\,,HKD@=0(P4$C+)KO!P\/61K,[P\0
MY:OPDR@D?_2R<IA0,]CKQZSYSLDO(G?/=1%#/5B]P0ZTX!H>TUY3G38GF)GI
M),]7E%']_;Y)<L7<-KXBO8REL> ;TU@56'O:XN::M"I M+LY25!5"FJ*@=VN
MDGULVP+VM8V5.]FV+7W@\5AQ;7(]M;+JPW(EJ"VK12QMS?8Y< 2NP];0?B9S
M&#*ZF#1:+0J]J7HX#1JHG,E1'1^-<A'];16%9,$BWR#E16 U@A1?O_(;0>^;
MHU7Z*S[W&/\KK+H60>M7<R6#2B$OU4O3C+'5W%4:1W,%MZ62P*I= Y-K BJ/
MRO4L^J7409XY?Y6E<XS#7+:Z4!Y)VRC#:KH-D/=;LRX"T3(D&X-5,>C*U['U
M#2Z*F,TMI@LZF)V\K ='58B0H1ZL1K4#S=WR:K3IK)OJHY,7U)Z)M\-' #>F
M9&%EI;V7#:M<4K6:-ZV:][;5O&FW>7TNJ+[%QX=@T<V3^=P(0V8++$(-/=6)
M@H,J47#4I%BEM^08?3'[^"&?! @%+&R?[F^7'_\>C=E6-\Y1SK84Z*[Q*HF*
MZ@C;3U0(J(S-X-/Z?R,=9HNZX08 BJ#J'FV8J(63#@EMN0HK8F /4 D7M?"B
M<DY?$,35*7'>I#L^0(K\WBW4B,'^YKL<^+SV_^ARNKKQU^5:H/>DVVV2N;VS
MSS-*6!9!>K0\2^F?[!ON6-SE0$ #V-T@U<L.NEK3F4JP;%8X;@4OT#]O-KA]
MTYU,,JZ!@/:/3J:L%V^=C*T3Z;.R_^AFIFWV 6XW^_"/;J:L%V_=;--9HY>.
M1G=J2K/&%*@DN%<L!HR *HSBU-95!+;/F-T6ZO/H419O+Y0"6_T<Q+VH?5(E
M!K7?2,&M_3[$?:C]RR@QX/Y:"FSM<Q#WH?:G)I4_!5_W?83[4/4W^!$G^LIO
MB8&M?A[C7C1 ]&Q0_;40W,KO(=R'JI^9,'\&GO=]A,JJ)\)@JO\^PP9^OR4&
MMPDXC'O!_Z?4H/IK(;B5WT,(N^KKX.W3.,CS:!'A<)0++H.*F\10&6!3V2$7
M-V%]@QW-FT)0D*-0<"761_/.Z),Q[!BONMM6)C#E6E(B!ZO1U""YUQRI='6$
M66<,+A7\!-ULO+2 \LZ["INP<_2$]VMD@5?K/#9%K3?"OFO=?D(%L.8%Z%1U
MOQ;?MPT\>'4O *>H^K6T[YJWW;@&6/,\.%7--]+[M7D!K]YY;(IJ;X1]U[K]
MGAW FA>@4]7]6GS_SBGAU;X(G:+V6^+[=E #K^X%X!15OY;V/;NTVRV%5^\\
M-M6\TI.WJ1^X*._3"K(9"@5^/?9>VVI<7 *K*CM5)>>UDB^)H*Z>US+@JEH
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MZ8+\&_ES_2?R7W2,(W_Y_U!+ P04    " " B6M0<[\O;A\J  #=& , %0
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MZ6?/>=[*P!:!;N$:2R8^YGXD@/,2C^#4X4*W3NRF?3+S8V6S8DP\U@;0Q@/
MD@4N%Q.S$T3X@X#%05J+HS)\Z@''8+O,HK3L- ;^+ ZD/2?2)<DGKME+\A?M
MCA%4G<Q<#NKH4#@(#?95D5.[;4YAI3Z9R;HAAPI 2).8V)W!PQ-0%3O.K)/N
MI_+\I,=:-F4THJU0%SNHK)LNUREQ"B=!^6V9[O+FJ7A^<>G?)G$V[-9S)HDJ
M-8S(%FP:P X-,]-BJQ$1;E)[:<W0JAGL^+"N>2K"TQ-;N:=*2P(]<'UZ]\T#
MCH#:V,%<,&XLP<"EY-+7]A_K5M #L#KEJ(Q.3US=LRCRV";.[^1MT[_-W0=<
M&SV:"L:-)1JXG&A[CV4;Z!%6G?*SE9ZS^7+VGGG88/&FJXH>4V6['C#C0'H;
ME.S:TE]?\.">!<_NI.E94DTSZ)%6G>QJE?B0IC:?.K,-M\IVT..WNMGZ]L:N
M8@R]629)(G]G8;V[N2Q4*H,>B04;%6LU(]U'DNZ=_"V3_?R5!1,WU,4!-&@*
M/;2JDV%0BQ-IFM..W@W/VK;0XZNZ&1)W@>DLK(A-I4< \\,$8\/U9DUY], J
MNTM.I<9]'6LXX=QCX=H*-@M>U0F&I@)ZH!3PL,*H\];!UA\:&:NAQS6U!;[;
MS6U'8??K/6 R7([]Z4K:W%KR)CCU'%?G8&_9#'KX$GB\:H3/ULXM_G"CN2+;
M6?T&?U,!2@&Y,XJRSCV!W6<RD/Z>.X>!:LP#LG5O41 )LLO=.=%DSJ+Q]+_C
M,'V7_8$;)G/;1J D(IX(-%&+TJS34ZZC/M\X!\X7VC1'V'M*\HZZ?Q[!N29R
MS-")SBT'X-3/\]PGD+:QC:^N#?L$SA[JQ.^)2 I1[V);<^'Q%\7[0C]!@]M%
M,Z.D'7J!ZVL5K>+5:VHA]K]K%DF!Q#0DUP73D[??! >7_CH)^W@2B15#\L*U
M4<DF;2&_7@1AL]2/FR-&8V;O*V]D7Q2UP'LWEEJ%]?<=$U/^Q/684'N3V^^!
M=]9)^_D:=M!,9T;2)QDTS(VT3T1OIT>]\MJM4\6.AMXBO]#6VQ'9%BW'^G&W
MO3 5>3A[YH83'OO1;< 6;KR 6DMM5>R8(C2#T0!)9.K9[O5U;Z=[VYQ,H/??
M.SH4D'B8I[>CP2T:2I-W?3J];"P^3'(AH$CC'R(Y@PD!A"!QH'IN EP;.W)J
M&XQ: 4)I?$=[2*TW/Z4M=^"]?X=-P!8P,9N=L?2_.:"RC$2@!]O!;:!'BG5V
M,&&/'(TQH49N&75]&@<2/=/F$%8;/>:L 3E&=I4H4>5U/$EV'N&M\Z9/>0NH
MBAZEU@.C"GRHTGF^6'K\C;$[YB5SA^L\NEXR4MDPJVL%/>RM!Y+-J.W^G@T^
MIW5Q5T@@GJZS2=P>.1JC@T+N"]=WQ(*XDUMB;5MT@NY:WQ,#,*/!N1!\PM@T
ME%O/.[9TWC+'#OVAC+X6>DA?"U(JE\E&=.CQJ,KH,O:GZ2^8^*,J#42-YC;M
MH8<#]L*]/:+TK");J]PZ0?1FT[O+M=#C 'OJW?7H]'2.FO]TW8E?7AS%8:I=
M$^BQ@.U9LU>::E>$IN31CD1-\O'T%W[8\[#;0[*>;:^9NU@K$PAW[(QH>^0:
M[ZF)O&\KU14K!OD?&1CP['AR-9GZ#97/&-368M<*G9A*^)ZJ"4[[8!MZSBD%
M9]IQV9HC4AG+S4S91*ST'_-IQ]6>Q1W%RV6:7\[Q5BA<^D\\6*1$F",ZH W0
M"0^%\VV)#HT%U\IE0CYP(Y80NEN*4D'\<%%+O,NW$+6*4V%%.DH\.*\L!!!3
M+8L?WMF2&Y7Z-.B1,:9"J4NQ80Z3&PA_NEYG)]&,@ -]>!/XT9JMR+0&:ZMI
MEY/XTN:IL.NJ0_GJ[VS(&G%C_F4U3-]%XN7C_@YZVG#5/!\SE=PC&$G#COL[
MS&G5\;!RB5'._W+<7_!C&ZY:IX6ATO_Z3,!TW-O!28?<M3_P$I-E'\PD(_?*
M@DX])PS=)Y=-Q^'&Q7GE)Z6ZTK)K LIJ?PY#K:;"!G#5C*=(.4!.G,FW6<!C
M?YI?5_O3.R;78NE5^/U2R+X6O9 7Y"^C@Y&,8?-X& =,_,^FO5&NP9$C_C]K
M<I2T.4H;[=!LKWDD%XH9<8ZW24RBV1/)FI"*B%N^FV#F^%G0H%@BA]QSIRN6
M;G,&<?-4H\&&FP=A'R>>]GJR^R]AI0N!TEJ[;>P+<#J=_LK]>^Q.\^-1H5/_
M7.[4F_)[W5\5@JZUUW4A6;*NX&[U )46U SXWIWY8I:=B#]F;OI)4C;/G>1O
MF0M&_;ELU+DV1IM&1NM6$./M*RH!\L1HZB!.7B=.Z(;)<<[&ZOVIEC[ 1-6N
M5>0<5F9V2_-1%QC2Z;K*-!GYWGKXH=Q;-]5&63T\H\[[ICV(97\HN).O$)A[
MJ;DF[H5<@1FKM2.H,G+/@_)6O:^#XM+Q.0M2%[UC/IN)WTFP"BZTA2YZ6.ZB
M^6JCI-[WN%H\8PNQV95?-2T7:TONWGI1HS"=64?5]>M-^ZAJVDGU45)_5&A@
MF(:VI);5=&35R&Y.2PUPHM,?+QPW2#+L_<H<*6HRRM1WQN-R9Y1U1TGE4:$V
MGLFNM=G(">B%^EJ(/;!.,$"?,U1#[F40CDH]#(0#G3XE[]W=] 90.EWS9$?(
M?.61R.''<L_*M9"<V!?;0/3456NVD=_<X2R;P71-AD@*Z)*V[2#WT48\EWV?
M&T%'IQ>G+TV8UZB?RITWK4AE<;H1+7$(6J="S%8MISS,'DQ[E,D2;[. ;',?
M;MLN8J<&BWZ2%QW0RULWC-SMN[&5TCC0$=IT!H:<:W+]B/!3]<Q4UABE50BX
ME-O,U=I*%/SC+4]'=;60NQ^ 'Y67_$[,J/?Q8\C^'HM6SY_5V\R*)\NFVBBK
MAQG^5%0!$N^DJH$:Q544"M!S-%6PWZ(Q<%*)T3+H3JC#Z*X6M;?LAQ77$<,M
M^^B'U4^8CT3MWX5[2;JW]-_PJW5C_1V]1 ?B0B/8ZS?IBG\>1NY"K%@U:2?*
MY;"?@+(FIUY1&B0H<AA ^Q.P.O:#3-:46<%",/P@R=>;W.>;J905-.71WTH"
M<V=0!)^LCN\O<AZZE[Z )%YLC!1PCZ&OCO[0D6V7M8*%QN![Q?W9 PL6TIL$
M,-@JBJ._,&3+E%9M&LS<"0B%#'(..&//S.-+:439\Q>F'@:JC/YJD"UK%I#0
MX'!]C ->S:AKH#_=8\N62?G=GP;/G< 7>,A\6\E!-YAE8T7T5WULR09"0:-;
MJFXKX'L.: /HS_58[SKLH*'!YU?.IR^NYXUEC&71E7CU)].$:=$$^A,ZUJ1:
MX[/[0_/E8BD6XTGZC.#,#9<\=+R;)[GLNW*?9>RP5!X^*S=J#?T5'OLINP5J
M-(:".S;) L0G3L&WHVZ-7"F*_LI.@R6Q0E\:=%RSEYQ* ??%CQ.6VPV#NZ!]
M2^BOZ5B3V12M';G8>I"O/"FNM6R#1T<_I*TUN]1219:L!0#H88B*:=@6YMWQ
M9,ZFL7QI<2Q$G+I>+#-KW+-)'"2YI<]?)UXL+")-*+]8QJL@_?+:'W+IW,.W
M, -[6EE.^1Z[-Q[HC!/E9:AF:#@R1ZKV/!C4"PON_Z;J)+K\A>N[$4M6>;7R
M6O5IB\9H=%H8P\I^:@T>C<792@&N4^ BEH^%C!<\B+*,+=EYJZU9=/,5M)OW
M#@VF2[SI#.FU 6>Z<;T2WJP(.VLWN@_Q9]IQOYI"36Y3HK7D]H._;8N[%[76
M%CT:H_]:R)SH6;>;WOAW<KD9B-5DXM;UF\\?0Q8\2W4N?;'B7+W\[B8TV80N
M=OHU;#^L-B&//<!.9S*HQECI9H)*-H":2*N^-_PR9>+-,B<J?'^OJ4IBC-\$
MX>1O=_)B9P](O=F/]LW;IK'R-_.N'/S;PDIC&JC7XI8%26I1^59GDA]^_.($
MTYLX"L5J=;IY<@QN,=U^AL@VP-YZ^D";B"&M.T8N/7U.ASON>1<\D)K9#S/6
M3:*Y^W8VO#1$D<X:(!=.J9O\*]E'\D&5O9_LE42T.-13UB31!\^R6WLA87JN
M,/:GN15GDVV=58,T9G<COYJ=70/\" [$2^ZSY!WV-139<=()\]F3&S4:BFT;
M)3);-[>&QD#2&8W!:>C/6.2X7G@M\^W+DXWZ4;N2V<8N+?WHA^PSH_5W^MK8
ME:)"R^K!MWG@AC#[OH1XSCW1G\)T$ZU\9J"FCT,JTQC8;5DM]VPX3'1ZL/9F
M.0.@OK-6,MD8G2NRYC"\*[)/=^->46D,M6]FR3Z3J4+7#8OE3#VN8J=H[@T*
MZBJ=KZA?WE^6 CVBN[+D31H 1;FRR#0IP-4SD!-_O2'&96%SH[()G+MSPV_C
M5U?#A[[6#C&C5R2W3B9!D<S])COZ@_CD&5\XK@^AJ*X6#8H@QJ<DK$ZMS6((
M>TV8GD']RA:/+#"L (M%L:_8(-96M[JK4YC(_GPU$*0KS\W>4C_&&:K1Z$%V
MTT^])KFC6<S8OJ)LIN%-49P8*SJ+*P?TU2M$8D3+W@(TC6:E8M@90+0654*_
M5D,:PU=+I^3Q0FX:U*1UU#QVZC+E9J)$=*=HTCFKJ+SHHCN>J$FK67'P[O=
M0B%N8Q=O2L<.&E_3KP$/-2L.<TT:AX% ]LJ.6$!<:(RZ&FG'DTF\B)-0[;S;
M<"->E6V1N<+IF&H#>/:!T)_3 =!G,]DF?B"T1O=KIO-=-M0CXF#1N4'D0&D<
M!1_QR/%HO#2FP.>H?B:NI.A5S\2CH^W.Q4=M)^,CZK-Q3<S'M2!=>OR()=_#
M"_.>V:_<C^;-IFR;YDG/ZQ5+L!CMK2&F/_M75<K4^4_F! \OO"MC*;=*>T70
MK9'4([KKMB&DT%Q#MFV7]@*A/_O(H[KC%G+!8\WQ6LMFT9*ZXMI''M-=-X^<
M=UB7YI$TBY;\%=D\\AYW+<U#L=1N+-N]^ZI8?+=K$BU[;#NJVRN^\Z/ ^"EB
M04]#0:EMM&2U>.-!+;KDK64;ITK=)[GMF^7OXUC)X#1>>;M&<[S4MU^X28.V
MQTVT_,+S@XP,82B*K+F--=0C?5 $]0:'@=.\VTK'<LH7 ;^%["GVKMRG1E-X
MOC;M,R&H/=@@1>?*O3;_CO;>O9)S49F I]7M^Y"!9W^" 4"PUG:JP>N?C-OE
M%3FO_U/N3YCT[DW2SKOAMY.W$^9/Y@LG,'C^FVON$$-F96A$ %3E7$EI<I,U
MUZ1!%]0@C026U6OI/ZO:UE3RD+UE'J2ATDDV63*9ZV'[_T-M+7\J!X:CIQ/6
MFN\+-62 J=QA)($)-W[ZFTBN+<_8HU!13**V9-FUBOV,7D=4-H&2R*G9:MET
M\K;^\=]=%@BYYF]7\D4K_60'K4]C# 5->5"5: 2%U.ZQJG*;9D'+9FC0:6>\
M*IIA&I.(,EF+EZ1>#!,5CTTQ)]I*V'-I(_-5,:E&A<9@6YN;54V<HOBNQ)%H
MM=V-0ZIZG]3C2OI_TRE54\_4X9QJ.*<:SJGPEX3#.15UAH9S*BIT#>=45-;6
MPSG5<$XUG%,-YU3#.165-?]P3C6<4PWG5%M*;M/Y096=C]U2M,JG0H@@(N!I
M5V.^?[C1O/*<3UA\SZ?X^$_B<'8;"T-W0IU!]/,U[#48V)[Z!)O& -&EADDW
MN?0G@6A*K$'3_V['MA2?1HOSPC0T+0U[9W7),UYB,#>$AO3U0;3P,D0+JX.<
MAEUUL=SY\P@Q'JR3!<^?1QTM><[]<HXA,B_^Z7S/CRN/O]8^^==S&OK<XTS6
M6>=U=2G<$^W6?9T%N,.M'<D#,L*W=D-.^2&G/!I%0T[Y(:?\%OBH?5=T+.\2
M9\D <?*V*7+KO,E?I8^,IK-L[H7)Z]C 9_>?VA4GN]Y0WH]SS[;P?$UNOB_]
M]'C$D)RXEX]A#TQ;LT0-U$0&-#G>7H9AS*9GL3S;2"5-GT?.[P_.7UDP<</-
M=E4Q UFVM3/W*<V!VOW<QKL\ZUF<8>%?LO2B?4_G7SMHA[^S4.8?]Z<R_]-$
M_/C Y:^R'BNW=GV;)UR"G;FOV38I1.;-[GKJ'\R=S24$SRQP9FPU?]P&[D1W
ML+@M 7;F F#+E'PG>XG0:H7;DRUW*01:ZKO.[;E[:G9D;#4IOM(-VRPMY0!:
MYL^[;YF-"-H1X]R3B=]BW_29OD%VA\FPFX(OW'$,O*U<X,/)G3?[;A@D-"X_
MFK%XM,-"/3+<,7F-)7Z_NMN*'>^!!8M#@V43D1%JY01.7@FAUHW%*SRFR"AZ
M5&/"4D)* D+M%_%0EQIDWX?Q'E,WWF.X\2*>[E*#[/LPWH_4C?<CW'@1'?VI
M0?8=+)35FP8Z"^5&,D+-G<@%"!'4]L+BTUB)C3]I>!/-6? P=[),$^%X-@L2
M)XU+H;_KA^XDB2O*C1$]V'@G4D&MFLAA,S)[>W37MTTDTP&%4!=8"02U?B(G
MVWB<$1K 6YQS5JZ;'N0+7T6]^SN/AGT=[ A)PR2WQ 8A^QL6$#FI+&X'CXAX
M<2,BM6=WABVV&+F]1!&Q'C>#NF]";7CW;T',R-/)7JV,<5>DKCZR"7)OFK;:
M&.:NEAH<[0YI@D*8]2X'O<-I&F+?B458#['O5)D98M^'V/?N![8A]GTO=L'K
M?%OC,(P7J^5H=L70TT40X)L[%0W?*^Z$[*O)N9).S]^Y)YJ1:<+O!-P]'/+9
M?!Q[3.K_B,^>BCVT/3GU7@1,[K.98#C:HN75?WIW@NRW1<,>6MVJFYV)W>Z4
M^5.$\:[XZ?V/NK>E80=.V#:>=H43MF.K$[;C(9'D]W6F-B22' [3AL.TX3!M
M.$SK_C!-Y;*^&7)O?/U#8?5%L3>C-@=D:BU:7JT_L^"1AZS-Q;J9GX<7#N4G
M5Q1[^=R"GXK"Q/D1!<$]J% 8^\F#-AQ5E:;-T@6/ RA)^;+8^5Y:<%15F3A%
M0DDP1;FRV'DFVE!449DV1??N*Y2A7%'H6H'B8J&B,7&"V#-3WW>6=<L71H^(
M;D-256O:-)W+0"@H387"Z.&3+6BJT9HV3=<N?&^4+PLEB>*JH:HS;8X>X./=
M@_UH1W'14-$8DZ =<M;I+Y1@#[UU5B>-Z4V-O-GBO@QAT!^B&JK1.**S.]^N
MUX3& ^(EV4SGIXKBQ%C165R))(5"-/P/2617V]G\>+M[K=]7=KQ=G=J[?I2@
M/]-N_N;1#OO<63QZA&U%%-+Q[%=^1B(^>T1 &X;<O7WH9(?=!-L_=-*%&5/S
M--RD12MX&GZT\C3\.'@:#IZ&@Z<A_IY_\#0</ T'3\/!TW#P-!P\#0=/P\'3
M</ T'#P-!T_#P=-P\#2D2]#@:;@+- V>ACM!T^!I2)^CP=-P'^[&!L>VP;%M
M<&RCX=!#^@GC[\=5S9(10AY!@U_9#MG6X%<V^)4-?F6[O'8>_,H&O[(]]RO[
M5.]7]LG*K^Q3GWYE<^X)TPM3 59Y]^S<RPQ-4-B>[[R7&8BFP=F,ZNG(%3EG
ML^'D"G1RA>QO-IQ<T3VY^L.1JR+U;5A6KE0,>ZNNM:@2^K4:$MII-UFG&E_1
MN^;^<[*([6WW8"_"WA\=-F6E\?:!WEO(O<#V5?;?]=NF&+9<E@![_"-@R_6D
M[/NX>L&#)^:*'HQIC35"[-89Y':IV7>;3+6]]"<!$W7/6/I?#,-42;+_!X<M
M2=IW$Z6W'+5X;OOC'IME#2J=K$GI/*W=+VS%AY]1[;HL"M"Z?_H>K+N>IF'?
M9;/$QS=UO3S8L4($[!U"V'=\Y0[=0L3"<O"M72,,T-1_WF-3-U+5=DFM\GWO
M3:/SUPD+0A>PID@\TK<O!W:DG]GJD( 9!M;=7R];[ <3UX-]'5<U\ P;0S-\
M]KZ0.C<%6F)"N\<^'S*WX'?G%B0-=*WSV.YW4FXF)'JX-?9:I@VWWX,A'^^"
M(1_##1GQ#)LB;.1N79I$91BQ&<]F 9L)?HIKN1QD/038="(5U*R)'%XCL[='
MY]C;1#*-\B#4!58"H2>PH&O]1<[VY,AE&/QS4MD<Q! YX$9$JJ<S&:0(M$M?
M_,@>G%>V"CVKCSS[J1QYEE8<)377(6<]!9Q5A00'FNFJHN8#3DU&"#8.0Q:%
MURS2Z)15T]?"<O:& U[;GR%0T-@V5"0]=99NY'A7/!0_!L';$P_D0*--N@UN
M MOA&<2+@4H30$1Y_<KY],7UO+$OS^3%O.(^>BS]DP6UVE:PO8>[8!< $U&"
MQ0^KW\EX<S]DA;6$/SUA/GMRH[#^%.64AS:C="=?PW;H[<)@.H2=J&')!6.J
MC.?Q%\?7)9 "5<9VF.V"=C4H]JOHS^FRU4_6Z03N->OPL5O 44B+WI[CG-J-
MMT81EVL%HMNBS<ZOL"_Z"VA?-#K:VL[HJ,76Z(C$WNC\Z8E-T@=%,@'O1%^_
M8Q/N3US/3;M%=,%$IW \>6P0"T'>"H75/;"3QJGNM"K<EZ/BNT.6QOP+42@Y
M6!)KBRLAAI?#K)V-J%M%V[=MPSI,8.Z.69S.Y7GAI=]J"=?YA]"VA=LPG@:0
M4[8G><GM^K'KSVZ68L!,CI!M3:6^#;2]7C]6H .JAF R2[YKF<9$:E._]/L9
MMO1;M[*U)>#ZBRV6@C5M('; S&[\F<51JZX.U06<DKE2/S/C8=6OLK_(?\E;
M,_&;_P502P$"% ,4    " " B6M0;OXJ+N?C  ">8@D $0
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M+3(P,3DQ,C,Q7VQA8BYX;6Q02P$"% ,4    " " B6M0<[\O;A\J  #=& ,
M%0              @ 'X4@$ 8FEV:2TR,#$Y,3(S,5]P<F4N>&UL4$L%!@
0   &  8 B@$  $I] 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6764378624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at September 30, 2019</a></td>
<td class="nump">$ 3,247,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at September 30, 2019</a></td>
<td class="nump">573,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember', window );">Derivative liability - Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at September 30, 2019</a></td>
<td class="nump">573,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember', window );">Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Beginning balance at July 1, 2019</a></td>
<td class="nump">8,109,724<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Additions to level 3 liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,367,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease', window );">Change in in fair value of level 3 liability</a></td>
<td class="num">(5,435,724)<span></span>
</td>
<td class="num">(257,288)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfer in and/or out of Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at September 30, 2019</a></td>
<td class="nump">2,674,000<span></span>
</td>
<td class="nump">8,109,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember', window );">Derivative Liability - Conversion Option on Convertible Debenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at September 30, 2019</a></td>
<td class="nump">2,674,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember', window );">Derivative Liability - Conversion Option on Convertible Debenture [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Beginning balance at July 1, 2019</a></td>
<td class="nump">2,533,668<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Additions to level 3 liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,638,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease', window );">Change in in fair value of level 3 liability</a></td>
<td class="num">(1,960,468)<span></span>
</td>
<td class="num">(105,298)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfer in and/or out of Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at September 30, 2019</a></td>
<td class="nump">$ 573,200<span></span>
</td>
<td class="nump">$ 2,533,668<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6638896688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Estimated Fair Value of Derivative Liability</a></td>
<td class="text"><p style="margin: 0; text-align: justify">At December 31, 2019, the estimated fair value of derivative
liabilities measured on a recurring basis are as follows:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="15" style="text-align: center"><b>Fair Value Measurements at</b></td></tr>
<tr>
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="15" style="border-bottom: black 1.5pt solid; text-align: center"><b>December 31, 2019</b></td></tr>
<tr>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><b>Level 1</b></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><b>Level 2</b></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><b>Level 3</b></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center"><b>Total</b></td></tr>
<tr>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr>
    <td style="width: 44%; padding-left: 5.4pt">Derivative liability - Warrants</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">&#8212;&#160;&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">&#8212;&#160;&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">2,674,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">2,674,000</td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Derivative liability -Conversion option on convertible debenture</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">573,200</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">573,200</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 4pt; padding-left: 5.4pt">&#160;&#160;&#160;Total derivatives</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">3,247,200</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">3,247,200</td>
    <td style="padding-bottom: 4pt">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Liabilities Measured at Fair Value</a></td>
<td class="text"><p style="margin: 0; text-align: justify">The following table presents the activity for liabilities
measured at fair value using unobservable inputs for the six months ended December 31, 2019:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Derivative liabilities - Warrants</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Derivative liability - Conversion Option on Convertible Debenture</b></td></tr>
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3">&#160;</td>
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Beginning balance at July 1, 2019</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#8212;&#160;&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#8212;&#160;&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="width: 58%; padding-left: 5.4pt">Additions to level 3 liabilities</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">8,367,012</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">2,638,966</td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Change in in fair value of level 3 liability</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(257,288</td>
    <td>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(105,298</td>
    <td>)</td></tr>
<tr>
    <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Transfer in and/or out of Level 3</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Balance at September 30, 2019</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">8,109,724</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,533,668</td>
    <td>&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Additions to level 3 liabilities</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;&#160;&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;&#160;&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Change in in fair value of level 3 liability</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(5,435,724</td>
    <td>)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">(1,960,468</td>
    <td>)</td></tr>
<tr>
    <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Transfer in and/or out of Level 3</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 4pt; padding-left: 5.4pt">Balance at December 31, 2019</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">2,674,000</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">573,200</td>
    <td style="padding-bottom: 4pt">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6768372032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive Securities excluded from the Computation of Diluted Loss Per Share</a></td>
<td class="nump">1,435,067<span></span>
</td>
<td class="nump">1,775,925<span></span>
</td>
<td class="nump">182,667<span></span>
</td>
<td class="nump">79,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive Securities excluded from the Computation of Diluted Loss Per Share</a></td>
<td class="nump">1,374,667<span></span>
</td>
<td class="nump">1,731,525<span></span>
</td>
<td class="nump">124,667<span></span>
</td>
<td class="nump">38,193<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive Securities excluded from the Computation of Diluted Loss Per Share</a></td>
<td class="nump">60,400<span></span>
</td>
<td class="nump">44,400<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="nump">41,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6761994512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="nump">$ 3,247,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="nump">573,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember', window );">Derivative liability - Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="nump">573,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember', window );">Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="nump">2,674,000<span></span>
</td>
<td class="nump">$ 8,109,724<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember', window );">Derivative Liability - Conversion Option on Convertible Debenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="nump">2,674,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember', window );">Derivative Liability - Conversion Option on Convertible Debenture [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="nump">$ 573,200<span></span>
</td>
<td class="nump">$ 2,533,668<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>33
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MCX$RB%H 4\O$>)SZ#BZ !4:8?/XNH%V)I?HGMG2 G9)3=FMJ',=Z;$MNWD'
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MJ[;#C1G+H549)EIT8QL63;U@_@]02P,$%     @ ?8EK4+EYC)A,!   :!0
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M]<-Q]SQ\@=#B[5N,KO\/4$L#!!0    ( ("):U#N^H^$< 4  /T;   8
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M_=P,'3 $3K=C<Y/I#Y/_ U!+ P04    " " B6M0L<!;J,\!  !M!   &
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MQ3?D;[I2R@):">[P=3?8^TL@H+)N^@GG>NJ *;"JGYN;+7^8_!]02P,$%
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MR>WUU/^3854_CS99_B_Y/U!+ P04    " " B6M0XKP*+;<!  #4 P  &0
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M;*=!FPQO^OD/L>4C%[\!4$L#!!0    ( ("):U #PLQ*S@$  &T$   9
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M0^&F*Z4L."O1C7O=C>O].1!063^]=7,]=L 86-5-S4WF/TS^'U!+ P04
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MC:Z,D-7M"5"-?^@:E7+L?9.MLDLO/5!_^__@<R-^8ZKI>HW.TM@WY&^ZEM*
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MCG-19%NZI*I:J96BJ]K^)O;Z0P?&!1)?W[Z ?3Z?@_K'L,O,,(L7TD&J%]T
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M8.=J?LWSPLAA:52R_BW*/U!+ P04    " " B6M0U"77BY@!  !: P  &0
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ML1_Y_JPX)BJ*#-3&1,'4GZ.V%JT 3%#:F#=Y4!I,3^IU9\Z>G%LN_RV3Z-A
MGH%\D&;Q=; L DM\(QJ.[@]7>=VM?B!ZJEKF[ @7SZ!ZK(Z$<"R2]Y_$O9:B
M08Z+&A^YG"9B3G6;T M.NJ$#>F,;SO\#4$L#!!0    ( ("):U!QH32)#0(
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MVFY3LY?#:!D"+;IQ:J)I=)=_ %!+ P04    " " B6M0JH,>PEH"   <"
M&0   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6R5EF^OFR 4QK^*\0-<4/#?
MC359VRQ;LB7-7;:]IBVMYJHXH/7NVP_0:RJRM7M3 9_GG-^A>C#O&7\5):72
M>VOJ5JS\4LKN&0!Q*&E#Q!/K:*ONG!AOB%13?@:BXY0<C:FI00AA#!I2M7Z1
MF[4=+W)VD775TAWWQ*5I"/^]IC7K5W[@OR^\5.=2Z@50Y!TYTV]4?N]V7,W
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M<VAE970R."YX;6R-5>N.HR 8?17C PSU;AMK,FW'V4UVDV8FN_N;6EK-H+A
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M+ /H2@Y-,X0])PE[>A<#N?"\>;&3ZRZ):>+6#B&)P>6Y1Q78[8^8 *KF#0^
MO!L-=SR^I>4'T+0DDF8Q0LX;<8'S W(M"G8'#-E#XJ& _0'?8A#8=8AY7=>Y
M8(_ D$FD'@K8)3!D$_/NPZY/D(32-,WGK\%E\QX+V$TP8"=N_^7 ]M&\2'VU
MP\:# >=Q^\^UGCM<I"AVBX>0*"&%I_\([$ $<B#G@^N"?!M-8/,A@/DXYW0
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M'%JLOCIO&<ER%6I15T>_D^?)Y>HY#:+G!)U5H(%9]XP_8;QK(KLE%L&(()G
MF(5ORV+MW^C]ZQTVM\0B-)*X18+%-9);D&=[GH'UM *M#Z?Z>&:<EH6)#&;S
M ),]P.3WF2M#H=50:#%D%'=M8\SRV)C ,&1CC!KF-B:R&XJLAB)+@-@P9&/F
MAB$;8WQ-F8TQ_CNYA9G_IT*QU5!L"6!6R,:8%7J R1Y@\OM,;PA-;I\:V%&W
M NX4]-0(]=>:K([=YL57MY>QOO:6&\^RGLGNU#>32_B^M?W [%@UW-E1(>],
M?;,=*!4@4Y\]R6*4LIN.$P('H89S.69]3^DG@K9#NT1CST[_ 5!+ P04
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M1;XWKOYW^2FS%N^4M-?8E5G=__5VU[HI\W&65DJ>_AA>ST7_>AO^$R?C,#R
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M_4 @W9X)=>B(230OB8(/ 9+QQ%HYAB%!--2[ HD2G0Y09$$_P<PD")I&7YA
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M.>.:#JZHLY#9G#&07>,HB-N<,5 \PQA7=' EG86)S1@#V<*&@IPL(R"8T5C
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MUW2U4L_>JC3&);H9HTFS'37)0H.+>\G.(UG-$J0)9HS$BY'8>'R'D?H-L-<
M6X/TSB!SZA@UF=5T5A.3)"V*W"GF49=E643^PY-Z>5(/#W%X1@U9Y,%D%;LT
MCZIXE>2Y'R;SPF0>&"?--GM,4Q31RH%Y5"597J29GX9X:8B'QCE/6_*0YT-,
MBHBX9W/G$18XB0OB)\J]1+F'R*E\Z]&X+.]*1@RTN)?FG?Q.Q:7I9'#@2E]Q
M>Q'/G"O0=M&3WNQ:/\WS@,%9F6ZN^V)\H,:!XOWT]J+Y U#] U!+ P04
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M':4T8"5&=_;6:MN-IP6'HW'3W,[5T).&A9'=V&[)U//+_U!+ P04    " "
MB6M0F]LA5[0!  #9 P  &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q]
M4^UNFS 4?17D!Z@!)VL6 =*::5JE5HHZ;?OMP"58]0>SG="^_?Q5E&1H_,"^
MU^<<SC%V-2G]:@8 F[T)+DV-!FO'+<:F'4!0<Z=&D&ZE5UI0ZTI]Q&;40+M
M$AR7>?X)"\HD:JK0V^NF4B?+F82]SLQ)"*K?'X"KJ48%^FB\L.-@?0,WU4B/
M\ /LSW&O785GE8X)D(8IF6GH:_2EV.Z(QP? +P:3N9AG/LE!J5=?/'8URKTA
MX-!:KT#=<(8=<.Z%G(T_21/-G_3$R_F'^K>0W64Y4 ,[Q7^SS@XUVJ"L@YZ>
MN'U1TW=(>=8H2^&?X S<P;T3]XU6<1/>67LR5HFDXJP(^A9')L,XQ95UD6C+
MA#(1RIE0K/Y+((E ;@@X.@M1OU)+FTJK*=/Q9XW4GXEB2]QFMKX9]BZLN;3&
M=<_-BI05/GNAA'F(F/("0S;7D-T"Y/,,P<[!;*-<M%$&/KFR098%R*( "0*K
M*X'538Z(60>,#)CU?>Z?FS#_XHK--2X:PA>;[ _],]5')DUV4-;]K["KO5(6
MG&9^Y^0&=\_F@D-O_?3>S74\;;&P:DP7"<^WN?D+4$L#!!0    ( ("):U#^
M28)^IXD  (PS @ 4    >&PO<VAA<F5D4W1R:6YG<RYX;6SLO7M3&UF6+_K_
M_A09/=1IB$A4>B 0]DQ'8(RKF+&-Q^#JF7OC_I%("627R%1G2F#ZTY_UW(]\
M"(&A>F[$1)PS[4*9._=C[?5>O_6O5;6,5GGV]U5Z7*SRY;_]:6\T_E/T_7:>
M5__VIYOE<O'FYY^KZ4UZFU2]8I'F\,M54=XF2_C/\OKG:E&FR:RZ2=/E[?SG
M8;^___-MDN5_^LN_5ME?_G7YE_?%='6;YLLHR6?12;[,E@_1:<XC9$7^KS\O
M__*O/^.C_/A^]*G(ES<5/#I+9_5?WZ?37C0:Q-&P/SBL_WA<W*5E]/\>75;+
M,IDN_[_&RSJ3BX=%6O_Q?'?P\U']CT?P^(Q>^3!/KNN_+LM58QCWQONTFI;9
MHFV-%S=I5*;7&<X3GKQ)R_3R(4KPU2I:WF25_17?CJIELDQI3/R/U?0FFL$?
MHJ*D_ZVBI(INDX?H,HWR=)I655(^1,LBFJ5S^&NVK*+TZBJ=+K.[E%^$0\[F
M\)U@$M5-,I]'5]D\C9+H:E7"SR5/B;Y\?Y/!=ZM%.LVNLBD\^L#3PODFR[63
MYI%QO#2Y6L*HE^FTN$V]665YE$RG13E+\FD:W6?+F^@<?X)A)MO)3E1<T6SA
M;ZLR6V;PT:/I$O\Z.!R-8EP_332=Q;@IS>6U3J@QBV!SDXI&."YN;[.J@O?A
M,_!8?ATM5F6UPAV#+?9G&=,AS%)8X6V6I[WZH0OI?W5;_AEF77_JW>G9;Z<G
MT>GGXZX!CF$)93*'.S1+OT?_D3[4G^OW^X/QI#_8:UP0&>$B^1Z=SF 8.DI:
MP.?5[65:UI_?V]\=C@?]@_VND4YS.+5%P3L<1^=+H4MB)$"%Q\6LL<+/OW4,
M=C2;E4"]L?XC^@C;&)WEC1&&@V$?AI[#=V=%='27YLU[N';,B_NB<?U7&4Q]
M..H_;:";,FUR$CC;!+D8;.YCH]D=^U(6=QE0?X.G-7A2?8@O!5#V//I_LD7K
M=A_V]_I[C5%I!+B/K:^,!L/ZGSX6<.>C+S<%++J=5H:3T>[XX'#4,=T/P%B
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M-6I:L9N^IQ/9X'TXVO3[E/D=OHYLRN-<&XR ;Z'1G$TW^J#_>-<\SQ8L9>^
MOS4EX\GWM)QF%0U:R)-=.[;NV:ZOLT8AUBCP5F2_K5(0'0US='&EWE>Z[%]_
M*X(#VV3O[ OD\FT3)35>S8NT1E:'/EI[B><#TG@*VBQ(Y[^M*GY[670NZS,\
M.2_:W$NS-7>IH="$CW==I*8>Y.W1(E1,R5<.?T2!G4:+>3)]E* W&Z&+;(X]
M3T9S+-C"J:>&_M#+T3;,C$^TP6.??L4[U[..NKM>:A[[>;IXSK&O?>U17OWX
M&QN36'-%:S7S[A4]X;7ZI%JB"IM<E\9KK?OVM)U^N3-Z?'8;K\LG^D>9WMJ'
MGT?73SB?)[Q6)YHG?&7M:X]2P=-.9NV;G9HE,)?HP[RXW]"4/CXZ_S7Z\/'L
MKZ&%!];@T?'%Z6\=;FTKP2IDH64Z+?(IQFUS$5KX5_PW:@/$9/%_5SC;RP=0
M ,C:1U\8.K3(U&O&&H0M![XT3ZJO,ZIQ'S(7%$A:7?OU%XAYJX.Z77.Y3' %
MON*BIG6G#2F_1U=E<;N9]]TS#;R-HB603NK9QXU-8[.W8[VU4$2;OO'H,3U&
M/1]./Q]]/GZ$>KZFB^1AG?7^I2RF:8I:$^Y:UJY(M'*3\,WY$P(9X9NM)_6T
M(;(:-[0ZAF]8=![" H.Q,SZ(*_9GKCT(?'&63LL42)3]OTV5_9A4\TO+<G _
MTS(KFFX]>A"5W<Y'SK]]^?+QY-/)9W2&6"J(3C]_./OZB3Q$K=%#]D_C-<[D
MAJQ_:IE\;UGKV>==^N3IY]].SIE7?7[?2GL;:X/,9A[1)<\;?B<\GJZ#?J9-
M4*TS"EK'>%0P,_>RILYT#APBN\HP.%&UN=X:E/TNF?Y^70+[F/EY4T3)7U/<
MT%2]Q8MYTRO P3!8E7/,.YG5<-[VHHZOO<N*W[(4G7J]:!LS8_[/OTR&P_Y;
M":S3?PW>[L!Y@'$QG6>8_##?K98):.=3?H8S9Y#V\7UB]C#[A]AXGM98PF:W
MMZB<)_- IN2%;-6L7-$@9;* V]B+_@IB!CC$E,.,<[BTQ908*;PI@],%K@U-
MDO_T-Q#P9ILC=:MBA;S_:D5$"G=DGF'LO,KR'9A9!!-(YU&R /Z03$FTXDJ6
M<.^72I=)-<UPPV>KE CZIL0\$#A<3$V;9F5Y4U093/EL5<H*'G0.L'4LX_!P
M=8V@B>"6XB?O4@HN)9?%:AGM]2.2*&7&ITN3L!P2=WPNN3VDF-2^'VTC#]6\
MJBJY30V<![&O1;*\N4\>**F*UP)+OX0OYL4R>L#+<I=D<V+J,!E\_5N.6@Y3
M%:R,5X,$,3AX6S'7A/.YQ@TBZE@ 1<*_[Y*J@%VO8 G395$:/)T;^&IU4]SG
MF)8%\Y\^\#U-9RMBP0O0&H" ;QZ +\(@=$IH-"Y!TT*UC>D6)W5?E/-9+\),
MN^L"7LGXMO+D<,.(!9:KQ9(>EZ76=R'FM#7@,S?)?*FD.WV8SHGAV)05_.5J
MO@*^R8& I4Q,J0&&R_"^]?0>@1P Z:B1 F "EA1Q;OHXF^I?;G!&0W>MX+#Q
M&F>Y?="0 P48*L9*,"Q>(\-D=H=,<M:@@X27_VGZRRJ#&V0#(*=P+MERM90;
M#Y_ZFDUO@+O.XNBW(_*<VHP!= 7VS&D>'2W*;"XAU7O,MLCA./"KRV*Q.\=\
M*;A+J[FH4C &15EO@:9D^I2G JHC4DREU/GA_1$=74)IF]%Q!%/E1,%/:<IG
M4N"YP8WGG#VDAH?@4PO0[J,";ER>?E^Z;:0'>[!"F @P#9ZX?M+J +?R%3BJ
ME<UWG$DJ::HG/C?)=9FR>*+52/:@,D>Z"S#FHL ;#J)@5MQR5%S2!#![@CPC
M./E96F77.9,O3B:95X6;$:9T5JMKT%/Y?L,0YEHWI03**LF @M.XQ510_$*%
M1L(,_PL$UZ+(R-?Q]U5"Z2K$'Z[P)))JI=[7@K39WU.D)8Q]V_.H4:%,%<__
M#&A/" (V4BC=HP(\F]6EY%/2_5':OOQY5!\75@M"K9@KEX5ML(S>Y^EX!V#3
M=T'3QU4;YM'S[.\KUF+(:2[?\QDZT=2J$BX&5X%W7CDNL@>,7Q*KN"7NRWII
M#A=NRAXGX,-R 8.87Y$3+TON"I@!,SM<D#\7X#Q%*:2$6:/%%&17='^3PI4&
M)>(VF<)8%9MV>A%Q$Q;%/6@,D6A1RFN);?+/^C%OUOC#30KLZX9/$$1<@LH+
MJF#*9ZK5U14S(=2>#5+#[O(&14I*RNJC\D3XS$V*0RXS(*X<HQK3XJ: ]V!O
M8:C"_AIM?P8-<H>%O3Y5W<)57.):#)+\AZ1:[EX /_N=,G=73)5G)>Q/'KU'
MX<B4QQM*ZBHL]+8 LT_T0*;7*@UG'RMOC"6GV;(=E$TX(F7%YDNSRI$U@<9'
M5)F#<=&+CG*=0B"?K[(29KLL=N'"_0XO+1\6DB0-1Y@2-SL X9F4M'GR4/I]
M.@=%XPZO8)LH-;HH72C\ @2[7>TXQH GGZ,2Z%0$U+1H<D&R-HV%!\H&+>T
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MY6.A]M00*[+=G2L-&9NNE21H<SBC'.,_+.4A342L[(<GSXJNY3WG)\<H^KQ
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M%MSD@IC>U:KBN+_KGKTCT2MB(#,#]@NJ[V$?>*&'V#7B/O90Y7%]2!OOX 1
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MV\-&U+#).(!(C]_N.K_>%D-%#M\&_\) "MF#_K\[QN*<8RK:5;34O+U?E_V
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M(@==(XZ.CZ+#_EY_C]@B-V=&N'6:G$M 544_IY9WZ2W!]W?E^U*)@;B5R"J
M]?& XO"HQ+F+VIP_LJS3>;0"Q<GFQ=*8N\M"<J9Y:-M!49XR=IKAG4=5BB"]
MB.I'?<J$T7U4Q!:@49A(#W/7X5G4AV%%W\X5+.I,,?(4PY=PK*R_A=]F_2P
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MW$(YM'&WE-"?<2*F;C)W-P;0:' 02MZI=X:T8DS%7*KV,;5*T RCT!-@U N
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M72 ?S?OF^V\,THJC:A%NI%KO(SK@!%7N\7@<]_?WD--@>/622__Q\VA8Q(?
MN4"N#@\.))6^I0L PKJ"VG08#4$N3_;&YC=[VD?VM+?(=! QMA-MJRZT8U!
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MZT/I87%81$+Z-UTV.XTK0@QJGVR,"FV%J6%SY(;(X4&,UE>D14KTL4H[<=3
MGY2\J5THUD(%W[Q*IBRX:(!>=/*=T@\XMX;QC+@Z4-]J3()QBT0!2)SFL+9.
M/%#05EIUQZ+ EUX/P&T)NAR-B[I2W5(%WC/MQ>&45,+2E8P!E)D/S&P2,A#"
M^@2BV*[R.2DTDCB2))&X@@[C U>T%8G3:UB&0?9;I]74BUJ*GF@A@G<1(P*(
M-<*YBV-K=6EV]6BI$*6IV[K<TO>YKJT>8C-QCF@K331)0F&IZG6EP;FLLX$)
M8,,D.A2'B,#BJ&ZXB_TLT)>2)3<"Y-!L4+L*__%[2LNRL3 V4OCOMM:UI"+5
MT,A.^.I%7AH)[N(N[^(N[N(N;(0ZXMKGBI%.9)-^#2[Q!YCY5-*8B/YG$@E3
MZ%WZHZ?>N1N@*HT3I7CI64')L9;7@\'Q:GZT](KT#U8QCVRP21SP9>K\36;M
M6&%BF\Z^:7T5"[59,#>1DCYLYAW*5[B$\V6F96VL*[(,B4U&->.Q2W^VN4NN
M*):RM^;I'07XL2@PN<=UBN>+)?(,%6BVA^XLPZK^;W?7UN.VD:7?ZU?PP<%V
M VQ%)$51\@(!?,WTPK$#V]E!L-@'V99M(6W)TU3'Z<7^^*USJSK%*E[4=C:S
M^S 3F5TLUO7<SW><^5V=.PA4<!;6&5@UG2US)$N*%@^LVG;9<(G=/$%OP&G>
M1G01$@0Q;Q^\S^), ]/")"7H.0KJ>*7.@$:=1]UD8'Q\B^0L;BA1!M#0[%J?
M<O;FEF"C1$R/7^?JQ!V,*5=K5"!K-@Q+TXT+C9*=5%%1HQR]9-FQU)!=D$/S
MX/2*OGE\BZ'1B3U A=X=6E7UL'M>CV9##-7CE;C^R-%*U -BZ_$J8(%XTD?U
M=K7DX0;"P.7+0QC#7 4HJO!5D&>8HK?.EZS__LX%U]I%=Y(IKCLR0;'4MKL_
M,K;]T*UP@8E5T;T9&U%Y6%AF]"WV)WBL+-YC_ YE8I*T3+% >+641PQ2HUV9
M=G(5@ R-9JGTT++*H4 "1?;KKF,#MAB6J+H.:D$&X9SR+P_Q$)?K\=:_P"CJ
MK)!;67ZI]?7.IPG$RK\/,X\O@O! 2732AY"+_ YOZ8256^43-]'<;1.!=Q!8
M%@5-6 [ZA=/K7'R$OHX=G%$=%T&L+MIZ=RKOF_AOT705P!:#:'4?F! [?#E'
MG._% O[C8N:AU%]#.%!%WE10I*LVKS&;L<@7%22IXU^:.E^7=5?)ZR?]2<:A
M*/Z5_%U3CEX"&1R*-'TWWX2(CM#WT5$;/6H_XC^9OOO7S5]"W\/#GIL_E[[3
M5/(!PFV^$>&><.>SD^X\R&<FD,\".(EAK(E3+WQ-$,$+*NWC+SS#OA&.G=SU
M58D/&T!WJ^*T=.B8/$HH0(OY8&J[2/)FC8$=9JUZ+;!.>/]>*%4_??#JH7GP
MZE'66!XN<502'8R+H+\N2E!@W*-]9%09L5Y?$(.DD;"&C_8^XG5AL2&LPXW.
M9UC9#Z(=XI#I4Q[\VIE97(9 7&;@&OU2J(QZ(^%9?*9$I)2BB10"*2?MG.0-
M^72V09M [OW@3@:@]"?5/;4%<N;1)#FL5))1$'*2-6!XCA"3%P(QZ=$//AW>
M;:^(EJ 515M(WVN%U]=VR_U#H>FM>@8[H*!W=NUO%^_!R^<TF6O4&I^B47=_
MX9;^:V?>]7UT\35E\N8OF'P63M[T3-[9L^!;_\4GW^XD2$?@92--GT0T'#\=
M?'V24;)D^S< D+2\AA2\ '8;[LB!J)UQ!L@Y":G2DE=:,%#9%!-<>G0HBA\]
MXVXRQ%=!Y5YZDJ%+,BP9"6&]C%O8'=O87&40%86@R@IBB#57S]CL=_K"@B42
M8>G5R?B=B5*P/T)'\%P9ASG?>QFCE^6."ZSKS@>A^3/'1*Y%C"3$0*+="FB<
M87&D[7R$W8LB?LB ;]S894FQ]>>K&VKO++3PF+BB/X*X%;LVJ+UB,-+Q]35>
MG=OL=K>]PG2%WU%S8-;+MB4$+G:4)>3Q3J?1LYAE?]_ZLP-OO-^R79CF=VM0
M<(GL&3\>#N_00.A^[%H/Q(O^/_QT&'V/N7E29P JYK#MCES];=?Q*?J/QZCR
M^$Z4V=F!>^(J/!TS)?L*6_PJQ8<!8MCNFE+YT7)CUTPF LX-25^BI;-B-K1J
M18K"VD!'B9F$\PR8%;Y+MIP[;W#ZHV$$@T=I<*T,)#)MOQ! ?DL7>R/,-H8R
M]L;GF_T.C75PPYT+B]U0OC(3$BZ9=!@>X?LRT)<=J.;;4SX?$DL(YP#IP$4F
M@:=L@REM?CS:_8YD2UKEAMV*\B#S\33Z$46\?'HCZ'AHJ3N\QV5NM_JC,![M
MEY1Q2L"7)#NY^!O3#?SRPV9,+70+O@??<(Y)G0#&QB4;T @IH^B/)2.K/^RX
MW0<BUW"=@02X\>$I=)N&<47^4$EB[?'V,]!DB.BG@T@^&PTRU#UT5O,XPM:^
M >*(V5*0G<R:$LAF6SL_CF/'PPA1"[NK</4<<%D8KI:>IX2=Y7@H&)<K%?ID
M2'\B(,"M<X==>8S?H\11=9 R=QC3JL@;/'6+YQ>N#4)9.^;?X\?<./Q#_RP=
M 7KI-\,N-'ICGR'/H8B?$YO3DRN"9<(G^OI&U"\/3U#G< !)AO@HPBRC"C)H
MSZ*02!WQ)X2-HV:.L2-<4J'PNL)E<FZBM\#/85\)%0W_X<0"&J<AO\S'+3MX
M*.2B#5UW3.QVK8]X'QK#\:!!V_<0&"XJ4?=ZFHY_R"-=LF4!>YQEE^-?%;:U
M(U7%?]2/):8.D,RL]H5I_*X5-@7<ZT'0Q.[3]8>M,%CVT;!+@T=EA^YER\20
MW;Q,E]6&1)SG_J.$$^>Z#<I0S 1$C/*"^G'[]N-^]X^;K0]\46*X+(WQ*Y%1
M6!-$CZ%W>\-\X3.0 _!9T26@7;(] (XV2C$NC$M)S#XDE!<F#C>5L%+33:5/
MKID.WJ"81_*^ RK$]NHJ=]1V?\!0"HBPV4(4 046P-P^ 3]T3E/O #;:0HR.
M3#>[#PB;PAZT'=%MO"BHV4-RHIN\G[%:!CD5?AU3_G;3;M\&@*#!8B6B-61
MC",ZVB![Q R4$*4QU%Z,2S[,_7JK)BI1#5:EV.[?<F2V9.5"!T$6C'#3Z^C+
M )AMMT0L]WLEFVPE&;#K_DO,9QLD'@#WV1_ QYT*7!QMWQ.3JQV_M"\HU3*8
M[7LTAZ@$NE=@&0-][Y?/[X)@_@>O?A%&+C']]O;XATB=&<,.R!R:W\@! J&Q
M&-*!\1YRMYE"<^ 8O*W\TQT/.VXGN"X^L81+JPZI(\&IPNON(U3##4A4D@6K
ME*1-VKG@7R[F36X4I)'3<L5J%9NKLK/7!RL-@6WK_'YF&>XU9#=+O-)SI=^3
MW>_B(:I>?MEY13M!AF9SM?NPYRWL#1B7V"@=(LK!UH%E@0J(GM0+ 6JY'F9\
MO$1%=YER! 5Q "N!O4V?,*'O]^V%J(T^+_N,83F/FS_.Z2V.W[97#P1!L;HB
MN=A^V*%T*('Y.J5&.(D+%$" $1P[9QOKN;,6'PWZC0KE"2K\J&'()PS%.. &
MM7))7-BR0UVC>@YNH*V?1H2]L>H(6D%F':P\TED04U4=#0BLVD! L(OP(*;^
M:7<\=E52--N^XY )&#<<<3%K7PEZ^!I?NE:@]9:RA6#7J715*@]^\\%N[=B%
M*BIWH500M3;3\?U9E7-[?U1YCZ?7FT_;+X?KW]SE>\3B)*N0JNU+C=(&VZ""
MNG_RWY*KA@DG>RL4N9!>1!&1"!V?]1?"OQV"2D-J#NU,3Q@-DQ,.A2'XE@B6
MY81==AF,1#"#40CIW 2Y;KRYI+L;GV,)3.-PM2-4E-%,/I47>3)OF\JKLI-X
ME?G3>%4VD5>9OX!79:?Q*C.=5Y&OE-C#ILNK)%S,V363?&H?]<=93BEVPR*L
M??Z.!@0HC1#CA1JB&W;F(NDH&&Z4%[IP\@W9+ _7AFUX9.:@G9#Z;[35J"]*
M#.PGDOC=ZQXI\LM>[9HN,9X:%'$AG*4982':XN$B&Z\MJ?W'S>;Z2!J%YH<,
M[GEE^05X=[?]Q",[>W-SA&"\]G#82\B_9G30-:WU<KX\'Z8U3G77+SM6X^%;
M4O3'' @Q(IU#K8K,-8GS'Q.!EJE 5V#%Y%/ G(.>+HIB)JSHB8@</]M5H& '
MOAKE<G[^K\!:X ,WN_8C?.>9+MH$%J0GY/KC=Q8K?*>3GO>W[3LLQ"[\K:C/
M[YO+F1X_[+8H,NG$(Q3"'L-1>XE5_9Y253^KS%Y>@@'$%T%ED>72%\R@P-\-
M6?%^\EAXYJ7'PDM_%> X>%B6*#"\VQ-P*(FS1?ZLNLU4M_8M=$,<*._IDAU?
M-!^SR5Z]M3<'X!VV+,(Q48--0H.%Q'+[@A1HD>TL3%SN$"_\JYLW1UGSBX6]
M&YVM,;(U3K!@EPF^C?/TALL7]A.TW1H7QP<A=(*KOGS<'JD ,ON'+^P*_*9Y
MJO'3@!O-])/ &%I<EZVL"Y>(])%?GL*B"8=]?/:LBGO$R[?>FBY#4LMGG)*O
M%.2=#%DY\MWZQ\O:-W/PZ?#$)*<;0L/#F<T,6;\0IH,;YQFXJ%QXQJ3=#NTC
MH5DCB(+7!VS7FI#BLOO$@7DJ67Q0A$?S>S^YU3*^;P#>&A-^)AQ> (I$6%'R
M=H[GBG8=K**8@$!$US$5JU=='Q#CF$#/(*U&1;VDSB$O<+)^*!3 VF[V;$<:
MU/!8+K<;C0LF$@_&51\9KUZ4/>,XFV=D\?J+"A-RH@"82N"^V(7%1N#6N6"]
M!.EXDQ6$>IG/R5A#KX'@Q4A#2CD9ZX)ZR*0P1#0"=IAC%**$DG8#3>/X27(J
M.ZB"(+3* 91-"A#\YG%5_1&^_]=C*?\?AZ M*02M#$+0EA2"5D8A:*I0$EO9
M)UR4^*43KD;T\N0-\]AONS8$B4'Z$<< # 0$!]N1.LU! ZQ<Y^ K?Q;XRGM9
MF9=K*C6L?IMG0. L!2$:#*(P.0#8#KFJJWQ5UU WJJG6>6&/[WGZ"SG6>[R'
MYQQP VO\7==VG^=1.&%ZX2Y3P)NYE%C>$-! 3GZ-C1KR1@]9XQ. %]KMQ/"Y
M_J:KYI8J.ZOGZ[Q9S\=7358*?C>K*E^OYG$0ICJ;3\E'YZS:P0@@LJ-[QB9M
MP9.N#U"OK9$Z2IV:2[_VE/&=9V>^XK//R8#RQ45A9[M:0\&7(BM+>^&;!OY1
MZG]4^A\+_8_:_0--C63T*II57BT*H\_@UT\Z.V'25+]&C?/DN:GI+.9-WMB3
M.7"-?DB;)/L)HSY ?M8A6H57;)R.>CMI&1\<4\DL&'KD%SAPWGHM)/ N.ALZ
MPCQZC#J$>(R*\_6MP>88DTK#P >"5R"P 1DR(/,XSH>YS2X\.F6J,-X]1$I=
M()=3OWOZ>J32:=C L4^'P$=%P>NFPH)<_%_FF1K )ST\VWK1X)OZ]]#)T*:)
MGY0_PZ_T'?@@B3#L#A7;'M;&)(U.'0#3XT0AY_U- N!A-/'+G8#[J8V!B:IM
M[CD&:N]>N+T+:WGPWIF'3L,3A04A=[R/)+571O)=T69XQ2=3C]'2MV63SXL2
MSID5G=;+I:H\M]MWKE>WB]OL# I%EJL5<*9B7EM^9G^:UP(7@WKDN^_M8EJ!
M$D\"]] YB^:AGY5'QG.<U<ITP/6 K.5U55F9;C4^M^XG3IM7C=(U?!)F9A<&
M2L=_]=QB42N\[7(ENY>)37FOM=%XBE(72,XGR*GZQ>P239K=YJG+2%*IBP=W
MUU&#*Z3B[@(-PYQR]V1N?^<\J(L''(C\1&"7?\:06_E[YN4':2EV-9"B$#3D
M@8.VMA*6Y1.07X9$RKS0N5-=A$]63"QW+6>UI:JSTOY>-?EB-3<_<OQUB3I>
M,UN4V6)6N!,BLY!!HV'_*44AVW]T"7?W@'6&%1\RUBUQ:.7:?KK&<U=8HO]$
ME?,X\5T&&R1X(TI0X$2P+245^.,A:6H7$B?>S5\(]]L,T%KW*%*\2>Z6@'V/
MQ,^?.;O<DW/S/*NSVK=3,?M-,;.JR7?9LIFMB^P[\Q*0EN*LB*R8+:&H9SFS
MU.X[\UC2P7_%H/2Y_8O]WU?<%W/2?1FM;;H2R\4_TWUILJKLW!<@AL4"G[H+
M4\RET6K6V&V;S15[BZ_-V<HV!G4 NXP9XL" 5FQ2@&_54%2FGJU2 UKF*R+5
MT(9N0V'/)[29>(WO11=YT@![*$QI6<8\OL@3WI2OOTXG,[$XB1Y%D\S9"G*;
M>G*8A(F(%^/G%+UP:&^]!,,H@N'U;E6<]VNN_7(]:QI[:XMY-2NJ@7M?SI9S
MO/?E]'NOV:I(Z)T47%U2Z8TJ (+9(M_ 0A2D#YWV]3X[TGW3(1CZX#KBT249
M5A%X[T@-9NY;#0+OM55&Y\@2\9=]O(0*(UPQ>&&/*_VT?VC@ )?T@FW$/^T?
MD$ 4W%%%OXR<>!*P[/;2+_N\Q M,[4M[U:5]B5]&*ZQ]7M$O>(X?7N'3$OX+
MS]0W[=EP?50%]0'?+"Q=HU__%#O9L?UUMVIH6R?OXK*SBVS9ADV9\VK2+BZ0
MEBYG#?^475QQ\U5B!Y?)':S4CH<[N$KN8)/803@=J1TL9PO^)FG(3$SY/T/W
MW2F 21$Z?0!(]'9O3A ;O#5>Y&V5I#^.7'(_-L%'%[A/.I"_>RD!S\;9KT1P
M)TH&G:,;<2])+[^7+9@S+^WOQK+B95UYSIQ+B6W;CIASHSBK)?SH=3Z9"\>C
MBX5D[Z6!H]V4_.VB6N<+*R/>V;KA=]H$.XU.5Q]"3D$G_C9'U]KOA-KL>//<
M+G']S>Z^!YL[0<1;@-^EL NQQ"L\G]5>$UK9"T_R"TDDE=NALP5MX[E[<9+X
M1N #8)/"^U^C:"9O^D/2%%5>557G,!5Y4:_S]6KE1C%T/I3 :0E&:47">HW#
MI2Y//E!3CCOP/S 51*<I!!N<Y,'2X(0G^'4%:\.^>8K[2KN6P>%[V$O\3DJW
M26'P=2VT0WZ7!)+@?0,CCE -<5&7P'E6L-AU#=[4A;F,?&EPI/*U/<_%.B^;
MAAV2"6P)4%/LL;8B:=WDJT5M_MWE!3UP$(7W\-"LYOG2RIKG5F6QBE"Q6F;G
M!CPWJ>FGS+##7D:!'<P>,G[=I(V"5+4]8&0&)584WJ-+Y?7 AH*0YT%V..".
M <LQF0,=;@IW$A$(758D1T80%D<')=YU/Z;D*@"NCE_%ZPAJ7<0'<\;]GZ-E
MF(;< <C,2M#UJX65^+%\!,$YYAEG"LA+,E"K&5A%XSME;O3)81ZG\J)<VW87
ME?U_TZ4S<4&-M[]]H'B7RTY%HY=<-Y5.Y"NLFWKV&.)8KMKL.7 +,#I'Q.#Y
MX?=9-F?F-?%S#]*?BP.K1YN\4,7URL"M([$S6ZEEL,F*^X4EYJGZL'P\=5U9
M!53$F +R'KY!6=&25@S]>L 4]?E_:5VA,D!L4*0[1%+"(K&%%#]^+P$M:@C/
M#U:+)'NMKV_V9=M3%-W#\ ;#I@@NS-J-.Z-,+@R9DIB:<,[X-=Q-T-$_>P2D
M#:JU7T!)I\YFV2][JFK ^ S;/XZ$5_%EU[HD WOP,:89@9>VG"<+K[0]T*9!
M_>APE?5BZ3 T!O96E:7?8R!NN/P:="IQZDX/DN)[<YY=\(AC'LJ!3:KZ5QS3
M]"B,:1*L+T0O<Y&\W:Y9WL_^XR>\%_^91$$26TI?HT0\BYK3+Z\>9V?W3@MM
M$5+2)QXD0Q"ZC?K"&B9UAO$,TR>:E5\[U;)OKN"*3SPK$L_*Q+,J\6R1>%8G
M#,?LP3]A&3SM_\KE<!WUGH$@3N0)XSPD"A5!==QG;)Q+ P$4<V+ODX,2QD_W
MJ^WGF1,1HI7M.KS[/YR[.@3BY>N[A&,N_Z]]+_OO["N']>Q.+NC_A9[O.+6Q
MXS%($P8=SU'C,2]\=#=&G-3=]J?XJ*/3/.:8GN145E<JR7/Z5Y(;=G1T'YJ.
M@%@0+]WS(JOH/7]U*O>TSX)9?NR#D-EA#Z@HX<.O#)FW.U825H FS'RDI[QO
M34;?ZU^MT^<QN"YZ#;]%?P.6Q<CO.'V=:U8;2S&%%B565.YKMW;M5H/M+,/B
MAN4BV?"$Z?1N]H(_MN1O]0SF&ZRDW9F^CQ?T<3N(U#0'3\&D[_;O7:\-^0Z4
M9I#$]/EM[SR@.TY+.59.H=C$Y2;I"1-\I;VO>+=IMPD&3T3N3PREB)^"QS5Z
M2O[7Z'&/-S9Z>[:,/P0A&HF'RWGB81FW#%V\W;_.9_.XG\$]JH;XZKWL^Q[%
M\]]N]DZ*;>*MT51VG#V.$@I]34%@[Z,)C1"_-%&(N6Q?1V-D6=I5(V1Y.;$_
M:;<::5=-(G[5M.4H)_*6:N)DRQ/;C2U*.7%1RFG3'66-TL]BI-W@?5K<[3X-
M]EF?>[5K@M@K+3O$/Y),Q'C=]WZ?J,=_9K=4_Y][!+Z!X3%_2@[J#B)N[P3'
MA=7TU$X2)R=]N>.F/F46];1C7X\(:WW/1X8Z*AR.W=IZ(K68N&0#B]XKV/3.
M(?1?3K!8)CQ\D3*<<O@-V,^2&4T_]#GZNNT2;K[(Y9+V[4U:"RO:#=KNU"NC
M5LR[^< BXEVD1)]JD7HZP6G6?665ZJ=./1STLG4;GY5KZ"-:S+,J_=ROK-@U
MQ9\Z;=M.-L(F-G+<_@HGZX6KW8=NAD=PZ$&#03P7_\+W;7O\X7\ 4$L#!!0
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M<F]P<R]A<' N>&UL4$L! A0#%     @ ?8EK4,+X[1?M    *P(  !$
M         ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ?8EK
M4)E<G",0!@  G"<  !,              ( !M0(  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " !]B6M0]//0!X("   7"@  &
M@ 'V"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ?8EK
M4+EYC)A,!   :!0  !@              ( !K@L  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( 'V):U!<&2)!;@(  #D)   8
M      "  3 0  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" !]B6M0&WY](F,%  #"&@  &               @ '4$@  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ ?8EK4(H6A?B4"@  T4@  !@
M             ( !;1@  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( ("):U#N^H^$< 4  /T;   8              "  3<C  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " " B6M0E@+?$<T!  !M
M!   &               @ '=*   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ @(EK4'D++3C- 0  ;00  !@              ( !X"H
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ("):U"QP%NH
MSP$  &T$   8              "  >,L  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " " B6M0=BSM-L\!  !K!   &0
M@ 'H+@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( (")
M:U#BO HMMP$  -0#   9              "  >XP  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ @(EK4 /"S$K. 0  ;00  !D
M         ( !W#(  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " " B6M02NQ-@K,!  #2 P  &0              @ 'A-   >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ("):U!,0#Q?S0$  &T$
M   9              "  <LV  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ @(EK4/_N%8/. 0  ;00  !D              ( !SS@
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " " B6M03M+,
M-K4!  #4 P  &0              @ '4.@  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( ("):U!,% /@S@$  &T$   9
M  "  < \  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M@(EK4/3Z(,*5 @  [@D  !D              ( !Q3X  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " " B6M0&?\\B\X!  !M!   &0
M            @ &100  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( ("):U!/&O6*X0$  /8$   9              "  99#  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ @(EK4*%K44#$ 0
M-P0  !D              ( !KD4  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " " B6M0[Q@_LO8!  !_!0  &0              @ &I
M1P  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ("):U#K
M-_'SQ@$  #D$   9              "  =9)  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ @(EK4-0EUXN8 0  6@,  !D
M     ( !TTL  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ("):U L*\N]/@(  +0'   9              "
M 917  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ @(EK
M4!>?1/;Q @  H L  !D              ( !"5H  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " " B6M0A7R4"8T#  !1$   &0
M        @ $Q70  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( ("):U#)[4F52@(  +\'   9              "  ?5@  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ @(EK4-, ><VK!   QQL
M !D              ( !=F,  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " " B6M04^V^7S($  !7&   &0              @ %8:
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ("):U#QA'.^
M2P,  &,-   9              "  <%L  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ @(EK4+<9J,D: @  # 8  !D
M ( !0W   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "
MB6M0P]0C<@\"  #_!0  &0              @ &4<@  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ("):U";VR%7M $  -D#   9
M          "  =IT  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#
M%     @ @(EK4/Y)@GZGB0  C#," !0              ( !Q78  'AL+W-H
M87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ @(EK4#I#MXY8 @  @@P   T
M             ( !G@ ! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " " B6M0
MFT\.[GH#  "W&0  #P              @ $A P$ >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ @(EK4*VBQXV8 0  MQ<  !H              ( !R 8!
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ @(EK4,E3
MY?BB 0  '!@  !,              ( !F @! %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&     "\ +P"[#   :PH!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6757921808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureIntangibleAssetsDetailsNarrativeAbstract', window );"><strong>Disclosure Intangible Assets Details Narrative Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization Expenses</a></td>
<td class="nump">$ 57,344<span></span>
</td>
<td class="nump">$ 57,344<span></span>
</td>
<td class="nump">$ 114,689<span></span>
</td>
<td class="nump">$ 114,689<span></span>
</td>
<td class="nump">$ 229,377<span></span>
</td>
<td class="nump">$ 229,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life of Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureIntangibleAssetsDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureIntangibleAssetsDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6758016640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureIntangibleAssetsTablesAbstract', window );"><strong>Disclosure Intangible Assets Tables Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><p style="margin: 0; text-align: justify">The following is a summary of the intangible assets as of December 31, 2019 and June 30, 2019:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>December 31, 2019</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>June 30, 2019</b></td></tr>
<tr>
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr>
    <td style="width: 58%; padding-left: 5.4pt">Intellectual Property</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">2,293,770</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">2,293,770</td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Less Accumulated Amortization</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">(853,855</td>
    <td style="padding-bottom: 1.5pt">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">(739,167</td>
    <td style="padding-bottom: 1.5pt">)</td></tr>
<tr>
    <td style="padding-bottom: 4pt; padding-left: 5.4pt">Intellectual Property, Net</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">1,439,915</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">1,554,603</td>
    <td style="padding-bottom: 4pt">&#160;</td></tr></table><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify">Intellectual property, stated at cost, less accumulated amortization consists of the
following:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">June 30, 2019</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">June 30, 2018</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 56%; text-align: left; padding-left: 5.4pt">Intellectual Property</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt; padding-bottom: 1pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">(739,167</td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">(509,790</td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt; padding-bottom: 2.5pt">Intellectual Property, Net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">1,554,603</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">1,783,980</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future expected Amortization of intangible assets</a></td>
<td class="text"><p style="margin: 0; text-align: justify">Estimated future amortization
expense is as follows:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="white-space: nowrap; width: 69%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Year ending June 30, 2020 (Remaining six months)</td>
    <td style="white-space: nowrap; width: 31%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;114,689 </td></tr>
<tr>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2021</td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;229,377 </td></tr>
<tr>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2022</td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;229,377 </td></tr>
<tr>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2023</td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;229,377 </td></tr>
<tr>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2024</td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;229,377 </td></tr>
<tr>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2025</td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;229,377 </td></tr>
<tr>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Thereafter</td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;178,341 </td></tr>
<tr>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="border-top: black 1.5pt solid; border-bottom: black 4.5pt double; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,439,915 </td></tr></table><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify">Estimated future amortization expense is as follows:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">Year ending June 30,</td><td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 70%; text-align: center; padding-left: 5.4pt">2020</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">229,377</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 5.4pt">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 5.4pt">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 5.4pt">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 5.4pt">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">407,718</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">1,554,603</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureIntangibleAssetsTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureIntangibleAssetsTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6634197136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Background Information and Reverse Stock Split (Details Narrative)<br></strong></div></th>
<th class="th"><div>Nov. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureSubsequentEventsDetailsNarrativeAbstract', window );"><strong>Background Information And Reverse Stock Split</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse Stock Split</a></td>
<td class="text">On November 21, 2019, the Company effected a 1:125 reverse stock split of the  Company's common stock. The reverse split combined each 125 shares of the Company's issued and outstanding  common stock into 1 share of the common stock. No fractional shares were issued in connection with the reverse split, and  any fractional shares resulting from the reverse split were rounded up to the nearest whole share. Unless the context otherwise requires,  all references in these financial statements to shares of the Company's common stock, including prices per share of its  common stock reflect the Reverse Stock Split.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureSubsequentEventsDetailsNarrativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureSubsequentEventsDetailsNarrativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6761817920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 1%"><b>5.</b></td>
    <td style="width: 99%"><b>Related Party Transactions</b></td></tr>
</table>
<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify"><i>Equity Transactions with Acuitas </i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On July 3, 2018, we entered into a Securities Purchase Agreement (the &#8220;Purchase
Agreement&#8221;) with Acuitas Group Holding, LLC (&#8220;Acuitas&#8221;) and certain other purchasers identified in the Purchase
Agreement (together with Acuitas, the &#8220;Purchasers&#8221;) pursuant to which (i) the Purchasers agreed to purchase an aggregate
of 2,133,332 shares of the our Series A Convertible Preferred Stock (the &#8220;Preferred Stock&#8221;) at a price per share of
$1.50 per share of Preferred Stock (the &#8220;Initial Sale&#8221;) and (ii) we agreed to issue warrants (the &#8220;Warrants&#8221;)
to purchase 1,706,666 shares of common stock, each subject to the terms and conditions set forth in the Purchase Agreement, for
an aggregate consideration of $3.2 million. We received $160,000 of the $3.2 million in April and May 2018 as prepaid equity.
Acuitas also received an additional 6,667 Warrants in connection with the payoff of a note issued by us in favor of Acuitas. The
Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas had the option to purchase up to an additional
1,600,000 shares of common stock at a price per share of $1.88, and warrants on the same terms as the Warrants, within two weeks
following the one year anniversary of the closing of the Initial Sale (the &#8220;Subsequent Sale&#8221;) in the event that we
did not obtain $3,000,000 of funding through various non-dilutive grants prior to the one year anniversary of the closing of the
Initial Sale, less any federal or FDA grant funding received by the Company. Acuitas is controlled by our Chairman and Chief Executive
Officer, Terren Peizer and the Purchasers included Jonathan Adams, James Lang, Cuong Do and Michael Sherman, who are members of
our Board.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Purchase Agreement contained customary representations and warranties. In connection
with the disclosure schedule associated with the representations and warranties, we also disclosed customary information, including
the following: (i) the existence of the Mallinckrodt petition before the U.S. Patent Trial and Appeal Board, (ii) our capitalization,
(iii) our obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared
among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated
April 11, 2016, by and between LAT Pharma LLC and us, (iv) our obligation to pay a low single digit royalty on net sales of all
terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement,
dated July 25, 2016, by and between us and the University of Padova (Italy), and (v) certain recent issuances of common stock
by us.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Each share of Preferred Stock automatically converted into 100 shares of common stock
(prior to reverse split) upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to our
Articles of Incorporation (the &#8220;Amendment&#8221;) on August 13, 2018 that increased the number of authorized shares of common
stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of our issued and
outstanding common stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar days following
the distribution of our Definitive Information Statement on Schedule 14 that was filed with the SEC on July 13, 2018.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Pursuant to a letter agreement dated June 24, 2019, Acuitas agreed to modify its existing
rights under the Purchase Agreement so that:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 20px; text-align: right; vertical-align: top">&#8211;</td>
    <td style="width: 7px">&#160;</td>
    <td style="text-align: justify">Acuitas agreed to immediately exchange its existing 1,606,667 Warrants
    for common stock such that it will have effectively exercised its Warrants in full pursuant to a cashless exercise thereof
    at an assumed current market price of $45.00 per share and, as a result received an aggregate of 95% of the shares covered
    thereby, or 1,526,094 shares of common stock;</td></tr>

<tr>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr>
    <td style="width: 20px; text-align: right; vertical-align: top">&#8211;</td>
    <td style="width: 7px">&#160;</td>
    <td style="text-align: justify">Acuitas agreed to (i) waive its rights to a 50% adjustment of the purchase
    price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants and the price per share in the Subsequent
    Sale in the event of certain reductions in the useful life of our current intellectual property rights, and (ii) effectively
    exercise its rights to purchase securities in a Subsequent Sale pursuant to a &#8220;cashless purchase&#8221; at an assumed
    current market price of approximately $11.25 per share, conditioned in each case on the listing of our common stock on Nasdaq
    or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than
    November 30, 2019, which will result Acuitas having irrevocably waived its rights to an adjustment in the purchase price of
    the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the
    Subsequent Sale upon the issuance by us of an aggregate of 1,339,958 shares of common stock (the &#8220;Subsequent Sale Shares&#8221;)
    to Acuitas, which is expected to occur concurrently with the closing of our potential public offering and listing on Nasdaq;</td></tr>

<tr>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr>
    <td style="width: 20px; text-align: right; vertical-align: top">&#8211;</td>
    <td style="width: 7px">&#160;</td>
    <td style="text-align: justify">Acuitas shall in exchange for the foregoing agreements and waivers have
    the option to purchase additional shares of common stock and warrants to purchase one share of common stock for each share
    of common stock purchased during the period from September 1, 2019 to November 30, 2019 at the then-effective purchase price
    of the Preferred Stock in the Initial Sale (the &#8220;Funding Option&#8221;), provided that any shares issued pursuant to
    any exercise of the Funding Option will reduce share-for-share the amount of shares issued pursuant to the deemed exercise
    of its rights to purchase securities in a Subsequent Sale mentioned above.</td></tr>
</table>
<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify"><i>Convertible Debenture Transaction with Acuitas</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On September 24, 2019, the Company entered into a Securities Purchase Agreement (the
&#8220;2019 Purchase Agreement&#8221;) with Acuitas pursuant to which (i) Acuitas agreed to purchase a 10% OID Convertible Delayed
Draw Debenture (the &#8220;Debenture&#8221;) due September 24, 2020 for an aggregate commitment amount of up to $2.0 million,
and (ii) the Company issued 1,125,000 shares (the &#8220;Commitment Shares&#8221;) of the Company&#8217;s common stock and warrants
(the &#8220;Commitment Warrants&#8221;) to purchase an equal number of shares, each subject to the terms and conditions set forth
in the 2019 Purchase Agreement. The Debenture accrues additional principal at the rate of 6% per annum and interest at the rate
of 10% per annum, is convertible into shares of common stock at $4.00 per share prior to the completion of the company&#8217;s
planned public offering of units (the &#8220;Public Offering&#8221;) or, subsequent to the closing of the Public Offering, the
lower of $4.00 or 80% of the offering price per unit to the public in the Public Offering and are mandatorily redeemable upon
such closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. The Commitment Warrants are
five-year warrants, exercisable upon the earlier of the effectiveness of the Company&#8217;s current reverse stock split or December
1, 2019, at an amount equal to the lower of $4.00 or 80% of the offering price per unit to the public in the Public Offering.
Upon entering into the 2019 Purchase Agreement, the Company drew an initial $500,000 under the Debenture and in accordance with
the 2019 Purchase Agreement, Acuitas received an additional 125,000 warrants (the &#8220;Bridge Warrants&#8221;) having the same
terms as the Commitment Warrants. Any future draws under the Debenture, which may be made from and after October 15, 2019, November
15, 2019 and December 15, 2019 in equal tranches of $500,000 each, will entitle Acuitas to receive additional Bridge Warrants
in equal amount upon such funding. In addition, the 2019 Purchase Agreement provides that, should the underwriters in the Public
Offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such
securities would result in Acuitas' beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%,
Acuitas shall be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants
to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60%.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The issuance of 1,125,000 shares of the Company&#8217;s commons stock and warrants to
purchase an equal amount number of shares, to its controlling stockholder for the Bridge Financing was accounted for as a deemed
dividend due to its related party nature and $17.1 million representing the excess of the fair value of the consideration given
for the financing, net of debt discount; was recorded in accumulated deficit for the six months ended December 31, 2019, accordingly.
(See accompanied Condensed Statements of Changes in Stockholders&#8217; (Deficit) Equity). A debt discount of $500,000 against
the debenture was recorded which will be amortized over the term of the debenture using the effective interest method. The Company
recognized amortization of this discount in the amount of $21,595 for the six-month period ended December 31, 2019.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company received partial draws of draw number two of&#160;the Debenture of $25,000
and $5,000 on December 5, 2019 and December 13,&#160;2019 respectively.&#160;&#160;Acuitas and the Company continue to discuss
the need and timing for some or&#160;all of&#160;the remaining draws under the Agreement. &#160;(See subsequent events).</p>

<p style="margin: 0; text-align: justify">&#160;</p>






<p style="margin: 0; text-align: justify">Pursuant to the 2019 Purchase Agreement, Acuitas has agreed to further modify its existing
rights under the Purchase Agreement dated July 3, 2018 with the Company so that Acuitas&#8217; previous agreement in June 2019
to waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the July 2018 transaction, the exercise
price of the warrants in such transaction and the price per share in a Subsequent Sale in the event of certain reductions in the
useful life of our current intellectual property rights, and effectively exercise its rights to purchase securities in a Subsequent
Sale pursuant to a &#8220;cashless purchase&#8221; at an assumed current market price of approximately $11.25 per share, conditioned
in each case on the listing of the Company&#8217;s common stock on Nasdaq or the raising of $2.0 million in additional funds in
the form of another securities offering, in either case not later than November 30, 2019, such that Acuitas will have irrevocably
waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of
the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 2,679,916 shares
of common stock and 2,679,916 warrants having the same terms as the Commitment Warrants to Acuitas, upon the closing of the Public
Offering.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Pursuant to an amendment to the 2019 Purchase Agreement dated October 9, 2019, Acuitas
agreed to modify its existing rights under the 2019 Purchase Agreement so that:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; vertical-align: top">&#8211;</td>
    <td style="text-align: justify">The Commitment Warrants (and related warrants issued upon the first draw under the Debenture)
    were replaced with warrants having similar terms, but which are automatically exercised upon the closing of the offering at
    an exercise price equal to the par value of the common stock;</td></tr>

<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr>
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; vertical-align: top">&#8211;</td>
    <td style="text-align: justify">Acuitas' existing rights under the Purchase Agreement dated July 3, 2018 with the Company
    were further amended so that the number of Subsequent Sale Shares would be multiplied by four (in lieu of the changes to the
    Purchase Agreement originally provided for in the 2019 Purchase Agreement); and</td></tr>

<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr>
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; vertical-align: top">&#8211;</td>
    <td style="text-align: justify">The provisions of the 2019 Purchase Agreement providing that, should the underwriters in the
    offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of
    such securities would result in Acuitas&#8217; beneficial ownership (on a fully diluted basis) of shares of common stock being
    below 60%, Acuitas will be issued a number of additional shares of common stock and warrants having the same terms as the
    Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60%
    have been modified such that, upon the exercise of such option by the underwriters, the Company will issue to Acuitas a number
    of securities that will result in Acuitas&#8217; fully diluted beneficial ownership after the exercise of such option being
    the same as prior thereto. </td></tr>
</table><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 5%"><b>6.</b></td>
    <td style="width: 95%"><b>Related Party Transactions</b></td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On March 23, 2017, Barrett Ehrlich agreed to defer the payment of his consulting fee
debt of $173,333 until&#160;December 31, 2019, through the issuance of a Promissory note.&#160; The promissory note does not carry
any interest charge as long as the amount is paid in full before&#160;December 31, 2019.&#160; The consulting fee debt was reclassified
from a current liability to a long-term liability on the balance sheet.&#160;Any portion of the balance due under the note that
remains unpaid after&#160;December 31, 2019&#160;will accrue interest at a rate of 5% per annum until paid in full.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On August 8, 2018, Barrett Ehrlich (Independent contractor, related party to Elliot
Ehrlich and shareholder) on behalf of The Barrett Edge Inc. (&#8220;Barrett&#8221;) entered into an Accord and Debt Satisfaction
Agreement with the Company in which Barrett agreed to release the Company from all liabilities including the original contract
to defer payment of accrued consulting fees dated March 23, 2017, the promissory note issued by the Company to defer payment of
accrued consulting fees; loan to the Company for $14,000, and subsequent unpaid consulting fees, totaling $543,014, and received
cash of $131,333 and 3,947 common shares in satisfaction. The common shares were valued at the market price on the date of settlement
at $16.25 per common share. The gain of $361,548 on the settlement of debt was reflected in the additional paid in capital for
the year ended June 30, 2019.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On March 23, 2017, Elliot Ehrlich agreed to forgive 50% of his salary debt of $444,056.&#160;
The adjusted salary debt is $222,028.&#160; Elliot Ehrlich also agreed to defer the payment of his salary debt of $222,028 until&#160;December
31, 2019, through the issuance of a Promissory note.&#160; The promissory note does not carry any interest charge as long as the
amount is paid in full before&#160;December 31, 2019.&#160; The salary debt was reclassified from a current liability to a long-term
liability on the balance sheet and the salary debt forgiven had been reflected on the income statement as other income.&#160;Any
portion of the balance due under the note that remains unpaid after&#160;December 31, 2019&#160;will accrue interest at a rate
of 5% per annum until paid in full.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On July 9, 2018, Elliot Ehrlich (former CEO and shareholder) entered into an Accord
and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all liabilities including the
original contract to defer payment of accrued salary dated March 23, 2017, totaling the amount of $1,777 the promissory note
issued by the Company to defer payment of accrued salary; and received cash of $22,273 and 222,028 common shares in satisfaction.
The common shares were valued at the market price on the date of settlement at $7.50 per common share. The gain of $186,503 on
the settlement of debt was reflected in the additional paid in capital for the year ended June 30, 2019.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On March 23, 2017, Jonathan Adams agreed to defer the payment of his salary debt of
$180,555 until&#160;December 31, 2019, through the issuance of a Promissory note.&#160; The promissory note does not carry any
interest charge as long as the amount is paid in full before&#160;December 31, 2019.&#160; The salary debt was reclassified from
a current liability to a long-term liability on the balance sheet.&#160;Any portion of the balance due under the note that remains
unpaid after&#160;December 31, 2019&#160;will accrue interest at a rate of 5% per annum until paid in full.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On July 9, 2018, Jonathan Adams (COO) entered into an Accord and Debt Satisfaction Agreement
with the Company in which he agreed to release the Company from all liabilities including the original contract to defer payment
of his accrued salary dated March 23, 2017, the promissory note issued by the Company to defer payment of accrued salary; and
subsequent unpaid salary, totaling the amount of $534,722, and received cash of $25,694 in satisfaction. The gain of $509,028
on the settlement of debt was reflected in the additional paid in capital for the year ended June 30, 2019.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The outstanding balance of the long-term note payable at June 30, 2019 and 2018 was
$0 and $575,918, respectively.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">See note 8 &#8220;Equity Transactions&#8221;, for other related party transactions with
Acuitas Group Holdings, LLC (&#8220;Acuitas&#8221;) and board of director members.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636132736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 1%"><b>3.</b></td>
    <td style="width: 99%"><b>Significant Accounting Policies</b></td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Basis of Presentation &#8211; Interim Financial Information</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The accompanying unaudited interim financial
statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State
of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect
all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair
presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for
the full year. The condensed balance sheet at June 30, 2019 was derived from audited annual financial statements but does not contain
all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included
under the heading: &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; should
be read in conjunction with our Company&#8217;s audited financial statements and related notes included in our Company&#8217;s
Form 10-K for the year ended June 30, 2019 filed with the SEC on September 27, 2019.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">For a summary of significant accounting
policies, see the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 filed with the SEC on September
27, 2019.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Net income (loss) per Common Share</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Basic net income (loss) per common share
is computed by dividing the net income (loss) before deemed dividend by the weighted average number of shares of common stock outstanding
during the period.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Diluted net income (loss) per common
share is computed by dividing by the weighted average number of shares of common stock outstanding and potentially outstanding
shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through
stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the six months ended December
31, 2019 and 2018 as such amounts were excluded from the diluted loss since their effect was considered anti-dilutive. For the
three months ended December 31, 2019, all potential securities were anti-dilutive as a result of the effect of the change in fair
value of the derivative liabilities and assumed conversion of debenture in determining the amount of net income (loss) attributable
to common stockholders. Due to the net loss for the three months ended December 31, 2018, amounts were excluded from the diluted
loss since their effect was considered anti-dilutive.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The table below shows the number of
outstanding stock options and warrants as of December 31, 2019 and 2018:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="text-align: center"><b>December 31, 2019</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="text-align: center"><b>December 31, 2018</b></td></tr>
<tr>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Number of Shares</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Number of Shares</b></td></tr>
<tr>
    <td style="width: 18%; padding-bottom: 1.5pt; padding-left: 5.4pt">Stock Options</td>
    <td style="width: 34%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 18%; text-align: right">60,400</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 8%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 18%; text-align: right">44,400</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Warrants</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">1,374,667</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">1,731,525</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 4pt; padding-left: 5.4pt"><b>Total</b></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><b>1,435,067</b></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><b>1,775,925</b></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
</table>


<p style="margin: 0; text-align: justify"><b>&#160;</b>&#160;</p>


<p style="margin: 0; text-align: justify"><i>Recent accounting pronouncements</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company considers the applicability
and impact of all Accounting Standard Updates (&#8220;ASU&#8217;s&#8221;). ASU&#8217;s not discussed below were assessed and determined
to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In June 2018, the FASB issued ASU 2018-07,
&#8220;Compensation &#8211; Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting&#8221;. This guidance
aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions
with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning
of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption
date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal
years. Early adoption is permitted. The Company has adopted this ASU as of July 1, 2019. There has been no impact on the financial
statements.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In August 2018, the FASB issued ASU 2018-13,
&#8220;Fair value measurement (Topic 820): Disclosure Framework &#8211; Changes to the Disclosure Requirements for Fair Value Measurement&#8221;.
The new guidance modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for fiscal years beginning
after December 15, 2019. Early adoption is permitted. The Company does not expect ASU 2018-13 to have a significant impact to its
condensed consolidated financial statements and related disclosures.</p><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 5%"><b>3.</b></td>
    <td style="width: 95%"><b>Significant Accounting Policies</b></td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Basis of Presentation </i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company&#8217;s financial statements have been prepared in accordance with accounting
principles generally accepted in the United States (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation
of the Company&#8217;s financial position for the periods presented.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Use of Estimates</i></p>

<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management
to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company
bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances.
The amounts of assets and liabilities reported in the Company&#8217;s balance sheet and the amounts of expenses reported for each
of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, accounting for share-based
compensation, accounting for derivatives and accounting for income taxes. Actual results could differ from those estimates.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Cash</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company considers all highly liquid instruments with original maturities of three
months or less to be cash equivalents. Cash is maintained at one financial institution and, at times, balances may exceed federally
insured limits. The Company has never experienced any losses related to these balances. All of the Company&#8217;s cash balances
were fully insured at June 30, 2019.&#160;</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Other Assets</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Other Assets consists of direct cost related to capital raise and filing of the registration
statement legal fees and investment banking fees incurred to raise capital. The costs will be expensed once the Company raises
the capital.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Fair Value of Financial Instruments</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Fair value is defined as the price that would be received from selling an asset or paid
to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair
value for applicable assets and liabilities, we consider the principal or most advantageous market in which we would transact
and we consider assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer
restrictions, and risk of nonperformance. This guidance also establishes a fair value hierarchy to prioritize inputs used in measuring
fair value as follows:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 35px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Level 1: Observable inputs such as quoted prices in active markets&#894;</td></tr>

<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="width: 35px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly&#894; and</td></tr>

<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="width: 35px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop
    its own assumptions</td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company&#8217;s financial instruments include cash, accounts payable, related party
loans and a demand promissory note. The carrying amounts of cash and accounts payable approximate their fair value, due to the
short-term nature of these items.&#160;</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Long-Term Notes Payable</i></p>

<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify">The Company&#8217;s long-term notes payable include accrued payroll to officers and
accrued payments to third party consultants.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Research and Development</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Research and development expenses consist primarily of costs associated with the preclinical
and/ or clinical trials of drug candidates, compensation and other expenses for research and development, personnel, supplies
and development materials, costs for consultants and related contract research and facility costs. Expenditures relating to research
and development are expensed as incurred.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Income Taxes</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company uses the asset and liability method of accounting for deferred income taxes.
Deferred income taxes are measured by applying enacted statutory rates to net operating loss carryforwards and to the differences
between the financial reporting and tax bases of assets and liabilities. Deferred tax assets are reduced, if necessary, by a valuation
allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company recognizes uncertainty in income taxes in the financial statements using
a recognition threshold and measurement attribute of a tax position taken or expected to be taken in a tax return. The Company
applies the &#8220;more-likely-than-not&#8221; recognition threshold to all tax positions, commencing at the adoption date of
the applicable accounting guidance, which resulted in no unrecognized tax benefits as of such date. Additionally, there have been
no unrecognized tax benefits subsequent to adoption. The Company has opted to classify interest and penalties that would accrue,
if any, according to the provisions of relevant tax law as general and administrative expenses, in the statements of operations.
For the years ended June 30, 2019 and 2018 there was no such interest or penalty.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Net Loss per Common Share</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Basic net loss per common share is computed by dividing the net loss before deemed dividend
by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed
by dividing net loss by the weighted average number of shares of common stock outstanding and potentially outstanding shares of
common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options,
warrants, convertible preferred stock and convertible debentures. Due to the net loss for the period, such amounts were excluded
from the diluted loss since their effect was considered anti-dilutive.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The table below shows the number of outstanding stock options and warrants as of June
30, 2019 and June 30, 2018:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">June 30, 2019</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">June 30, 2018</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Number of Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Number of Shares</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 56%; text-align: left; padding-left: 5.4pt">Stock Options</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">58,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">41,200</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">124,667</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">38,193</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; padding-left: 5.4pt; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">182,667</td><td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">79,393</td><td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Stock-based Compensation</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company has accounted for stock-based compensation under the provisions of FASB
ASC 718 &#8211; &#8220;Stock Compensation&#8221; which requires the use of the fair-value based method to determine compensation
for all arrangements under which employees and others receive shares of stock or equity instruments (stock options and common
stock purchase warrants). For employee awards, the fair value of each stock option award is estimated on the date of grant using
the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free
interest rate. For non-employees, the fair value of each stock option award is estimated on the measurement date using the Black-Scholes
valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.
For non-employees, the Company utilizes the graded vesting attribution method under which the entity treats each separately vesting
portion (tranche) as a separate award and recognizes compensation cost for each tranche over its separate vesting schedule. Expected
volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the stock
options. For employee awards, the expected term of options granted is derived using the &#8220;simplified method&#8221; which
computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the
U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. We recognize forfeitures as they
occur.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Goodwill</i></p>

<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify">Goodwill is recorded when the purchase price paid for an acquisition exceeds the fair
value of net identified tangible and intangible assets acquired. The Company performs an annual impairment test of goodwill and
further periodic tests to the extent indicators of impairment develop between annual impairment tests. The Company&#8217;s impairment
review process compares the fair value of the reporting unit to its carrying value, including the goodwill related to the reporting
unit. To determine the fair value of the reporting unit, the Company may use various approaches including an asset or cost approach,
market approach or income approach or any combination thereof. These approaches may require the Company to make certain estimates
and assumptions including future cash flows, revenue and expenses. These estimates and assumptions are reviewed each time the
Company tests goodwill for impairment and are typically developed as part of the Company&#8217;s routine business planning and
forecasting process. While the Company believes its estimates and assumptions are reasonable, variations from those estimates
could produce materially different results. The Company did not recognize any goodwill impairments for the years ended June 30th,
2018 and June 30th, 2019.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Impairment of Long-Lived Assets</i></p>

<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify">Long-lived assets, including intangible assets, are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets
to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows
expected to be generated by the asset.&#160;</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">If the carrying amount of an asset exceeds its undiscounted estimated future cash flows,
an impairment review is performed. An impairment charge is recognized in the amount by which the carrying amount of the asset
exceeds the fair value of the asset. Generally, fair value is determined using valuation techniques such as expected discounted
cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented in the balance sheet and reported
at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated or amortized. The assets and
liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability
sections of the balance sheet.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Reclassifications</i></p>

<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify">Certain prior year amounts have been reclassified for consistency with current year
presentation. These reclassifications had no effect on the reported results of operations.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Recent accounting pronouncements</i></p>

<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify">The Company considers the applicability and impact of all Accounting Standard Updates
(&#8220;ASU&#8217;s&#8221;). ASU&#8217;s not discussed below were assessed and determined to be either not applicable or expected
to have minimal impact on our balance sheets or statement of operations.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In June 2018, the FASB issued ASU 2018-07, &#8220;Compensation &#8211; Stock Compensation
(Topic 718): Improvements to Non-employee share based accounting&#8221;, which simplifies the accounting for non-employee share-based
payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor
acquires goods or services to be used or consumed in a grantor&#8217;s own operations by issuing share-based payment awards. The
standard will be effective for the Company in the first quarter of fiscal year 2020, although early adoption is permitted (but
no sooner than the adoption of Topic 606). The Company does not expect that the adoption of this ASU will have a significant impact
on its financial statements.</p>

<p style="margin: 0; text-align: justify">&#160;&#160;</p>

<p style="margin: 0; text-align: justify">In July 2017, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2017-11.
&#8220;Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815):
I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily
Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with
a Scope Exception. ASU 2017-11 revises the guidance for instruments with down round features in Subtopic 815-40, Derivatives and
Hedging &#8211; Contracts in Entity&#8217;s Own Equity, which is considered in determining whether an equity-linked financial
instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments
would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception.
If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017-11 is
effective for annual and interim periods beginning December 15, 2018, and early adoption is permitted, including adoption in an
interim period. ASU 2017-11 provides that upon adoption, an entity may apply this standard retrospectively to outstanding financial
instruments with a down round feature by means of a cumulative-effect adjustment to the opening balance of retaining earnings
in the fiscal year and interim period adopted. The Company is currently in the process of assessing the impact of this ASU on
its financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6608277472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 5%"><b>9.</b></td>
    <td style="width: 95%"><b>Income Taxes </b></td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Deferred income taxes reflect the net tax effects of temporary differences between the
carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">At June 30, 2018, the Company has a Net Operating Loss (&#8220;NOL&#8221;) carryforward
of approximately $1,800,000. The NOL expires during the years 2032 to 2037. Realization of any portion of the $832,186 of net
deferred tax assets at June 30, 2018 is not considered more likely than not by management; accordingly, a valuation allowance
has been established for the full amount. The valuation allowance as of June 30, 2018 was $832,186. The change in the valuation
allowance from June 30, 2017 to June 30, 2018 amounted to $357,231.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">At June 30, 2019, the Company had a Net Operating Loss (&#8220;NOL&#8221;) carryforward
of approximately $5,700,000. NOL&#8217;s generated prior to 2018 will expire during the years 2032 to 2037. Realization of any
portion of the $1,680,613 deferred tax assets at June 30, 2019 is not considered more likely than not by management; accordingly,
a valuation allowance has been established for the full amount, which as of June 30, 2019 was $1,680,613. The change in the valuation
allowance during the year ended June 30, 2019 amounted to $848,427. The Company does not have any uncertain tax positions or events
leading to uncertainty in a tax position. The Company&#8217;s 2016, 2017 and 2018 Corporate Income Tax Returns are subject to
Internal Revenue Service examination.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On December 22, 2017, the Tax Cuts and Jobs Act (the &#8220;Act&#8221;) was signed into
law. The Act decreases the U.S. corporate federal income tax rate from a maximum of 35% to a flat 21% effective January 1, 2018.
The Act also includes a number of other provisions including, among others, the elimination of net operating loss carrybacks and
limitations on the use of future losses, NOL&#8217;s generated in 2018 and later having an indefinite life, the repeal of the
Alternative Minimum Tax regime, and the repeal of the domestic production activities deduction. The impact on the Company&#8217;s
financial statements is immaterial, primarily because the Company has a valuation allowance on deferred tax assets.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Given the significant complexity of the Act and anticipated additional implementation
guidance from the Internal Revenue Service, further implications of the Act may be identified in future periods.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Significant components of the Company&#8217;s deferred tax assets are as follows:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"><b>June 30, 2019</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"><b>June 30, 2018</b></td></tr>
<tr>
    <td style="padding-left: 5.4pt">Deferred tax assets:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="width: 58%; padding-left: 5.4pt">Tax loss carryforward</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">1,624,887</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">555,064</td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Intangible assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">36,917</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">19,277</td>
    <td>&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Stock based compensation</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">18,809</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">257,845</td>
    <td>&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt; padding-bottom: 1pt">Valuation Allowance</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">$</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">(1,680,613</td>
    <td style="padding-bottom: 1pt">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">(832,186</td>
    <td style="padding-bottom: 1pt">)</td></tr>
<tr>
    <td style="padding-left: 5.4pt; padding-bottom: 2.5pt">Net deferred tax assets</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">$</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">$</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Since management of the Company believes that it is more likely than not that the net
deferred tax assets will not provide future benefit, the Company has established a 100 percent valuation allowance on the net
deferred tax assets as of June 30, 2019 and 2018.&#160;&#160;The Company&#8217;s NOL carryover up to the date of the July 2018
financing will be subject to Section 382 usage limitations since a greater than 50% ownership change took place from the financing
event.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Reconciliation of the differences between income tax benefit computed at the federal
and state statutory tax rates and the provision for income tax benefit for the years ended June 30, 2019 and 2018 is as follows:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 56%; text-align: left; padding-left: 5.4pt">Income tax expense (benefit) at federal statutory rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">34</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">-29</td><td style="text-align: left; padding-bottom: 1pt">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">-39</td><td style="text-align: left; padding-bottom: 1pt">%</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6779233200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Changes in Stockholders' (Deficit) Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jun. 30, 2017</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 3,492,254<span></span>
</td>
<td class="num">$ (2,335,009)<span></span>
</td>
<td class="nump">$ 1,157,319<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Jun. 30, 2017</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">735,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of shares and warrants for cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">444,998<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">444,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares and warrants for cash, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">13,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SettlementOfDebtByIssuanceOfCommonStock', window );">Issuance of shares in exchange for debt settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">642,846<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">642,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares for services, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">37,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_OptionsVested', window );">Options vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">238,165<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">238,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options for cash</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options for cash, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock option compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_CashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of warrants for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,469<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfWarrantsWithDebt', window );">Issuance of warrants with debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,519<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividend', window );">Deemed dividend for commitment shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividendsForRatchetAdjustmentsToWarrants', window );">Deemed dividends for ratchet adjustment to warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,995<span></span>
</td>
<td class="num">(20,995)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,413,122)<span></span>
</td>
<td class="num">(2,413,122)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jun. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">4,880,246<span></span>
</td>
<td class="num">(4,769,126)<span></span>
</td>
<td class="nump">111,199<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Jun. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">788,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfPreferredStockInPrivatePlacement', window );">Issuance of preferred stock in a private placement</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfPreferredStockInPrivatePlacementShares', window );">Issuance of preferred stock in a private placement, Shares</a></td>
<td class="nump">2,133,332<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ConversionOfPreferredStockToCommonStock', window );">Conversion of preferred stock to common stock</a></td>
<td class="num">$ (3,200,000)<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
<td class="num">(171)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ConversionOfPreferredStockToCommonStockInShares', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="num">(2,133,332)<span></span>
</td>
<td class="nump">1,706,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SettlementOfDebtByIssuanceOfCommonStock', window );">Issuance of shares in exchange for debt settlement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,150,134<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,150,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SettlementOfDebtByIssuanceOfCommonStockShares', window );">Issuance of shares in exchange for debt settlement, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock option compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,412<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_CashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_CashlessExerciseOfWarrantsShares', window );">Cashless exercise of warrants, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">17,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividendsForRatchetAdjustmentsToWarrants', window );">Deemed dividends for ratchet adjustment to warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">48,659<span></span>
</td>
<td class="num">(48,659)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(439,871)<span></span>
</td>
<td class="num">(439,871)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Sep. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">9,282,278<span></span>
</td>
<td class="num">(5,257,656)<span></span>
</td>
<td class="nump">4,024,875<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Sep. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,520,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jun. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">4,880,246<span></span>
</td>
<td class="num">(4,769,126)<span></span>
</td>
<td class="nump">111,199<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Jun. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">788,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SettlementOfDebtByIssuanceOfCommonStock', window );">Issuance of shares in exchange for debt settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,150,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock option compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_CashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividend', window );">Deemed dividend for commitment shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividendsForRatchetAdjustmentsToWarrants', window );">Deemed dividends for ratchet adjustment to warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(940,381)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">9,298,563<span></span>
</td>
<td class="num">(5,758,166)<span></span>
</td>
<td class="nump">3,540,650<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,520,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jun. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">4,880,246<span></span>
</td>
<td class="num">(4,769,126)<span></span>
</td>
<td class="nump">111,199<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Jun. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">788,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfPreferredStockInPrivatePlacement', window );">Issuance of preferred stock in a private placement</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_IssuanceOfPreferredStockInPrivatePlacementShares', window );">Issuance of preferred stock in a private placement, Shares</a></td>
<td class="nump">2,133,332<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ConversionOfPreferredStockToCommonStock', window );">Conversion of preferred stock to common stock</a></td>
<td class="num">$ (3,200,000)<span></span>
</td>
<td class="nump">$ 171<span></span>
</td>
<td class="num">(171)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ConversionOfPreferredStockToCommonStockInShares', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="num">(2,133,332)<span></span>
</td>
<td class="nump">1,706,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SettlementOfDebtByIssuanceOfCommonStock', window );">Issuance of shares in exchange for debt settlement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,150,134<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,150,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SettlementOfDebtByIssuanceOfCommonStockShares', window );">Issuance of shares in exchange for debt settlement, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of shares for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">48,999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">49,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of shares for services, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock option compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">64,860<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">64,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_CashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="num">(154)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">19,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_CashlessExerciseOfWarrantsShares', window );">Cashless exercise of warrants, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,544,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividend', window );">Deemed dividend for commitment shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividendsForRatchetAdjustmentsToWarrants', window );">Deemed dividends for ratchet adjustment to warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">48,659<span></span>
</td>
<td class="num">(48,659)<span></span>
</td>
<td class="nump">48,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,444,287)<span></span>
</td>
<td class="num">(2,444,287)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jun. 30, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
<td class="nump">9,392,573<span></span>
</td>
<td class="num">(7,262,072)<span></span>
</td>
<td class="nump">2,130,907<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Jun. 30, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,058,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Sep. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">9,282,278<span></span>
</td>
<td class="num">(5,257,656)<span></span>
</td>
<td class="nump">4,024,875<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Sep. 30, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,520,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock option compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,285<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividend', window );">Deemed dividend for commitment shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(500,510)<span></span>
</td>
<td class="num">(500,510)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
<td class="nump">9,298,563<span></span>
</td>
<td class="num">(5,758,166)<span></span>
</td>
<td class="nump">3,540,650<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2018</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,520,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jun. 30, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
<td class="nump">9,392,573<span></span>
</td>
<td class="num">(7,262,072)<span></span>
</td>
<td class="nump">2,130,907<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Jun. 30, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,058,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of commitment shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="nump">10,068,638<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,068,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of commitment shares, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividend', window );">Deemed dividend for commitment shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,099,058)<span></span>
</td>
<td class="num">(17,099,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,821,227)<span></span>
</td>
<td class="num">(3,821,227)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Sep. 30, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 518<span></span>
</td>
<td class="nump">19,461,211<span></span>
</td>
<td class="num">(28,182,357)<span></span>
</td>
<td class="num">(8,720,628)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Sep. 30, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,183,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Jun. 30, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
<td class="nump">9,392,573<span></span>
</td>
<td class="num">(7,262,072)<span></span>
</td>
<td class="nump">2,130,907<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Jun. 30, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,058,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SettlementOfDebtByIssuanceOfCommonStock', window );">Issuance of shares in exchange for debt settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock option compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_CashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividend', window );">Deemed dividend for commitment shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,099,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividendsForRatchetAdjustmentsToWarrants', window );">Deemed dividends for ratchet adjustment to warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,843,811<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 518<span></span>
</td>
<td class="nump">19,472,373<span></span>
</td>
<td class="num">(21,517,319)<span></span>
</td>
<td class="num">(2,044,428)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,183,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Sep. 30, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 518<span></span>
</td>
<td class="nump">19,461,211<span></span>
</td>
<td class="num">(28,182,357)<span></span>
</td>
<td class="num">(8,720,628)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Sep. 30, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,183,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock option compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,162<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividend', window );">Deemed dividend for commitment shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,665,038<span></span>
</td>
<td class="nump">6,665,038<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 518<span></span>
</td>
<td class="nump">$ 19,472,373<span></span>
</td>
<td class="num">$ (21,517,319)<span></span>
</td>
<td class="num">$ (2,044,428)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,183,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_CashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cashless Exercise of Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_CashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_CashlessExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cashless Exercise of Warrants Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_CashlessExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ConversionOfPreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Preferred Stock To Common Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ConversionOfPreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ConversionOfPreferredStockToCommonStockInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Preferred Stock To Common Stock (in shares)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ConversionOfPreferredStockToCommonStockInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DeemedDividendsForRatchetAdjustmentsToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividends for Ratchet Adjustments to Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DeemedDividendsForRatchetAdjustmentsToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_IssuanceOfPreferredStockInPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Preferred Stock In Private Placement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_IssuanceOfPreferredStockInPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_IssuanceOfPreferredStockInPrivatePlacementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance Of Preferred Stock In Private Placement, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_IssuanceOfPreferredStockInPrivatePlacementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_IssuanceOfWarrantsWithDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Warrant with Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_IssuanceOfWarrantsWithDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_OptionsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options Vested</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_OptionsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SettlementOfDebtByIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Debt By Issuance Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SettlementOfDebtByIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SettlementOfDebtByIssuanceOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement of Debt by Issuance of Common Stock, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SettlementOfDebtByIssuanceOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6768244912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant to Section 8(a), may determine.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOVIE INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001580149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-2510769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2120 Colorado Avenue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Santa Monica<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">283-5793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6765495104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details 5) - Warrant [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrant Outstanding at the beginning of the year</a></td>
<td class="nump">124,667<span></span>
</td>
<td class="nump">38,193<span></span>
</td>
<td class="nump">49,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Warrant Granted</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">1,713,332<span></span>
</td>
<td class="nump">28,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Warrant Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease', window );">Warrant Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,626,859)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrant Outstanding at the end of year</a></td>
<td class="nump">1,374,667<span></span>
</td>
<td class="nump">124,667<span></span>
</td>
<td class="nump">38,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Weighted Average Exercise Price at the beginning of the year</a></td>
<td class="nump">$ 45.00<span></span>
</td>
<td class="nump">$ 36.25<span></span>
</td>
<td class="nump">$ 62.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">4.00<span></span>
</td>
<td class="nump">45.00<span></span>
</td>
<td class="nump">27.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Weighted Average Exercise Price at the end of year</a></td>
<td class="nump">$ 7.72<span></span>
</td>
<td class="nump">$ 45.00<span></span>
</td>
<td class="nump">$ 36.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Life at the beginning of the year</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1', window );">Weighted Average Remaining Life, Granted</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3', window );">Weighted Average Remaining Life at the end of year</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding at beginning of period</a></td>
<td class="nump">$ 716,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate Intrinsic Value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,159,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding at end of period</a></td>
<td class="nump">$ 139,498<span></span>
</td>
<td class="nump">$ 716,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share weighted average intrinsic value of equity-based compensation awards excersied. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted, Weighted Average Remaining Contractual Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6777608608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details) - Stock Option [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at beginning of period</a></td>
<td class="nump">58,000<span></span>
</td>
<td class="nump">41,200<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Option Granted</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">16,800<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding at end of period</a></td>
<td class="nump">60,400<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="nump">41,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable at end of period</a></td>
<td class="nump">60,400<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding Weighted Average Exercise Price at the beginning of period</a></td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">7.42<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
<td class="nump">18.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding Weighted Average Exercise Price at the end of period</a></td>
<td class="nump">12.29<span></span>
</td>
<td class="nump">12.50<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Excersiable Weighted Average Exercise Price at the end of period</a></td>
<td class="nump">$ 12.29<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term at the beginning of period</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4', window );">Weighted Average Remaining Contractual Term at the end</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Excersiable Weighted Average Remaining Contractual Term at the end of period</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding at beginning of period</a></td>
<td class="nump">$ 87,480<span></span>
</td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="nump">$ 142,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">131,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options Exercised or Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value Outstanding at end of period</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">87,480<span></span>
</td>
<td class="nump">$ 142,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value Exercisable</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 273,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6703739760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureStockOptionsTablesAbstract', window );"><strong>Disclosure Stock Options Tables Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Issued</a></td>
<td class="text"><p style="margin: 0; text-align: justify">The following table summarizes the activity relating to the Company&#8217;s stock options
for the six months ended December 31, 2019:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Options</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Weighted-Average Exercise Price</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Weighted Remaining Average Contractual Term</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Aggregate Intrinsic Value</b></td></tr>
<tr>
    <td style="width: 44%; padding-left: 5.4pt">Outstanding at June 30, 2019</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">58,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">12.50</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">5.2</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">87,480</td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Granted</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,400</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">7.42</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4.1</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;&#160;&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Options Exercised or Forfeited</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 4pt; padding-left: 5.4pt">Outstanding at December 31, 2019</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">60,400</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">12.29</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">4.5</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">2,100</td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 4pt; padding-left: 5.4pt">Exercisable at December 31, 2019</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">60,400</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">12.29</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">4.5</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">2,100</td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
</table>
<p style="margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="margin: 0; text-align: justify">The pricing model reflected the following weighted-average assumptions for the six months
ended December 31, 2019:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>December 31 2019</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>December 31 2018</b></td></tr>
<tr>
    <td style="width: 58%; padding-left: 5.4pt">Expected life of options (In years)</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">5</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">5</td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Expected volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">71.55</td>
    <td>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">67.91</td>
    <td>%</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Risk free interest rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1.61</td>
    <td>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2.98</td>
    <td>%</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Dividend Yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">0</td>
    <td>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">0</td>
    <td>%</td></tr>
</table><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify">The following table summarizes the activity
relating to the Company&#8217;s stock options for the years ended June 30, 2018 and 2019:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Options</b></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Weighted-Average Exercise Price</b></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Weighted Remaining Average Contractual Term</b></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Aggregate Intrinsic Value</b></td></tr>
<tr>
    <td style="width: 44%; padding-left: 5.4pt">Outstanding at June 30, 2017</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">32,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">12.50</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">5.9</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">142,000</td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Granted</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">10,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">18.75</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">5.0</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#8212;&#160;&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt; padding-bottom: 1pt">Options Exercised</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">(800</td>
    <td style="padding-bottom: 1pt">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">$</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">2.50</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">$</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Outstanding at June 30, 2018</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">41,200</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">15.00</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">5.8</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">142,000</td>
    <td>&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Granted</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">16,800</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">5.00</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4.5</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">131,000</td>
    <td>&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt; padding-bottom: 1pt">Options Exercised or Forfeited</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">$</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">$</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt; padding-bottom: 2.5pt">Outstanding at June 30, 2019</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">58,000</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">$</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">12.50</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">5.2</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">$</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">273,000</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt; padding-bottom: 2.5pt">Exercisable at June 30, 2019</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">58,000</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">$</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">12.50</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">5.2</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">$</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The fair value of each option grant
on the date of grant is estimated using the Black-Scholes Option &#8211; Pricing model reflecting the following weighted-average
assumptions:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 56%; text-align: left; padding-left: 5.4pt">Expected life of options (In years)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69.77</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103.13</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.60</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.28</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt">Dividend Yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock', window );">Schedule of option outstanding and exercisable by exercise price</a></td>
<td class="text"><p style="margin: 0; text-align: justify">The following is a summary of stock
options outstanding and exercisable by exercise price as of December 31, 2019:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Exercise Price</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Outstanding</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Weighted Average Contract Life</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Exercisable</b></td></tr>
<tr>
    <td style="width: 1%">$</td>
    <td style="width: 20%; text-align: right">3.75</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%; text-align: right">5,600</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%; text-align: right">4.1</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%; text-align: right">5,600</td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td>$</td>
    <td style="text-align: right">6.25</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">11,200</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4.2</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">11,200</td>
    <td>&#160;</td></tr>
<tr>
    <td>$</td>
    <td style="text-align: right">7.50</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">25,600</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">6.2</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">25,600</td>
    <td>&#160;</td></tr>
<tr>
    <td>$</td>
    <td style="text-align: right">8.75</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,600</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4.3</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,600</td>
    <td>&#160;</td></tr>
<tr>
    <td>$</td>
    <td style="text-align: right">12.50</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">3.1</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4,000</td>
    <td>&#160;</td></tr>
<tr>
    <td>$</td>
    <td style="text-align: right">25.00</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,600</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2.8</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,600</td>
    <td>&#160;</td></tr>
<tr>
    <td>$</td>
    <td style="text-align: right">26.25</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4,400</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2.3</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4,400</td>
    <td>&#160;</td></tr>
<tr>
    <td>$</td>
    <td style="text-align: right">27.50</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">800</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2.2</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">800</td>
    <td>&#160;</td></tr>
<tr>
    <td>$</td>
    <td style="text-align: right">28.75</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,600</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2.6</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,600</td>
    <td>&#160;</td></tr>
<tr>
    <td>$</td>
    <td style="text-align: right">31.25</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1.9</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4,000</td>
    <td>&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify">The following is a summary of stock
options outstanding and exercisable by exercise price as of June 30, 2019:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted Average</td><td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Outstanding</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Contract Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Exercisable</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">3.75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">5,600</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">4.6</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">5,600</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">$</td><td style="text-align: right">6.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,400</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">$</td><td style="text-align: right">7.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,800</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">$</td><td style="text-align: right">8.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">$</td><td style="text-align: right">12.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">$</td><td style="text-align: right">25.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">$</td><td style="text-align: right">26.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,400</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">$</td><td style="text-align: right">27.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">$</td><td style="text-align: right">28.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">$</td><td style="text-align: right">31.25</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">4,000</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right">2.4</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">4,000</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: right">Total</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">58,000</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">58,000</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">Schedule of Warrants Issued</a></td>
<td class="text"><p style="margin: 0; text-align: justify"><i>Stock Warrants</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The following table summarizes the warrants activity during the six months ended December
31, 2019:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Number of Shares</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Weighted Average Exercise Price</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Weighted Average Remaining Life (Years)</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Aggregate Intrinsic Value</b></td></tr>
<tr>
    <td style="width: 44%; padding-left: 5.4pt">Outstanding and exercisable at June 30, 2019</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">124,667</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">45.00</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">5.6</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">716,653</td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Granted</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,250,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">4.00</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4.7</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#8212;&#160;&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Expired</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">$</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">$</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Outstanding and exercisable at December 31, 2019</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">1,374,667</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">$</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">7.72</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">4.7</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">$</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">139,498</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
</table><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify">The following table summarizes
the warrants that have been issued:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="margin: 0; text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Aggregate</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Intrinsic</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Life (Years)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Value</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 40%; padding-left: 5.4pt">Outstanding at June 30, 2017</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">49,391</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">62.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">0.5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,802</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">27.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">(40,000</td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">62.50</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt">Outstanding at June 30, 2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,193</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">36.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,713,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">45.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,159,988</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">(1,626,859</td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">45.00</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt; padding-bottom: 1pt">Outstanding and exercisable at June 30, 2019</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">124,667</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">45.00</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">5.6</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">1,202,678</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureStockOptionsTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureStockOptionsTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6715060656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureIntangibleAssetsDetailsAbstract', window );"><strong>Disclosure Intangible Assets Details Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intellectual Property</a></td>
<td class="nump">$ 2,293,770<span></span>
</td>
<td class="nump">$ 2,293,770<span></span>
</td>
<td class="nump">$ 2,293,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(853,855)<span></span>
</td>
<td class="num">(739,167)<span></span>
</td>
<td class="num">(509,790)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intellectual Property, Net</a></td>
<td class="nump">$ 1,439,915<span></span>
</td>
<td class="nump">$ 1,554,603<span></span>
</td>
<td class="nump">$ 1,783,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureIntangibleAssetsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureIntangibleAssetsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6758082624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureIncomeTaxesDetails2Abstract', window );"><strong>Disclosure Income Taxes Details 2Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax expense (benefit) at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(29.00%)<span></span>
</td>
<td class="num">(39.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income Tax Expense Benefit</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureIncomeTaxesDetails2Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureIncomeTaxesDetails2Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6778052944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details 3) - Stock Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">5,600<span></span>
</td>
<td class="nump">5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">11,200<span></span>
</td>
<td class="nump">10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">11,200<span></span>
</td>
<td class="nump">10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">25,600<span></span>
</td>
<td class="nump">24,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">25,600<span></span>
</td>
<td class="nump">24,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 12.29<span></span>
</td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Option Outstanding</a></td>
<td class="nump">60,400<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="nump">41,200<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Option Excersiable</a></td>
<td class="nump">60,400<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636303280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 1%"><b>4.</b></td>
    <td style="width: 99%"><b>Intangible Assets</b></td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company&#8217;s
intangible assets consist of intellectual property acquired from LAT Pharma, Inc. and are amortized over their estimated useful
lives. The following is a summary of the intangible assets as of December 31, 2019 and June 30, 2019:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>December 31, 2019</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>June 30, 2019</b></td></tr>
<tr>
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr>
    <td style="width: 58%; padding-left: 5.4pt">Intellectual Property</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">2,293,770</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">2,293,770</td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Less Accumulated Amortization</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">(853,855</td>
    <td style="padding-bottom: 1.5pt">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">(739,167</td>
    <td style="padding-bottom: 1.5pt">)</td></tr>
<tr>
    <td style="padding-bottom: 4pt; padding-left: 5.4pt">Intellectual Property, Net</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">1,439,915</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">1,554,603</td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Amortization expense
for the three-month period ended December 31, 2019 and 2018 was $57,344 and $57,344 respectively Amortization expense for the six-month
period ended December 31, 2019 and 2018 was $114,689 and $114,689 respectively.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Estimated future amortization
expense is as follows:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="white-space: nowrap; width: 69%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Year ending June 30, 2020 (Remaining six months)</td>
    <td style="white-space: nowrap; width: 31%; padding-right: 5.4pt; padding-left: 5.4pt">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;114,689 </td></tr>
<tr>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2021</td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;229,377 </td></tr>
<tr>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2022</td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;229,377 </td></tr>
<tr>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2023</td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;229,377 </td></tr>
<tr>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2024</td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;229,377 </td></tr>
<tr>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">2025</td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;229,377 </td></tr>
<tr>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Thereafter</td>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;178,341 </td></tr>
<tr>
    <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;</td>
    <td style="border-top: black 1.5pt solid; border-bottom: black 4.5pt double; white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&#160;$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1,439,915 </td></tr>
</table><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 5%"><b>4.</b></td>
    <td style="width: 95%"><b>Intangible Assets</b></td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Intellectual property, stated at cost, less accumulated amortization consists of the
following:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">June 30, 2019</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">June 30, 2018</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 56%; text-align: left; padding-left: 5.4pt">Intellectual Property</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt; padding-bottom: 1pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">(739,167</td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">(509,790</td><td style="text-align: left; padding-bottom: 1pt">)</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt; padding-bottom: 2.5pt">Intellectual Property, Net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">1,554,603</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">1,783,980</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Amortization expense amounted to $229,377 and $229,377 for the years ended June 30,
2019 and 2018, respectively. The Company amortizes intellectual property over the expected original useful lives of 10 years.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Estimated future amortization expense is as follows:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: center">Year ending June 30,</td><td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 70%; text-align: center; padding-left: 5.4pt">2020</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right">229,377</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 5.4pt">2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 5.4pt">2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 5.4pt">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 5.4pt">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">229,377</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">Thereafter</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">407,718</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 2.5pt double">$</td><td style="text-align: right; border-bottom: Black 2.5pt double">1,554,603</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6766391408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 1%"><b>8.</b></td>
    <td style="width: 99%"><b>Commitments and Contingencies</b>&#160;</td></tr>
</table>
<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify"><i>Office Lease&#160;</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On July 1, 2019, the Company&#8217;s office moved with Acuitas&#8217; new offices to
2120 Colorado Avenue Ste 230, Santa Monica, CA 90404. There is no lease agreement for the new premises and the Company continues
to accrue monthly lease payments of $1,000 for the new office under the terms of the previous month-to-month lease for the previous
premises which may be cancelled upon 30 days&#8217; written notice.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Challenge to US Patent</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On April 30, 2018, we received notice that Mallinckrodt had petitioned the U.S. Patent
and Trademark Office (&#8220;USPTO&#8221;) to institute an Inter Partes Review of our U.S. Patent No. 9,655,945 titled &#8220;Treatment
of Ascites&#8221; (the &#8220;&#8217;945 patent&#8221;). Inter Partes Review is a trial proceeding conducted with the USPTO Patent
Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds
of novelty and obviousness on the basis of prior art consisting of patents and printed publications.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On November 13, 2019, the Patent Trial and Appeal Board of the United States Patent
and Trademark Office (the &#8220;Board&#8221;) issued a written decision in the <i>inter partes</i> review (&#8220;IPR&#8221;)
action that was brought by Mallinckrodt Pharmaceuticals Ireland Limited (&#8220;Mallinckrodt&#8221;) against BioVie Inc. (&#8220;BioVie&#8221;
or &#8220;Company&#8221;). In that action, Mallinckrodt sought to invalidate BioVie&#8217;s patent (U.S. Pat. No. 9,655,945, &#8220;Treatment
of Ascites&#8221;) (the &#8220;&#8217;945 Patent&#8221;). In its decision, the Board determined that all claims of the &#8216;945
Patent were not patentable because they were either anticipated or obvious in light of prior art. The Board also denied BioVie&#8217;s
Motion to Amend the claims on similar grounds. The result of the Board&#8217;s decision is that the &#8216;945 patent is no longer
valid or enforceable. Acuitas Group Holdings, LLC was aware of this patent challenge when it purchased a majority ownership interest
in the company in July 2018.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">This ruling is unrelated to the Company&#8217;s Orphan drug designations for ascites
and hepatorenal syndrome (&#8220;HRS&#8221;), which remain unchanged. An Orphan drug that is first-to-market typically receives
7 years of market exclusivity in the United States for the designated use(s). In addition, the ruling does not affect the Company&#8217;s
rights in its pending patent application directed to proprietary liquid formulations of terlipressin for use in its planned Phase
2b/3 trial, subject to FDA clearance, which could eventually provide up to 20 years of patent coverage in each country in which
the Company seeks patent protection, such as the United States, if a patent issues from a patent application according to the
patent laws of each issuing country.</p>

<p style="margin: 0; text-align: justify">&#160;</p>


<p style="margin: 0; text-align: justify"><i>Royalty Agreements</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016 between
our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net
sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett
Edge, Inc.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company and PharmaIN Corporation, LAT Pharma&#8217;s former partner focused on the
development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties
equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed
to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial
ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on
a related debt. PharmaIN, Corp. rights to our program remain unchanged. Additionally the Company obligation to pay a low single
digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, and The
Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC. The Company
has an obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up
to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the
University of Padova (Italy).</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Pursuant to the Technology Transfer Agreement entered into on July 25, 2016 between
BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit royalty on net sales of all terlipressin
products covered by US patent no. 9,655,645 and any future foreign issuances capped at a maximum of $200,000 per year.</p><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 5%"><b>7.</b></td>
    <td style="width: 95%"><b>Commitments and Contingencies</b></td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Office Lease</i>&#160;</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On October 1, 2018, the Company executed a
lease agreement with Acuitas Group Holdings, LLC (related party) for the Company&#8217;s Corporate office space at the Acuitas&#8217;
offices at 11100 Wilshire Boulevard, Los Angeles , CA 90025. The lease is a month-to-month lease that may be cancelled upon 30
days&#8217; written notice and requires monthly payments of $1,000. On July 1, 2019, the Company&#8217;s office moved with Acuitas&#8217;
new offices to 2120 Colorado Avenue Ste 230, Santa Monica, CA 90404.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Challenge to US Patent</i></p>

<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify">On April 30, 2018, we received notice that
Mallinckrodt had petitioned the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) to institute an Inter Partes Review of
our U.S. Patent No. 9,655,945 titled &#8220;Treatment of Ascites&#8221; (the &#8220;&#8217;945 patent&#8221;). Inter Partes Review
is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more
claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents
and printed publications.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On August 15, 2018, we submitted a Preliminary
Response to the PTAB providing a rationale as to why, in our opinion, Mallinckrodt&#8217;s request to institute the IPR should
not be granted. On November 14, 2018, the PTAB granted institution of the IPR challenge after determining that there was a reasonable
likelihood of success in proving that at least one of our 14 claims was unpatentable. On March 7, 2019, we submitted a Patent
Owner&#8217;s Response and a Patent Owner&#8217;s Contingent Motion to Amend our patent claims, and Declaration of Dr. Jaime Bosch,
MD, PhD, our medical expert. On June 26 and June 28, 2019, we submitted a Patent Owner&#8217;s Reply In Support Of Its Contingent
Motion To Amend Under 37 C.F.R.&#167; 42.121 to amend our patent claims and a Patent Sur-Reply supported by the Supplemental Declaration
of Dr. Jaime Bosch to the Reply and the Opposition to Motion to Amend, filed by Petitioner Mallinckrodt, filed June 6, 2019. On
July 29, 2019, we submitted a Patent Owner&#8217;s Opposition to Petitioner&#8217;s Motion to Strike. On July 17, 2019, we received
from the PTAB an Order Oral Hearing in response to our request of an Oral Hearing which was held on August 12, 2019 at 1:00PM
EST. We are actively defending the &#8217;945 patent and we are exploring the possibility of settlement with Mallinckrodt. However,
there can be no assurance that a favorable outcome will result, or if settlement is reached that the PTAB will accept it. A reasonable
estimate cannot be made at this time. Although the PTAB encourages settlement, in view of public-interest considerations, the
PTAB may continue the proceeding to a final written decision even if the parties settle. If the IPR is not terminated due to settlement,
the PTAB is statutorily required to issue its final written decision in this case before November 14, 2019 (within one year from
the date of institution). At June 30, 2019, no adjustments or accruals have been reflected in our financial statements related
to this matter.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Royalty Agreements</i></p>

<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify">Pursuant to the Agreement and Plan of Merger
entered into on April 11, 2016 between LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit
royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation;
and The Barrett Edge, Inc.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company and PharmaIN Corporation, LAT
Pharma&#8217;s former partner focused on the development of new modified drug candidates in the same therapeutic field but not
including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development
programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24,
2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously
paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Pursuant to the Technology Transfer Agreement
entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit
royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped at
a maximum of $200,000 per year.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6640464784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background Information and Reverse Stock Split<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Background Information and Reverse Stock Split</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 1%"><b>1.</b></td>
    <td style="width: 99%"><b>Background Information</b></td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">BioVie Inc. (the &#8220;Company&#8221;) is a clinical-stage company pursuing the discovery,
development, and commercialization of innovative drug therapies. We are currently focused on developing and commercializing BIV201
(continuous infusion terlipressin), a novel approach to the treatment of ascites due to chronic liver cirrhosis. Our therapy BIV201
is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis (part of the same
disease pathway as ascites), but not yet available in the United States. BIV201&#8217;s active agent is a potent vasoconstrictor
and has shown efficacy for reducing portal hypertension in studies around the world. The goal is for BIV201 to interrupt the ascites
disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">BioVie began administering BIV201 to patients in a Phase 2a clinical trial in patients
with refractory ascites due to advanced liver cirrhosis at the McGuire Research Institute Inc. in Richmond, VA in September 2017.
In April 2019, we announced top-line results and in June met with representatives of the FDA for a Type C Guidance Meeting to
discuss the study results and plan our next clinical study. In July 2019, the FDA provided meeting minutes that documented general
agreement with the Company&#8217;s proposed randomized and controlled study design. The FDA also provided its suggestions and
guidance regarding primary and secondary endpoints, quality of life measures and other key aspects of the clinical trial design.
In October 2019, BioVie announced the submission of a Phase 2b/3 clinical trial protocol to the FDA. We are developing a patent-pending
novel liquid formulation of terlipressin for use in this study that is intended to improve convenience for outpatient administration
and avoid potential formulation errors that may occur when pharmacists reconstitute the powder version.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">BIV201 has the potential to improve the health of thousands of patients suffering from
life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. It has
FDA Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which represents a significant
unmet medical need. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States
for the designated use(s). The FDA has never approved any drug specifically for treating ascites.&#160;In addition, the Company
has a pending patent application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2b/3
trial, subject to FDA clearance, which could eventually provide up to 20 years of patent coverage in each country in which the
Company seeks patent protection, such as the United States, if a patent issues according to the patent laws of the issuing country.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company
acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development and marketing
rights to its drug candidate. The Company and PharmaIN, Corp. (&#8220;PharmaIN&#8221;), LAT Pharma&#8217;s former partner focused
on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties
equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed
to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial
ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on
a related debt. PharmaIN, Corp.&#8217;s rights to our program remain unchanged.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company&#8217;s activities are subject to significant risks and uncertainties including
failure to secure additional funding to properly execute the Company&#8217;s business plan.</p><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 5%"><b>1.</b></td>
    <td style="width: 95%"><b>Background Information and Reverse Stock Split</b></td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>








<p style="margin: 0; text-align: justify"><i>Background Information</i>&#160;</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">We are a clinical-stage company pursuing the discovery, development, and commercialization
of innovative drug therapies. We are currently focused on developing and commercializing BIV201 (continuous infusion terlipressin),
a novel approach to the treatment of ascites due to chronic liver cirrhosis. Our therapy BIV201 is based on a drug that is approved
in about 40 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not
yet available in the United States. BIV201&#8217;s active agent is a potent vasoconstrictor and has shown efficacy for reducing
portal hypertension in studies around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby halting
the cycle of accelerating fluid generation in ascites patients.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In April 2017, we entered into a CRADA with the McGuire Research Institute Inc. in Richmond,
VA, and began administering BIV201 to patients in September 2017. In April 2019, we announced top-line results for our Phase 2a
clinical trial of BIV201 (continuous infusion terlipressin) in six patients with refractory ascites due to advanced liver cirrhosis.
On June 18, 2019, we met with representatives of the FDA for Type C Guidance Meeting to plan our next clinical study following
the recently completed Phase 2a clinical trial. We discussed our clinical development efforts with the FDA and proposed trial
endpoints. While the FDA has not provided final guidance nor do we have certainty as to what that guidance would entail, our goal
remains to proceed into a Phase 2b/3 or Phase 3 clinical trial in a manner consistent with what was reviewed with the FDA. We
may still need to address certain risks associated with unvalidated quality of life measures. In July 2019, the FDA provided meeting
minutes for the June 18, 2019 meeting that documented general agreement with the Company proposed randomized study design. The
FDA also provided its suggestions and guidance regarding primary and secondary endpoints and other key aspects of our clinical
trial design and the Company is incorporating those suggestions as it moves forward. We are developing a proprietary novel liquid
formulation of terlipressin that is intended to improve convenience for outpatient administration and avoid potential formulation
errors when pharmacists reconstitute the powder version.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">BIV201 has the potential to improve the health of thousands of patients suffering from
life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. It has
FDA Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which represents a significant
unmet medical need. The FDA has never approved any drug specifically for treating ascites. The Company has secured a US Patent
covering the use of BIV201 for the treatment of ascites patients in the outpatient setting using ambulatory pump infusion, and
has filed patent applications for its product candidate in Japan, and Europe, Hong Kong, and China. BIV201 also received Orphan
Drug designation for hepatorenal syndrome (&#8220;HRS&#8221;) in November 2018.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company
acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development and marketing
rights to its drug candidate. The Company and PharmaIN, Corp. (&#8220;PharmaIN&#8221;), LAT Pharma&#8217;s former partner focused
on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties
equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed
to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial
ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on
a related debt. PharmaIN, Corp.&#8217;s rights to our program remain unchanged.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company&#8217;s activities are subject to significant risks and uncertainties including
failure to secure additional funding to properly execute the Company&#8217;s business plan.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Reverse Stock Split</i></p>

<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify">On November 21, 2019, the Company effected a 1:125 reverse stock split of the Company&#8217;s
common stock. The reverse split combined each 125 shares of the Company&#8217;s issued and outstanding common stock into 1 share
of the common stock. No fractional shares were issued in connection with the reverse split, and any fractional shares resulting
from the reverse split were rounded up to the nearest whole share. Unless the context otherwise requires, all references in these
financial statements to shares of the Company&#8217;s common stock, options and warrants, including prices per share of its
common stock reflect the Reverse Stock Split.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6776347312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="margin: 0; text-align: justify"><i>Basis of Presentation &#8211; Interim Financial Information</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The accompanying unaudited interim financial
statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State
of America (&#8220;U.S. GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information
and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect
all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair
presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for
the full year. The condensed balance sheet at June 30, 2019 was derived from audited annual financial statements but does not contain
all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included
under the heading: &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; should
be read in conjunction with our Company&#8217;s audited financial statements and related notes included in our Company&#8217;s
Form 10-K for the year ended June 30, 2019 filed with the SEC on September 27, 2019.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">For a summary of significant accounting
policies, see the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 filed with the SEC on September
27, 2019.</p><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><i>Basis of Presentation </i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company&#8217;s financial statements have been prepared in accordance with accounting
principles generally accepted in the United States (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation
of the Company&#8217;s financial position for the periods presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><i>Use of Estimates</i></p>

<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management
to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company
bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances.
The amounts of assets and liabilities reported in the Company&#8217;s balance sheet and the amounts of expenses reported for each
of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, accounting for share-based
compensation, accounting for derivatives and accounting for income taxes. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><i>Cash</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company considers all highly liquid instruments with original maturities of three
months or less to be cash equivalents. Cash is maintained at one financial institution and, at times, balances may exceed federally
insured limits. The Company has never experienced any losses related to these balances. All of the Company&#8217;s cash balances
were fully insured at June 30, 2019.&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_OtherAssetPolicyTextBlock', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><i>Other Assets</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Other Assets consists of direct cost related to capital raise and filing of the registration
statement legal fees and investment banking fees incurred to raise capital. The costs will be expensed once the Company raises
the capital.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><i>Fair Value of Financial Instruments</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Fair value is defined as the price that would be received from selling an asset or paid
to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair
value for applicable assets and liabilities, we consider the principal or most advantageous market in which we would transact
and we consider assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer
restrictions, and risk of nonperformance. This guidance also establishes a fair value hierarchy to prioritize inputs used in measuring
fair value as follows:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 35px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Level 1: Observable inputs such as quoted prices in active markets&#894;</td></tr>

<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="width: 35px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly&#894; and</td></tr>

<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="width: 35px">&#160;</td>
    <td style="width: 24px">&#9679;</td>
    <td>Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop
    its own assumptions</td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company&#8217;s financial instruments include cash, accounts payable, related party
loans and a demand promissory note. The carrying amounts of cash and accounts payable approximate their fair value, due to the
short-term nature of these items.&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-Term Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><i>Long-Term Notes Payable</i></p>

<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify">The Company&#8217;s long-term notes payable include accrued payroll to officers and
accrued payments to third party consultants.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><i>Research and Development</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Research and development expenses consist primarily of costs associated with the preclinical
and/ or clinical trials of drug candidates, compensation and other expenses for research and development, personnel, supplies
and development materials, costs for consultants and related contract research and facility costs. Expenditures relating to research
and development are expensed as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><i>Income Taxes</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company uses the asset and liability method of accounting for deferred income taxes.
Deferred income taxes are measured by applying enacted statutory rates to net operating loss carryforwards and to the differences
between the financial reporting and tax bases of assets and liabilities. Deferred tax assets are reduced, if necessary, by a valuation
allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company recognizes uncertainty in income taxes in the financial statements using
a recognition threshold and measurement attribute of a tax position taken or expected to be taken in a tax return. The Company
applies the &#8220;more-likely-than-not&#8221; recognition threshold to all tax positions, commencing at the adoption date of
the applicable accounting guidance, which resulted in no unrecognized tax benefits as of such date. Additionally, there have been
no unrecognized tax benefits subsequent to adoption. The Company has opted to classify interest and penalties that would accrue,
if any, according to the provisions of relevant tax law as general and administrative expenses, in the statements of operations.
For the years ended June 30, 2019 and 2018 there was no such interest or penalty.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="margin: 0; text-align: justify"><i>Net income (loss) per Common Share</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Basic net income (loss) per common share
is computed by dividing the net income (loss) before deemed dividend by the weighted average number of shares of common stock outstanding
during the period.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Diluted net income (loss) per common
share is computed by dividing by the weighted average number of shares of common stock outstanding and potentially outstanding
shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through
stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the six months ended December
31, 2019 and 2018 as such amounts were excluded from the diluted loss since their effect was considered anti-dilutive. For the
three months ended December 31, 2019, all potential securities were anti-dilutive as a result of the effect of the change in fair
value of the derivative liabilities and assumed conversion of debenture in determining the amount of net income (loss) attributable
to common stockholders. Due to the net loss for the three months ended December 31, 2018, amounts were excluded from the diluted
loss since their effect was considered anti-dilutive.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The table below shows the number of
outstanding stock options and warrants as of December 31, 2019 and 2018:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="text-align: center"><b>December 31, 2019</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="text-align: center"><b>December 31, 2018</b></td></tr>
<tr>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Number of Shares</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Number of Shares</b></td></tr>
<tr>
    <td style="width: 18%; padding-bottom: 1.5pt; padding-left: 5.4pt">Stock Options</td>
    <td style="width: 34%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 18%; text-align: right">60,400</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 8%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 18%; text-align: right">44,400</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Warrants</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">1,374,667</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">1,731,525</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 4pt; padding-left: 5.4pt"><b>Total</b></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><b>1,435,067</b></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><b>1,775,925</b></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr></table><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><i>Net Loss per Common Share</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Basic net loss per common share is computed by dividing the net loss before deemed dividend
by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed
by dividing net loss by the weighted average number of shares of common stock outstanding and potentially outstanding shares of
common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options,
warrants, convertible preferred stock and convertible debentures. Due to the net loss for the period, such amounts were excluded
from the diluted loss since their effect was considered anti-dilutive.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The table below shows the number of outstanding stock options and warrants as of June
30, 2019 and June 30, 2018:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">June 30, 2019</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">June 30, 2018</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Number of Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Number of Shares</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 56%; text-align: left; padding-left: 5.4pt">Stock Options</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">58,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">41,200</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">124,667</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">38,193</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; padding-left: 5.4pt; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">182,667</td><td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">79,393</td><td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><i>Stock-based Compensation</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company has accounted for stock-based compensation under the provisions of FASB
ASC 718 &#8211; &#8220;Stock Compensation&#8221; which requires the use of the fair-value based method to determine compensation
for all arrangements under which employees and others receive shares of stock or equity instruments (stock options and common
stock purchase warrants). For employee awards, the fair value of each stock option award is estimated on the date of grant using
the Black-Scholes valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free
interest rate. For non-employees, the fair value of each stock option award is estimated on the measurement date using the Black-Scholes
valuation model that uses assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate.
For non-employees, the Company utilizes the graded vesting attribution method under which the entity treats each separately vesting
portion (tranche) as a separate award and recognizes compensation cost for each tranche over its separate vesting schedule. Expected
volatilities are based on historical volatility of peer companies and other factors estimated over the expected term of the stock
options. For employee awards, the expected term of options granted is derived using the &#8220;simplified method&#8221; which
computes expected term as the average of the sum of the vesting term plus the contract term. The risk-free rate is based on the
U.S. Treasury yield curve in effect at the time of grant for the period of the expected term. We recognize forfeitures as they
occur.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><i>Goodwill</i></p>

<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify">Goodwill is recorded when the purchase price paid for an acquisition exceeds the fair
value of net identified tangible and intangible assets acquired. The Company performs an annual impairment test of goodwill and
further periodic tests to the extent indicators of impairment develop between annual impairment tests. The Company&#8217;s impairment
review process compares the fair value of the reporting unit to its carrying value, including the goodwill related to the reporting
unit. To determine the fair value of the reporting unit, the Company may use various approaches including an asset or cost approach,
market approach or income approach or any combination thereof. These approaches may require the Company to make certain estimates
and assumptions including future cash flows, revenue and expenses. These estimates and assumptions are reviewed each time the
Company tests goodwill for impairment and are typically developed as part of the Company&#8217;s routine business planning and
forecasting process. While the Company believes its estimates and assumptions are reasonable, variations from those estimates
could produce materially different results. The Company did not recognize any goodwill impairments for the years ended June 30th,
2018 and June 30th, 2019.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><i>Impairment of Long-Lived Assets</i></p>

<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify">Long-lived assets, including intangible assets, are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets
to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows
expected to be generated by the asset.&#160;</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">If the carrying amount of an asset exceeds its undiscounted estimated future cash flows,
an impairment review is performed. An impairment charge is recognized in the amount by which the carrying amount of the asset
exceeds the fair value of the asset. Generally, fair value is determined using valuation techniques such as expected discounted
cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented in the balance sheet and reported
at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated or amortized. The assets and
liabilities of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability
sections of the balance sheet.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Reclassifications', window );">Reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><i>Reclassifications</i></p>

<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify">Certain prior year amounts have been reclassified for consistency with current year
presentation. These reclassifications had no effect on the reported results of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><p style="margin: 0; text-align: justify"><i>Recent accounting pronouncements</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company considers the applicability
and impact of all Accounting Standard Updates (&#8220;ASU&#8217;s&#8221;). ASU&#8217;s not discussed below were assessed and determined
to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In June 2018, the FASB issued ASU 2018-07,
&#8220;Compensation &#8211; Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting&#8221;. This guidance
aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions
with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning
of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption
date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal
years. Early adoption is permitted. The Company has adopted this ASU as of July 1, 2019. There has been no impact on the financial
statements.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In August 2018, the FASB issued ASU 2018-13,
&#8220;Fair value measurement (Topic 820): Disclosure Framework &#8211; Changes to the Disclosure Requirements for Fair Value Measurement&#8221;.
The new guidance modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for fiscal years beginning
after December 15, 2019. Early adoption is permitted. The Company does not expect ASU 2018-13 to have a significant impact to its
condensed consolidated financial statements and related disclosures.</p><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify"><i>Recent accounting pronouncements</i></p>

<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify">The Company considers the applicability and impact of all Accounting Standard Updates
(&#8220;ASU&#8217;s&#8221;). ASU&#8217;s not discussed below were assessed and determined to be either not applicable or expected
to have minimal impact on our balance sheets or statement of operations.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In June 2018, the FASB issued ASU 2018-07, &#8220;Compensation &#8211; Stock Compensation
(Topic 718): Improvements to Non-employee share based accounting&#8221;, which simplifies the accounting for non-employee share-based
payment transactions. The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor
acquires goods or services to be used or consumed in a grantor&#8217;s own operations by issuing share-based payment awards. The
standard will be effective for the Company in the first quarter of fiscal year 2020, although early adoption is permitted (but
no sooner than the adoption of Topic 606). The Company does not expect that the adoption of this ASU will have a significant impact
on its financial statements.</p>

<p style="margin: 0; text-align: justify">&#160;&#160;</p>

<p style="margin: 0; text-align: justify">In July 2017, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2017-11.
&#8220;Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815):
I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily
Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with
a Scope Exception. ASU 2017-11 revises the guidance for instruments with down round features in Subtopic 815-40, Derivatives and
Hedging &#8211; Contracts in Entity&#8217;s Own Equity, which is considered in determining whether an equity-linked financial
instrument qualifies for a scope exception from derivative accounting. An entity still is required to determine whether instruments
would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception.
If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017-11 is
effective for annual and interim periods beginning December 15, 2018, and early adoption is permitted, including adoption in an
interim period. ASU 2017-11 provides that upon adoption, an entity may apply this standard retrospectively to outstanding financial
instruments with a down round feature by means of a cumulative-effect adjustment to the opening balance of retaining earnings
in the fiscal year and interim period adopted. The Company is currently in the process of assessing the impact of this ASU on
its financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_OtherAssetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Assets [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_OtherAssetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Reclassifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Reclassifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6768421296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">800,000,000<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares Issued</a></td>
<td class="nump">5,183,724<span></span>
</td>
<td class="nump">4,058,442<span></span>
</td>
<td class="nump">788,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">5,183,724<span></span>
</td>
<td class="nump">4,058,442<span></span>
</td>
<td class="nump">788,026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6700351376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Tax loss carryforward</a></td>
<td class="nump">$ 1,624,887<span></span>
</td>
<td class="nump">$ 555,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">36,917<span></span>
</td>
<td class="nump">19,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">18,809<span></span>
</td>
<td class="nump">257,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="num">(1,680,613)<span></span>
</td>
<td class="num">(832,186)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6697701968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details 2) - Stock Option [Member]<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (In years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">71.55%<span></span>
</td>
<td class="nump">67.91%<span></span>
</td>
<td class="nump">69.77%<span></span>
</td>
<td class="nump">103.13%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.61%<span></span>
</td>
<td class="nump">2.98%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.28%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6777772464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">$ 2,843,811<span></span>
</td>
<td class="num">$ (940,381)<span></span>
</td>
<td class="num">$ (2,444,287)<span></span>
</td>
<td class="num">$ (2,413,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash to cash used by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common shares issued for service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">642,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">114,689<span></span>
</td>
<td class="nump">114,689<span></span>
</td>
<td class="nump">229,377<span></span>
</td>
<td class="nump">229,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expense</a></td>
<td class="nump">11,162<span></span>
</td>
<td class="nump">19,697<span></span>
</td>
<td class="nump">64,860<span></span>
</td>
<td class="nump">238,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on settlement of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">51,400<span></span>
</td>
<td class="nump">51,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_InterestExpenseFromConvertibleDebenture', window );">Interest expense from convertible debenture</a></td>
<td class="nump">3,497,264<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfDerivatives', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(7,758,778)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other assets</a></td>
<td class="num">(216,660)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(334,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts Payable</a></td>
<td class="nump">641,697<span></span>
</td>
<td class="num">(456,422)<span></span>
</td>
<td class="num">(117,777)<span></span>
</td>
<td class="nump">413,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued Payroll</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">229,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used by operating activities</a></td>
<td class="num">(866,815)<span></span>
</td>
<td class="num">(1,211,017)<span></span>
</td>
<td class="num">(2,501,577)<span></span>
</td>
<td class="num">(621,341)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Repayment of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(244,300)<span></span>
</td>
<td class="num">(244,300)<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,040,000<span></span>
</td>
<td class="nump">3,040,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from loan payable - related party</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ProceedsFromConvertibleDebentureRelatedParty', window );">Proceeds from convertible debenture - related party</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">446,999<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">530,000<span></span>
</td>
<td class="nump">2,795,700<span></span>
</td>
<td class="nump">2,795,700<span></span>
</td>
<td class="nump">661,999<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash</a></td>
<td class="num">(336,815)<span></span>
</td>
<td class="nump">1,584,683<span></span>
</td>
<td class="nump">294,123<span></span>
</td>
<td class="nump">40,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, beginning of period</a></td>
<td class="nump">339,923<span></span>
</td>
<td class="nump">45,800<span></span>
</td>
<td class="nump">45,800<span></span>
</td>
<td class="nump">5,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, end of period</a></td>
<td class="nump">3,108<span></span>
</td>
<td class="nump">1,630,483<span></span>
</td>
<td class="nump">339,923<span></span>
</td>
<td class="nump">45,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,272<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>NON-CASH INVESTING AND FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ConversionOfPreferredSharesToCommonStock', window );">Conversion of preferred shares to common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_SettlementOfDebtByIssuanceOfCommonStock', window );">Settlement of debt by issuance of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,150,135<span></span>
</td>
<td class="nump">1,150,135<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_CashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="nump">19,309<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividendsForRatchetAdjustmentsToWarrants', window );">Deemed dividends for ratchet adjustments to warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">48,659<span></span>
</td>
<td class="nump">48,659<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DeemedDividend', window );">Deemed dividends for commitment shares</a></td>
<td class="nump">17,099,058<span></span>
</td>
<td class="nump">48,659<span></span>
</td>
<td class="nump">$ 48,659<span></span>
</td>
<td class="nump">$ 20,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_StockWarrantsClassifiedAsDerivativeLiability', window );">Stock warrants classified as derivative liability</a></td>
<td class="nump">$ 7,530,308<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_CashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cashless Exercise of Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_CashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ConversionOfPreferredSharesToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Preferred Shares To Common Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ConversionOfPreferredSharesToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DeemedDividendsForRatchetAdjustmentsToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividends for Ratchet Adjustments to Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DeemedDividendsForRatchetAdjustmentsToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_InterestExpenseFromConvertibleDebenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest expense from convertible debenture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_InterestExpenseFromConvertibleDebenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ProceedsFromConvertibleDebentureRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Convertible Debenture Related Party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ProceedsFromConvertibleDebentureRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SettlementOfDebtByIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Debt By Issuance Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SettlementOfDebtByIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_StockWarrantsClassifiedAsDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock warrants classified as derivative liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_StockWarrantsClassifiedAsDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6606540416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureSignificantAccountingPoliciesTablesAbstract', window );"><strong>Disclosure Significant Accounting Policies Tables Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Dilutive securities were excluded from the computation of diluted loss per share</a></td>
<td class="text"><p style="margin: 0; text-align: justify">The table below shows the number of outstanding stock options and warrants as of December
31, 2019 and 2018:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="text-align: center"><b>December 31, 2019</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="text-align: center"><b>December 31, 2018</b></td></tr>
<tr>
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Number of Shares</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Number of Shares</b></td></tr>
<tr>
    <td style="width: 18%; padding-bottom: 1.5pt; padding-left: 5.4pt">Stock Options</td>
    <td style="width: 34%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 18%; text-align: right">60,400</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 8%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 18%; text-align: right">44,400</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Warrants</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">1,374,667</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">1,731,525</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 4pt; padding-left: 5.4pt"><b>Total</b></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><b>1,435,067</b></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><b>1,775,925</b></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr></table><span></span>
</td>
<td class="text"><p style="margin: 0; text-align: justify">The table below shows the number of outstanding stock options and warrants as of June
30, 2019 and June 30, 2018:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">June 30, 2019</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">June 30, 2018</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Number of Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Number of Shares</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 56%; text-align: left; padding-left: 5.4pt">Stock Options</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">58,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">41,200</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">124,666</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">38,192</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; padding-left: 5.4pt; padding-bottom: 2.5pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">182,666</td><td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">79,392</td><td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureSignificantAccountingPoliciesTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureSignificantAccountingPoliciesTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6768146704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 3,108<span></span>
</td>
<td class="nump">$ 339,923<span></span>
</td>
<td class="nump">$ 45,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other Assets</a></td>
<td class="nump">550,810<span></span>
</td>
<td class="nump">334,150<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">553,918<span></span>
</td>
<td class="nump">674,073<span></span>
</td>
<td class="nump">45,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>OTHER ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets</a></td>
<td class="nump">1,439,915<span></span>
</td>
<td class="nump">1,554,603<span></span>
</td>
<td class="nump">1,783,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">345,711<span></span>
</td>
<td class="nump">345,711<span></span>
</td>
<td class="nump">345,711<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Fixed Assets</a></td>
<td class="nump">1,785,626<span></span>
</td>
<td class="nump">1,900,314<span></span>
</td>
<td class="nump">2,129,691<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">2,339,544<span></span>
</td>
<td class="nump">2,574,387<span></span>
</td>
<td class="nump">2,175,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts Payable and accrued expenses</a></td>
<td class="nump">1,085,177<span></span>
</td>
<td class="nump">443,480<span></span>
</td>
<td class="nump">884,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DerivativeLiabilitiesWarrantCurrent', window );">Derivative liability - warrants</a></td>
<td class="nump">2,674,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DerivativeLiabilitiesConversionOptionCurrent', window );">Derivative liability - conversion option on convertible debenture</a></td>
<td class="nump">573,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Loan payable - related party</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_ConvertibleDebentureRelatedParty', window );">Convertible debenture - related party, net of discount $498,466 and $0 at September 30, 2019 and 2018, respectively</a></td>
<td class="nump">21,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued Payroll</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">354,167<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">4,383,972<span></span>
</td>
<td class="nump">443,480<span></span>
</td>
<td class="nump">1,238,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Demand Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesNoncurrent', window );">Notes Payable, Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">575,918<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Long Term Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">825,918<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">4,383,972<span></span>
</td>
<td class="nump">443,480<span></span>
</td>
<td class="nump">2,064,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 800,000,000, 800,000,000 and 300,000,000 shares authorized at December 31, 2019, June 30, 2019 and June 30, 2018, respectively; 5,183,724, 4,058,442 and 788,026 shares issued and outstanding at December 31, 2019, June 30, 2019 and June 30, 2018, respectively</a></td>
<td class="nump">518<span></span>
</td>
<td class="nump">406<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">19,472,373<span></span>
</td>
<td class="nump">9,392,573<span></span>
</td>
<td class="nump">4,880,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(21,517,319)<span></span>
</td>
<td class="num">(7,262,072)<span></span>
</td>
<td class="num">(4,769,126)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="num">(2,044,428)<span></span>
</td>
<td class="nump">2,130,907<span></span>
</td>
<td class="nump">111,199<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 2,339,544<span></span>
</td>
<td class="nump">$ 2,574,387<span></span>
</td>
<td class="nump">$ 2,175,491<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ConvertibleDebentureRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible debenture - related party</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ConvertibleDebentureRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DerivativeLiabilitiesConversionOptionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative liability - conversion option on convertible debenture</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DerivativeLiabilitiesConversionOptionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DerivativeLiabilitiesWarrantCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative liability - warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DerivativeLiabilitiesWarrantCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6766442768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Renegotiated Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_NotesToFinancialStatementsAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DemandNoteTextBlock', window );">Renegotiated Debt</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 5%"><b>5.</b></td>
    <td style="width: 95%"><b>Renegotiated Debt</b></td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On July 19, 2018, Geis-Hides Consulting LLC entered into an Accord and Debt Satisfaction
Agreement with the Company in which the consulting firm agreed to release the Company from all liabilities arising from the Original
Contract and Debt Repayment Plan dated December 15, 2013 totaling $132,000 and received cash of $65,000 and 2,080 common shares
in satisfaction. The common shares were valued at the market price on the date of settlement at $7.50 per common share. The gain
of $51,400 on the settlement of debt was reflected on the Statements of Operations as &#8220;other income&#8221; for the year
ended June 30, 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DemandNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Demand Note [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DemandNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_NotesToFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_NotesToFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6634032272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Transactions</a></td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 1%"><b>7.</b></td>
    <td style="width: 99%"><b>Equity Transactions</b></td></tr>
</table>
<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify"><i>Stock Options</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The following table summarizes the activity relating to the Company&#8217;s stock options
for the six months ended December 31, 2019:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Options</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Weighted-Average Exercise Price</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Weighted Remaining Average Contractual Term</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Aggregate Intrinsic Value</b></td></tr>
<tr>
    <td style="width: 44%; padding-left: 5.4pt">Outstanding at June 30, 2019</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">58,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">12.50</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">5.2</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">87,480</td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Granted</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2,400</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">7.42</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4.1</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#8212;&#160;&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Options Exercised or Forfeited</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 4pt; padding-left: 5.4pt">Outstanding at December 31, 2019</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">60,400</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">12.29</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">4.5</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">2,100</td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 4pt; padding-left: 5.4pt">Exercisable at December 31, 2019</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">60,400</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">12.29</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">4.5</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">2,100</td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
</table>
<p style="margin: 0; text-align: justify"><b>&#160;</b></p>



<p style="margin: 0; text-align: justify">The fair value of each option grant on the date of grant is estimated using the Black-Scholes
option. The pricing model reflected the following weighted-average assumptions for the six months ended December 31, 2019:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>December 31 2019</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>December 31 2018</b></td></tr>
<tr>
    <td style="width: 58%; padding-left: 5.4pt">Expected life of options (In years)</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">5</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">5</td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Expected volatility</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">71.55</td>
    <td>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">67.91</td>
    <td>%</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Risk free interest rate</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1.61</td>
    <td>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2.98</td>
    <td>%</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Dividend Yield</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">0</td>
    <td>%</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">0</td>
    <td>%</td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Expected volatility is based on the historical volatilities of three comparable companies
of the daily closing price of their respective common stock and the expected life of options is based on historical data with
respect to employee exercise periods. The Company accounts for forfeitures as they are incurred.</p>

<p style="margin: 0; text-align: justify">The Company recorded stock-based compensation expense of $0 and $11,162 for the three-
and six- month periods ended December 31, 2019, respectively, and $16,285 and $19,697 for the three- and six- month periods ended
December 31, 2018, respectively.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The following is a summary of stock options outstanding and exercisable by exercise
price as of December 31, 2019:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Exercise Price</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Outstanding</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Weighted Average Contract Life</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Exercisable</b></td></tr>
<tr>
    <td style="width: 1%">$</td>
    <td style="width: 20%; text-align: right">3.75</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%; text-align: right">5,600</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%; text-align: right">4.1</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 19%; text-align: right">5,600</td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td>$</td>
    <td style="text-align: right">6.25</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">11,200</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4.2</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">11,200</td>
    <td>&#160;</td></tr>
<tr>
    <td>$</td>
    <td style="text-align: right">7.50</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">25,600</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">6.2</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">25,600</td>
    <td>&#160;</td></tr>
<tr>
    <td>$</td>
    <td style="text-align: right">8.75</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,600</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4.3</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,600</td>
    <td>&#160;</td></tr>
<tr>
    <td>$</td>
    <td style="text-align: right">12.50</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">3.1</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4,000</td>
    <td>&#160;</td></tr>
<tr>
    <td>$</td>
    <td style="text-align: right">25.00</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,600</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2.8</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,600</td>
    <td>&#160;</td></tr>
<tr>
    <td>$</td>
    <td style="text-align: right">26.25</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4,400</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2.3</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4,400</td>
    <td>&#160;</td></tr>
<tr>
    <td>$</td>
    <td style="text-align: right">27.50</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">800</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2.2</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">800</td>
    <td>&#160;</td></tr>
<tr>
    <td>$</td>
    <td style="text-align: right">28.75</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,600</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">2.6</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,600</td>
    <td>&#160;</td></tr>
<tr>
    <td>$</td>
    <td style="text-align: right">31.25</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1.9</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4,000</td>
    <td>&#160;</td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Stock Warrants</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The following table summarizes the warrants activity during the six months ended December
31, 2019:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Number of Shares</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Weighted Average Exercise Price</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Weighted Average Remaining Life (Years)</b></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center"><b>Aggregate Intrinsic Value</b></td></tr>
<tr>
    <td style="width: 44%; padding-left: 5.4pt">Outstanding and exercisable at June 30, 2019</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">124,667</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">45.00</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">5.6</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">716,653</td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Granted</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">1,250,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">4.00</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4.7</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#8212;&#160;&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Expired</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">$</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">$</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr>
    <td style="padding-bottom: 1.5pt; padding-left: 5.4pt">Outstanding and exercisable at December 31, 2019</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">1,374,667</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">$</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">7.72</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">4.7</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">$</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">139,498</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Of the above warrants, 9,391 expire in fiscal year ending June 30, 2022, 4,455 expire
in fiscal year ending June 30, 2023, and 1,360,821 expire in fiscal year ending June 30, 2025.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Offerings of Common Stock and Warrants</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Issuance of Stock Options</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On October 1, 2019, the Company issued stock options to purchase 800 shares of common
stock to the Chief Financial Officer as part of her compensation. The stock options were issued and are exercisable at an exercise
price of $8.75 at any time from date of issuance and expire in 5 years from the date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On October 13, 2019, the Company issued stock options to purchase 800 shares of common
stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $7.50 at any
time from date of issuance and expire in 5 years from the date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On November 10, 2019, the Company issued stock options to purchase 800 shares of common
stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $6.25 at any
time from date of issuance and expire in 5 years from the date of issuance.&#160;</p><span></span>
</td>
<td class="text"><table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 5%"><b>8.</b></td>
    <td style="width: 95%"><b>Equity Transactions</b></td></tr>
</table>
<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify"><i>Stock Options</i></p>

<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify">The following table summarizes the activity
relating to the Company&#8217;s stock options for the years ended June 30, 2018 and 2019:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Options</b></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Weighted-Average Exercise Price</b></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Weighted Remaining Average Contractual Term</b></td>
    <td>&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>Aggregate Intrinsic Value</b></td></tr>
<tr>
    <td style="width: 44%; padding-left: 5.4pt">Outstanding at June 30, 2017</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">32,000</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">12.50</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 10%; text-align: right">5.9</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 10%; text-align: right">142,000</td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Granted</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">10,000</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">18.75</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">5.0</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">&#8212;&#160;&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt; padding-bottom: 1pt">Options Exercised</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">(800</td>
    <td style="padding-bottom: 1pt">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">$</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">2.50</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">$</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Outstanding at June 30, 2018</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">41,200</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">15.00</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">5.8</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">142,000</td>
    <td>&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Granted</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">16,800</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">5.00</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">4.5</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">131,000</td>
    <td>&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt; padding-bottom: 1pt">Options Exercised or Forfeited</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">$</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">$</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt; padding-bottom: 2.5pt">Outstanding at June 30, 2019</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">58,000</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">$</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">12.50</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">5.2</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">$</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">273,000</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt; padding-bottom: 2.5pt">Exercisable at June 30, 2019</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">58,000</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">$</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">12.50</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">5.2</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">$</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The fair value of each option grant
on the date of grant is estimated using the Black-Scholes Option &#8211; Pricing model reflecting the following weighted-average
assumptions:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 56%; text-align: left; padding-left: 5.4pt">Expected life of options (In years)</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">5</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69.77</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">103.13</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt">Risk free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.60</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.28</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt">Dividend Yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
</table>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Expected volatility is based on the
historical volatilities of three comparable companies of the daily closing price of their respective common stock and the expected
life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as
they are incurred.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Company recorded stock-based compensation
expense of $64,860 for the year ended June 30, 2019 and $238,165 for the year ended June 30, 2018.</p>


<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The following is a summary of stock
options outstanding and exercisable by exercise price as of June 30, 2019:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted Average</td><td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Outstanding</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Contract Life</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Exercisable</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">3.75</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">5,600</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">4.6</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 19%; text-align: right">5,600</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">$</td><td style="text-align: right">6.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,400</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">$</td><td style="text-align: right">7.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,800</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">$</td><td style="text-align: right">8.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">$</td><td style="text-align: right">12.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">$</td><td style="text-align: right">25.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">$</td><td style="text-align: right">26.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,400</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,400</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">$</td><td style="text-align: right">27.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.7</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">800</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">$</td><td style="text-align: right">28.75</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">$</td><td style="text-align: right">31.25</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">4,000</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right">2.4</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">4,000</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="text-align: right">Total</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">58,000</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">58,000</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr>
</table>

<p style="margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="margin: 0; text-align: justify"><i>Issuance of Shares for Cash</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In July 2017 and August 2017, the Company
sold and issued an aggregate of 7,091 shares of common stock and warrants to purchase 3,546 shares of common stock in a private
placement transaction for aggregate gross proceeds of approximately $195,000. The purchase price for the common stock and warrants
was $27.50 per share. The warrants are exercisable at an exercise price of $75.00 at any time from date of issuance until 5 years
from the date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Between July 2017 and September 2017,
the Company sold an aggregate of 2,000 shares of common stock in transactions under the Aspire Equity Line for aggregate gross
proceeds of $50,000. The average purchase price for the common stock was $25.00 per share.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In October 2017, the Company sold and
issued an aggregate of 1,273 shares of common stock and warrants to purchase 637 shares of common stock in a private placement
transaction for aggregate gross proceeds of approximately $35,000. The purchase price for the common stock and warrants was $27.50
per share. The warrants are exercisable at an exercise price of $75.00 at any time from date of issuance until 5 years from the
date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In November 2017, the Company also sold and issued an aggregate of 546 shares of common
stock and warrants to purchase 273 shares of common stock in a private placement transaction for aggregate gross proceeds of approximately
$15,000. The purchase price for the common stock and warrants was $27.50 per share. The warrants are exercisable at an exercise
price of $75.00 at any time from date of issuance until 5 years from the date of issuance.&#160;</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In January 2018, the Company sold an
aggregate of 2,667 shares of common stock and warrants to purchase 2,667 shares of common stock to a member of its board of directors
for aggregate gross proceeds of $50,000. The purchase price for the common stock and warrants was $18.75 per share. The warrants
are exercisable at an exercise price of $18.75 at any time from date of issuance until 7 years from the date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On July 3, 2018, we entered into a Securities
Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Acuitas Group Holdings, LLC (&#8220;Acuitas&#8221;)and certain other
purchasers identified in the Purchase Agreement (together with Acuitas, the &#8220;Purchasers&#8221;) pursuant to which (i) the
Purchasers agreed to purchase an aggregate of 2,133,332 shares of the our Series A Convertible Preferred Stock (the &#8220;Preferred
Stock&#8221;) at a price per share of $1.50 per share of Preferred Stock (the &#8220;Initial Sale&#8221;) and (ii) we agreed
to issue warrants (the &#8220;Warrants&#8221;) to purchase 1,706,666 shares of common stock, each subject to the terms and conditions
set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. We received $160,000 of the $3.2 million in
April and May 2018 as prepaid equity. Acuitas also received an additional 6,667 Warrants in connection with the payoff of a note
issued by us in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas
had the option to purchase up to an additional 1,600,000 shares of common stock at a price per share of $1.875, and warrants on
the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale (the &#8220;Subsequent
Sale&#8221;) in the event that we did not obtain $3,000,000 of funding through various non-dilutive grants prior to the one year
anniversary of the closing of the Initial Sale, less any federal or FDA grant funding received by the Company. Acuitas is controlled
by our Chairman and Chief Executive Officer, Terren Peizer and the Purchasers included Jonathan Adams, James Lang, Cuang Do and
Michael Sherman, who are members of our Board of Directors.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The Purchase Agreement contained customary
representations and warranties. In connection with the disclosure schedule associated with the representations and warranties,
we also disclosed customary information, including the following: (i) the existence of the Mallinckrodt petition before the U.S.
Patent Trial and Appeal Board, (ii) our capitalization, (iii) our obligation to pay a low single digit royalty on the net sales
of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge,
Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and us, (iv) our obligation
to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000
per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy),
and (v) certain recent issuances of common stock by us.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Each share of Preferred Stock automatically
converted into 1 shares of common stock upon the filing with the Secretary of State of the State of Nevada of a Certificate of
Amendment to our Articles of Incorporation (the &#8220;Amendment&#8221;) on August 13, 2018 that increased the number of authorized
shares of common stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of
our issued and outstanding common stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar
days following the distribution of our Definitive Information Statement on Schedule 14 that was filed with the SEC on July 13,
2018.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Pursuant to the Purchase Agreement, Terren Peizer, the Chairman of Acuitas, was appointed
as a member of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) and as the Chief Executive Officer of the Company,
effective July 3, 2018. The issuance of the Preferred Stock, the Warrants and the underlying common stock under the Purchase Agreement
is exempt from registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), pursuant to the exemption
for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Pursuant to a letter agreement dated June 24,
2019, Acuitas has agreed to modify its existing rights under the Purchase Agreement so that:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 30px">&#160;</td>
    <td style="margin: 0; text-align: justify; width: 12px">&#8226;</td>
    <td style="margin: 0; text-align: justify">Acuitas agreed to immediately exchange its existing 1,606,667 Warrants for common stock such that it will have effectively exercised its Warrants in full pursuant to a cashless exercise thereof at an assumed current market price of $45.00 per share and, as a result received an aggregate of 95% of the shares covered thereby, or 1,526,333 shares of common stock;</td></tr>
</table>
<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 30px">&#160;</td>
    <td style="margin: 0; text-align: justify; width: 12px">&#8226;</td>
    <td style="margin: 0; text-align: justify">Acuitas agreed to (i) waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants and the price per share in the Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and (ii) effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a &#8220;cashless purchase&#8221; at an assumed current market price of approximately $11.25 per share, conditioned in each case on the listing of our common stock on NASDAQ or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, which will result Acuitas having irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 1,339,958 shares of common stock (the &#8220;Subsequent Sale Shares&#8221;) to Acuitas.</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Issuance of Warrants for Cash and
Cashless Exercise of Warrants </i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In December 2017, the Company issued
warrants for cash to purchase 20,000 shares of common stock in a private placement transaction for aggregate gross proceeds of
$100,000. The purchase price for the warrants were $25.00 per warrant. The warrants are exercisable at an exercise price of $5.00
at any time from date of issuance until 7 years from the date of issuance. As a result of the conversion of the Series A Preferred
Stock in July 2018, the exercise of warrants to purchase 20,000 shares of common stock was reduced from $18.75 per share to $1.875
per share. On August 4, 2018, the Company issued 17,936 shares of common stock pursuant to a cashless exercise of warrants to purchase
20,000 shares at an exercise price of $1.875 per share.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On May 13, 2019, the Company issued
479 shares of common stock pursuant to a cashless exercise of warrants to purchase 478 shares at an exercise price of $13.75 per
share.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On June 24, 2019, the Company issued
1,526,094 shares of common stock pursuant to a cashless exercise of warrants to purchase 1,606,667 shares at an exercise price
of $45.00 per share.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Issuance of Warrants Services</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In January 2018, the Company
issued warrants to purchase 840 shares of common stock in exchange for services. The warrants are exercisable at an exercise price
of $18.75 any time from the date of issuance until 7 years from the date of issuance. The warrants were valued at $9,444. The fair
value of the warrants granted was estimated using the Black Scholes Method and the following assumptions: volatility &#8211; 166.7%;
Term &#8211; 7 years; Risk Free Rate &#8211; 2.48%; dividend rate &#8211; 0.00%</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In February 2018, the Company
issued warrants to purchase 840 shares of common stock in a termination agreement. The warrants are exercisable at an exercise
price of $18.75 any time from the date of issuance until 7 years from the date of issuance. The warrants were valued at $3,025.
The fair value of the warrants granted was estimated using the Black Scholes Method and the following assumptions: volatility &#8211;
166.7%; Term &#8211; 7 years; Risk Free Rate &#8211; 2.81%; dividend rate &#8211; 0.00%</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Issuance of Shares for Services</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In August 2017, the Company issued 12,000 shares
of common stock to Aspire Capital in exchange for services. The shares were valued at $27.50 per share which was the trading price
on date of issuance, and the value of the services were $330,000.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In November 2017, the Company issued 1,200
shares of common in exchange for services. The shares were valued at $28.75 per share which was the trading price on date of issuance,
and the value of the services were $34,500.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In January 2018, The Company issued 240 shares
of common stock in exchange for services. The shares were valued at $16.25 per share which was the trading price on date of issuance,
and the value of the services were $3,900.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In January 2018, the Company issued 11,200
shares of common stock as compensation for the Board of Directors. The shares were valued at $18.75 per share which was the trading
price on date of issuance, and the value of the compensation was $210,000.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In February 2018, the Company issued 4,800 shares of common
stock in exchange for services. The shares were valued at $5.94 per share which was the trading price on date of issuance, and
the value of the services were $28,500.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In April 2018, the Company issued
2,400 shares of common in exchange for services. The shares were valued at $5.63 per share, and the value of the services were
$13,500. In April 2018, the Company issued 1,200 shares of common in exchange for services. The shares were valued at $3.00 per
share which was the trading price on date of issuance, and the value of the services were $3,600.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In May 2018, the Company issued
2,000 shares of common in exchange for services. The shares were valued at $2.25 per share which was the trading price on date
of issuance, and the value of the services were $4,500.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In May 2018, the Company issued
548 shares of common in exchange for services. The shares were valued at $12.50 per share which was the trading price on date of
issuance, and the value of the services were $6,850.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In June 2018, the Company issued
2,400 shares of common in exchange for services. The shares were valued at $3.13 per share which was the trading price on date
of issuance, and the value of the services were $7,500.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On January 2, 2019, the Company issued
11,200 shares of common stock as part of the annual board of director compensation. The share price on date of issuance was $4.38
per share.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Issuance of Shares in Settlement of Debt</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">During the year ended June 30, 2019,
the Company settled $1,475,765 of debt and accrued compensation including $1,313,765 owed to related parties, by issuing 7,803
shares of common stock with a fair value of $1,150,135. See notes 5 and 6.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Issuance of Stock Options </i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In November 2017, the Company extended the maturity date of stock options to acquire
6,400 shares at exercise prices ranging from $26.25 to $31.25 issued to the board of directors between November 2016 and December
2016 by 3 years. The Company recorded an incremental expense of $79,491 based on the increase in fair value of the options.</p>

<p style="margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="margin: 0; text-align: justify">In June 2018, 800 shares of stock options were exercised for $2,000.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On October 1, 2018, the Company issued
stock options to purchase 800 shares of common stock to the Chief Financial Officer as part of her compensation. The stock options
were issued and are exercisable at an exercise price of $8.75 at any time from date of issuance and expire in 5 years from the
date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On October 13, 2018, the Company issued
stock options to purchase 800 shares of common stock as part of their annual board of director compensation. The stock options
were issued and are exercisable at $6.25 at any time from date of issuance and expire in 5 years from the date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On October 27, 2018, the Company issued
stock options to purchase 800 shares of common stock as part of their annual board of director compensation. The stock options
were issued and are exercisable at $6.25 at any time from date of issuance and expire in 5 years from the date of issuance</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On November 10, 2018, the Company issued
stock options to purchase 800 shares of common stock as part of their annual board of director compensation. The stock options
are exercisable at an exercise price of $6.25 at any time from date of issuance and expire in 5 years from the date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On January 19, 2019, the Company issued
stock options to purchase 800 shares of common stock to each of five key employees or consultants and two company directors as
part of his or her annual compensation, for an aggregate total of 5,600 stock options. The stock options are exercisable at an
exercise price of $3.125 at any time from date of issuance until 5 years from the date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">On March 11, 2019, the Company issued
stock options to purchase 8,000 shares of common stock to an investor relations (IR) consultant. The stock options were issued
and are exercisable at $6.25 at any time from date of issuance and expire in 5 years from the date of issuance.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify"><i>Warrant Price Adjustment</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In December 2017, the Company issued
warrants to purchase 20,000 shares of common stock in a private placement transaction for aggregate gross proceeds of $100,000.
The warrants were exercisable at an exercise price of $25.00 at any time from date of issuance until 7 years from the date of issuance.
The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In January
2018, the Company sold shares at $18.75, which therefore triggered the reduction in the strike price. The Company calculated the
difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $20,995
as a deemed dividend. In July 2018, the Company sold shares at $1.88, which therefore triggered the reduction in the strike price.
The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise
price and recorded $44,889 as a deemed dividend. The fair value of the warrants granted was estimated using the Black Scholes Method.</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">In January and February 2018, the Company
issued warrants to purchase 1,680 shares of common stock in exchange for banking services which was recognized at fair value.
The warrants were exercisable at an exercise price of $18.75 at any time from date of issuance until 7 years from the date of issuance.
The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In July 2018,
the Company sold shares at $1.88, which therefore triggered the reduction in the strike price. The Company calculated the difference
in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $3,770 as a deemed
dividend. The fair value of the warrants granted was estimated using the Black Scholes Method.<i>&#160;</i></p>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">The following table summarizes
the warrants that have been issued:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="margin: 0; text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Aggregate</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center">Intrinsic</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Shares</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Life (Years)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">Value</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 40%; padding-left: 5.4pt">Outstanding at June 30, 2017</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">49,391</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">62.50</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">0.5</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,802</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">27.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">(40,000</td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">62.50</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt">Outstanding at June 30, 2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38,193</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">36.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,713,333</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">45.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.6</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,159,988</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; padding-bottom: 1pt">Exercised</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">(1,626,859</td><td style="text-align: left; padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">45.00</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt; padding-bottom: 1pt">Outstanding and exercisable at June 30, 2019</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">124,667</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">45.00</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">5.6</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid">1,202,678</td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
</table>

<p style="margin: 0; text-align: justify">&#160;</p>

<p style="margin: 0; text-align: justify">Of the above warrants, 9,391
expire in fiscal year ending June 30, 2022, 4,815 expire in fiscal year ending June 30, 2023 and 110,461 expire in fiscal
year ended June 30, 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6766365360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureIncomeTaxesTablesAbstract', window );"><strong>Disclosure Income Taxes Tables Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"><p style="margin: 0; text-align: justify">Significant components of the Company&#8217;s deferred tax assets are as follows:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"><b>June 30, 2019</b></td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="3" style="text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"><b>June 30, 2018</b></td></tr>
<tr>
    <td style="padding-left: 5.4pt">Deferred tax assets:</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr>
    <td style="width: 58%; padding-left: 5.4pt">Tax loss carryforward</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">1,624,887</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 8%">&#160;</td>
    <td style="width: 1%">$</td>
    <td style="width: 11%; text-align: right">555,064</td>
    <td style="width: 1%">&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Intangible assets</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">36,917</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">19,277</td>
    <td>&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt">Stock based compensation</td>
    <td>&#160;</td>
    <td>$</td>
    <td style="text-align: right">18,809</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">257,845</td>
    <td>&#160;</td></tr>
<tr>
    <td style="padding-left: 5.4pt; padding-bottom: 1pt">Valuation Allowance</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">$</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">(1,680,613</td>
    <td style="padding-bottom: 1pt">)</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid">&#160;</td>
    <td style="text-align: right; border-bottom: Black 1pt solid">(832,186</td>
    <td style="padding-bottom: 1pt">)</td></tr>
<tr>
    <td style="padding-left: 5.4pt; padding-bottom: 2.5pt">Net deferred tax assets</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">$</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double">$</td>
    <td style="text-align: right; border-bottom: Black 2.5pt double">&#8212;&#160;&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income tax Benefits</a></td>
<td class="text"><p style="margin: 0; text-align: justify">Reconciliation of the differences between income tax benefit computed at the federal
and state statutory tax rates and the provision for income tax benefit for the years ended June 30, 2019 and 2018 is as follows:</p>

<p style="margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="3" style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 56%; text-align: left; padding-left: 5.4pt">Income tax expense (benefit) at federal statutory rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">34</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 5.4pt; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">-29</td><td style="text-align: left; padding-bottom: 1pt">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid">-39</td><td style="text-align: left; padding-bottom: 1pt">%</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 5.4pt; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 2.5pt">&#160;</td><td style="text-align: right; border-bottom: Black 2.5pt double">&#8212;&#160;&#160;</td><td style="text-align: left; padding-bottom: 2.5pt">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureIncomeTaxesTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureIncomeTaxesTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6764674320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details 2) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_DisclosureIntangibleAssetsDetails2Abstract', window );"><strong>Disclosure Intangible Assets Details 2Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths', window );">2020</a></td>
<td class="nump">$ 114,689<span></span>
</td>
<td class="nump">$ 229,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo', window );">2021</a></td>
<td class="nump">229,377<span></span>
</td>
<td class="nump">229,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree', window );">2022</a></td>
<td class="nump">229,377<span></span>
</td>
<td class="nump">229,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour', window );">2023</a></td>
<td class="nump">229,377<span></span>
</td>
<td class="nump">229,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive', window );">2024</a></td>
<td class="nump">229,377<span></span>
</td>
<td class="nump">229,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bivi_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix', window );">2025</a></td>
<td class="nump">229,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive', window );">Thereafter</a></td>
<td class="nump">178,341<span></span>
</td>
<td class="nump">407,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intellectual Property, Net</a></td>
<td class="nump">$ 1,439,915<span></span>
</td>
<td class="nump">$ 1,554,603<span></span>
</td>
<td class="nump">$ 1,783,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureIntangibleAssetsDetails2Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureIntangibleAssetsDetails2Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the sixth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>137</ContextCount>
  <ElementCount>284</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>19</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/BalanceSheets</Role>
      <ShortName>Condensed Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Statements of Changes in Stockholders' (Deficit) Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/StatementsOfChangesInStockholdersDeficitEquity</Role>
      <ShortName>Condensed Statements of Changes in Stockholders' (Deficit) Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Background Information and Reverse Stock Split</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/BackgroundInformationAndReverseStockSplit</Role>
      <ShortName>Background Information and Reverse Stock Split</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Renegotiated Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/RenegotiatedDebt</Role>
      <ShortName>Renegotiated Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Equity Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/EquityTransactions</Role>
      <ShortName>Equity Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/IntangibleAssets</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/FairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Equity Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/EquityTransactionsTables</Role>
      <ShortName>Equity Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/EquityTransactions</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/IncomeTaxes</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Background Information and Reverse Stock Split (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/BackgroundInformationAndReverseStockSplitDetailsNarrative</Role>
      <ShortName>Background Information and Reverse Stock Split (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/BackgroundInformationAndReverseStockSplit</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/IntangibleAssetsTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Intangible Assets (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IntangibleAssetsDetails2</Role>
      <ShortName>Intangible Assets (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/IntangibleAssetsTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Intangible Assets (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>Intangible Assets (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/IntangibleAssetsTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Equity Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/EquityTransactionsDetails</Role>
      <ShortName>Equity Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/EquityTransactionsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Equity Transactions (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/EquityTransactionsDetails2</Role>
      <ShortName>Equity Transactions (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/EquityTransactionsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Equity Transactions (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/EquityTransactionsDetails3</Role>
      <ShortName>Equity Transactions (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/EquityTransactionsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Equity Transactions (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/EquityTransactionsDetails4</Role>
      <ShortName>Equity Transactions (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/EquityTransactionsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Equity Transactions (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/EquityTransactionsDetails5</Role>
      <ShortName>Equity Transactions (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/EquityTransactionsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/IncomeTaxesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/IncomeTaxesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bivi-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://nanoantibiotics.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://nanoantibiotics.com/role/IncomeTaxesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bivi-20191231.xml</File>
    <File>bivi-20191231.xsd</File>
    <File>bivi-20191231_cal.xml</File>
    <File>bivi-20191231_def.xml</File>
    <File>bivi-20191231_lab.xml</File>
    <File>bivi-20191231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
